
<html lang="en"     class="pb-page"  data-request-id="4f771ab3-789f-4a1a-9b99-2a332993a87c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00960;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry" /></meta><meta name="dc.Creator" content="Patrick  Mäder" /></meta><meta name="dc.Creator" content="Lars  Kattner" /></meta><meta name="dc.Description" content="Sulfoximines have been largely disregarded in medicinal chemistry for a long time. However, recently, they have risen to the apparent level of stardom on the drug discovery scene. Considering the o..." /></meta><meta name="Description" content="Sulfoximines have been largely disregarded in medicinal chemistry for a long time. However, recently, they have risen to the apparent level of stardom on the drug discovery scene. Considering the o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 1, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00960" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00960" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00960" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00960" /></link>
        
    
    

<title>Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00960" /></meta><meta property="og:title" content="Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0026.jpeg" /></meta><meta property="og:description" content="Sulfoximines have been largely disregarded in medicinal chemistry for a long time. However, recently, they have risen to the apparent level of stardom on the drug discovery scene. Considering the outstanding properties of sulfoximines, this versatile functional group has advanced to implementation in several drug discovery programs. Currently, this fashionable functional group can be found in various hit-to-lead and lead optimization studies in early stages and in several compounds currently in clinical trials. Herein, we review recent developments to demonstrate the scope and limitations of this interesting and versatile functional group in medicinal chemistry and drug discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00960"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00960">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00960&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00960&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00960&amp;href=/doi/10.1021/acs.jmedchem.0c00960" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14243-14275</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00934" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01013" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Patrick Mäder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Mäder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Endotherm GmbH, Science Park 2, 66123 Saarbruecken, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++M%C3%A4der">Patrick Mäder</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Lars Kattner</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lars Kattner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Endotherm GmbH, Science Park 2, 66123 Saarbruecken, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +49-(0)-681-3946-7570. Email: <a href="/cdn-cgi/l/email-protection#ff939e8d8cd1949e8b8b919a8dbf9a919b908b979a8d92d19b9a"><span class="__cf_email__" data-cfemail="ea868b9899c4818b9e9e848f98aa8f848e859e828f9887c48e8f">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lars++Kattner">Lars Kattner</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2923-8234" title="Orcid link">http://orcid.org/0000-0003-2923-8234</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00960&amp;href=/doi/10.1021%2Facs.jmedchem.0c00960" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14243–14275</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 1, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 June 2020</li><li><span class="item_label"><b>Published</b> online</span>1 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00960" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00960</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14243%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPatrick%2BM%25C3%25A4der%252C%2BLars%2BKattner%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c00960%26title%3DSulfoximines%2Bas%2BRising%2BStars%2Bin%2BModern%2BDrug%2BDiscovery%253F%2BCurrent%2BStatus%2Band%2BPerspective%2Bon%2Ban%2BEmerging%2BFunctional%2BGroup%2Bin%2BMedicinal%2BChemistry%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14275%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00960"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6509</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00960" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Mäder&quot;},{&quot;first_name&quot;:&quot;Lars&quot;,&quot;last_name&quot;:&quot;Kattner&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14243-14275&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00960&quot;},&quot;abstract&quot;:&quot;Sulfoximines have been largely disregarded in medicinal chemistry for a long time. However, recently, they have risen to the apparent level of stardom on the drug discovery scene. Considering the outstanding properties of sulfoximines, this versatile functional group has advanced to implementation in several drug discovery programs. Currently, this fashionable functional group can be found in various hit-to-lead and lead optimization studies in early stages and in several compounds currently in clinical trials. Herein, we review recent developments to demonstrate the scope and limitations of this interesting and versatile functional group in medicinal chemistry and drug discovery.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00960&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00960" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00960&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00960" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00960&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00960" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00960&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00960&amp;href=/doi/10.1021/acs.jmedchem.0c00960" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00960" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00960" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00960%26sid%3Dliteratum%253Aachs%26pmid%3D32870008%26genre%3Darticle%26aulast%3DM%25C3%25A4der%26date%3D2020%26atitle%3DSulfoximines%2Bas%2BRising%2BStars%2Bin%2BModern%2BDrug%2BDiscovery%253F%2BCurrent%2BStatus%2Band%2BPerspective%2Bon%2Ban%2BEmerging%2BFunctional%2BGroup%2Bin%2BMedicinal%2BChemistry%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14243%26epage%3D14275%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Sulfoximines have been largely disregarded in medicinal chemistry for a long time. However, recently, they have risen to the apparent level of stardom on the drug discovery scene. Considering the outstanding properties of sulfoximines, this versatile functional group has advanced to implementation in several drug discovery programs. Currently, this fashionable functional group can be found in various hit-to-lead and lead optimization studies in early stages and in several compounds currently in clinical trials. Herein, we review recent developments to demonstrate the scope and limitations of this interesting and versatile functional group in medicinal chemistry and drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In modern drug discovery, medicinal chemists face numerous challenges during the course of hit selection and lead generation, such as affinity and/or selectivity issues, toxicity concerns, the necessity to improve or tune physicochemical and/or ADMET properties, or the need for novelty with regard to intellectual property (IP) generation. The most prevalent techniques in lead optimization involve the systematic use of common bioisosteres or scaffolds (“scaffold hopping”).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In the latter approach, the aim is to discover structurally novel compounds by modifying the central core structure of known active compounds.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Since medicinal chemists are likely to use previously established scaffolds or functional groups, common scaffolds are found in analogues related to various targets, which is limiting the expansion of chemical diversity.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Novel approaches are often viewed critically, as exemplified by the anticancer drug bortezomib (<b>1</b>, Velcade, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), the first approved boron-containing inhibitor. Early in the development, <b>1</b> encountered certain prejudice due to its molecular target being the proteasome and to its generally disapproved boronate moiety.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In spite of these major obstacles, <b>1</b> managed not only to receive approval but also did so in record time and at a significantly lower cost than an average drug in the biopharmaceutical industry.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Since then, boron-containing compounds have been used in several medicinal chemistry programs. Although most of these compounds are considered synthetically challenging, they are actually present in small molecules with biological activities against a variety of targets (e.g., SCYX-7158 (<b>2</b>), tavaborole (<b>3</b>), and RPX7009 (<b>4</b>), cf. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> Thereby, new and unique chemical series of potential medicinal interest were generated clearly demonstrating the potential of the implementation of novel functional groups.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of selected boron-containing biologically active compounds.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5−8)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the success of boron-containing compounds, sulfoximines (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), the monoaza analogues of sulfones (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), have emerged as new and valuable isosteres of the sulfur-containing functional groups, such as sulfons, for the application in medicinal chemistry due to the potential ease of modulation of their physicochemical properties. The same considerations are true for sulfondiimines (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) and sulfonimidamides (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), the aza analogues of sulfonamides (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Sulfoximines bear a stereocenter at the tetrahedral sulfur atom (if not substituted symmetrically) due to the introduction of a mildly basic nitrogen atom (p<i>K</i><sub>a</sub> (NH<sub>2</sub><sup>+</sup>) = 2.7, in water),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and they are chemically and configurationally stable (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Sulfoximines are almost isosteric with sulfones and offer an additional vector capable of projecting a wide range of functionalities.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> The nitrogen atom is capable of complexing metal ions and forming salts with mineral acids.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Modification of the substitution pattern at the nitrogen atom enables the modulation of the acidic/basic properties of the compounds.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Sulfoximines offer unique H-bond donor/acceptor capabilities. The sulfur-bound heteroatoms are hydrogen-bond acceptors, and <i>N</i>-unsubstituted sulfoximines may serve as hydrogen-bond donors (via N<i>H</i>) and acceptors. Sulfoximines have an increased solubility in protic solvents (e.g., water or alcohols) compared to that of their sulfone counterparts.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These properties suggest that the sulfoximine group has significant potential to serve as a small, hydrophilic, and stable functional group in drug discovery and thus can be considered an isosteric alternative to the commonly used sulfone.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) General structure of sulfur-containing functional groups. (B) General properties of sulfoximines. (C) General properties of sulfonimidamides.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9−15)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first sulfoximine (methioninesulfoximine, MSO, <b>10</b>, see chapter 2) was discovered almost 70 years ago; however, the sulfoximine functional group was surprisingly neglected in drug discovery for a long time. The number of compounds containing a sulfoximine group currently in clinical trials is modest but is increasing. However, to date, none of these compounds have been approved. The reasons for the rare appearance of the group in advanced drug candidates remain poorly understood; however, safety concerns during the synthesis (e.g., due to the use of sodium azide) and the unfamiliar properties of this scaffold may play an important role.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Over the past two decades, new, safe, and more practical synthetic methodologies have been developed. These game-changing methodologies include copious functional group tolerance, application of safer nitrogen sources, valuable one-pot synthesis, and asymmetric synthetic methodologies.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(16−23)</a> Especially, the outstanding work of Bolm,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Bull,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and Lücking<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in the field of sulfoximines and the work of Arvidsson<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in the field of sulfonimidamides (in addition to many other studies) led to an increased interest in sulfoximines in medicinal chemistry and thus in drug discovery (cf. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). However, this review is not focused on the synthetic methods, as they are excellently reviewed elsewhere.<a onclick="showRef(event, 'ref9 ref20 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref9 ref20 ref26 ref27 ref28 ref29 ref30 ref31">(9,20,26−31)</a> This review will rather focus on several approaches toward the implementation of novel biologically active compounds bearing a sulfoximine moiety (and its congeners), a powerful but disregarded functional group in medicinal chemistry.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the numbers of publications per decade containing the keyword “sulfoximine” (blue bars) and of reactions per decade containing a sulfoximine substructure (red bars) according to SciFinder (accessed July 17, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Pioneers for the Application of Sulfoximines</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Methionine sulfoximine (MSO, <b>10</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) was the first known sulfoximine discovered in the late 1940s.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Compound <b>10</b> was formed during the “agene process”, a method of bleaching freshly milled wheat using nitrogen chloride (“agene”). Unfortunately, dogs fed with agenized flour experienced epileptic seizures and death, revealing the toxicity of the compound.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33−36)</a> Years later, <span class="smallcaps smallerCapital">l</span>-methionine-(<i>S</i>)-sulfoximine, the active stereoisomer of <b>10</b>, was found to act as a mimetic of glutamate (after phosphorylation of <b>10</b>) and therefore reduce GSH biosynthesis by inhibiting γ-glutamylcysteine synthetase and glutamine synthetase.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> Several alkyl analogues of <b>10</b> were synthesized and evaluated, leading to the discovery of buthionine sulfoximine (BSO, <b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), a competitive and selective γ-glutamylcysteine synthetase inhibitor.<a onclick="showRef(event, 'ref36 ref37 ref40'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref40">(36,37,40)</a> Due to the ability of <b>11</b> to reduce the intracellular GSH levels and consequently increase the activity of cytotoxic agents, <b>11</b> was evaluated in several studies directed at its potential in the treatment of GSH-overexpressing tumors.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Despite being well-tolerated and safe in these studies, the compound <b>11</b> never reached approval.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Nevertheless, <b>11</b> is one of the most investigated sulfoximines so far and is widely used in studies that interrogate the role of GSH in cellular processes.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of methionine sulfoximine (<b>10</b>), buthionine sulfoximine (<b>11</b>), and sulfoxaflor (<b>12</b>).<a onclick="showRef(event, 'ref36 ref42'); return false;" href="javascript:void(0);" class="ref ref36 ref42">(36,42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sulfoxaflor (<b>12</b>, Isoclast, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), approved in 2013, was the first commercially available sulfoximine-based insecticide and can therefore be regarded as a pioneer for the application of sulfoximines in medicinal chemistry. Compound <b>12</b> acts as a neonicotinoid to competitively modulate the nicotinic acetylcholine receptor (nAChR), leading to uncontrolled nerve impulses and consequential muscle tremors followed by paralysis and death. Compound <b>12</b> has a broad spectrum in the sap-feeding insect control (e.g., aphids, whiteflies, and hoppers) compared to the spectrum of other insecticides, while having improved UV stability and thus improved residual insect control.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Another key attribute of <b>12</b> is its lack of cross-resistance with a variety of conventional insecticides, which is assumed to result from significantly lower degradation of <b>12</b> by cytochrome P450 monooxygenases (e.g., CYP6G1) known to metabolize other neonicotinoids (e.g., imidacloprid and acetamiprid).<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></div><div class="NLM_p last">Distinct chemical and biochemical properties of <b>12</b> were recognized by the Insecticide Resistance Action Committee (IRAC) and resulted in its classification as group 4C insecticides instead of group 4A neonicotinoid insecticides.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Thus, <i>N</i>-cyano sulfoximines attracted significant attention in lead generation in agrochemical research.<a onclick="showRef(event, 'ref25 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref25 ref47 ref48">(25,47,48)</a> It should be mentioned that <b>12</b> was highly condemned for its potential impact on bumblebees. Sublethal doses of <b>12</b> affect the fitness of bumblebee colonies and reproductive success, although there is no evidence of a negative impact on the olfactory conditioning or working memory of the bees.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> The topic remains a matter of controversy, and further studies are required to investigate this phenomenon.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  Investigative Studies of Sulfoximines to Characterize Their Properties in Vitro</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The sulfoximine moiety offers a unique combination of interesting properties (e.g., structural diversity, advanced chemical and metabolic stability, and favorable physicochemical and in vitro parameters); however, the available data of the literature have been rather limited for a long time. To close this gap, several studies were published within the past years investigating sulfoximine-containing small molecules or their fragments and other sulfur-containing functional groups (matched molecular pair analysis) or related analogues to compare their physicochemical and in vitro properties.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  Studies of Drug-Like Properties of Sulfoximine Tool Compounds and Matched Molecular Pair Analysis</h3><div class="NLM_p">In 2017, Gnamm and co-workers published a comprehensive overview of the physicochemical (e.g., log <i>P</i>, dissociation constants, chemical stability, and aqueous solubility) and in vitro properties (e.g., microsomal stability and permeability) of several sulfoximines and their analogues/isosteres.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">The first part of this study describes fragment-like tool compounds (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) and their corresponding drug-like properties (values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The following trend for lipophilicity (log <i>P</i>) was observed: <b>18</b> (log <i>P</i> = −0.5) = <b>13</b> (log <i>P</i> = −0.3) < <b>16</b> (log <i>P</i> = 0.1), <b>17</b> (log <i>P</i> = 0.2) = <b>23</b> (log <i>P</i> = 0.2) < <b>21</b> (log <i>P</i> = 0.3) < <b>19</b> (log <i>P</i> = 0.4) < <b>22</b> (log <i>P</i> = 0.5) ≪ <b>14</b> (log <i>P</i> = 1.5) = <b>20</b> (log <i>P</i> = 1.5). However, Gnamm and co-workers struggled to get valid data for all compounds by HPLC, which highlights the limits of the fragment-like character of the investigated tool compounds. Therefore, they measured the lipophilicity of compounds <b>15</b> (log <i>P</i> = 2.0), <b>18</b> (log <i>P</i> = 0.9), <b>24</b> (log <i>P</i> = 1.4), and <b>25</b> (log <i>P</i> = 2.3) using a potentiometric assay. Notwithstanding, compounds <b>18</b> and <b>24</b> were found to be more polar than <b>15</b>, which is slightly more lipophilic than <b>25</b>. Gnamm and co-workers were able to confirm that compounds <b>15</b> (p<i>K</i><sub>b</sub> = 2.5), <b>17</b> (p<i>K</i><sub>b</sub> = 3.8), and <b>18</b> (p<i>K</i><sub>b</sub> = 2.4) are weakly basic, whereas no dissociation constant could be measured for compounds <b>16</b>, <b>19</b>, and <b>20</b> within the assay window (pH 2–12). These results are in agreement with the general properties of sulfoximines described in the introduction chapter of this review. Desirable aqueous solubility of sulfoximines was expected based on their log <i>P</i> values and dissociations constants. The majority of the tool compounds were highly soluble (>200 μM) due to their fragment-like properties; however, the solubility of sulfoximine <b>15</b> was comparable to that of sulfoxide <b>13</b> (cf. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and 10–100-fold higher than that of sulfone <b>14</b>, amides <b>21</b>–<b>23</b>, or sulfonamides <b>24</b>–<b>26</b>. Unfortunately, significant results describing permeability were not obtained since almost all compounds had high permeability due to their low molecular weight. Different results might have been anticipated due to the variable polarity of compounds <b>13</b>–<b>26</b>. Furthermore, sulfoximine <b>15</b> and its analogues <b>16</b>–<b>20</b> had high metabolic stability in human liver microsomes (<i>t</i><sub>1/2</sub> > 130 min), indicating favorable metabolic stability; however, a comparison was not possible due to missing data for sulfoxide <b>13</b> and sulfone <b>14</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of selected tool compounds (<b>13</b>–<b>26</b>) investigated by Gnamm and co-workers.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Log <i>P</i>, Dissociation Constants, Microsomal Stability, Aqueous Solubility, and Permeability Assays of Compounds <b>13</b>–<b>26</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> <a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">log <i>P</i></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">human liver microsome stability</th><th class="rowsep1 colsep0" colspan="2" align="center">aqueous solubility [μg/mL]</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center" char=".">HPLC assay</th><th class="colsep0 rowsep0" align="center">potentio-metric assay</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub>/p<i>K</i><sub>b</sub></th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> [min]</th><th class="colsep0 rowsep0" align="center">%Q<sub>H</sub></th><th class="colsep0 rowsep0" align="center">HPLC assay</th><th class="colsep0 rowsep0" align="center">shake flask assay</th><th class="colsep0 rowsep0" align="center">PAMPA <i>P</i><sub>app</sub> [10<sup>–6</sup> cm/s]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center" char=".">–0.3</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">>46</td><td class="colsep0 rowsep0" align="center">11 100</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center" char=".">1.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">>47</td><td class="colsep0 rowsep0" align="center">300</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center" char="."><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2.0<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">p<i>K</i><sub>b</sub> = 2.5</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">>50</td><td class="colsep0 rowsep0" align="center">9100</td><td class="colsep0 rowsep0" align="center">6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center" char=".">0.1</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">no p<i>K</i><sub>a</sub>/p<i>K</i><sub>b</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">>54</td><td class="colsep0 rowsep0" align="center">2400</td><td class="colsep0 rowsep0" align="center">11.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center" char=".">0.2</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">p<i>K</i><sub>b</sub> = 3.8</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">>59</td><td class="colsep0 rowsep0" align="center">4700</td><td class="colsep0 rowsep0" align="center">9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center" char=".">–0.5</td><td class="colsep0 rowsep0" align="center">0.9<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">p<i>K</i><sub>b</sub> = 2.4</td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center">45</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">6900</td><td class="colsep0 rowsep0" align="center">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center" char=".">0.4</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">no p<i>K</i><sub>a</sub>/p<i>K</i><sub>b</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">1200</td><td class="colsep0 rowsep0" align="center">9.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center" char=".">1.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">no p<i>K</i><sub>a</sub>/p<i>K</i><sub>b</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">1200</td><td class="colsep0 rowsep0" align="center">9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center" char=".">0.3</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">>44</td><td class="colsep0 rowsep0" align="center">300</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center" char=".">0.5</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">200</td><td class="colsep0 rowsep0" align="center">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center" char=".">0.2</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">700</td><td class="colsep0 rowsep0" align="center">11.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center">1.4<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub> = 9.4</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">>48</td><td class="colsep0 rowsep0" align="center">800</td><td class="colsep0 rowsep0" align="center">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center">2.3<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub> = 10.7</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center"><23</td><td class="colsep0 rowsep0" align="center">>49</td><td class="colsep0 rowsep0" align="center">900</td><td class="colsep0 rowsep0" align="center">6.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="center" char=".">2.7</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center">90</td><td class="colsep0 rowsep0" align="center"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">For assay details, refer to ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>. ND = not determined.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">No valid results were obtained.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Measured at pH = 12.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">No p<i>K</i><sub>a</sub>/p<i>K</i><sub>b</sub> was measured within the range of the assay (pH 2–12).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Measured at pH = 2.</p></div></div></div><div class="NLM_p">In the second part of their study, Gnamm and co-workers performed a matched molecular pair analysis using the Boehringer Ingelheim Corporate Database (CDB). A substructure search was performed to identify matched molecular pairs of sulfoximines and related common functional groups, such as carboxylic acids, esters, amides, sulfoxides, sulfones, sulfonamides, amines, ureas, and carbamates.<a onclick="showRef(event, 'ref24 ref51'); return false;" href="javascript:void(0);" class="ref ref24 ref51">(24,51)</a> Molecular weight (250 < MW < 750) and availability of the data for at least one physicochemical or in vitro property (microsomal stability, aqueous solubility, or Caco-2 permeability) were the filter criteria for the selection of the compounds, which resulted in 13 000 data sets for microsomal stability, 8000 data sets for aqueous solubility, and 3000 data sets for Caco-2 permeability. The authors indicated that the major limitation of their study was due to insufficient statistical reliability of the evaluation of the data, e.g., due to the variability of the biological assays. Thus, data points were classified as “desirable”, “acceptable”, or “undesirable”. The criteria for classification in the corresponding classes are listed in Table 1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>. The ratios of two values were not obtained (e.g., an <i>n</i>-fold increase in Caco-2 permeability); however, this part of their study provided valuable trends to guide the incorporation of sulfoximines. Replacing a sulfoxide or a sulfone by an NH-sulfoximine did not lead to any significant effect on microsomal stability, while replacing sulfonamides was beneficial for microsomal stability. Surprisingly, cyanation and methylation of the sulfoximine nitrogen had opposite effects, and methylation was unfavorable for metabolic stability (in 40% of all classes). The introduction of sulfondiimines did not significantly influence microsomal stability, and the introduction of sulfonimidamides decreased metabolic stability. In general, no clear trend was apparent when a sulfoximine moiety (or analogue) was introduced. NH-sulfoximines did not increase Caco-2 permeability. Permeability was decreased when sulfones were replaced with sulfoximines, and the replacement of sulfonamides resulted in comparable permeability. <i>N</i>-Methylated sulfoximines are more lipophilic than their NH-sulfoximine counterparts but do not have higher permeability. Similar to these findings, sulfonimidamide compounds were demonstrated to have higher permeability in most cases (also when used to replace the corresponding NH-sulfoximine).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p last">In summary, Gnamm and co-workers synthesized several series of fragment-like tool compounds of sulfoximines, their analogues, isosteres, and related compounds, and assessed their physicochemical and in vitro properties. A similar analysis was performed in the matched molecular pairs by using the CDB. However, a statistical comparison was not performed, and some properties were determined using different assays (e.g., log <i>P</i> or aqueous solubility). Additionally, the first part of their study only analyzed the tool compounds, and the data are limited due to the fragment-like character of the tool compounds (e.g., permeability values). In the second part of their study, no chemical structures were shown, and the impact of the introduction of a sulfoximine moiety on biological activity was not investigated. Therefore, this study is not sizable enough to offer general guidance toward the use of the sulfoximine moiety in medicinal chemistry. Nonetheless, the results clearly emphasize the impact of sulfoximines on important properties, such as solubility, log <i>P</i>, and metabolic stability (also in comparison to common moieties, such as sulfonamides and sulfones). Thus, sulfoximines and their analogues represent powerful tools for fine-tuning drug-like properties in drug discovery.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.2.  Sulfoximine Analogues of Marketed Drugs and Clinical Candidates</h3><div class="NLM_p">To investigate the impact of the sulfoximine moiety in more detail, sulfoximine analogues of approved drugs and/or clinical candidates were synthesized and evaluated by various groups to overcome the limitations of the “fragment-based” approach described in chapter 3.1. This approach has two major advantages: (i) physicochemical properties and biological activities of the parent compounds are available and were already demonstrated as favorable, and (ii) relevant assay systems are established. Therefore, the properties of the corresponding matched molecular pairs can be easily compared in a reliable manner.</div><div class="NLM_p">In 2017, Sirvent and Lücking published a study of six sulfoximine analogues of marketed drugs or clinical candidates and compared the in vitro properties of each matched molecular pair (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In addition to replacing sulfones, an investigation of amine replacement by sulfoximines was performed to gain a better understanding of this uncommon functional group. Four kinase inhibitors (imatinib (<b>27</b>, Brc-Abl tyrosine kinase inhibitor), AT7519 (<b>29</b>, pan-CDK inhibitor), palbociclib (<b>31</b>, selective CDK4/6 inhibitor), and ribociclib (<b>33</b>, selective CDK4/6 inhibitor)), PDE5 inhibitor vardenafil (<b>35</b>), and a selective estrogen receptor degrader fulvestrant (<b>37</b>) were used in the study. The selection was driven mainly by synthetic accessibility of the target compounds, a general interest in kinase inhibitors, and the ability to determine the biological activities of each matched molecular pair. After successful synthesis of the corresponding sulfoximine analogues, Lücking and co-workers investigated the following in vitro properties: biological activity, aqueous solubility, log <i>D</i>, metabolic stability, permeability (including efflux ratio), and RO5 analysis (molecular weight, topological polar surface area, and number of hydrogen-bond donors/acceptors).<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(52−54)</a> A detailed overview of the data is shown in Table 2, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>. No general trend was detected in in vitro potency. Compounds <b>35</b> (IC<sub>50 (PDE5)</sub> (<b>35</b>) = 0.029 nM vs IC<sub>50 (PDE5)</sub> (<b>36</b>) = 0.025 nM) and <b>37</b> (IC<sub>50 (ESR1 WT)</sub> (<b>37</b>) = 2.0 nM vs IC<sub>50 (ESR1 WT)</sub> (<b>38</b>) = 1.8 nM) were equipotent to their sulfoximine counterparts. The biological activities of the sulfoximine analogues <b>28</b>, <b>30</b>, and <b>32</b> remained in the nanomolar range; however, a general drop in the activity of the kinase inhibitors was observed. In all cases, the sulfoximine groups were expected to bind at the entry of the binding pocket; however, the selectivity profile of the compounds was modulated due to unknown factors. With the exception of the fulvestrant analogue <b>38</b>, the introduction of a sulfoximine moiety had beneficial effects on metabolic stability. This effect was the most prominent in the case of compound <b>30</b>, which showed a significantly lower blood clearance in rat hepatocytes (Cl<sub>b</sub> (<b>30</b>) = 0.06 L h<sup>–1</sup> kg<sup>–1</sup> vs Cl<sub>b</sub> (<b>29</b>) = 1.76 L h<sup>–1</sup> kg<sup>–1</sup>) and human liver microsomes (Cl<sub>b</sub> (<b>30</b>) = 0.06 L h<sup>–1</sup> kg<sup>–1</sup> vs Cl<sub>b</sub> (<b>29</b>) = 0.24 L h<sup>–1</sup> kg<sup>–1</sup>) compared to that of the parent compound <b>29</b>. These results suggest that unfavorable clearance may be modified by the introduction of a sulfoximine group. In the case of lipophilicity, the log <i>D</i> values were similar to that of the corresponding parent compounds for analogues <b>28</b>, <b>30</b>, <b>32</b>, and <b>34</b>. For <b>36</b> and <b>38</b>, the log <i>D</i> values were significantly decreased compared to that of the parent compounds. Improved aqueous solubility was expected since it is associated with decreased lipophilicity. Surprisingly, a decrease in aqueous solubility (at pH = 6.5) was observed in the case of sulfoximine analogues <b>30</b>, <b>34</b>, and <b>36</b>. Compounds <b>28</b> and <b>32</b> had similar solubility to that of the parent compounds. However, it is unclear whether lowered aqueous solubilities of <b>30</b>, <b>34</b>, and <b>36</b> were due to the introduction of the sulfoximine group or to the solid state of the compounds. Excluding <b>30</b>, all analogues had decreased permeability and increased efflux. This effect was the most pronounced in the case of sulfoximine analogue of vardenafil (<i>P</i><sub>app A→B</sub> (<b>35</b>) = 206 × 10<sup>–6</sup> cm/s vs <i>P</i><sub>app A→B</sub> (<b>36</b>) = 0.71 × 10<sup>–6</sup> cm/s; efflux ratio (<b>35</b>) = 0.87 vs efflux ratio (<b>36</b>) = 288). Some compounds violated drug-like properties, such as TPSA (see Table 3, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>); however, the authors concluded that permeability properties may be associated with sulfoximines and should therefore be evaluated during the early stages of drug discovery.<a onclick="showRef(event, 'ref52 ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54 ref55 ref56">(52−56)</a><i>N</i>-Methylation was proposed to circumvent the permeability issues.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of matched molecular pairs <b>27</b>–<b>38</b> investigated by Sirvent and Lücking.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2010, Arvidsson and co-workers investigated whether sulfonimidamides may serve as bioisosteres of sulfonamides. Begacestat (<b>39</b>) and GSI-136 (<b>41</b>), two known γ-secretase inhibitors developed for the treatment of Alzheimer’s disease (AD), were selected for this study (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59">(57−59)</a> Biological activities and ADME-related parameters of each molecular pair were investigated (see Tables 3 and 4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of matched molecular pairs <b>39</b>–<b>44</b> investigated in several studies.<a onclick="showRef(event, 'ref58 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref60">(58,60)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate the abilities of sulfonimidamides as sulfonamide bioisosteres, the potency of each matched molecular pair in γ-secretase and notch inhibition assays was investigated. Due to the additional stereogenic center at the sulfur atom, both sulfonimidamides <b>40</b> and <b>42</b> have two diastereoisomers. HPLC separation was performed to investigate the influence of their stereochemistry on biological activity. For an unknown reason, one of the diastereoisomers of <b>40</b> was found to rapidly epimerize after isolation. Thus, the isolated 1:1 mixture of the epimers was evaluated. Epimerization of sulfonimidamides does not generally occur, since the two diastereoisomers of <b>42</b> were found to be stable toward epimerization under the in vitro and in vivo conditions. A decrease in activity in vitro (in γ-secretase inhibition assay and in γ-secretase-mediated notch processing) by approximately one log unit was detected for the sulfonimidamide analogues compared to the potency of the corresponding sulfonamide counterparts. Nonetheless, the sulfonimidamide analogues remained highly active, showing the double-digit nanomolar IC<sub>50</sub> values of γ-secretase inhibition. Interestingly, the selectivity index (ratio of IC<sub>50</sub> (Notch)/IC<sub>50</sub> (Aβ1–42)) was found to be comparable between the compounds. A decrease in the activity may be explained by a decrease in lipophilicity (log <i>D</i>) of the investigated sulfonimidamide analogues (by approximately one log unit), since lipophilicity is a major driver of potency against intramembrane proteases, such as γ-secretase and notch. The activity of the diastereoisomeric mixture of <b>40</b> was different from that of the stable diastereoisomer of <b>42</b>, suggesting a possible advantage of the chirality of sulfonimidamides as a means for fine-tuning the potency and/or selectivity. However, the impact of chirality cannot be assessed in this specific case due to the limited number of investigated diastereoisomers.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Then, ADME-related properties of the matched molecular pairs were investigated. Lipophilicity is an important property in drug discovery due to its influence on a number of major parameters, such as metabolic stability, plasma protein binding (PPB), and solubility.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> A decrease in log <i>D</i> of sulfonimidamides was associated with an increase in solubility (especially in the case of sulfonimidamide <b>42</b>) and a decrease in plasma protein binding (see Table 4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Surprisingly, permeability properties (in Caco-2 assay) of sulfonimidamides <b>40</b> and <b>42</b> were comparable to those of the parent counterparts; however, the hydrogen-bond interaction was inverted (from hydrogen-bond acceptor to hydrogen-bond donor). It has been shown previously that the efflux ratio of sulfonimidamides <b>40</b> and <b>42</b> is slightly higher than that of the parent sulfonamides, which is less favorable for drugs acting on the CNS (such as γ-secretase inhibitors). Additionally, slight differences in in vitro metabolic stability were observed (in human liver microsomes and hepatocytes); however, properties of both sulfonimidamide analogues were overall improved.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">In 2016, Bolm and co-workers investigated the sulfonimidamide analogue <b>44</b> of tasisulam (<b>43</b>).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Compound <b>43</b> is an acylsulfonamide-based anticancer agent currently under investigation for the treatment of various human cancers. The compound has a unique dual mechanism of action, which involves antiangiogenic effects and mitotic inhibition.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><b>43</b> has high potency against several human cancer cell lines and high hematological toxicity due to low clearance that leads to drug accumulation, high-affinity albumin binding, and rapid and extensive metabolism of free <b>43</b>.<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62−64)</a> The sulfonimidamide analogue <b>44</b> was investigated to overcome the toxicity issues of <b>43</b> while maintaining its potency. Compounds <b>43</b> and <b>44</b> were evaluated in cell proliferation assays in two melanoma cell lines (SKMel23 and A375). A comparable reduction in cell proliferation in a time- and dose-dependent manner was observed (reduction in cell proliferation down to 25% by <b>43</b> and down to 40% by <b>44</b> in A375 cell line after 72 h at 25 μM concentration). Thus, it was shown that sulfonimidamides may serve as sulfonamide bioisosteres with regard to the in vitro potency. No additional data on the anticipated reduction in toxicity of <b>43</b> were revealed. Thus, additional preclinical studies will be needed to evaluate the effect of the sulfonimidamide moiety on the improvement of the safety profile.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">In summary, the studies described above have rationally explored sulfoximines and sulfonimidamides as potential bioisosteres of sulfones, sulfonamides, or amines and investigated the impact on the potencies and properties of these analogues. These new functional groups were shown to be suitable for the medicinal chemist’s toolbox, especially for fine-tuning of drug-like properties (e.g., solubility, permeability, and plasma protein binding). Furthermore, the gap in knowledge can be narrowed by these data, which may lead to a more targeted use of sulfoximines and sulfonimidamides as functional groups in medicinal chemistry. However, these studies are not general guidelines due to the limited number of investigated analogues and limited selection of the classes of compounds or biological targets. Nonetheless, these new results demonstrate that sulfoximines and sulfonimidamides deserve increased attention in small molecule drug discovery.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">4.  Sulfoximines as a Novel Lead Structure in Medicinal Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.1.  Antineoplastic Agents</h3><div class="NLM_p">Cancer remains one of the leading causes of death in the world.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Great progress in anticancer therapies was achieved within the past decades; however, the variability of the forms of cancer and the development of resistances jeopardize the treatments. Therefore, there is an urgent need to develop novel antineoplastic agents. An increased understanding of cancer pathophysiology and discovery of novel molecular targets led to the discovery of promising antineoplastic agents, some of which contain a sulfoximine moiety.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">4.1.1.  CDK Inhibitors</h4><div class="NLM_p">Cyclin-dependent kinases (CDKs) belong to the family of serine/threonine kinases. Physiological functions of CDKs depend on the formation of the heterodimeric complexes with regulatory proteins, cyclins, through specific interactions. These complexes are the critical regulators of cellular processes.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> CDKs are divided into cell cycle CDKs and transcriptional CDKs with a total of 21 known CDK isoforms.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Inhibition of the CDK activity results in dysregulation of the cell cycle checkpoints and an increase in the expression of antiapoptotic proteins linked to the molecular pathology of cancer. Thus, CDKs have been considered promising targets for anticancer agents. Since the 1990s, several low molecular weight inhibitors of CDKs, such as flavopiridol and (<i>R</i>)-roscovitine, have entered clinical trials but have failed to receive approval due to toxicity issues or moderate selectivity indices.<a onclick="showRef(event, 'ref69 ref70 ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71 ref72 ref73">(69−73)</a> As a consequence, medicinal chemists focused their attention on the identification of novel CDK inhibitors with an enhanced selectivity toward specific isoforms of the CDK family.</div><div class="NLM_p">Researchers at Bayer identified ZK-304709 (<b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), a potent multitargeted inhibitor of CDK and vascular endothelial growth factor receptor (VEGF-R). Compound <b>45</b> blocks tumor cell proliferation and induces apoptosis by inhibition of the cell cycle progression and tumor-induced angiogenesis (detailed IC<sub>50</sub> values are listed in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Compound <b>45</b> was investigated in phase I clinical trials but was discontinued due to limited absorption at the oral doses above 90 mg/kg and high interpatient variability of the exposure. The unfavorable pharmacokinetic profile of the compound was assumed to be caused by low aqueous solubility (8 μg/mL at pH = 7.4) and the ensuing need for administration of high doses. Additionally, carbonic anhydrase II (CA-II) was found to be an off-target of <b>45</b> (IC<sub>50</sub> (CA-II) = 514 nM); inhibition of CA-II was suggested to be mediated by the <i>N</i>-unsubstituted arenesulfonamide moiety of <b>45</b> and led to the accumulation of the compound in erythrocytes.<a onclick="showRef(event, 'ref74 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76">(74−76)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Chemical structures and biological data of some pan-CDK inhibitors <b>45</b>–<b>48</b>. (B) Chemical structures and biological data of some CDK9-selective inhibitors <b>49</b>–<b>53</b>.<a onclick="showRef(event, 'ref15 ref74 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref15 ref74 ref77 ref78">(15,74,77,78)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Thus, <b>45</b> served as a starting point for further studies focusing primarily on the following parameters: (i) improvement of CDK inhibitory properties to decrease the dose, (ii) increase in the aqueous solubility, and (iii) elimination of inhibition of carbonic anhydrase activity as an off-target effect. To improve the in vitro activity of <b>45</b>, the <span class="smallcaps smallerCapital">d</span>-alaninol side chain was initially investigated. An analogue bearing a (2<i>R</i>,3<i>R</i>)-butane-2,3-diol side chain was found to be significantly more active in vitro (IC<sub>50</sub> (CDK2/CycE) = 9 nM, IC<sub>50</sub> (CDK1/CycB) = 4 nM). Furthermore, several heteroaromatic analogues and substituted phenylsulfonamides were investigated and determined to have high CDK inhibition and strong antiproliferative activity in vitro. However, these potent analogues suffered from low in vivo activity or poor metabolic stability. The undesired inhibition of carbonic anhydrase was addressed by rational design. Since <i>N</i>-unsubstituted arenesulfonamides are the known inhibitors of CA-II, <i>N</i>-substituted sulfonamides were investigated. In the case of an <i>N</i>-methyl sulfonamide analogue, the introduction of a simple methyl group was sufficient to eliminate the CA-II off-target activity, whereas the CDK and VEGF-R inhibition was maintained. The in vitro ADME data (e.g., metabolic stability in human and rat liver microsomes) were promising; however, the <i>N</i>-methyl sulfonamide analogue was rapidly demethylated to its <i>N</i>-unsubstituted sulfonamide counterpart in mice (within 2 h after oral administration) restoring CA-II inhibitory properties. Thus, the development of <i>N</i>-substituted sulfonamides was discontinued. Exchanging of sulfonamide by a sulfoximine moiety was suggested to eliminate the undesired CA affinity. Compound <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) had single-digit nanomolar CDK inhibition (IC<sub>50</sub> (CDK2/CycE) = 2 nM, IC<sub>50</sub> (CDK1/CycB) = 3 nM, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and highly potent antiproliferative activity against MCF7 cells (IC<sub>50</sub> = 44 nM) as a single enantiomer (absolute configuration was not determined), while lacking CA-II inhibition (IC<sub>50</sub> > 10 μM). These results clearly emphasize the properties of sulfoximines as sulfonamide isosteres. Since <b>46</b> was also shown to be potent in vivo and had promising PK/PD properties, extensive lead optimization studies were performed, resulting in the identification of BAY-1000394 (<b>47</b>, subsequently named roniciclib, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a low nanomolar pan-CDK inhibitor (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Compound <b>47</b> was found to have superior pharmacological properties compared with those of the parent compound <b>45</b>. In addition to the absence of CA-II off-target activity, the aqueous solubility of <b>47</b> was approximately 22-fold higher than that of <b>45</b> (182 mg L<sup>–1</sup> for <b>47</b> and 8 mg L<sup>–1</sup> for <b>45</b>, respectively). Additional evaluation in the xenograft models revealed potent antitumor efficacy with the required dose of <b>47</b> being 50-fold lower than that of <b>45</b>. The sulfone analogue <b>48</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) of <b>47</b> was also a potent pan-CDK inhibitor (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) that did not inhibit CA-II. Compound <b>48</b> had 7-fold lower aqueous solubility, lower efficacy in a xenograft model, and a moderate toxicity profile compared with the corresponding characteristics of <b>47</b> (a detailed overview can be found in Table 5, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Therefore, development of <b>48</b> was discontinued.<a onclick="showRef(event, 'ref77 ref79'); return false;" href="javascript:void(0);" class="ref ref77 ref79">(77,79)</a></div><div class="NLM_p">Compound <b>47</b> was the first sulfoximine to be selected for investigation in clinical trials in patients with advanced solid tumors due to its promising antiproliferative activity in vitro and in vivo and its superiority over the parent compound <b>45</b>.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a> Preliminary safety and efficacy data from phase II clinical trials demonstrated an unfavorable benefit/risk balance for patients receiving <b>47</b>; therefore, further clinical development of this compound was discontinued.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">After the development of pan-CDK inhibitors was discontinued, Bayer focused their efforts on the identification of selective CDK inhibitors. CDK9 heterodimer is pivotal to transcription of short-lived antiapoptotic survival proteins and oncogenes (e.g., MYC and MCL-1). Therefore, inhibition of the CDK9 heterodimer represents another promising mechanism of action for novel antineoplastic agents.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a></div><div class="NLM_p">BAY-958 (<b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) had promising in vitro activity (IC<sub>50</sub> (CDK9) = 11 nM) and selectivity (selectivity index over other CDKs > 90). Compound <b>49</b> also had acceptable antiproliferative activity in vitro (HeLa cells IC<sub>50</sub> = 1000 nM; MOLM-13 cells IC<sub>50</sub> = 280 nM) and metabolic stability (in rat hepatocytes and rat liver microsomes). Therefore, <b>49</b> was selected as a lead structure for the development of a selective CDK9 inhibitor. However, <b>49</b> had unfavorable physicochemical and DMPK properties, such as low aqueous solubility, moderate permeability, and high efflux, resulting in low oral bioavailability in rats (detailed values are shown in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Structural modifications of the 2-methoxy-4-fluorophenyl moiety did not improve the properties of the compound. The <i>ortho</i>-alkoxy substituent was found to be crucial for CDK9 inhibitory potency/selectivity, and several other substituents, except for 4-fluoro (e.g., 4-H or 4-Cl), decreased the metabolic stability and the in vitro and/or in vivo activity. Docking experiments indicated a pivotal interaction of the triazine core and the aniline NH with the hinge region of CDK9; thus, this moiety was not further investigated. However, concerns about the use of the benzyl sulfonamide group were raised due to the polarity, ability of the sulfonamide group to participate in multiple hydrogen-bond interactions, and the potential instability of the benzylic position. Initially, the sulfonamide moiety was replaced by a methylsulfone. The in vitro and in vivo properties of the sulfone analogue were comparable to those of <b>49</b> (IC<sub>50</sub> (CDK9) = 24 nM, selectivity index over other CDKs > 67, and IC<sub>50</sub> (HeLa) = 1500 nM), even though the hydrogen-bonding ability was altered (compared to that of <b>49</b>). However, the aqueous solubility of the sulfone analogue was even lower than that of <b>49</b>. To remove the potentially unstable benzylic position, elimination, methylation, and fluorination of the benzylic methylene group as well as inclusion into an annulated ring system were investigated and led to analogues exhibiting a significant decrease in CDK9 inhibition and/or selectivity toward other CDKs (e.g., CDK2).</div><div class="NLM_p">Considering the results obtained from the pan-CDK inhibitor project (as described above), the sulfonamide group was replaced by a sulfoximine moiety. BAY-1143572 (<b>50</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was found to be highly potent (IC<sub>50</sub> (CDK9) = 13 nM, IC<sub>50</sub> (HeLa) = 1100 nM) and selective (e.g., selectivity index over CDK2 = 100). The corresponding (<i>S</i>)-enantiomer was slightly less potent. Furthermore, <b>50</b> displayed a higher aqueous solubility (479 mg L<sup>–1</sup>, 43-fold), improved Caco-2 permeability, and a decreased efflux ratio compared to those of the lead compound <b>49</b>. Additionally, the compound demonstrated very promising in vivo PK data and potency (detailed values are shown in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref15 ref78'); return false;" href="javascript:void(0);" class="ref ref15 ref78">(15,78)</a></div><div class="NLM_p">Compound <b>50</b> was efficient in the human xenograft tumor models of acute myeloid leukemia in mice and rats administered once daily or using intermittent dosing schedules. Considering the excellent properties of <b>50</b>, the compound was selected as a clinical candidate and entered phase I clinical trials for the treatment of advanced cancer and leukemia (<b>50</b> was named atuveciclib).<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Daily oral administration of <b>50</b> induced neutropenia; thus, phase I clinical trials were terminated, and the development of the compound was discontinued.</div><div class="NLM_p">Due to the side effects of <b>50</b> observed after oral administration, the identification of a selective CDK9 inhibitor suitable for the intravenous application was pursued. The follow-up project started from sulfoximine BAY-332 (<b>51</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a potent (IC<sub>50</sub> (CDK9) = 37 nM) and selective (selectivity index over CDK2 = 107) CDK9 inhibitor with only moderate aqueous solubility (<i>S</i><sub>W</sub> (pH = 6.5) = 24 mg L<sup>–1</sup>, additional PK values are shown in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>), which is a prerequisite for intravenous application. Despite the scarcity of the literature on this class of sulfoximine compounds, certain structure–activity relationships pointed to the investigation of the corresponding sulfondiimine analogue <b>52</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) to increase the aqueous solubility. Fortunately, <b>52</b> had a 4-fold higher aqueous solubility (<i>S</i><sub>W</sub> (pH = 6.5) = 91 mg L<sup>–1</sup>) compared to that of the parent <b>51</b>; however, CDK9 inhibition by <b>52</b> was 3-fold weaker, and the selectivity was maintained. Furthermore, <b>52</b> displayed a promising metabolic stability and PK data (detailed values are shown in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>); however, the difficulty of synthesizing a sufficient amount of the compound hampered its development. Thus, further scaffold modification led to the slightly modified sulfoximine BAY-1251152 (<b>53</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a very promising CDK9 inhibitor (IC<sub>50</sub> (CDK9) = 4 nM) with significantly improved selectivity (selectivity index over CDK2 = 730). Compound <b>53</b> was suitable for intravenous administration once weekly due to high aqueous solubility and low predicted therapeutic dose, and antineoplastic efficacy of <b>53</b> was validated in various xenograft models (detailed PK values are shown in Table 6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref15 ref88'); return false;" href="javascript:void(0);" class="ref ref15 ref88">(15,88)</a> Thus, <b>53</b> was selected as a clinical candidate for the treatment of solid tumors, aggressive non-Hodgkin’s lymphoma, and hematologic neoplasms. The compound entered phase I clinical trials but was discontinued at the end of 2019.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a></div><div class="NLM_p last">Development of pan-CDK inhibitors and selective CDK9 inhibitors demonstrated that replacement of a functional group (e.g., sulfonamide) by a sulfoximine moiety leads to potent and promising inhibitors with improved activity, solubility, and PK properties, thus clearly emphasizing the impact of the sulfoximine moiety. However, almost all sulfoximine-based CDK inhibitors that entered clinical trials have been discontinued. Since several selective CDK4/6 inhibitors have already been approved (palbociclib, ribociclib, and abemaciclib), investigations to lower the side effects of the sulfoximine-based inhibitors would be of high interest.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">4.1.2.  Ataxia Telangiectasia and Rad3-Related (ATR) Kinase Inhibitors</h4><div class="NLM_p">Environmental and endogenous triggers may cause serious DNA damage events. Consequently, human cells are highly dependent on the DNA damage response (DDR). Genome integrity is regulated by a network of biological pathways that result in the resolution of the DNA damage or in apoptotic cell death depending on the nature and severity of the lesions.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Disruption of the DNA repair pathways constrains tumor cells to rely on collateral repair pathways to maintain genome stability. Apoptosis is the ultimate consequence of DNA damage; hence, the concept of DDR inhibition evolved as a novel strategy for cancer therapy.<a onclick="showRef(event, 'ref91 ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref91 ref93 ref94">(91,93,94)</a> Ataxia telangiectasia and rad3-related (ATR) kinase is a serine/threonine-protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of proteins and plays a pivotal role in the regulation of the DNA replication stress response and DNA-damage-activated checkpoints.<a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95−97)</a> Since ATR is activated in response to persistent single-stranded DNA, which is a common intermediate formed during the DNA damage detection and repair, inhibition of the repair pathways mediated by ATR may result in increased replication stress and may thus represent a promising target for chemotherapy.</div><div class="NLM_p">Researchers at AstraZeneca identified a series of sulfonylmethyl morpholinopyrimidine-based ATR inhibitors. Within this series, AZ20 (<b>54</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was found to be highly potent in the ATR kinase assay (IC<sub>50</sub> = 5 nM) and ATR cell (pChk1) assay in HT29 tumor cells (IC<sub>50</sub> = 61 nM). The compound had promising kinase selectivity; however, <b>54</b> was not considered a suitable candidate for clinical trials because of its time-dependent inhibition of CYP3A4 (50% at 10 μM) and low aqueous solubility (10 μM at pH = 7.4) (detailed properties are shown in Table 7, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Therefore, further optimization of the compound was required.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures and key properties of ATR inhibitors AZ20 (<b>54</b>) and AZD6738 (<b>55</b>) and its metabolites <b>56</b> and <b>57</b>.<a onclick="showRef(event, 'ref98 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref98 ref99 ref100">(98−100)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since variations at the morpholinopyrimidine pharmacophore were known to decrease the activity and/or selectivity, replacement of the indole core structure and the (methylsulfonyl)cyclopropyl moiety was proposed. Exchanging the indole moiety by an unsubstituted 7-azaindole moiety gave an analogue comparable to the parent <b>54</b> in terms of ATR potency and aqueous solubility; however, the time-dependent inhibition of CYP3A4 was decreased (detailed values are shown in Table 7, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Other analogues bearing 6-azaindole or 2-aminobenzimidazole scaffolds displayed improved aqueous solubility and/or ATR potency; however, other properties of the analogues were suboptimal, such as their kinase selectivity or hERG activity. To improve the metabolic stability, substituted (aza)indole and benzimidazole analogues were investigated, and similar results were obtained. The sulfone moiety was replaced by a sulfoxide group considering several interactions (e.g., methylsulfone to methylsulfone contact, hydrogen bonding between indole N<i>H</i> and sulfone oxygen) of the methylsulfone moiety in the solid state of <b>54</b>, which may be associated with high melting points and low aqueous solubility. The resulting analogues, (<i>R</i>)-<b>56</b> and (<i>S</i>)-<b>56</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), turned out to be similar to <b>56</b> in terms of ATR potency; however, their aqueous solubility was significantly improved (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Since sulfoxides are sensitive to oxidation in vivo, further development of both compounds was discontinued.</div><div class="NLM_p">Subsequently, the sulfone moiety was replaced by a sulfoximine moiety. AZD6738 (<b>55</b>) has the (<i>R</i>)-configuration at the chiral sulfoximine moiety and was found to be highly active in the ATR kinase (IC<sub>50</sub> = 4 nM) and ATR cell (pChk1) assays using HT29 tumor cells (IC<sub>50</sub> = 74 nM). The corresponding (<i>S</i>)-enantiomer was found to be less active. <b>55</b> had reduced lipophilicity (<b>55</b> log <i>D</i><sub>7.4</sub> = 1.9; <b>54</b> log <i>D</i><sub>7.4</sub> = 2.5) and 66-fold higher aqueous solubility (<i>S</i><sub>W</sub> (pH 7.4) = 661 μM) compared to those of <b>54</b>. A reduction in hERG activity (IC<sub>50</sub> = 166 μM) and elimination of the time-dependent inhibition of the five major human P450 isoforms were also observed for <b>55</b> (detailed values are shown in Table 7, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). Further investigation of the compound <b>55</b> revealed that it was highly selective over other kinases (less than 50% inhibition for more than 400 kinases at a concentration of 1 μM). Additionally, <b>55</b> had high metabolic stability (in human hepatocytes) and suitable permeability (in Caco-2 cells). In vivo experiments in the xenografted mouse models (human LoVo colorectal adenocarcinoma) clearly demonstrated the efficacy of the compound, since promising tumor growth inhibition was observed upon oral administration once or twice daily at the moderate doses (12.5/25 mg/kg). Compound <b>55</b> was selected as a clinical candidate since all drawbacks (e.g., time-dependent CYP inhibition and low aqueous solubility) of the parent lead have been eliminated, and the PK data were favorable (see Table 8, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> Compound <b>55</b> is currently investigated in multiple phase I/II clinical trials as monotherapy and in combination with other antineoplastic agents.<a onclick="showRef(event, 'ref101 ref102 ref103 ref104 ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103 ref104 ref105 ref106 ref107">(101−107)</a></div><div class="NLM_p">In 2017, Bolm and co-workers published a study describing sulfoximine analogues of the sulfone VE-821, a known ATR inhibitor.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The activities of these analogues were comparable to that of VE-821. However, the study was hampered by high concentrations (in the micromolar range) used in their assay, since other ATR inhibitors had IC<sub>50</sub> values in the single-digit nanomolar range.</div><div class="NLM_p">The attempts to incorporate the sulfoximine moiety in the bioactive molecules have increased over the past years; however, the metabolism data for several sulfoximines that entered clinical trials are not currently available (an excellent review on general conversion and degradation pathways of sulfoximines was published by Bolm and co-workers).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Jones et al. (AstraZeneca) performed an extensive study to characterize the in vitro metabolism of <b>55</b>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> After incubation of <b>55</b> in human hepatic S9 cytosol and microsome fraction, sulfoxide <b>56</b> and sulfone <b>57</b> were identified as metabolites (see <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The formation of both metabolites occurred only in the presence of NADPH, indicating that the deimination was an oxidative process mediated by the enzymes in the microsomal fraction, such as P450 family members or flavin-containing monooxygenases. These results were unexpected since deimination processes are usually reductive reactions. Therefore, the rate of metabolism was studied in a panel of 11 recombinant members of the P450 family and three recombinant members of the flavin-containing monooxygenases. The study revealed that the sulfoxide metabolite <b>56</b> was formed by CYP2C8 and CYP2J2; however, the latter was assumed to be a minor contributor to the metabolism of <b>55</b> due to the relatively low level of expression of this enzyme in human liver tissue. Other members of the P450 family (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) and flavin-containing monooxygenases (FMO3, FMO5, and NADPH P450-reductase) did not metabolize <b>55</b>. The sulfone metabolite <b>57</b> was assumed to be formed by deamination mediated by CYP2J2/CYP2C8 and subsequent reaction with CYP3A4/CYP3A5. These data are consistent with a possibility of oxidative deimination of <b>55</b>. The detailed mechanism remains unclear; however, the authors proposed an <i>N</i>-oxidation followed by a second oxidation to deliver the sulfoxide <b>56</b> and nitrous acid (<b>58</b>). The latter is assumed to induce cellular damage due to the formation of reactive <i>N</i>-nitroso species. Both metabolites were active as ATR inhibitors in vitro; however, their IC<sub>50</sub> values were slightly increased (<2-fold compared to that of <b>55</b>, see <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). A significantly lower aqueous solubility of both metabolites was observed (3-fold and 83-fold for the sulfoxide metabolite <b>56</b> and the sulfone metabolite <b>57</b>, respectively).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0025.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Proposed Mechanism for the Oxidative Deimination of AZD6738 (<b>55</b>) (Stereochemistry Not Shown)<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It was shown that <b>55</b> undergoes oxidative deimination to the corresponding sulfoxide (mediated by CYP2C8) and subsequent oxidation to the sulfone (via CYP3A). The metabolic pathway was rather unexpected; however, CYP2C8 is increasingly recognized as a key human drug-metabolizing enzyme and may therefore be added to the standard human P450 isoform panel. The metabolism of <b>55</b> does not seem to influence the ATR inhibitory potency; however, a decrease in aqueous solubility and the formation of nitrous acid (<b>58</b>) may be the factors responsible for idiosyncratic drug toxicity. Currently, it remains unclear whether this metabolic pathway is unique for <b>55</b> or is related to its sulfoximine moiety.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">4.1.3.  <span class="smallcaps smallerCapital">l</span>-Asparagine Synthetase Inhibitors</h4><div class="NLM_p">Acute lymphoblastic leukemia (ALL) is one of the most common forms of pediatric cancer. ALL is characterized by the development of large numbers of immature lymphocytes.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> ALL is acute leukemia that rapidly progresses and is typically fatal within several weeks or months if left untreated. Substantial progress in the clinical treatment of ALL has been achieved.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Most of the current treatment regimens target the enzyme <span class="smallcaps smallerCapital">l</span>-asparagine amidohydrolase (ASNase), which catalyzes the hydrolysis of <span class="smallcaps smallerCapital">l</span>-asparagine to yield <span class="smallcaps smallerCapital">l</span>-aspartate and ammonia. Significant drawbacks of ASNase are (i) a narrow therapeutic range with up to two-thirds of patients exhibiting a hypersensitive immune response and (ii) occurrence of remission (in approximately 10% of all cases) due to the emergence of ASNase-resistant leukemic blasts.<a onclick="showRef(event, 'ref113 ref114 ref115 ref116 ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref113 ref114 ref115 ref116 ref117 ref118">(113−118)</a> The de novo biosynthesis of <span class="smallcaps smallerCapital">l</span>-asparagine proceeds via a tetrahedral transition state (ammonia addition to the β-aspartyl-AMP intermediate); thus, medicinal chemists investigated stable transition state analogues as <span class="smallcaps smallerCapital">l</span>-asparagine synthase (ASNS) inhibitors.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">Sulfoximines are tetrahedrally hybridized and may thus serve as stable transition state analogues. Hiratake and co-workers investigated potential ASNS inhibitors and found that sulfoximine <b>59</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) is a highly potent, slow-binding ASNS inhibitor (<i>K</i><sub>i</sub> = 24 nM). The compound had a cytostatic effect against the ASNase-resistant leukemia cell line MOLT-4R. However, the antiproliferative effect was observed only at high concentrations (>100 μM) of <b>59</b> due to the charged state of the molecule. The charged functional groups are known to be important for recognition while interfering with cell permeability. Thus, Hiratake and co-workers performed additional studies to improve cell permeability and metabolic stability. The carboxylate moiety was removed because of the moderate cell permeability of the parent compound <b>59</b>. The resulting sulfoximine <b>60</b> was found to be approximately 4-fold more potent (<i>K</i><sub>i</sub> = 8 nM). The results of testing of sulfoximine <b>61</b> (<i>K</i><sub>i</sub> = 840 nM) indicated that the amino moiety was crucial for ASNS inhibitory activity and that the carboxylate moiety was not important. X-ray structure analysis confirmed that the difference in the binding affinity is due to the crucial interaction of the amino moiety with Glu348 of the binding site, which plays a pivotal role in the formation of the β-aspartyl-AMP intermediate. A 10-fold lower concentration of sulfoximine <b>60</b> was required to suppress the proliferation of MOLT-4R cells compared to that observed in the case of <b>59</b>. Apparently, the improved activity in the cellular MOLT-4R assay was a result of the absence of a net charge at cellular pH values.<a onclick="showRef(event, 'ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121">(119−121)</a> Further investigations are required (e.g., the influence of the stereochemistry of the sulfoximine moiety or PK/PD studies); however, the results reported by Hiratake and co-workers provide essential evidence that ASNS represents a druggable target for the treatment of ALL. The crystal structure of the sulfoximine <b>60</b> complex with recombinant human ASNS was recently solved, and thus, computer-aided drug design may support further development of ASNS inhibitors.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of sulfoximine-based ASNS inhibitors <b>59</b>–<b>61</b>.<a onclick="showRef(event, 'ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121">(119−121)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">4.1.4.  COX-2 Inhibitors</h4><div class="NLM_p">Cyclooxygenases (COX) are enzymes responsible for the formation of prostanoids (e.g., thromboxanes and prostaglandins) from arachidonic acid. Therefore, they are common targets for anti-inflammatory drugs. Two main isoforms of cyclooxygenases are known, COX-1 and COX-2. COX-1 is involved in the synthesis of prostaglandins and thromboxanes in various cells and tissues including gastrointestinal tract and circulating platelets. COX-2 plays a major role in prostaglandin biosynthesis in the inflammatory cells and in the central nervous system. Prostaglandin synthesis in these sites is pivotal for the development of inflammation and hyperalgesia.<a onclick="showRef(event, 'ref123 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125">(123−125)</a> Recently, several mechanistic and clinical studies indicated that COX-2 is involved in apoptosis resistance, angiogenesis, and tumor progression. Epidemiological data suggest that selective COX-2 inhibitors may prevent the development of cancers. COX-2 was found to be overexpressed in various cancers (e.g., colorectal, stomach, breast, prostate, bladder, and ovarian cancer), suggesting that COX-2 may serve as an attractive therapeutic target for the prevention and treatment of numerous forms of cancer.<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> Thus, medicinal chemists were refocusing the development of novel COX-2-selective compounds as antineoplastic agents.</div><div class="NLM_p">Evaluation of the enormous amount of data collected in the course of the development of COX-2 selective inhibitors (COXIBs, e.g., celecoxib (<b>62</b>) or rofecoxib (<b>63</b>), <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A) identified a clear SAR of the following moieties crucial for selective COX-2 inhibition: (i) a diaryl heterocycle with <i>cis</i>-stilbene character and (ii) a sulfonyl or sulfonamido group in the <i>para</i> position of one of the two aryl rings (exception: lumiracoxib, an arylalkanoic acid). Guided by the known SAR, Bolm and co-workers investigated sulfoximine analogues (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B) of rofecoxib (<b>63</b>) and DuP697 (<b>67</b>).<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> The <i>N</i>-methyl sulfoximine analogue (<b>65</b>) was identified as a nonselective inhibitor of COX-1 and COX-2 (at 10 μM). However, the free sulfoximine analogue (<b>64</b>) displayed certain COX-1/2 selectivity (no binding to COX-1 and 26% inhibition of COX-2 at 10 μM). Although both analogues were less potent than <b>63</b> (IC<sub>50</sub> (COX-2) = 156 nM), hERG activities of both analogues were investigated. Surprisingly, the free sulfoximine analogue <b>64</b> exhibited reduced hERG activity compared to that of the parent sulfone <b>63</b>.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> On the basis of the known structure and properties of sulfoxaflor (<b>12</b>, see Chapter 2) and a decrease in the hERG activity of compound <b>64</b>, Bolm and co-workers designed analogues of <b>67</b>, the prototype of all COXIBs, and <b>63</b>, which bears an <i>N</i>-cyano sulfoximine moiety. Compound <b>66</b> had significant COX-2 selectivity (inhibition of COX-1 and COX-2 by 1% and 48%, respectively, at 10 μM). However, compound <b>68</b>, a racemic mixture <i>N</i>-cyano sulfoximine analogue of <b>67</b>, was found to be a potent and moderately selective inhibitor of COX-2 (inhibition of COX-1 and COX-2 by 69% and 97%, respectively, at 10 μM). The pure enantiomers of compound <b>68</b> had profoundly different activities; (<i>R</i>)-<b>68</b> was shown to be a potent and selective COX-2 inhibitor (inhibition of COX-1 and COX-2 by 9% and 97%, respectively, at 10 μM), whereas (<i>S</i>)-<b>68</b> displayed rather weak COX-1 and COX-2 inhibition (by 8% and 28%, respectively, at 10 μM). The relationship between COX-2 inhibition and anticancer activity resulted in the submission of (<i>R</i>)-<b>68</b> for screening on a cell panel of the US National Cancer Institute (NCI) that included 60 cancer cell lines (e.g., leukemia, melanoma, and lung cancer cells). Compound (<i>R</i>)-<b>68</b> significantly affected the growth of several cancer cell lines in a single dose assay (10 μM) and in a full five-dose assay (concentrations from 10<sup>–4</sup> M to 10<sup>–8</sup> M).<a onclick="showRef(event, 'ref127 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref127 ref129 ref130">(127,129,130)</a> Additionally, (<i>R</i>)-<b>68</b> did not have any mutagenic potential in the Ames assay and showed only moderate cytotoxicity (cell viability assay of human keratinocyte cell line HaCaT), demonstrating the potential drug-likeness of the <i>N</i>-cyano sulfoximine moiety.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> At this point, it is unclear whether inhibition of cancer cell growth by (<i>R</i>)-<b>68</b> is linked to COX-2 inhibition; however, the results justify further development of this class of compounds.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structures of celecoxib (<b>62</b>) and rofecoxib (<b>63</b>). (B) Overview of sulfoximine-based COX-2 inhibitors <b>64</b>–<b>68</b>.<a onclick="showRef(event, 'ref128 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref128 ref129 ref130">(128−130)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2.  Anti-Infective Agents</h3><div class="NLM_p">Anti-infectives have significantly increased human life expectancy. However, multidrug resistance has become a serious problem since conventional anti-infectives are becoming increasingly ineffective, mainly due to their unbridled use. Despite the urgent need for new anti-infectives, only a few new clinical candidates have been developed in the past 30 years because the search for new drugs in this therapeutic area appears economically unattractive for the majority of pharmaceutical companies. However, substantial efforts of small biotech companies and academic institutions searching for anti-infective R&D resulted in the discovery of numerous novel anti-infective agents. The agents that contain a sulfoximine moiety in their structure will be described in this chapter.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.2.1.  Antimalarial Agents</h4><div class="NLM_p">Malaria affects the world’s poorest population of 3.3 billion people living in the areas with a higher risk of developing the disease. In 2017, the WHO (World Health Organization) reported an estimated number of 435 000 deaths and more than 219 million cases of malaria. Young children (61% of all malaria deaths) and pregnant women are particularly vulnerable to malaria.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Despite years of continuous efforts to eradicate malaria, the disease remains one of the major causes of mortality worldwide. The majority of the deadly malaria infections are caused by protozoan parasites <i>Plasmodium falciparum</i>, <i>P. vivax</i>, and, to a lesser extent, by <i>P. malariae</i> and <i>P. ovale</i>. The disease is predominant in Africa, and significant morbidity is also detected in South America and Asia.<a onclick="showRef(event, 'ref131 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref131 ref132 ref133">(131−133)</a> Currently, various control measures (e.g., insecticide-treated bed nets) and chemotherapy are the major means to fight malaria (cf. Table 9, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref134 ref135 ref136 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136 ref137 ref138">(134−138)</a> Combination therapy of two or more drugs with different modes of action, such as ACT (artemisinin-based combination therapy), is recommended by the WHO due to lack of drugs effective against all <i>Plasmodium</i> strains. Antimalarial dosing therapies are highly dependent on the geographic location of the infection, the major <i>Plasmodium</i> species, and the severity of the disease. The emergence of the drug-resistant strains of malaria jeopardizes the current treatment therapy. One of the most commonly used drugs, chloroquine, became ineffective due to rapidly increasing resistance. Newer chemotherapeutic agents, such as mefloquine or artemisinin, are facing similar resistance issues.<a onclick="showRef(event, 'ref131 ref139 ref140 ref141 ref142 ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref131 ref139 ref140 ref141 ref142 ref143 ref144 ref145">(131,139−145)</a> Therefore, novel compounds bearing different scaffolds, with a different mechanism of actions, are required to develop alternative treatment options for malaria.</div><div class="NLM_p">In 2014, Kinfe and co-workers reported carbohydrate-based thiochromans as potent antimalarial agents. Sulfone <b>69</b> emerged as a promising compound of this class with the IC<sub>50</sub> values of 0.3–0.4 μM against chloroquine-sensitive and chloroquine-resistant strains (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A).<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a> However, Kinfe and co-workers failed to improve the IC<sub>50</sub> to low nanomolar values for two main reasons: (i) lack of structural derivatization points and (ii) epimerization of the sugar anomeric center after derivatization at the α-carbon adjacent to the sulfone (C* in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, part A). To introduce another structural derivatization point, the sulfone was replaced by a sulfoximine moiety (compound <b>70,</b><a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A). The sulfoxide precursor of compound <b>70</b> could be separated, and thus, both epimers were evaluated in vitro (against a chloroquine-sensitive strain). Interestingly, sulfoximine <b>70a</b> was inactive, and the potency of its epimer <b>70b</b> was comparable to that of the parent sulfone <b>69</b> (IC<sub>50</sub> (<b>70b</b>) = 0.8 ± 0.3 μM); the compounds were nontoxic to HeLa cells at 20 μM concentration. The difference in the activity between the two epimers suggests the requirement of an H-bond acceptor on the <i>endo</i>-face of the thiochroman scaffold. To verify this hypothesis, the authors inverted the H-bond properties of <b>70a</b> (from donor to acceptor) by simple <i>N</i>-alkylation. As expected, alkylation resulted in compounds with improved activity. Simple <i>N</i>-methylation gave an analogue (IC<sub>50</sub> = 0.9 ± 0.4 μM) equipotent to the active epimer <b>70b</b>. However, longer alkyl chains were associated with a decrease in the antimalarial activity. This tendency may be attributed to increased hydrophobicity and steric hindrance. It should be noted that even the most active compounds of this series were approximately 40-fold less active than chloroquine (IC<sub>50</sub> = 0.019 μM). No data on activity against a chloroquine-resistant strain were presented; this type of data would be highly appreciated due to an increase in the cases of chloroquine resistance. This study emphasizes the potential of this class of compounds as a starting point for novel antimalarial agents and of the sulfoximine scaffold as a promising derivatization point with an added stereocenter.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Chemical structures and IC<sub>50</sub> values of the parent carbohydrate-based thiochroman <b>69</b> and its sulfoximine analogues <b>70a</b>/<b>b</b>. (B) chemical structure and IC<sub>50</sub> value of the most potent sulfoximine-triazole hybrid <b>71</b>.<a onclick="showRef(event, 'ref146 ref147 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref149 ref150">(146,147,149,150)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Over the past decade, a number of established antimalarial agents were “hybridized” with a triazole moiety to increase their potency and/or enhance their physicochemical properties.<a onclick="showRef(event, 'ref148 ref151 ref152 ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref148 ref151 ref152 ref153 ref154">(148,151−154)</a> Triazoles possess favorable properties, such as dipole character, H-bond donor/acceptor capabilities, and stability toward acidic and basic conditions.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The initial potency of this class of compounds was low; however, Kinfe and Belay investigated a series of the thiosemicarbazone–triazole hybrid compounds as antimalarial agents.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> The authors investigated a small series of sulfoximine-triazole hybrids against a chloroquine-sensitive strain based on the studies on sulfoximine-containing antimalarial agents. Compound <b>71</b> was the most active sulfoximine-triazole hybrid (IC<sub>50</sub> = 6.6 μM). The antimalarial activity was shown to be highly dependent on a long alkyl chain, since analogues with shorter alkyl chains (e.g., methyl or butyl) and precursors of <b>71</b> were inactive. Additionally, all investigated compounds were not cytotoxic against HeLa cells at 20 μM.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The phenyl residue or the triazole moiety was not examined; hence, the authors concluded that <b>71</b> may serve as a prototype for novel derivatives with improved antiplasmodial activities. Further investigations of the SAR, ADME profile, and in vivo potency of this class of compounds are needed to reach clinical trials.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.2.2.  Antibacterial Agents</h4><div class="NLM_p">Antibacterials had saved millions of lives and made possible various medical procedures, such as common surgeries, cancer treatments, and organ transplants. The period from the 1950s to 1970s was considered a golden age for the discovery of novel antibiotic classes.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> However, the rapid emergence of resistant bacteria jeopardizes the efficacy of antimicrobials.<a onclick="showRef(event, 'ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref158 ref159">(158,159)</a> Resistance mainly arises through one of the following four mechanisms: drug inactivation or modification (e.g., β-lactamases), alteration of target and/or binding site (e.g., alteration of penicillin-binding proteins), alteration of metabolic pathways (e.g., loss of requirement of <i>para</i>-aminobenzoic acid as a precursor for nucleic acids in bacteria), or reduced drug accumulation (e.g., efflux pumps).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> As a consequence, antibiotic resistance (ABR) leads to increased medical costs, prolonged hospital stays, and increased mortality. ABR has been accelerated by the overuse and misuse of these medications, a lack of new drug development by the pharmaceutical industry, and challenging regulatory requirements of antimicrobial R&D.<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> Thus, new antimicrobial treatments are desperately needed to help patients suffering from drug-resistant infections.</div><div class="NLM_p">In 2001, a patent by Pharmacia and Upjohn Company was filed describing oxazolidinone-based sulfoximines (<b>72</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A) as promising antibacterial agents. Many compounds were found to be active against a broad range of pathogens, including <i>S. aureus</i>, <i>E. faecium</i>, <i>S. pneumoniae</i>, <i>S. pyrogenes</i>, and <i>H. influenzae</i>. The determined minimum inhibitory concentrations (MICs) were within a range of 0.05–10 μg/mL against at least three different pathogens. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, all compounds were investigated as single enantiomers. This class of compounds was not further studied and never reached clinical trials despite promising antibacterial activities presumably due to the shifted prioritization of the projects in the course of the acquisition of Pharmacia and Upjohn Company by Pfizer in 2002.<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163,164)</a></div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0013.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Oxazolidinone-based sulfoximines (<b>72</b>) as antibacterial agents. (B) <i>N</i>-Trifluoromethylthiolated sulfoximines and sulfonimidamides (<b>73</b>–<b>79</b>) as antitubercular agents.<a onclick="showRef(event, 'ref163 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref163 ref165 ref166">(163,165,166)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In 2019, Arvidsson and co-workers reported a series of <i>N</i>-trifluoromethylthiolated sulfoximines and sulfonimidamides (<b>73</b>–<b>79</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B) with promising activity against <i>Mycobacterium tuberculosis</i> (Mtb), the causative agent of tuberculosis (TB), in which multidrug resistance is even more severe than that in antibiotic treatment of other infections.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B, the most potent compounds had MIC values of 4–8 μg/mL against the H<sub>37</sub>Rv Mtb strain. This antitubercular activity of the compounds is comparable with that of the current antitubercular drugs (ethambutol MIC = 1–4 μg/mL; meropenem MIC = 5–10 μg/mL). Furthermore, <b>73</b>, <b>75</b>, <b>76</b>, and <b>77</b> were found to be selective over Gram-positive/Gram-negative bacteria and over <i>Mycobacterium abscessus</i>, which is remarkable for these structurally simple compounds. Unfortunately, all compounds were shown to be cytotoxic in HepG2 cells with MIC values from 15 to 90 μg/mL. Considering the moderate activity of compounds <b>78</b> and <b>79</b> (MIC<sub>Mtb</sub> > 64 μg/mL) and lack of cytotoxicity (MIC<sub>HepG2</sub> > 200 μg/mL), it was assumed that antitubercular activities and cytotoxicity resulted from the presence of the <i>N</i>-trifluoromethylthiol moiety.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Nonetheless, these remarkable results justify further development of this class of compounds.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.3.  Antidiabetic Agents</h3><div class="NLM_p">Diabetes mellitus is a group of metabolic disorders characterized by high blood sugar levels over a prolonged period of time. As estimated in 2017, 425 million people are currently living with diabetes mellitus; approximately 90% of all cases are type 2 diabetes mellitus (T2DM). Data suggest that prevalence of T2DM will continue to rise and may exceed 592 million by 2035 with a 10.1% global prevalence due to environmental factors, such as obesity (BMI > 30), unhealthy nutrition, physical inactivity, stress, consequences of urbanization, and genetic factors; these factors are considered the main contributors to multiple pathophysiological disturbances responsible for impaired glucose homeostasis in T2DM.<a onclick="showRef(event, 'ref167 ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169">(167−169)</a> Currently, the management of T2DM includes patient education (loss of weight, dietary changes, and increase in sports activity), blood glucose monitoring, insulin injections, or antidiabetic therapy. Treatment with antidiabetic drugs is required to maintain normoglycaemia, which can prevent or reverse the microvascular complications.<a onclick="showRef(event, 'ref170 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref170 ref171 ref172">(170−172)</a> Various efforts to effectively manage diabetes have been implemented over multiple years; however, there is still a high unmet medical need for orally available, safe, and effective drugs.</div><div class="NLM_p">Dipeptidyl peptidase-4 (DPP-4) inhibitors (“gliptins”) are a widely used, safe, and efficacious class of oral hypoglycemic agents. Glucagon-like peptide-1 (GLP-1) is an intestinal hormone with potent insulinotropic and glucagonostatic effects. GLP-1 can normalize blood glucose levels in patients with T2DM; however, the native peptide is not therapeutically useful due to its inherent metabolic instability. DPP-4 is known to inactivate GLP-1 and gastric inhibitory peptide in vivo; DPP-4 inhibitors can thus increase the incretin levels (glucose-dependent insulinotropic polypeptide (GIP) and GLP-1). Glucagon release is thereby inhibited, which leads to an increase in insulin secretion, a decrease in gastric emptying, and a decrease in the blood glucose levels.<a onclick="showRef(event, 'ref172 ref173 ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref172 ref173 ref174 ref175">(172−175)</a></div><div class="NLM_p">In 2014, a patent filed by Merck, Sharp, and Dohme revealed a class of dihydropyrrolopyrazoles as DPP-4 inhibitors (see <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Compounds without a substituent on the pyrazole (compound <b>80</b>) or with sulfonamide substitution (compound <b>81</b>) were moderately active (<b>80</b>, IC<sub>50</sub> = 34 nM; <b>81</b>, IC<sub>50</sub> = 37 nM). The introduction of a benzoyl group at the sulfonyl urea nitrogen atom (compound <b>82</b>) led to an increase in potency (IC<sub>50</sub> = 8.8 nM), while replacement of the sulfonyl urea moiety by a sulfonimidamide moiety (compound <b>83</b>) gave a slightly less active compound (IC<sub>50</sub> = 18 nM).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> For comparison, approved DPP-4 inhibitors, such as sitagliptin (<b>84</b>, IC<sub>50</sub> = 18 nM) or linagliptin (<b>85</b>, IC<sub>50</sub> = 1 nM), are equipotent to or more active than <b>82</b> and <b>83</b>.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> Selectivity toward other dipeptidyl peptidases, in vivo efficacy, cytotoxicity, or oral bioavailability of the compounds remain unclear. Further development of these compounds has not yet been reported.</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures and IC<sub>50</sub> values of DPP-4 inhibitors (<b>80</b>–<b>83</b>) investigated by Merck, Sharp, and Dohme, sitagliptin (<b>84</b>), and linagliptin (<b>85</b>).<a onclick="showRef(event, 'ref176 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref176 ref177 ref178">(176−178)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Adenosine 5′ monophosphate-activated protein kinase (AMPK) is an enzyme that is known as the key regulator of energy metabolism. AMPK is a sensor of the cellular energy status activated by metabolic stresses that increases the cellular ADP/ATP and/or AMP/ATP ratios. Once activated, AMPK triggers catabolic pathways that generate ATP while switching off biosynthetic pathways and cell cycle progress. These effects suggest that AMPK activators may be useful for the treatment and/or prevention of T2DM. Several studies have demonstrated that widely used antidiabetic drug metformin can indirectly activate AMPK.<a onclick="showRef(event, 'ref179 ref180'); return false;" href="javascript:void(0);" class="ref ref179 ref180">(179,180)</a> Thus, modulators of AMPK are expected to be suitable for prophylaxis and treatment of metabolic conditions associated with the disease (e.g., insulin resistance, obesity, cardiovascular disease, and dyslipidemia).</div><div class="NLM_p">Researchers at Boehringer Ingelheim identified sulfonimidamide-containing, hexahydrofurofuran-substituted azabenzimidazole derivatives as AMPK activators (see <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A). The <i>S</i>-linked (compound <b>86</b>: EC<sub>50</sub> = 2 nM) and <i>N</i>-linked (compound <b>87</b>: EC<sub>50</sub> = 20 nM) derivatives in this series were highly active in vitro. Both epimers of compound <b>87</b> were separated by supercritical fluid chromatography on a chiral stationary phase; however, the biochemical data were reported only for the epimeric mixture.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><figure id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0015.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Chemical structures and EC<sub>50</sub> values of sulfonimidamide-based AMPK activators (<b>86</b> and <b>87</b>) investigated by Boehringer Ingelheim. (B) Chemical structures and key properties of selected GK-GKRP disruptors (<b>88</b>–<b>93</b>) investigated by Amgen.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Glucokinase (GK) is the major glucose-phosphorylating enzyme involved in the first step of glucose metabolism in pancreatic β-cells and liver hepatocytes. Therefore, GK plays a pivotal role in blood glucose homeostasis. In β-cells, GK serves as a glucose sensor that essentially assays blood glucose concentrations and regulates glucose-stimulated insulin secretion. In hepatocytes, GK regulates the rate of hepatic glucose uptake and glycogen synthesis. Additionally, GK suppresses the hepatic glucose production.<a onclick="showRef(event, 'ref183 ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref183 ref184 ref185">(183−185)</a> GK is a potential drug target; allosteric activation of GK by small molecules has been recently investigated for the treatment of diabetes.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Hypoglycemia and the resulting increase in insulin secretion are mainly caused by the activation of pancreatic GK; hence, some programs have been shifted toward identification of the compounds that activate only hepatic GK.<a onclick="showRef(event, 'ref187 ref188'); return false;" href="javascript:void(0);" class="ref ref187 ref188">(187,188)</a> However, this approach leads to direct activation of GK and thereby to an increase in the overall GK activity. An alternative strategy involves the identification of small molecules that alter the level of physiologically active GK in selected tissues without influencing the intrinsic catalytic activity of the enzyme. Therefore, targeting glucokinase regulatory protein (GKRP) was identified as a promising approach.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> GKRP plays a pivotal role in GK regulation in hepatocytes and serves as an endogenous inhibitor of GK catalytic activity (in combination with glucose).<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></div><div class="NLM_p last">To identify an allosteric binding site on GKRP, researchers at Amgen discovered small molecules acting as disruptors of the GK–GKRP complex by HTS and structure-guided drug design.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> After several optimization cycles, sulfonylpiperazine AMG-3969 (<b>88</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B) emerged as the most potent GK-GKRP disruptor (IC<sub>50</sub> (hGK–hGKRP) = 3.7 nM). Compound <b>88</b> was highly effective (EC<sub>50</sub> = 202 nM) in the functional mouse hepatocyte assay (the measurement of the translocation of GK from the nucleus to the cytoplasm). The compound showed promising pharmacokinetic properties in vivo in rats (detailed values are shown in Table 11, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>) and significantly lowered blood glucose in mice.<a onclick="showRef(event, 'ref182 ref191 ref192 ref193 ref194'); return false;" href="javascript:void(0);" class="ref ref182 ref191 ref192 ref193 ref194">(182,191−194)</a> Previous SAR studies have demonstrated that the arylsulfonylpiperazine moiety of <b>88</b> is essential for hGK-hGKRP disruption; however, the phenyl carbinol region was not extensively investigated. The X-ray crystal structure of the allosteric binding site revealed that the phenyl ring of the carbinol moiety of <b>88</b> was protruding into the hydrophobic pocket of the binding site. The carbinol moiety was found to be essential for biological activity (formation of a hydrogen bond between the hydroxyl group and Arg525), while the two trifluoromethyl groups occupied two small hydrophobic channels. These findings were confirmed by the low potency of compound <b>89</b> that lacked the mentioned carbinol moiety (IC<sub>50</sub> (hGK–hGKRP) = 25.0 μM). Arg525 is protonated under physiological conditions, and the carbinol hydroxyl moiety was assumed to act as a hydrogen-bond acceptor. Therefore, the investigation of other oxygen-containing groups was performed. Ketone or amide moieties were not tolerated (most likely due to the lack of three-dimensionality of each functional group), and analogues bearing a sulfoxide or sulfone were moderately active (e.g., IC<sub>50</sub> (hGK–hGKRP) = 401 nM for the sulfone analogue). Surprisingly, the sulfonamide analogue <b>90</b> was a potent hGK-hGKRP disruptor (binding IC<sub>50</sub> = 61 nM, cellular EC<sub>50</sub> = 37 nM) despite the absence of the hydrophobic residues that interact with the two hydrophobic channels mentioned above. Subsequently, the sulfonamide was <i>N</i>-methylated, and the resulting analogue showed a modest improvement in the biochemical activity; however, the cellular potency was not improved. The introduction of substituents larger than methyl (e.g., cyclopropyl) decreased the potency. The introduction of a sulfoximine moiety was proposed starting from the promising sulfonamide analogue <b>90</b> due to known alcohol/sulfone isosteric properties, mildly basic nitrogen, and chiral sulfur center. The methyl sulfoximine analogue <b>91</b> had a modest activity (IC<sub>50</sub> (hGK–hGKRP) = 310 nM); however, the trifluoromethylsulfoximine analogue <b>92</b> was significantly more potent than its methyl counterpart in the biochemical assay (IC<sub>50</sub> (hGK–hGKRP) = 45 nM). Furthermore, (<i>S</i>)-<b>92</b> (IC<sub>50</sub> (hGK–hGKRP) = 17 nM, EC<sub>50</sub> = 388 nM) was found to be more potent than (<i>R</i>)-<b>92</b> (IC<sub>50</sub> (hGK–hGKRP) = 182 nM, EC<sub>50</sub> = 2220 nM) in the binding and cellular assays and displayed excellent overall microsomal stability (detailed values are shown in Table 12, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). The potency of (<i>S</i>)-<b>92</b> was comparable to that of the parent <b>88</b> in the binding and cellular assays. <i>N</i>-Methylation decreased potency and microsomal stability of <b>93</b> compared to those of <b>92</b>. Additional pharmacokinetic studies were performed with potent and metabolically stable (rat liver microsomes) GK–GKRP disruptors (e.g., <b>90</b> or (<i>S</i>)-<b>92</b>). Compound <b>90</b> had unfavorable PK properties (e.g., CL<sub>int</sub> = 2.8 L kg<sup>–1</sup> h<sup>–1</sup>) and low oral bioavailability (F = 5%). On the other hand, (<i>S</i>)-<b>92</b> displayed a favorable pharmacokinetic profile with low clearance, good oral bioavailability, and high exposure in rats and mice (detailed values are shown in Table 13, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). The pharmacokinetic profile of (<i>S</i>)-<b>92</b> was slightly improved compared to that of the parent <b>88</b>. Therefore, the in vivo efficacy of (<i>S</i>)-<b>92</b> was evaluated in mice, and the compound was found to significantly lower blood glucose levels (by as much as 58%) in db/db mice after oral administration of various doses (10, 30, and 100 mg/kg) at 3 and 6 h time points (results comparable to that of the parent <b>88</b>). Thus, further assessment of <b>88</b> and (<i>S</i>)-<b>92</b> was suggested to evaluate their potential as therapeutic antidiabetic agents.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.4.  Antiretroviral Agents</h3><div class="NLM_p">The human immunodeficiency virus type 1 (HIV-1) is the lentiviral etiological agent of acquired immunodeficiency syndrome (AIDS). HIV-1 remains one of the greatest public health challenges in the world considering the overall mortality over 35 million since its discovery in 1981.<a onclick="showRef(event, 'ref195 ref196'); return false;" href="javascript:void(0);" class="ref ref195 ref196">(195,196)</a> AIDS is incurable due to the persistence of HIV in the infected host cell reservoir; however, HIV has become a chronic condition due to the highly active antiretroviral therapy (HAART) and consequential increasingly rare progression to AIDS.<a onclick="showRef(event, 'ref197 ref198'); return false;" href="javascript:void(0);" class="ref ref197 ref198">(197,198)</a> An expansion of the drug repertoire to maintain the efficacy of HAART is urgently needed due to the rapid emergence of drug-resistant strains.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> The HIV protease is a C<sub>2</sub> symmetric homodimeric aspartyl protease, which catalyzes the proteolysis of the polyprotein precursor during viral assembly and maturation. The strategy to develop HIV protease inhibitors was successfully pursued for almost 30 years and led to the discovery of ten HIV protease inhibitors (PIs) that were approved by the FDA.<a onclick="showRef(event, 'ref200 ref201 ref202 ref203'); return false;" href="javascript:void(0);" class="ref ref200 ref201 ref202 ref203">(200−203)</a> All approved PIs (e.g., indinavir, <b>94</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A), except tipranavir, feature a secondary alcohol as a peptidomimetic analogue of the tetrahedral hybridized amide linkage transition state during catalytic cleavage (see <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). The alcohol moiety is pivotal for the activity of PIs due to its direct interaction with the catalytic Asp25 and Asp250 in the active site of the HIV protease as an H-bond donor and acceptor.<a onclick="showRef(event, 'ref204 ref205'); return false;" href="javascript:void(0);" class="ref ref204 ref205">(204,205)</a></div><figure id="fig16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0016.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Chemical structures and IC<sub>50</sub> values of indinavir (<b>94</b>) and L700417 (<b>95</b>). (B) Comparison of tetrahedral transition state and tetrahedral transition state mimetics. (C) Chemical structures and IC<sub>50</sub> values of the most potent sulfoximine-based antiretroviral agents.<a onclick="showRef(event, 'ref206 ref207 ref208 ref209 ref210'); return false;" href="javascript:void(0);" class="ref ref206 ref207 ref208 ref209 ref210">(206−210)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Sulfoximines and sulfonimidamides have the potential to mimic the tetrahedral transition state due to their tetrahedral hybridization and can simultaneously act as H-bond donors and acceptors (see <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). Vince and co-workers evaluated several sulfoximine-based HIV protease inhibitors starting from the known and highly potent HIV protease inhibitor L700417 (<b>95</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, A, Merck, IC<sub>50</sub> (enzyme) = 0.6 nM).<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Symmetric sulfoximine <b>96</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C) was the most promising compound in their study. <b>96</b> had no apparent cytotoxicity (CC<sub>50</sub> > 10 μM) and was highly active in the enzymatic (IC<sub>50</sub> (enzyme) = 2.5 nM) and cell-based assays (IC<sub>50</sub> = 408 nM).<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(206,207)</a> The corresponding sulfoxide and <i>N</i>-methyl sulfoximine analogues were evaluated as a proof of concept. Both compounds induced a significant decrease in enzymatic activity (sulfoxide, 10-fold less potent; <i>N</i>-methyl sulfoximine, 180-fold less potent) in agreement with the corresponding H-bonding capability. Docking studies of <b>96</b> in the HIV-1 protease active site confirmed that the sulfoximine moiety is within the hydrogen-bonding distance of the catalytic aspartates; these results substantiate the assumption that sulfoximines may act as transition state mimetics.<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(206,207)</a></div><div class="NLM_p">Subsequently, Vince and co-workers introduced a sulfoximine moiety into the approved PI <b>94</b>. Unexpectedly, in contrast to the previous results, compound <b>97</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C) was almost inactive compared to <b>94</b> (<b>94</b> IC<sub>50</sub> = 0.4 nM; <b>97</b> IC<sub>50</sub> = 100 μM). Computational studies suggested that <b>97</b> did not have sufficient conformational flexibility resulting in a loss of key interactions within the active site and a consequential dramatic decrease in the binding affinity. Displacement of the crystallographic water resulted in the disruption of the hydrogen-bonding network of crystallographic water and may be another possible cause of the loss of the binding affinity. However, it should be noted that only the racemic sulfoximine <b>97</b> was investigated in the enzymatic assay. Separation of the enantiomers could have led to a better binding affinity.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> In conclusion, sulfoximines were confirmed as valid transition state mimetics in the design of potent anti-HIV drugs due to their ability to act simultaneously as hydrogen-bond donor and acceptor with the catalytic aspartates. Nonetheless, further studies, especially on SAR and mechanism of inhibition, are needed because the example of <b>97</b> has demonstrated that the concept is not easily transferable.</div><div class="NLM_p last">Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are an essential part of HAART. In the 1990s, enormous efforts were made to identify novel NNRTI scaffolds. At this time, Antonucci and co-workers investigated a series of benzothiadiazine derivatives. The heterocyclic sulfoximine NSC 287474 (<b>98</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, C) was shown to be a potent HIV-1 reverse transcriptase inhibitor. The compound was active against several laboratory and clinical strains of HIV-1 (including the AZT-resistant strain G910–6) and was an excellent lymphocyte protector against HIV-1. However, <b>98</b> was inactive against HIV-2 and showed (cross-)resistance against several strains, including nevirapine- and pyridinone-resistant strains (NIl9 and A17, respectively).<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Development of <b>98</b> was discontinued due to the discovery of more potent and/or less resistant NNRTIs (e.g., efavirenz or etravirin). Similar results were reported by Satzinger for compound <b>99</b>.<a onclick="showRef(event, 'ref211 ref212'); return false;" href="javascript:void(0);" class="ref ref211 ref212">(211,212)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.5.  Agents for Treatment of Skin Diseases</h3><div class="NLM_p">Psoriasis is a chronic autoimmune and multisystem inflammatory disease of skin and joints characterized by typical red, dry, and itchy patches of abnormal skin. The severity of the disease varies from small, localized patches to complete body surface coverage.<a onclick="showRef(event, 'ref213 ref214 ref215 ref216'); return false;" href="javascript:void(0);" class="ref ref213 ref214 ref215 ref216">(213−216)</a> Treatment of psoriasis often necessitates a long-term therapy, which is defined by the disease severity (mild/moderate or severe psoriasis) and comorbidities. Mild to moderate psoriasis can be treated topically with a combination of glucocorticoids, vitamin D analogues, and phototherapy. Moderate to severe psoriasis often requires systemic treatment (e.g., biologics, methotrexate, cyclosporine, or retinoids); however, severe side effects hamper the efficacy of the treatment (e.g., teratotoxicity). Additionally, the majority of people experience a recurrence of psoriasis after systemic treatment is discontinued.<a onclick="showRef(event, 'ref217 ref218'); return false;" href="javascript:void(0);" class="ref ref217 ref218">(217,218)</a> Thus, significant efforts in drug discovery have been made in the treatment of psoriasis, including the identification of novel targets. Several drug discovery programs focused on targeting the retinoic acid receptor-related orphan receptor γ (RORγ, RORc, or NR1F3), a member of the retinoic acid receptor (RAR)-related orphan receptor subfamily.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> RORγ is the key transcription factor involved in the production and regulation of a proinflammatory cytokine interleukin 17 (IL-17) produced by T helper 17 (TH17) cells.<a onclick="showRef(event, 'ref220 ref221'); return false;" href="javascript:void(0);" class="ref ref220 ref221">(220,221)</a> Thus, RORγ represents a promising target for the treatment of immune-mediated diseases, such as psoriasis, acne, rosacea, atopic dermatitis, and rheumatoid arthritis.<a onclick="showRef(event, 'ref222 ref223 ref224 ref225 ref226'); return false;" href="javascript:void(0);" class="ref ref222 ref223 ref224 ref225 ref226">(222−226)</a></div><div class="NLM_p">Researchers at GlaxoSmithKline identified GSK2981278 (<b>100</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A) as a highly potent and selective inverse agonist of RORγ (IC<sub>50</sub> (RORγ-GAL4 cell) = 17 nM) that inhibits activation of the IL17 promoter and attenuates inflammation in a mouse model of psoriasis.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Compound <b>100</b> entered phase I clinical trials in 2016 for topical treatment of psoriasis due to its favorable potency and skin penetration ability.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> To identify a novel inverse agonist of RORγ with well-balanced log <i>D</i> (which is linked to improved skin penetration and lowered systemic exposure), researchers at Nestlé Skin Health selected <b>100</b> as a starting point for their drug discovery program. During the development of another potent inverse agonist of RORγ, CD12681, the studies at Nestlé Skin Health realized that alternative substituents at the sulfonamide nitrogen other than isobutyl and 4-(ethyl)phenyl failed to retain potency.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> The des-hydroxymethyl analogue showed a 23-fold lower activity (IC<sub>50</sub> (RORγ-GAL4 cell) = 390 nM) than that of its counterpart; hence, the hydroxymethyl group was assumed to be pivotal for hydrophilic interactions with the RORγ ligand-binding domain (cf. Table 12, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). However, the identification of suitable replacements for this group was proposed.<a onclick="showRef(event, 'ref228 ref229'); return false;" href="javascript:void(0);" class="ref ref228 ref229">(228,229)</a> Replacement of the hydroxymethyl moiety with sulfur moieties, such as sulfoxide, sulfone, and sulfonamide, led to analogues with decreased potency and/or lowered lipophilic ligand efficiency (LipE, detailed values are shown in Table 12, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). The impact of lipophilic ligand efficiency was excellently reviewed elsewhere.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> However, the introduction of a sulfoximine moiety ((<i>S</i>)-<b>101</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A) as an alcohol mimetic retained the RORγ potency (IC<sub>50</sub> (RORγ-GAL4 cell) = 26 nM) but significantly modulated the LipE and lipophilicity of the compound (<b>100</b> Chromlog <i>D</i><sub>6.5</sub> = 5.9, LipE = 1.9; <b>101</b> Chromlog <i>D</i><sub>6.5</sub> = 4.6, LipE = 2.7). Thus, further modifications of the sulfoximine moiety were investigated. <i>N</i>-Alkylation and extension of the <i>S</i>-alkyl residues were not beneficial for potency/lipophilicity (detailed values are shown in Table 12, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). The potency and lipophilicity of an amide analogue were comparable to those of <b>100</b>; however, it is unclear whether the development of amide analogues was pursued further. Modifications of the 4-(oxymethyl)tetrahydropyran moiety did not significantly improve the properties of the compounds. The most promising compound (S)-<b>101</b> was shown to be selective over a panel of nuclear receptors (RORα, RARγ, LXRβ, VDR, and PPARγ). Furthermore, no genotoxicity or phototoxicity of the compound was observed. A high clearance was determined in human hepatocytes (180 mL/min/10<sup>6</sup> cells); however, this property was assumed to be beneficial for topical application to prevent systemic side effects. Compound (<i>S</i>)-<b>101</b> was evaluated in vivo (imiquimod-induced skin inflammation mouse model) and induced a significant decrease in thickness, redness, and desquamation of the skin after 3 days of topical application. Furthermore, a significant and dose-dependent attenuation of epidermal hyperplasia was observed. Thus, compound (<i>S</i>)-<b>101</b> was selected for further preclinical evaluation.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> To the best of our knowledge, this was the first report of a topical application of a sulfoximine-containing compound.</div><figure id="fig17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0017.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) Chemical structures and IC<sub>50</sub> values of inverse agonists of RORγ <b>100</b> and <b>101</b> investigated by Nestlé Skin Health. (B) Chemical structures of sulfonimidamide-based CCR10 antagonists <b>102</b>–<b>104</b> investigated by Kyowa Hakko Kirin Co., Ltd..<a onclick="showRef(event, 'ref222 ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref222 ref231 ref232">(222,231,232)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Atopic dermatitis (AD) is characterized by intense pruritus and dry skin and is considered one of the most common inflammatory dermatological disorders. The etiopathogenesis of AD is multifaceted; the key elements include an impaired skin barrier and a dysregulated immune response.<a onclick="showRef(event, 'ref233 ref234'); return false;" href="javascript:void(0);" class="ref ref233 ref234">(233,234)</a> To identify novel molecular targets for the treatment of inflammatory skin diseases, the chemokine CCL27 and its receptor CCR10 (CC chemokine receptor 10) were prioritized as important homing molecules for T-cell migration to the skin. Moreover, it was found that CCL27 inhibition suppresses certain inflammatory responses in the skin, suggesting that therapies targeting CCR10 can be used to treat several human skin disorders, such as atopic dermatitis and psoriasis.<a onclick="showRef(event, 'ref235 ref236 ref237'); return false;" href="javascript:void(0);" class="ref ref235 ref236 ref237">(235−237)</a></div><div class="NLM_p last">In 2014, a patent was filed by Kyowa Hakko Kirin Co., Ltd., describing a large number of heterocyclic CCR10 antagonists for the treatment of skin-related diseases (e.g., atopic dermatitis). Three sulfonimidamides (compounds <b>102</b>, <b>103</b>, and <b>104</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>B) were reported within the list of compounds. All three compounds caused >50% reduction in CCR10 activity at concentrations below 1 μM; however, no detailed information on their activities and/or further development was revealed.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.6.  Agents for Treatment of Respiratory Diseases</h3><div class="NLM_p">Respiratory diseases, including allergies, asthma, and chronic obstructive pulmonary disease (COPD), are a major public health burden worldwide. WHO estimated that 300 million people worldwide suffer from asthma, 210 million people have COPD, and millions of people are affected by allergies. The prevalence of these diseases is increasing, and new and improved therapies are, thus, urgently needed.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a></div><div class="NLM_p">Allergic diseases are complex multifactorial disorders caused by hypersensitivity of the immune system to allergens or certain foods (e.g., nuts) leading to allergic rhinitis, food allergies, atopic dermatitis, allergic asthma, or anaphylaxis.<a onclick="showRef(event, 'ref238 ref239 ref240 ref241'); return false;" href="javascript:void(0);" class="ref ref238 ref239 ref240 ref241">(238−241)</a> Disease manifestation is determined by interactions of genetic and environmental factors and results in various phenotypes. Several mechanisms are involved, and a number of the mechanisms are related to IgE-mediated reactions.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> In particular, the allergen impact on the mucosal surface triggers an adaptive immune response and an allergic inflammation. Uptake of the corresponding allergen by antigen-presenting cells and presentation to T cells results in T cell activation and elaboration of cytokines. This process leads to the production of immunoglobulins, such as immunoglobulin E (IgE), which are bound to the mast cells via the Fcε receptor. Degranulation of the mast cells leads to the release of inflammatory agents, such as histamine, leukotrienes, and prostaglandin D<sub>2</sub>. Thus, immediate phase reactions occur, such as bronchospasm, sneezing, and itching of the tissues.<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a></div><div class="NLM_p">Mast cell degranulation is pivotal for the release of these inflammatory agents; hence, mast cell stabilizers came into focus of several drug discovery programs as a potential target back in the 1970s. Disodium chromoglycate (DSCG, <b>105</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>A) stabilizes mast cells and thus prevents the release of histamine. In rats, <b>105</b> inhibits IgE-mediated passive cutaneous anaphylaxis (PCA) after intravenous injection with high potency (ED<sub>50</sub> = 1.21 mg kg<sup>–1</sup>); however, <b>105</b> is ineffective after oral administration.<a onclick="showRef(event, 'ref244'); return false;" href="javascript:void(0);" class="ref ref244">(244)</a> Xanthone-2-carboxylic acid (see <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>A, highlighted in red) was selected as a lead structure due to DSCG-like activity after oral administration and was used to develop novel antiasthmatic agents for oral administration. Initially, the sulfoximine group was proposed to serve as a bioisostere for the carboxylate moiety; however, subsequent studies indicated that this group is critically important for the activity. Thus, the sulfoximine moiety was used to modulate and potentially enhance the activity within the series of xanthone-2-carboxylic acids. Sulfoximine <b>106</b> was active upon intravenous (ED<sub>50</sub> = 0.033 mg kg<sup>–1</sup>) and oral administration (ED<sub>50</sub> = 2.72 mg kg<sup>–1</sup>). Substitution on the sulfoximine nitrogen resulted in a decrease of antiallergic activity in all cases. The introduction of an <i>n</i>-hexyl substituent at the C-5 position led to the discovery of RU-31156 (sudexanox, <b>107</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>A); the activity of <b>107</b> was increased 10-fold upon oral administration (ED<sub>50</sub> = 0.19 mg kg<sup>–1</sup>) of a tromethammonium salt, and the compound was selected as a clinical candidate.<a onclick="showRef(event, 'ref244 ref245'); return false;" href="javascript:void(0);" class="ref ref244 ref245">(244,245)</a> Unlike <b>105</b>, <b>107</b> never received approval for undisclosed reasons.</div><figure id="fig18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0018.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (A) Chemical structures and ED<sub>50</sub> values of disodium chromoglycate (DSCG, <b>105</b>), sulfoximine <b>106</b>, and sudedanox (<b>107</b>). (B) chemical (core) structures and IC<sub>50</sub> values of sulfoximine-based hNE inhibitors (<b>108</b>–<b>111</b>).<a onclick="showRef(event, 'ref244 ref246 ref247 ref248'); return false;" href="javascript:void(0);" class="ref ref244 ref246 ref247 ref248">(244,246−248)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Human neutrophil elastase (hNE) is a highly active proteolytic enzyme of the chymotrypsin-like serine protease family with broad substrate specificity. hNE is stored in azurophil granules within the neutrophil cytoplasm and is involved in a variety of biological pathways, such as cleavage of endogenous and exogenous proteins, activation of other bioactive proteases (e.g., matrix metalloproteinases), the release of growth factors, and degradation of endogenous proteinase inhibitors (e.g., tissue inhibitors of metalloproteases) and exogenous virulence factors.<a onclick="showRef(event, 'ref249 ref250'); return false;" href="javascript:void(0);" class="ref ref249 ref250">(249,250)</a> Furthermore, hNE is one of the rare proteases that can degrade the extracellular matrix proteins collagen and elastin, and elastin is responsible for the elasticity of the lung tissue.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> This diverse activity of hNE suggested a pivotal role of this enzyme in tissue remodeling processes and in the onset and progression of inflammation. An imbalance in hNE activity may result in inflammatory diseases, especially the diseases associated with the cardiopulmonary system. Therefore, hNE was considered a promising target in the search for the treatment of various diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis (BE), cystic fibrosis (CF), or pulmonary arterial hypertension (PAH).<a onclick="showRef(event, 'ref252 ref253 ref254 ref255 ref256 ref257'); return false;" href="javascript:void(0);" class="ref ref252 ref253 ref254 ref255 ref256 ref257">(252−257)</a> An enormous number of novel hNE inhibitors have been identified in the past three decades; however, only two of them have received approval: purified α1-antitrypsin and sivelestat. However, both drugs were hampered by drawbacks, such as lack of oral bioavailability or moderate off-target selectivity.<a onclick="showRef(event, 'ref258 ref259'); return false;" href="javascript:void(0);" class="ref ref258 ref259">(258,259)</a></div><div class="NLM_p">An enormous effort has been undertaken to overcome various drawbacks of both approved hNE inhibitors by the identification of novel hNE inhibitors with improved potency/selectivity and oral bioavailability. Almost every large pharmaceutical company has had an elastase inhibitor program; hence, numerous hNE inhibitors with variable pharmacophores were identified, including several sulfoximine-based hNE inhibitors. Boehringer Ingelheim filed a patent describing <i>N</i>-cyanosulfoximine-based 4-oxo-1,4-dihydropyridines as hNE inhibitors (core scaffold <b>108</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>B) for the treatment and/or prevention of pulmonary, gastrointestinal, and genitourinary diseases. Almost all compounds presented in the patent showed single-digit or subnanomolar activity. The <i>N</i>-cyano group appeared to be crucial for the activity. However, the <i>N</i>-methyl counterparts were less active. Furthermore, it was shown that the configuration of the sulfoximine moiety did not impact the hNE inhibitory activity since the reported IC<sub>50</sub> values of single enantiomers and the racemic mixture were within the same range.<a onclick="showRef(event, 'ref246 ref247'); return false;" href="javascript:void(0);" class="ref ref246 ref247">(246,247)</a> A number of condensed dihydropyrimidones were patented by Boehringer Ingelheim. Several compounds (such as compound <b>109</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>B) had single-digit or subnanomolar hNE inhibitory activity. Promising pharmacokinetic properties, metabolic stability, and permeability suitable for oral administration were reported for these compounds.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> These data were unavailable for the <i>N</i>-cyano sulfoximines suggesting that their development has been discontinued. Interestingly, researchers at Bayer identified hexahydroquinolines, which are structurally related to condensed dihydropyrimidones reported by Boehringer Ingelheim, as a lead scaffold for their development program of hNE inhibitors. BAY 85–8501 (<b>110</b>) was identified as a hNE inhibitor with picomolar potency (IC<sub>50</sub> = 0.065 nM). The corresponding sulfoximine <b>111</b> showed comparable potency (IC<sub>50</sub> = 0.250 nM) and improved aqueous solubility. However, <b>110</b> was selected as a preclinical candidate due to its overall balanced profile.<a onclick="showRef(event, 'ref260 ref261'); return false;" href="javascript:void(0);" class="ref ref260 ref261">(260,261)</a> Further development of this compound demonstrated in vivo efficacy in various preclinical animal models. Consequently, <b>110</b> was selected as a clinical candidate for the treatment of BE. Early phase I clinical trials showed promising tolerability, and pharmacokinetics and phase 2 clinical trials are currently being conducted.<a onclick="showRef(event, 'ref262 ref263'); return false;" href="javascript:void(0);" class="ref ref262 ref263">(262,263)</a></div><div class="NLM_p last">hNE inhibitors represent a hot topic in medicinal chemistry due to their pivotal role in inflammatory diseases as demonstrated by the enormous number of hNE inhibitors patented within the past decade. Interestingly, numerous sulfoximines can be found among these compounds with potency in the (sub)nanomolar range. Unfortunately, insufficient information on the selectivity or ADME/PK properties of the compounds is available, which is a remarkable Achilles’ heel of many hNE inhibitors. As a consequence, only a very limited number of the compounds entered clinical trials. Therefore, the possibility of approval of a sulfoximine-based hNE inhibitor in the future is currently uncertain.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.7.  CYP24 Hydroxylase Inhibitors</h3><div class="NLM_p">The secosteroid 1,25-dihydroxyvitamin D<sub>3</sub> (1α,25(OH)<sub>2</sub>D<sub>3</sub>, calcitriol, <b>113</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) is the active metabolite of vitamin D<sub>3</sub>. Calcitriol is essential for skeletal health due to its role in the regulation of intestinal calcium and phosphate absorption. Thus, <b>113</b> preserves extracellular calcium levels and bone mineralization. The compound modulates cell growth and differentiation of osteoblasts and osteoclasts.<a onclick="showRef(event, 'ref264 ref265 ref266 ref267 ref268'); return false;" href="javascript:void(0);" class="ref ref264 ref265 ref266 ref267 ref268">(264−268)</a> Vitamin D deficiency results in defective bone mineralization that may lead to osteoporosis, which is the most common reason for a broken bone in the elderly.<a onclick="showRef(event, 'ref266 ref267'); return false;" href="javascript:void(0);" class="ref ref266 ref267">(266,267)</a> Compound <b>113</b> binds to vitamin D receptor (VDR), a steroid hormone receptor, and promotes interaction with vitamin D response elements (VDREs) in the promoter regions of the target genes.<a onclick="showRef(event, 'ref269 ref270'); return false;" href="javascript:void(0);" class="ref ref269 ref270">(269,270)</a> The expression of mitochondrial 1,25(OH)<sub>2</sub>D<sub>3</sub> 24-hydroxylase (CYP24A1) is elevated in numerous diseases (e.g., various types of cancer) and as a consequence of supplementation with endogenous vitamin D analogues. Side-chain hydroxylation of <b>113</b> at the C-23, C-24, and C-26 positions by CYP24A1 leads to fast metabolic inactivation of the compound and hampers the effectiveness of the treatment.<a onclick="showRef(event, 'ref271 ref272'); return false;" href="javascript:void(0);" class="ref ref271 ref272">(271,272)</a> The effects of <b>113</b> are also limited by the development of hypercalcemia and hypercalciuria.<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> Compounds of the class of azoles, such as the antifungal agent ketoconazole (<b>112</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), can inhibit CYP24A1 and act synergistically with vitamin D analogues in cell culture.<a onclick="showRef(event, 'ref274'); return false;" href="javascript:void(0);" class="ref ref274">(274)</a> However, low selectivity is the major drawback of a number of azole inhibitors.<a onclick="showRef(event, 'ref275'); return false;" href="javascript:void(0);" class="ref ref275">(275)</a> Therefore, various drug discovery programs aimed at the identification of novel noncalcemic vitamin D analogues or selective CYP24A1 inhibitors.</div><figure id="fig19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0019.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures and biological activities of the known CYP24 hydroxylase inhibitor ketoconazole (<b>112</b>), calcitriol (<b>113</b>), and its analogues <b>114</b>–<b>116</b> with CYP24 hydroxylase inhibitory activity.<a onclick="showRef(event, 'ref274 ref276 ref277 ref278 ref279'); return false;" href="javascript:void(0);" class="ref ref274 ref276 ref277 ref278 ref279">(274,276−279)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2004, Posner and co-workers reported a series of 24-sulfone calcitriol analogues as CYP24A1 inhibitors (see <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> A sulfone moiety replacement of the 24-hydroxy group was identified earlier, and the beneficial transcriptional activities and low-calcemic properties of the analogues were confirmed.<a onclick="showRef(event, 'ref277 ref278'); return false;" href="javascript:void(0);" class="ref ref277 ref278">(277,278)</a> In this new series, compound <b>114</b> was shown to be the most potent CYP24A1 inhibitor (IC<sub>50</sub> = 28 nM). Compound <b>114</b> is 10 times more potent than the commonly used CYP24 inhibitor ketoconazole (<b>112</b>, IC<sub>50</sub> = 300 nM). Additionally, <b>114</b> is less calcemic (according to the urinary calcium excretion assay in rats) and selectively inhibits CYP24 (selectivity ratio CYP24/CYP27A > 350/1). The SAR study of this series indicated a general trend: (i) sterically more demanding substituents (e.g., naphthyl versus phenyl) decreased the potency of CYP24 inhibition; (ii) electron-donating/withdrawing substituents (e.g., 4-chlorophenyl, 4-fluorophenyl, 4-pyridyl, or 4-methylphenyl versus the phenyl ring) were not tolerated; and (iii) aliphatic residues (e.g., isopropyl versus the phenyl ring) significantly decreased the potency.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> Based on these findings, a series of 24-sulfoximine analogues was investigated. The data on compound <b>115</b> indicated that CYP24 inhibition potency was increased by the introduction of a sulfoximine moiety, and the (<i>S</i>)-configuration analogue was more potent than its (<i>R</i>)-counterpart (IC<sub>50</sub> (24<i>S</i>-<b>115</b>) = 7.4 ± 4.2 nM, IC<sub>50</sub> (24<i>R</i>-<b>115</b>) = 28 ± 10 nM). Similar to compound <b>114</b>, (24<i>S</i>)-<b>115</b> was highly selective toward CYP24 (CYP27A1 IC<sub>50</sub> > 1000 nM, CYP27B IC<sub>50</sub> = 554 nM) and low-calcemic (according to the urinary calcium excretion assay in rats).<a onclick="showRef(event, 'ref279'); return false;" href="javascript:void(0);" class="ref ref279">(279)</a></div><div class="NLM_p">Favorable properties of compound <b>115</b> (now named CTA-091) indicate that it can serve as a promising candidate for further preclinical drug development for the treatment of diseases involving defective cell growth and differentiation, such as chronic kidney disease (CKD). Several vitamin D analogues (e.g., <b>113</b>) were used for the treatment of secondary hyperparathyroidism (sHPT) in CKD patients. However, the therapeutic impact of these compounds is limited due to their induction of hypercalcemia and VDR binding efficacy.<a onclick="showRef(event, 'ref280 ref281'); return false;" href="javascript:void(0);" class="ref ref280 ref281">(280,281)</a> Posner and co-workers investigated the in vitro and in vivo biological properties of <b>115</b> and CTA-018 (<b>116</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), another potent CYP24 hydroxylase inhibitor (IC<sub>50</sub> = 27 ± 6 nM).<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a> The data of the in vitro competitive binding assay indicated that affinity of <b>116</b> binding to VDR was 15-fold lower than that of <b>113</b>, whereas <b>115</b> was not able to efficiently induce the VDR expression in concentrations up to 2000 nM. Additionally, <b>116</b> was confirmed to be potent in vivo.<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a> A very conclusive docking study investigating the difference in the biological effects of the compounds was published in 2018 and revealed that the VDR binding ability of <b>116</b> may be attributed to the lone electron pair of the sulfone moiety that interacts with His393 in the VDR-binding pocket (similarly to <b>113</b>). The sulfoximine moiety of <b>115</b> was unable to interact with His393.<a onclick="showRef(event, 'ref283'); return false;" href="javascript:void(0);" class="ref ref283">(283)</a></div><div class="NLM_p last">Thus, <b>116</b> was selected as a potent and selective drug candidate to treat CKD and sHPT in patients who regularly undergo hemodialysis. The compound is currently evaluated in phase II clinical trials.<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> The development of <b>115</b> was discontinued; however, Posner and co-workers emphasized the importance of selective CYP24 inhibitors. The authors concluded that these compounds may be therapeutically useful in combination with vitamin D supplementation or with <b>113</b> for two main reasons: (i) amplification of renal <b>113</b> production and (ii) modification of metabolism in the target tissues by altering the ratio of CYP24 to CYP27B1 activities. Therefore, it cannot be rigorously excluded that sulfoximine-based CYP24 inhibitors, such as <b>115</b>, will reach the stage of clinical trials in the near future.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">4.8.  Proline-Rich Tyrosine Kinase 2 (PYK2) Inhibitors</h3><div class="NLM_p">Osteoporosis is a bone disorder that increases the personal risk of fractures due to low bone mineral density, impaired bone mineralization, and/or decreased bone strength as a result of an imbalance between bone resorption (by osteoclasts) and bone formation (by osteoblasts). Osteoporosis-related fractures may cause pain, disability, nursing home placement, an increase in total health care costs, and mortality.<a onclick="showRef(event, 'ref285 ref286 ref287 ref288 ref289'); return false;" href="javascript:void(0);" class="ref ref285 ref286 ref287 ref288 ref289">(285−289)</a> Oral treatment of osteoporosis includes bisphosphonates and (selective) estrogen receptor modulators. These agents fail to restore bone in critical osteoporotic patients and have severe drawbacks, such as a delayed mode of action (bisphosphonates) or an increased risk of blood clots and stroke (raloxifene).<a onclick="showRef(event, 'ref290'); return false;" href="javascript:void(0);" class="ref ref290">(290)</a> Teriparatide (a recombinant parathyroid hormone) is the only currently approved bone anabolic agent. Teriparatide is effective (8% increase in bone density in the spine after one year); however, its route of administration (injection once daily) is highly inconvenient.<a onclick="showRef(event, 'ref291 ref292'); return false;" href="javascript:void(0);" class="ref ref291 ref292">(291,292)</a> An orally bioavailable bone anabolic agent may offer a new opportunity to address this unmet medical need, particularly in the aging population.</div><div class="NLM_p">Proline-rich tyrosine kinase 2 (PYK2) is a nonreceptor tyrosine kinase of the focal adhesion kinase subfamily and has evolved as a promising target for the development of small molecule bone anabolic agents.<a onclick="showRef(event, 'ref293'); return false;" href="javascript:void(0);" class="ref ref293">(293)</a> Unlike the focal adhesion kinase (FAK), which is the second member of this ubiquitously expressed kinase subfamily, PYK2 is mainly expressed in the brain and the hematopoietic system. PYK2 is expressed in bone-forming osteoblasts and bone-resorbing osteoclasts; however, pharmacological and PYK2 knockout data clearly demonstrated that inhibition of PYK2 is linked to bone anabolism. However, the exact mechanism of action of PYK2 in bone formation is not well-defined.<a onclick="showRef(event, 'ref294 ref295'); return false;" href="javascript:void(0);" class="ref ref294 ref295">(294,295)</a> Several pharmaceutical companies initiated drug discovery programs to identify orally bioavailable small molecules as PYK2 inhibitors.</div><div class="NLM_p">Researchers at Pfizer identified sulfone <b>117</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) as a promising lead structure. <b>117</b> is a potent PYK2 inhibitor (enzyme IC<sub>50</sub> = 95 nM, cellular IC<sub>50</sub> = 60 nM) and was shown to be highly stable in human liver microsomes (hepatic extraction ratio <0.29). However, <b>117</b> was impeded by modest FAK selectivity (only 17-fold selective) and safety concerns due to significant hERG liability in the dofetilide binding assay (cf. Table 13, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). To overcome these drawbacks, additional analogues were synthesized. The sulfone moiety was replaced by an <i>N</i>-methyl sulfonamide (<b>118</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>); however, only minor changes in potency and hERG liability were observed (detailed values for all PYK2 inhibitors shown in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a> are given in Table 13, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">Supporting Information</a>). A series of sulfoximine analogues was also synthesized. In the case of sulfoximine <b>119</b>, the potency (enzyme IC<sub>50</sub> = 67 nM, cellular IC<sub>50</sub> = 320 nM) was decreased. It was assumed that the diminished cellular activity was due to low cell permeability. However, <i>N</i>-alkylated sulfoximines, such as compound <b>120</b>, displayed good PYK2 cellular activity (<b>120</b>, cellular IC<sub>50</sub> = 76 nM) and stability in HLM (hepatic extraction ratio = 0.46) but retained moderate FAK selectivity (24-fold). Separation of both enantiomers and subsequent assessment revealed that (<i>S</i>)-<b>120</b> was 4-fold more active than (<i>R</i>)-<b>120</b>. Due to the higher activity of (<i>S</i>)-<b>120</b>, selectivity over FAK was increased (39-fold). Unexpectedly, (<i>S</i>)-<b>120</b> showed a significant decrease in potency in the dofetilide binding assay compared to that of the corresponding sulfone or sulfonamide analogues, which was in agreement with an approximately 4-fold improvement in the hERG patch-clamp assay over that of <b>113</b>. Thus, (<i>S</i>)-<b>120</b> was selected for further profiling and revealed good oral exposure in a rat pharmacokinetic model.<a onclick="showRef(event, 'ref296'); return false;" href="javascript:void(0);" class="ref ref296">(296)</a></div><figure id="fig20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0020.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures and key properties of investigated PYK2 inhibitors <b>117</b>–<b>120</b>.<a onclick="showRef(event, 'ref296'); return false;" href="javascript:void(0);" class="ref ref296">(296)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These promising results suggested further profiling of (<i>S</i>)-<b>120</b> in additional safety-related assays and an animal efficacy model of osteoporosis. Unfortunately, data in the literature and reports of clinical trials are unavailable, indicating that the development of this compound was discontinued. To the best of our knowledge, no other selective PYK2 inhibitors have entered clinical trials for the treatment of osteoporosis until this moment.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.9.  Factor Xa Inhibitors</h3><div class="NLM_p">Thrombotic disorders are pathological processes associated with the formation of clots (thrombi) within blood vessels. As a consequence, the blood flow through the cardiovascular system is impeded. Thrombotic disorders may occur in the venous and arterial systems. However, the pathophysiology of arterial thrombosis differs from that of venous thrombosis, and different ways of treatment reflect this difference.<a onclick="showRef(event, 'ref297'); return false;" href="javascript:void(0);" class="ref ref297">(297)</a> Anticoagulants are promising in arterial and venous thrombotic disorders; however, they are more frequently used for the treatment of venous thrombosis due to the prevention of fibrin formation, which is essential for the stability of the thrombi. For a long time, anticoagulant therapy was limited to heparins and vitamin K antagonists. However, the route of administration (intravenous or subcutaneous) of herapins was suboptimal, and vitamin K antagonists had side effects (e.g., bleeding, necrosis, and osteoporosis), slow onset of action, and a narrow therapeutic window. Thus, the unmet need for orally bioavailable and safe anticoagulants has stimulated extensive research leading to the identification and approval of nonvitamin K oral anticoagulants (NOACs), including thrombin inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban). Both classes of compounds offer an improved profile with a rapid onset of action (for use in acute and chronic settings), no significant food interactions (contrary to vitamin K antagonists), low potential for drug interactions, and a predictable anticoagulant effect. Furthermore, an antidote is available for factor Xa inhibitors (andexanet alfa), which reverses the anticoagulant activity of direct Xa inhibitors in the event of a major bleeding.<a onclick="showRef(event, 'ref297 ref298 ref299 ref300'); return false;" href="javascript:void(0);" class="ref ref297 ref298 ref299 ref300">(297−300)</a></div><div class="NLM_p">NOACs are superior to their predecessors; however, they have certain disadvantages, such as higher cost, limited experience with this drug class, and contraindications, e.g., pregnancy or severe renal and hepatic disease.<a onclick="showRef(event, 'ref300'); return false;" href="javascript:void(0);" class="ref ref300">(300)</a> Therefore, studies on the identification of novel factor Xa inhibitors are ongoing. Pandya and co-workers investigated a series of anthranilamide-based factor Xa inhibitors containing less basic sulfoximine moiety used to replace the highly basic amidine moiety, which is included in several factor Xa inhibitors (such as betrixaban, <b>121</b>, see <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) and is known to have low oral bioavailability. Contrary to the expectations, unsubstituted sulfoximines <b>122</b> and <b>123</b> were only modest inhibitors of factor Xa in vitro (<b>122</b>: 42% inhibition of factor Xa at 0.1 μM; <b>123</b>: 76% inhibition of factor Xa at 0.1 μM). Evaluation of the structure–activity relationships of the sulfoximine nitrogen finally led to the identification of the <i>N</i>,<i>N</i>-diethylaminoacyl analogue <b>124</b>, which was a highly potent inhibitor of factor Xa (IC<sub>50</sub> = 2.1 nM). Moreover, <b>124</b> had a potent anticoagulant activity ex vivo in the prothrombin time (PT) assay (doubled clotting time PTCT<sub>2</sub> (rats) = 0.8 μM; PTCT<sub>2</sub> (humans) = 0.68 μM). Pharmacokinetic studies of <b>124</b> in rats demonstrated that the promising activity is ascribed mainly to its desethyl metabolite <b>125</b> formed after oral administration. Nonetheless, a promising pharmacokinetic profile (<i>C</i><sub>max</sub>, <i>T</i><sub>1/2</sub>, and AUC), selectivity over several other serine proteases (>1000-fold for thrombin, plasmin, and trypsin), and low inhibition of CYP3A4 (<25% at 10 μM) justified the evaluation of <b>124</b> in rats. In vivo antithrombotic efficacy was evaluated in a FeCl<sub>3</sub>-induced arterial and venous thrombosis model, and the data clearly demonstrated the ability of <b>124</b> to reduce the weight of arterial and venous thrombi in a dose-dependent manner (oral administration of 10 mg/kg or 30 mg/kg of <b>124</b>).<a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">(301)</a></div><figure id="fig21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0021.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of betrixaban (<b>121</b>) and sulfoximine-based factor Xa inhibitors (<b>122</b>–<b>125</b>).<a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">(301)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The ethylamino moiety apparently served as a replacement for the amidine moiety due to the moderate factor Xa inhibition of the unsubstituted sulfoximines <b>122</b> and <b>123</b> according to the interpretation of the results of the study. Thus, the sulfoximine moiety itself was not a suitable replacement for the basic moieties, such as amidines. Nevertheless, the promising activities of compound <b>124</b> and its active desethyl metabolite <b>125</b> justified further evaluations of these sulfoximine-containing factor Xa inhibitors.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">4.10.  β-Secretase Inhibitors</h3><div class="NLM_p">Dementia and particularly Alzheimer’s disease (AD) as its main cause are considered the most prominent healthcare challenge of the 21st century as a consequence of increasing life expectancy. AD is associated with loss of memory, disorientation, difficulty speaking or writing, loss of reasoning skills, delusions, and other symptoms. The disease is highly associated with advanced age, since more than 90% of all cases occur beyond the age of 65. The exact pathobiology remains unclear; it is generally assumed that three factors are critical for the manifestation of the disease: the presence of a specific neuropathological profile, the extracellular deposition of β-amyloid plaques, and the presence of intraneuronal neurofibrillary tangles consisting of aggregated hyperphosphorylated tau protein.<a onclick="showRef(event, 'ref302 ref303 ref304'); return false;" href="javascript:void(0);" class="ref ref302 ref303 ref304">(302−304)</a> For a long time, β-secretase (also known as BACE1) was considered the most promising target for the treatment of AD. BACE1 is involved in the cleavage of the amyloid precursor protein (APP) and leads to the formation of β-amyloid plaques. Thus, almost all big pharmaceutical companies launched a medicinal chemistry program to identify potent inhibitors of this aspartic protease.<a onclick="showRef(event, 'ref305'); return false;" href="javascript:void(0);" class="ref ref305">(305)</a> In 2015 and 2016, three patents were filed by Hoffmann-La Roche, reporting highly potent sulfonimidamide-based β-secretase inhibitors. The most potent compounds <b>126</b>–<b>130</b> (shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) had the IC<sub>50</sub> values in the single-digit nanomolar or subnanomolar range. The stereochemistry at the carbon and sulfur atoms was shown to have a significant influence on potency (most potent stereoisomers are shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). However, no information on the in vivo efficacy or the brain-penetrating ability of the compounds was provided.<a onclick="showRef(event, 'ref306 ref307 ref308'); return false;" href="javascript:void(0);" class="ref ref306 ref307 ref308">(306−308)</a></div><figure id="fig22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0022.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures and IC<sub>50</sub> values of selected sulfonimidamide-based β-secretase inhibitors <b>126</b>–<b>130</b>.<a onclick="showRef(event, 'ref306 ref307 ref308'); return false;" href="javascript:void(0);" class="ref ref306 ref307 ref308">(306−308)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Within the past two decades, several small molecules and monoclonal antibody drugs targeting β-secretase (e.g., LY2811376, LY2886721, AZD3839, verubecestat, atabecestat, or lanabecestat) have entered clinical trials; however, the development of these clinical candidates was discontinued due to inefficacy or severe side effects.<a onclick="showRef(event, 'ref309'); return false;" href="javascript:void(0);" class="ref ref309">(309)</a> This lack of success challenged the theory of β-secretase inhibitors being the holy grail of AD therapy. Currently, a shift in AD drug discovery toward tau- and ApoE-directed therapeutics is apparent. Most of these approaches remain at an early stage of development. Preclinical and clinical data suggested a coexistence of tau and Aβ in the pathobiology of AD; hence, a simultaneous clearance of tau and Aβ may be beneficial for the treatment of AD. Therefore, a handful of clinical trials targeting tau are currently underway. These data may decide on the fate of β-secretase inhibitors in AD drug discovery.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.11.  Bromodomain and Extraterminal Domain (BET) Inhibitors</h3><div class="NLM_p">Histone acetylation and deacetylation are the essential parts of gene transcription and expression and are typically associated with enzymes with histone acetyltransferase (HAT) or histone deacetylase (HDAC) activity acting on the lysine residues.<a onclick="showRef(event, 'ref310'); return false;" href="javascript:void(0);" class="ref ref310">(310)</a> Bromodomains (BRDs) are protein modules that exclusively recognize acetylated lysine in histones and other proteins and thus enable the regulation of gene expression by various effects. BRDs are flanked by several other epigenetic reader domains or have a tandem arrangement in the bromodomain and extraterminal domain (BET) proteins (BRD2, BRD3, BRD4, or BRDT). Targeting BET with BET inhibitors prevents protein–protein interaction between the BET proteins and acetylated histones and transcription factors, making them a valuable target for drug discovery.<a onclick="showRef(event, 'ref311'); return false;" href="javascript:void(0);" class="ref ref311">(311)</a> The disclosure of the first small molecule BET inhibitors in 2010 with anticancer (JG-1, <b>131</b>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>A)<a onclick="showRef(event, 'ref312'); return false;" href="javascript:void(0);" class="ref ref312">(312)</a> or anti-inflammatory (GSK525762A, <b>132</b>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>A)<a onclick="showRef(event, 'ref313'); return false;" href="javascript:void(0);" class="ref ref313">(313)</a> activities significantly boosted the research of BET inhibitors. By now, more than ten BET inhibitors have entered clinical trials for various forms of cancer, type 2 diabetes mellitus, cardiovascular disease, and coronary artery disease.<a onclick="showRef(event, 'ref311 ref314'); return false;" href="javascript:void(0);" class="ref ref311 ref314">(311,314)</a></div><figure id="fig23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0023.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. (A) Chemical structures and IC<sub>50</sub> values of JQ-1 (<b>131</b>) and GSK525762A (<b>132</b>). (B) Chemical structure of the parent PFI-1 (<b>133</b>), the most potent sulfoximine (<i>S</i>)-<b>134</b>, and the most potent sulfondiimide <b>135</b>.<a onclick="showRef(event, 'ref312 ref313 ref315'); return false;" href="javascript:void(0);" class="ref ref312 ref313 ref315">(312,313,315)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2020, Bolm and co-workers published a study on sulfoximine and sulfondiimide analogues of the BRD-4-selective BET inhibitor PFI-1 (<b>133</b>, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>B) to investigate the replacement of the sulfonamide group by a sulfoximine or sulfondiimide and to determine the impact of chirality of the newly introduced stereogenic center.<a onclick="showRef(event, 'ref315'); return false;" href="javascript:void(0);" class="ref ref315">(315)</a> Several analogues were investigated in the MTT viability assays in leukemia cell lines (HEL, Molm-14, and K562 cells (BET inhibitor-insensitive)). Racemic sulfoximine <b>134</b> and sulfondiimide <b>135</b> were the most efficient in reducing the relative metabolic activity of HEL and Molm-14 cells at a concentration of 10 μM. After separation of enantiomers, (<i>S</i>)-<b>134</b> (IC<sub>50</sub> (HEL) = 0.5 μM, IC<sub>50</sub> (Molm-14) = 1.0 μM) was found to be superior to (<i>R</i>)-<b>134</b> (which was inactive in both cell lines) and parent <b>133</b> (IC<sub>50</sub> (HEL) = 2.0 μM, IC<sub>50</sub> (Molm-14) = 2.7 μM). Contrary to this finding, enantiopure (<i>S</i>)-<b>135</b> and (<i>R</i>)-<b>135</b> showed comparable efficacy. Further characterization in myeloid cell lines and primary cells from patients with acute myeloid leukemia (AML) clearly demonstrated that (<i>S</i>)-<b>134</b> was superior to the parent <b>133</b>. To gain further insight into this increase in efficacy, Bolm and co-workers investigated the in silico models to understand the binding mode of <b>133</b> and (<i>S</i>)-<b>134</b>. The authors concluded that the beneficial efficacy of (<i>S</i>)-<b>134</b> was multifactorial and may be traced back to better stabilization of (<i>S</i>)-<b>134</b> in the hydrophobic binding pocket (due to a decrease in the hydrogen-bond acceptor strength of sulfoximines compared to that of sulfonamides) and to a reduction in flexibility (due to the loss of free rotation around the N–S bond).<a onclick="showRef(event, 'ref315'); return false;" href="javascript:void(0);" class="ref ref315">(315)</a></div><div class="NLM_p last">This study clearly demonstrated the value of replacement of the functional groups (such as sulfonamides) by sulfoximines considering the introduction of a new stereocenter. However, subsequent studies are needed to investigate whether the introduction of sulfoximines may be beneficial for the development of novel BET inhibitors.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">5.  Summary and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The sulfoximine moiety and its congeners were neglected by the medicinal chemistry community for quite a long time despite the early discovery of MSO (<b>10</b>) and the broad activity and sufficient safety profile of BSO (<b>11</b>). In fact, sulfoximines enable fine-tuning of several important parameters, such as physicochemical properties, metabolic and chemical stability, and hydrogen-bond acceptor/donor capability. Additionally, sulfoximines allow structural diversity by various substitution patterns around the nitrogen of the sulfoximine moiety and the stereocenter at the tetrahedral sulfur atom in case of nonsymmetrical substitution. Two main reasons are assumed to account for the rare occurrence of sulfoximines in medicinal chemistry programs: (i) safety concerns due to the use of potential explosive reagents (such as sodium azide) during the synthesis and (ii) lack of knowledge concerning the favorable properties of these functional groups. Over the past two decades, new, safe, and more practical synthetic methodologies were developed. These game-changing methodologies include copious functional group tolerance, application of safer nitrogen sources, valuable one-pot synthesis, and asymmetric synthetic methods.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(16−23)</a> The outstanding work of Bolm,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Bull,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and Lücking<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in the field of sulfoximines and the work of Arvidsson<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in the field of sulfonimidamides (in addition to a number of others) led to an increased interest in sulfoximines and, to a lesser extent, in sulfonimidamides in medicinal chemistry and drug discovery.</div><div class="NLM_p">In several studies, the physicochemical and in vitro properties of approved drugs and/or clinical candidates were compared with their sulfoximine or sulfonimidamide analogues (see Chapter 3). In these opportunistic approaches, both functional groups served as a bioisostere for a variety of common functional groups, including alcohols, amines, sulfones, and sulfonamides. The sulfoximine or sulfonimidamide analogues have been shown to be beneficial for drug-like parameters, such as metabolic stability, aqueous solubility (as shown for <b>42</b>), etc. As expected, a decrease in membrane permeability was observed due to the lowered lipophilicity of the sulfoximine analogues (as shown for <b>36</b>). The impact of the introduction of a sulfoximine moiety on biological activity often remains somewhat unpredictable (cf. biological activities of <b>28</b> and <b>38</b>) and still requires experimentation. The studies described in this manuscript should not be considered general guidelines due to the limited number of analogues investigated. Additionally, the selection of the classes of the compounds or biological targets was quite limited. However, these studies endorse that sulfoximines and sulfonimidamides deserve an increase in attention in small molecule drug discovery.</div><div class="NLM_p">An increased amount of data available in the literature, feasible and safe synthetic accessibility, and the approval of the insecticide sulfoxaflor (<b>12</b>) resulted in the evaluation of the sulfoximine group in a broad range of biological targets, thus yielding candidates in various (pre)clinical stages (screening hits, clinical candidates, and compounds that entered clinical trials). The sulfoximine group has been shown to assume the pioneering role since at least four sulfoximine-containing antineoplastic agents (as shown in <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) entered clinical trials in the past years. The development of roniciclib (<b>47</b>) and atuveciclib (<b>50</b>) was discontinued due to an unfavorable benefit-risk balance and an emerging neutropenia, respectively. Phase I clinical trial of BAY-1251152 (<b>53</b>) was discontinued at the end of 2019. However, it remains unclear whether these end points were actually triggered by the sulfoximine moiety. Clinical trials of AZD6738 (<b>55</b>, phase I/II) are still ongoing.</div><figure id="fig24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0024.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Overview and status of biologically active sulfoximines that entered clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, an increasing number of sulfoximine- and sulfonimidamide-containing compounds appeared in scientific articles and patent applications addressing a broad range of biological targets. Promising results were shown for the GK-GKRP disruptors <b>91</b>–<b>93</b>, hNE inhibitor <b>111</b>, CYP24 hydroxylase inhibitor <b>115</b>, and PYK2 inhibitor <b>120</b>. These compounds have favorable biological activities and were shown to be nontoxic with promising PK and drug-like properties. Additionally, several examples (e.g., the BET inhibitor (<i>S</i>)-<b>134</b>) demonstrated the benefit of a newly introduced stereogenic center by using this functional group that enables the alteration of the activities by variation in chirality. This novel functional group represents a valuable option within drug discovery programs since medicinal chemists are facing biological targets of increased complexity. The highly potent and selective inverse agonist of RORγ (<i>S</i>)-<b>101</b> is the first reported example of the topical application of a sulfoximine-containing compound, clearly indicating the versatility of this scaffold. To the best of our knowledge, no sulfonimidamides entered clinical trials at this time. Nevertheless, several sulfonimidamides with promising properties (e.g., the antitubercular agents <b>73</b>–<b>77</b>, AMPK activators <b>86</b> and <b>87</b>, or γ-secretase inhibitors <b>126</b>–<b>130</b>) were reported. These increasingly numerous reports on sulfoximine- or sulfonimidamide-containing compounds with promising properties emphasize a rising acceptance of this class of compounds by medicinal chemists.</div><div class="NLM_p last">This review exemplifies that sulfoximines and their congeners may substantially enrich the toolbox of medicinal chemists and thereby paves the way for the extension of the chemical space and generation of novel intellectual property. We hope that the knowledge we have assembled in this review based on the data of the literature will encourage medicinal chemists to consider the potential benefits of these versatile scaffolds in their future drug discovery endeavors.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00960" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00960?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00960</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Categories applied for the rating of experimental data; measured in vitro properties; biological activities; ADME-related properties; results of the biochemical and cellular assays of selected ATR inhibitors; physicochemical and ADME characterization; available classes of antimalarial drugs and their modes of action; results of the biochemical and cellular assays; pharmacokinetic properties; biological data on arylsulfoximine-substituted PYK2 inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf">jm0c00960_si_001.pdf (415.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00960" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lars Kattner</span> - <span class="hlFld-Affiliation affiliation">Endotherm GmbH, Science Park 2, 66123 Saarbruecken, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2923-8234" title="Orcid link">http://orcid.org/0000-0003-2923-8234</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#93fff2e1e0bdf8f2e7e7fdf6e1d3f6fdf7fce7fbf6e1febdf7f6"><span class="__cf_email__" data-cfemail="90fcf1e2e3befbf1e4e4fef5e2d0f5fef4ffe4f8f5e2fdbef4f5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Mäder</span> - <span class="hlFld-Affiliation affiliation">Endotherm GmbH, Science Park 2, 66123 Saarbruecken, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>All authors are employees of Endotherm GmbH.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Patrick Mäder</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=BIO-d7e5107-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dr. Patrick Mäder</b> works as a medicinal chemist at Endotherm GmbH in Saarbruecken (Germany). He graduated in Pharmacy (2012) and in Chemistry (2013) from the Philipps-University Marburg (Germany). In 2013, he started his Ph.D. thesis in Medicinal Chemistry under the supervision of Prof. M. Schlitzer. He received his Ph.D. degree in 2016 for his achievements in the synthesis and evaluation of novel chemical entities against the neglected tropical disease schistosomiasis. Afterward, he spent two years as a postdoctoral fellow with Prof. K.-H. Altmann at ETH Zürich (Switzerland), where he has been involved in several medicinal chemistry projects, such as the development of selective endocannabinoid reuptake inhibitors or mycolactone analogues.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Lars Kattner</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=BIO-d7e5112-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dr. Lars Kattner</b> founded Endotherm GmbH in 1999. He received his Ph.D. degree in Chemistry in 1991 from the Freie Universität Berlin (Germany), working with Prof. J. Mulzer on the development of novel stereoselective synthetic methods and their application to the synthesis of various natural products. During a subsequent postdoctoral study with Dr. M.R. Uskokovic at the Medicinal Chemistry Department of Hoffmann-La Roche (Nutley, USA), he developed a new versatile methodology for the synthesis of vitamin D metabolites and steroids. Afterward, he joined the group of Prof. R.W. Hartmann at the Department of Pharmaceutical Chemistry of the Saarland University (Germany), where he has been involved in the development of new enzyme inhibitors to be used as potential drugs against hormone-mediated prostate cancer.</p></figure></div><div class="ack" id="ACK-d7e5139-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The help of Dr. Maryline Kienle and Dr. Tanja Stach in proofreading of the manuscript is acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABR</td><td class="NLM_def"><p class="first last">antibiotic resistance</p></td></tr><tr><td class="NLM_term">ACT</td><td class="NLM_def"><p class="first last">artemisinin-based combination therapy</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">adenosine 5′ monophosphate-activated protein kinase</p></td></tr><tr><td class="NLM_term">ASNase</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-asparagine amidohydrolase</p></td></tr><tr><td class="NLM_term">ASNS</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-asparagine synthase</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and rad3-related</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal domain</p></td></tr><tr><td class="NLM_term">BRD</td><td class="NLM_def"><p class="first last">bromodomain</p></td></tr><tr><td class="NLM_term">BSO</td><td class="NLM_def"><p class="first last">buthionine sulfoximine</p></td></tr><tr><td class="NLM_term">CA-II</td><td class="NLM_def"><p class="first last">carbonic anhydrase II</p></td></tr><tr><td class="NLM_term">CCR10</td><td class="NLM_def"><p class="first last">C–C chemokine receptor 10</p></td></tr><tr><td class="NLM_term">CDB</td><td class="NLM_def"><p class="first last">Boehringer Ingelheim Corporate Database</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">COXIB</td><td class="NLM_def"><p class="first last">COX-2 selective inhibitor</p></td></tr><tr><td class="NLM_term">Cpd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">DPP-4</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase-4</p></td></tr><tr><td class="NLM_term">DSCG</td><td class="NLM_def"><p class="first last">disodium chromoglycate</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FMO</td><td class="NLM_def"><p class="first last">flavin-containing monooxygenase</p></td></tr><tr><td class="NLM_term">GIP</td><td class="NLM_def"><p class="first last">glucose-dependent insulinotropic polypeptide</p></td></tr><tr><td class="NLM_term">GK</td><td class="NLM_def"><p class="first last">glucokinase</p></td></tr><tr><td class="NLM_term">GKRP</td><td class="NLM_def"><p class="first last">glucokinase regulatory protein</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HAART</td><td class="NLM_def"><p class="first last">highly active antiretroviral therapy</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">hNE</td><td class="NLM_def"><p class="first last">human neutrophil elastase</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intellectual property</p></td></tr><tr><td class="NLM_term">IRAC</td><td class="NLM_def"><p class="first last">Insecticide Resistance Action Committee</p></td></tr><tr><td class="NLM_term">LXR</td><td class="NLM_def"><p class="first last">liver X receptor</p></td></tr><tr><td class="NLM_term">MCL-1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia sequence 1</p></td></tr><tr><td class="NLM_term">MSO</td><td class="NLM_def"><p class="first last">methionine sulfoximine</p></td></tr><tr><td class="NLM_term">Mtb</td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NNRTI</td><td class="NLM_def"><p class="first last">nonnucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">NOAC</td><td class="NLM_def"><p class="first last">nonvitamin K oral anticoagulant</p></td></tr><tr><td class="NLM_term">PCA</td><td class="NLM_def"><p class="first last">passive cutaneous anaphylaxis</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">protease inhibitor</p></td></tr><tr><td class="NLM_term">PIKK</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase-related kinase</p></td></tr><tr><td class="NLM_term">PT</td><td class="NLM_def"><p class="first last">prothrombin time</p></td></tr><tr><td class="NLM_term">PYK2</td><td class="NLM_def"><p class="first last">proline-rich tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">R&D</td><td class="NLM_def"><p class="first last">research and development</p></td></tr><tr><td class="NLM_term">RAR</td><td class="NLM_def"><p class="first last">retinoic acid receptor</p></td></tr><tr><td class="NLM_term">ROR</td><td class="NLM_def"><p class="first last">RAR-related orphan receptor</p></td></tr><tr><td class="NLM_term">sHPT</td><td class="NLM_def"><p class="first last">secondary hyperparathyroidism</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">VDR</td><td class="NLM_def"><p class="first last">vitamin D receptor</p></td></tr><tr><td class="NLM_term">VDRE</td><td class="NLM_def"><p class="first last">vitamin D response element</p></td></tr><tr><td class="NLM_term">VEGF-R</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 315 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <i>Bioisosteres in Medicinal Chemistry</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Weinheim</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2F9783527654307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Brown&title=Bioisosteres+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2F9783527654307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527654307%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26btitle%3DBioisosteres%2520in%2520Medicinal%2520Chemistry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Classification of Scaffold-Hopping Approaches</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.drudis.2011.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22056715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=310-324&author=H.+Sunauthor=G.+Tawaauthor=A.+Wallqvist&title=Classification+of+Scaffold-Hopping+Approaches&doi=10.1016%2Fj.drudis.2011.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of scaffold-hopping approaches</span></div><div class="casAuthors">Sun, Hongmao; Tawa, Gregory; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">310-324</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The general goal of drug discovery is to identify novel compds. that are active against a preselected biol. target with acceptable pharmacol. properties defined by marketed drugs.  Scaffold hopping has been widely applied by medicinal chemists to discover equipotent compds. with novel backbones that have improved properties.  In this article we classify scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics and topol.-based hopping.  We review the structural diversity of original and final scaffolds with respect to each category.  We discuss the advantages and limitations of small, medium and large-step scaffold hopping.  Finally, we summarize software that is frequently used to facilitate different kinds of scaffold-hopping methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAONaJ8Be0x7Vg90H21EOLACvtfcHk0lgrYGKS5yifrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D&md5=5f1143cc255c81b88ea4f83ac9f8efc6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DClassification%2520of%2520Scaffold-Hopping%2520Approaches%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D310%26epage%3D324%26doi%3D10.1016%2Fj.drudis.2011.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutchukian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilyeva, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span> <span> </span><span class="NLM_article-title">Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e48476</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0048476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0048476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23185259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVagsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e48476&author=P.+S.+Kutchukianauthor=N.+Y.+Vasilyevaauthor=J.+Xuauthor=M.+K.+Lindvallauthor=M.+P.+Dillonauthor=M.+Glickauthor=J.+D.+Coleyauthor=N.+Brooijmans&title=Inside+the+Mind+of+a+Medicinal+Chemist%3A+The+Role+of+Human+Bias+in+Compound+Prioritization+during+Drug+Discovery&doi=10.1371%2Fjournal.pone.0048476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery</span></div><div class="casAuthors">Kutchukian, Peter S.; Vasilyeva, Nadya Y.; Xu, Jordan; Lindvall, Mika K.; Dillon, Michael P.; Glick, Meir; Coley, John D.; Brooijmans, Natasja</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e48476</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Medicinal chemists' "intuition" is crit. for success in modern drug discovery.  Early in the discovery process, chemists select a subset of compds. for further research, often from many viable candidates.  These decisions det. the success of a discovery campaign, and ultimately what kind of drugs are developed and marketed to the public.  Surprisingly little is known about the cognitive aspects of chemists' decision-making when they prioritize compds.  We investigate (1) how and to what extent chemists simplify the problem of identifying promising compds., (2) whether chemists agree with each other about the criteria used for such decisions, and (3) how accurately chemists report the criteria they use for these decisions.  Chemists were surveyed and asked to select chem. fragments that they would be willing to develop into a lead compd. from a set of ∼4,000 available fragments.  Based on each chemist's selections, computational classifiers were built to model each chemist's selection strategy.  Results suggest that chemists greatly simplified the problem, typically using only 1-2 of many possible parameters when making their selections.  Although chemists tended to use the same parameters to select compds., differing value preferences for these parameters led to an overall lack of consensus in compd. selections.  Moreover, what little agreement there was among the chemists was largely in what fragments were undesirable.  Furthermore, chemists were often unaware of the parameters (such as compd. size) which were statistically significant in their selections, and overestimated the no. of parameters they employed.  A crit. evaluation of the problem space faced by medicinal chemists and cognitive models of categorization were esp. useful in understanding the low consensus between chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2xkFnkLMFbVg90H21EOLACvtfcHk0li78UmiDImHwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVagsr3N&md5=a94653786832db485777a60e05dbb848</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048476%26sid%3Dliteratum%253Aachs%26aulast%3DKutchukian%26aufirst%3DP.%2BS.%26aulast%3DVasilyeva%26aufirst%3DN.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLindvall%26aufirst%3DM.%2BK.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DColey%26aufirst%3DJ.%2BD.%26aulast%3DBrooijmans%26aufirst%3DN.%26atitle%3DInside%2520the%2520Mind%2520of%2520a%2520Medicinal%2520Chemist%253A%2520The%2520Role%2520of%2520Human%2520Bias%2520in%2520Compound%2520Prioritization%2520during%2520Drug%2520Discovery%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De48476%26doi%3D10.1371%2Fjournal.pone.0048476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the Medicinal Chemistry Synthetic Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd.2018.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30140018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=709-727&author=J.+Bostr%C3%B6mauthor=D.+G.+Brownauthor=R.+J.+Youngauthor=G.+M.+Keser%C3%BC&title=Expanding+the+Medicinal+Chemistry+Synthetic+Toolbox&doi=10.1038%2Fnrd.2018.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinal chemistry synthetic toolbox</span></div><div class="casAuthors">Bostrom Jonas; Brown Dean G; Young Robert J; Keseru Gyorgy M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The key objectives of medicinal chemistry are to efficiently design and synthesize bioactive compounds that have the potential to become safe and efficacious drugs.  Most medicinal chemistry programmes rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemistry reactions.  Analysis of the role of synthetic organic chemistry in subsequent hit and lead optimization efforts suggests that only a few reactions dominate.  Thus, the uptake of new synthetic methodologies in drug discovery is limited.  Starting from the known limitations of reaction parameters, synthesis design tools, synthetic strategies and innovative chemistries, here we highlight opportunities for the expansion of the medicinal chemists' synthetic toolbox.  More intense crosstalk between synthetic and medicinal chemists in industry and academia should enable enhanced impact of new methodologies in future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8c_ueHSwcYMcDoIzZtNkfW6udTcc2eYTxiWULnFKJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D&md5=d87e988602808139597576ced56faa88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.116%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DExpanding%2520the%2520Medicinal%2520Chemistry%2520Synthetic%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D709%26epage%3D727%26doi%3D10.1038%2Fnrd.2018.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dessain, S.</span>; <span class="NLM_string-name">Fishman, S. E.</span></span> <i>Preserving the Promise: Improving the Culture of Biotech Investment</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Dessain&author=S.+E.+Fishman&title=Preserving+the+Promise%3A+Improving+the+Culture+of+Biotech+Investment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDessain%26aufirst%3DS.%26btitle%3DPreserving%2520the%2520Promise%253A%2520Improving%2520the%2520Culture%2520of%2520Biotech%2520Investment%26pub%3DAcademic%2520Press%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span> <span> </span><span class="NLM_article-title">An Upcoming Drug for Onychomycosis: Tavaborole</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.171870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4103%2F0976-500X.171870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26816482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC28nltV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=236-239&author=N.+Sharmaauthor=D.+Sharma&title=An+Upcoming+Drug+for+Onychomycosis%3A+Tavaborole&doi=10.4103%2F0976-500X.171870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An upcoming drug for onychomycosis: Tavaborole</span></div><div class="casAuthors">Sharma Neha; Sharma Dhruva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">236-9</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">Fungal infection of the nail as well as nail bed is termed as 'onychomycosis'.  It is caused by dermatophytes, non-dermatophytic fungal species and yeasts like Candida albicans.  It is traditionally treated by topical antifungals, systemic agents like ketoconazole, griseofulvin, itraconazole, fluconazole, etc.  Chemical avulsion or surgical removal of nail can also be tried to treat this disease.  In spite of all these treatment options available, podiatrists were always in search of an ideal drug molecule with lesser side effects and which may improve the patient compliance.  This exhaustive search led to the discovery of a better antifungal agent, known as "Tavaborole." A systematic literature search was carried out using databases such as PubMed, Cochrane Reviews, Google Scholar, etc.  Detailed information about onychomycosis and tavaborole was gathered.  Tavaborole is the first oxaborole antifungal agent approved by FDA in July 2014.  It is marketed under the trade name "Kerydin." It acts by inhibiting protein synthesis in the fungus.  It inhibits an enzyme known as cytosolic leucyl-transfer RNA synthetase, or LeuRS, which plays a key role in fungal essential protein synthesis.  Dermatitis at the site of topical application, erythema, exfoliation and ingrowing toe nail has been reported in 1% of subjects.  Tavaborole may offer a promising role in the treatment of onychomycosis and may compell podiatrists to offer its use in onychomycosis.  The present study describes about chemical nature, mechanism of action and two completed phase 3 clinical trial findings of Tavaborole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT31to254tzSUg6wdEZmT2rfW6udTcc2ebpWP_73WV7dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nltV2hug%253D%253D&md5=65f0361466ec28d85a354341c13fa39b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.171870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.171870%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DD.%26atitle%3DAn%2520Upcoming%2520Drug%2520for%2520Onychomycosis%253A%2520Tavaborole%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2015%26volume%3D6%26spage%3D236%26epage%3D239%26doi%3D10.4103%2F0976-500X.171870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaukel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarlett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span> <span> </span><span class="NLM_article-title">SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1151</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pntd.0001151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21738803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=e1151&author=R.+T.+Jacobsauthor=B.+Nareauthor=S.+A.+Wringauthor=M.+D.+Orrauthor=D.+Chenauthor=J.+M.+Sligarauthor=M.+X.+Jenksauthor=R.+A.+Noeauthor=T.+S.+Bowlingauthor=L.+T.+Mercerauthor=C.+Rewertsauthor=E.+Gaukelauthor=J.+Owensauthor=R.+Parhamauthor=R.+Randolphauthor=B.+Beaudetauthor=C.+J.+Bacchiauthor=N.+Yarlettauthor=J.+J.+Plattnerauthor=Y.+Freundauthor=C.+Dingauthor=T.+Akamaauthor=Y.+K.+Zhangauthor=R.+Brunauthor=M.+Kaiserauthor=I.+Scandaleauthor=R.+Don&title=SCYX-7158%2C+an+Orally-Active+Benzoxaborole+for+the+Treatment+of+Stage+2+Human+African+Trypanosomiasis&doi=10.1371%2Fjournal.pntd.0001151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African trypanosomiasis</span></div><div class="casAuthors">Jacobs, Robert T.; Nare, Bakela; Wring, Stephen A.; Orr, Matthew D.; Chen, Daitao; Sligar, Jessica M.; Jenks, Matthew X.; Noe, Robert A.; Bowling, Tana S.; Mercer, Luke T.; Rewerts, Cindy; Gaukel, Eric; Owens, Jennifer; Parham, Robin; Randolph, Ryan; Beaudet, Beth; Bacchi, Cyrus J.; Yarlett, Nigel; Plattner, Jacob J.; Freund, Yvonne; Ding, Charles; Akama, Tsutomu; Zhang, Y.-K.; Brun, Reto; Kaiser, Marcel; Scandale, Ivan; Don, Robert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1151</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals.  An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods.  We have discovered and optimized a novel class of small-mol. boron-contg. compds., benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT.  Methodol./Principal Findings: A drug discovery project employing integrated biol. screening, medicinal chem. and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2 murine HAT models and has physicochem. and in vitro absorption, distribution, metab., elimination and toxicol. (ADMET) properties consistent with the compd. being orally available, metabolically stable and CNS permeable.  In a murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD × 7 days).  In vivo pharmacokinetic characterization of SCYX-7158 demonstrates that the compd. is highly bioavailable in rodents and non-human primates, has low i.v. plasma clearance and has a 24-h elimination half-life and a vol. of distribution that indicate good tissue distribution.  Most importantly, in rodents brain exposure of SCYX-7158 is high, with Cmax>10 μg/mL and AUC0-24 hr>100 μg*h/mL following a 25 mg/kg oral dose.  Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to achieve therapeutically relevant concns. in this compartment.  Conclusions/Significance: The biol. and pharmacokinetic properties of SCYX-7158 suggest that this compd. will be efficacious and safe to treat stage 2 HAT.  SCYX-7158 has been selected to enter preclin. studies, with expected progression to phase 1 clin. trials in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdyaAga5lprVg90H21EOLACvtfcHk0ljYBxv-t-jP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D&md5=a54f2d57149e6714c7f6acf5f5280a7d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0001151%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26aulast%3DNare%26aufirst%3DB.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DOrr%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSligar%26aufirst%3DJ.%2BM.%26aulast%3DJenks%26aufirst%3DM.%2BX.%26aulast%3DNoe%26aufirst%3DR.%2BA.%26aulast%3DBowling%26aufirst%3DT.%2BS.%26aulast%3DMercer%26aufirst%3DL.%2BT.%26aulast%3DRewerts%26aufirst%3DC.%26aulast%3DGaukel%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DJ.%26aulast%3DParham%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DR.%26aulast%3DBeaudet%26aufirst%3DB.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26aulast%3DYarlett%26aufirst%3DN.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DScandale%26aufirst%3DI.%26aulast%3DDon%26aufirst%3DR.%26atitle%3DSCYX-7158%252C%2520an%2520Orally-Active%2520Benzoxaborole%2520for%2520the%2520Treatment%2520of%2520Stage%25202%2520Human%2520African%2520Trypanosomiasis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2011%26volume%3D5%26spage%3De1151%26doi%3D10.1371%2Fjournal.pntd.0001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+Cyclic+Boronic+Acid+%CE%B2-Lactamase+Inhibitor+%28RPX7009%29+with+Utility+vs+Class+A+Serine+Carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0ljOlriRGij8ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520Cyclic%2520Boronic%2520Acid%2520%25CE%25B2-Lactamase%2520Inhibitor%2520%2528RPX7009%2529%2520with%2520Utility%2520vs%2520Class%2520A%2520Serine%2520Carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reggelin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zur, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: Structures, Properties and Synthetic Applications</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2000</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1055/s-2000-6217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1055%2Fs-2000-6217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2000&publication_year=2000&pages=1-64&author=M.+Reggelinauthor=C.+Zur&title=Sulfoximines%3A+Structures%2C+Properties+and+Synthetic+Applications&doi=10.1055%2Fs-2000-6217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6217%26sid%3Dliteratum%253Aachs%26aulast%3DReggelin%26aufirst%3DM.%26aulast%3DZur%26aufirst%3DC.%26atitle%3DSulfoximines%253A%2520Structures%252C%2520Properties%2520and%2520Synthetic%2520Applications%26jtitle%3DSynthesis%26date%3D2000%26volume%3D2000%26spage%3D1%26epage%3D64%26doi%3D10.1055%2Fs-2000-6217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. R.</span></span> <span> </span><span class="NLM_article-title">Applications of Sulfoximines in Synthesis</span>. <i>Chem. Informationsdienst</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1002/chin.198548352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fchin.198548352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1985&pages=3-10&author=C.+R.+Johnson&title=Applications+of+Sulfoximines+in+Synthesis&doi=10.1002%2Fchin.198548352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fchin.198548352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchin.198548352%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26atitle%3DApplications%2520of%2520Sulfoximines%2520in%2520Synthesis%26jtitle%3DChem.%2520Informationsdienst%26date%3D1985%26volume%3D16%26spage%3D3%26epage%3D10%26doi%3D10.1002%2Fchin.198548352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9399</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1002/anie.201302209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201302209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9399-9408&author=U.+L%C3%BCcking&title=Sulfoximines%3A+A+Neglected+Opportunity+in+Medicinal+Chemistry&doi=10.1002%2Fanie.201302209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span></div><div class="casAuthors">Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9399-9408</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Innovation has frequently been described as the key to drug discovery.  However, in the daily routine, medicinal chemists often tend to stick to the functional groups and structural elements they know and love.  Blockbuster cancer drug Velcade (bortezomib), for example, was rejected by more than 50 companies, supposedly because of its unusual boronic acid function (as often repeated: "only a moron would put boron in a drug!").  Similarly, in the discovery process of the pan-CDK inhibitor BAY 1000394, the unconventional proposal to introduce a sulfoximine group into the lead series also led to sneers and raised eyebrows, since sulfoximines have seldom been used in medicinal chem.  However, it was the introduction of the sulfoximine group that finally allowed the fundamental issues of the project to be overcome, culminating in the identification of the clin. sulfoximine pan-CDK inhibitor BAY 1000394.  This Minireview provides an overview of a widely neglected opportunity in medicinal chem.-the sulfoximine group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcpeepAANfbVg90H21EOLACvtfcHk0ljOlriRGij8ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI&md5=6850d8d77b1141d9d9344410822c00c3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302209%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DSulfoximines%253A%2520A%2520Neglected%2520Opportunity%2520in%2520Medicinal%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9399%26epage%3D9408%26doi%3D10.1002%2Fanie.201302209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordwell, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branca, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanier, N. R.</span></span> <span> </span><span class="NLM_article-title">Acidities of Sulfoximines and Related Oxosulfonium Cations. Cyclopropyl Effects and Structures of Alpha-Sulfonyl-Type Carbanions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3884</span>– <span class="NLM_lpage">3889</span>, <span class="refDoi"> DOI: 10.1021/jo01307a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01307a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3cXlvVGmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=3884-3889&author=F.+G.+Bordwellauthor=J.+C.+Brancaauthor=C.+R.+Johnsonauthor=N.+R.+Vanier&title=Acidities+of+Sulfoximines+and+Related+Oxosulfonium+Cations.+Cyclopropyl+Effects+and+Structures+of+Alpha-Sulfonyl-Type+Carbanions&doi=10.1021%2Fjo01307a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acidities of sulfoximines and related oxosulfonium cations.  Cyclopropyl effects and structures of α-sulfonyl-type carbanions</span></div><div class="casAuthors">Bordwell, Frederick G.; Branca, John C.; Johnson, Carl R.; Vanier, Noel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3884-9</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">PhS(O)(:N+Me2)Me was more acidic than PhS(O)(:NMe)Me, by about 19 pKa units.  The latter is about equal in acidity to PhS(O)Me and about 5 pKa units less acidic than PhSO2Me.  I [R = PhS(O):NMe2, MeC6H4S(O):N+Me2, PhS(O):NSO2Ph] were 4-7 pKa units less acidic than their acyclic Me analogs, MeR due to a demand on the part of sulfone-type groups for p character in the cyclopropyl carbanions of their conjugate bases.  Evidence is presented to show that RCH2- [R = R1SO2, R1S(O)(:NR1), R1SO, Ph2PO, (R1O)2PO] are planar or nearly planar.  Acidity data indicate that the preferential generation of chiral, rather than achiral, planar α-sulfonyl carbanions is a consequence of a preferred kinetics path rather than an inherent greater thermodn. stability.  Factors controlling the stereoselective generation and reactions of carbanions are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiGPX1NRoDYLVg90H21EOLACvtfcHk0ljOlriRGij8ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlvVGmsLY%253D&md5=cb49c609c7a76a1ed24d115c2540f60b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo01307a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01307a030%26sid%3Dliteratum%253Aachs%26aulast%3DBordwell%26aufirst%3DF.%2BG.%26aulast%3DBranca%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26aulast%3DVanier%26aufirst%3DN.%2BR.%26atitle%3DAcidities%2520of%2520Sulfoximines%2520and%2520Related%2520Oxosulfonium%2520Cations.%2520Cyclopropyl%2520Effects%2520and%2520Structures%2520of%2520Alpha-Sulfonyl-Type%2520Carbanions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D3884%26epage%3D3889%26doi%3D10.1021%2Fjo01307a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides: Synthesis and Applications in Preparative Organic Chemistry</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2976</span>– <span class="NLM_lpage">3001</span>, <span class="refDoi"> DOI: 10.1002/adsc.201800273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fadsc.201800273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=2976-3001&author=G.+C.+Nandiauthor=P.+I.+Arvidsson&title=Sulfonimidamides%3A+Synthesis+and+Applications+in+Preparative+Organic+Chemistry&doi=10.1002%2Fadsc.201800273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides: Synthesis and Applications in Preparative Organic Chemistry</span></div><div class="casAuthors">Nandi, Ganesh Chandra; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2976-3001</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  During the last one and half decades, chemists within vastly different areas of science have witnessed a rising interest in chem. matters incorporating the sulfonimidamide functional group.  New synthetic routes to sulfonimidamides have been reported, and the utility of these products has been demonstrated in synthetic, medicinal, agrochem., and material science applications.  In this review, we described the synthesis of sulfonimidamide and their applications in synthetic org. chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr23MHhVOyTLbVg90H21EOLACvtfcHk0liTZMNusroshQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgur7M&md5=116efc3e7ea9fa58a7d7459c8af9063d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201800273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201800273%26sid%3Dliteratum%253Aachs%26aulast%3DNandi%26aufirst%3DG.%2BC.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%253A%2520Synthesis%2520and%2520Applications%2520in%2520Preparative%2520Organic%2520Chemistry%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2018%26volume%3D360%26spage%3D2976%26epage%3D3001%26doi%3D10.1002%2Fadsc.201800273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liTZMNusroshQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Neglected Sulfur(vi) Pharmacophores in Drug Discovery: Exploration of Novel Chemical Space by the Interplay of Drug Design and Method Development</span>. <i>Org. Chem. Front.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1319</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.1039/C8QO01233D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC8QO01233D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslemtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1319-1324&author=U.+L%C3%BCcking&title=Neglected+Sulfur%28vi%29+Pharmacophores+in+Drug+Discovery%3A+Exploration+of+Novel+Chemical+Space+by+the+Interplay+of+Drug+Design+and+Method+Development&doi=10.1039%2FC8QO01233D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected sulfur(VI) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development</span></div><div class="casAuthors">Luecking, U.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Chemistry Frontiers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1319-1324</span>CODEN:
                <span class="NLM_cas:coden">OCFRA8</span>;
        ISSN:<span class="NLM_cas:issn">2052-4129</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Historically, sulfoximines, sulfondiimines and sulfonimidamides have been neglected pharmacophores in drug discovery even though they offer very interesting properties.  This highlight shares the key learnings of various lead optimization approaches at Bayer AG that have successfully utilized these neglected sulfur(VI) functional groups to deliver multiple clin. candidates.  In this context, the key synthetic methods utilized for the synthetic prepn. of these unusual compds. will be outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcX6XF4X_NJbVg90H21EOLACvtfcHk0liTZMNusroshQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslemtL8%253D&md5=eae9b5efca8d68f3d8ab46e8fe29be99</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2FC8QO01233D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8QO01233D%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNeglected%2520Sulfur%2528vi%2529%2520Pharmacophores%2520in%2520Drug%2520Discovery%253A%2520Exploration%2520of%2520Novel%2520Chemical%2520Space%2520by%2520the%2520Interplay%2520of%2520Drug%2520Design%2520and%2520Method%2520Development%26jtitle%3DOrg.%2520Chem.%2520Front.%26date%3D2019%26volume%3D6%26spage%3D1319%26epage%3D1324%26doi%3D10.1039%2FC8QO01233D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">6391</span>– <span class="NLM_lpage">6399</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b00844</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b00844" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFaku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=6391-6399&author=M.+Zenzolaauthor=R.+Doranauthor=R.+Luisiauthor=J.+A.+Bull&title=Synthesis+of+Sulfoximine+Carbamates+by+Rhodium-Catalyzed+Nitrene+Transfer+of+Carbamates+to+Sulfoxides&doi=10.1021%2Facs.joc.5b00844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides</span></div><div class="casAuthors">Zenzola, Marina; Doran, Robert; Luisi, Renzo; Bull, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6391-6399</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sulfoximines are of considerable interest for incorporation into medicinal compds.  A convenient synthesis of N-protected sulfoximines is achieved, under mild conditions, by rhodium-catalyzed transfer of carbamates to sulfoxides.  The first examples of 4-membered thietane-oximines are prepd.  Sulfoximines bearing Boc and Cbz groups are stable to further cross coupling reactions, and readily deprotected.  This method may facilitate the prepn. of NH-sulfoximines providing improved (global) deprotection strategies, which is illustrated in the synthesis of methionine sulfoxide (MSO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptKhE9GKYkx7Vg90H21EOLACvtfcHk0liw1TK-sP61AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFaku78%253D&md5=7c1584e0c90c9fe9da756cbc95efd44f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b00844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b00844%26sid%3Dliteratum%253Aachs%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DDoran%26aufirst%3DR.%26aulast%3DLuisi%26aufirst%3DR.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520Sulfoximine%2520Carbamates%2520by%2520Rhodium-Catalyzed%2520Nitrene%2520Transfer%2520of%2520Carbamates%2520to%2520Sulfoxides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D6391%26epage%3D6399%26doi%3D10.1021%2Facs.joc.5b00844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span> <span> </span><span class="NLM_article-title">Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7203</span>– <span class="NLM_lpage">7207</span>, <span class="refDoi"> DOI: 10.1002/anie.201602320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201602320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFehsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7203-7207&author=M.+Zenzolaauthor=R.+Doranauthor=L.+Degennaroauthor=R.+Luisiauthor=J.+A.+Bull&title=Transfer+of+Electrophilic+NH+Using+Convenient+Sources+of+Ammonia%3A+Direct+Synthesis+of+NH+Sulfoximines+from+Sulfoxides&doi=10.1002%2Fanie.201602320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides</span></div><div class="casAuthors">Zenzola, Marina; Doran, Robert; Degennaro, Leonardo; Luisi, Renzo; Bull, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7203-7207</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new system for NH transfer is developed for the prepn. of sulfoximines, which are emerging as valuable motifs for drug discovery.  The protocol employs readily available sources of nitrogen without the requirement for either preactivation or for metal catalysts.  Mixing ammonium salts with diacetoxyiodobenzene directly converts sulfoxides into sulfoximines.  This report describes the first example of using of ammonia sources with diacetoxyiodobenzene to generate an electrophilic nitrogen center.  Control and mechanistic studies suggest a short-lived electrophilic intermediate, which is likely to be PhINH or PhIN+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbS6BCDLgzLLVg90H21EOLACvtfcHk0liw1TK-sP61AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFehsro%253D&md5=5374bfd2d888f59a68acca77e2e6eac8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201602320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201602320%26sid%3Dliteratum%253Aachs%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DDoran%26aufirst%3DR.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DLuisi%26aufirst%3DR.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26atitle%3DTransfer%2520of%2520Electrophilic%2520NH%2520Using%2520Convenient%2520Sources%2520of%2520Ammonia%253A%2520Direct%2520Synthesis%2520of%2520NH%2520Sulfoximines%2520from%2520Sulfoxides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7203%26epage%3D7207%26doi%3D10.1002%2Fanie.201602320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tota, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Campbell, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanazzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of NH-Sulfoximines from Sulfides by Chemoselective One-Pot N- and O-Transfers</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1039/C6CC08891K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC6CC08891K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2gs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=348-351&author=A.+Totaauthor=M.+Zenzolaauthor=S.+J.+Chawnerauthor=S.+S.+John-Campbellauthor=C.+Carlucciauthor=G.+Romanazziauthor=L.+Degennaroauthor=J.+A.+Bullauthor=R.+Luisi&title=Synthesis+of+NH-Sulfoximines+from+Sulfides+by+Chemoselective+One-Pot+N-+and+O-Transfers&doi=10.1039%2FC6CC08891K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of NH-sulfoximines from sulfides by chemoselective one-pot N- and O-transfers</span></div><div class="casAuthors">Tota, Arianna; Zenzola, Marina; Chawner, Stephen J.; John-Campbell, Sahra St; Carlucci, Claudia; Romanazzi, Giuseppe; Degennaro, Leonardo; Bull, James A.; Luisi, Renzo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-351</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Direct synthesis of NH-sulfoximines from sulfides were achieved through O and NH transfer in the same reaction, occurring with complete selectivity.  The reaction was mediated by bisacetoxyiodobenzene under simple conditions and employs inexpensive N-sources.  Preliminary studies indicated that NH-transfer was likely to be first, followed by oxidn., but the reaction proceedes successfully in either order.  A wide range of functional groups and biol. relevant compds. were tolerated.  The use of AcO15NH4 affords 15N-labeled compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0BQ01T3hNbVg90H21EOLACvtfcHk0liw1TK-sP61AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2gs7vE&md5=fd5d9d3e50c2d117b670fffb5db5808b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FC6CC08891K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC08891K%26sid%3Dliteratum%253Aachs%26aulast%3DTota%26aufirst%3DA.%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DChawner%26aufirst%3DS.%2BJ.%26aulast%3DJohn-Campbell%26aufirst%3DS.%2BS.%26aulast%3DCarlucci%26aufirst%3DC.%26aulast%3DRomanazzi%26aufirst%3DG.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26aulast%3DLuisi%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520NH-Sulfoximines%2520from%2520Sulfides%2520by%2520Chemoselective%2520One-Pot%2520N-%2520and%2520O-Transfers%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D348%26epage%3D351%26doi%3D10.1039%2FC6CC08891K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaabouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthelemy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glachet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagousset, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pégot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, V.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Aryl- and Alkyl S-Perfluoroalkylated NH-Sulfoximines from Sulfides</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">17006</span>– <span class="NLM_lpage">17010</span>, <span class="refDoi"> DOI: 10.1002/chem.201805055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fchem.201805055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30300956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=17006-17010&author=S.+Chaabouniauthor=J.+F.+Lohierauthor=A.+L.+Barthelemyauthor=T.+Glachetauthor=E.+Anselmiauthor=G.+Dagoussetauthor=P.+Diterauthor=B.+P%C3%A9gotauthor=E.+Magnierauthor=V.+Reboul&title=One-Pot+Synthesis+of+Aryl-+and+Alkyl+S-Perfluoroalkylated+NH-Sulfoximines+from+Sulfides&doi=10.1002%2Fchem.201805055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Aryl- and Alkyl S-Perfluoroalkylated NH-Sulfoximines from Sulfides</span></div><div class="casAuthors">Chaabouni, Slim; Lohier, Jean-Francois; Barthelemy, Anne-Laure; Glachet, Thomas; Anselmi, Elsa; Dagousset, Guillaume; Diter, Patrick; Pegot, Bruce; Magnier, Emmanuel; Reboul, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">64</span>),
    <span class="NLM_cas:pages">17006-17010</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Perfluoroalkyl and fluoroalkyl sulfoximines such as 4-MeOC6H4S(:O)(:NH)R (R = F3C, BrF2C, F2HC) were prepd. in one or two steps from the corresponding sulfide by reaction with ammonium carbamate mediated by phenyliodine diacetate in 2,2,2-trifluoroethanol followed (in some cases) by hydrolysis of N-acetylsulfoximines.  The conditions were used for fluoromethyl, dichlorofluoromethyl, difluoromethyl, bromodifluoromethyl, trifluoromethyl, and nonafluorobutyl sulfides.  A nitridosulfur intermediate in the prepn. of 4-MeOC6H4S(:O)(:NH)CHF2 was detected by 19F NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohYhnqP7mOqLVg90H21EOLACvtfcHk0liw1TK-sP61AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWqsrvO&md5=30dc245218c49ed98c2d1f8c4b940c5f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fchem.201805055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201805055%26sid%3Dliteratum%253Aachs%26aulast%3DChaabouni%26aufirst%3DS.%26aulast%3DLohier%26aufirst%3DJ.%2BF.%26aulast%3DBarthelemy%26aufirst%3DA.%2BL.%26aulast%3DGlachet%26aufirst%3DT.%26aulast%3DAnselmi%26aufirst%3DE.%26aulast%3DDagousset%26aufirst%3DG.%26aulast%3DDiter%26aufirst%3DP.%26aulast%3DP%25C3%25A9got%26aufirst%3DB.%26aulast%3DMagnier%26aufirst%3DE.%26aulast%3DReboul%26aufirst%3DV.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Aryl-%2520and%2520Alkyl%2520S-Perfluoroalkylated%2520NH-Sulfoximines%2520from%2520Sulfides%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D17006%26epage%3D17010%26doi%3D10.1002%2Fchem.201805055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span> <span> </span><span class="NLM_article-title">Straightforward Strategies for the Preparation of NH-Sulfoximines: A Serendipitous Story</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2525</span>– <span class="NLM_lpage">2538</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1590874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1055%2Fs-0036-1590874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2525-2538&author=J.+A.+Bullauthor=L.+Degennaroauthor=R.+Luisi&title=Straightforward+Strategies+for+the+Preparation+of+NH-Sulfoximines%3A+A+Serendipitous+Story&doi=10.1055%2Fs-0036-1590874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Straightforward Strategies for the Preparation of NH-Sulfoximines: A Serendipitous Story</span></div><div class="casAuthors">Bull, James A.; Degennaro, Leonardo; Luisi, Renzo</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2525-2538</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Sulfoximines are emerging as valuable new isosteres for use in medicinal chem., with the potential to modulate physicochem. properties.  Recent developments in synthetic strategies have made the unprotected 'free' NH-sulfoximine group more readily available, facilitating further study.  This account reviews approaches to NH-sulfoximines, with a focus on the authors' contribution to the field.  Starting from the development of catalytic strategies involving transition metals, more sustainable metal-free processes were discovered.  In particular, the use of hypervalent iodine reagents to mediate NH-transfer to sulfoxides is described, along with an assessment of the substrate scope.  Furthermore, a one-pot strategy to convert sulfides directly into NH-sulfoximines is discussed, with N- and O-transfer occurring under the reaction conditions.  Mechanistic evidence for the new procedures is included as well as relevant synthetic applications that further exemplify the potential of these approaches.  Topics discussed include: strategies to form NH-sulfoximines involving transition-metal catalysts; metal-free strategies to prep. NH-sulfoximines; mechanistic evidence for the direct synthesis of NH-sulfoximines from sulfoxides and sulfides; and further applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiXvIO62R7C7Vg90H21EOLACvtfcHk0lgxgN2F0Z3uVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGktr3K&md5=4691f2fff7a0a87a9f3945da04f88c98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1590874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1590874%26sid%3Dliteratum%253Aachs%26aulast%3DBull%26aufirst%3DJ.%2BA.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DLuisi%26aufirst%3DR.%26atitle%3DStraightforward%2520Strategies%2520for%2520the%2520Preparation%2520of%2520NH-Sulfoximines%253A%2520A%2520Serendipitous%2520Story%26jtitle%3DSynlett%26date%3D2017%26volume%3D28%26spage%3D2525%26epage%3D2538%26doi%3D10.1055%2Fs-0036-1590874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glachet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzag, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaumont, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, V.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Investigation of the NH-Sulfoximination of Sulfide. Evidence for λ6-Sulfanenitrile Intermediates</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2067</span>, <span class="refDoi"> DOI: 10.1039/C6CC09940H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC6CC09940H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28133647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=2064-2067&author=J.+F.+Lohierauthor=T.+Glachetauthor=H.+Marzagauthor=A.+C.+Gaumontauthor=V.+Reboul&title=Mechanistic+Investigation+of+the+NH-Sulfoximination+of+Sulfide.+Evidence+for+%CE%BB6-Sulfanenitrile+Intermediates&doi=10.1039%2FC6CC09940H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic investigation of the NH-sulfoximination of sulfide. Evidence for λ6-sulfanenitrile intermediates</span></div><div class="casAuthors">Lohier, Jean-Francois; Glachet, Thomas; Marzag, Hamid; Gaumont, Annie-Claude; Reboul, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2064-2067</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report a new procedure for the prepn. of NH-sulfoximines from sulfides using PIDA as an oxidant and ammonium carbamate as the ammonia source.  Excellent yields were obtained with a wide range of sulfides.  The formation of acetoxy- and methoxy-λ6-sulfanenitrile as intermediates was proposed, both of which were converted to the NH-sulfoximine by the action of the solvent.  The structure of these intermediates was confirmed by 1H, 13C and 15N NMR and HRMS anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rt5nwaunPbVg90H21EOLACvtfcHk0lgxgN2F0Z3uVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSnsL8%253D&md5=71625d993d0c7f648d07ed50639e265e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC6CC09940H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC09940H%26sid%3Dliteratum%253Aachs%26aulast%3DLohier%26aufirst%3DJ.%2BF.%26aulast%3DGlachet%26aufirst%3DT.%26aulast%3DMarzag%26aufirst%3DH.%26aulast%3DGaumont%26aufirst%3DA.%2BC.%26aulast%3DReboul%26aufirst%3DV.%26atitle%3DMechanistic%2520Investigation%2520of%2520the%2520NH-Sulfoximination%2520of%2520Sulfide.%2520Evidence%2520for%2520%25CE%25BB6-Sulfanenitrile%2520Intermediates%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D2064%26epage%3D2067%26doi%3D10.1039%2FC6CC09940H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Chiral Sulfoximines via the S-Arylation of Sulfinamides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">19263</span>– <span class="NLM_lpage">19268</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b11298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b11298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=19263-19268&author=Y.+Aotaauthor=T.+Kanoauthor=K.+Maruoka&title=Asymmetric+Synthesis+of+Chiral+Sulfoximines+via+the+S-Arylation+of+Sulfinamides&doi=10.1021%2Fjacs.9b11298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric synthesis of chiral sulfoximines via the S-arylation of sulfinamides</span></div><div class="casAuthors">Aota, Yusuke; Kano, Taichi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">19263-19268</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optically active sulfoximines are a promising substructure in me-dicinal chem.  However, a methodol. for prepg. chiral sulfoximines in a stereoselective manner has been underdeveloped.  Herein, an asym. synthesis of chiral sulfoximines having an aryl group by the newly developed sulfur-selective arylation of easily accessible chiral sulfinamides is reported.  The utility of the pre-sent method is demonstrated by the asym. synthesis of a key intermediate of a COX-2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2nOBzRq3-7Vg90H21EOLACvtfcHk0lgxgN2F0Z3uVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmtL%252FE&md5=fd46b1ede617df78a1a3ccc8f113a2c5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b11298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b11298%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Chiral%2520Sulfoximines%2520via%2520the%2520S-Arylation%2520of%2520Sulfinamides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D19263%26epage%3D19268%26doi%3D10.1021%2Fjacs.9b11298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Chiral Sulfoximines through the S-Alkylation of Sulfinamides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17661</span>– <span class="NLM_lpage">17665</span>, <span class="refDoi"> DOI: 10.1002/anie.201911021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201911021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=17661-17665&author=Y.+Aotaauthor=T.+Kanoauthor=K.+Maruoka&title=Asymmetric+Synthesis+of+Chiral+Sulfoximines+through+the+S-Alkylation+of+Sulfinamides&doi=10.1002%2Fanie.201911021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis of Chiral Sulfoximines through the S-Alkylation of Sulfinamides</span></div><div class="casAuthors">Aota, Yusuke; Kano, Taichi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17661-17665</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Innovation in drug discovery critically depends on the development of new bioisosteric groups.  Chiral sulfoximines, which contain a tetrasubstituted sulfur atom that bears one nitrogen, one oxygen, and two different carbon substituents, represent an emerging chiral bioisostere in medicinal chem.  Chiral sulfoximines are conventionally prepd. by a stereospecific nitrene transfer reaction to chiral sulfoxides; however, the no. of readily available chiral sulfoxides remains limited.  Herein, we report the asym. synthesis of a class of hitherto difficult-to-access chiral sulfoximines with two structurally similar alkyl chains.  Our synthetic approach is based on the sulfur-selective alkylation of easily accessible chiral sulfinamides with com. available reagents under simple and safe conditions.  This stereospecific S-alkylation offers a general and scalable approach to the asym. synthesis of chiral sulfoximines, which represent important substructures in bioactive mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0_RGMof7wbVg90H21EOLACvtfcHk0litoQB1Tkub2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValurnO&md5=ab5e5707d7fd5ad82ba7a198bd2904c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fanie.201911021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201911021%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Chiral%2520Sulfoximines%2520through%2520the%2520S-Alkylation%2520of%2520Sulfinamides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D17661%26epage%3D17665%26doi%3D10.1002%2Fanie.201911021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines from a Medicinal Chemist’s Perspective: Physicochemical and <i>in Vitro</i> Parameters Relevant for Drug Discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2016.09.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27821325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=225-245&author=M.+Fringsauthor=C.+Bolmauthor=A.+Blumauthor=C.+Gnamm&title=Sulfoximines+from+a+Medicinal+Chemist%E2%80%99s+Perspective%3A+Physicochemical+and+in+Vitro+Parameters+Relevant+for+Drug+Discovery&doi=10.1016%2Fj.ejmech.2016.09.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery</span></div><div class="casAuthors">Frings, Marcus; Bolm, Carsten; Blum, Andreas; Gnamm, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored variants of the common sulfone or sulfonamide motif.  In this study, we report the physicochem. and in vitro properties of sulfoximines and compare them with related analogs and isosteres.  Furthermore, we present a matched mol. pair anal. of compds. from drug discovery projects within Boehringer Ingelheim.  We demonstrate that the sulfoximine moiety is a chem. stable, comparatively polar and weakly basic functional group, often leading to favorable aq. soly., permeability and metabolic stability.  Moreover, their addnl. vectors at nitrogen enable simple chem. modifications and thus facilitate exploration and fine-tuning of the mol. properties.  We conclude that sulfoximines and their congeners do not exhibit any intrinsic flaw but significantly enrich the toolbox of medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0FlXXURKybVg90H21EOLACvtfcHk0litoQB1Tkub2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK&md5=8a7939f22425f46ad9eb87fcddd29099</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.091%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DBolm%26aufirst%3DC.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DGnamm%26aufirst%3DC.%26atitle%3DSulfoximines%2520from%2520a%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%253A%2520Physicochemical%2520and%2520in%2520Vitro%2520Parameters%2520Relevant%2520for%2520Drug%2520Discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D225%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.09.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chinthakindi, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naicker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides in Medicinal and Agricultural Chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4100</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1002/anie.201610456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201610456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=4100-4109&author=P.+K.+Chinthakindiauthor=T.+Naickerauthor=N.+Thotaauthor=T.+Govenderauthor=H.+G.+Krugerauthor=P.+I.+Arvidsson&title=Sulfonimidamides+in+Medicinal+and+Agricultural+Chemistry&doi=10.1002%2Fanie.201610456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides in Medicinal and Agricultural Chemistry</span></div><div class="casAuthors">Chinthakindi, Praveen K.; Naicker, Tricia; Thota, Niranjan; Govender, Thavendran; Kruger, Hendrik G.; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4100-4109</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The synthesis and evaluation of structural analogs and isosteres are of central importance in medicinal and agricultural chem.  The sulfonamide functional group represents one of the most important amide isosteres in contemporary drug design, and about 500 such compds. have overcome both the pharmacol. and regulatory hurdles that precede studies in humans.  The mono aza analogs of sulfonamides, i.e., sulfonimidamides, are rapidly gaining popularity as a novel functional group among synthetic chemists involved in the design of biol. active compds. for both pharmaceutical and agrochem. applications.  Herein, we review these recent developments to showcase the promise of this functional group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zj9KqdepKbVg90H21EOLACvtfcHk0litoQB1Tkub2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlynu7k%253D&md5=3460c3a7c17bd914174be7c81d645fb0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201610456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201610456%26sid%3Dliteratum%253Aachs%26aulast%3DChinthakindi%26aufirst%3DP.%2BK.%26aulast%3DNaicker%26aufirst%3DT.%26aulast%3DThota%26aufirst%3DN.%26aulast%3DGovender%26aufirst%3DT.%26aulast%3DKruger%26aufirst%3DH.%2BG.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%2520in%2520Medicinal%2520and%2520Agricultural%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D4100%26epage%3D4109%26doi%3D10.1002%2Fanie.201610456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bizet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfur Imidations: Access to Sulfimides and Sulfoximines</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3378</span>– <span class="NLM_lpage">3390</span>, <span class="refDoi"> DOI: 10.1039/C5CS00208G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC5CS00208G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25941981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=3378-3390&author=V.+Bizetauthor=C.+M.+Hendriksauthor=C.+Bolm&title=Sulfur+Imidations%3A+Access+to+Sulfimides+and+Sulfoximines&doi=10.1039%2FC5CS00208G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfur imidations: access to sulfimides and sulfoximines</span></div><div class="casAuthors">Bizet, Vincent; Hendriks, Christine M. M.; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3378-3390</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Being mono-aza analogs of sulfoxides and sulfones, sulfimides and sulfoximines, resp., are important compds. in asym. synthesis, crop protection and medicinal chem. various methods were developed for their prepn.  For their prepn. various methods were developed.  In the search for the optimal synthetic approach for a given target compd., several parameters have to be considered which also include safety issues and availability of starting materials.  An overview of sulfur imidation methods, classified by imidating agents and compds. with a related behavior were reviewed.  The aim of this survey was to provide a practical ''tool box'' for the synthetic chemist by mapping the advantages and disadvantages assocd. with the use of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLkp3i4O2QrVg90H21EOLACvtfcHk0litoQB1Tkub2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yisrw%253D&md5=f783729be2df3166e6e3b09c3b6d311f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC5CS00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00208G%26sid%3Dliteratum%253Aachs%26aulast%3DBizet%26aufirst%3DV.%26aulast%3DHendriks%26aufirst%3DC.%2BM.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfur%2520Imidations%253A%2520Access%2520to%2520Sulfimides%2520and%2520Sulfoximines%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D3378%26epage%3D3390%26doi%3D10.1039%2FC5CS00208G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Fluorinated Sulfoximines: Preparation, Reactions and Applications</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">4437</span>– <span class="NLM_lpage">4451</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201402086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fejoc.201402086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=4437-4451&author=X.+Shenauthor=J.+Hu&title=Fluorinated+Sulfoximines%3A+Preparation%2C+Reactions+and+Applications&doi=10.1002%2Fejoc.201402086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorinated Sulfoximines: Preparation, Reactions and Applications</span></div><div class="casAuthors">Shen, Xiao; Hu, Jinbo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4437-4451</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The selective incorporation of fluorine atoms or fluorinated groups into org. mols. has become a hot research topic in modern org. chem.  However, selective and efficient synthesis of organofluorine compds. greatly depends on the development of powerful fluorination or fluoroalkylation reagents and reactions.  In this context, the past decade has witnessed rapid research progress in the development of α-fluoro sulfoximines as versatile fluoroalkylation reagents.  Many efficient nucleophilic, electrophilic and radical fluoroalkylation reactions based on α-fluoro sulfoximine reagents have been developed; among these, several chiral sulfoximine reagents were successfully used in the synthesis of enantiomerically enriched organofluorine compds.  It was found that α-fluoro sulfoximines show unique chem. behavior characteristics (such as difluorocarbene and fluoroalkyl radical reactivity) significantly different from those of their non-fluorinated counterparts.  In addn. to the rapid development of fluorinated sulfoximines in org. synthesis, research into their application in materials science has also attracted increasing attention.  Sulfoximines are important bioactive substances, and more recently the synthesis and application of fluorinated sulfoximines has attracted much attention in life sciences and the pharmaceutical industry.  In this microreview the authors summarize the prepn., reactions and applications of fluorinated sulfoximines (mainly α-fluoro sulfoximines).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRzT5ZgNCtbVg90H21EOLACvtfcHk0li5Y6CeG5ttQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVGitbs%253D&md5=dbff1f6ff4aa7f4947708b693bb7199b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201402086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201402086%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DFluorinated%2520Sulfoximines%253A%2520Preparation%252C%2520Reactions%2520and%2520Applications%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D2014%26spage%3D4437%26epage%3D4451%26doi%3D10.1002%2Fejoc.201402086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Building Block Approach for the Synthesis of Sulfoximines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5348</span>– <span class="NLM_lpage">5351</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b02678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b02678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=5348-5351&author=A.+D.+Steinkampauthor=S.+Wiezorekauthor=F.+Brosgeauthor=C.+Bolm&title=Building+Block+Approach+for+the+Synthesis+of+Sulfoximines&doi=10.1021%2Facs.orglett.6b02678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Building Block Approach for the Synthesis of Sulfoximines</span></div><div class="casAuthors">Steinkamp, Anne-Dorothee; Wiezorek, Stefan; Brosge, Felix; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5348-5351</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A cross-coupling strategy for the prepn. of novel sulfoximines via preformed sulfoximidoyl-contg. building blocks has been developed.  It allows obtaining a wide range of products in good yields under mild reaction conditions, and it can be applied in late-stage functionalizations, as demonstrated by the synthesis of a sulfoximine-based analog of a recently reported potent valosine-contg. protein inhibitor, I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUr7J5CfXcnbVg90H21EOLACvtfcHk0li5Y6CeG5ttQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtLfO&md5=c7580aa3d515cffd7bc65ef24f105733</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b02678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b02678%26sid%3Dliteratum%253Aachs%26aulast%3DSteinkamp%26aufirst%3DA.%2BD.%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DBrosge%26aufirst%3DF.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DBuilding%2520Block%2520Approach%2520for%2520the%2520Synthesis%2520of%2520Sulfoximines%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D5348%26epage%3D5351%26doi%3D10.1021%2Facs.orglett.6b02678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: Synthesis and Catalytic Applications</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1246/cl.2004.482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1246%2Fcl.2004.482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFemu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=482-487&author=H.+Okamuraauthor=C.+Bolm&title=Sulfoximines%3A+Synthesis+and+Catalytic+Applications&doi=10.1246%2Fcl.2004.482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: Synthesis and catalytic applications</span></div><div class="casAuthors">Okamura, Hiroaki; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">482-487</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Chiral sulfoximines have a stereogenic center at the sulfur atom and their use in asym. synthesis is well established.  Recently, sulfoximines have been recognized as an interesting new class of chiral ligands, which can be applied in various asym. metal catalyzes.  This review summarizes the latest progress in synthetic methods towards sulfoximines and the application of chiral derivs. in catalytic asym. reactions.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVmt7dFHJS7Vg90H21EOLACvtfcHk0li5Y6CeG5ttQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFemu78%253D&md5=bf4314a99485e415de467c7f68967bf4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1246%2Fcl.2004.482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2004.482%26sid%3Dliteratum%253Aachs%26aulast%3DOkamura%26aufirst%3DH.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfoximines%253A%2520Synthesis%2520and%2520Catalytic%2520Applications%26jtitle%3DChem.%2520Lett.%26date%3D2004%26volume%3D33%26spage%3D482%26epage%3D487%26doi%3D10.1246%2Fcl.2004.482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barthelemy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnier, E.</span></span> <span> </span><span class="NLM_article-title">Recent Trends in Perfluorinated Sulfoximines</span>. <i>C. R. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.crci.2018.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.crci.2018.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFeqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=711-722&author=A.+L.+Barthelemyauthor=E.+Magnier&title=Recent+Trends+in+Perfluorinated+Sulfoximines&doi=10.1016%2Fj.crci.2018.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent trends in perfluorinated sulfoximines</span></div><div class="casAuthors">Barthelemy, Anne-Laure; Magnier, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus Chimie</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">CRCOCR</span>;
        ISSN:<span class="NLM_cas:issn">1631-0748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  This short review summarizes the recent works in S-perfluoroalkylated sulfoximines.  This review will consequently focus on an overview of the new trends in this research area, since 2014.  The structural diversification of the skeleton of sulfoximines via N-functionalization or ortho-lithiation, their applications in catalytic and organocatalytic systems, their use as perfluoroalkylating reagents, and their potential as biol. active mols. have been discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNJS4hcrHvzrVg90H21EOLACvtfcHk0li5Y6CeG5ttQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFeqsrk%253D&md5=2a101a7000e27b2c1d0c0be6431fa969</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.crci.2018.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crci.2018.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DBarthelemy%26aufirst%3DA.%2BL.%26aulast%3DMagnier%26aufirst%3DE.%26atitle%3DRecent%2520Trends%2520in%2520Perfluorinated%2520Sulfoximines%26jtitle%3DC.%2520R.%2520Chim.%26date%3D2018%26volume%3D21%26spage%3D711%26epage%3D722%26doi%3D10.1016%2Fj.crci.2018.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomé, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Chiral Sulfoximine-Based Thioureas and Their Application in Asymmetric Organocatalysis</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.3762/bjoc.8.164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3762%2Fbjoc.8.164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23019479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWrs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1443-1451&author=M.+Fringsauthor=I.+Thom%C3%A9author=C.+Bolm&title=Synthesis+of+Chiral+Sulfoximine-Based+Thioureas+and+Their+Application+in+Asymmetric+Organocatalysis&doi=10.3762%2Fbjoc.8.164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of chiral sulfoximine-based thioureas and their application in asymmetric organocatalysis</span></div><div class="casAuthors">Frings, Marcus; Thome, Isabelle; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1443-1451, No. 164</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">For the first time, chiral sulfoximine derivs. have been applied as asym. organocatalysts.  In combination with a thiourea-type backbone the sulfonimidoyl moiety leads to organocatalysts showing good reactivity in the catalytic desymmetrization of a cyclic meso-anhydride and moderate enantioselectivity in the catalytic asym. Biginelli reaction.  Straightforward synthetic routes provide the newly designed thiourea-sulfoximine catalysts in high overall yields without affecting the stereohomogeneity of the sulfur-contg. core fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFfuM-KD5frVg90H21EOLACvtfcHk0liwlbkf1fNWEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWrs7rE&md5=44bbd7d1d1331311126d34603e067bd8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.8.164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.8.164%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DThom%25C3%25A9%26aufirst%3DI.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520Chiral%2520Sulfoximine-Based%2520Thioureas%2520and%2520Their%2520Application%2520in%2520Asymmetric%2520Organocatalysis%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D8%26spage%3D1443%26epage%3D1451%26doi%3D10.3762%2Fbjoc.8.164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span> <span> </span><span class="NLM_article-title">Action of Nitrogen Trichloride on Proteins: Progress in the Isolation of the Toxic Factor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/163675a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2F163675a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18120748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaH1MXktFGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1949&pages=675-676&author=H.+R.+Bentleyauthor=E.+E.+McDermottauthor=J.+Paceauthor=J.+K.+Whiteheadauthor=T.+Moran&title=Action+of+Nitrogen+Trichloride+on+Proteins%3A+Progress+in+the+Isolation+of+the+Toxic+Factor&doi=10.1038%2F163675a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Action of nitrogen trichloride on proteins. Progress in the isolation of the toxic factor</span></div><div class="casAuthors">Bentley, H. R.; McDermott, E. E.; Pace, J.; Whitehead, J. K.; Moran, T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">675-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Finely powd. zein (treated with NCl3 at a level of 5.5 mg./g. by absorption from a mixt. of NCl3 vapor and Cl2 dild. with moist air) was digested with pancreatin.  Dialysis through Cellophane sepd. the toxic factor in the dialyzate, which was then extd. successively with H2O-satd. BuOH at 80° and then with phenol in the cold.  The phenol-sol. material was hydrolyzed by boiling under reflux for 3 hrs. with 8 N HCl (the bulk of excess HCl removed by repeated evapn. in vacuo and the residue redissolved in H2O), again repeatedly extd. with hot BuOH and decolorized with charcoal.  The aq. phase contg. the toxic factor after BuOH extn. was brought to 95% acetone concn. when the toxic factor was distributed between the gummy ppt. and the sol. fraction.  The ppt., redissolved in H2O, was electrodialyzed in a 3-compartment cell and the material from the middle compartment was then applied to a resin column (Zeo-Karb 215).  On elution with NH3 (0.15 N) the amino acids appear in the effluent in the same order as that described by Partridge (Chemistry & Industry 1949, 27) the toxic factor being eluted in a broad band following proline and extending to the point of the NH3 "break through."  When examd. on paper chromatograms, the material of the toxic band was found to contain several ninhydrin-reacting substances; proline, a substance A (probably methionine) with an RF value of 0.75, and unidentified substances giving a group of purple spots of RF values in the range of 0.1-0.3 (Whatman No. 4 paper run with phenol).  These substances of low RF values were impurities and not identified with the toxic factor; feeding expts. showed them to be nontoxic.  Hydrolysis of the toxic material did not yield new ninhydrin-reacting substances; consequently, it was considered that the toxic factor was not a peptide unless it was present in amt. below the sensitivity of the ninhydrin test.  The toxicity of the most concd. material represented a 2500-fold increase on that of the original treated zein; the toxic dose is 2 mg. and 5 g., resp., when tested on 1-kg. rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGit5KlK9v8rVg90H21EOLACvtfcHk0liwlbkf1fNWEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH1MXktFGqtg%253D%253D&md5=e35b639d96d205381eb78d3460c76f08</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2F163675a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F163675a0%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DH.%2BR.%26aulast%3DMcDermott%26aufirst%3DE.%2BE.%26aulast%3DPace%26aufirst%3DJ.%26aulast%3DWhitehead%26aufirst%3DJ.%2BK.%26aulast%3DMoran%26aufirst%3DT.%26atitle%3DAction%2520of%2520Nitrogen%2520Trichloride%2520on%2520Proteins%253A%2520Progress%2520in%2520the%2520Isolation%2520of%2520the%2520Toxic%2520Factor%26jtitle%3DNature%26date%3D1949%26volume%3D163%26spage%3D675%26epage%3D676%26doi%3D10.1038%2F163675a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">Dist and Canine Hysteria; Experimental Production by Treated Flour</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1136/bmj.2.4484.885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fbmj.2.4484.885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20278492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaH2s%252FktVSjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1946&pages=885-887&author=E.+Mellanby&title=Dist+and+Canine+Hysteria%3B+Experimental+Production+by+Treated+Flour&doi=10.1136%2Fbmj.2.4484.885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dist and canine hysteria; experimental production by treated flour</span></div><div class="casAuthors">MELLANBY E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4484</span>),
    <span class="NLM_cas:pages">885-7</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvQ1qqyubszJWtyewyzkyLfW6udTcc2eZFW0g9OeD6Q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH2s%252FktVSjtA%253D%253D&md5=1734ca5f1208114f45b0d40e623d2a86</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1136%2Fbmj.2.4484.885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.2.4484.885%26sid%3Dliteratum%253Aachs%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DDist%2520and%2520Canine%2520Hysteria%253B%2520Experimental%2520Production%2520by%2520Treated%2520Flour%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1946%26volume%3D2%26spage%3D885%26epage%3D887%26doi%3D10.1136%2Fbmj.2.4484.885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">Further Observations on the Production of Canine Hysteria by Flour Treated with Nitrogen Trichloride (Agene Process)</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1947</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1136/bmj.2.4520.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fbmj.2.4520.288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20257560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaH2s%252FhvFSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1947&pages=288-289&author=E.+Mellanby&title=Further+Observations+on+the+Production+of+Canine+Hysteria+by+Flour+Treated+with+Nitrogen+Trichloride+%28Agene+Process%29&doi=10.1136%2Fbmj.2.4520.288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Further observations on the production of canine hysteria by flour treated with nitrogen trichloride (agene process)</span></div><div class="casAuthors">MELLANBY E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1947</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4520</span>),
    <span class="NLM_cas:pages">288</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgtJH1gKZ31EEksK8CslK8fW6udTcc2eZFW0g9OeD6Q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH2s%252FhvFSktg%253D%253D&md5=56667154a76d451488b8b0a3597813a5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fbmj.2.4520.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.2.4520.288%26sid%3Dliteratum%253Aachs%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DFurther%2520Observations%2520on%2520the%2520Production%2520of%2520Canine%2520Hysteria%2520by%2520Flour%2520Treated%2520with%2520Nitrogen%2520Trichloride%2520%2528Agene%2520Process%2529%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1947%26volume%3D2%26spage%3D288%26epage%3D289%26doi%3D10.1136%2Fbmj.2.4520.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Work, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">The Isolation of a Toxic Substance from Agenized Wheat Flour</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1951</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1042/bj0480106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2Fbj0480106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14820791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaG3MXislOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1951&pages=106-113&author=P.+N.+Campbellauthor=T.+S.+Workauthor=E.+Mellanby&title=The+Isolation+of+a+Toxic+Substance+from+Agenized+Wheat+Flour&doi=10.1042%2Fbj0480106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a toxic substance from agenized wheat flour</span></div><div class="casAuthors">Campbell, P. N.; Work, T. S.; Mellanby, E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106-13</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">cf. C.A. 44, 6044g.  Digestion of agenized gluten with pepsin and trypsin converted about 80% of the N into dialyzable substances but the latter were as toxic as the nondialyzable portion.  The toxic substance must, therefore, be an integral part of the protein.  Acid hydrolysis destroyed about 30% of toxicity and the amino N/total N was increased from 0.25 to 0.60, thus decreasing the av. mol. wt.  Electrodialysis achieved considerable purification of the toxic substance since 36% of the amino N was removed as glutamic and about 10% as basic amino acids.  Removal of aromatic amino acids by charcoal was a necessary preliminary to fractionation on a Zeo-Karb 215 column.  The toxic substance was found in this column immediately following the proline fraction, the max. toxicity being confined to a relatively small fraction.  γ-Aminobutyric acid was isolated by paper chromatography (46.7 mg. thrice recrystd., m.p. 193°, from 1800 g. gluten) and identified as such.  Since it does not occur in untreated gluten, this amino acid must be regarded as being formed under the action of NCl3, but it is not the toxic agent.  Further fractionation was made on a column of powd. paper (complete fractionation achieved with 1000 g. paper pulp to 100 mg. N).  Extensive expts. lead to the conclusion that the toxic substance is a deriv. of methionine, although methionine peptides treated with NCl3 did not produce the toxic substance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwj1kzS3-N7Vg90H21EOLACvtfcHk0lgV8VHxGeIpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3MXislOrtQ%253D%253D&md5=c026c5e997a922c5e246b0a8defca4fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1042%2Fbj0480106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj0480106%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DP.%2BN.%26aulast%3DWork%26aufirst%3DT.%2BS.%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DThe%2520Isolation%2520of%2520a%2520Toxic%2520Substance%2520from%2520Agenized%2520Wheat%2520Flour%26jtitle%3DBiochem.%2520J.%26date%3D1951%26volume%3D48%26spage%3D106%26epage%3D113%26doi%3D10.1042%2Fbj0480106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Potent and Specific Inhibition of Glutathione Synthesis by Buthionine Sulfoximine (S-n-Butyl Homocysteine Sulfoximine)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">7558</span>– <span class="NLM_lpage">7560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=38242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1MXlvVOhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=7558-7560&author=O.+W.+Griffithauthor=A.+Meister&title=Potent+and+Specific+Inhibition+of+Glutathione+Synthesis+by+Buthionine+Sulfoximine+%28S-n-Butyl+Homocysteine+Sulfoximine%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)</span></div><div class="casAuthors">Griffith, Owen W.; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7558-60</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">DL-Buthionine-SR-sulfoximine)  [5072-26-4] inhibited γ-glutamylcysteine synthetase  [9023-64-7] ∼20 times more effectively that did DL-prothionine-SR-sulfoximine  [70085-86-8] and ≥100 times more effectively than L-methionine-SR-sulfoximine  [15985-39-4].  The S-alkyl moiety of the sulfoximine apparently binds at the enzyme site that normally binds the acceptor amino acid.  Thus, the affinity of the enzyme for the S-Et, S-n-Pr, and S-n-Bu sulfoximines increases in a manner which is parallel to those of the corresponding isosteric acceptor amino acid substrates, i.e. glycine, alanine, and α-aminobutyrate.  Buthionine sulfoximine did not inhibit glutamine synthetase  [9023-70-5], detectably, nor did it produce convulsions when injected into mice.  Injection of buthionine sulfoximine into mice decreased the level of glutathione  [70-18-8] in the kidney to a greater extent (<20% of the control level) than found previously after giving prothionine sulfoximine.  α-Methyl-DL-buthionine-SR-sulfoximine  [71806-54-7] was also prepd. and was almost as effective as buthionine sulfoximine, this compd. would not be expected to undergo substantial degradative metab.  Buthionine sulfoximine and α-Me buthionine sulfoximine may be useful agents for inhibition of glutathione synthesis in various exptl. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV-FKkR0surVg90H21EOLACvtfcHk0lgV8VHxGeIpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlvVOhu70%253D&md5=60a87fed5e007d1c70204b879fec3383</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DO.%2BW.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DPotent%2520and%2520Specific%2520Inhibition%2520of%2520Glutathione%2520Synthesis%2520by%2520Buthionine%2520Sulfoximine%2520%2528S-n-Butyl%2520Homocysteine%2520Sulfoximine%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D7558%26epage%3D7560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Identification of L-Methionine S-Sulfoximine as the Diastereoisomer of L-Methionine SR-Sulfoximine that Inhibits Glutamine Synthetase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2681</span>– <span class="NLM_lpage">2685</span>, <span class="refDoi"> DOI: 10.1021/bi00834a066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00834a066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaF1MXktlKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1969&pages=2681-2685&author=J.+M.+Manningauthor=S.+Mooreauthor=W.+B.+Roweauthor=A.+Meister&title=Identification+of+L-Methionine+S-Sulfoximine+as+the+Diastereoisomer+of+L-Methionine+SR-Sulfoximine+that+Inhibits+Glutamine+Synthetase&doi=10.1021%2Fbi00834a066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of L-methionine S-sulfoximine as the diastereoisomer of L-methionine SR-sulfoximine that inhibits glutamine synthetase</span></div><div class="casAuthors">Manning, James M.; Moore, Stanford; Rowe, William Bruce; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2681-5</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The diastereoisomers of L-methionine SR-sulfoximine phosphate have been sepd. as the corresponding α-N-L-leucyl derivs. by ion-exchange chromatog. on an amino acid analyzer.  The diastereoisomers of L-methionine SR-sulfoximine and L-methionine SR-sulfoxide can be sepd. without derivatization.  Chromatographic study of the L-methionine sulfoximine phosphate obtained from sheep brain glutamine synthetase inhibited by treatment with L-methionine SR-sulfoximine, ATP, and Mg2+ showed the presence of only 1 diastereoisomer.  Studies with prepns. of L-methionine S-sulfoximine and L-methionine R-sulfoximine indicate that only the former diastereoisomer is phosphorylated and inhibits the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcEBp15neEeLVg90H21EOLACvtfcHk0lgV8VHxGeIpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXktlKjtbo%253D&md5=c6fb76051344971ca0dcf9e8252d52d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi00834a066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00834a066%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DRowe%26aufirst%3DW.%2BB.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520L-Methionine%2520S-Sulfoximine%2520as%2520the%2520Diastereoisomer%2520of%2520L-Methionine%2520SR-Sulfoximine%2520that%2520Inhibits%2520Glutamine%2520Synthetase%26jtitle%3DBiochemistry%26date%3D1969%26volume%3D8%26spage%3D2681%26epage%3D2685%26doi%3D10.1021%2Fbi00834a066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of γ-Glutamylcysteine Synthetase by L-Methionine-S-sulfoximine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">6684</span>– <span class="NLM_lpage">6690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=4147652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE3sXlsVers78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1973&pages=6684-6690&author=P.+G.+Richmanauthor=M.+Orlowskiauthor=A.+Meister&title=Inhibition+of+%CE%B3-Glutamylcysteine+Synthetase+by+L-Methionine-S-sulfoximine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of γ-glutamylcysteine synthetase by L-methionine-S-sulfoximine</span></div><div class="casAuthors">Richman, Paul G.; Orlowski, Marian; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6684-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Methionine sulfoximine was an effective inhibitor of γ-glutamylcysteine synthetase.  The data indicated that methionine sulfoximine bound to the glutamate site of the enzyme and that, in the presence of ATP and metal ions (Mg2+ or Mn2+ it was converted to methionine sulfoximine phosphate.  Of the 4 stereoisomers of methionine sulfoximine, only L-methionine-S-sulfoximine inhibited the enzyme; this is the same stereoisomer which inhibits glutamine synthetase and which causes convulsions in mice.  Chem. synthesized L-methionine sulfoximine phosphate inhibited the enzyme in the presence of Mg2+ or Mn2+.  These findings indicated that the mechanism of inhibition of γ-glutamylcysteine synthetase by methionine sulfoximine was similar to that by which this compd. was previously shown to inhibit glutamine synthetase.  However, methionine sulfoximine phosphate was less tightly bound to γ-glutamylcysteine synthetase than to glutamine synthetase; thus, under certain conditions methionine sulfoximine phosphate can be released from inhibited γ-glutamylcysteine synthetase with restoration of catalytic activity.  The findings were in accord with the view that enzyme-bound γ-glutamyl phosphate was an intermediate in the reaction catalyzed by γ-glutamylcysteine synthetase, and that phosphorylation of methionine sulfoximine by the enzyme reflected the phosphorylation step of the normal catalytic reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHwgmWByORorVg90H21EOLACvtfcHk0liWZuFg9g9wtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXlsVers78%253D&md5=44297b3f3856849740ccbab5eb60405e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DP.%2BG.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520%25CE%25B3-Glutamylcysteine%2520Synthetase%2520by%2520L-Methionine-S-sulfoximine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1973%26volume%3D248%26spage%3D6684%26epage%3D6690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, J. K.</span></span> <span> </span><span class="NLM_article-title">Action of Nitrogen Trichloride on Proteins: A Synthesis of the Toxic Factor from Methionine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1950</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">735</span>, <span class="refDoi"> DOI: 10.1038/165735b0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2F165735b0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15416824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaG3cXjvVOqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1950&pages=735&author=H.+R.+Bentleyauthor=E.+E.+McDermottauthor=J.+K.+Whitehead&title=Action+of+Nitrogen+Trichloride+on+Proteins%3A+A+Synthesis+of+the+Toxic+Factor+from+Methionine&doi=10.1038%2F165735b0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Action of nitrogen trichloride on proteins-synthesis of the toxic factor from methionine</span></div><div class="casAuthors">Bentley, H. R.; McDermott, E. E.; Whitehead, J. K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1950</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">735</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">cf. C.A. 43, 7523e; 44, 181c.  A cryst. compd. identical with the toxic factor of agenized zein or wheat gluten was synthesized from DL-methionine sulfoxide and NH3 (Schmidt reaction).  Its structure, HO2CCH(NH2)CH2CH2S++Me-(O-)(N-H), was proved by comparison with the factor isolated from NCl3-treated cereal, by using paper chromatog. and rabbit toxicity tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEplW5BF_qQ7Vg90H21EOLACvtfcHk0liWZuFg9g9wtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3cXjvVOqsQ%253D%253D&md5=e7cebe3ee6b522534a1e027322cc49c8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2F165735b0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F165735b0%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DH.%2BR.%26aulast%3DMcDermott%26aufirst%3DE.%2BE.%26aulast%3DWhitehead%26aufirst%3DJ.%2BK.%26atitle%3DAction%2520of%2520Nitrogen%2520Trichloride%2520on%2520Proteins%253A%2520A%2520Synthesis%2520of%2520the%2520Toxic%2520Factor%2520from%2520Methionine%26jtitle%3DNature%26date%3D1950%26volume%3D165%26spage%3D735%26doi%3D10.1038%2F165735b0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H. H.</span></span> <span> </span><span class="NLM_article-title">L-S,R-Buthionine Sulfoximine: Historical Development and Clinical Issues</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>111–112</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(97)00164-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0009-2797%2897%2900164-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9679558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111%E2%80%93112&publication_year=1998&pages=239-254&author=H.+H.+Bailey&title=L-S%2CR-Buthionine+Sulfoximine%3A+Historical+Development+and+Clinical+Issues&doi=10.1016%2FS0009-2797%2897%2900164-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">L-S,R-buthionine sulfoximine: historical development and clinical issues</span></div><div class="casAuthors">Bailey, Howard H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111-112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-254</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 39 refs.  L-S,R-buthionine sulfoximine (L-S,R BSO) is a potent specific inhibitor of γ-glutamylcysteine synthetase, the rate-limiting step in glutathione (GSH) biosynthesis.  GSH is an important component of tumor drug resistance based on a strong assocn. and recent transfection studies.  Depletion of intracellular GSH by BSO significantly enhances the cytotoxicity of many cytotoxic agents, principally alkylating agents and platinating compds. but also irradn. and anthracyclines.  Phase I clin. trials of BSO + melphalan (L-PAM) have been carried out and obsd. little toxicity with BSO alone and increased myelosuppression with BSO + L-PAM.  Consistent and profound (<10% of control) GSH depletion was obsd. in serial detns. of tumor GSH levels in patients receiving continuous infusion (CI) BSO.  Evidence of clin. activity has been obsd. in patients with alkylating or platinating agent-refractory tumors.  Phase II evaluation of CI BSO with L-PAM is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEjK5eJejBWbVg90H21EOLACvtfcHk0liWZuFg9g9wtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSksbk%253D&md5=10a1d55d64a05b6d5d82d2e375825b91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2897%2900164-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252897%252900164-6%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%2BH.%26atitle%3DL-S%252CR-Buthionine%2520Sulfoximine%253A%2520Historical%2520Development%2520and%2520Clinical%2520Issues%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1998%26volume%3D111%25E2%2580%2593112%26spage%3D239%26epage%3D254%26doi%3D10.1016%2FS0009-2797%2897%2900164-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Breijo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monserrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez-Rubio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Laviada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Moreno, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Román, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisbert, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guijarro, L. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of Azathioprine Plus Buthionine Sulfoximine in the Treatment of Human Hepatocarcinoma and Colon Carcinoma</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3899</span>– <span class="NLM_lpage">3911</span>, <span class="refDoi"> DOI: 10.3748/wjg.v17.i34.3899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3748%2Fwjg.v17.i34.3899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22025878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyqtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3899-3911&author=B.+Hern%C3%A1ndez-Breijoauthor=J.+Monserratauthor=S.+Ram%C3%ADrez-Rubioauthor=E.+P.+Cuevasauthor=D.+Varaauthor=I.+D%C3%ADaz-Laviadaauthor=M.+D.+Fern%C3%A1ndez-Morenoauthor=I.+D.+Rom%C3%A1nauthor=J.+P.+Gisbertauthor=L.+G.+Guijarro&title=Preclinical+Evaluation+of+Azathioprine+Plus+Buthionine+Sulfoximine+in+the+Treatment+of+Human+Hepatocarcinoma+and+Colon+Carcinoma&doi=10.3748%2Fwjg.v17.i34.3899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma</span></div><div class="casAuthors">Hernandez-Breijo, Borja; Monserrat, Jorge; Ramirez-Rubio, Sara; Cuevas, Eva P.; Vara, Diana; Diaz-Laviada, Ines; Fernandez-Moreno, M. Dolores; Roman, Irene D.; Gisbert, Javier P.; Guijarro, Luis G.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3899-3911</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">To evaluate the efficacy and the safety of azathioprine (AZA) and buthionine sulfoximine (BSO) by localized application into HepG2 tumor in vivo.  Different hepatoma and colon carcinoma cell lines (HepG2, HuH7, Chang liver, LoVo, RKO, SW-48, SW-480) were grown in minimal essential medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic soln. and maintained in a humidified 37°C incubator with 5% CO2.  These cells were pretreated with BSO for 24 h and then with AZA for different times.  We examd. the effects of this combination on some proteins and on cellular death.  We also studied the efficacy and the safety of AZA (6 mg/kg per day) and BSO (90 mg/kg per day) in HepG2 tumor growth in vivo using athymic mice.  We measured safety by serol. markers such as amino-transferases and creatine kinase.  The in vitro studies revealed a new mechanism of action for the AZA plus BSO combination in the cancer cells compared with other thiopurines (6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine and 6-methylthioguanine) in combination with BSO.  The cytotoxic effect of AZA plus BSO in HepG2 cells resulted from necroptosis induction in a mitochondrial-dependent manner.  From kinetic studies we suggest that glutathione (GSH) depletion stimulates c-Jun amino-terminal kinase and Bax translocation in HepG2 cells with subsequent deregulation of mitochondria (cytochrome c release, loss of membrane potential), and proteolysis activation leading to loss of membrane integrity, release of lactate dehydrogenase and DNA degrdn.  Some of this biochem. and cellular changes could be reversed by N-acetylcysteine (a GSH replenisher).  In vivo studies showed that HepG2 tumor growth was inhibited when AZA was combined with BSO.  Our studies suggest that a combination of AZA plus BSO could be useful for localized treatment of hepatocellular carcinoma as in the currently used transarterial chemoembolization method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa0uPLZFLPLVg90H21EOLACvtfcHk0liWZuFg9g9wtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyqtLjP&md5=8d6ebb1b52dbda23b3f811eced5e98b6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v17.i34.3899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v17.i34.3899%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Breijo%26aufirst%3DB.%26aulast%3DMonserrat%26aufirst%3DJ.%26aulast%3DRam%25C3%25ADrez-Rubio%26aufirst%3DS.%26aulast%3DCuevas%26aufirst%3DE.%2BP.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26aulast%3DFern%25C3%25A1ndez-Moreno%26aufirst%3DM.%2BD.%26aulast%3DRom%25C3%25A1n%26aufirst%3DI.%2BD.%26aulast%3DGisbert%26aufirst%3DJ.%2BP.%26aulast%3DGuijarro%26aufirst%3DL.%2BG.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Azathioprine%2520Plus%2520Buthionine%2520Sulfoximine%2520in%2520the%2520Treatment%2520of%2520Human%2520Hepatocarcinoma%2520and%2520Colon%2520Carcinoma%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D17%26spage%3D3899%26epage%3D3911%26doi%3D10.3748%2Fwjg.v17.i34.3899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renga, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBoer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Sulfoxaflor, a Novel Insecticide Targeting Sap-Feeding Pests</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2950</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1021/jf102765x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf102765x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=2950-2957&author=Y.+Zhuauthor=M.+R.+Losoauthor=G.+B.+Watsonauthor=T.+C.+Sparksauthor=R.+B.+Rogersauthor=J.+X.+Huangauthor=B.+C.+Gerwickauthor=J.+M.+Babcockauthor=D.+Kelleyauthor=V.+B.+Hegdeauthor=B.+M.+Nugentauthor=J.+M.+Rengaauthor=I.+Denholmauthor=K.+Gormanauthor=G.+J.+DeBoerauthor=J.+Haslerauthor=T.+Meadeauthor=J.+D.+Thomas&title=Discovery+and+Characterization+of+Sulfoxaflor%2C+a+Novel+Insecticide+Targeting+Sap-Feeding+Pests&doi=10.1021%2Fjf102765x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Sulfoxaflor, a Novel Insecticide Targeting Sap-Feeding Pests</span></div><div class="casAuthors">Zhu, Yuan-Ming; Loso, Michael R.; Watson, Gerald. B.; Sparks, Thomas C.; Rogers, Richard B.; Huang, Jim X.; Gerwick, B. Clifford; Babcock, Jonathan M.; Kelley, Donald; Hegde, Vidyadhar B.; Nugent, Benjamin M.; Renga, James M.; Denholm, Ian; Gorman, Kevin; DeBoer, Gerrit J.; Hasler, James; Meade, Thomas; Thomas, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2950-2957</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of sulfoxaflor [N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-λ4-sulfanylidene] cyanamide] resulted from an investigation of the sulfoximine functional group as a novel bioactive scaffold for insecticidal activity and a subsequent extensive structure-activity relationship study.  Sulfoxaflor, the first product from this new class (the sulfoximines) of insect control agents, exhibits broad-spectrum efficacy against many sap-feeding insect pests, including aphids, whiteflies, hoppers, and Lygus, with levels of activity that are comparable to those of other classes of insecticides targeting sap-feeding insects, including the neonicotinoids.  However, no cross-resistance has been obsd. between sulfoxaflor and neonicotinoids such as imidacloprid, apparently the result of differences in susceptibility to oxidative metab.  Available data are consistent with sulfoxaflor acting via the insect nicotinic receptor in a complex manner.  These observations reflect the unique structure of the sulfoximines compared with neonicotinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHh1N6zSdO7bVg90H21EOLACvtfcHk0lj_SIp_v227Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzJ&md5=1fb0ba843a6cd43cb8b3a451cef00afd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjf102765x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf102765x%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DRogers%26aufirst%3DR.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DGerwick%26aufirst%3DB.%2BC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DKelley%26aufirst%3DD.%26aulast%3DHegde%26aufirst%3DV.%2BB.%26aulast%3DNugent%26aufirst%3DB.%2BM.%26aulast%3DRenga%26aufirst%3DJ.%2BM.%26aulast%3DDenholm%26aufirst%3DI.%26aulast%3DGorman%26aufirst%3DK.%26aulast%3DDeBoer%26aufirst%3DG.%2BJ.%26aulast%3DHasler%26aufirst%3DJ.%26aulast%3DMeade%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Sulfoxaflor%252C%2520a%2520Novel%2520Insecticide%2520Targeting%2520Sap-Feeding%2520Pests%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2011%26volume%3D59%26spage%3D2950%26epage%3D2957%26doi%3D10.1021%2Fjf102765x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Insecticides: Targets, Selectivity, Resistance, and Secondary Effects</span>. <i>Annu. Rev. Entomol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1146/annurev-ento-120811-153645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-ento-120811-153645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23317040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=99-117&author=J.+E.+Casidaauthor=K.+A.+Durkin&title=Neuroactive+Insecticides%3A+Targets%2C+Selectivity%2C+Resistance%2C+and+Secondary+Effects&doi=10.1146%2Fannurev-ento-120811-153645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive insecticides: targets, selectivity, resistance, and secondary effects</span></div><div class="casAuthors">Casida, John E.; Durkin, Kathleen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Entomology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-117</span>CODEN:
                <span class="NLM_cas:coden">ARENAA</span>;
        ISSN:<span class="NLM_cas:issn">0066-4170</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neuroactive insecticides are the principal means of protecting crops, people, livestock, and pets from pest insect attack and disease transmission.  Currently, the four major nerve targets are acetylcholinesterase for organophosphates and methylcarbamates, the nicotinic acetylcholine receptor for neonicotinoids, the γ-aminobutyric acid receptor/chloride channel for polychlorocyclohexanes and fiproles, and the voltage-gated sodium channel for pyrethroids and dichlorodiphenyltrichloroethane.  Species selectivity and acquired resistance are attributable in part to structural differences in binding subsites, receptor subunit interfaces, or transmembrane regions.  Addnl. targets are sites in the sodium channel (indoxacarb and metaflumizone), the glutamate-gated chloride channel (avermectins), the octopamine receptor (amitraz metabolite), and the calcium-activated calcium channel (diamides).  Secondary toxic effects in mammals from off-target serine hydrolase inhibition include organophosphate-induced delayed neuropathy and disruption of the cannabinoid system.  Possible assocns. between pesticides and Parkinson's and Alzheimer's diseases are proposed but not established based on epidemiol. observations and mechanistic considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98rRbt7XflbVg90H21EOLACvtfcHk0lj_SIp_v227Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVWjtrk%253D&md5=ad091517bf34bf0b36ab3bbf25b8525c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1146%2Fannurev-ento-120811-153645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-ento-120811-153645%26sid%3Dliteratum%253Aachs%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26atitle%3DNeuroactive%2520Insecticides%253A%2520Targets%252C%2520Selectivity%252C%2520Resistance%252C%2520and%2520Secondary%2520Effects%26jtitle%3DAnnu.%2520Rev.%2520Entomol.%26date%3D2013%26volume%3D58%26spage%3D99%26epage%3D117%26doi%3D10.1146%2Fannurev-ento-120811-153645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span> <span> </span><span class="NLM_article-title">Sulfoxaflor and the Sulfoximine Insecticides: Chemistry, Mode of Action and Basis for Efficacy on Resistant Insects</span>. <i>Pestic. Biochem. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.pestbp.2013.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.pestbp.2013.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25149228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1-7&author=T.+C.+Sparksauthor=G.+B.+Watsonauthor=M.+R.+Losoauthor=C.+Gengauthor=J.+M.+Babcockauthor=J.+D.+Thomas&title=Sulfoxaflor+and+the+Sulfoximine+Insecticides%3A+Chemistry%2C+Mode+of+Action+and+Basis+for+Efficacy+on+Resistant+Insects&doi=10.1016%2Fj.pestbp.2013.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoxaflor and the sulfoximine insecticides: Chemistry, mode of action and basis for efficacy on resistant insects</span></div><div class="casAuthors">Sparks, Thomas C.; Watson, Gerald B.; Loso, Michael R.; Geng, Chaoxian; Babcock, Jon M.; Thomas, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Biochemistry and Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">PCBPBS</span>;
        ISSN:<span class="NLM_cas:issn">0048-3575</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The sulfoximines, as exemplified by sulfoxaflor ([N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-λ4-sulfanylidene]cyanamide) represent a new class of insecticides.  Sulfoxaflor exhibits a high degree of efficacy against a wide range of sap-feeding insects, including those resistant to neonicotinoids and other insecticides.  Sulfoxaflor is an agonist at insect nicotinic acetylcholine receptors (nAChRs) and functions in a manner distinct from other insecticides acting at nAChRs.  The sulfoximines also exhibit structure activity relationships (SAR) that are different from other nAChR agonists such as the neonicotinoids.  This review summarizes the sulfoximine SAR, mode of action and the biochem. underlying the obsd. efficacy on resistant insect pests, with a particular focus on sulfoxaflor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Fm-KpdpakrVg90H21EOLACvtfcHk0lj_SIp_v227Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgt7vE&md5=92a0bbcdffbab995170c24526dae2811</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.pestbp.2013.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pestbp.2013.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26atitle%3DSulfoxaflor%2520and%2520the%2520Sulfoximine%2520Insecticides%253A%2520Chemistry%252C%2520Mode%2520of%2520Action%2520and%2520Basis%2520for%2520Efficacy%2520on%2520Resistant%2520Insects%26jtitle%3DPestic.%2520Biochem.%2520Physiol.%26date%3D2013%26volume%3D107%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.pestbp.2013.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Longhurst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span> <span> </span><span class="NLM_article-title">Cross-Resistance Relationships of the Sulfoximine Insecticide Sulfoxaflor with Neonicotinoids and Other Insecticides in the Whiteflies <i>Bemisia tabaci</i> and <i>Trialeurodes vaporariorum</i></span>. <i>Pest Manage. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/ps.3439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fps.3439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23203347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCktLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=809-813&author=C.+Longhurstauthor=J.+M.+Babcockauthor=I.+Denholmauthor=K.+Gormanauthor=J.+D.+Thomasauthor=T.+C.+Sparks&title=Cross-Resistance+Relationships+of+the+Sulfoximine+Insecticide+Sulfoxaflor+with+Neonicotinoids+and+Other+Insecticides+in+the+Whiteflies+Bemisia+tabaci+and+Trialeurodes+vaporariorum&doi=10.1002%2Fps.3439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-resistance relationships of the sulfoximine insecticide sulfoxaflor with neonicotinoids and other insecticides in the whiteflies Bemisia tabaci and Trialeurodes vaporariorum</span></div><div class="casAuthors">Longhurst, Christopher; Babcock, Jonathan M.; Denholm, Ian; Gorman, Kevin; Thomas, James D.; Sparks, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Pest Management Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">PMSCFC</span>;
        ISSN:<span class="NLM_cas:issn">1526-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Agrochem. compds. effective against insect pests such as the whiteflies Bemisia tabaci and Trialeurodes vaporariorum which often show resistance to a range of insecticidal modes of action (MOA) have particular value in insect pest resistance management programs.  The sulfoximine insecticides are chem. unique as the first group to incorporate a sulfoximine functional group.  Sulfoxaflor is the first sulfoximine compd. under com. development for the control of sap-feeding insects.  The sulfoxaflor cross-resistance relations were studied by comparing the responses of field-collected strains and insecticide-susceptible lab. strains of B. tabaci and T. vaporariorum.  Sulfoxaflor, imidacloprid, acetamiprid, deltamethrin, thiamethoxam, profenofos, and dinotefuran insecticides were used in the assays.  Sulfoxaflor had very low (<3-fold) resistance ratios (RR) when tested against B. tabaci strains that had RR up to 1000-fold to imidacloprid and cross-resistance to other neonicotinoid insecticides.  Sulfoxaflor showed no cross-resistance in a B. tabaci strain with resistance to pyrethroid (deltamethrin) and organophosphate (profenophos) insecticides.  No cross-resistance was obsd. between sulfoxaflor and imidacloprid in T. vaporariorum.  One population of the 3 field strains tested showed slightly decrease susceptibility to sufloxaflor with RR = 4.17.  This same population had RR >23.8-fold for imidacloprid relative to the susceptible population.  Despite sharing the target site with neonicotinoids (nicotinic acetylcholine receptor), the sulfoxaflor activity was largely unaffected by existing neonicotinoid resistance in B. tabaci and T. vaporariorum.  Neonicotinoid resistance mechanisms in these whitefly species are primarily based on enhanced detoxification of insecticides.  This lack of cross-resistance indicates that sulfoxaflor can be a valuable tool for the management of sap-feeding insect pests already resistant to established insecticide groups.  © 2012 Society of Chem. Industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYzFNkSuWVbVg90H21EOLACvtfcHk0li7jBQuqFyIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCktLfP&md5=857d94f1fcb98705635dfa13df41d748</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fps.3439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fps.3439%26sid%3Dliteratum%253Aachs%26aulast%3DLonghurst%26aufirst%3DC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DDenholm%26aufirst%3DI.%26aulast%3DGorman%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26atitle%3DCross-Resistance%2520Relationships%2520of%2520the%2520Sulfoximine%2520Insecticide%2520Sulfoxaflor%2520with%2520Neonicotinoids%2520and%2520Other%2520Insecticides%2520in%2520the%2520Whiteflies%2520Bemisia%2520tabaci%2520and%2520Trialeurodes%2520vaporariorum%26jtitle%3DPest%2520Manage.%2520Sci.%26date%3D2013%26volume%3D69%26spage%3D809%26epage%3D813%26doi%3D10.1002%2Fps.3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Insecticide Resistance Action Committee</span>. <a href="http://www.irac-online.org" class="extLink">http://www.irac-online.org</a> (Accessed July 12, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Insecticide+Resistance+Action+Committee.+http%3A%2F%2Fwww.irac-online.org+%28Accessed+July+12%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolting, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Biological Characterization of Sulfoxaflor, a Novel Insecticide</span>. <i>Pest Manage. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1002/ps.2069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fps.2069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21308958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=328-334&author=J.+M.+Babcockauthor=C.+B.+Gerwickauthor=J.+X.+Huangauthor=M.+R.+Losoauthor=G.+Nakamuraauthor=S.+P.+Noltingauthor=R.+B.+Rogersauthor=T.+C.+Sparksauthor=J.+Thomasauthor=G.+B.+Watsonauthor=Y.+Zhu&title=Biological+Characterization+of+Sulfoxaflor%2C+a+Novel+Insecticide&doi=10.1002%2Fps.2069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of sulfoxaflor, a novel insecticide</span></div><div class="casAuthors">Babcock, Jonathan M.; Gerwick, Clifford B.; Huang, Jim X.; Loso, Michael R.; Nakamura, Genta; Nolting, Steven P.; Rogers, Richard B.; Sparks, Thomas C.; Thomas, James; Watson, Gerald B.; Zhu, Yuan-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Pest Management Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-334</span>CODEN:
                <span class="NLM_cas:coden">PMSCFC</span>;
        ISSN:<span class="NLM_cas:issn">1526-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The commercialization of new insecticides is important for ensuring that multiple effective product choices are available.  In particular, new insecticides that exhibit high potency and lack insecticidal cross-resistance are particularly useful in insecticide resistance management (IRM) programs.  Sulfoxaflor possesses these characteristics and is the first compd. under development from the novel sulfoxamine class of insecticides.  Results: In the lab., sulfoxaflor demonstrated high levels of insecticidal potency against a broad range of sap-feeding insect species.  The potency of sulfoxaflor was comparable with that of com. products, including neonicotinoids, for the control of a wide range of aphids, whiteflies (Homoptera) and true bugs (Heteroptera).  Sulfoxaflor performed equally well in the lab. against both insecticide-susceptible and insecticide-resistant populations of sweetpotato whitefly, Bemisia tabaci Gennadius, and brown planthopper, Nilaparvata lugens (Stal), including populations resistant to the neonicotinoid insecticide imidacloprid.  These lab. efficacy trends were confirmed in field trials from multiple geogs. and crops, and in populations of insects with histories of repeated exposure to insecticides.  In particular, a sulfoxaflor use rate of 25 g ha-1 against cotton aphid (Aphis gossypii Glover) outperformed acetamiprid (25 g ha-1) and dicrotophos (560 g ha-1).  Sulfoxaflor (50 g ha-1) provided a control of sweetpotato whitefly equiv. to that of acetamiprid (75 g ha-1) and imidacloprid (50 g ha-1) and better than that of thiamethoxam (50 g ha-1).  Conclusion: The novel chem. of sulfoxaflor, its unique biol. spectrum of activity and its lack of cross-resistance highlight the potential of sulfoxaflor as an important new tool for the control of sap-feeding insect pests.  Copyright © 2010 Society of Chem. Industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hJPxMY9l2rVg90H21EOLACvtfcHk0li7jBQuqFyIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yltbg%253D&md5=6dda9d2ece173d9940b769395008c576</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fps.2069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fps.2069%26sid%3Dliteratum%253Aachs%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DGerwick%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DNakamura%26aufirst%3DG.%26aulast%3DNolting%26aufirst%3DS.%2BP.%26aulast%3DRogers%26aufirst%3DR.%2BB.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DBiological%2520Characterization%2520of%2520Sulfoxaflor%252C%2520a%2520Novel%2520Insecticide%26jtitle%3DPest%2520Manage.%2520Sci.%26date%3D2011%26volume%3D67%26spage%3D328%26epage%3D334%26doi%3D10.1002%2Fps.2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letherer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span> <span> </span><span class="NLM_article-title">Novel Nicotinic Action of the Sulfoximine Insecticide Sulfoxaflor</span>. <i>Insect Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ibmb.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ibmb.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21296156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslKls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=432-439&author=G.+B.+Watsonauthor=M.+R.+Losoauthor=J.+M.+Babcockauthor=J.+M.+Haslerauthor=T.+J.+Lethererauthor=C.+D.+Youngauthor=Y.+Zhuauthor=J.+E.+Casidaauthor=T.+C.+Sparks&title=Novel+Nicotinic+Action+of+the+Sulfoximine+Insecticide+Sulfoxaflor&doi=10.1016%2Fj.ibmb.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Novel nicotinic action of the sulfoximine insecticide sulfoxaflor</span></div><div class="casAuthors">Watson, Gerald B.; Loso, Michael R.; Babcock, Jonathan M.; Hasler, James M.; Letherer, Theodore J.; Young, Cathy D.; Zhu, Yuanming; Casida, John E.; Sparks, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Insect Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">432-439</span>CODEN:
                <span class="NLM_cas:coden">IBMBES</span>;
        ISSN:<span class="NLM_cas:issn">0965-1748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The novel sulfoximine insecticide sulfoxaflor is as potent or more effective than the neonicotinoids for toxicity to green peach aphids (GPA, Myzus persicae).  The action of sulfoxaflor was characterized at insect nicotinic acetylcholine receptors (nAChRs) using electrophysiol. and radioligand binding techniques.  When tested for agonist properties on Drosophila melanogaster Dα2 nAChR subunit co-expressed in Xenopus laevis oocytes with the chicken β2 subunit, sulfoxaflor elicited very high amplitude (efficacy) currents.  Sulfoximine analogs of sulfoxaflor were also agonists on Dα2/β2 nAChRs, but none produced maximal currents equiv. to sulfoxaflor nor were any as toxic to GPAs.  Addnl., except for clothianidin, none of the neonicotinoids produced maximal currents as large as those produced by sulfoxaflor.  These data suggest that the potent insecticidal activity of sulfoxaflor may be due to its very high efficacy at nAChRs.  In contrast, sulfoxaflor displaced [3H]imidacloprid (IMI) from GPA nAChR membrane prepns. with weak affinity compared to most of the neonicotinoids examd.  The nature of the interaction of sulfoxaflor with nAChRs apparently differs from that of IMI and other neonicotinoids, and when coupled with other known characteristics (novel chem. structure, lack of cross-resistance, and metabolic stability), indicate that sulfoxaflor represents a significant new insecticide option for the control of sap-feeding insects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtziFh6WNRm7Vg90H21EOLACvtfcHk0li7jBQuqFyIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslKls70%253D&md5=dd9a5d0273f164707d90c667f7143630</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ibmb.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ibmb.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DHasler%26aufirst%3DJ.%2BM.%26aulast%3DLetherer%26aufirst%3DT.%2BJ.%26aulast%3DYoung%26aufirst%3DC.%2BD.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26atitle%3DNovel%2520Nicotinic%2520Action%2520of%2520the%2520Sulfoximine%2520Insecticide%2520Sulfoxaflor%26jtitle%3DInsect%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D41%26spage%3D432%26epage%3D439%26doi%3D10.1016%2Fj.ibmb.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siviter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbeater, E.</span></span> <span> </span><span class="NLM_article-title">Sulfoxaflor Exposure Reduces Bumblebee Reproductive Success</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0430-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs41586-018-0430-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30111837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2018&pages=109-112&author=H.+Siviterauthor=M.+J.+F.+Brownauthor=E.+Leadbeater&title=Sulfoxaflor+Exposure+Reduces+Bumblebee+Reproductive+Success&doi=10.1038%2Fs41586-018-0430-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoxaflor exposure reduces bumblebee reproductive success</span></div><div class="casAuthors">Siviter, Harry; Brown, Mark J. F.; Leadbeater, Ellouise</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">7721</span>),
    <span class="NLM_cas:pages">109-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Intensive agriculture currently relies on pesticides to maximize crop yield1,2.  Neonicotinoids are the most widely used insecticides globally3, but increasing evidence of neg. impacts on important pollinators4-9 and other non-target organisms10 has led to legislative reassessment and created demand for the development of alternative products.  Sulfoximine-based insecticides are the most likely successor11, and are either licensed for use or under consideration for licensing in several worldwide markets3, including within the European Union12, where certain neonicotinoids (imidacloprid, clothianidin and thiamethoxam) are now banned from agricultural use outside of permanent greenhouse structures.  There is an urgent need to pre-emptively evaluate the potential sub-lethal effects of sulfoximine-based pesticides on pollinators11, because such effects are rarely detected by std. ecotoxicol. assessments, but can have major impacts at larger ecol. scales13-15.  Chronic exposure to the sulfoximine-based insecticide sulfoxaflor, at dosages consistent with potential post-spray field exposure, has severe sub-lethal effects on bumblebee (Bombus terrestris) colonies.  Field-based colonies that were exposed to sulfoxaflor during the early growth phase produced significantly fewer workers than unexposed controls, and ultimately produced fewer reproductive offspring.  Differences between the life-history trajectories of treated and control colonies first became apparent when individuals exposed as larvae began to emerge, suggesting that direct or indirect effects on a small cohort may have cumulative long-term consequences for colony fitness.  The authors' results caution against the use of sulfoximines as a direct replacement for neonicotinoids.  To avoid continuing cycles of novel pesticide release and removal, with concomitant impacts on the environment, a broad evidence base needs to be assessed prior to the development of policy and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMsnr51RgoLVg90H21EOLACvtfcHk0ljKJqCoFredyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahsbrI&md5=559b39bf3adf2478d80d663105f68ad6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0430-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0430-6%26sid%3Dliteratum%253Aachs%26aulast%3DSiviter%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BF.%26aulast%3DLeadbeater%26aufirst%3DE.%26atitle%3DSulfoxaflor%2520Exposure%2520Reduces%2520Bumblebee%2520Reproductive%2520Success%26jtitle%3DNature%26date%3D2018%26volume%3D561%26spage%3D109%26epage%3D112%26doi%3D10.1038%2Fs41586-018-0430-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siviter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pull, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbeater, E.</span></span> <span> </span><span class="NLM_article-title">No Evidence for Negative Impacts of Acute Sulfoxaflor Exposure on Bee Olfactory Conditioning or Working Memory</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e7208</span>, <span class="refDoi"> DOI: 10.7717/peerj.7208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.7717%2Fpeerj.7208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31423353" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=e7208&author=H.+Siviterauthor=A.+Scottauthor=G.+Pasquierauthor=C.+D.+Pullauthor=M.+J.+F.+Brownauthor=E.+Leadbeater&title=No+Evidence+for+Negative+Impacts+of+Acute+Sulfoxaflor+Exposure+on+Bee+Olfactory+Conditioning+or+Working+Memory&doi=10.7717%2Fpeerj.7208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.7208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.7208%26sid%3Dliteratum%253Aachs%26aulast%3DSiviter%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DPasquier%26aufirst%3DG.%26aulast%3DPull%26aufirst%3DC.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BF.%26aulast%3DLeadbeater%26aufirst%3DE.%26atitle%3DNo%2520Evidence%2520for%2520Negative%2520Impacts%2520of%2520Acute%2520Sulfoxaflor%2520Exposure%2520on%2520Bee%2520Olfactory%2520Conditioning%2520or%2520Working%2520Memory%26jtitle%3DPeerJ%26date%3D2019%26volume%3D7%26spage%3De7208%26doi%3D10.7717%2Fpeerj.7208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, C.</span></span> <span> </span><span class="NLM_article-title">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ci900450m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900450m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=339-348&author=J.+Hussainauthor=C.+Rea&title=Computationally+Efficient+Algorithm+to+Identify+Matched+Molecular+Pairs+%28MMPs%29+in+Large+Data+Sets&doi=10.1021%2Fci900450m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span></div><div class="casAuthors">Hussain, Jameed; Rea, Ceara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern drug discovery organizations generate large vols. of SAR data.  A promising methodol. that can be used to mine this chem. data to identify novel structure-activity relationships is the matched mol. pair (MMP) methodol.  However, before the full potential of the MMP methodol. can be utilized, a MMP identification method that is capable of identifying all MMPs in large chem. data sets on modest computational hardware is required.  In this paper we report an algorithm that is capable of systematically generating all MMPs in chem. data sets.  Addnl., the algorithm is computationally efficient enough to be applied on large data sets.  As an example the algorithm was used to identify the MMPs in the ∼300k NIH MLSMR set.  The algorithm identified ∼5.3 million matched mol. pairs in the set.  These pairs cover ∼2.6 million unique mol. transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0rN8jaKSjrVg90H21EOLACvtfcHk0ljKJqCoFredyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D&md5=23964abebc23274f5c36c319bee52bab</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fci900450m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900450m%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DRea%26aufirst%3DC.%26atitle%3DComputationally%2520Efficient%2520Algorithm%2520to%2520Identify%2520Matched%2520Molecular%2520Pairs%2520%2528MMPs%2529%2520in%2520Large%2520Data%2520Sets%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D339%26epage%3D348%26doi%3D10.1021%2Fci900450m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28221724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=487-501&author=J.+A.+Sirventauthor=U.+L%C3%BCcking&title=Novel+Pieces+for+the+Emerging+Picture+of+Sulfoximines+in+Drug+Discovery%3A+Synthesis+and+Evaluation+of+Sulfoximine+Analogues+of+Marketed+Drugs+and+Advanced+Clinical+Candidates&doi=10.1002%2Fcmdc.201700044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span></div><div class="casAuthors">Sirvent, Juan Alberto; Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late.  In particular, the clin. kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention.  While the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chem.-relevant properties of sulfoximines.  Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogs of marketed drugs and advanced clin. candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5kfVM3I45LVg90H21EOLACvtfcHk0ljKJqCoFredyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D&md5=5b4589d7af32c8984d4fd3027c31c168</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700044%26sid%3Dliteratum%253Aachs%26aulast%3DSirvent%26aufirst%3DJ.%2BA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNovel%2520Pieces%2520for%2520the%2520Emerging%2520Picture%2520of%2520Sulfoximines%2520in%2520Drug%2520Discovery%253A%2520Synthesis%2520and%2520Evaluation%2520of%2520Sulfoximine%2520Analogues%2520of%2520Marketed%2520Drugs%2520and%2520Advanced%2520Clinical%2520Candidates%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D487%26epage%3D501%26doi%3D10.1002%2Fcmdc.201700044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G. M.</span></span> <span> </span><span class="NLM_article-title">Nonleadlikeness and Leadlikeness in Biochemical Screening</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/S1359644602025722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS1359644602025722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12565011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252Fls1SjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=86-96&author=G.+M.+Rishton&title=Nonleadlikeness+and+Leadlikeness+in+Biochemical+Screening&doi=10.1016%2FS1359644602025722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Nonleadlikeness and leadlikeness in biochemical screening</span></div><div class="casAuthors">Rishton Gilbert M</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-96</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Biochemical assays have largely supplanted functional biological assays as drug screening tools in the early stages of drug discovery.  The de-selection of compounds that are 'nonleadlike' binders (and bonders) and the proactive selection of those compounds that are 'leadlike' in their binding to the target are vital components of the screening effort.  The physiochemical properties of leadlikeness and the surprising differences between those properties and the now classical definitions of druglikeness are becoming apparent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFoWSt5LTTmsrRqEXsZufAfW6udTcc2eYYHM8RV92LHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252Fls1SjtQ%253D%253D&md5=5e34cece6f751fa727f949c3526aa95c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1359644602025722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359644602025722%26sid%3Dliteratum%253Aachs%26aulast%3DRishton%26aufirst%3DG.%2BM.%26atitle%3DNonleadlikeness%2520and%2520Leadlikeness%2520in%2520Biochemical%2520Screening%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D86%26epage%3D96%26doi%3D10.1016%2FS1359644602025722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0li_S_DFHu8p6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Kinase Inhibitors: An Analysis of FDA-Approved Drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-Molecule+Kinase+Inhibitors%3A+An+Analysis+of+FDA-Approved+Drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0li_S_DFHu8p6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-Molecule%2520Kinase%2520Inhibitors%253A%2520An%2520Analysis%2520of%2520FDA-Approved%2520Drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties that Influence the Oral Bioavailability of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+Properties+that+Influence+the+Oral+Bioavailability+of+Drug+Candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0li_S_DFHu8p6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520Properties%2520that%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreft, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmies, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casebier, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comery, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamantidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingboe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubrak, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg-Reines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woller, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, J. S.</span></span> <span> </span><span class="NLM_article-title">(S)-N-(5-Chlorothiophene-2-Sulfonyl)-β,β-Diethylalaninol a Notch-1-Sparing γ-Secretase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2008.11.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19097890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=926-929&author=D.+C.+Coleauthor=J.+R.+Stockauthor=A.+F.+Kreftauthor=M.+Antaneauthor=S.+H.+Aschmiesauthor=K.+P.+Atchisonauthor=D.+S.+Casebierauthor=T.+A.+Comeryauthor=G.+Diamantidisauthor=J.+W.+Ellingboeauthor=B.+L.+Harrisonauthor=Y.+Huauthor=M.+Jinauthor=D.+M.+Kubrakauthor=P.+Luauthor=C.+W.+Mannauthor=R.+L.+Martoneauthor=W.+J.+Mooreauthor=A.+Oganesianauthor=D.+R.+Riddellauthor=J.+Sonnenberg-Reinesauthor=S.+C.+Sunauthor=E.+Wagnerauthor=Z.+Wangauthor=K.+R.+Wollerauthor=Z.+Xuauthor=H.+Zhouauthor=J.+S.+Jacobsen&title=%28S%29-N-%285-Chlorothiophene-2-Sulfonyl%29-%CE%B2%2C%CE%B2-Diethylalaninol+a+Notch-1-Sparing+%CE%B3-Secretase+Inhibitor&doi=10.1016%2Fj.bmcl.2008.11.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor</span></div><div class="casAuthors">Cole, Derek C.; Stock, Joseph R.; Kreft, Anthony F.; Antane, Madelene; Aschmies, Suzan H.; Atchison, Kevin P.; Casebier, David S.; Comery, Thomas A.; Diamantidis, George; Ellingboe, John W.; Harrison, Boyd L.; Hu, Yun; Jin, Mei; Kubrak, Dennis M.; Lu, Peimin; Mann, Charles W.; Martone, Robert L.; Moore, William J.; Oganesian, Aram; Riddell, David R.; Sonnenberg-Reines, June; Sun, Shaiu-Ching; Wagner, Erik; Wang, Zheng; Woller, Kevin R.; Xu, Zheng; Zhou, Hua; Jacobsen, J. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-929</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Accumulation of beta-amyloid (Aβ), produced by the proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretase, is widely believed to be assocd. with Alzheimer's disease (AD).  Research around the high-throughput screening hit (S)-4-chlorophenylsulfonyl isoleucinol led to the identification of the Notch-1-sparing (9.5-fold) γ-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-β,β-diethylalaninol 7.b.2 (Aβ40/42 EC50 = 28 nM), which is efficacious in redn. of Aβ prodn. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdqzZ7gfiP7Vg90H21EOLACvtfcHk0ljYHJCU6aTz6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itLk%253D&md5=64713282284d9577a317dfcf737a5ec7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.116%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DStock%26aufirst%3DJ.%2BR.%26aulast%3DKreft%26aufirst%3DA.%2BF.%26aulast%3DAntane%26aufirst%3DM.%26aulast%3DAschmies%26aufirst%3DS.%2BH.%26aulast%3DAtchison%26aufirst%3DK.%2BP.%26aulast%3DCasebier%26aufirst%3DD.%2BS.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DDiamantidis%26aufirst%3DG.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKubrak%26aufirst%3DD.%2BM.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DC.%2BW.%26aulast%3DMartone%26aufirst%3DR.%2BL.%26aulast%3DMoore%26aufirst%3DW.%2BJ.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DSonnenberg-Reines%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DWagner%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWoller%26aufirst%3DK.%2BR.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DJacobsen%26aufirst%3DJ.%2BS.%26atitle%3D%2528S%2529-N-%25285-Chlorothiophene-2-Sulfonyl%2529-%25CE%25B2%252C%25CE%25B2-Diethylalaninol%2520a%2520Notch-1-Sparing%2520%25CE%25B3-Secretase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D926%26epage%3D929%26doi%3D10.1016%2Fj.bmcl.2008.11.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehgelmeble, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotticci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundkvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, <i>in Vitro</i>, and <i>in Vivo</i> Studies with γ-Secretase Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201200014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22307979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=396-399&author=F.+Sehgelmebleauthor=J.+Jansonauthor=C.+Rayauthor=S.+Rosqvistauthor=S.+Gustavssonauthor=L.+I.+Nilssonauthor=A.+Minidisauthor=J.+Holenzauthor=D.+Rotticciauthor=J.+Lundkvistauthor=P.+I.+Arvidsson&title=Sulfonimidamides+as+Sulfonamides+Bioisosteres%3A+Rational+Evaluation+through+Synthetic%2C+in+Vitro%2C+and+in+Vivo+Studies+with+%CE%B3-Secretase+Inhibitors&doi=10.1002%2Fcmdc.201200014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, in Vitro, and in Vivo Studies with γ-Secretase Inhibitors</span></div><div class="casAuthors">Sehgelmeble, Fernando; Janson, Juliette; Ray, Colin; Rosqvist, Susanne; Gustavsson, Susanne; Nilsson, Linda I.; Minidis, Alexander; Holenz, Joerg; Rotticci, Didier; Lundkvist, Johan; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">396-399</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel sulfonimidamide analogs were prepd., as potential sulfonamides bioisosteres, and their γ-secretase inhibiting activity tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7JaMdVVAfKrVg90H21EOLACvtfcHk0ljYHJCU6aTz6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSit7c%253D&md5=2a806cd471c27d5a949db37a26e596d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200014%26sid%3Dliteratum%253Aachs%26aulast%3DSehgelmeble%26aufirst%3DF.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DC.%26aulast%3DRosqvist%26aufirst%3DS.%26aulast%3DGustavsson%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DL.%2BI.%26aulast%3DMinidis%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DRotticci%26aufirst%3DD.%26aulast%3DLundkvist%26aufirst%3DJ.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%2520as%2520Sulfonamides%2520Bioisosteres%253A%2520Rational%2520Evaluation%2520through%2520Synthetic%252C%2520in%2520Vitro%252C%2520and%2520in%2520Vivo%2520Studies%2520with%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D396%26epage%3D399%26doi%3D10.1002%2Fcmdc.201200014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fietkau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375</span>. <i>Skin Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1159/000453042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1159%2F000453042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2017&pages=281-290&author=A.+D.+Steinkampauthor=L.+Schmittauthor=X.+Chenauthor=K.+Fietkauauthor=R.+Heiseauthor=J.+M.+Baronauthor=C.+Bolm&title=Synthesis+of+a+Sulfonimidamide-Based+Analog+of+Tasisulam+and+Its+Biological+Evaluation+in+the+Melanoma+Cell+Lines+SKMel23+and+A375&doi=10.1159%2F000453042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1159%2F000453042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000453042%26sid%3Dliteratum%253Aachs%26aulast%3DSteinkamp%26aufirst%3DA.%2BD.%26aulast%3DSchmitt%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFietkau%26aufirst%3DK.%26aulast%3DHeise%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520a%2520Sulfonimidamide-Based%2520Analog%2520of%2520Tasisulam%2520and%2520Its%2520Biological%2520Evaluation%2520in%2520the%2520Melanoma%2520Cell%2520Lines%2520SKMel23%2520and%2520A375%26jtitle%3DSkin%2520Pharmacol.%2520Physiol.%26date%3D2017%26volume%3D29%26spage%3D281%26epage%3D290%26doi%3D10.1159%2F000453042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lijqTYwlYNbmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Considine, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Dios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durst, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferritto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin
Cabrejas, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richett, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span> <span> </span><span class="NLM_article-title">Acyl Sulfonamide Anti-Proliferatives: Benzene Substituent Structure–Activity Relationships for a Novel Class of Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5367</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm030594r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030594r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsleis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5367-5380&author=K.+L.+Lobbauthor=P.+A.+Hipskindauthor=J.+A.+Aikinsauthor=E.+Alvarezauthor=Y.-Y.+Cheungauthor=E.+L.+Considineauthor=A.+De+Diosauthor=G.+L.+Durstauthor=R.+Ferrittoauthor=C.+S.+Grossmanauthor=D.+D.+Gieraauthor=B.+A.+Hollisterauthor=Z.+Huangauthor=P.+W.+Iversenauthor=K.+L.+Lawauthor=T.+Liauthor=H.+S.+Linauthor=B.+Lopezauthor=J.+E.+Lopezauthor=L.+M.+Martin%0ACabrejasauthor=D.+J.+McCannauthor=V.+Moleroauthor=J.+E.+Reillyauthor=M.+E.+Richettauthor=C.+Shihauthor=B.+Teicherauthor=J.+H.+Wikelauthor=W.+T.+Whiteauthor=M.+M.+Mader&title=Acyl+Sulfonamide+Anti-Proliferatives%3A+Benzene+Substituent+Structure%E2%80%93Activity+Relationships+for+a+Novel+Class+of+Antitumor+Agents&doi=10.1021%2Fjm030594r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl Sulfonamide Anti-Proliferatives: Benzene Substituent Structure-Activity Relationships for a Novel Class of Antitumor Agents</span></div><div class="casAuthors">Lobb, Karen L.; Hipskind, Philip A.; Aikins, James A.; Alvarez, Enrique; Cheung, Yiu-Yin; Considine, Eileen L.; De Dios, Alfonso; Durst, Gregory L.; Ferritto, Rafael; Grossman, Cora Sue; Giera, Deborah D.; Hollister, Beth A.; Huang, Zhongping; Iversen, Philip W.; Law, Kevin L.; Li, Tiechao; Lin, Ho-Shen; Lopez, Beatriz; Lopez, Jose E.; Cabrejas, Luisa M. Martin; McCann, Denis J.; Molero, Victoriano; Reilly, John E.; Richett, Michael E.; Shih, Chuan; Teicher, Beverly; Wikel, James H.; White, Wesley T.; Mader, Mary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5367-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related diaryl acylsulfonamides were recently reported as potent antitumor agents against a broad spectrum of human tumor xenografts (colon, lung, breast, ovary, and prostate) in nude mice.  Esp. intriguing was their activity against colorectal cancer xenografts.  In this paper, rapid parallel synthesis along with traditional medicinal chem. techniques were used to quickly delineate the structure-activity relationships of the substitution patterns in both Ph rings of the acylsufonamide anti-proliferative scaffold.  Although the mol. target of the compds. remains unclear, we detd. that the vascular endothelial growth factor-dependent human umbilical vein endothelial cells assay in combination with a soft agar disk diffusion assay allowed for optimization of potency in the series.  The pharmacokinetic properties and in vivo activity in an HCT116 xenograft model are reported for representative compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeCysoz5N61bVg90H21EOLACvtfcHk0ljjsTxspXqgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsleis7Y%253D&md5=e10193988e21a4cecf4040e5e8ad996e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm030594r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030594r%26sid%3Dliteratum%253Aachs%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DAikins%26aufirst%3DJ.%2BA.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DY.-Y.%26aulast%3DConsidine%26aufirst%3DE.%2BL.%26aulast%3DDe%2BDios%26aufirst%3DA.%26aulast%3DDurst%26aufirst%3DG.%2BL.%26aulast%3DFerritto%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DC.%2BS.%26aulast%3DGiera%26aufirst%3DD.%2BD.%26aulast%3DHollister%26aufirst%3DB.%2BA.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DLaw%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DH.%2BS.%26aulast%3DLopez%26aufirst%3DB.%26aulast%3DLopez%26aufirst%3DJ.%2BE.%26aulast%3DMartin%2BCabrejas%26aufirst%3DL.%2BM.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26aulast%3DMolero%26aufirst%3DV.%26aulast%3DReilly%26aufirst%3DJ.%2BE.%26aulast%3DRichett%26aufirst%3DM.%2BE.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DWikel%26aufirst%3DJ.%2BH.%26aulast%3DWhite%26aufirst%3DW.%2BT.%26aulast%3DMader%26aufirst%3DM.%2BM.%26atitle%3DAcyl%2520Sulfonamide%2520Anti-Proliferatives%253A%2520Benzene%2520Substituent%2520Structure%25E2%2580%2593Activity%2520Relationships%2520for%2520a%2520Novel%2520Class%2520of%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5367%26epage%3D5380%26doi%3D10.1021%2Fjm030594r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermisch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alwis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eschbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manegold, C.</span></span> <span> </span><span class="NLM_article-title">Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients with Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3182519d79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FJTO.0b013e3182519d79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22588156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1053-1057&author=G.+V.+Scagliottiauthor=R.+Ilariaauthor=S.+Novelloauthor=J.+von+Pawelauthor=J.+R.+Fischerauthor=S.+Ermischauthor=D.+P.+de+Alwisauthor=J.+Andrewsauthor=M.+Reckauthor=L.+Crinoauthor=C.+Eschbachauthor=C.+Manegold&title=Tasisulam+Sodium+%28LY573636+Sodium%29+as+Third-Line+Treatment+in+Patients+with+Unresectable%2C+Metastatic+Non%E2%80%93Small-Cell+Lung+Cancer%3A+A+Phase-II+Study&doi=10.1097%2FJTO.0b013e3182519d79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: A phase-II study</span></div><div class="casAuthors">Scagliotti, Giorgio V.; Ilaria, Robert, Jr.; Novello, Silvia; von Pawel, J.; Fischer, Juergen R.; Ermisch, Sabine; de Alwis, Dinesh P.; Andrews, Joan; Reck, Martin; Crino, Lucio; Eschbach, Corinna; Manegold, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Tasisulam sodium (hereafter referred to as tasisulam) is a novel anticancer compd. that induces apoptosis and exhibits antiangiogenesis activity in a broad range of cancer models, including non-small-cell lung cancer (NSCLC).  Methods: Tasisulam was administered as a 2-h infusion every 21 days as third-line treatment in patients with advanced (stage IIIB/IV) NSCLC.  Results: Thirty-two patients received a Cmax target dose of 420 μg/mL.  Median time to progression was 3.12 mo, median progression-free survival was 2.69 mo, and median overall survival was 8.48 mo.  There were no objective responses; 43.8% of patients achieved stable disease.  A high rate of grade-4 hematol. toxicity in the first 30 patients led to exploration of a lower Cmax target dose of 380 μg/mL.  The rate of grade-4 hematol. toxicity (thrombocytopenia and/or neutropenia) at the 380-μg/mL dose (n = 20) was 20% vs. 34% at the 420-μg/mL dose.  Conclusions: Tasisulam has only modest activity as a third-line treatment of patients with unresectable/metastatic NSCLC.  The high rate of grade-4 hematol. toxicity obsd. with this highly albumin-bound compd. in this patient population provided challenges for fixed Cmax-based dosing.  Alternative dosing methods, including varying the Cmax target dose by predose albumin, are under investigation in other studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-A4REc-NTRbVg90H21EOLACvtfcHk0ljjsTxspXqgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShtbnF&md5=f4612b2e4144ba59a4ba1288e0bfd1b3</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182519d79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182519d79%26sid%3Dliteratum%253Aachs%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DIlaria%26aufirst%3DR.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DJ.%2BR.%26aulast%3DErmisch%26aufirst%3DS.%26aulast%3Dde%2BAlwis%26aufirst%3DD.%2BP.%26aulast%3DAndrews%26aufirst%3DJ.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DEschbach%26aufirst%3DC.%26aulast%3DManegold%26aufirst%3DC.%26atitle%3DTasisulam%2520Sodium%2520%2528LY573636%2520Sodium%2529%2520as%2520Third-Line%2520Treatment%2520in%2520Patients%2520with%2520Unresectable%252C%2520Metastatic%2520Non%25E2%2580%2593Small-Cell%2520Lung%2520Cancer%253A%2520A%2520Phase-II%2520Study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1053%26epage%3D1057%26doi%3D10.1097%2FJTO.0b013e3182519d79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jotte, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becerra, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conkling, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert-Vizcarrondo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">An Innovative, Multi-Arm, Complete Phase 1b Study of the Novel Anti-Cancer Agent Tasisulam in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0160-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs10637-014-0160-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25260842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KgsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=148-158&author=R.+M.+Jotteauthor=D.+D.+Von+Hoffauthor=F.+Braitehauthor=C.+R.+Becerraauthor=D.+A.+Richardsauthor=D.+A.+Smithauthor=L.+Garboauthor=J.+Stephensonauthor=P.+R.+Conklingauthor=F.+Robert-Vizcarrondoauthor=J.+Chenauthor=P.+K.+Turnerauthor=K.+H.+Chowauthor=D.+F.+Taiauthor=R.+Ilaria&title=An+Innovative%2C+Multi-Arm%2C+Complete+Phase+1b+Study+of+the+Novel+Anti-Cancer+Agent+Tasisulam+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0160-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors</span></div><div class="casAuthors">Jotte, Robert M.; Von Hoff, Daniel D.; Braiteh, Fadi; Becerra, Carlos R.; Richards, Donald A.; Smith, David A.; Garbo, Lawrence; Stephenson, Joe; Conkling, Paul R.; Robert-Vizcarrondo, Francisco; Chen, Jian; Turner, P. Kellie; Chow, Kay Hoong; Tai, D. Fritz; Ilaria, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-158</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacol., combined with std. chemotherapies in patients with advanced solid tumors, with the ultimate goal of accelerating drug development.  Methods: Patients received escalating doses of tasisulam (3 + 3 schema; target Cmax 300-400 μg/mL) every 28 days plus 1,000 mg/m2 gemcitabine HCl (days 1 and 15), 60 mg/m2 docetaxel, 200 mg/m2/day temozolomide, 75 mg/m2 cisplatin, or 150 mg/day erlotinib.  Following dose-escalation, patients were enrolled into specific tumor subtype arms, chosen based on the established activity of the std. agent.  Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-cor. exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).  Results: A total of 234 patients were enrolled.  The safety profile of tasisulam with std. chemotherapies was sufficient to allow enrollment into the dose-confirmation phase in all arms.  The primary dose-limiting toxicities were hematol. (thrombocytopenia and neutropenia).  The most common grade ≥3 drug-related treatment-emergent adverse event was neutropenia, with the highest incidence in the docetaxel arm.  Conclusions: The multi-arm design allowed the efficient detn. of the max. tolerated dose of tasisulam across multiple combinations, and a preliminary characterization of pharmacokinetics, safety, and potential efficacy.  Although enrollment into all planned groups was not completed due to termination of compd. development, these data support the feasibility of this approach for accelerated cancer drug development, even for drugs with complex pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FP30ceoed7Vg90H21EOLACvtfcHk0ljjsTxspXqgbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KgsbnI&md5=255ef33e89c87b0d8557c2d737a59342</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0160-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0160-z%26sid%3Dliteratum%253Aachs%26aulast%3DJotte%26aufirst%3DR.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DBraiteh%26aufirst%3DF.%26aulast%3DBecerra%26aufirst%3DC.%2BR.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DGarbo%26aufirst%3DL.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DConkling%26aufirst%3DP.%2BR.%26aulast%3DRobert-Vizcarrondo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTurner%26aufirst%3DP.%2BK.%26aulast%3DChow%26aufirst%3DK.%2BH.%26aulast%3DTai%26aufirst%3DD.%2BF.%26aulast%3DIlaria%26aufirst%3DR.%26atitle%3DAn%2520Innovative%252C%2520Multi-Arm%252C%2520Complete%2520Phase%25201b%2520Study%2520of%2520the%2520Novel%2520Anti-Cancer%2520Agent%2520Tasisulam%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D148%26epage%3D158%26doi%3D10.1007%2Fs10637-014-0160-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahka-Kemppinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Open-Label Clinical Trial of Tasisulam Sodium versus Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">2016</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1002/cncr.28635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcncr.28635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24676877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWktr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2016-2024&author=O.+Hamidauthor=R.+Ilariaauthor=C.+Garbeauthor=P.+Wolterauthor=M.+Maioauthor=T.+E.+Hutsonauthor=A.+Aranceauthor=P.+Loriganauthor=J.+Leeauthor=A.+Hauschildauthor=P.+Mohrauthor=M.+Hahka-Kemppinenauthor=C.+Kaiserauthor=P.+K.+Turnerauthor=I.+Contiauthor=J.+J.+Grob&title=A+Randomized%2C+Open-Label+Clinical+Trial+of+Tasisulam+Sodium+versus+Paclitaxel+as+Second-Line+Treatment+in+Patients+with+Metastatic+Melanoma&doi=10.1002%2Fcncr.28635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma</span></div><div class="casAuthors">Hamid, Omid; Ilaria, Robert, Jr.; Garbe, Claus; Wolter, Pascal; Maio, Michele; Hutson, Thomas E.; Arance, Ana; Lorigan, Paul; Lee, Jeeyun; Hauschild, Axel; Mohr, Peter; Hahka-Kemppinen, Marjo; Kaiser, Christopher; Turner, P. Kellie; Conti, Ilaria; Grob, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2016-2024</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.  METHODS : In this open-label phase 3 study, patients with AJCC stage IV melanoma received tasisulam (targeting an albumin-cor. exposure of 1200-6400 h (hour).μg/mL on day 1) or paclitaxel (80 mg/m2 on days 1, 8, and 15) every 28 days as second-line treatment.  RESULTS : The study was placed on clin. hold after randomization of 336 patients when a safety review indicated an imbalance of possibly drug-related deaths in the tasisulam arm.  Efficacy results for tasisulam vs. paclitaxel revealed a response rate of 3.0% vs. 4.8%, a median progression-free survival of 1.94 mo vs. 2.14 mo (P = .048), and a median overall survival of 6.77 mo vs. 9.36 mo (P = .121).  The most common drug-related grade ≥3 lab. toxicities (graded according to Common Terminol. for Adverse Events [version 3.0]) were thrombocytopenia (18.9%) for patients treated with tasisulam and neutropenia/leukopenia (8.7%) among those receiving paclitaxel.  There were 13 possibly related deaths reported to occur on the study, with the majority occurring during cycle 2 in the setting of grade 4 myelosuppression, all in the tasisulam arm.  Investigation of the unexpectedly high rate of hematol. toxicity revealed a subset of patients with low tasisulam clearance, leading to drug accumulation and high albumin-cor. exposure in cycle 2.  CONCLUSIONS : Although the study was stopped early because of safety issues in the tasisulam arm, tasisulam was considered unlikely to be superior to paclitaxel, and paclitaxel activity in the second-line treatment of melanoma was much lower than expected.  The toxicity imbalance was attributed to an unexpectedly low tasisulam clearance in a subset of patients, underscoring the importance of pharmacokinetic monitoring of compds. with complex dosing, even in late-phase studies.  Cancer 2014;120:2016-2024. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHr_f6DAfpzbVg90H21EOLACvtfcHk0lj_0lFVScV3fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWktr3E&md5=96830e138ca2b73dfc47dffdb56c121e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28635%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DIlaria%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHahka-Kemppinen%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DP.%2BK.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Randomized%252C%2520Open-Label%2520Clinical%2520Trial%2520of%2520Tasisulam%2520Sodium%2520versus%2520Paclitaxel%2520as%2520Second-Line%2520Treatment%2520in%2520Patients%2520with%2520Metastatic%2520Melanoma%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D2016%26epage%3D2024%26doi%3D10.1002%2Fcncr.28635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassanpour, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehghani, M.</span></span> <span> </span><span class="NLM_article-title">Review of Cancer from Perspective of Molecular</span>. <i>Journal of Cancer Research and Practice</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.jcrpr.2017.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jcrpr.2017.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=127-129&author=S.+H.+Hassanpourauthor=M.+Dehghani&title=Review+of+Cancer+from+Perspective+of+Molecular&doi=10.1016%2Fj.jcrpr.2017.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jcrpr.2017.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcrpr.2017.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHassanpour%26aufirst%3DS.%2BH.%26aulast%3DDehghani%26aufirst%3DM.%26atitle%3DReview%2520of%2520Cancer%2520from%2520Perspective%2520of%2520Molecular%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Practice%26date%3D2017%26volume%3D4%26spage%3D127%26epage%3D129%26doi%3D10.1016%2Fj.jcrpr.2017.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Protein Kinase Inhibitors Including Palbociclib as Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.phrs.2016.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26995305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=249-275&author=R.+Roskoski&title=Cyclin-Dependent+Protein+Kinase+Inhibitors+Including+Palbociclib+as+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2016.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-275</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle progression.  The levels of the cell cycle CDKs are generally const. and their activities are controlled by cyclins, proteins whose levels oscillate during each cell cycle.  Addnl. CDK family members were subsequently discovered that play significant roles in a wide range of activities including the control of gene transcription, metab., and neuronal function.  In response to mitogenic stimuli, cells in the G1 phase of the cell cycle produce cyclins of the D type that activate CDK4/6.  These activated enzymes catalyze the monophosphorylation of the retinoblastoma protein.  Then CDK2-cyclin E catalyzes the hyperphosphorylation of Rb that promotes the release and activation of the E2F transcription factors, which in turn lead to the generation of several proteins required for cell cycle progression.  As a result, cells pass through the G1-restriction point and are committed to complete cell division.  CDK2-cyclin A, CDK1-cyclin A, and CDK1-cyclin B are required for S, G2, and M-phase progression.  Increased cyclin or CDK expression or decreased levels of endogenous CDK inhibitors such as INK4 or CIP/KIP have been obsd. in various cancers.  In contrast to the mutational activation of EGFR, Kit, or B-Raf in the pathogenesis of malignancies, mutations in the CDKs that cause cancers are rare.  Owing to their role in cell proliferation, CDKs represent natural targets for anticancer therapies.  Abemaciclib (LY2835219), ribociclib (Lee011), and palbociclib (Ibrance or PD0332991) target CDK4/6 with IC50 values in the low nanomolar range.  Palbociclib and other CDK inhibitors bind in the cleft between the small and large lobes of the CDKs and inhibit the binding of ATP.  Like ATP, palbociclib forms hydrogen bonds with residues in the hinge segment of the cleft.  Like the adenine base of ATP, palbociclib interacts with catalytic spine residues CS6 and CS7.  CDK antagonists are in clin. trials for the treatment of a variety of malignancies.  Significantly, palbociclib has been approved by the FDA for the treatment of hormone-receptor pos./human epidermal growth factor receptor-2 neg. breast cancer in conjunction with letrozole as a first-line therapy and with fulvestrant as a second-line treatment.  As inhibitors of the cell cycle, it is not surprising that one of their most common toxicities is myelosuppression with decreased neutrophil prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol0On7HAFtl7Vg90H21EOLACvtfcHk0lj_0lFVScV3fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D&md5=0356807b16735e3903706eac10635bc7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DCyclin-Dependent%2520Protein%2520Kinase%2520Inhibitors%2520Including%2520Palbociclib%2520as%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D107%26spage%3D249%26epage%3D275%26doi%3D10.1016%2Fj.phrs.2016.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Kinases as Therapeutic Targets for Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+Cycle+Kinases+as+Therapeutic+Targets+for+Cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0lj_0lFVScV3fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520Cycle%2520Kinases%2520as%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-Dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lht0zKK4Apeiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-Dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26115571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVeis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+S%C3%A1nchez-Mart%C3%ADnezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Gelbert, Lawrence M.; Lallena, Maria Jose; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3420-3435</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sustained proliferative capacity is a hallmark of cancer.  In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate crit. checkpoints.  CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point.  This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compds. under clin. evaluation.  Chem. structures, structure activity relationships, and relevant preclin. properties will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwE7MEzEetPbVg90H21EOLACvtfcHk0lht0zKK4Apeiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVeis7fN&md5=d4451fdbfd0ef0b08165105b9c8a38dc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinomas by Inducing Apoptosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1681</span>, <span class="refDoi"> DOI: 10.1172/JCI3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+Novel+Cyclin-Dependent+Kinase+Inhibitor%2C+Suppresses+the+Growth+of+Head+and+Neck+Squamous+Cell+Carcinomas+by+Inducing+Apoptosis&doi=10.1172%2FJCI3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0lht0zKK4Apeiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520Novel%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%252C%2520Suppresses%2520the%2520Growth%2520of%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinomas%2520by%2520Inducing%2520Apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2FJCI3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulinoux, J. P.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.t01-2-00527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9030781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=527-536&author=L.+Meijerauthor=A.+Borgneauthor=O.+Mulnerauthor=J.+P.+Chongauthor=J.+J.+Blowauthor=N.+Inagakiauthor=M.+Inagakiauthor=J.+G.+Delcrosauthor=J.+P.+Moulinoux&title=Biochemical+and+Cellular+Effects+of+Roscovitine%2C+a+Potent+and+Selective+Inhibitor+of+the+Cyclin-Dependent+Kinases+cdc2%2C+cdk2+and+cdk5&doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5</span></div><div class="casAuthors">Meijer, Laurent; Borgne, Annie; Mulner, Odile; Chong, James P. J.; Blow, J. Julian; Inagaki, Naoyuki; Inagaki, Masaki; Delcros, Jean Guy; Moulinoux, Jacques Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (cdk) play an essential role in the intracellular control of the cell division cycle (cdc).  These kinases and their regulators are frequently deregulated in human tumors.  Enzymic screening has recently led to the discovery of specific inhibitors of cyclin-dependent kinases, such as butyrolactone I, flavopiridol and the purine olomoucine.  Among a series of C2, N6,N9-substituted adenines tested on purified cdc2/cyclin B, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (roscovitine) displays high efficiency and high selectivity towards some cyclin-dependent kinases.  The kinase specificity of roscovitine was investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl).  Most kinases are not significantly inhibited by roscovitine.  Cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 only are substantially inhibited (IC50 values of 0.65, 0.7, 0.7 and 0.2 μM, resp.).  Cdk4/cyclin D1 and cdk6/cyclin D2 are very poorly inhibited by roscovitine (IC50>100 μM).  Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, resp.  Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late prophase.  Roscovitine inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg exts.  It blocks progesterone-induced oocyte maturation of Xenopus oocytes and in vivo phosphorylation of the elongation factor eEF-1.  Roscovitine inhibits the proliferation of mammalian cell lines with an av. IC50 of 16 μM.  In the presence of roscovitine L1210 cells arrest in G1 and accumulate in G2.  In vivo phosphorylation of vimentin on Ser55 by cdc2/cyclin B is inhibited by roscovitine.  Through its unique selectivity for some cyclin-dependent kinases, roscovitine provides a useful anti-mitotic reagent for cell cycle studies and may prove interesting to control cells with deregulated cdc2, cdk2 or cdk5 kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO61Tu2_0pWLVg90H21EOLACvtfcHk0lhgb5c8OOMRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D&md5=d55100def53ac8811e485d9d34c46b79</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.t01-2-00527.x%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBorgne%26aufirst%3DA.%26aulast%3DMulner%26aufirst%3DO.%26aulast%3DChong%26aufirst%3DJ.%2BP.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DDelcros%26aufirst%3DJ.%2BG.%26aulast%3DMoulinoux%26aufirst%3DJ.%2BP.%26atitle%3DBiochemical%2520and%2520Cellular%2520Effects%2520of%2520Roscovitine%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520the%2520Cyclin-Dependent%2520Kinases%2520cdc2%252C%2520cdk2%2520and%2520cdk5%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D527%26epage%3D536%26doi%3D10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorokinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankunas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meskinyte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankevicius, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupinis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valius, M.</span></span> <span> </span><span class="NLM_article-title">Roscovitine in Cancer and Other Diseases</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26207228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12it7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=135&author=J.+Cicenasauthor=K.+Kalyanauthor=A.+Sorokinasauthor=E.+Stankunasauthor=J.+Levyauthor=I.+Meskinyteauthor=V.+Stankeviciusauthor=A.+Kaupinisauthor=M.+Valius&title=Roscovitine+in+Cancer+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Roscovitine in cancer and other diseases</span></div><div class="casAuthors">Cicenas, Jonas; Kalyan, Karthik; Sorokinas, Aleksandras; Stankunas, Edvinas; Levy, Josh; Meskinyte, Ingrida; Stankevicius, Vaidotas; Kaupinis, Algirdas; Valius, Mindaugas</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">135/1-135/12</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small mol. that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site.  It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6.  Roscovitine is widely used as a biol. tool in cell cycle, cancer, apoptosis and neurobiol. studies.  Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis.  This review focuses on the use of roscovitine in the disease model as well as clin. model research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5_9cy7XHJtrVg90H21EOLACvtfcHk0lhgb5c8OOMRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12it7rM&md5=452d3346e3361d657d3f4b5884b99db8</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DKalyan%26aufirst%3DK.%26aulast%3DSorokinas%26aufirst%3DA.%26aulast%3DStankunas%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DMeskinyte%26aufirst%3DI.%26aulast%3DStankevicius%26aufirst%3DV.%26aulast%3DKaupinis%26aufirst%3DA.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DRoscovitine%2520in%2520Cancer%2520and%2520Other%2520Diseases%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26spage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lhgb5c8OOMRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detjen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Coy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosslet, K.</span></span> <span> </span><span class="NLM_article-title">Molecular and Pharmacodynamic Characteristics of the Novel Multi-Target Tumor Growth Inhibitor ZK 304709</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2006.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.biopha.2006.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16887322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=269-272&author=G.+Siemeisterauthor=U.+Lueckingauthor=C.+Wagnerauthor=K.+Detjenauthor=C.+Mc+Coyauthor=K.+Bosslet&title=Molecular+and+Pharmacodynamic+Characteristics+of+the+Novel+Multi-Target+Tumor+Growth+Inhibitor+ZK+304709&doi=10.1016%2Fj.biopha.2006.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709</span></div><div class="casAuthors">Siemeister, G.; Luecking, U.; Wagner, C.; Detjen, K.; Mc Coy, C.; Bosslet, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">269-272</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier SAS</span>)
        </div><div class="casAbstract">Loss of cell cycle control and tumor-induced neovascularization are major drivers of human tumor growth.  The multi-target tumor growth inhibitor ZK 304709 is a nanomolar inhibitor of cyclin-dependent kinases 1, 2, 4, 7 and 9, as well as vascular endothelial growth factor receptor tyrosine kinase 1-3 and of platelet-derived growth factor receptor β tyrosine kinase.  The multi-targeted mode of action of ZK 304709 acting on cell cycle and angiogenesis resulted in superior efficacy compared to std. chemotherapeutic compds. both in s.c. human tumor xenografts as well as orthotopic human pancreatic carcinoma models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgwXX1ZRgTYLVg90H21EOLACvtfcHk0lhgb5c8OOMRzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWms7Y%253D&md5=6d8b6528242d0e9d5a2462229c61aac4</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2006.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2006.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DDetjen%26aufirst%3DK.%26aulast%3DMc%2BCoy%26aufirst%3DC.%26aulast%3DBosslet%26aufirst%3DK.%26atitle%3DMolecular%2520and%2520Pharmacodynamic%2520Characteristics%2520of%2520the%2520Novel%2520Multi-Target%2520Tumor%2520Growth%2520Inhibitor%2520ZK%2520304709%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2006%26volume%3D60%26spage%3D269%26epage%3D272%26doi%3D10.1016%2Fj.biopha.2006.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detjen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedenmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, J.</span></span> <span> </span><span class="NLM_article-title">Open-Label, Non-Randomised, Inter-Individual Dose Escalation of ZK 304709 with the Evaluation of Safety, Tolerability, Pharmacokinetics, Oral Bioavailability and Orientating Efficacy after Daily Administration in Patients with Advanced Cancer (7 d Treatment and 14 d Recovery)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2162</span>– <span class="NLM_lpage">2168</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2008.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejca.2008.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18653327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sis73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=2162-2168&author=J.+S.+Grahamauthor=R.+Plummerauthor=C.+McCoyauthor=K.+Kowalauthor=H.+Wiesingerauthor=K.+Detjenauthor=H.+Calvertauthor=B.+Wiedenmannauthor=J.+Cassidy&title=Open-Label%2C+Non-Randomised%2C+Inter-Individual+Dose+Escalation+of+ZK+304709+with+the+Evaluation+of+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+Oral+Bioavailability+and+Orientating+Efficacy+after+Daily+Administration+in+Patients+with+Advanced+Cancer+%287+d+Treatment+and+14+d+Recovery%29&doi=10.1016%2Fj.ejca.2008.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)</span></div><div class="casAuthors">Graham, Janet S.; Plummer, Ruth; McCoy, Candice; Kowal, Kristin; Wiesinger, Herbert; Detjen, Katharina; Calvert, Hilary; Wiedenmann, Bertram; Cassidy, Jim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2162-2168</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The primary objectives of this study were to det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ZK 304709, a novel multi-targeted growth inhibitor (MTGI), in man.  Secondary end-points included safety evaluation, tolerability, pharmacokinetic profiling and assessment of response using std. and novel surrogate pharmacodynamic end-points.  Patients (n = 40) with advanced solid malignancies were treated with ZK 304709, administered orally once daily for 7 d with 14 d recovery.  Doses were escalated in sequential cohorts of three patients with expansion to 6-7 patients should a dose-limiting toxicity occur.  ZK 304709 was safely administered up to 360 mg.  However, above 90 mg blood concns. increased only slightly.  As this dose was not deemed likely to result in meaningful pharmacol. or clin. activity, the trial was stopped before the MTD was ascertained.  It was therefore not possible to make a reliable assessment of efficacy or pharmacodynamic end-points.  Due to the lack of further increment in blood concns. above a dose of 90 mg, which was felt from previous animal studies to be unlikely to result in meaningful pharmacol. or clin. activity, this study was stopped early.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQcjQ5EPkn7Vg90H21EOLACvtfcHk0ljOuYkmKe8uJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sis73I&md5=cf889c430e869cbcb528a89f2bab793e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2008.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2008.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DDetjen%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DH.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DOpen-Label%252C%2520Non-Randomised%252C%2520Inter-Individual%2520Dose%2520Escalation%2520of%2520ZK%2520304709%2520with%2520the%2520Evaluation%2520of%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520Oral%2520Bioavailability%2520and%2520Orientating%2520Efficacy%2520after%2520Daily%2520Administration%2520in%2520Patients%2520with%2520Advanced%2520Cancer%2520%25287%2520d%2520Treatment%2520and%252014%2520d%2520Recovery%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D2162%26epage%3D2168%26doi%3D10.1016%2Fj.ejca.2008.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J.</span></span> <span> </span><span class="NLM_article-title">A Phase I Dose Escalation Study of the Pharmacokinetics and Tolerability of ZK 304709, an Oral Multi-Targeted Growth Inhibitor (MTGI), in Patients with Advanced Solid Tumours</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-0968-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00280-009-0968-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19280191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=425-429&author=E.+N.+Scottauthor=A.+L.+Thomasauthor=L.+R.+Molifeauthor=S.+Ahmedauthor=S.+Blagdenauthor=P.+C.+Fongauthor=K.+Kowalauthor=C.+McCoyauthor=H.+Wiesingerauthor=W.+Stewardauthor=J.+De+Bono&title=A+Phase+I+Dose+Escalation+Study+of+the+Pharmacokinetics+and+Tolerability+of+ZK+304709%2C+an+Oral+Multi-Targeted+Growth+Inhibitor+%28MTGI%29%2C+in+Patients+with+Advanced+Solid+Tumours&doi=10.1007%2Fs00280-009-0968-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span></div><div class="casAuthors">Scott, Edwina N.; Thomas, Anne L.; Molife, L. Rhoda; Ahmed, Samreen; Blagden, Sarah; Fong, Peter C.; Kowal, Kristin; McCoy, Candice; Wiesinger, Herbert; Steward, Will; De Bono, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-429</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery.  Methods: Patients with solid tumors resistant to std. treatments were enrolled in an accelerated titrn. design.  Results: Thirty-seven patients received ZK 304709 from 15 to 285 mg daily.  The most common drug-related adverse events were vomiting, diarrhea and fatigue.  Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses.  Thirteen patients had stable disease as best response as per RECIST criteria.  Conclusions: There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not detd.  This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHmxGlOkQx7Vg90H21EOLACvtfcHk0ljOuYkmKe8uJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D&md5=fe0e50036e3fc15838425c5f52e30426</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-0968-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-0968-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DE.%2BN.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DDe%2BBono%26aufirst%3DJ.%26atitle%3DA%2520Phase%2520I%2520Dose%2520Escalation%2520Study%2520of%2520the%2520Pharmacokinetics%2520and%2520Tolerability%2520of%2520ZK%2520304709%252C%2520an%2520Oral%2520Multi-Targeted%2520Growth%2520Inhibitor%2520%2528MTGI%2529%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26spage%3D425%26epage%3D429%26doi%3D10.1007%2Fs00280-009-0968-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span> <span> </span><span class="NLM_article-title">The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-Hydroxy-1-Methylpropyl]Oxy}-5-(Trifluoromethyl)Pyrimidin-2-yl]Amino}Phenyl)Sulfoximide (BAY 1000394) for the Treatment of Cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1085</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201300096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23671017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFemsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1067-1085&author=U.+L%C3%BCckingauthor=R.+Jautelatauthor=M.+Kr%C3%BCgerauthor=T.+Brumbyauthor=P.+Lienauauthor=M.+Sch%C3%A4ferauthor=H.+Briemauthor=J.+Schulzeauthor=A.+Hillischauthor=A.+Reichelauthor=A.+M.+Wengnerauthor=G.+Siemeister&title=The+Lab+Oddity+Prevails%3A+Discovery+of+Pan-CDK+Inhibitor+%28R%29-S-Cyclopropyl-S-%284-%7B%5B4-%7B%5B%281R%2C2R%29-2-Hydroxy-1-Methylpropyl%5DOxy%7D-5-%28Trifluoromethyl%29Pyrimidin-2-yl%5DAmino%7DPhenyl%29Sulfoximide+%28BAY+1000394%29+for+the+Treatment+of+Cancer&doi=10.1002%2Fcmdc.201300096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Jautelat, Rolf; Krueger, Martin; Brumby, Thomas; Lienau, Philip; Schaefer, Martina; Briem, Hans; Schulze, Julia; Hillisch, Alexander; Reichel, Andreas; Wengner, Antje Margret; Siemeister, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-1085</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK 304709 (I), a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclin. profile.  Nevertheless, I failed in phase I studies due to dose-limited absorption and high inter-patient variability, which was attributed to limited aq. soly. and off-target activity against carbonic anhydrases.  Further lead optimization efforts to address the off-target activity profile finally resulted in the introduction of a sulfoximine group, which is still a rather unusual approach in medicinal chem.  However, the sulfoximine series of compds. quickly revealed very interesting properties, culminating in the identification of the nanomolar pan-CDK inhibitor BAY 1000394 (II), which is currently being investigated in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMw3zOAyohGbVg90H21EOLACvtfcHk0liKXp9jozrXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFemsbo%253D&md5=28b7bc5cb05381908f19d099460d925e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300096%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DBrumby%26aufirst%3DT.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DSchulze%26aufirst%3DJ.%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26atitle%3DThe%2520Lab%2520Oddity%2520Prevails%253A%2520Discovery%2520of%2520Pan-CDK%2520Inhibitor%2520%2528R%2529-S-Cyclopropyl-S-%25284-%257B%255B4-%257B%255B%25281R%252C2R%2529-2-Hydroxy-1-Methylpropyl%255DOxy%257D-5-%2528Trifluoromethyl%2529Pyrimidin-2-yl%255DAmino%257DPhenyl%2529Sulfoximide%2520%2528BAY%25201000394%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1067%26epage%3D1085%26doi%3D10.1002%2Fcmdc.201300096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bömer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rühter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&author=U.+L%C3%BCckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+B%C3%B6merauthor=M.+Sch%C3%A4ferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+R%C3%BChterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+Atuveciclib+%28BAY+1143572%29%2C+the+First+Highly+Selective%2C+Clinical+PTEFb%2FCDK9+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0liKXp9jozrXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DB%25C3%25B6mer%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DR%25C3%25BChter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Atuveciclib%2520%2528BAY%25201143572%2529%252C%2520the%2520First%2520Highly%2520Selective%252C%2520Clinical%2520PTEFb%252FCDK9%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&author=G.+Siemeisterauthor=U.+L%C3%BCckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+1000394%2C+a+Novel+Cyclin-Dependent+Kinase+Inhibitor%2C+with+Potent+Antitumor+Activity+in+Mono-+and+in+Combination+Treatment+upon+Oral+Application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0liKXp9jozrXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%25201000394%252C%2520a%2520Novel%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%252C%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Mono-%2520and%2520in%2520Combination%2520Treatment%2520upon%2520Oral%2520Application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span>Identifier:
NCT02522910. <a href="https://clinicaltrials.gov/ct2/show/NCT02522910" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02522910</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02522910.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02522910+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span> <span> </span><span class="NLM_article-title">Phase Ib/II Study of the Pan-Cyclin-Dependent Kinase Inhibitor Roniciclib in Combination with Chemotherapy in Patients with Extensive-Disease Small-Cell Lung Cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.lungcan.2018.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30089585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=14-21&author=B.+C.+Choauthor=G.+K.+Dyauthor=R.+Govindanauthor=D.+W.+Kimauthor=N.+A.+Pennellauthor=G.+Zalcmanauthor=B.+Besseauthor=J.+H.+Kimauthor=G.+Kocaauthor=P.+Rajagopalanauthor=S.+Langerauthor=M.+Ockerauthor=H.+Nogaiauthor=F.+Barlesi&title=Phase+Ib%2FII+Study+of+the+Pan-Cyclin-Dependent+Kinase+Inhibitor+Roniciclib+in+Combination+with+Chemotherapy+in+Patients+with+Extensive-Disease+Small-Cell+Lung+Cancer&doi=10.1016%2Fj.lungcan.2018.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span></div><div class="casAuthors">Cho Byoung Chul; Dy Grace K; Govindan Ramaswamy; Kim Dong-Wan; Pennell Nathan A; Zalcman Gerard; Besse Benjamin; Kim Joo-Hang; Koca Goekben; Ocker Matthias; Nogai Hendrik; Rajagopalan Prabhu; Langer Simon; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).  PATIENTS AND METHODS:  In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule.  Cisplatin 75 mg/m(2) or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m(2) on days 1-3, of 21-day cycles.  Phase Ib used a dose-escalation design to define the MTD for phase II.  Pharmacokinetics were assessed.  RESULTS:  Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]).  The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP.  Common adverse events were nausea (90.7%) and vomiting (69.8%).  Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5-1 h), with a 30-40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics.  The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).  CONCLUSION:  Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy.  An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS891qx-r3xr-b6AVA-44PTfW6udTcc2earvHGil-otq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D&md5=ec4e685886d5caf2a6db31b0364cdc2b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKoca%26aufirst%3DG.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DNogai%26aufirst%3DH.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520Ib%252FII%2520Study%2520of%2520the%2520Pan-Cyclin-Dependent%2520Kinase%2520Inhibitor%2520Roniciclib%2520in%2520Combination%2520with%2520Chemotherapy%2520in%2520Patients%2520with%2520Extensive-Disease%2520Small-Cell%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D123%26spage%3D14%26epage%3D21%26doi%3D10.1016%2Fj.lungcan.2018.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span>Identifier:
NCT01188252. <a href="https://clinicaltrials.gov/ct2/show/NCT01188252" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01188252</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01188252.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01188252+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span> <span> </span><span class="NLM_article-title">CYCLINg through Transcription: Posttranslational Modifications of P-TEFb Regulate Transcription Elongation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.4161/cc.9.9.11346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4161%2Fcc.9.9.11346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20436276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12itrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1697-1705&author=S.+Choauthor=S.+Schroederauthor=M.+Ott&title=CYCLINg+through+Transcription%3A+Posttranslational+Modifications+of+P-TEFb+Regulate+Transcription+Elongation&doi=10.4161%2Fcc.9.9.11346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">CYCLINg through transcription: Posttranslational modifications of P-TEFb regulate transcription elongation</span></div><div class="casAuthors">Cho, Sungyoo; Schroeder, Sebastian; Ott, Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The cyclin T/CDK9 complex, also called pos. transcription elongation factor b (P-TEFb) phosphorylates the C-terminal domain of the large fragment of the RNA polymerase II.  This action is a hallmark of the transition from transcription initiation to elongation.  P-TEFb is itself modified by phosphorylation and ubiquitination.  Recently, the core components of P-TEFb, cyclin T1 and CDK9, were identified as novel substrates of histone acetyltransferases.  Here, we review how posttranslational modifications regulate the activity of the P-TEFb complex and discuss how acetylation of the complex optimizes transcription elongation in the context of other posttranslational modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewigj-ZyWYLVg90H21EOLACvtfcHk0lhJo1Wt_57f6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12itrrN&md5=740e639378f047ae7f2a5c59fcdca72b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.9.11346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.9.11346%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DM.%26atitle%3DCYCLINg%2520through%2520Transcription%253A%2520Posttranslational%2520Modifications%2520of%2520P-TEFb%2520Regulate%2520Transcription%2520Elongation%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D1697%26epage%3D1705%26doi%3D10.4161%2Fcc.9.9.11346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, R.</span></span> <span> </span><span class="NLM_article-title">Perspective of Cyclin-Dependent Kinase 9 (CDK9) as a Drug Target</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2883</span>– <span class="NLM_lpage">2890</span>, <span class="refDoi"> DOI: 10.2174/138161212800672750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F138161212800672750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22571657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2883-2890&author=V.+Krystofauthor=S.+Baumliauthor=R.+F%C3%BCrst&title=Perspective+of+Cyclin-Dependent+Kinase+9+%28CDK9%29+as+a+Drug+Target&doi=10.2174%2F138161212800672750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target</span></div><div class="casAuthors">Krystof, Vladimir; Baumli, Sonja; Furst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2883-2890</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review,.  The deregulation of cyclin-dependent kinases (CDKs) has been assocd. with many cancer types and has evoked an interest in chem. inhibitors with possible therapeutic benefit.  While most known inhibitors display broad selectivity toward multiple CDKs, recent work highlights CDK9 as the crit. target responsible for the anticancer activity of clin. evaluated drugs.  Here, the authors discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 toward applications in cancer therapy.  The authors also highlight the role of CDK9 in inflammatory processes and diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppF9ic2C9FM7Vg90H21EOLACvtfcHk0lhJo1Wt_57f6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrw%253D&md5=27c49385a4c0fab8b0ce6bfbef49cc5b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F138161212800672750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672750%26sid%3Dliteratum%253Aachs%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DPerspective%2520of%2520Cyclin-Dependent%2520Kinase%25209%2520%2528CDK9%2529%2520as%2520a%2520Drug%2520Target%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2883%26epage%3D2890%26doi%3D10.2174%2F138161212800672750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Overview of CDK9 as a Target in Cancer Research</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+Target+in+Cancer+Research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0lhVq5byJ2Pl7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520Target%2520in%2520Cancer%2520Research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span>Identifier:
NCT02345382. <a href="https://clinicaltrials.gov/ct2/show/NCT02345382" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02345382</a> (Accessed Sep
29, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02345382.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02345382+%28Accessed+Sep%0A29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span>Identifier:
NCT01938638. <a href="https://clinicaltrials.gov/ct2/show/NCT01938638" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01938638</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01938638.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01938638+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Bömer, U.</span></span> <span> </span><span class="NLM_article-title">Disubstituted 5-Fluoro Pyrimidine Derivatives Containing a Sulfondiimine Group</span>. <span class="NLM_patent">WO/2015/150273</span>, Oct 8, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=U.+L%C3%BCcking&author=A.+Scholz&author=P.+Lienau&author=G.+Siemeister&author=R.+Bohlmann&author=U.+B%C3%B6mer&title=Disubstituted+5-Fluoro+Pyrimidine+Derivatives+Containing+a+Sulfondiimine+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DDisubstituted%25205-Fluoro%2520Pyrimidine%2520Derivatives%2520Containing%2520a%2520Sulfondiimine%2520Group%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span>Identifier:
NCT02745743. <a href="https://clinicaltrials.gov/ct2/show/NCT02745743" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02745743</a> (Accessed Sep
29, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02745743.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02745743+%28Accessed+Sep%0A29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span>Identifier:
NCT02635672. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02635672" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02635672</a> (Accessed Sep 26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02635672.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02635672+%28Accessed+Sep+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the DNA Damage Response in Cancer</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.molcel.2015.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26590714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyqtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=547-560&author=M.+J.+O%E2%80%99Connor&title=Targeting+the+DNA+Damage+Response+in+Cancer&doi=10.1016%2Fj.molcel.2015.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">O'Connor, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-560</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">An underlying hallmark of cancers is their genomic instability, which is assocd. with a greater propensity to accumulate DNA damage.  Historical treatment of cancer by radiotherapy and DNA-damaging chemotherapy is based on this principle, yet it is accompanied by significant collateral damage to normal tissue and unwanted side effects.  Targeted therapy based on inhibiting the DNA damage response (DDR) in cancers offers the potential for a greater therapeutic window by tailoring treatment to patients with tumors lacking specific DDR functions.  The recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tumors harboring BRCA1 or BRCA2 mutations, represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles' heel.  This review highlights the different concepts behind targeting DDR in cancer and how this can provide significant opportunities for DDR-based therapies in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWZ64MrshabrVg90H21EOLACvtfcHk0lhVq5byJ2Pl7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyqtbvI&md5=b3f0d737d3e7dbf1f404b3f7658ab271</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520the%2520DNA%2520Damage%2520Response%2520in%2520Cancer%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D60%26spage%3D547%26epage%3D560%26doi%3D10.1016%2Fj.molcel.2015.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">DNA REPAIR. Drugging DNA Repair</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1179</span>, <span class="refDoi"> DOI: 10.1126/science.aab0958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.aab0958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27257245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFWnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&pages=1178-1179&author=S.+P.+Jacksonauthor=T.+Helleday&title=DNA+REPAIR.+Drugging+DNA+Repair&doi=10.1126%2Fscience.aab0958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging DNA repair</span></div><div class="casAuthors">Jackson, Stephen P.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">6290</span>),
    <span class="NLM_cas:pages">1178-1179</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCagmHvG64VrVg90H21EOLACvtfcHk0lhVq5byJ2Pl7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFWnsbc%253D&md5=d5ee2615d0034d26060761f921791a70</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab0958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab0958%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DDNA%2520REPAIR.%2520Drugging%2520DNA%2520Repair%26jtitle%3DScience%26date%3D2016%26volume%3D352%26spage%3D1178%26epage%3D1179%26doi%3D10.1126%2Fscience.aab0958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfettini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Cell Death by Mitotic Catastrophe: A Molecular Definition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fsj.onc.1207528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15077146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFKmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=2825-2837&author=M.+Castedoauthor=J.+L.+Perfettiniauthor=T.+Roumierauthor=K.+Andreauauthor=R.+Medemaauthor=G.+Kroemer&title=Cell+Death+by+Mitotic+Catastrophe%3A+A+Molecular+Definition&doi=10.1038%2Fsj.onc.1207528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death by mitotic catastrophe: a molecular definition</span></div><div class="casAuthors">Castedo, Maria; Perfettini, Jean-Luc; Roumier, Thomas; Andreau, Karine; Medema, Rene; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2825-2837</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The current literature is devoid of a clearcut definition of mitotic catastrophe, a type of cell death that occurs during mitosis.  Here, we propose that mitotic catastrophe results from a combination of deficient cell-cycle checkpoints (in particular the DNA structure checkpoints and the spindle assembly checkpoint) and cellular damage.  Failure to arrest the cell cycle before or at mitosis triggers an attempt of aberrant chromosome segregation, which culminates in the activation of the apoptotic default pathway and cellular demise.  Cell death occurring during the metaphase/anaphase transition is characterized by the activation of caspase-2 (which can be activated in response to DNA damage) and/or mitochondrial membrane permeabilization with the release of cell death effectors such as apoptosis-inducing factor and the caspase-9 and-3 activator cytochrome c.  Although the morphol. aspect of apoptosis may be incomplete, these alterations constitute the biochem. hallmarks of apoptosis.  Cells that fail to execute an apoptotic program in response to mitotic failure are likely to divide asym. in the next round of cell division, with the consequent generation of aneuploid cells.  This implies that disabling of the apoptotic program may actually favor chromosomal instability, through the suppression of mitotic catastrophe.  Mitotic catastrophe thus may be conceived as a mol. device that prevents aneuploidization, which may participate in oncogenesis.  Mitotic catastrophe is controlled by numerous mol. players, in particular, cell-cycle-specific kinases (such as the cyclin B1-dependent kinase Cdk1, polo-like kinases and Aurora kinases), cell-cycle checkpoint proteins, survivin, p53, caspases and members of the Bcl-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aIJ_tZK95bVg90H21EOLACvtfcHk0lgICN8VcSS-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFKmsLo%253D&md5=3b32e733e56e6e9b682fd44b38050d9e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207528%26sid%3Dliteratum%253Aachs%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DPerfettini%26aufirst%3DJ.%2BL.%26aulast%3DRoumier%26aufirst%3DT.%26aulast%3DAndreau%26aufirst%3DK.%26aulast%3DMedema%26aufirst%3DR.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCell%2520Death%2520by%2520Mitotic%2520Catastrophe%253A%2520A%2520Molecular%2520Definition%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D2825%26epage%3D2837%26doi%3D10.1038%2Fsj.onc.1207528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Mitotic Catastrophe: A Mechanism for Avoiding Genomic Instability</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1038/nrm3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21527953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=385-392&author=I.+Vitaleauthor=L.+Galluzziauthor=M.+Castedoauthor=G.+Kroemer&title=Mitotic+Catastrophe%3A+A+Mechanism+for+Avoiding+Genomic+Instability&doi=10.1038%2Fnrm3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic catastrophe: a mechanism for avoiding genomic instability</span></div><div class="casAuthors">Vitale, Ilio; Galluzzi, Lorenzo; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-392</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The improper distribution of chromosomes during mitosis compromises cellular functions and can reduce cellular fitness or contribute to malignant transformation.  As a countermeasure, higher eukaryotes have developed strategies for eliminating mitosis-incompetent cells, one of which is mitotic catastrophe.  Mitotic catastrophe is driven by a complex and poorly understood signalling cascade but, from a functional perspective, it can be defined as an oncosuppressive mechanism that precedes (and is distinct from) apoptosis, necrosis or senescence.  Accordingly, the disruption of mitotic catastrophe ppts. tumorigenesis and cancer progression, and its induction constitutes a therapeutic endpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_SWBPBcc957Vg90H21EOLACvtfcHk0lgICN8VcSS-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D&md5=1af21f749fca1bf75d526c38a75df61b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrm3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3115%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMitotic%2520Catastrophe%253A%2520A%2520Mechanism%2520for%2520Avoiding%2520Genomic%2520Instability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D385%26epage%3D392%26doi%3D10.1038%2Fnrm3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey-Boltz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unsal-Kaçmaz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev.biochem.73.011303.073723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15189136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=39-85&author=A.+Sancarauthor=L.+A.+Lindsey-Boltzauthor=K.+Unsal-Ka%C3%A7mazauthor=S.+Linn&title=Molecular+Mechanisms+of+Mammalian+DNA+Repair+and+the+DNA+Damage+Checkpoints&doi=10.1146%2Fannurev.biochem.73.011303.073723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints</span></div><div class="casAuthors">Sancar, Aziz; Lindsey-Boltz, Laura A.; Uensal-Kacmaz, Keziban; Linn, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-85</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  DNA damage is a relatively common event in the life of a cell and may lead to mutation, cancer, and cellular or organismic death.  Damage to DNA induces several cellular responses that enable the cell either to eliminate or cope with the damage or to activate a programmed cell death process, presumably to eliminate cells with potentially catastrophic mutations.  These DNA damage response reactions include: (a) removal of DNA damage and restoration of the continuity of the DNA duplex; (b) activation of a DNA damage checkpoint, which arrests cell cycle progression so as to allow for repair and prevention of the transmission of damaged or incompletely replicated chromosomes: (c) transcriptional response, which causes changes in the transcription profile that may be beneficial to the cell; and (d) apoptosis, which eliminates heavily damaged or seriously deregulated cells.  DNA repair mechanisms include direct repair, base excision repair, nucleotide excision repair, double-strand break repair, and cross-link repair.  The DNA damage checkpoints employ damage sensor proteins, such as ATM, ATR, the Rad17-RFC complex, and the 9-1-1 complex, to detect DNA damage and to initiate signal transduction cascades that employ Chk1 and Chk2 Ser/Thr kinases and Cdc25 phosphatases.  The signal transducers activate p53 and inactivate cyclin-dependent kinases to inhibit cell cycle progression from G1 to S (the G1/S checkpoint), DNA replication (the intra-S checkpoint), or G2 to mitosis (the G2/M checkpoint).  In this review the mol. mechanisms of DNA repair and the DNA damage checkpoints in mammalian cells are analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_p5BqBCbTf7Vg90H21EOLACvtfcHk0lgICN8VcSS-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsrk%253D&md5=63f88da9f19d721af81defffba832615</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073723%26sid%3Dliteratum%253Aachs%26aulast%3DSancar%26aufirst%3DA.%26aulast%3DLindsey-Boltz%26aufirst%3DL.%2BA.%26aulast%3DUnsal-Ka%25C3%25A7maz%26aufirst%3DK.%26aulast%3DLinn%26aufirst%3DS.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Mammalian%2520DNA%2520Repair%2520and%2520the%2520DNA%2520Damage%2520Checkpoints%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D39%26epage%3D85%26doi%3D10.1146%2Fannurev.biochem.73.011303.073723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazinski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span> <span> </span><span class="NLM_article-title">Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway</span>. <i>Annu. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1146/annurev-genet-121415-121658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-genet-121415-121658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27617969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFensbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=155-173&author=S.+A.+Yazinskiauthor=L.+Zou&title=Functions%2C+Regulation%2C+and+Therapeutic+Implications+of+the+ATR+Checkpoint+Pathway&doi=10.1146%2Fannurev-genet-121415-121658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway</span></div><div class="casAuthors">Yazinski, Stephanie A.; Zou, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-173</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">The ATR (ATM and rad3-related) pathway is crucial for proliferation, responding to DNA replication stress and DNA damage.  This crit. signaling pathway is carefully orchestrated through a multistep process requiring initial priming of ATR prior to damage, recruitment of ATR to DNA damage lesions, activation of ATR signaling, and, finally, modulation of ATR activity through a variety of post-translational modifications.  Following activation, ATR functions in several vital cellular processes, including suppression of replication origin firing, promotion of deoxynucleotide synthesis and replication fork restart, prevention of double-stranded DNA break formation, and avoidance of replication catastrophe and mitotic catastrophe.  In many cancers, tumor cells have increased dependence on ATR signaling for survival, making ATR a promising target for cancer therapy.  Tumor cells compromised in DNA repair pathways or DNA damage checkpoints, cells reliant on homologous recombination, and cells with increased replication stress are particularly sensitive to ATR inhibition.  Understanding ATR signaling and modulation is essential to unraveling which tumors have increased dependence on ATR signaling as well as how the ATR pathway can best be exploited for targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqftgE3FgvtQLVg90H21EOLACvtfcHk0lgICN8VcSS-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFensbfJ&md5=d05c2ace8255cabbaaa2c82c5c31784c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1146%2Fannurev-genet-121415-121658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-genet-121415-121658%26sid%3Dliteratum%253Aachs%26aulast%3DYazinski%26aufirst%3DS.%2BA.%26aulast%3DZou%26aufirst%3DL.%26atitle%3DFunctions%252C%2520Regulation%252C%2520and%2520Therapeutic%2520Implications%2520of%2520the%2520ATR%2520Checkpoint%2520Pathway%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D50%26spage%3D155%26epage%3D173%26doi%3D10.1146%2Fannurev-genet-121415-121658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span> <span> </span><span class="NLM_article-title">ATR: An Essential Regulator of Genome Integrity</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1038/nrm2450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm2450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18594563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosl2rsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=616-627&author=K.+A.+Cimprichauthor=D.+Cortez&title=ATR%3A+An+Essential+Regulator+of+Genome+Integrity&doi=10.1038%2Fnrm2450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">ATR: an essential regulator of genome integrity</span></div><div class="casAuthors">Cimprich, Karlene A.; Cortez, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">616-627</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genome maintenance is a const. concern for cells, and a coordinated response to DNA damage is required to maintain cellular viability and prevent disease.  The ataxia-telangiectasia mutated (ATM) and ATM and RAD3-related (ATR) protein kinases act as master regulators of the DNA-damage response by signaling to control cell-cycle transitions, DNA replication, DNA repair and apoptosis.  Recent studies have provided new insights into the mechanisms that control ATR activation, have helped to explain the overlapping but non-redundant activities of ATR and ATM in DNA-damage signaling, and have clarified the crucial functions of ATR in maintaining genome integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQNdqvNUR2-bVg90H21EOLACvtfcHk0lgXM_5wAXtPfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosl2rsb0%253D&md5=6257723ff4145b2aca32ca0707499ade</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrm2450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2450%26sid%3Dliteratum%253Aachs%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26aulast%3DCortez%26aufirst%3DD.%26atitle%3DATR%253A%2520An%2520Essential%2520Regulator%2520of%2520Genome%2520Integrity%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D616%26epage%3D627%26doi%3D10.1038%2Fnrm2450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6[1-(Methylsulfonyl)Cyclopropyl]Pyrim idin-2-yl}-1H-Indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy <i>in Vivo</i> Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6%5B1-%28Methylsulfonyl%29Cyclopropyl%5DPyrim+idin-2-yl%7D-1H-Indole+%28AZ20%29%3A+A+Potent+and+Selective+Inhibitor+of+ATR+Protein+Kinase+with+Monotherapy+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0lgXM_5wAXtPfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6%255B1-%2528Methylsulfonyl%2529Cyclopropyl%255DPyrim%2520idin-2-yl%257D-1H-Indole%2520%2528AZ20%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520ATR%2520Protein%2520Kinase%2520with%2520Monotherapy%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+W.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+M.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+Characterization+of+AZD6738%2C+a+Potent+Inhibitor+of+Ataxia+Telangiectasia+Mutated+and+Rad3+Related+%28ATR%29+Kinase+with+Application+as+an+Anticancer+Agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0lgXM_5wAXtPfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%2BM.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520AZD6738%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Ataxia%2520Telangiectasia%2520Mutated%2520and%2520Rad3%2520Related%2520%2528ATR%2529%2520Kinase%2520with%2520Application%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Conversion and Degradation Pathways of Sulfoximines</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5408</span>– <span class="NLM_lpage">5423</span>, <span class="refDoi"> DOI: 10.1039/C9CS00483A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC9CS00483A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31535112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=5408-5423&author=S.+Wiezorekauthor=P.+Lamersauthor=C.+Bolm&title=Conversion+and+Degradation+Pathways+of+Sulfoximines&doi=10.1039%2FC9CS00483A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion and degradation pathways of sulfoximines</span></div><div class="casAuthors">Wiezorek, Stefan; Lamers, Philip; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5408-5423</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In recent years, sulfoximines have received significant attention in both academia and industry.  This development has been reinforced by the introduction of new methods for prepg. and efficiently accessing key sulfur-based reagents allowing further functionalizations.  For all fields and in particular those related to pharmaceutical and agrochem. applications, the knowledge of potential degrdn. pathways of sulfoximines is vital.  Being aware of possible metabolites minimises the risks of late stage failures.  In this review, we describe chem. transformations in the lab. leading to sulfoximine degrdns.  Those include reductive and oxidative pathways as well as C-S bond cleavage reactions.  In a wide frame the intention of this summary is to provide a better understanding of decompn.-like reactions of sulfoximines thereby enabling a more focussed search and anal. of byproducts and potential metabolites in biorelevant systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe95QU-R9QSbVg90H21EOLACvtfcHk0lgw63spbhaqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSgu7vF&md5=d61b3464fcdf0b7966eaee26297e970a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1039%2FC9CS00483A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CS00483A%26sid%3Dliteratum%253Aachs%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DLamers%26aufirst%3DP.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DConversion%2520and%2520Degradation%2520Pathways%2520of%2520Sulfoximines%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D5408%26epage%3D5423%26doi%3D10.1039%2FC9CS00483A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span>Identifier:
NCT02264678. <a href="https://clinicaltrials.gov/ct2/show/NCT02264678" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02264678</a> (Accessed Dec
10, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02264678.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02264678+%28Accessed+Dec%0A10%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span>Identifier:
NCT02630199. <a href="https://clinicaltrials.gov/ct2/show/NCT02630199" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02630199</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02630199.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02630199+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span>Identifier:
NCT02223923. <a href="https://clinicaltrials.gov/ct2/show/NCT02223923" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02223923</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02223923.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02223923+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span>Identifier:
NCT03462342. <a href="https://clinicaltrials.gov/ct2/show/NCT03462342" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03462342</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03462342.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03462342+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span>Identifier:
NCT03330847. <a href="https://clinicaltrials.gov/ct2/show/NCT03330847" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03330847</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03330847.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03330847+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span>Identifier:
NCT03328273. <a href="https://clinicaltrials.gov/ct2/show/NCT03328273" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03328273</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03328273.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03328273+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span>Identifier:
NCT03334617. <a href="https://clinicaltrials.gov/ct2/show/NCT03334617" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03334617</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03334617.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03334617+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, C. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as ATR Inhibitors: Analogs of VE-821</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2659</span>– <span class="NLM_lpage">2662</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2017.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28479198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2659-2662&author=C.+M.+M.+Hendriksauthor=J.+Hartkampauthor=S.+Wiezorekauthor=A.-D.+Steinkampauthor=G.+Rossettiauthor=B.+L%C3%BCscherauthor=C.+Bolm&title=Sulfoximines+as+ATR+Inhibitors%3A+Analogs+of+VE-821&doi=10.1016%2Fj.bmcl.2017.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as ATR inhibitors: Analogs of VE-821</span></div><div class="casAuthors">Hendriks, Christine M. M.; Hartkamp, Joerg; Wiezorek, Stefan; Steinkamp, Anne-Dorothee; Rossetti, Giulia; Luescher, Bernhard; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2659-2662</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATM- and Rad3-related (ATR) kinases play a key role in DNA repair processes and thus ATR is an attractive target for cancer therapy.  Here the authors designed and synthesized sulfilimidoyl- and sulfoximidoyl-substituted analogs of the sulfone VE-821, a reported ATR inhibitor.  The properties of these analogs have been investigated by calcg. physicochem. parameters and studying their potential to specifically inhibit ATR in cells.  Prolonged inhibition of ATR by the analogs in a Burkitt lymphoma cell line resulted in enhanced DNA damage and a substantial amt. of apoptosis.  Together the authors' findings suggest that the sulfilimidoyl- and sulfoximidoyl-substituted analogs are efficient ATR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6PEFPAEFrLVg90H21EOLACvtfcHk0lgw63spbhaqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFamsbk%253D&md5=0f008f6e8bffd2543fbf90fa8eb9f3cf</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DC.%2BM.%2BM.%26aulast%3DHartkamp%26aufirst%3DJ.%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DSteinkamp%26aufirst%3DA.-D.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfoximines%2520as%2520ATR%2520Inhibitors%253A%2520Analogs%2520of%2520VE-821%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2659%26epage%3D2662%26doi%3D10.1016%2Fj.bmcl.2017.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markandu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarfe, G.</span></span> <span> </span><span class="NLM_article-title">CYP-Mediated Sulfoximine Deimination of AZD6738</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.077776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fdmd.117.077776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28835442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1133-1138&author=B.+C.+Jonesauthor=R.+Markanduauthor=C.+Guauthor=G.+Scarfe&title=CYP-Mediated+Sulfoximine+Deimination+of+AZD6738&doi=10.1124%2Fdmd.117.077776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">CYP-mediated sulfoximine deimination of AZD6738</span></div><div class="casAuthors">Jones, Barry C.; Markandu, Roshini; Gu, Chungang; Scarfe, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1133-1138</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In hepatic S9 and human liver microsomes (HLMs) the sulfoximine moiety of the ATR inhibitor AZD6738 is metabolized to its corresponding sulfoxide (AZ8982) and sulfone (AZ0002).  The initial deimination to AZ8982 is nominally a reductive reaction, but in HLMs it required both NADPH and oxygen and also was inhibited by 1-aminobenzotriazole at a concn. of 1 mM.  Studies conducted in a panel of 11 members of the cytochrome P 450 (P 450) family (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 CYP2J2, CYP3A4, and CYP3A5) confirmed that deimination was an oxidative process that was mediated largely by CYP2C8 with some CYP2J2 involvement, whereas the subsequent oxidn. to sulfone was carried out largely by CYP2J2, CYP3A4, and CYP3A5.  There was no measureable metab. in flavin-contg. monooxygenase (FMO) enzymes FMO3, FMO5 or NADPH cytochrome C reductase.  Studies using Silensomes, a com. available HLM in which specific members of the P 450 family have been inhibited by selective mechanism-based inhibitors, showed that when CYP2C8 was inhibited, the rate of deimination was reduced by 95%, suggesting that CYP2J2 is only playing a minor role in HLMs.  When CYP3A4 was inhibited, the rate increased by 58% due to the inhibition of the subsequent sulfone formation.  Correlation studies conducted in HLM samples from different individuals confirmed the role of CYP2C8 in the deimination over CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.  Hence, although nominally a redn., the deimination of AZD6738 to its sulfoxide metabolite AZ8982 is an oxidn. mediated by CYP2C8, and this metabolite is subsequently oxidized to the sulfone (AZ0002) largely by CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkjsC18qUf7Vg90H21EOLACvtfcHk0lhS-b6bPDtHsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlehtrw%253D&md5=37babaa5f98d9aba9fe0788c3ccc290b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.077776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.077776%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMarkandu%26aufirst%3DR.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DScarfe%26aufirst%3DG.%26atitle%3DCYP-Mediated%2520Sulfoximine%2520Deimination%2520of%2520AZD6738%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1133%26epage%3D1138%26doi%3D10.1124%2Fdmd.117.077776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">National Cancer Institute</span>. <a href="https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq#section/all" class="extLink">https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq#section/all</a> (Accessed Sep 19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fleukemia%2Fpatient%2Fchild-all-treatment-pdq%23section%2Fall+%28Accessed+Sep+19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greaves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span> <span> </span><span class="NLM_article-title">Acute Lymphoblastic Leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)62187-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2812%2962187-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23523389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3svovFWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=1943-1955&author=H.+Inabaauthor=M.+Greavesauthor=C.+G.+Mullighan&title=Acute+Lymphoblastic+Leukaemia&doi=10.1016%2FS0140-6736%2812%2962187-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Acute lymphoblastic leukaemia</span></div><div class="casAuthors">Inaba Hiroto; Greaves Mel; Mullighan Charles G</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9881</span>),
    <span class="NLM_cas:pages">1943-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age.  Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles.  Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.  However, innovative approaches are needed to further improve survival while reducing adverse effects.  Prognosis remains poor in infants and adults.  Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvyNMEVGJXbeWhZTslLrfffW6udTcc2ea8dyWYu2WWDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svovFWisA%253D%253D&md5=6a13740d2abd2b597f6e4f09a97b22cf</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2962187-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252962187-4%26sid%3Dliteratum%253Aachs%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DGreaves%26aufirst%3DM.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DAcute%2520Lymphoblastic%2520Leukaemia%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D1943%26epage%3D1955%26doi%3D10.1016%2FS0140-6736%2812%2962187-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update</span>. <i>Blood Cancer Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e577</span>, <span class="refDoi"> DOI: 10.1038/bcj.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fbcj.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28665419" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e577&author=T.+Terwilligerauthor=M.+Abdul-Hay&title=Acute+Lymphoblastic+Leukemia%3A+A+Comprehensive+Review+and+2017+Update&doi=10.1038%2Fbcj.2017.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520Lymphoblastic%2520Leukemia%253A%2520A%2520Comprehensive%2520Review%2520and%25202017%2520Update%26jtitle%3DBlood%2520Cancer%2520Journal%26date%3D2017%26volume%3D7%26spage%3De577%26doi%3D10.1038%2Fbcj.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goekbuget, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrappe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pui, C. H.</span></span> <span> </span><span class="NLM_article-title">L-Asparaginase Treatment in Acute Lymphoblastic Leukemia: A Focus on <i>Erwinia</i> Asparaginase</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1002/cncr.25489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcncr.25489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20824725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=238-249&author=R.+Pietersauthor=S.+P.+Hungerauthor=J.+Boosauthor=C.+Rizzariauthor=L.+Silvermanauthor=A.+Baruchelauthor=N.+Goekbugetauthor=M.+Schrappeauthor=C.+H.+Pui&title=L-Asparaginase+Treatment+in+Acute+Lymphoblastic+Leukemia%3A+A+Focus+on+Erwinia+Asparaginase&doi=10.1002%2Fcncr.25489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase</span></div><div class="casAuthors">Pieters, Rob; Hunger, Stephen P.; Boos, Joachim; Rizzari, Carmelo; Silverman, Lewis; Baruchel, Andre; Goekbuget, Nicola; Schrappe, Martin; Pui, Ching-Hon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols.  Extensive clin. data have shown that intensive asparaginase treatment improves clin. outcomes in childhood ALL.  Three asparaginase prepns. are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG-asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase.  Clin. hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases.  Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL.  Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible.  Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols.  Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues.  This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cX8iktXNrbVg90H21EOLACvtfcHk0lhS-b6bPDtHsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yrsbs%253D&md5=3fe58f228c57c343666031618da60e07</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25489%26sid%3Dliteratum%253Aachs%26aulast%3DPieters%26aufirst%3DR.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DBoos%26aufirst%3DJ.%26aulast%3DRizzari%26aufirst%3DC.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBaruchel%26aufirst%3DA.%26aulast%3DGoekbuget%26aufirst%3DN.%26aulast%3DSchrappe%26aufirst%3DM.%26aulast%3DPui%26aufirst%3DC.%2BH.%26atitle%3DL-Asparaginase%2520Treatment%2520in%2520Acute%2520Lymphoblastic%2520Leukemia%253A%2520A%2520Focus%2520on%2520Erwinia%2520Asparaginase%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D238%26epage%3D249%26doi%3D10.1002%2Fcncr.25489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aghaiypour, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubkowski, J.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Activity and Substrate Specificity of <i>Erwinia chrysanthemi</i> L-Asparaginase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5655</span>– <span class="NLM_lpage">5664</span>, <span class="refDoi"> DOI: 10.1021/bi0029595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0029595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislKhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=5655-5664&author=K.+Aghaiypourauthor=A.+Wlodawerauthor=J.+Lubkowski&title=Structural+Basis+for+the+Activity+and+Substrate+Specificity+of+Erwinia+chrysanthemi+L-Asparaginase&doi=10.1021%2Fbi0029595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase</span></div><div class="casAuthors">Aghaiypour, Khosrow; Wlodawer, Alexander; Lubkowski, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5655-5664</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bacterial L-asparaginases, enzymes that catalyze the hydrolysis of L-asparagine to aspartic acid, have been used for over 30 yr as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.  Other substrates of asparaginases include L-glutamine, D-asparagine, and succinic acid monoamide.  Here, the authors present high-resoln. crystal structures of the complexes of E. chrysanthemi L-asparaginase (ErA) with the products of such reactions that also can serve as substrates, namely L-glutamic acid (L-Glu), D-aspartic acid (D-Asp), and succinic acid (Suc).  Comparison of the 4 independent active sites within each complex indicated unique and specific binding of the ligand mols.; the mode of binding was also similar between complexes.  The lack of the α-NH3+ group in Suc, compared to L-Asp, did not affect the binding mode.  The side-chain of L-Glu, larger than that of L-Asp, caused several structural distortions in the ErA active side.  The active site flexible loop (residues 15-33) did not exhibit a stable conformation, resulting in suboptimal orientation of the nucleophile, Thr-15.  Addnl., the δ-COO- plane of L-Glu was approx. perpendicular to the plane of γ-COO- in L-Asp bound to the asparaginase active site.  The binding of D-Asp to the ErA active site was very distinctive compared to the other ligands, suggesting that the low activity of ErA against D-Asp could be mainly attributed to the low kcat value.  A comparison of the amino acid sequence and the crystal structure of ErA with those of other bacterial L-asparaginases showed that the presence of 2 active site residues, Glu-63 and Ser-254, may correlate with significant glutaminase activity, whereas their substitution by Gln and Asn, resp., may lead to minimal L-glutaminase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlJZYG4GKFGbVg90H21EOLACvtfcHk0ljdrVaCQuf_PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislKhsr4%253D&md5=a4dab6f94a3c0f771012c92afc56cfd9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fbi0029595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0029595%26sid%3Dliteratum%253Aachs%26aulast%3DAghaiypour%26aufirst%3DK.%26aulast%3DWlodawer%26aufirst%3DA.%26aulast%3DLubkowski%26aufirst%3DJ.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Activity%2520and%2520Substrate%2520Specificity%2520of%2520Erwinia%2520chrysanthemi%2520L-Asparaginase%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D5655%26epage%3D5664%26doi%3D10.1021%2Fbi0029595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kislitsin, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranova, I.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Structures of L-Asparaginase from <i>Erwinia carotovora</i> Complexed with Aspartate and Glutamate</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1107/S0907444907065766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1107%2FS0907444907065766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18323619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVaqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=248-256&author=O.+Kravchenkoauthor=Y.+A.+Kislitsinauthor=A.+Popovauthor=S.+Nikonovauthor=I.+Kuranova&title=Three-Dimensional+Structures+of+L-Asparaginase+from+Erwinia+carotovora+Complexed+with+Aspartate+and+Glutamate&doi=10.1107%2FS0907444907065766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structures of L-asparaginase from Erwinia carotovora complexed with aspartate and glutamate</span></div><div class="casAuthors">Kravchenko, O. V.; Kislitsin, Yu. A.; Popov, A. N.; Nikonov, S. V.; Kuranova, I. P.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-256</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The crystal structures of E. carotovora L-asparaginase (I) complexed with L-aspartate and L-glutamate were detd. at 1.9 and 2.2 Å, resp., using the mol.-replacement method and were refined to R factors of ∼21% in both cases.  The positions of the ligands in the active site were located.  A comparison of the new structures with the known structures of Escherichia coli I and Erwinia chrysanthemi I was performed.  It was found that the arrangement of the ligands practically coincided in all 3 enzymes.  The peculiarities of the quaternary structure of the enzyme, the possible role of water mols. in enzyme action, and the conformational changes during the catalyzed reaction were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWUGWrq1vkbVg90H21EOLACvtfcHk0ljdrVaCQuf_PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVaqtr0%253D&md5=1f8ffba849dbbea806b99dee1d74cbb6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1107%2FS0907444907065766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444907065766%26sid%3Dliteratum%253Aachs%26aulast%3DKravchenko%26aufirst%3DO.%26aulast%3DKislitsin%26aufirst%3DY.%2BA.%26aulast%3DPopov%26aufirst%3DA.%26aulast%3DNikonov%26aufirst%3DS.%26aulast%3DKuranova%26aufirst%3DI.%26atitle%3DThree-Dimensional%2520Structures%2520of%2520L-Asparaginase%2520from%2520Erwinia%2520carotovora%2520Complexed%2520with%2520Aspartate%2520and%2520Glutamate%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D248%26epage%3D256%26doi%3D10.1107%2FS0907444907065766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syrigou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makrilia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K. N.</span></span> <span> </span><span class="NLM_article-title">Hypersensitivity Reactions to Antineoplastic Agents: An Overview</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e32831961b3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FCAD.0b013e32831961b3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19342995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1-6&author=E.+Syrigouauthor=N.+Makriliaauthor=I.+Kotiauthor=M.+W.+Saifauthor=K.+N.+Syrigos&title=Hypersensitivity+Reactions+to+Antineoplastic+Agents%3A+An+Overview&doi=10.1097%2FCAD.0b013e32831961b3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Hypersensitivity reactions to antineoplastic agents: an overview</span></div><div class="casAuthors">Syrigou, Ekaterini; Makrilia, Nektaria; Koti, Ioanna; Saif, Muhammad W.; Syrigos, Kostas N.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Hypersensitivity reactions to antineoplastic agents are defined as unexpected reactions with signs and symptoms inconsistent with known toxicity of antineoplastic drugs.  These reactions are uncommon and usually assocd. with certain antineoplastic categories, such as taxanes, platinum-contg. compds., epipodofyllotoxins, asparaginase, procarbazine and, more rarely, with doxorubicin and 6-mercaptopurine.  The mechanisms that are responsible for hypersensitivity reactions are unclear and vary between agents.  Symptoms of these reactions range from mild skin rashes to more severe reactions, such as arthralgia, respiratory arrest or even death in some cases.  Once hypersensitivity reactions are obsd., basic principles that allow their management and possible continuance and completion of the regimen should be followed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS-9pc34PLDbVg90H21EOLACvtfcHk0ljdrVaCQuf_PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVajsA%253D%253D&md5=a5c5dde4b31ba5836a1669c1797196d6</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e32831961b3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e32831961b3%26sid%3Dliteratum%253Aachs%26aulast%3DSyrigou%26aufirst%3DE.%26aulast%3DMakrilia%26aufirst%3DN.%26aulast%3DKoti%26aufirst%3DI.%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DSyrigos%26aufirst%3DK.%2BN.%26atitle%3DHypersensitivity%2520Reactions%2520to%2520Antineoplastic%2520Agents%253A%2520An%2520Overview%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D1%26epage%3D6%26doi%3D10.1097%2FCAD.0b013e32831961b3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asselin, B. L.</span></span> <span> </span><span class="NLM_article-title">The Three Asparaginases. Comparative Pharmacology and Optimal Use in Childhood Leukemia</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1007/978-1-4615-4811-9_69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2F978-1-4615-4811-9_69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10500842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1Ciurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=1999&pages=621-629&author=B.+L.+Asselin&title=The+Three+Asparaginases.+Comparative+Pharmacology+and+Optimal+Use+in+Childhood+Leukemia&doi=10.1007%2F978-1-4615-4811-9_69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia</span></div><div class="casAuthors">Asselin, Barbara L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">Drug Resistance in Leukemia and Lymphoma III</span>),
    <span class="NLM_cas:pages">621-629</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Asparaginase (ASP) is a std. component of the antileukemia armamentarium.  There are currently 3 prepns. of asparaginase available: (1) E. coli (ASP, Elspar); (2) the enzyme derived from Erwinia chrysanthemi (ERW, Erwinase); (3) pegaspargase (PEG, Oncaspar), the E. coli enzyme modified by covalent attachment of polyethylene glycol.  This report describes the findings of 3 pharmacol. end points: ASP enzyme activity in patients' sera, depletion of asparagine and the development of anti-ASP antibodies.  Pharmacokinetics and pharmacodynamic studies in a group of naive children with newly diagnosed ALL demonstrate a significant difference in apparent half-life (1.24 days E. coli vs. 0.65 ERW vs. 5.73 PEG; p < 0.001) and days of asparagine depletion (14-23 E. coli vs. 7-15 ERW vs. 26-34 PEG; p < 0.01) for the 3 different prepns.  Data from Pediatric Oncol. Group (POG) Protocol #8866 show that high antibody levels correlated with rapid ASP clearance and a significantly lower response rate (NR = 26% vs. CR + PR+64%).  The pharmacol. characteristics of ASP in terms of clearance of enzyme activity and ability to deplete serum asparagine was dependent upon the nature of the enzyme and are significantly altered in patients who develop anti-ASP antibodies regardless of their clin. status.  In addn., these data demonstrate that ASP pharmacokinetics are directly related to its anti-leukemic effect.  In order to maximize the therapeutic benefits of ASP, the optimal dose and schedule of treatment should be detd. based on pharmacol. testing rather than by clin. alone.  Future studies will focus on the role of "silent hypersensitivity" as a mechanism of resistance to ASP and strategies to maximize the therapeutic efficacy of ASP as part of ALL therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNqT1YeegAbVg90H21EOLACvtfcHk0ljdrVaCQuf_PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1Ciurk%253D&md5=3e09955abd379f80c34dda98578a9fdb</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4811-9_69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-4811-9_69%26sid%3Dliteratum%253Aachs%26aulast%3DAsselin%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Three%2520Asparaginases.%2520Comparative%2520Pharmacology%2520and%2520Optimal%2520Use%2520in%2520Childhood%2520Leukemia%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1999%26volume%3D457%26spage%3D621%26epage%3D629%26doi%3D10.1007%2F978-1-4615-4811-9_69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pui, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandlund, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaste, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubnitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onciu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kun, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handgretinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Relling, M. V.</span></span> <span> </span><span class="NLM_article-title">Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2741</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0900386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa0900386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19553647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1eit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2730-2741&author=C.+H.+Puiauthor=D.+Campanaauthor=D.+Peiauthor=W.+P.+Bowmanauthor=J.+T.+Sandlundauthor=S.+C.+Kasteauthor=R.+C.+Ribeiroauthor=J.+E.+Rubnitzauthor=S.+C.+Raimondiauthor=M.+Onciuauthor=E.+Coustan-Smithauthor=L.+E.+Kunauthor=S.+Jehaauthor=C.+Chengauthor=S.+C.+Howardauthor=V.+Simmonsauthor=A.+Baylesauthor=M.+L.+Metzgerauthor=J.+M.+Boyettauthor=W.+Leungauthor=R.+Handgretingerauthor=J.+R.+Downingauthor=W.+E.+Evansauthor=M.+V.+Relling&title=Treating+Childhood+Acute+Lymphoblastic+Leukemia+without+Cranial+Irradiation&doi=10.1056%2FNEJMoa0900386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Treating childhood acute lymphoblastic leukemia without cranial irradiation</span></div><div class="casAuthors">Pui, Ching-Hon; Campana, Dario; Pei, Deqing; Bowman, W. Paul; Sandlund, John T.; Kaste, Sue C.; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Raimondi, Sausana C.; Onciu, Mihaela; Coustan-Smith, Elaine; Kun, Larry E.; Jeha, Sima; Cheng, Cheng; Howard, Scott C.; Simmons, Vickey; Bayles, Amy; Metzger, Monika L.; Boyett, James M.; Leung, Wing; Handgretinger, Rupert; Downing, James R.; Evans, William E.; Relling, Mary V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2730-2741</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Prophylactic cranial irradn. has been a std. treatment with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.  METHODS We conducted a clin. trials to test whether prophylactic cranial irradn. could be omitted from treatment in all children with newly diagnosed ALL.  A total of 498 patients who could be evaluated were enrolled.  Treatment intensity was based on presenting features and the level of minimal residual disease after remission-induction treatment.  The duration of continuous complete remission in the 71 patients who previously would have received prophylactic cranial irradn. was compared with that of 56 historical controls who received it.  RESULTS The 5-yr event-free and overall survival probabilities for all 498 patients were 85.6% (95% confidence interval [CI], 79.9 to 91.3) and 93.5% (95% CI, 89.8 to 07.2), resp.  The 5-yr cumulative risk of isolated CNS relapse was 2.7% (95% CI, 1.1 to 4.3), and that of any CNS relapse (including isolated relapse and combined relapse) was 3.9% (95% CI, 1.9 to 5.9).  The 71 patients had significantly longer continuous complete remission than the 56 historical controls (P = 0.04).  All 11 patients with isolated CNS relapse remained in second remission for 0.4 to 5.5 years.  CNS leukemia (CNS-3 status) or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease (≥1%) after 6 wk of remission induction were significantly assocd. with poorer event-free survival.  Risk factors for CNS relapse included the genetic abnormality t(1;19)(TCF3-PBX1), any CNS involvement at diagnosis, and T-cell immunophenotype.  CONCLUSIONS With effective risk-adjusted chemotherapy, prophylactic cranial irradn. can be safely omitted from the treatment of childhood ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PfSfNhQRRbVg90H21EOLACvtfcHk0limTltPHXIkqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1eit78%253D&md5=3c815f963c3edd10df1686b3a6ef1b81</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900386%26sid%3Dliteratum%253Aachs%26aulast%3DPui%26aufirst%3DC.%2BH.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DBowman%26aufirst%3DW.%2BP.%26aulast%3DSandlund%26aufirst%3DJ.%2BT.%26aulast%3DKaste%26aufirst%3DS.%2BC.%26aulast%3DRibeiro%26aufirst%3DR.%2BC.%26aulast%3DRubnitz%26aufirst%3DJ.%2BE.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DOnciu%26aufirst%3DM.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DKun%26aufirst%3DL.%2BE.%26aulast%3DJeha%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DHoward%26aufirst%3DS.%2BC.%26aulast%3DSimmons%26aufirst%3DV.%26aulast%3DBayles%26aufirst%3DA.%26aulast%3DMetzger%26aufirst%3DM.%2BL.%26aulast%3DBoyett%26aufirst%3DJ.%2BM.%26aulast%3DLeung%26aufirst%3DW.%26aulast%3DHandgretinger%26aufirst%3DR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DRelling%26aufirst%3DM.%2BV.%26atitle%3DTreating%2520Childhood%2520Acute%2520Lymphoblastic%2520Leukemia%2520without%2520Cranial%2520Irradiation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2730%26epage%3D2741%26doi%3D10.1056%2FNEJMoa0900386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, J. i.</span></span> <span> </span><span class="NLM_article-title">A Potent Transition-State Analogue Inhibitor of <i>Escherichia coli</i> Asparagine Synthetase A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">5799</span>– <span class="NLM_lpage">5800</span>, <span class="refDoi"> DOI: 10.1021/ja990851a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja990851a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVKhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=5799-5800&author=M.+Koizumiauthor=J.+Hiratakeauthor=T.+Nakatsuauthor=H.+Katoauthor=J.+i.+Oda&title=A+Potent+Transition-State+Analogue+Inhibitor+of+Escherichia+coli+Asparagine+Synthetase+A&doi=10.1021%2Fja990851a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Transition-State Analogue Inhibitor of Escherichia coli Asparagine Synthetase A</span></div><div class="casAuthors">Koizumi, Mitsuteru; Hiratake, Jun; Nakatsu, Toru; Kato, Hiroaki; Oda, Jun'ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5799-5800</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">L-Asparagine synthetase [L-aspartate: ammonia ligase (AMP-forming) EC 6.3.1.1] (AS-A) from Escherichia coli is typical of ammonia-dependent asparagine synthetases and catalyzes the formation of L-Asn from L-Asp and ammonia with concomitant hydrolysis of ATP to AMP and pyrophosphate.  Asparagine synthetase is a potential target for cancer chemotherapy because asparagine depletion caused by the administration of L-asparaginase is a currently implemented protocol for the treatment of acute lymphoblastic leukemia.  It is therefore highly desirable to obtain good inhibitors of AS-A not only for use as a probe to define the detailed reaction mechanisms of asparagine synthetases but also for generating a lead for chemotherapeutic agents targeted toward the inhibition of asparagine biosynthesis.  For these purposes transition-state analogs are far more suitable than substrate analogs or intermediate mimics.  We now describe the synthesis and characterization of an N-adenylated S-methyl-L-cysteine sulfoximine as a transition-state analog.  This compd. serves as an extremely potent slow-binding inhibitor of E. coli AS-A with an overall inhibition const. of 67 nM.  An X-ray crystal structure of the enzyme-inhibitor complex reveals several key amino acid residues responsible for catalysis as well as residues responsible for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2H0NO9uyK6rVg90H21EOLACvtfcHk0limTltPHXIkqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVKhsbg%253D&md5=5a02295d58c673efc9e0b683017f8724</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fja990851a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja990851a%26sid%3Dliteratum%253Aachs%26aulast%3DKoizumi%26aufirst%3DM.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DNakatsu%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DJ.%2Bi.%26atitle%3DA%2520Potent%2520Transition-State%2520Analogue%2520Inhibitor%2520of%2520Escherichia%2520coli%2520Asparagine%2520Synthetase%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D5799%26epage%3D5800%26doi%3D10.1021%2Fja990851a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koroniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Human Asparagine Synthetase Suppresses Proliferation of an L-Asparaginase-Resistant Leukemia Cell Line</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chembiol.2006.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17185229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1339-1347&author=J.+A.+Gutierrezauthor=Y.+X.+Panauthor=L.+Koroniakauthor=J.+Hiratakeauthor=M.+S.+Kilbergauthor=N.+G.+J.+Richards&title=An+Inhibitor+of+Human+Asparagine+Synthetase+Suppresses+Proliferation+of+an+L-Asparaginase-Resistant+Leukemia+Cell+Line&doi=10.1016%2Fj.chembiol.2006.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line</span></div><div class="casAuthors">Gutierrez, Jemy A.; Pan, Yuan-Xiang; Koroniak, Lukasz; Hiratake, Jun; Kilberg, Michael S.; Richards, Nigel G. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1339-1347</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drug resistance in lymphoblastic and myeloblastic leukemia cells is poorly understood, with several lines of evidence suggesting that resistance can be correlated with upregulation of human asparagine synthetase (hASNS) expression, although this hypothesis is controversial.  New tools are needed to investigate this clin. important question, including potent hASNS inhibitors.  In vitro expts. show an adenylated sulfoximine to be a slow-onset, tight-binding inhibitor of hASNS with nanomolar affinity.  This binding affinity represents a 10-fold improvement over that reported for the only other well-characterized hASNS inhibitor.  The adenylated sulfoximine has a cytostatic effect on L-asparaginase-resistant MOLT-4 cells cultured in the presence of L-asparaginase, an enzyme that depletes L-asparagine in the growth medium.  These observations represent direct evidence that potent hASNS inhibitors may prove to be effective agents for the clin. treatment of acute lymphoblastic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEX4MJhrzHLVg90H21EOLACvtfcHk0limTltPHXIkqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CjsQ%253D%253D&md5=084645b1658ca32681db4fee11925159</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DJ.%2BA.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DKoroniak%26aufirst%3DL.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DKilberg%26aufirst%3DM.%2BS.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DAn%2520Inhibitor%2520of%2520Human%2520Asparagine%2520Synthetase%2520Suppresses%2520Proliferation%2520of%2520an%2520L-Asparaginase-Resistant%2520Leukemia%2520Cell%2520Line%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1339%26epage%3D1347%26doi%3D10.1016%2Fj.chembiol.2006.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otokawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegazy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">A Sulfoximine-Based Inhibitor of Human Asparagine Synthetase Kills L-Asparaginase-Resistant Leukemia Cells</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5915</span>– <span class="NLM_lpage">5927</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmc.2012.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22951255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OjsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5915-5927&author=H.+Ikeuchiauthor=Y.-M.+Ahnauthor=T.+Otokawaauthor=B.+Watanabeauthor=L.+Hegazyauthor=J.+Hiratakeauthor=N.+G.+J.+Richards&title=A+Sulfoximine-Based+Inhibitor+of+Human+Asparagine+Synthetase+Kills+L-Asparaginase-Resistant+Leukemia+Cells&doi=10.1016%2Fj.bmc.2012.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells</span></div><div class="casAuthors">Ikeuchi, Hideyuki; Ahn, Yong-Mo; Otokawa, Takuya; Watanabe, Bunta; Hegazy, Lamees; Hiratake, Jun; Richards, Nigel G. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5915-5927</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An adenylated sulfoximine transition-state analog 1, which inhibits human asparagine synthetase (hASNS) with nanomolar potency, has been reported to suppress the proliferation of an l-asparagine amidohydrolase (ASNase)-resistant MOLT-4 leukemia cell line (MOLT-4R) when l-asparagine is depleted in the medium.  We now report the synthesis and biol. activity of two new sulfoximine analogs of 1 that have been studied as part of systematic efforts to identify compds. with improved cell permeability and/or metabolic stability.  One of these new analogs, an amino sulfoximine 5 having no net charge at cellular pH, is a better hASNS inhibitor (KI* = 8 nM) than 1 and suppresses proliferation of MOLT-4R cells at 10-fold lower concn. (IC50 = 0.1 mM).  More importantly, and in contrast to the lead compd. 1, the presence of sulfoximine 5 at concns. above 0.25 mM causes the death of MOLT-4R cells even when ASNase is absent in the culture medium.  The amino sulfoximine 5 exhibits different dose-response behavior when incubated with an ASNase-sensitive MOLT-4 cell line (MOLT-4S), supporting the hypothesis that sulfoximine 5 exerts its effect by inhibiting hASNS in the cell.  Our work provides further evidence for the idea that hASNS represents a chemotherapeutic target for the treatment of leukemia, and perhaps other cancers, including those of the prostate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfnqk-3n-4ULVg90H21EOLACvtfcHk0lhUY1YBbWokGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OjsbzK&md5=8e2b3e66218778e9b9e74e78fec55faa</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DIkeuchi%26aufirst%3DH.%26aulast%3DAhn%26aufirst%3DY.-M.%26aulast%3DOtokawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DB.%26aulast%3DHegazy%26aufirst%3DL.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DA%2520Sulfoximine-Based%2520Inhibitor%2520of%2520Human%2520Asparagine%2520Synthetase%2520Kills%2520L-Asparaginase-Resistant%2520Leukemia%2520Cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5915%26epage%3D5927%26doi%3D10.1016%2Fj.bmc.2012.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radadiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Márquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coricello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of Human Asparagine Synthetase Enables Analysis of Inhibitor Binding and Selectivity</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">345</span>, <span class="refDoi"> DOI: 10.1038/s42003-019-0587-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs42003-019-0587-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31552298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=345&author=W.+Zhuauthor=A.+Radadiyaauthor=C.+Bissonauthor=S.+Wenzelauthor=B.+E.+Nordinauthor=F.+Mart%C3%ADnez-M%C3%A1rquezauthor=T.+Imasakiauthor=S.+E.+Sedelnikovaauthor=A.+Coricelloauthor=P.+Baumannauthor=A.+H.+Berryauthor=T.+K.+Nomanbhoyauthor=J.+W.+Kozarichauthor=Y.+Jinauthor=D.+W.+Riceauthor=Y.+Takagiauthor=N.+G.+J.+Richards&title=High-Resolution+Crystal+Structure+of+Human+Asparagine+Synthetase+Enables+Analysis+of+Inhibitor+Binding+and+Selectivity&doi=10.1038%2Fs42003-019-0587-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of human asparagine synthetase enables analysis of inhibitor binding and selectivity</span></div><div class="casAuthors">Zhu Wen; Radadiya Ashish; Coricello Adriana; Baumann Patrick; Jin Yi; Richards Nigel G J; Zhu Wen; Bisson Claudine; Bisson Claudine; Sedelnikova Svetlana E; Rice David W; Wenzel Sabine; Martinez-Marquez Francisco; Imasaki Tsuyoshi; Takagi Yuichiro; Nordin Brian E; Nomanbhoy Tyzoon K; Kozarich John W; Nordin Brian E; Imasaki Tsuyoshi; Berry Alexandria H; Richards Nigel G J</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">345</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Expression of human asparagine synthetase (ASNS) promotes metastatic progression and tumor cell invasiveness in colorectal and breast cancer, presumably by altering cellular levels of L-asparagine.  Human ASNS is therefore emerging as a bona fide drug target for cancer therapy.  Here we show that a slow-onset, tight binding inhibitor, which exhibits nanomolar affinity for human ASNS in vitro, exhibits excellent selectivity at 10 μM concentration in HCT-116 cell lysates with almost no off-target binding.  The high-resolution (1.85 ÅA) crystal structure of human ASNS has enabled us to identify a cluster of negatively charged side chains in the synthetase domain that plays a key role in inhibitor binding.  Comparing this structure with those of evolutionarily related AMP-forming enzymes provides insights into intermolecular interactions that give rise to the observed binding selectivity.  Our findings demonstrate the feasibility of developing second generation human ASNS inhibitors as lead compounds for the discovery of drugs against metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTJXPyXuaAyIxhnOQkIHOxfW6udTcc2eYGLIZDk_T9grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVOhtQ%253D%253D&md5=170f03110a151e50197375386f54d189</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0587-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0587-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DRadadiya%26aufirst%3DA.%26aulast%3DBisson%26aufirst%3DC.%26aulast%3DWenzel%26aufirst%3DS.%26aulast%3DNordin%26aufirst%3DB.%2BE.%26aulast%3DMart%25C3%25ADnez-M%25C3%25A1rquez%26aufirst%3DF.%26aulast%3DImasaki%26aufirst%3DT.%26aulast%3DSedelnikova%26aufirst%3DS.%2BE.%26aulast%3DCoricello%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DA.%2BH.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DRice%26aufirst%3DD.%2BW.%26aulast%3DTakagi%26aufirst%3DY.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520Human%2520Asparagine%2520Synthetase%2520Enables%2520Analysis%2520of%2520Inhibitor%2520Binding%2520and%2520Selectivity%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26spage%3D345%26doi%3D10.1038%2Fs42003-019-0587-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase 2 Inhibitors: Discovery, Selectivity and the Future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(99)01385-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0165-6147%2899%2901385-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10542447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXns1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=465-469&author=L.+J.+Marnettauthor=A.+S.+Kalgutkar&title=Cyclooxygenase+2+Inhibitors%3A+Discovery%2C+Selectivity+and+the+Future&doi=10.1016%2FS0165-6147%2899%2901385-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase 2 inhibitors: discovery, selectivity and the future</span></div><div class="casAuthors">Marnett, Lawrence J.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">465-469</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 52 refs.  The recent marketing of two selective cyclooxygenase 2 (COX-2) inhibitors climaxes the first phase of an exciting and fast-paced effort to exploit a novel mol. target for nonsteroidal anti-inflammatory drugs (NSAIDs).  Much has been written in the lay and scientific press about the potential of COX-2 inhibitors as anti-inflammatory and analgesic agents that lack the gastrointestinal side-effects of traditional NSAIDs.  Although research on COX-2 inhibitors has focussed mainly on inflammation and pain, exptl. and epidemiol. data suggest that COX-2 inhibitors could be used in the treatment or prevention of a broader range of diseases.  In this review, some key points and unresolved issues related to the discovery of COX-2 inhibitors, the kinetic and structural basis for their selectivity, and possible complications in their development and use will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc42Ho_aiYKLVg90H21EOLACvtfcHk0lhUY1YBbWokGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1yltr8%253D&md5=dfd4f9ae3e7015f0be283c5672a1fefd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2899%2901385-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252899%252901385-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DCyclooxygenase%25202%2520Inhibitors%253A%2520Discovery%252C%2520Selectivity%2520and%2520the%2520Future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1999%26volume%3D20%26spage%3D465%26epage%3D469%26doi%3D10.1016%2FS0165-6147%2899%2901385-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mardini, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs</span>. <i>Mol. Interventions</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14993336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1ersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=30-38&author=I.+A.+Mardiniauthor=G.+A.+FitzGerald&title=Selective+Inhibitors+of+Cyclooxygenase-2%3A+A+Growing+Class+of+Anti-Inflammatory+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugs</span></div><div class="casAuthors">Mardini, Issam A.; FitzGerald, Garret A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Interventions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">MIONAR</span>;
        ISSN:<span class="NLM_cas:issn">1534-0384</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review, with 55 refs., on the selective inhibitors of cyclooxygenase (COX)-2, which have been hailed as powerful addns. to the armamentarium of nonsteroidal anti-inflammatory drugs, covers the exptl. verification of COX inhibitor selectivity; COX-2 hypothesis; and implications of selective COX inhibitors in cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3DOFyqXG47Vg90H21EOLACvtfcHk0limGKBLzriXRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1ersr8%253D&md5=80c3d9b889268a24f9b0563d4427f70a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMardini%26aufirst%3DI.%2BA.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DSelective%2520Inhibitors%2520of%2520Cyclooxygenase-2%253A%2520A%2520Growing%2520Class%2520of%2520Anti-Inflammatory%2520Drugs%26jtitle%3DMol.%2520Interventions%26date%3D2001%26volume%3D1%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Design of Selective Inhibitors of Cyclooxygenase-2 as Nonulcerogenic Anti-Inflammatory Agents</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(98)80124-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS1367-5931%2898%2980124-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9736921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=482-490&author=L.+J.+Marnettauthor=A.+S.+Kalgutkar&title=Design+of+Selective+Inhibitors+of+Cyclooxygenase-2+as+Nonulcerogenic+Anti-Inflammatory+Agents&doi=10.1016%2FS1367-5931%2898%2980124-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents</span></div><div class="casAuthors">Marnett, Lawrence J.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review is given with 61 refs.  The discovery of a 2nd isoform of cyclooxygenase (cyclooxygenase-2) that is expressed in inflammatory cells and the central nervous system, but not in the gastric mucosa, offers the possibility of developing antiinflammatory and analgesic agents that lack the gastrointestinal side effects of currently available nonsteroidal antiinflammatory drugs.  Lead compds. from several different structural classes were identified and shown to be slow, tight-binding inhibitors that express their selectivity for cyclooxygenase-2 in the time-dependent step.  The detn. of structures of enzyme-inhibitor co-crystals along with site-directed mutagenesis expts. reveal the mol. basis for selectivity of some, but not all, inhibitors.  Preclin. and clin. studies suggest cyclooxygenase-2 inhibitors are highly promising new agents for the treatment of pain and inflammation, and for the prevention of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1iROc_OE4ybVg90H21EOLACvtfcHk0limGKBLzriXRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWnsrw%253D&md5=a85635956cadcadcd19fad063979437e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2898%2980124-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252898%252980124-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDesign%2520of%2520Selective%2520Inhibitors%2520of%2520Cyclooxygenase-2%2520as%2520Nonulcerogenic%2520Anti-Inflammatory%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D1998%26volume%3D2%26spage%3D482%26epage%3D490%26doi%3D10.1016%2FS1367-5931%2898%2980124-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase Inhibitors: Scope of Their Use and Development in Cancer Chemotherapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1002/med.20182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fmed.20182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19967720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12ktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=161-201&author=M.+N.+Khanauthor=Y.+S.+Lee&title=Cyclooxygenase+Inhibitors%3A+Scope+of+Their+Use+and+Development+in+Cancer+Chemotherapy&doi=10.1002%2Fmed.20182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy</span></div><div class="casAuthors">Khan, Mohammed Naseer A.; Lee, Yong Sup</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-201</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The traditional nonsteroidal anti-inflammatory drugs (NSAIDs) exert their effect by inhibition of cyclooxygenase-1 (COX-1) as well as COX-2 enzymes.  As COX-1 is responsible for maintaining normal biol. functions, the nonselective inhibition of these enzymes caused side effects including gastrointestinal (GI) problems.  Recently developed selective COX-2 inhibitors could reduce these adverse effects, but the evidence of cardiovascular side effects including an increased risk of myocardial infarction began to emerge, and some of the COX-2 inhibitors were eventually withdrawn from the market and this led to the downfall of this research.  So, the discovery of novel COX-2 inhibitors with their safety profile became the biggest challenge in pharmaceutical research.  However, recent mechanistic and clin. studies revolutionized this area by indicating the fact that COX-2 is involved in apoptosis resistance, angiogenesis, and tumor progression.  Epidemiol. data suggest that selective COX-2 inhibitors might prevent the development of cancers.  Moreover, COX-2 is overexpressed in many cancers thus making it an attractive therapeutic target for the prevention and treatment of a no. of malignancies.  The purpose of this review is to focus on the medicinal chem. aspects of COX-2 inhibitors in cancer chemotherapy and recent reports on these inhibitors as anticancer agents.  We attempted to cover only the COX inhibitors that showed anticancer activity, although a no. of potent COX-2 inhibitors have been reported without their anticancer effects.  Furthermore, structure-activity relationships (SAR) of different classes of compds. for COX-2 inhibition as well as anticancer activity, and their future applications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqumWKRUpyajbVg90H21EOLACvtfcHk0limGKBLzriXRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12ktLg%253D&md5=5523a7b7f4611af41007f71317fedc91</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fmed.20182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20182%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DM.%2BN.%26aulast%3DLee%26aufirst%3DY.%2BS.%26atitle%3DCyclooxygenase%2520Inhibitors%253A%2520Scope%2520of%2520Their%2520Use%2520and%2520Development%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D161%26epage%3D201%26doi%3D10.1002%2Fmed.20182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grösch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1093/jnci/djj206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjnci%2Fdjj206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16757698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD28zktl2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=736-747&author=S.+Gr%C3%B6schauthor=T.+J.+Maierauthor=S.+Schiffmannauthor=G.+Geisslinger&title=Cyclooxygenase-2+%28COX-2%29%E2%80%93Independent+Anticarcinogenic+Effects+of+Selective+COX-2+Inhibitors&doi=10.1093%2Fjnci%2Fdjj206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors</span></div><div class="casAuthors">Grosch Sabine; Maier Thorsten Jurgen; Schiffmann Susanne; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer.  One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues.  Overexpression of COX-2 increases cell proliferation and inhibits apoptosis.  However, selective COX-2 inhibitors can also act through COX-independent mechanisms.  In this review, we describe the COX-2-independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors.  We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmpLQT5sXhncSzjBFCN0BJfW6udTcc2eazybGlUqSdR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zktl2qsw%253D%253D&md5=11649e472d380b2480f709534c82013e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj206%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25B6sch%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DT.%2BJ.%26aulast%3DSchiffmann%26aufirst%3DS.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DCyclooxygenase-2%2520%2528COX-2%2529%25E2%2580%2593Independent%2520Anticarcinogenic%2520Effects%2520of%2520Selective%2520COX-2%2520Inhibitors%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D736%26epage%3D747%26doi%3D10.1093%2Fjnci%2Fdjj206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dannhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, W.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase Inhibitors – Current Status and Future Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(01)01197-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0223-5234%2801%2901197-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11311743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtF2gtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=109-126&author=G.+Dannhardtauthor=W.+Kiefer&title=Cyclooxygenase+Inhibitors+%E2%80%93+Current+Status+and+Future+Prospects&doi=10.1016%2FS0223-5234%2801%2901197-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors - current status and future prospects</span></div><div class="casAuthors">Dannhardt, Gerd; Kiefer, Werner</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-126</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review with 118 refs.  Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases.  Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2.  Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiol. roles.  Meanwhile, the responsible genes and their regulation have been clarified.  COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a no. of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation.  In contrast, the inducible form is expressed in response to inflammatory and other physiol. stimuli and growth factors, and is involved in the prodn. of the prostaglandins that mediate pain and support the inflammatory process.  All the classic NSAIDs inhibit both COX-1 and COX-2 at std. anti-inflammatory doses.  The beneficial anti-inflammatory and analgesic effects are based on the inhibition of COX-2, but the gastrointestinal toxicity and the mild bleeding diathesis are a result of the concurrent inhibition of COX-1.  Agents that inhibit COX-2 while sparing COX-1 represent a new attractive therapeutic development and could represent a major advance in the treatment of rheumatoid arthritis and osteoarthritis.  Apart from its involvement in inflammatory processes, COX-2 seems to play a role in angiogenesis, colon cancer and Alzheimer's disease, based on the fact that it is expressed during these diseases.  The benefits of specific and selective COX-2 inhibitors are currently under discussion and offer a new perspective for a further use of COX-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SuyNXVrw77Vg90H21EOLACvtfcHk0lh_WoacT8PfjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtF2gtL8%253D&md5=21a93f7148930ac5c21e689d29109b97</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2801%2901197-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252801%252901197-7%26sid%3Dliteratum%253Aachs%26aulast%3DDannhardt%26aufirst%3DG.%26aulast%3DKiefer%26aufirst%3DW.%26atitle%3DCyclooxygenase%2520Inhibitors%2520%25E2%2580%2593%2520Current%2520Status%2520and%2520Future%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2001%26volume%3D36%26spage%3D109%26epage%3D126%26doi%3D10.1016%2FS0223-5234%2801%2901197-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Bioactive Sulfoximines: Syntheses and Properties of Vioxx® Analogs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4890</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2011.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21752640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Smtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4888-4890&author=S.+J.+Parkauthor=H.+Buschmannauthor=C.+Bolm&title=Bioactive+Sulfoximines%3A+Syntheses+and+Properties+of+Vioxx%C2%AE+Analogs&doi=10.1016%2Fj.bmcl.2011.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive sulfoximines: Syntheses and properties of Vioxx analogs</span></div><div class="casAuthors">Park, Seong Jun; Buschmann, Helmut; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4888-4890</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The syntheses and biol. profiles of sulfoximine-based Vioxx analogs, I and II, are described.  Interesting data have been obtained for arylsulfoximine I, which shows a selective COX-2 inhibition (albeit not as strong as Vioxx itself) exhibiting reduced hERG activity compare to the parent sulfone Vioxx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrelQluvcnRcbVg90H21EOLACvtfcHk0lh_WoacT8PfjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Smtr0%253D&md5=233cc524860fca1691793ad0487b36a4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DBioactive%2520Sulfoximines%253A%2520Syntheses%2520and%2520Properties%2520of%2520Vioxx%25C2%25AE%2520Analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4888%26epage%3D4890%26doi%3D10.1016%2Fj.bmcl.2011.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baars, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mersmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redelstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">N-Cyano Sulfoximines: COX Inhibition, Anticancer Activity, Cellular Toxicity, and Mutagenicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201200403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23225780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslymsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=217-220&author=S.+J.+Parkauthor=H.+Baarsauthor=S.+Mersmannauthor=H.+Buschmannauthor=J.+M.+Baronauthor=P.+M.+Amannauthor=K.+Czajaauthor=H.+Hollertauthor=K.+Bluhmauthor=R.+Redelsteinauthor=C.+Bolm&title=N-Cyano+Sulfoximines%3A+COX+Inhibition%2C+Anticancer+Activity%2C+Cellular+Toxicity%2C+and+Mutagenicity&doi=10.1002%2Fcmdc.201200403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cyano Sulfoximines: COX Inhibition, Anticancer Activity, Cellular Toxicity, and Mutagenicity</span></div><div class="casAuthors">Park, Seong Jun; Baars, Hannah; Mersmann, Stefanie; Buschmann, Helmut; Baron, Jens Malte; Amann, Philipp M.; Czaja, Katharina; Hollert, Henner; Bluhm, Kerstin; Redelstein, Regine; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-220</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The COX inhibition, anticancer activity, cellular toxicity, and mutagenicity of N-cyano sulfoximines, e.g. I, is reported.  I was prepd. by metal-free oxidative imination of the corresponding sulfide with cyanogen amine as the nitrogen source followed by oxidn. with m-chloroperoxybenzoic acid.  I significantly affected the growth of non-small-cell lung cancer and melanoma cell lines.  The examd. N-cyano sulfoximines showed no significant toxicity towards HaCaT skin cells.  No mutagenic potential could be found for N-cyanosulfoximine I using the Ames fluctuation assay.  I showed potent COX-2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLfOT_LApsKLVg90H21EOLACvtfcHk0lh_WoacT8PfjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslymsbzF&md5=351ebaa6eecd1fa86af43888e1c5b2b9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200403%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DBaars%26aufirst%3DH.%26aulast%3DMersmann%26aufirst%3DS.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DAmann%26aufirst%3DP.%2BM.%26aulast%3DCzaja%26aufirst%3DK.%26aulast%3DHollert%26aufirst%3DH.%26aulast%3DBluhm%26aufirst%3DK.%26aulast%3DRedelstein%26aufirst%3DR.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DN-Cyano%2520Sulfoximines%253A%2520COX%2520Inhibition%252C%2520Anticancer%2520Activity%252C%2520Cellular%2520Toxicity%252C%2520and%2520Mutagenicity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D217%26epage%3D220%26doi%3D10.1002%2Fcmdc.201200403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">World
Health Organization</span>, World Malaria Report
2018. <a href="https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf?ua=1" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf?ua=1</a> (Accessed May 31, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World%0AHealth+Organization%2C+World+Malaria+Report%0A2018.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F275867%2F9789241565653-eng.pdf%3Fua%3D1+%28Accessed+May+31%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gething, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulikoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. S.</span></span> <span> </span><span class="NLM_article-title">Mapping <i>Plasmodium falciparum</i> Mortality in Africa between 1990 and 2015</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2435</span>– <span class="NLM_lpage">2445</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1606701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa1606701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27723434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2svns1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2435-2445&author=P.+W.+Gethingauthor=D.+C.+Caseyauthor=D.+J.+Weissauthor=D.+Bisanzioauthor=S.+Bhattauthor=E.+Cameronauthor=K.+E.+Battleauthor=U.+Dalrympleauthor=J.+Rozierauthor=P.+C.+Raoauthor=M.+J.+Kutzauthor=R.+M.+Barberauthor=C.+Huynhauthor=K.+A.+Shackelfordauthor=M.+M.+Coatesauthor=G.+Nguyenauthor=M.+S.+Fraserauthor=R.+Kulikoffauthor=H.+Wangauthor=M.+Naghaviauthor=D.+L.+Smithauthor=C.+J.+L.+Murrayauthor=S.+I.+Hayauthor=S.+S.+Lim&title=Mapping+Plasmodium+falciparum+Mortality+in+Africa+between+1990+and+2015&doi=10.1056%2FNEJMoa1606701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping Plasmodium falciparum Mortality in Africa between 1990 and 2015</span></div><div class="casAuthors">Gething Peter W; Casey Daniel C; Weiss Daniel J; Bisanzio Donal; Bhatt Samir; Cameron Ewan; Battle Katherine E; Dalrymple Ursula; Rozier Jennifer; Rao Puja C; Kutz Michael J; Barber Ryan M; Huynh Chantal; Shackelford Katya A; Coates Matthew M; Nguyen Grant; Fraser Maya S; Kulikoff Rachel; Wang Haidong; Naghavi Mohsen; Smith David L; Murray Christopher J L; Hay Simon I; Lim Stephen S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2435-2445</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Malaria control has not been routinely informed by the assessment of subnational variation in malaria deaths.  We combined data from the Malaria Atlas Project and the Global Burden of Disease Study to estimate malaria mortality across sub-Saharan Africa on a grid of 5 km(2) from 1990 through 2015.  METHODS:  We estimated malaria mortality using a spatiotemporal modeling framework of geolocated data (i.e., with known latitude and longitude) on the clinical incidence of malaria, coverage of antimalarial drug treatment, case fatality rate, and population distribution according to age.  RESULTS:  Across sub-Saharan Africa during the past 15 years, we estimated that there was an overall decrease of 57% (95% uncertainty interval, 46 to 65) in the rate of malaria deaths, from 12.5 (95% uncertainty interval, 8.3 to 17.0) per 10,000 population in 2000 to 5.4 (95% uncertainty interval, 3.4 to 7.9) in 2015.  This led to an overall decrease of 37% (95% uncertainty interval, 36 to 39) in the number of malaria deaths annually, from 1,007,000 (95% uncertainty interval, 666,000 to 1,376,000) to 631,000 (95% uncertainty interval, 394,000 to 914,000).  The share of malaria deaths among children younger than 5 years of age ranged from more than 80% at a rate of death of more than 25 per 10,000 to less than 40% at rates below 1 per 10,000.  Areas with high malaria mortality (>10 per 10,000) and low coverage (<50%) of insecticide-treated bed nets and antimalarial drugs included much of Nigeria, Angola, and Cameroon and parts of the Central African Republic, Congo, Guinea, and Equatorial Guinea.  CONCLUSIONS:  We estimated that there was an overall decrease of 57% in the rate of death from malaria across sub-Saharan Africa over the past 15 years and identified several countries in which high rates of death were associated with low coverage of antimalarial treatment and prevention programs. (Funded by the Bill and Melinda Gates Foundation and others.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5crYzD3IVsdK0qsdY6Nc1fW6udTcc2eYs5JA3hGiFs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svns1ymtA%253D%253D&md5=c103e5b72e3641e186204a4b94667c52</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1606701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1606701%26sid%3Dliteratum%253Aachs%26aulast%3DGething%26aufirst%3DP.%2BW.%26aulast%3DCasey%26aufirst%3DD.%2BC.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DBisanzio%26aufirst%3DD.%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DE.%26aulast%3DBattle%26aufirst%3DK.%2BE.%26aulast%3DDalrymple%26aufirst%3DU.%26aulast%3DRozier%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DP.%2BC.%26aulast%3DKutz%26aufirst%3DM.%2BJ.%26aulast%3DBarber%26aufirst%3DR.%2BM.%26aulast%3DHuynh%26aufirst%3DC.%26aulast%3DShackelford%26aufirst%3DK.%2BA.%26aulast%3DCoates%26aufirst%3DM.%2BM.%26aulast%3DNguyen%26aufirst%3DG.%26aulast%3DFraser%26aufirst%3DM.%2BS.%26aulast%3DKulikoff%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNaghavi%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DLim%26aufirst%3DS.%2BS.%26atitle%3DMapping%2520Plasmodium%2520falciparum%2520Mortality%2520in%2520Africa%2520between%25201990%2520and%25202015%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2435%26epage%3D2445%26doi%3D10.1056%2FNEJMoa1606701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del Prado, G. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cea, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinilla, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, I. A.</span></span> <span> </span><span class="NLM_article-title">Malaria in Developing Countries</span>. <i>J. Infect. Dev. Countries</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.3855/jidc.4610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3855%2Fjidc.4610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24423706" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1-4&author=G.+R.+L.+Del+Pradoauthor=C.+H.+Garc%C3%ADaauthor=L.+M.+Ceaauthor=V.+F.+Espinillaauthor=M.+F.+Morenoauthor=A.+M%C3%A1rquezauthor=M.+J.+Poloauthor=I.+A.+Garc%C3%ADa&title=Malaria+in+Developing+Countries&doi=10.3855%2Fjidc.4610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.3855%2Fjidc.4610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3855%252Fjidc.4610%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BPrado%26aufirst%3DG.%2BR.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DC.%2BH.%26aulast%3DCea%26aufirst%3DL.%2BM.%26aulast%3DEspinilla%26aufirst%3DV.%2BF.%26aulast%3DMoreno%26aufirst%3DM.%2BF.%26aulast%3DM%25C3%25A1rquez%26aufirst%3DA.%26aulast%3DPolo%26aufirst%3DM.%2BJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DI.%2BA.%26atitle%3DMalaria%2520in%2520Developing%2520Countries%26jtitle%3DJ.%2520Infect.%2520Dev.%2520Countries%26date%3D2014%26volume%3D8%26spage%3D1%26epage%3D4%26doi%3D10.3855%2Fjidc.4610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogstad, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herwaldt, B. L.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Agents: Mechanisms of Action</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1128/AAC.32.6.793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1128%2FAAC.32.6.793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3046479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXksVOltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=793-798&author=P.+H.+Schlesingerauthor=D.+J.+Krogstadauthor=B.+L.+Herwaldt&title=Antimalarial+Agents%3A+Mechanisms+of+Action&doi=10.1128%2FAAC.32.6.793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial agents:  Mechanisms of action</span></div><div class="casAuthors">Schlesinger, Paul H.; Krogstad, Donald J.; Herwaldt, Barbara L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">793-8</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">A review with 75 refs. examg. the antimalarial mechanisms of action of mefloquine, chloroquine, quinine, quinidine, sulfonamides, dihydrofolate reductase inhibitors, protein synthesis inhibitors, 8-aminoquinolines, and investigational drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp20U0Ba4nP_7Vg90H21EOLACvtfcHk0lgdH8FdQZHn9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXksVOltr0%253D&md5=ef40c5b563fe7200005354e3b72efa35</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FAAC.32.6.793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.32.6.793%26sid%3Dliteratum%253Aachs%26aulast%3DSchlesinger%26aufirst%3DP.%2BH.%26aulast%3DKrogstad%26aufirst%3DD.%2BJ.%26aulast%3DHerwaldt%26aufirst%3DB.%2BL.%26atitle%3DAntimalarial%2520Agents%253A%2520Mechanisms%2520of%2520Action%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1988%26volume%3D32%26spage%3D793%26epage%3D798%26doi%3D10.1128%2FAAC.32.6.793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warhurst, D. C.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Drugs: Mode of Action and Resistance</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1093/jac/18.Supplement_B.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjac%2F18.Supplement_B.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3793663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL2sXnvVWisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1986&pages=51-59&author=D.+C.+Warhurst&title=Antimalarial+Drugs%3A+Mode+of+Action+and+Resistance&doi=10.1093%2Fjac%2F18.Supplement_B.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drugs:  mode of action and resistance</span></div><div class="casAuthors">Warhurst, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Suppl. B</span>),
    <span class="NLM_cas:pages">51-9</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    </div><div class="casAbstract">A review with 44 refs.  By virtue of their chem. structure and their activity on different stages of the malaria life cycle, it is possible to classify currently used antimalarial drugs into 3 groups.  These are the antimetabolites, the 8-aminoquinolines, and the blood-schizontocides.  In addn., it is possible to recognize another group, antibacterial antibiotics with antimalarial activity.  The relation of these mechanisms to resistance is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbySnrM8a0PrVg90H21EOLACvtfcHk0lgdH8FdQZHn9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXnvVWisg%253D%253D&md5=a2242afbdaa515ff90c0a4f7c39b0929</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F18.Supplement_B.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F18.Supplement_B.51%26sid%3Dliteratum%253Aachs%26aulast%3DWarhurst%26aufirst%3DD.%2BC.%26atitle%3DAntimalarial%2520Drugs%253A%2520Mode%2520of%2520Action%2520and%2520Resistance%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1986%26volume%3D18%26spage%3D51%26epage%3D59%26doi%3D10.1093%2Fjac%2F18.Supplement_B.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">The Molecular Mechanism of Action of Artemisinin--the Debate Continues</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.3390/molecules15031705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3390%2Fmolecules15031705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20336009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ygurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1705-1721&author=P.+M.+O%E2%80%99Neillauthor=V.+E.+Bartonauthor=S.+A.+Ward&title=The+Molecular+Mechanism+of+Action+of+Artemisinin%2D%2Dthe+Debate+Continues&doi=10.3390%2Fmolecules15031705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanism of action of artemisinin - the debate continues</span></div><div class="casAuthors">O'Neill, Paul M.; Barton, Victoria E.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1705-1721</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Despite international efforts to 'roll back malaria' the 2008 World Malaria Report revealed the disease still affects approx. 3 billion people in 109 countries; 45 within the WHO African region.  The latest report however does provide some 'cautious optimism'; more than one-third of malarious countries have documented >50% redns. in malaria cases in 2008 compared to 2000.  The goal of the Member States at the World Health Assembly and 'Roll Back Malaria' (RBM) partnership is to reduce the nos. of malaria cases and deaths recorded in 2000 by 50% or more by the end of 2010.  Although malaria is preventable it is most prevalent in poorer countries where prevention is difficult and prophylaxis is generally not an option.  The burden of disease has increased by the emergence of multi drug resistant (MDR) parasites which threatens the use of established and cost effective antimalarial agents.  After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitemia and quick resoln. of symptoms.  Since artemisinin and its derivs. are eliminated rapidly, artemisinin combination therapies (ACT's) are now recommended to delay resistance mechanisms.  In spite of these precautionary measures reduced susceptibility of parasites to the artemisinin-based component of ACT's has developed at the Thai-Cambodian border, a historical 'hot spot' for MDR parasite evolution and emergence.  This development raises serious concerns for the future of the artemisinins and this is not helped by controversy related to the mode of action.  Although a no. of potential targets were proposed the actual mechanism of action remains ambiguous.  Interestingly, artemisinins have also shown potent and broad anticancer properties in cell lines and animal models and are becoming established as anti-schistosomal agents.  In this review we will discuss the recent evidence explaining bioactivation and potential mol. targets in the chemotherapy of malaria and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtgBcY1E6K97Vg90H21EOLACvtfcHk0liRad5Xn8tvyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ygurY%253D&md5=be4d50f93ea4c66578d5043f164dab31</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.3390%2Fmolecules15031705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules15031705%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DBarton%26aufirst%3DV.%2BE.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Molecular%2520Mechanism%2520of%2520Action%2520of%2520Artemisinin--the%2520Debate%2520Continues%26jtitle%3DMolecules%26date%3D2010%26volume%3D15%26spage%3D1705%26epage%3D1721%26doi%3D10.3390%2Fmolecules15031705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Divo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Oxygen- and Time-Dependent Effects of Antibiotics and Selected Mitochondrial Inhibitors on <i>Plasmodium falciparum</i> in Culture</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1128/AAC.27.1.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1128%2FAAC.27.1.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3885844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL2MXht1ylsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1985&pages=21-27&author=A.+A.+Divoauthor=T.+G.+Gearyauthor=J.+B.+Jensen&title=Oxygen-+and+Time-Dependent+Effects+of+Antibiotics+and+Selected+Mitochondrial+Inhibitors+on+Plasmodium+falciparum+in+Culture&doi=10.1128%2FAAC.27.1.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture</span></div><div class="casAuthors">Divo, Alan A.; Geary, Timothy G.; Jensen, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-7</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Several antibiotics which inhibit protein synthesis on 70 S ribosomes, including clindamycin, pirlimycin, 4'-pentyl-N-demethyl clindamycin, 4 tetracyclines, chloramphenicol, thiamphenicol, and erythromycin, had antimalarial effects against P. falciparum in culture which were greatly influenced by the duration of the drug exposure and by O tension.  In 96-h incubations, potency was increased by a ≤106-fold over the 1st 48-h period and by ≤104-fold in 15% O vs. 1% O.  Two aminoglycosides, kanamycin and tobramycin, had no antimalarial activity.  Rifampin and nalidixic acid, which inhibit nucleic acid synthesis, were not similar to the 70 S inhibitors.  The mitochondrial inhibitors, Janus Green, rhodamine 123, antimycin A1, and 8-methylamino-8-desmethyl riboflavin, had activities which were influenced by the duration of exposure and O tension.  Quinoline-contg. antimalarial agents, ionophores, and other antimalarial drugs were influenced to a minor extent by the duration of exposure, but were not affected by O tension.  Apparently, antimalarial 70 S ribosome-specific protein synthesis inhibitors are toxic to the parasites by acting on the mitochondrion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j0MWx_kSf7Vg90H21EOLACvtfcHk0liRad5Xn8tvyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1ylsbc%253D&md5=7065aa3f037be5ae9140b32fa82f6db5</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1128%2FAAC.27.1.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.27.1.21%26sid%3Dliteratum%253Aachs%26aulast%3DDivo%26aufirst%3DA.%2BA.%26aulast%3DGeary%26aufirst%3DT.%2BG.%26aulast%3DJensen%26aufirst%3DJ.%2BB.%26atitle%3DOxygen-%2520and%2520Time-Dependent%2520Effects%2520of%2520Antibiotics%2520and%2520Selected%2520Mitochondrial%2520Inhibitors%2520on%2520Plasmodium%2520falciparum%2520in%2520Culture%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1985%26volume%3D27%26spage%3D21%26epage%3D27%26doi%3D10.1128%2FAAC.27.1.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geary, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Effects of Antibiotics on <i>Plasmodium falciparum in Vitro</i></span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1983.32.221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4269%2Fajtmh.1983.32.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=6340539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3sXitFaksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=221-225&author=T.+G.+Gearyauthor=J.+B.+Jensen&title=Effects+of+Antibiotics+on+Plasmodium+falciparum+in+Vitro&doi=10.4269%2Fajtmh.1983.32.221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of antibiotics on Plasmodium falciparum in vitro</span></div><div class="casAuthors">Geary, Timothy G.; Jensen, James B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-5</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">Twelve antibiotics were tested against P. falciparum in vitro; they included cycloheximide, streptomycin, erythromycin, tetracycline, chloramphenicol, clindamycin, actinomycin D, rifampin, nalidixic acid, penicillin G, chlorhexidine, and isoniazid.  Inhibitory effects obtained at various drug concns. in vitro were compared to drug levels reported to be effective against bacteria in vivo.  Several antibacterial drugs, including erythromycin, chloramphenicol, clindamycin, rifampin, and tetracycline demonstrated significant antiparasitic effects at concns. within or near those obsd. during therapy in vivo; the potency of erythromycin and tetracycline was greater at 96 h of exposure than at 48 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKlMzKHBq2rVg90H21EOLACvtfcHk0liRad5Xn8tvyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFaksLY%253D&md5=67abd6f30316e36873be77579a5bdb3b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1983.32.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1983.32.221%26sid%3Dliteratum%253Aachs%26aulast%3DGeary%26aufirst%3DT.%2BG.%26aulast%3DJensen%26aufirst%3DJ.%2BB.%26atitle%3DEffects%2520of%2520Antibiotics%2520on%2520Plasmodium%2520falciparum%2520in%2520Vitro%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1983%26volume%3D32%26spage%3D221%26epage%3D225%26doi%3D10.4269%2Fajtmh.1983.32.221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enserink, M.</span></span> <span> </span><span class="NLM_article-title">Combating Malaria. Malaria Treatment: ACT Two</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1126/science.318.5850.560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.318.5850.560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17962536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Cmtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=560-563&author=M.+Enserink&title=Combating+Malaria.+Malaria+Treatment%3A+ACT+Two&doi=10.1126%2Fscience.318.5850.560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria Treatment: ACT Two</span></div><div class="casAuthors">Enserink, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5850</span>),
    <span class="NLM_cas:pages">560-561, 563</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An influx of money and a new generation of drugs called artemisinin-based combination therapies (ACTs) are raising optimism that malaria's toll can be reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIojWvbthNvrVg90H21EOLACvtfcHk0liRad5Xn8tvyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Cmtb7N&md5=2a528406da0d202db45a30c1d00ca523</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1126%2Fscience.318.5850.560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.318.5850.560%26sid%3Dliteratum%253Aachs%26aulast%3DEnserink%26aufirst%3DM.%26atitle%3DCombating%2520Malaria.%2520Malaria%2520Treatment%253A%2520ACT%2520Two%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D560%26epage%3D563%26doi%3D10.1126%2Fscience.318.5850.560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutabingwa, T. K.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-Based Combination Therapies (ACTs): Best Hope for Malaria Treatment but Inaccessible to the Needy!</span>. <i>Acta Trop.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.actatropica.2005.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.actatropica.2005.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16098946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=305-315&author=T.+K.+Mutabingwa&title=Artemisinin-Based+Combination+Therapies+%28ACTs%29%3A+Best+Hope+for+Malaria+Treatment+but+Inaccessible+to+the+Needy%21&doi=10.1016%2Fj.actatropica.2005.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!</span></div><div class="casAuthors">Mutabingwa, T. K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Tropica</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">ACTRAQ</span>;
        ISSN:<span class="NLM_cas:issn">0001-706X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Artemisinin-based combination therapies (ACTs) are the best anti-malarial drugs available now.  Artemisinin enhances efficacy and has the potential of lowering the rate at which resistance emerges and spreads.  Under low transmission intensity, ACTs have an addnl. public health benefit of reducing the overall malaria transmission and studies are urgently needed to investigate modalities of attaining similar benefits under high transmission.  Despite being recommended by WHO since 2001, overall deployment of ACT has been slow.  Limiting factors are high cost, limited knowledge and public awareness on the concept of combination therapy (CT) and ACT in particular, limited knowledge on safety of ACTs in pregnancy, operational issue such as inappropriate drug use, lack of suitable drug formulations, lack of post-marketing surveillance (PMS) systems, and the imbalance between demand and supply.  Through concerted efforts of multilateral organizations, the local scientific community with involvement of policy-makers progress has been on several fonts leading to improved ACT uptake rates in the last 2 years.  Of 43 countries that had adopted ACT by Feb. 2005, 18 (42%) adopted the policy in 2004.  Preference to co-formulated Coartem has led to a surge in its demand with consequent shortage.  Alternative ways for increased prodn. of ACTs are urgently needed otherwise most policies will remain adopted on paper.  Despite limitations, opportunities are opening up for effective malaria control.  Insecticides, insecticide-treated nets (ITNs) and ACTs are proven efficacious controls available that should be accessed by many.  Substantial funding is now available for biomedical malaria research and for policy implementation.  While the Global Fund is the financial engine behind the scaling up of ACT uptake, delays in cash flow after grant approval has led to many countries adopting ACT in 2004 but only few (nine) implementing it.  Clear policies on granted funds and minimal politics within funding agencies might improve the situation.  Increased interest in drug development together with the public and private sector partnership have led to new anti-malarials, some less expensive and therefore affordable by poor malaria endemic countries.  Dihydroartemisinin-piperaquine (Artekin) has a cost advantage over other ACTs (US$$ 1 for an adult treatment) making it a potential best candidate for deployment in Africa.  Part of available funds should be invested into capacity building and strengthening (personnel, resources and infrastructure) of institutions in malaria endemic countries.  This will create enabling environment and a crit. mass of scientists and public health experts to spearhead ACT policy implementation.  Active involvement of scientists from malaria endemic countries in recent International Scientific Forums like the Malaria in Pregnancy Working Group and the Consortium on ACT Implementation is the best way forward to emulate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjXH1lCc038LVg90H21EOLACvtfcHk0lhBV6cknG8qQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1emtbk%253D&md5=b0ebba6b642d70fd50e18f046c8aab1d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.actatropica.2005.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actatropica.2005.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DMutabingwa%26aufirst%3DT.%2BK.%26atitle%3DArtemisinin-Based%2520Combination%2520Therapies%2520%2528ACTs%2529%253A%2520Best%2520Hope%2520for%2520Malaria%2520Treatment%2520but%2520Inaccessible%2520to%2520the%2520Needy%2521%26jtitle%3DActa%2520Trop.%26date%3D2005%26volume%3D95%26spage%3D305%26epage%3D315%26doi%3D10.1016%2Fj.actatropica.2005.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-Based Combination Treatment of Falciparum Malaria</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2007.77.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4269%2Fajtmh.2007.77.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18165491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1anuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2007&pages=181-192&author=F.+Nostenauthor=N.+J.+White&title=Artemisinin-Based+Combination+Treatment+of+Falciparum+Malaria&doi=10.4269%2Fajtmh.2007.77.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination treatment of falciparum malaria</span></div><div class="casAuthors">Nosten, Francois; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6, Suppl.</span>),
    <span class="NLM_cas:pages">181-192</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">A review.  Artemisinin-based combination treatments (ACTs) are now generally accepted as the best treatments for uncomplicated falciparum malaria.  They are rapidly and reliably effective.  Efficacy is detd. by the drug partnering the artemisinin deriv. and, for artesunate-mefloquine, artemether-lumefantrine, and dihydroartemisinin-piperaquine, this usually exceeds 95%.  Artesunate-sulfadoxine-pyrimethamine and artesunate-amodiaquine are effective in some areas, but in other areas resistance to the partner precludes their use.  There is still uncertainty over the safety of artemisinin derivs. in the first trimester of pregnancy, when they should not be used unless there are no effective alternatives.  Otherwise, except for occasional hypersensitivity reactions, the artemisinin derivs. are safe and remarkably well tolerated.  The adverse effect profiles of the artemisinin-based combination treatments are detd. by the partner drug.  Most malaria endemic countries have now adopted artemisinin-based combination treatments as first-line treatment of falciparum malaria, but in most of these only a minority of the patients that need artemisinin-based combination treatments actually receive them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFIreJy8VF7Vg90H21EOLACvtfcHk0lhBV6cknG8qQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1anuro%253D&md5=1fea5377a810d40f4797d7bd985c9990</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2007.77.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2007.77.181%26sid%3Dliteratum%253Aachs%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin-Based%2520Combination%2520Treatment%2520of%2520Falciparum%2520Malaria%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2007%26volume%3D77%26spage%3D181%26epage%3D192%26doi%3D10.4269%2Fajtmh.2007.77.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieten, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bélard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vugt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M. P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Artemisinin Combination Therapy (ACT) for Non-Falciparum Malaria: A Systematic Review</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">463</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-13-463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1475-2875-13-463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25428624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Klur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=463&author=B.+J.+Visserauthor=R.+W.+Wietenauthor=D.+Kroonauthor=I.+M.+Nagelauthor=S.+B%C3%A9lardauthor=M.+van+Vugtauthor=M.+P.+Grobusch&title=Efficacy+and+Safety+of+Artemisinin+Combination+Therapy+%28ACT%29+for+Non-Falciparum+Malaria%3A+A+Systematic+Review&doi=10.1186%2F1475-2875-13-463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review</span></div><div class="casAuthors">Visser, Benjamin J.; Wieten, Rosanne W.; Kroon, Danielle; Nagel, Ingeborg M.; Belard, Sabine; van Vugt, Michele; Grobusch, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">463/1-463/31, 31 pp.</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Artemisinin combination therapy (ACT) is recommended as first-line treatment for uncomplicated Plasmodium falciparum malaria, whereas chloroquine is still commonly used for the treatment of non-falciparum species (Plasmodium vivax, Plasmodium ovale and Plasmodium malariae).  A more simplified, more uniform treatment approach across all malaria species is worthwhile to be considered both in endemic areas and for malaria as an imported condition alike.  Methods: A PROSPERO-registered systematic review to det. the efficacy and safety of ACT for the treatment of non-falciparum malaria was conducted, following PRISMA guidelines.  Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies published up to Nov. 2014.  Results: The literature search identified 986 reports; 40 publications were found eligible for inclusion, all of them on non-falciparum malaria in endemic areas.  Most evidence was available for P. vivax (n = 35).  Five clin. trials in total were identified evaluating ACT for P. ovale, P. malariae and Plasmodium knowlesi.  Most ACT presentations have high efficacy against P. vivax parasites; artemisinin-based combinations have shorter parasite and fever clearance times compared to chloroquine.  ACT is as effective as chloroquine in preventing recurrent parasitemia before day 28.  Artemisinin-based combinations with long half-lives show significantly fewer recurrent parasitemia up to day 63.  The limited evidence available supports both the use of chloroquine and an ACT for P. ovale and P. malariae.  ACT seems to be preferable for optimal treatment of P. knowlesi.  Conclusion: ACT is at least equiv. to chloroquine in effectively treating non-falciparum malaria.  These findings may facilitate development of simplified protocols for treating all forms of malaria with ACT, including returning travellers.  Obtaining comprehensive efficacy and safety data on ACT use for non-falciparum species particularly for P. ovale, P. malariae and P. knowlesi should be a research priority.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpjHp8bYXMILVg90H21EOLACvtfcHk0lhBV6cknG8qQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Klur4%253D&md5=2df58218346d276a01098d41ae9946f0</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-13-463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-13-463%26sid%3Dliteratum%253Aachs%26aulast%3DVisser%26aufirst%3DB.%2BJ.%26aulast%3DWieten%26aufirst%3DR.%2BW.%26aulast%3DKroon%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DI.%2BM.%26aulast%3DB%25C3%25A9lard%26aufirst%3DS.%26aulast%3Dvan%2BVugt%26aufirst%3DM.%26aulast%3DGrobusch%26aufirst%3DM.%2BP.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Artemisinin%2520Combination%2520Therapy%2520%2528ACT%2529%2520for%2520Non-Falciparum%2520Malaria%253A%2520A%2520Systematic%2520Review%26jtitle%3DMalar.%2520J.%26date%3D2014%26volume%3D13%26spage%3D463%26doi%3D10.1186%2F1475-2875-13-463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeuvray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N.</span></span> <span> </span><span class="NLM_article-title">Designing the Next Generation of Medicines for Malaria Control and Eradication</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-12-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1475-2875-12-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23742293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3sjgsVSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=187&author=J.+N.+Burrowsauthor=R.+H.+van+Huijsduijnenauthor=J.+J.+M%C3%B6hrleauthor=C.+Oeuvrayauthor=T.+N.+Wells&title=Designing+the+Next+Generation+of+Medicines+for+Malaria+Control+and+Eradication&doi=10.1186%2F1475-2875-12-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Designing the next generation of medicines for malaria control and eradication</span></div><div class="casAuthors">Burrows Jeremy N; van Huijsduijnen Rob Hooft; Mohrle Jorg J; Oeuvray Claude; Wells Timothy N C</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the fight against malaria new medicines are an essential weapon.  For the parts of the world where the current gold standard artemisinin combination therapies are active, significant improvements can still be made: for example combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or improved stability under field conditions.  For those parts of the world where the existing combinations show less than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a secondary role.  For new medicines to be optimal in malaria control they must also be able to reduce transmission and prevent relapse of dormant forms: additional constraints on a combination medicine.  In the absence of a highly effective vaccine, new medicines are also needed to protect patient populations.  In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested.  In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles).  MMV presents now a suggested framework for combining the new candidates to produce the new medicines.  Sustained investment over the next decade in discovery and development of new molecules is essential to enable the long-term delivery of the medicines needed to combat malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjy7sj0k3cHtFxYDaSSP8XfW6udTcc2eYAHjeadiU4Trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjgsVSisA%253D%253D&md5=c4283af83b04bc217f40528dde196e23</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-12-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-12-187%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3Dvan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26aulast%3DOeuvray%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DDesigning%2520the%2520Next%2520Generation%2520of%2520Medicines%2520for%2520Malaria%2520Control%2520and%2520Eradication%26jtitle%3DMalar.%2520J.%26date%3D2013%26volume%3D12%26spage%3D187%26doi%3D10.1186%2F1475-2875-12-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovannaroth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchatsoonthorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharoen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Htut, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaosebikan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folaranmi, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanthavong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongvanthong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashraheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacInnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakulthaew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intharabut, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihokhern, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunasol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowe, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1314981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa1314981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25075834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=411-423&author=E.+A.+Ashleyauthor=M.+Dhordaauthor=R.+M.+Fairhurstauthor=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=J.+M.+Andersonauthor=S.+Maoauthor=B.+Samauthor=C.+Sophaauthor=C.+M.+Chuorauthor=C.+Nguonauthor=S.+Sovannarothauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chotivanichauthor=K.+Chutasmitauthor=C.+Suchatsoonthornauthor=R.+Runcharoenauthor=T.+T.+Hienauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=N.+H.+Phuauthor=Y.+Htutauthor=K.+T.+Hanauthor=K.+H.+Ayeauthor=O.+A.+Mokuoluauthor=R.+R.+Olaosebikanauthor=O.+O.+Folaranmiauthor=M.+Mayxayauthor=M.+Khanthavongauthor=B.+Hongvanthongauthor=P.+N.+Newtonauthor=M.+A.+Onyambokoauthor=C.+I.+Fanelloauthor=A.+K.+Tshefuauthor=N.+Mishraauthor=N.+Valechaauthor=A.+P.+Phyoauthor=F.+Nostenauthor=P.+Yiauthor=R.+Tripuraauthor=S.+Borrmannauthor=M.+Bashraheilauthor=J.+Peshuauthor=M.+A.+Faizauthor=A.+Ghoseauthor=M.+A.+Hossainauthor=R.+Samadauthor=M.+R.+Rahmanauthor=M.+M.+Hasanauthor=A.+Islamauthor=O.+Miottoauthor=R.+Amatoauthor=B.+MacInnisauthor=J.+Stalkerauthor=D.+P.+Kwiatkowskiauthor=Z.+Bozdechauthor=A.+Jeeyapantauthor=P.+Y.+Cheahauthor=T.+Sakulthaewauthor=J.+Chalkauthor=B.+Intharabutauthor=K.+Silamutauthor=S.+J.+Leeauthor=B.+Vihokhernauthor=C.+Kunasolauthor=M.+Imwongauthor=J.+Tarningauthor=W.+J.+Taylorauthor=S.+Yeungauthor=C.+J.+Woodrowauthor=J.+A.+Fleggauthor=D.+Dasauthor=J.+Smithauthor=M.+Venkatesanauthor=C.+V.+Ploweauthor=K.+Stepniewskaauthor=P.+J.+Guerinauthor=A.+M.+Dondorpauthor=N.+P.+Dayauthor=N.+J.+White&title=Spread+of+Artemisinin+Resistance+in+Plasmodium+falciparum+Malaria&doi=10.1056%2FNEJMoa1314981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Spread of artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Ashley, E. A.; Dhorda, M.; Fairhurst, R. M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J. M.; Mao, S.; Sam, B.; Sopha, C.; Chuor, C. M.; Nguon, C.; Sovannaroth, S.; Pukrittayakamee, S.; Jittamala, P.; Chotivanich, K.; Chutasmit, K.; Suchatsoonthorn, C.; Runcharoen, R.; Hien, T. T.; Thuy-Nhien, N. T.; Thanh, N. V.; Phu, N. H.; Htut, Y.; Han, K.-T.; Aye, K. H.; Mokuolu, O. A.; Olaosebikan, R. R.; Folaranmi, O. O.; Mayxay, M.; Khanthavong, M.; Hongvanthong, B.; Newton, P. N.; Onyamboko, M. A.; Fanello, C. I.; Tshefu, A. K.; Mishra, N.; Valecha, N.; Phyo, A. P.; Nosten, F.; Yi, P.; Tripura, R.; Borrmann, S.; Bashraheil, M.; Peshu, J.; Faiz, M. A.; Ghose, A.; Hossain, M. A.; Samad, R.; Rahman, M. R.; Hasan, M. M.; Islam, A.; Miotto, O.; Amato, R.; MacInnis, B.; Stalker, J.; Kwiatkowski, D. P.; Bozdech, Z.; Jeeyapant, A.; Cheah, P. Y.; Sakulthaew, T.; Chalk, J.; Intharabut, B.; Silamut, K.; Lee, S. J.; Vihokhern, B.; Kunasol, C.; Imwong, M.; Tarning, J.; Taylor, W. J.; Yeung, S.; Woodrow, C. J.; Flegg, J. A.; Das, D.; Smith, J.; Venkatesan, M.; Plowe, C. V.; Stepniewska, K.; Guerin, P. J.; Dondorp, A. M.; Day, N. P.; White, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-423, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria.  Mapping the geog. extent of resistance is essential for planning containment and elimination strategies.  Methods: Between May 2011 and Apr. 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa).  Patients received artesunate, administered orally at a daily dose of either 2 mg per kg of body wt. per day or 4 mg per kg, for 3 days, followed by a std. 3-day course of artemisinin-based combination therapy.  Parasite counts in peripheral-blood samples were measured every 6 h, and the parasite clearance half-lives were detd.  Results: The median parasite clearance half-lives ranged from 1.9 h in the Democratic Republic of Congo to 7.0 h at the Thailand-Cambodia border.  Slowly clearing infections (parasite clearance half-life >5 h), strongly assocd. with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from Southern Vietnam to central Myanmar.  The incidence of pre-treatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission.  In Western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was assocd. with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days.  Conclusions: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is assocd. with mutations in kelch13.  Prolonged courses of artemisinin- based combination therapies are currently efficacious in areas where std. 3-day treatments are failing. (Funded by the U.K. Department of International Development and others).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7aJ4A3O4W8rVg90H21EOLACvtfcHk0lhsnwiemN82hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF&md5=bb2f2a4d554ba6a1f4c605868be43f6e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1314981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1314981%26sid%3Dliteratum%253Aachs%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DNguon%26aufirst%3DC.%26aulast%3DSovannaroth%26aufirst%3DS.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSuchatsoonthorn%26aufirst%3DC.%26aulast%3DRuncharoen%26aufirst%3DR.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DPhu%26aufirst%3DN.%2BH.%26aulast%3DHtut%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DK.%2BT.%26aulast%3DAye%26aufirst%3DK.%2BH.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DOlaosebikan%26aufirst%3DR.%2BR.%26aulast%3DFolaranmi%26aufirst%3DO.%2BO.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DKhanthavong%26aufirst%3DM.%26aulast%3DHongvanthong%26aufirst%3DB.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DOnyamboko%26aufirst%3DM.%2BA.%26aulast%3DFanello%26aufirst%3DC.%2BI.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DMishra%26aufirst%3DN.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DBashraheil%26aufirst%3DM.%26aulast%3DPeshu%26aufirst%3DJ.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DGhose%26aufirst%3DA.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26aulast%3DSamad%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DM.%2BR.%26aulast%3DHasan%26aufirst%3DM.%2BM.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DMacInnis%26aufirst%3DB.%26aulast%3DStalker%26aufirst%3DJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DSakulthaew%26aufirst%3DT.%26aulast%3DChalk%26aufirst%3DJ.%26aulast%3DIntharabut%26aufirst%3DB.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DVihokhern%26aufirst%3DB.%26aulast%3DKunasol%26aufirst%3DC.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DW.%2BJ.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DPlowe%26aufirst%3DC.%2BV.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DSpread%2520of%2520Artemisinin%2520Resistance%2520in%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D411%26epage%3D423%26doi%3D10.1056%2FNEJMoa1314981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spitzmüller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span> <span> </span><span class="NLM_article-title">Prediction of the <i>P. falciparum</i> Target Space Relevant to Malaria Drug Discovery</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1003257</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1003257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pcbi.1003257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24146604" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003257&author=A.+Spitzm%C3%BCllerauthor=J.+Mestres&title=Prediction+of+the+P.+falciparum+Target+Space+Relevant+to+Malaria+Drug+Discovery&doi=10.1371%2Fjournal.pcbi.1003257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003257%26sid%3Dliteratum%253Aachs%26aulast%3DSpitzm%25C3%25BCller%26aufirst%3DA.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520the%2520P.%2520falciparum%2520Target%2520Space%2520Relevant%2520to%2520Malaria%2520Drug%2520Discovery%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3De1003257%26doi%3D10.1371%2Fjournal.pcbi.1003257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshapo, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makolo, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, C.</span></span> <span> </span><span class="NLM_article-title">Preparation and Antimalarial Activity of a Novel Class of Carbohydrate-Derived, Fused Thiochromans</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2014.09.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25255435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=197-202&author=H.+H.+Kinfeauthor=P.+T.+Moshapoauthor=F.+L.+Makoloauthor=D.+W.+Gammonauthor=M.+Ehlersauthor=C.+Schmuck&title=Preparation+and+Antimalarial+Activity+of+a+Novel+Class+of+Carbohydrate-Derived%2C+Fused+Thiochromans&doi=10.1016%2Fj.ejmech.2014.09.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and antimalarial activity of a novel class of carbohydrate-derived, fused thiochromans</span></div><div class="casAuthors">Kinfe, Henok H.; Moshapo, Paseka T.; Makolo, Felix L.; Gammon, David W.; Ehlers, Martin; Schmuck, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-202</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel class of fused thiochroman derivs., e.g. I, has been prepd. by an efficient and versatile synthetic procedure involving nucleophilic displacement of the side-chain iodo substituent in 2-deoxy-2-C-iodomethyl glucosides by thiophenolate ions, and subsequent intramol. C-glycoside formation.  A range of arom. substituents is tolerated, and the subsequent facile selective oxidn. of the sulfur to the sulfoxide or sulfone level expands the range and mol. diversity of the series of compds.  A selection of the sulfoxide and sulfone derivs. bearing lipophilic substituents on the arom. portion were found to have antimalarial activities in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIi49vLzOoGbVg90H21EOLACvtfcHk0lhd05jZVANUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrt7nN&md5=c39335e29430e6a5d73404dba889364e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.060%26sid%3Dliteratum%253Aachs%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26aulast%3DMoshapo%26aufirst%3DP.%2BT.%26aulast%3DMakolo%26aufirst%3DF.%2BL.%26aulast%3DGammon%26aufirst%3DD.%2BW.%26aulast%3DEhlers%26aufirst%3DM.%26aulast%3DSchmuck%26aufirst%3DC.%26atitle%3DPreparation%2520and%2520Antimalarial%2520Activity%2520of%2520a%2520Novel%2520Class%2520of%2520Carbohydrate-Derived%252C%2520Fused%2520Thiochromans%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D197%26epage%3D202%26doi%3D10.1016%2Fj.ejmech.2014.09.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madumo, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshapo, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Effects of Lipophilicity, Protecting Group and Stereochemistry on the Antimalarial Activity of Carbohydrate-Derived Thiochromans</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1007/s00044-017-2105-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00044-017-2105-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=817-833&author=G.+K.+Madumoauthor=P.+T.+Moshapoauthor=H.+H.+Kinfe&title=Effects+of+Lipophilicity%2C+Protecting+Group+and+Stereochemistry+on+the+Antimalarial+Activity+of+Carbohydrate-Derived+Thiochromans&doi=10.1007%2Fs00044-017-2105-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of lipophilicity, protecting group and stereochemistry on the antimalarial activity of carbohydrate-derived thiochromans</span></div><div class="casAuthors">Madumo, Gilbert K.; Moshapo, Paseka T.; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">817-833</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A series of novel carbohydrate-derived thiochromans has been successfully synthesized in order to investigate the influence of alkyl substituents on the arom. ring of the thiophenol moiety in addn. to the effect of protecting groups and stereochem. on the sugar component of the target mols.  Results from the evaluation of the thiochromans for their antimalarial activity against the chloroquine-sensitive (3D7) strain of Plasmodium falciparum suggest that the presence of short chain alkyl substituents, a benzyl ether protecting group and equatorial orientation of the C-4 substituent on the sugar moiety are crucial structural features that impart high antimalarial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomk2u731mMbVg90H21EOLACvtfcHk0lhd05jZVANUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Ghsw%253D%253D&md5=239ce3dee7885d89800a1fa468630c69</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1007%2Fs00044-017-2105-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-017-2105-5%26sid%3Dliteratum%253Aachs%26aulast%3DMadumo%26aufirst%3DG.%2BK.%26aulast%3DMoshapo%26aufirst%3DP.%2BT.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DEffects%2520of%2520Lipophilicity%252C%2520Protecting%2520Group%2520and%2520Stereochemistry%2520on%2520the%2520Antimalarial%2520Activity%2520of%2520Carbohydrate-Derived%2520Thiochromans%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2018%26volume%3D27%26spage%3D817%26epage%3D833%26doi%3D10.1007%2Fs00044-017-2105-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Azide-Alkyne Cycloaddition En Route to 1H-1,2,3-Triazole-Tethered 7-Chloroquinoline-Isatin Chimeras: Synthesis and Antimalarial Evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">590</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23434528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=590-596&author=R.+Rajauthor=P.+Singhauthor=P.+Singhauthor=J.+Gutauthor=P.+J.+Rosenthalauthor=V.+Kumar&title=Azide-Alkyne+Cycloaddition+En+Route+to+1H-1%2C2%2C3-Triazole-Tethered+7-Chloroquinoline-Isatin+Chimeras%3A+Synthesis+and+Antimalarial+Evaluation&doi=10.1016%2Fj.ejmech.2013.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Azide-alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: Synthesis and antimalarial evaluation</span></div><div class="casAuthors">Raj, Raghu; Singh, Pardeep; Singh, Parvesh; Gut, Jiri; Rosenthal, Philip J.; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">590-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We describe the synthesis and antimalarial activities of 1H-1,2,3-triazole tethered 7-chloroquinoline-isatin hybrids.  Activity against cultured parasites was dependent on the C-5 substituent of the isatin ring as well as the alkyl chain length between the isatin and 7-chloroquinoline moieties.  Compd. I displayed the best activity among the test compds., with IC50 value of 1.21 μM against cultured W2-strain Plasmodium falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpffhW2sdt177Vg90H21EOLACvtfcHk0lhd05jZVANUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSrtL8%253D&md5=9442940ccbcff64cb989f9c2e1942960</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DRaj%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DAzide-Alkyne%2520Cycloaddition%2520En%2520Route%2520to%25201H-1%252C2%252C3-Triazole-Tethered%25207-Chloroquinoline-Isatin%2520Chimeras%253A%2520Synthesis%2520and%2520Antimalarial%2520Evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D590%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2013.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chizema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabasa, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppe, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antiplasmodial Evaluation of a Series of Novel Sulfoximine Analogues of Carbohydrate-Based Thiochromans</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fcbdd.13408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30264436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=254-261&author=M.+Chizemaauthor=T.+F.+Mabasaauthor=H.+C.+Hoppeauthor=H.+H.+Kinfe&title=Design%2C+Synthesis%2C+and+Antiplasmodial+Evaluation+of+a+Series+of+Novel+Sulfoximine+Analogues+of+Carbohydrate-Based+Thiochromans&doi=10.1111%2Fcbdd.13408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and antiplasmodial evaluation of a series of novel sulfoximine analogues of carbohydrate-based thiochromans</span></div><div class="casAuthors">Chizema, Munashe; Mabasa, Tommy F.; Hoppe, Heinrich C.; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">254-261</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sulfone/sulfoxide-contg. carbohydrate derived thiochromans were found to be highly active antiplasmodial agents.  However, the inability of the sulfone/sulfoxide functional groups for further derivatization and manipulation limited the potential for further exploration.  In this study, based on the interesting and important physicochem. properties, as well as amenability of sulfoximines (isosters of sulfones) for further derivatization, a series of novel sulfoximine-type carbohydrate-derived thiochroman derivs. have been successfully synthesized, characterized, and evaluated for their antiplasmodial activity.  Although the replacement of the sulfone functional group with a sulfoximine unit improved the antiplasmodial activity of the scaffolds, the activity was highly dependent on the configuration of the stereogenic center at the sulfur atom.  Moreover, anal. of the crystal structures of the sulfoximine analogs revealed that the bond between the sulfur and nitrogen atoms of the sulfoximine functional group is not a true double bond but rather a polarized single bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNHAtIBj2mjbVg90H21EOLACvtfcHk0liV1mNCxbO8Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eitbbK&md5=43bf6df41241087c21879dd4c824ae11</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13408%26sid%3Dliteratum%253Aachs%26aulast%3DChizema%26aufirst%3DM.%26aulast%3DMabasa%26aufirst%3DT.%2BF.%26aulast%3DHoppe%26aufirst%3DH.%2BC.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antiplasmodial%2520Evaluation%2520of%2520a%2520Series%2520of%2520Novel%2520Sulfoximine%2520Analogues%2520of%2520Carbohydrate-Based%2520Thiochromans%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2019%26volume%3D93%26spage%3D254%26epage%3D261%26doi%3D10.1111%2Fcbdd.13408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mabasa, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-Triazole Hybrids as Potential Antimalarial Prototypes</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/1573406415666190206232308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F1573406415666190206232308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30727905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWrsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=685-692&author=T.+F.+Mabasaauthor=B.+Aweauthor=D.+Lamingauthor=H.+H.+Kinfe&title=Design%2C+Synthesis+and+Antiplasmodial+Evaluation+of+Sulfoximine-Triazole+Hybrids+as+Potential+Antimalarial+Prototypes&doi=10.2174%2F1573406415666190206232308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-triazole Hybrids as Potential Antimalarial Prototypes</span></div><div class="casAuthors">Mabasa, Tommy F.; Awe, Babatunde; Laming, Dustin; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-692</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Malaria, caused by the deadly Plasmodium falciparum strain, claims the lives of millions of people annually.  The emergence of drug-resistant strains of P. falciparum to the artemisinin-based combination therapy (ACT), the last line of defense against malaria, is worrisome and urges for the development of new chemo-types with a new mode of action.  In the search of new antimalarial agents, hybrids of triazoles and other known antimalarial drugs have been reported to possess better activity than either of the parent compds. administered individually.  In the hope of developing new antimalarial prototypes, we propose the design, synthesis and antimalarial evaluation of novel sulfoximine-triazole hybrids owing to their interesting biol. and physiol. properties.  Propargylation of the NH moiety of the sulfoximine followed by copper-catalyzed click chem. with benzyl azide was envisaged to provide the target sulfoximine-triazole hybrids.  Results: Five novel sulfoximine-triazole hybrids possessing various substituents on the sulfoximine moiety have been successfully synthesized and evaluated for their antiplasmodial and cytotoxicity activities.  The results revealed that the co-presence of the sulfoximine and triazole moieties along with a lipophilic alkyl substituent on the sulfur atom impart significant activity.  Sulfoximine-triazole hybrids could be used as a prototype for the synthesis of new derivs. with better antiplasmodial activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_-OKIT2I9nrVg90H21EOLACvtfcHk0liV1mNCxbO8Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWrsr3K&md5=8f8929bf534e9fb76aff0012a474b30c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.2174%2F1573406415666190206232308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406415666190206232308%26sid%3Dliteratum%253Aachs%26aulast%3DMabasa%26aufirst%3DT.%2BF.%26aulast%3DAwe%26aufirst%3DB.%26aulast%3DLaming%26aufirst%3DD.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antiplasmodial%2520Evaluation%2520of%2520Sulfoximine-Triazole%2520Hybrids%2520as%2520Potential%2520Antimalarial%2520Prototypes%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D685%26epage%3D692%26doi%3D10.2174%2F1573406415666190206232308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawat, D. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-Aminoquinoline-1,2,3-Triazole and 4-Aminoquinoline-1,2,3-Triazole-1,3,5-Triazine Hybrids as Potential Antimalarial Agents</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2011.01115.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1747-0285.2011.01115.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21457474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVamtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=124-136&author=S.+Manoharauthor=S.+I.+Khanauthor=D.+S.+Rawat&title=Synthesis+of+4-Aminoquinoline-1%2C2%2C3-Triazole+and+4-Aminoquinoline-1%2C2%2C3-Triazole-1%2C3%2C5-Triazine+Hybrids+as+Potential+Antimalarial+Agents&doi=10.1111%2Fj.1747-0285.2011.01115.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents</span></div><div class="casAuthors">Manohar, Sunny; Khan, Shabane I.; Rawat, Diwan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">124-136</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The authors report the synthesis of a series of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids and evaluation of their antimalarial activity against D6 and W2 strains of Plasmodium falciparum.  To study the structure-activity relationship of substituted 4-aminoquinoline-based hybrids, 34 structurally diverse compds. were synthesized and tested against D6 and W2 strains of P. falciparum.  Some of the compds. showed promising antimalarial activity without toxicity against Vero cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4ZoiSw8UKrVg90H21EOLACvtfcHk0liV1mNCxbO8Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVamtLY%253D&md5=bbe9769364f7966cadf8f212e6d6b2b2</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01115.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01115.x%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DRawat%26aufirst%3DD.%2BS.%26atitle%3DSynthesis%2520of%25204-Aminoquinoline-1%252C2%252C3-Triazole%2520and%25204-Aminoquinoline-1%252C2%252C3-Triazole-1%252C3%252C5-Triazine%2520Hybrids%2520as%2520Potential%2520Antimalarial%2520Agents%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D124%26epage%3D136%26doi%3D10.1111%2Fj.1747-0285.2011.01115.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandão, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arantes, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Paula, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Nascimento, M. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Rocha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, A. B.</span></span> <span> </span><span class="NLM_article-title">7-Chloroquinolinotriazoles: Synthesis by the Azide–Alkyne Cycloaddition Click Chemistry, Antimalarial Activity, Cytotoxicity and SAR Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24469080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=295-309&author=G.+R.+Pereiraauthor=G.+C.+Brand%C3%A3oauthor=L.+M.+Arantesauthor=H.+A.+de+Oliveiraauthor=R.+C.+de+Paulaauthor=M.+F.+A.+do+Nascimentoauthor=F.+M.+dos+Santosauthor=R.+K.+da+Rochaauthor=J.+C.+D.+Lopesauthor=A.+B.+de+Oliveira&title=7-Chloroquinolinotriazoles%3A+Synthesis+by+the+Azide%E2%80%93Alkyne+Cycloaddition+Click+Chemistry%2C+Antimalarial+Activity%2C+Cytotoxicity+and+SAR+Studies&doi=10.1016%2Fj.ejmech.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloroquinolinotriazoles: Synthesis by the azide-alkyne cycloaddition click chemistry, antimalarial activity, cytotoxicity and SAR studies</span></div><div class="casAuthors">Pereira, Guilherme R.; Brandao, Geraldo Celio; Arantes, Lucas M.; de Oliveira, Haliton A., Jr.; de Paula, Renata Cristina; do Nascimento, Maria Fernanda A.; dos Santos, Fabio M.; da Rocha, Ramon K.; Lopes, Julio Cesar D.; Braga de Oliveira, Alaide</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty-seven 7-chloroquinolinotriazole derivs. with different substituents in the triazole moiety were synthesized via copper-catalyzed cycloaddn. (CuAAC) click chem. between 4-azido-7-chloroquinoline and several alkynes.  All the synthetic compds. were evaluated for their in vitro activity against Plasmodium falciparum (W2) and cytotoxicity to Hep G2A16 cells.  All the products disclosed low cytotoxicity (CC50 > 100 μM) and five of them have shown moderate antimalarial activity (IC50 from 9.6 to 40.9 μM).  As chloroquine analogs, it was expected that these compds. might inhibit the heme polymn. and SAR studies were performed aiming to explain their antimalarial profile.  New structural variations can be designed on the basis of the results obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53hpmXI1iX7Vg90H21EOLACvtfcHk0lj3FClvaA80HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSisbw%253D&md5=10ae802353f6cfcffc7c1d13f00a38dc</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DG.%2BR.%26aulast%3DBrand%25C3%25A3o%26aufirst%3DG.%2BC.%26aulast%3DArantes%26aufirst%3DL.%2BM.%26aulast%3Dde%2BOliveira%26aufirst%3DH.%2BA.%26aulast%3Dde%2BPaula%26aufirst%3DR.%2BC.%26aulast%3Ddo%2BNascimento%26aufirst%3DM.%2BF.%2BA.%26aulast%3Ddos%2BSantos%26aufirst%3DF.%2BM.%26aulast%3Dda%2BRocha%26aufirst%3DR.%2BK.%26aulast%3DLopes%26aufirst%3DJ.%2BC.%2BD.%26aulast%3Dde%2BOliveira%26aufirst%3DA.%2BB.%26atitle%3D7-Chloroquinolinotriazoles%253A%2520Synthesis%2520by%2520the%2520Azide%25E2%2580%2593Alkyne%2520Cycloaddition%2520Click%2520Chemistry%252C%2520Antimalarial%2520Activity%252C%2520Cytotoxicity%2520and%2520SAR%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D295%26epage%3D309%26doi%3D10.1016%2Fj.ejmech.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackie, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Triazole-Linked 2-Trichloromethylquinazolines and Exploration of Their Efficacy against <i>P. falciparum</i></span>. <i>S. Afr. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWhsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=231-236&author=A.+R.+Hamannauthor=C.+de+Kockauthor=P.+J.+Smithauthor=W.+A.+van+Otterloauthor=M.+A.+Blackie&title=Synthesis+of+Triazole-Linked+2-Trichloromethylquinazolines+and+Exploration+of+Their+Efficacy+against+P.+falciparum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of triazole-linked 2-trichloromethylquinazolines and exploration of their efficacy against P. falciparum</span></div><div class="casAuthors">Hamann, Anton R.; de Kock, Carmen; Smith, Peter J.; van Otterlo, Willem A. L.; Blackie, Margaret A. L.</div><div class="citationInfo"><span class="NLM_cas:title">South African Journal of Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-236</span>CODEN:
                <span class="NLM_cas:coden">SAJCDG</span>;
        ISSN:<span class="NLM_cas:issn">0379-4350</span>.
    
            (<span class="NLM_cas:orgname">South African Chemical Institute</span>)
        </div><div class="casAbstract">Using 2-trichloromethyl quinazoline as scaffold, seven novel triazole-linked compds., e.g., I, have been synthesized using CuAAC chem.  The in vitro biol. activity of four of the compds. on the Plasmodium falciparum chloroquine-sensitive strain NF54 was then detd.  The compds. which were tested showed moderate activity with 1.45 μM as the lowest inhibitory concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQdm2_Ypj3DrVg90H21EOLACvtfcHk0lj3FClvaA80HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWhsbjP&md5=1a40c96644a315308a1eba349240c24c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DA.%2BR.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%26aulast%3DBlackie%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520of%2520Triazole-Linked%25202-Trichloromethylquinazolines%2520and%2520Exploration%2520of%2520Their%2520Efficacy%2520against%2520P.%2520falciparum%26jtitle%3DS.%2520Afr.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D231%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackie, M. A. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Triazole-Linked Mefloquine Derivatives: Biological Evaluation against <i>Plasmodium falciparum</i></span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5466</span>– <span class="NLM_lpage">5469</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2014.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25455485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5466-5469&author=A.+R.+Hamannauthor=C.+de+Kockauthor=P.+J.+Smithauthor=W.+A.+L.+van+Otterloauthor=M.+A.+L.+Blackie&title=Synthesis+of+Novel+Triazole-Linked+Mefloquine+Derivatives%3A+Biological+Evaluation+against+Plasmodium+falciparum&doi=10.1016%2Fj.bmcl.2014.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel triazole-linked mefloquine derivatives: Biological evaluation against Plasmodium falciparum</span></div><div class="casAuthors">Hamann, Anton R.; de Kock, Carmen; Smith, Peter J.; van Otterlo, Willem A. L.; Blackie, Margaret A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5466-5469</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using 2,8-bis(trifluoromethyl)quinoline, the pharmacophore of mefloquine, as scaffold, eleven novel triazole-linked compds. of formula I [R = substituted piperazinyl; dicyclohexylamino, tert-butylamino, etc.] have been synthesized by the application of CuAAC chem.  The in vitro biol. activity of the compds. on the Plasmodium falciparum chloroquine-sensitive strain NF54 was then detd.  The compds. all showed IC50 values in the low μM range with I (R = 2-adamantylamino) exhibiting the best activity with an IC50 value of 1.00 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvdaQuprF1cbVg90H21EOLACvtfcHk0lj3FClvaA80HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrrP&md5=04751be9552f0e1fffb4481cb9dc5537</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DA.%2BR.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DBlackie%26aufirst%3DM.%2BA.%2BL.%26atitle%3DSynthesis%2520of%2520Novel%2520Triazole-Linked%2520Mefloquine%2520Derivatives%253A%2520Biological%2520Evaluation%2520against%2520Plasmodium%2520falciparum%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5466%26epage%3D5469%26doi%3D10.1016%2Fj.bmcl.2014.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. d. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, F. P.</span></span> <span> </span><span class="NLM_article-title">1-Phenyl-1H- and 2-Phenyl-2H-1,2,3-Triazol Derivatives: Design, Synthesis and Inhibitory Effect on Alpha-Glycosidases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24487194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2jt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=461-476&author=D.+Gonzagaauthor=M.+R.+Sengerauthor=F.+d.+C.+da+Silvaauthor=V.+F.+Ferreiraauthor=F.+P.+Silva&title=1-Phenyl-1H-+and+2-Phenyl-2H-1%2C2%2C3-Triazol+Derivatives%3A+Design%2C+Synthesis+and+Inhibitory+Effect+on+Alpha-Glycosidases&doi=10.1016%2Fj.ejmech.2013.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: Design, synthesis and inhibitory effect on alpha-glycosidases</span></div><div class="casAuthors">Gonzaga, Daniel; Senger, Mario Roberto; de Carvalho da Silva, Fernando; Ferreira, Vitor Francisco; Silva, Floriano Paes, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Due to aging and increasingly overweight human population, the incidence of non-insulin dependent diabetes mellitus (NIDDM or Type 2 DM) is increasing considerably.  Therefore, searching for new α-glycosidase inhibitors (GIs) capable of slowing down carbohydrate assimilation by humans is an important strategy towards control of NIDDM.  In this report, the authors disclose the search for new easily accessible synthetic triazoles as antidiabetic compds.  Two series of non-glycoside triazoles were synthesized (series A and B) and screened against Saccharomyces cerevisiae (baker's yeast) α-glucosidase (MAL12) and porcine pancreatic α-amylase activity (PPA).  Of the 60 compds. tested at 500 μM, were considered hits (≥60% inhibition) six triazoles against MAL12 and three against PPA, with the inhibition reaching up to 99.4% on MAL12 and 88.6% on PPA.  The IC50 values were calcd. for both enzymes and ranged from 54 to 482 μM for MAL12 and 145 to 282 μM for PPA.  These results demonstrated the potential activity of simple and non-glycosidic triazoles as an important novel class of GIs for the development of drugs to treat Type 2 DM.  The synthesis of the target compds. was achieved by an azide-alkyne 1,3-dipolar cycloaddn., alkenylation, formylation method.  The title compds. thus formed included 1-phenyl-1H-1,2,3-triazole-4-methanol, 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-methanol 4-acetate (ester), 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-methanol 4-benzoate (ester), 1-phenyl-1H-1,2,3-triazole-4-carboxaldehyde (aldehyde), 4-ethenyl-1-phenyl-1H-1,2,3-triazole (alkene) and related substances, such as hydrazones, isomers, 2-phenyl-2H-1,2,3-triazole-4-methanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphOl3bKI2aDrVg90H21EOLACvtfcHk0lgKB5bfkt4alA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2jt7k%253D&md5=b4113eac48f12d8df99b2d6fe726d74d</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DGonzaga%26aufirst%3DD.%26aulast%3DSenger%26aufirst%3DM.%2BR.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2Bd.%2BC.%26aulast%3DFerreira%26aufirst%3DV.%2BF.%26aulast%3DSilva%26aufirst%3DF.%2BP.%26atitle%3D1-Phenyl-1H-%2520and%25202-Phenyl-2H-1%252C2%252C3-Triazol%2520Derivatives%253A%2520Design%252C%2520Synthesis%2520and%2520Inhibitory%2520Effect%2520on%2520Alpha-Glycosidases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D461%26epage%3D476%26doi%3D10.1016%2Fj.ejmech.2013.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klnfe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belay, Y. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Thiosemicarbazone–Triazole Hybrid Compounds Antimalarial Agents</span>. <i>S. Afr. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=130-135&author=H.+Klnfeauthor=Y.+H.+Belay&title=Synthesis+and+Biological+Evaluation+of+Novel+Thiosemicarbazone%E2%80%93Triazole+Hybrid+Compounds+Antimalarial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlnfe%26aufirst%3DH.%26aulast%3DBelay%26aufirst%3DY.%2BH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Thiosemicarbazone%25E2%2580%2593Triazole%2520Hybrid%2520Compounds%2520Antimalarial%2520Agents%26jtitle%3DS.%2520Afr.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D130%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J.</span></span> <span> </span><span class="NLM_article-title">Where Have All the Antibiotics Gone?</span>. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1155/2006/707296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1155%2F2006%2F707296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18382641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD1c3isVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=287-290&author=J.+Davies&title=Where+Have+All+the+Antibiotics+Gone%3F&doi=10.1155%2F2006%2F707296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Where have All the Antibiotics Gone?</span></div><div class="casAuthors">Davies Julian</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">287-90</span>
        ISSN:<span class="NLM_cas:issn">1712-9532</span>.
    </div><div class="casAbstract">The discovery of antibiotics some 60 years ago was anticipated to herald the end of infectious diseases.  However, microbial evolution and genetic jugglery have dispelled this notion; the constant increase in the appearance of resistant strains has not been matched by the introduction of new therapeutic agents.  On the contrary, the dire need for novel antibiotics has coincided with a reduction in antibiotic discovery programs in the pharmaceutical industry.  As a result, the treatment of microbial diseases has reached a point where many infections are essentially untreatable by the antimicrobial agents currently available.  At the present time, numerous initiatives are being undertaken by physicians and by governments in an attempt to redress this situation.  In addition, alternative approaches to antibiotics for the treatment of infectious diseases are being explored intensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS39oRQPOIHnrmQt-ICR3qNfW6udTcc2ebTzSFdWYEcIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3isVSltw%253D%253D&md5=ba2232e1cf5d7068573fe957cfda85cd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1155%2F2006%2F707296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2006%252F707296%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DJ.%26atitle%3DWhere%2520Have%2520All%2520the%2520Antibiotics%2520Gone%253F%26jtitle%3DCanadian%2520Journal%2520of%2520Infectious%2520Diseases%2520%2526%2520Medical%2520Microbiology%26date%3D2006%26volume%3D17%26spage%3D287%26epage%3D290%26doi%3D10.1155%2F2006%2F707296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Centers for Disease Control and Prevention</span>. <a href="https://www.cdc.gov/drugresistance/about.html" class="extLink">https://www.cdc.gov/drugresistance/about.html</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Centers+for+Disease+Control+and+Prevention.+https%3A%2F%2Fwww.cdc.gov%2Fdrugresistance%2Fabout.html+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance" class="extLink">https://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fen%2Fnews-room%2Ffact-sheets%2Fdetail%2Fantibiotic-resistance+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reygaert, W. C.</span></span> <span> </span><span class="NLM_article-title">An Overview of the Antimicrobial Resistance Mechanisms of Bacteria</span>. <i>AIMS Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.3934/microbiol.2018.3.482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3934%2Fmicrobiol.2018.3.482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31294229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslShur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=482-501&author=W.+C.+Reygaert&title=An+Overview+of+the+Antimicrobial+Resistance+Mechanisms+of+Bacteria&doi=10.3934%2Fmicrobiol.2018.3.482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the antimicrobial resistance mechanisms of bacteria</span></div><div class="casAuthors">Reygaert, Wanda C.</div><div class="citationInfo"><span class="NLM_cas:title">AIMS Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">482-501</span>CODEN:
                <span class="NLM_cas:coden">AMIIDH</span>;
        ISSN:<span class="NLM_cas:issn">2471-1888</span>.
    
            (<span class="NLM_cas:orgname">AIMS Press</span>)
        </div><div class="casAbstract">Resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide.  When antibiotics were first introduced in the 1900's, it was thought that we had won the war against microorganisms.  It was soon discovered however, that the microorganisms were capable of developing resistance to any of the drugs that were used.  Apparently most pathogenic microorganisms have the capability of developing resistance to at least some antimicrobial agents.  The main mechanisms of resistance are: limiting uptake of a drug, modification of a drug target, inactivation of a drug, and active efflux of a drug.  These mechanisms may be native to the microorganisms, or acquired from other microorganisms.  Understanding more about these mechanisms should hopefully lead to better treatment options for infective diseases, and development of antimicrobial drugs that can withstand the microorganisms attempts to become resistant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-z_mr8zG27Vg90H21EOLACvtfcHk0lgKB5bfkt4alA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslShur7F&md5=36fabb687fa636cb2e85c272508db088</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.3934%2Fmicrobiol.2018.3.482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3934%252Fmicrobiol.2018.3.482%26sid%3Dliteratum%253Aachs%26aulast%3DReygaert%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Overview%2520of%2520the%2520Antimicrobial%2520Resistance%2520Mechanisms%2520of%2520Bacteria%26jtitle%3DAIMS%2520Microbiol.%26date%3D2018%26volume%3D4%26spage%3D482%26epage%3D501%26doi%3D10.3934%2Fmicrobiol.2018.3.482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeli, Y.</span></span> <span> </span><span class="NLM_article-title">The Negative Impact of Antibiotic Resistance</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.cmi.2015.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.cmi.2015.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26706614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC28rkvFaktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=416-422&author=N.+D.+Friedmanauthor=E.+Temkinauthor=Y.+Carmeli&title=The+Negative+Impact+of+Antibiotic+Resistance&doi=10.1016%2Fj.cmi.2015.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The negative impact of antibiotic resistance</span></div><div class="casAuthors">Friedman N D; Temkin E; Carmeli Y</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibacterial therapy is one of the most important medical developments of the twentieth century; however, the spread of resistance in healthcare settings and in the community threatens the enormous gains made by the availability of antibiotic therapy.  Infections caused by resistant bacteria lead to up to two-fold higher rates of adverse outcomes compared with similar infections caused by susceptible strains.  These adverse outcomes may be clinical or economic and reflect primarily the failure or delay of antibiotic treatment.  The magnitude of these adverse outcomes will be more pronounced as disease severity, strain virulence, or host vulnerability increases.  The negative impacts of antibacterial resistance can be measured at the patient level by increased morbidity and mortality, at the healthcare level by increased resource utilization, higher costs and reduced hospital activity and at the society level by antibiotic treatment guidelines favouring increasingly broad-spectrum empiric therapy.  In this review we will discuss the negative impact of antibiotic resistance on patients, the healthcare system and society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgWHlR74U1QVVwdslNBF-tfW6udTcc2eZzbV8iOFZlA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rkvFaktg%253D%253D&md5=0e374fdb882ce959b3ec4241649b9545</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.cmi.2015.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmi.2015.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DN.%2BD.%26aulast%3DTemkin%26aufirst%3DE.%26aulast%3DCarmeli%26aufirst%3DY.%26atitle%3DThe%2520Negative%2520Impact%2520of%2520Antibiotic%2520Resistance%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2016%26volume%3D22%26spage%3D416%26epage%3D422%26doi%3D10.1016%2Fj.cmi.2015.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaplewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piddock, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of New Antibacterial Drugs: Learning from Experience?</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1452</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1093/jac/dky019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjac%2Fdky019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29438542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvFensrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1452-1459&author=N.+Jacksonauthor=L.+Czaplewskiauthor=L.+J.+V.+Piddock&title=Discovery+and+Development+of+New+Antibacterial+Drugs%3A+Learning+from+Experience%3F&doi=10.1093%2Fjac%2Fdky019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of new antibacterial drugs: learning from experience?</span></div><div class="casAuthors">Jackson, Nicole; Czaplewski, Lloyd; Piddock, Laura J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1452-1459</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Antibiotic (antibacterial) resistance is a serious global problem and the need for new treatments is urgent.  The current antibiotic discovery model is not delivering new agents at a rate that is sufficient to combat present levels of antibiotic resistance.  This has led to fears of the arrival of a 'post-antibiotic era'.  Scientific difficulties, an unfavorable regulatory climate, multiple company mergers and the low financial returns assocd. with antibiotic drug development have led to the withdrawal of many pharmaceutical companies from the field.  The regulatory climate has now begun to improve, but major scientific hurdles still impede the discovery and development of novel antibacterial agents.  To facilitate discovery activities there must be increased understanding of the scientific problems experienced by pharmaceutical companies.  This must be coupled with addressing the current antibiotic resistance crisis so that compds. and ultimately drugs are delivered to treat the most urgent clin. challenges.  By understanding the causes of the failures and successes of the pharmaceutical industry's research history, duplication of discovery programs will be reduced, increasing the productivity of the antibiotic drug discovery pipeline by academia and small companies.  The most important scientific issues to address are getting mols. into the Gram-neg. bacterial cell and avoiding their efflux.  Hence screening programs should focus their efforts on whole bacterial cells rather than cell-free systems.  Despite falling out of favor with pharmaceutical companies, natural product research still holds promise for providing new mols. as a basis for discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuEyGokOC1LLVg90H21EOLACvtfcHk0lgZS47T8FH5lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvFensrg%253D&md5=b238daaabc100b0bf57d64ef63772917</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky019%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DN.%26aulast%3DCzaplewski%26aufirst%3DL.%26aulast%3DPiddock%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520New%2520Antibacterial%2520Drugs%253A%2520Learning%2520from%2520Experience%253F%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1452%26epage%3D1459%26doi%3D10.1093%2Fjac%2Fdky019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hester, J. B. J.</span>; <span class="NLM_string-name">Alexander, D. L.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones Having a Sulfoximine Functionality and Their Use as Antimicrobial Agents</span>. <span class="NLM_patent">WO2001046185A1</span>, Jun 28, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.+B.+J.+Hester&author=D.+L.+Alexander&title=Oxazolidinones+Having+a+Sulfoximine+Functionality+and+Their+Use+as+Antimicrobial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHester%26aufirst%3DJ.%2BB.%2BJ.%26atitle%3DOxazolidinones%2520Having%2520a%2520Sulfoximine%2520Functionality%2520and%2520Their%2520Use%2520as%2520Antimicrobial%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremillion, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span> <span> </span><span class="NLM_article-title">Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis</span>. <i>Intern. Med. (Tokyo, Jpn.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2423</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.49.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2169%2Finternalmedicine.49.4010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21088343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2423-2432&author=K.+Iwataauthor=A.+Doiauthor=G.+Ohjiauthor=H.+Okaauthor=Y.+Obaauthor=K.+Takimotoauthor=W.+Igarashiauthor=D.+H.+Gremillionauthor=T.+Shimada&title=Effect+of+Neutrophil+Elastase+Inhibitor+%28Sivelestat+Sodium%29+in+the+Treatment+of+Acute+Lung+Injury+%28ALI%29+and+Acute+Respiratory+Distress+Syndrome+%28ARDS%29%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.2169%2Finternalmedicine.49.4010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis</span></div><div class="casAuthors">Iwata Kentaro; Doi Asako; Ohji Goh; Oka Hideaki; Oba Yuichiro; Takimoto Kohei; Igarashi Wataru; Gremillion David H; Shimada Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2423-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury.  However, the clinical efficacy of the medication has not been convincingly demonstrated.  METHODS:  We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome.  Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies.  Authors were contacted if necessary.  ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE.  The primary outcome was mortality within 28-30 days after randomization.  Relative risks were pooled with the random effect model.  RESULTS:  8 trials were included in the analysis.  There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26).  Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28).  There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO(2)/FiO(2) ratio (0.30, 0.05 to 0.56).  Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias.  CONCLUSION:  Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRv_-Z2qP_xPh3YQQtAhNufW6udTcc2eZzbV8iOFZlA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D&md5=12473c878a1d894ff1847afb7a655f04</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.49.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.49.4010%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DA.%26aulast%3DOhji%26aufirst%3DG.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DOba%26aufirst%3DY.%26aulast%3DTakimoto%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DW.%26aulast%3DGremillion%26aufirst%3DD.%2BH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DEffect%2520of%2520Neutrophil%2520Elastase%2520Inhibitor%2520%2528Sivelestat%2520Sodium%2529%2520in%2520the%2520Treatment%2520of%2520Acute%2520Lung%2520Injury%2520%2528ALI%2529%2520and%2520Acute%2520Respiratory%2520Distress%2520Syndrome%2520%2528ARDS%2529%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DIntern.%2520Med.%2520%2528Tokyo%252C%2520Jpn.%2529%26date%3D2010%26volume%3D49%26spage%3D2423%26epage%3D2432%26doi%3D10.2169%2Finternalmedicine.49.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajbongshi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuturgoon, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somboro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naicker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">N-Trifluoromethylthiolated Sulfonimidamides and Sulfoximines: Anti-Microbial, Anti-Mycobacterial, and Cytotoxic Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKju7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1457-1461&author=N.+Thotaauthor=P.+Makamauthor=K.+K.+Rajbongshiauthor=S.+Nagiahauthor=N.+S.+Abdulauthor=A.+A.+Chuturgoonauthor=A.+Kaushikauthor=G.+Lamichhaneauthor=A.+M.+Somboroauthor=H.+G.+Krugerauthor=T.+Govenderauthor=T.+Naickerauthor=P.+I.+Arvidsson&title=N-Trifluoromethylthiolated+Sulfonimidamides+and+Sulfoximines%3A+Anti-Microbial%2C+Anti-Mycobacterial%2C+and+Cytotoxic+Activity&doi=10.1021%2Facsmedchemlett.9b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">N-Trifluoromethylthiolated Sulfonimidamides and Sulfoximines: Anti-microbial, Anti-mycobacterial, and Cytotoxic Activity</span></div><div class="casAuthors">Thota, Niranjan; Makam, Parameshwar; Rajbongshi, Kamal K.; Nagiah, Savania; Abdul, Naeem Sheik; Chuturgoon, Anil A.; Kaushik, Amit; Lamichhane, Gyanu; Somboro, Anou M.; Kruger, Hendrik G.; Govender, Thavendran; Naicker, Tricia; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1457-1461</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We demonstrate the expanded utility of a recently described N-trifluoromethylthiolation protocol to sulfonimidamide contg. substances.  The novel N-trifluoromethylthio sulfonimidamide derivs. thus obtained were evaluated for antibacterial activity against Mycobacterium tuberculosis and Mycobacterium abscessus and Gram + Ve (Streptococcus aureus, Bacillus subtilis), and Gram - Ve (Escherichia coli, Pseudomonas aeruginosa) bacteria.  Two compds. (I and II) showed high antimycobacterial activity with MIC value of 4-8 μg/mL; i.e. comparable to WHO recommended 1st line antibiotic for TB infection ethambutol.  The same compds. were also cytotoxic in HepG2 cells (I IC50 = 15 and II 65 μg/mL).  A structure activity relation, using matched pair anal., gave the unexpected conclusion that the trifluoromethylthio moiety was responsible for the cellular and bacterial toxicity.  Given the increasing use of the trifluoromethylthio group in contemporary medicinal chem., this observation calls for considerations before implementation of the functionality in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EAHBZr3I-rVg90H21EOLACvtfcHk0liG_1rFb8mMpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKju7bF&md5=42018042a1e12ba323bd22356c6c2595</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00285%26sid%3Dliteratum%253Aachs%26aulast%3DThota%26aufirst%3DN.%26aulast%3DMakam%26aufirst%3DP.%26aulast%3DRajbongshi%26aufirst%3DK.%2BK.%26aulast%3DNagiah%26aufirst%3DS.%26aulast%3DAbdul%26aufirst%3DN.%2BS.%26aulast%3DChuturgoon%26aufirst%3DA.%2BA.%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DSomboro%26aufirst%3DA.%2BM.%26aulast%3DKruger%26aufirst%3DH.%2BG.%26aulast%3DGovender%26aufirst%3DT.%26aulast%3DNaicker%26aufirst%3DT.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DN-Trifluoromethylthiolated%2520Sulfonimidamides%2520and%2520Sulfoximines%253A%2520Anti-Microbial%252C%2520Anti-Mycobacterial%252C%2520and%2520Cytotoxic%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1457%26epage%3D1461%26doi%3D10.1021%2Facsmedchemlett.9b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalakas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Management of Drug-Resistant Tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31882-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2819%2931882-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31526739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=953-966&author=C.+Langeauthor=K.+Dhedaauthor=D.+Chesovauthor=A.+M.+Mandalakasauthor=Z.+Udwadiaauthor=C.+R.+Horsburgh&title=Management+of+Drug-Resistant+Tuberculosis&doi=10.1016%2FS0140-6736%2819%2931882-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Management of drug-resistant tuberculosis</span></div><div class="casAuthors">Lange, Christoph; Dheda, Keertan; Chesov, Dumitru; Mandalakas, Anna Maria; Udwadia, Zarir; Horsburgh, C. Robert Jr</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10202</span>),
    <span class="NLM_cas:pages">953-966</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-resistant tuberculosis is a major public health concern in many countries.  Over the past decade, the no. of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase.  Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%.  Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 mo) and patients with multidrug-resistant tuberculosis have less favorable outcomes than those treated for drug-susceptible tuberculosis.  Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes.  Some clin. trials are evaluating 6-mo regimens to simplify management and improve outcomes of patients with multidrug-resistant tuberculosis.  Here we review optimal diagnostic and treatment strategies for patients with drug-resistant tuberculosis and their contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGregCFW97a6-rVg90H21EOLACvtfcHk0liG_1rFb8mMpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShurnM&md5=c6ff64bf9bbcdef8f48354b3c87f07c4</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931882-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931882-3%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DChesov%26aufirst%3DD.%26aulast%3DMandalakas%26aufirst%3DA.%2BM.%26aulast%3DUdwadia%26aufirst%3DZ.%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26atitle%3DManagement%2520of%2520Drug-Resistant%2520Tuberculosis%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D953%26epage%3D966%26doi%3D10.1016%2FS0140-6736%2819%2931882-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">International Diabetes Federation</span>. <a href="https://diabetesatlas.org/en/resources" class="extLink">https://diabetesatlas.org/en/resources</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International+Diabetes+Federation.+https%3A%2F%2Fdiabetesatlas.org%2Fen%2Fresources+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F. B.</span></span> <span> </span><span class="NLM_article-title">The Global Implications of Diabetes and Cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60886-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2814%2960886-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24910221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgs1KntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=1947-1948&author=Y.+Shiauthor=F.+B.+Hu&title=The+Global+Implications+of+Diabetes+and+Cancer&doi=10.1016%2FS0140-6736%2814%2960886-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">The global implications of diabetes and cancer</span></div><div class="casAuthors">Shi Yuankai; Hu Frank B</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9933</span>),
    <span class="NLM_cas:pages">1947-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWtmcQeIqOz-R_TJajKxJDfW6udTcc2eaukWLUC4-9irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgs1KntA%253D%253D&md5=5f6ae34cb370a60ee4b2ad9fa3376ceb</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960886-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960886-2%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DF.%2BB.%26atitle%3DThe%2520Global%2520Implications%2520of%2520Diabetes%2520and%2520Cancer%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D1947%26epage%3D1948%26doi%3D10.1016%2FS0140-6736%2814%2960886-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeFronzo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrannini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groop, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, R.</span></span> <span> </span><span class="NLM_article-title">Type 2 Diabetes Mellitus</span>. <i>Nature Reviews Disease Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15019</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrdp.2015.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27189025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1Smsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15019&author=R.+A.+DeFronzoauthor=E.+Ferranniniauthor=L.+Groopauthor=R.+R.+Henryauthor=W.+H.+Hermanauthor=J.+J.+Holstauthor=F.+B.+Huauthor=C.+R.+Kahnauthor=I.+Razauthor=G.+I.+Shulmanauthor=D.+C.+Simonsonauthor=M.+A.+Testaauthor=R.+Weiss&title=Type+2+Diabetes+Mellitus&doi=10.1038%2Fnrdp.2015.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 diabetes mellitus</span></div><div class="casAuthors">DeFronzo Ralph A; Ferrannini Ele; Groop Leif; Henry Robert R; Herman William H; Holst Jens Juul; Hu Frank B; Kahn C Ronald; Raz Itamar; Shulman Gerald I; Simonson Donald C; Testa Marcia A; Weiss Ram</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15019</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus (T2DM) is an expanding global health problem, closely linked to the epidemic of obesity.  Individuals with T2DM are at high risk for both microvascular complications (including retinopathy, nephropathy and neuropathy) and macrovascular complications (such as cardiovascular comorbidities), owing to hyperglycaemia and individual components of the insulin resistance (metabolic) syndrome.  Environmental factors (for example, obesity, an unhealthy diet and physical inactivity) and genetic factors contribute to the multiple pathophysiological disturbances that are responsible for impaired glucose homeostasis in T2DM.  Insulin resistance and impaired insulin secretion remain the core defects in T2DM, but at least six other pathophysiological abnormalities contribute to the dysregulation of glucose metabolism.  The multiple pathogenetic disturbances present in T2DM dictate that multiple antidiabetic agents, used in combination, will be required to maintain normoglycaemia.  The treatment must not only be effective and safe but also improve the quality of life.  Several novel medications are in development, but the greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.  For an illustrated summary of this Primer, visit: http://go.nature.com/V2eGfN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp7RmPT9C1jpPq5LRczm8ffW6udTcc2easf18gg7P0-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1Smsw%253D%253D&md5=e373d9ca912e9365d8b3fb6571b9ad13</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.19%26sid%3Dliteratum%253Aachs%26aulast%3DDeFronzo%26aufirst%3DR.%2BA.%26aulast%3DFerrannini%26aufirst%3DE.%26aulast%3DGroop%26aufirst%3DL.%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DHerman%26aufirst%3DW.%2BH.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DHu%26aufirst%3DF.%2BB.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DRaz%26aufirst%3DI.%26aulast%3DShulman%26aufirst%3DG.%2BI.%26aulast%3DSimonson%26aufirst%3DD.%2BC.%26aulast%3DTesta%26aufirst%3DM.%2BA.%26aulast%3DWeiss%26aufirst%3DR.%26atitle%3DType%25202%2520Diabetes%2520Mellitus%26jtitle%3DNature%2520Reviews%2520Disease%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15019%26doi%3D10.1038%2Fnrdp.2015.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verspohl, E. J.</span></span> <span> </span><span class="NLM_article-title">Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/pr.110.003319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fpr.110.003319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22407617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=188-237&author=E.+J.+Verspohl&title=Novel+Pharmacological+Approaches+to+the+Treatment+of+Type+2+Diabetes&doi=10.1124%2Fpr.110.003319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pharmacological approaches to the treatment of type 2 diabetes</span></div><div class="casAuthors">Verspohl, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-237</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The huge increase in type 2 diabetes is a burden worldwide.  Many marketed compds. do not address relevant aspects of the disease; they may already compensate for defects in insulin secretion and insulin action, but loss of secreting cells (β-cell destruction), hyperglucagonemia, gastric emptying, enzyme activation/inhibition in insulin-sensitive cells, substitution or antagonizing of physiol. hormones and pathways, finally leading to secondary complications of diabetes, are not sufficiently addressed.  In addn., side effects for established therapies such as hypoglycemias and wt. gain have to be diminished.  At present, nearly 1000 compds. have been described, and approx. 180 of these are going to be developed (already in clin. studies), some of them directly influencing enzyme activity, influencing pathophysiol. pathways, and some using G-protein-coupled receptors.  In addn., immunol. approaches and antisense strategies are going to be developed.  Many compds. are derived from physiol. compds. (hormones) aiming at improving their kinetics and selectivity, and others are chem. compds. that were obtained by screening for a newly identified target in the physiol. or pathophysiol. machinery.  In some areas, great progress is obsd. (e.g., incretin area); in others, no great progress is obvious (e.g., glucokinase activators), and other areas are not recommended for further research.  For all scientific areas, conclusions with respect to their impact on diabetes are given.  Potential targets for which no chem. compd. has yet been identified as a ligand (agonist or antagonist) are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSgTyKdbrIarVg90H21EOLACvtfcHk0lhpkEqxy-y47g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslKksbs%253D&md5=75a2134cceb893d4190ca720d38f2505</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003319%26sid%3Dliteratum%253Aachs%26aulast%3DVerspohl%26aufirst%3DE.%2BJ.%26atitle%3DNovel%2520Pharmacological%2520Approaches%2520to%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D188%26epage%3D237%26doi%3D10.1124%2Fpr.110.003319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalabalik, J.</span></span> <span> </span><span class="NLM_article-title">Management of Type-2 Diabetes Mellitus in Adults: Focus on Individualizing Non-Insulin Therapies</span>. <i>P & T</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23319847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3s3psFCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=687-696&author=L.+Brunettiauthor=J.+Kalabalik&title=Management+of+Type-2+Diabetes+Mellitus+in+Adults%3A+Focus+on+Individualizing+Non-Insulin+Therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies</span></div><div class="casAuthors">Brunetti Luigi; Kalabalik Julie</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">687-96</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Successful management of hyperglycemia may involve glucose and non-glucose therapies, non-drug approaches, and non-insulin agents.  Treatment should be tailored to each patient, with an emphasis on safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfXBjPdvtDn8rRqEXsZufAfW6udTcc2easf18gg7P0-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3psFCqtw%253D%253D&md5=d3d50d32a418b43ef3a797fd2ce3077b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrunetti%26aufirst%3DL.%26aulast%3DKalabalik%26aufirst%3DJ.%26atitle%3DManagement%2520of%2520Type-2%2520Diabetes%2520Mellitus%2520in%2520Adults%253A%2520Focus%2520on%2520Individualizing%2520Non-Insulin%2520Therapies%26jtitle%3DP%2520%2526%2520T%26date%3D2012%26volume%3D37%26spage%3D687%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, C. F.</span></span> <span> </span><span class="NLM_article-title">Peptide Degradation and the Role of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.peptides.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29412814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2018&pages=150-157&author=C.+F.+Deacon&title=Peptide+Degradation+and+the+Role+of+DPP-4+Inhibitors+in+the+Treatment+of+Type+2+Diabetes&doi=10.1016%2Fj.peptides.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes</span></div><div class="casAuthors">Deacon, Carolyn F.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-157</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Dipeptidyl peptidase-4 (DPP-4) inhibitors are now a widely used, safe and efficacious class of antidiabetic drugs, which were developed prospectively using a rational drug design approach based on a thorough understanding of the endocrinol. and degrdn. of glucagon-like peptide-1 (GLP-1).  GLP-1 is an intestinal hormone with potent insulinotropic and glucagonostatic effects and can normalize blood glucose levels in patients with type 2 diabetes, but the native peptide is not therapeutically useful because of its inherent metabolic instability.  Using the GLP-1/DPP-4 system and type 2 diabetes as an example, this review summarises how knowledge of a peptide's biol. effects coupled with an understanding of the pathways involved in its metabolic clearance can be exploited in a rational, step-by-step manner to develop a therapeutic agent, which is effective and well tolerated, and any side effects are minor and largely predictable.  Other peptides with metabolic effects which can also be degraded by DPP-4 will be reviewed, and their potential role as addnl. mediators of the effects of DPP-4 inhibitors will be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAu3aVseiELVg90H21EOLACvtfcHk0lhpkEqxy-y47g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFyisrk%253D&md5=0c8421485e0f6790aad8ce89267ef9a1</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26atitle%3DPeptide%2520Degradation%2520and%2520the%2520Role%2520of%2520DPP-4%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DPeptides%26date%3D2018%26volume%3D100%26spage%3D150%26epage%3D157%26doi%3D10.1016%2Fj.peptides.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, C. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospisilik, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, R.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl Peptidase IV Inhibitors: How Do They Work as New Antidiabetic Agents?</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2004.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.regpep.2004.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15780435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVajsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=159-165&author=C.+H.+S.+McIntoshauthor=H.-U.+Demuthauthor=J.+A.+Pospisilikauthor=R.+Pederson&title=Dipeptidyl+Peptidase+IV+Inhibitors%3A+How+Do+They+Work+as+New+Antidiabetic+Agents%3F&doi=10.1016%2Fj.regpep.2004.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?</span></div><div class="casAuthors">McIntosh, Christopher H. S.; Demuth, Hans-Ulrich; Pospisilik, J. Andrew; Pederson, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of new approaches to diabetes therapy are currently undergoing clin. trials, including those involving stimulation of the pancreatic β-cell with the gut-derived insulinotropic hormones (incretins), GIP and GLP-1.  The current review focuses on an approach based on the inhibition of dipeptidyl peptidase IV (DP IV), the major enzyme responsible for degrading the incretins in vivo.  The rationale for this approach was that blockade of incretin degrdn. would increase their physiol. actions, including the stimulation of insulin secretion and inhibition of gastric emptying.  It is now clear that both GIP and GLP-1 also have powerful effects on β-cell differentiation, mitogenesis and survival.  By potentiating these pleiotropic actions of the incretins, DP IV inhibition can therefore preserve β-cell mass and improve secretory function in diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrub2GeHyCJMrVg90H21EOLACvtfcHk0lhiyMR2VuO5RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVajsLo%253D&md5=72f1cca0efcad5c0bd2bf67b1bed8f65</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2004.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2004.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntosh%26aufirst%3DC.%2BH.%2BS.%26aulast%3DDemuth%26aufirst%3DH.-U.%26aulast%3DPospisilik%26aufirst%3DJ.%2BA.%26aulast%3DPederson%26aufirst%3DR.%26atitle%3DDipeptidyl%2520Peptidase%2520IV%2520Inhibitors%253A%2520How%2520Do%2520They%2520Work%2520as%2520New%2520Antidiabetic%2520Agents%253F%26jtitle%3DRegul.%2520Pept.%26date%3D2005%26volume%3D128%26spage%3D159%26epage%3D165%26doi%3D10.1016%2Fj.regpep.2004.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behme, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupré, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. J.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1 Improved Glycemic Control in Type 1 Diabetes</span>. <i>BMC Endocr. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/1472-6823-3-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1472-6823-3-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12697069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnt12qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=3&author=M.+T.+Behmeauthor=J.+Dupr%C3%A9author=T.+J.+McDonald&title=Glucagon-Like+Peptide+1+Improved+Glycemic+Control+in+Type+1+Diabetes&doi=10.1186%2F1472-6823-3-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1 improved glycemic control in type 1 diabetes</span></div><div class="casAuthors">Behme Margaret T; Dupre John; McDonald Thomas J</div><div class="citationInfo"><span class="NLM_cas:title">BMC endocrine disorders</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying.  We examined the potential of GLP-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion.  METHODS: Dose-finding studies were carried out to establish mid range doses for delay of gastric emptying indicated by postponement of pancreatic polypeptide responses after meals.  The selected dose of 0.63 micrograms/kg GLP-1 was administered before breakfast and lunch in 8-hour studies in hospital to establish the efficacy and safety of GLP-1.  In outside-hospital studies, GLP-1 or vehicle was self-administered double-blind before meals with usual insulin for five consecutive days by five males and three females with well-controlled C-peptide-negative type 1 diabetes.  Capillary blood glucose values were self-monitored before meals, at 30 and 60 min after breakfast and supper, and at bedtime.  Breakfast tests with GLP-1 were conducted on the day before and on the day after 5-day studies.  Paired t-tests and ANOVA were used for statistical analysis.  RESULTS: In 8-hour studies time-averaged incremental (delta) areas under the curves(AUC) for plasma glucose through 8 hours were decreased by GLP-1 compared to vehicle (3.2 PlusMinus; 0.9, mean PlusMinus; se, vs 5.4 PlusMinus; 0.8 mmol/l, p <.05), and for pancreatic polypeptide, an indicator of gastric emptying, through 30 min after meals (4.0 PlusMinus; 3.1 vs 37 PlusMinus; 9.6 pmol/l, p <.05) with no adverse effects.  Incremental glucagon levels through 60 min after meals were depressed by GLP-1 compared to vehicle (-3.7 PlusMinus; 2.5 vs 3.1 PlusMinus; 1.9 ng/l, p <.04).  In 5-day studies, AUC for capillary blood glucose levels were lower with GLP-1 than with vehicle (-0.64 PlusMinus; 0.33 vs 0.34 PlusMinus; 0.26 mmol/l, p <.05).  No assisted episode of hypoglycaemia or change in insulin dosage occurred.  Breakfast tests on the days immediately before and after 5-day trials showed no change in the effects of GLP-1.  CONCLUSION: We have demonstrated that subcutaneous GLP-1 can improve glucose control in type 1 diabetes without adverse effects when self-administered before meals with usual insulin during established intensive insulin treatment programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpyQ38jGmgUvx2phytoz6_fW6udTcc2eZ291nt7SWkYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnt12qtw%253D%253D&md5=21aa6485e764d1208c1d04fc1c6f1295</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1186%2F1472-6823-3-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6823-3-3%26sid%3Dliteratum%253Aachs%26aulast%3DBehme%26aufirst%3DM.%2BT.%26aulast%3DDupr%25C3%25A9%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DT.%2BJ.%26atitle%3DGlucagon-Like%2520Peptide%25201%2520Improved%2520Glycemic%2520Control%2520in%2520Type%25201%2520Diabetes%26jtitle%3DBMC%2520Endocr.%2520Disord.%26date%3D2003%26volume%3D3%26spage%3D3%26doi%3D10.1186%2F1472-6823-3-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behme, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hramiak, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. J.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.2337/diabetes.44.6.626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdiab.44.6.626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7789625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1antLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1995&pages=626-630&author=J.+Dupreauthor=M.+T.+Behmeauthor=I.+M.+Hramiakauthor=P.+McFarlaneauthor=M.+P.+Williamsonauthor=P.+Zabelauthor=T.+J.+McDonald&title=Glucagon-Like+Peptide+I+Reduces+Postprandial+Glycemic+Excursions+in+IDDM&doi=10.2337%2Fdiabetes.44.6.626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM</span></div><div class="casAuthors">Dupre, John; Behme, Margaret T.; Hramiak, Irene M.; McFarlane, Philip; Williamson, M. Paul; Zabel, Pamela; McDonald, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-30</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Effects of human glucagon-like peptide I (GLP-I)(7-36)amide were examd. in volunteers having insulin-dependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion (7 men and 1 woman; age, 31 yr; body mass index, 24.7 kg/m2; duration of diabetes, 3.2 yr; insulin dose, 0.41 U/kg/day; meal-stimulated CP, 1.0 nmol/L).  After a mixed meal (Sustacal, 30 kJ/kg), i.v. injection of GLP-I, 1.2 pmol/kg/min through 120 min, virtually abolished increments of plasma glucose, CP, pancreatic polypeptide (PP), and glucagon concns., with no significant effect on plasma gastrin levels during the infusions.  At reduced dosage (0.75 pmol/kg/min), GLP-I had lesser effects on plasma glucose and CP levels.  On cessation of i.v. GLP-I infusions after the meals, plasma glucose, CP, PP, and glucagon concns. rebounded toward control levels by 180 min, and the response of plasma gastrin was prolonged.  These rebound responses are consistent with intestinal delivery of food retained in the stomach on escape from inhibition of gastric emptying by GLP-I.  Infusion of 1.2 pmol/kg/min GLP-I with 20 g glucose (10% dextrose in water) injected i.v. over 60 min enhanced plasma responses of immunoreactive CP; the mean incremental areas under concn. curves (0-60 min) increased 6-fold, but the glycemic excursion was not affected.  Thus, in CP-pos. IDDM, pharmacol. doses of GLP-I reduce glycemic excursions after meals by a mechanism(s) not dependent on stimulation of insulin secretion, presumably involving delayed gastric emptying.  This effect of the peptide on blood glucose levels after meals may have therapeutic implications in both IDDM and non-insulin-dependent diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl20unSla1kbVg90H21EOLACvtfcHk0lgYDvqmlGcmFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1antLg%253D&md5=7eeddb1e7266a365e0ef806828db46f9</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.2337%2Fdiab.44.6.626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.44.6.626%26sid%3Dliteratum%253Aachs%26aulast%3DDupre%26aufirst%3DJ.%26aulast%3DBehme%26aufirst%3DM.%2BT.%26aulast%3DHramiak%26aufirst%3DI.%2BM.%26aulast%3DMcFarlane%26aufirst%3DP.%26aulast%3DWilliamson%26aufirst%3DM.%2BP.%26aulast%3DZabel%26aufirst%3DP.%26aulast%3DMcDonald%26aufirst%3DT.%2BJ.%26atitle%3DGlucagon-Like%2520Peptide%2520I%2520Reduces%2520Postprandial%2520Glycemic%2520Excursions%2520in%2520IDDM%26jtitle%3DDiabetes%26date%3D1995%26volume%3D44%26spage%3D626%26epage%3D630%26doi%3D10.2337%2Fdiabetes.44.6.626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biftu, T.</span>; <span class="NLM_string-name">Khan, T.</span>; <span class="NLM_string-name">Treating, A.</span></span> <span> </span><span class="NLM_article-title">Diabetes with Dipeptidyl Peptidase-IV Inhibitors</span>. <span class="NLM_patent">WO/2014/018355, US/2015/0175609</span>, Jan 30, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Biftu&author=T.+Khan&author=A.+Treating&title=Diabetes+with+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26atitle%3DDiabetes%2520with%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karasik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. P.</span></span> <span> </span><span class="NLM_article-title">Sitagliptin, a DPP-4 Inhibitor for the Treatment of Patients with Type 2 Diabetes: A Review of Recent Clinical Trials</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1185/030079908X261069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1185%2F030079908X261069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18182122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlahsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=489-496&author=A.+Karasikauthor=P.+Aschnerauthor=H.+Katzeffauthor=M.+J.+Daviesauthor=P.+P.+Stein&title=Sitagliptin%2C+a+DPP-4+Inhibitor+for+the+Treatment+of+Patients+with+Type+2+Diabetes%3A+A+Review+of+Recent+Clinical+Trials&doi=10.1185%2F030079908X261069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials</span></div><div class="casAuthors">Karasik, Avraham; Aschner, Pablo; Katzeff, Harvey; Davies, Michael J.; Stein, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antihyperglycemic agents that enhance the body's ability to regulate blood glucose by increasing the active levels of incretins, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).  There are numerous DPP-4 inhibitors in development with sitagliptin as the first approved agent for the treatment of patients with type 2 diabetes.  Objective: The purpose of this review is to provide an overview of the clin. trial results with sitagliptin.  Methods: Clin. trials published between Jan. 2005 (first sitagliptin publication) and Nov. 2007 were included in this review.  Medline was searched using the search terms: MK-0431 or sitagliptin.  Findings: Sitagliptin, an oral, once-daily, and highly selective DPP-4 inhibitor, has been evaluated in clin. trials as monotherapy, as add-on therapy, or as initial combination therapy with metformin.  Sitagliptin provided effective fasting and postprandial glycemic control in a wide range of patients with type 2 diabetes.  Markers of β-cell function (HOMA-β and proinsulin/insulin ratio) were improved with sitagliptin treatment.  In these clin. trials, sitagliptin was generally well tolerated with an overall incidence of adverse experiences comparable to placebo, a low risk of hypoglycemia or gastrointestinal adverse experiences, and a neutral effect on body wt.  The findings presented in this review are limited to the specific patient population enrolled in each clin. trial and for durations for up to 1 yr.  Future clin. studies should evaluate whether this class of agents has the potential to delay progression and/or prevent type 2 diabetes.  Conclusions: Sitagliptin has been shown to be effective and well-tolerated in various treatment regimens and may be considered for both initial therapy and as add-on therapy for patients with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC59qTagO1NrVg90H21EOLACvtfcHk0lg4AqCRmLRf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlahsrg%253D&md5=c8a6a7b3d6b8cdff8cba2d8245a6ec50</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1185%2F030079908X261069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F030079908X261069%26sid%3Dliteratum%253Aachs%26aulast%3DKarasik%26aufirst%3DA.%26aulast%3DAschner%26aufirst%3DP.%26aulast%3DKatzeff%26aufirst%3DH.%26aulast%3DDavies%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DP.%2BP.%26atitle%3DSitagliptin%252C%2520a%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Type%25202%2520Diabetes%253A%2520A%2520Review%2520of%2520Recent%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2008%26volume%3D24%26spage%3D489%26epage%3D496%26doi%3D10.1185%2F030079908X261069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfrengle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span> <span> </span><span class="NLM_article-title">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-Ynyl-3-Methyl-1-(4-Methyl-Quinazolin-2-Ylmethyl)-3,7-Dihydropurine-2,6-Dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1021/jm701280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6450-6453&author=M.+Eckhardtauthor=E.+Langkopfauthor=M.+Markauthor=M.+Tadayyonauthor=L.+Thomasauthor=H.+Narauthor=W.+Pfrengleauthor=B.+Guthauthor=R.+Lotzauthor=P.+Siegerauthor=H.+Fuchsauthor=F.+Himmelsbach&title=8-%283-%28R%29-Aminopiperidin-1-yl%29-7-but-2-Ynyl-3-Methyl-1-%284-Methyl-Quinazolin-2-Ylmethyl%29-3%2C7-Dihydropurine-2%2C6-Dione+%28BI+1356%29%2C+a+Highly+Potent%2C+Selective%2C+Long-Acting%2C+and+Orally+Bioavailable+DPP-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm701280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Eckhardt, Matthias; Langkopf, Elke; Mark, Michael; Tadayyon, Moh; Thomas, Leo; Nar, Herbert; Pfrengle, Waldemar; Guth, Brian; Lotz, Ralf; Sieger, Peter; Fuchs, Holger; Himmelsbach, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chem. class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated.  Systematic structural variations have led to 1 (BI 1356, I), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species.  1 Is currently undergoing clin. phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVyDZtAZGjgLVg90H21EOLACvtfcHk0lg4AqCRmLRf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ&md5=442ec88b800d899cc7a1f1528e1af4fa</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Fjm701280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701280z%26sid%3Dliteratum%253Aachs%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DLangkopf%26aufirst%3DE.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPfrengle%26aufirst%3DW.%26aulast%3DGuth%26aufirst%3DB.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DHimmelsbach%26aufirst%3DF.%26atitle%3D8-%25283-%2528R%2529-Aminopiperidin-1-yl%2529-7-but-2-Ynyl-3-Methyl-1-%25284-Methyl-Quinazolin-2-Ylmethyl%2529-3%252C7-Dihydropurine-2%252C6-Dione%2520%2528BI%25201356%2529%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520Long-Acting%252C%2520and%2520Orally%2520Bioavailable%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6450%26epage%3D6453%26doi%3D10.1021%2Fjm701280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, S. A.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase: A Target for Drugs Both Ancient and Modern</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chembiol.2012.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23102217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1222-1236&author=D.+G.+Hardieauthor=F.+A.+Rossauthor=S.+A.+Hawley&title=AMP-Activated+Protein+Kinase%3A+A+Target+for+Drugs+Both+Ancient+and+Modern&doi=10.1016%2Fj.chembiol.2012.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern</span></div><div class="casAuthors">Hardie, D. Grahame; Ross, Fiona A.; Hawley, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1222-1236</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status.  It is activated, by a mechanism requiring the tumor suppressor LKB1, by metabolic stresses that increase cellular ADP:ATP and/or AMP:ATP ratios.  Once activated, it switches on catabolic pathways that generate ATP, while switching off biosynthetic pathways and cell-cycle progress.  These effects suggest that AMPK activators might be useful for treatment and/or prevention of type 2 diabetes and cancer.  Indeed, AMPK is activated by the drugs metformin and salicylate, the latter being the major breakdown product of aspirin.  Metformin is widely used to treat diabetes, while there is epidemiol. evidence that both metformin and aspirin provide protection against cancer.  We review the mechanisms of AMPK activation by these and other drugs, and by natural products derived from traditional herbal medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIhWqL6rSH0bVg90H21EOLACvtfcHk0lg4AqCRmLRf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbfF&md5=b1a6cd59d2ef144bc91abb772a4674cc</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DHardie%26aufirst%3DD.%2BG.%26aulast%3DRoss%26aufirst%3DF.%2BA.%26aulast%3DHawley%26aufirst%3DS.%2BA.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%253A%2520A%2520Target%2520for%2520Drugs%2520Both%2520Ancient%2520and%2520Modern%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1222%26epage%3D1236%26doi%3D10.1016%2Fj.chembiol.2012.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungaro, P.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase: A Target for Old Drugs against Diabetes and Cancer</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bcp.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23747347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVehtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=339-350&author=G.+L.+Russoauthor=M.+Russoauthor=P.+Ungaro&title=AMP-Activated+Protein+Kinase%3A+A+Target+for+Old+Drugs+against+Diabetes+and+Cancer&doi=10.1016%2Fj.bcp.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase: A target for old drugs against diabetes and cancer</span></div><div class="casAuthors">Russo, Gian Luigi; Russo, Maria; Ungaro, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-350</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The AMP-activated protein kinase (AMPK) is considered a key checkpoint to ensure energy balance in both cells and organisms.  AMPK is an αβγ heterotrimer controlled by allosteric regulation by AMP, ADP and ATP, auto-inhibitory features and phosphorylation, with the threonine-172 phosphorylation on the catalytic α-subunit by LKB1, CaMKKβ or Tak1 being essential for its fully activation.  AMPK acts as a protective response to energy stress in numerous systems, but it is also a key player in diabetes and related metabolic diseases and cancer.  Pharmacol. activation of AMPK by metformin or other compds. holds a considerable potential to reverse the metabolic abnormalities assocd. with type 2 diabetes.  In cancer, correction of the dysregulated metabolic pathway LKB1/AMPK/mTORC1 can lower the Warburg effect, suggesting AMPK as a potential target for cancer prevention and/or treatment.  In this commentary, the authors review recent findings that support the role and function of AMPK in normal and pathol. conditions.  The authors also discuss how the activation of AMPK by naturally occurring compds. could help to prevent the development of numerous chronic diseases contributing in such a way to the well-being of aging population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgRcW2jWm9prVg90H21EOLACvtfcHk0ljOBYCpuPiywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVehtbnN&md5=4abcc8123a8c48c4f15a3963e97cd390</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DG.%2BL.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DUngaro%26aufirst%3DP.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%253A%2520A%2520Target%2520for%2520Old%2520Drugs%2520against%2520Diabetes%2520and%2520Cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D339%26epage%3D350%26doi%3D10.1016%2Fj.bcp.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span>; <span class="NLM_string-name">Blum, A.</span></span> <span> </span><span class="NLM_article-title">Azabenzimidazole Derivatives</span>. <span class="NLM_patent">US20160039846A1</span>, Feb 11, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Langkopf&author=A.+Blum&title=Azabenzimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLangkopf%26aufirst%3DE.%26atitle%3DAzabenzimidazole%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 3. Structure-Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N’-Arylpiperazine Series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3094</span>– <span class="NLM_lpage">3116</span>, <span class="refDoi"> DOI: 10.1021/jm5000497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5000497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3094-3116&author=N.+Nishimuraauthor=M.+H.+Normanauthor=L.+Liuauthor=K.+C.+Yangauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=S.+Chmaitauthor=J.+Chenauthor=R.+Cupplesauthor=C.+Fotschauthor=J.+Helmeringauthor=S.+R.+Jordanauthor=R.+K.+Kunzauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=A.+Siegmundauthor=G.+Sivitsauthor=D.+J.+Lloydauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+3.+Structure-Activity+Relationships+within+the+Aryl+Carbinol+Region+of+the+N-Arylsulfonamido-N%E2%80%99-Arylpiperazine+Series&doi=10.1021%2Fjm5000497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 3. Structure-Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N'-arylpiperazine Series</span></div><div class="casAuthors">Nishimura, Nobuko; Norman, Mark H.; Liu, Longbin; Yang, Kevin C.; Ashton, Kate S.; Bartberger, Michael D.; Chmait, Samer; Chen, Jie; Cupples, Rod; Fotsch, Christopher; Helmering, Joan; Jordan, Steven R.; Kunz, Roxanne K.; Pennington, Lewis D.; Poon, Steve F.; Siegmund, Aaron; Sivits, Glenn; Lloyd, David J.; Hale, Clarence; St. Jean, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3094-3116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small mol. to its endogenous inhibitor, glucokinase regulatory protein (GKRP).  These initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol (I, AMG-3969), a compd. that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals.  Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series.  Guided by the X-ray cocrystal structure of compd. I bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region.  Among them, sulfoximine and pyridinyl derivs. II and III possessed excellent potency as well as favorable PK properties.  When dosed orally in db/db mice, both compds. significantly lowered fed blood glucose levels (up to 58%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq--wNW0LMFO7Vg90H21EOLACvtfcHk0ljOBYCpuPiywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOns7o%253D&md5=8ca40e15429af254f75f8304aa5a0fa2</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fjm5000497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5000497%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25203.%2520Structure-Activity%2520Relationships%2520within%2520the%2520Aryl%2520Carbinol%2520Region%2520of%2520the%2520N-Arylsulfonamido-N%25E2%2580%2599-Arylpiperazine%2520Series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3094%26epage%3D3116%26doi%3D10.1021%2Fjm5000497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agius, L.</span></span> <span> </span><span class="NLM_article-title">Glucokinase and Molecular Aspects of Liver Glycogen Metabolism</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1042/BJ20080595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2FBJ20080595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18651836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2008&pages=1-18&author=L.+Agius&title=Glucokinase+and+Molecular+Aspects+of+Liver+Glycogen+Metabolism&doi=10.1042%2FBJ20080595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase and molecular aspects of liver glycogen metabolism</span></div><div class="casAuthors">Agius, Loranne</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-18</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Conversion of glucose into glycogen is a major pathway that contributes to the removal of glucose from the portal vein by the liver in the postprandial state.  It is regulated in part by the increase in blood-glucose concn. in the portal vein, which activates glucokinase, the first enzyme in the pathway, causing an increase in the concn. of glucose 6-P (glucose 6-phosphate), which modulates the phosphorylation state of downstream enzymes by acting synergistically with other allosteric effectors.  Glucokinase is regulated by a hierarchy of transcriptional and post-transcriptional mechanisms that are only partially understood.  In the fasted state, glucokinase is in part sequestered in the nucleus in an inactive state, complexed to a specific regulatory protein, GKRP (glucokinase regulatory protein).  This reserve pool is rapidly mobilized to the cytoplasm in the postprandial state in response to an elevated concn. of glucose.  The translocation of glucokinase between the nucleus and cytoplasm is modulated by various metabolic and hormonal conditions.  The elevated glucose 6-P concn., consequent to glucokinase activation, has a synergistic effect with glucose in promoting dephosphorylation (inactivation) of glycogen phosphorylase and inducing dephosphorylation (activation) of glycogen synthase.  The latter involves both a direct ligand-induced conformational change and depletion of the phosphorylated form of glycogen phosphorylase, which is a potent allosteric inhibitor of glycogen synthase phosphatase activity assocd. with the glycogen-targeting protein, GL [hepatic glycogen-targeting subunit of PP-1 (protein phosphatase-1) encoded by PPP1R3B].  Defects in both the activation of glucokinase and in the dephosphorylation of glycogen phosphorylase are potential contributing factors to the dysregulation of hepatic glucose metab. in Type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY34FiWICqI7Vg90H21EOLACvtfcHk0ljOBYCpuPiywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCisbs%253D&md5=3dcd4b879731094f020a0eaf797ba49d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1042%2FBJ20080595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080595%26sid%3Dliteratum%253Aachs%26aulast%3DAgius%26aufirst%3DL.%26atitle%3DGlucokinase%2520and%2520Molecular%2520Aspects%2520of%2520Liver%2520Glycogen%2520Metabolism%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D414%26spage%3D1%26epage%3D18%26doi%3D10.1042%2FBJ20080595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">Glucokinase as Glucose Sensor and Metabolic Signal Generator in Pancreatic β-Cells and Hepatocytes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.2337/diab.39.6.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdiab.39.6.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2189759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3cXktlOqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=647-652&author=F.+M.+Matschinsky&title=Glucokinase+as+Glucose+Sensor+and+Metabolic+Signal+Generator+in+Pancreatic+%CE%B2-Cells+and+Hepatocytes&doi=10.2337%2Fdiab.39.6.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-52</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    </div><div class="casAbstract">A review, with 31 refs., on evidence for a pivotal role of glucokinase as glucose sensor of the pancreatic β-cells.  Glucokinase explains the capacity, hexose specificity, affinities, sigmoidicity, and anomeric preference of pancreatic islet glycolysis, and because stimulation of glucose metab. is a prerequisite of glucose stimulation of insulin release, glucokinase also explains many characteristics of this β-cell function.  Tissue-specific regulation corresponds with observations that liver and pancreatic β-cell glucokinase are structurally distinct.  Glucokinase could play a glucose-sensor role in hepatocytes as well, and certain forms of diabetes mellitus might be due to glucokinase deficiencies in pancreatic β-cells, hepatocytes, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdI-s6D2kzbVg90H21EOLACvtfcHk0lhd9LEkbkOERQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlOqtbY%253D&md5=a267592dce249b83fda5f9573ec2f0d6</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.2337%2Fdiab.39.6.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.39.6.647%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGlucokinase%2520as%2520Glucose%2520Sensor%2520and%2520Metabolic%2520Signal%2520Generator%2520in%2520Pancreatic%2520%25CE%25B2-Cells%2520and%2520Hepatocytes%26jtitle%3DDiabetes%26date%3D1990%26volume%3D39%26spage%3D647%26epage%3D652%26doi%3D10.2337%2Fdiab.39.6.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">Glucokinase, Glucose Homeostasis, and Diabetes Mellitus</span>. <i>Curr. Diabetes Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1007/s11892-005-0005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs11892-005-0005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15929862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSkt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=171-176&author=F.+M.+Matschinsky&title=Glucokinase%2C+Glucose+Homeostasis%2C+and+Diabetes+Mellitus&doi=10.1007%2Fs11892-005-0005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase, glucose homeostasis, and diabetes mellitus</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Current Science Inc.</span>)
        </div><div class="casAbstract">A review.  The enzyme glucokinase (GK) regulates the rate of glucose metab. in many tissues, including liver, the pancreatic β cells, certain neurons, enteroendocrine cells, and the pituitary, serving as a glucose sensor in many of these.  Thus, GK plays a crit. role in glucose homeostasis.  Spontaneous mutants of GK in humans result in autosomal-dominant hypo- and hyperglycemia syndromes described as "GK disease.".  GK activator drugs have been discovered that lower blood glucose in normal and diabetic animals and promise to be useful in the treatment of type 2 diabetes mellitus.  There is no question that the GK mol. and related issues will continue to be a fruitful topic for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Z-ncpR-k3rVg90H21EOLACvtfcHk0lhd9LEkbkOERQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSkt7jJ&md5=84049ae306771ea998694d62309e02a4</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1007%2Fs11892-005-0005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-005-0005-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGlucokinase%252C%2520Glucose%2520Homeostasis%252C%2520and%2520Diabetes%2520Mellitus%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2005%26volume%3D5%26spage%3D171%26epage%3D176%26doi%3D10.1007%2Fs11892-005-0005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelent, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doliba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderkooi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsby, J.</span></span> <span> </span><span class="NLM_article-title">Glucokinase Activators for Diabetes Therapy: May 2010 Status Report</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S236</span>– <span class="NLM_lpage">S243</span>, <span class="refDoi"> DOI: 10.2337/dc11-s236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdc11-s236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21525462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlKksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=S236-S243&author=F.+M.+Matschinskyauthor=B.+Zelentauthor=N.+Dolibaauthor=C.+Liauthor=J.+M.+Vanderkooiauthor=A.+Najiauthor=R.+Sarabuauthor=J.+Grimsby&title=Glucokinase+Activators+for+Diabetes+Therapy%3A+May+2010+Status+Report&doi=10.2337%2Fdc11-s236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase activators for diabetes therapy: May 2010 status report</span></div><div class="casAuthors">Matschinsky, Franz M.; Zelent, Bogumil; Doliba, Nicolai; Li, Changhong; Vanderkooi, Jane M.; Naji, Ali; Sarabu, Ramakanth; Grimsby, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S236-S243</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review on the essential aspect of the role of glucokinase (GK) in glucose homeostasis, of the biochem. pharmacol. of GK activator (GKA), and of the current status of GKA research and development and therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGPdUYzBgUbVg90H21EOLACvtfcHk0lhd9LEkbkOERQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlKksL8%253D&md5=ef51e1f08da702fea401c70f27db21ff</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.2337%2Fdc11-s236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-s236%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26aulast%3DZelent%26aufirst%3DB.%26aulast%3DDoliba%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DVanderkooi%26aufirst%3DJ.%2BM.%26aulast%3DNaji%26aufirst%3DA.%26aulast%3DSarabu%26aufirst%3DR.%26aulast%3DGrimsby%26aufirst%3DJ.%26atitle%3DGlucokinase%2520Activators%2520for%2520Diabetes%2520Therapy%253A%2520May%25202010%2520Status%2520Report%26jtitle%3DDiabetes%2520Care%26date%3D2011%26volume%3D34%26spage%3DS236%26epage%3DS243%26doi%3D10.2337%2Fdc11-s236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lather, V.</span></span> <span> </span><span class="NLM_article-title">Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.2174/1389557514666140722082713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F1389557514666140722082713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25052034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=585-602&author=A.+S.+Grewalauthor=B.+S.+Sekhonauthor=V.+Lather&title=Recent+Updates+on+Glucokinase+Activators+for+the+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.2174%2F1389557514666140722082713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Grewal, Ajmer Singh; Sekhon, Bhupinder Singh; Lather, Viney</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">585-602</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory actions in pancreatic β-cells and liver hepatocytes.  Conversion of glucose to glucose-6-phosphate by GK promotes glycogen synthesis in liver hepatocytes, and insulin release in the pancreatic β-cells.  Small mols. called glucokinase activators (GKAs) which bind to an allosteric activator site of the GK enzyme have indeed been discovered and developed, and thus hold great promise as new, effective and safe antidiabetic agents.  GKAs enhance the catalytic activity of GK and promising clin. trials in humans demonstrated that they are highly useful in the treatment of type 2 diabetes mellitus.  Most of the reported GKAs include amide derivs. like benzamides, acrylamides, carboxamides, acetamides and acrylamides.  Examples include Piragliatin, AZD1656, AZD6370, R1440 GKA2, GKA 50, YH GKA, PSN 010, and LY2121260.  Recent findings on GKAs including lead compds. and overview of current hypothesis on mechanism of GK activation along with summary of the recently published patents as well as the GKAs of natural origin are reported in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosQe6QzxAtg7Vg90H21EOLACvtfcHk0lhd9LEkbkOERQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgsrfL&md5=7cc627f098582d93f7bd43431759adb8</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.2174%2F1389557514666140722082713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557514666140722082713%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DA.%2BS.%26aulast%3DSekhon%26aufirst%3DB.%2BS.%26aulast%3DLather%26aufirst%3DV.%26atitle%3DRecent%2520Updates%2520on%2520Glucokinase%2520Activators%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D585%26epage%3D602%26doi%3D10.2174%2F1389557514666140722082713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfefferkorn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Aquila, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbonais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdougall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapworth, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landro, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddish-Berhane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duignan, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammirati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (S)-6-(3-Cyclopentyl-2-(4-(Trifluoromethyl)-1H-Imidazol-1-yl)Propanamido)Nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1021/jm2014887</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2014887" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Ojur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1318-1333&author=J.+A.+Pfefferkornauthor=A.+Guzman-Perezauthor=J.+Litchfieldauthor=R.+Aielloauthor=J.+L.+Treadwayauthor=J.+Pettersenauthor=M.+L.+Minichauthor=K.+J.+Filipskiauthor=C.+S.+Jonesauthor=M.+Tuauthor=G.+Aspnesauthor=H.+Risleyauthor=J.+Bianauthor=B.+D.+Stevensauthor=P.+Bourassaauthor=T.+D%E2%80%99Aquilaauthor=L.+Bakerauthor=N.+Barucciauthor=A.+S.+Robertsonauthor=F.+Bourbonaisauthor=D.+R.+Derksenauthor=M.+Macdougallauthor=O.+Cabreraauthor=J.+Chenauthor=A.+L.+Lapworthauthor=J.+A.+Landroauthor=W.+J.+Zavadoskiauthor=K.+Atkinsonauthor=N.+Haddish-Berhaneauthor=B.+Tanauthor=L.+Yaoauthor=R.+E.+Kosaauthor=M.+V.+Varmaauthor=B.+Fengauthor=D.+B.+Duignanauthor=A.+El-Kattanauthor=S.+Murdandeauthor=S.+Liuauthor=M.+Ammiratiauthor=J.+Knafelsauthor=P.+Dasilva-Jardineauthor=L.+Sweetauthor=S.+Lirasauthor=T.+P.+Rolph&title=Discovery+of+%28S%29-6-%283-Cyclopentyl-2-%284-%28Trifluoromethyl%29-1H-Imidazol-1-yl%29Propanamido%29Nicotinic+Acid+as+a+Hepatoselective+Glucokinase+Activator+Clinical+Candidate+for+Treating+Type+2+Diabetes+Mellitus&doi=10.1021%2Fjm2014887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Pfefferkorn, Jeffrey A.; Guzman-Perez, Angel; Litchfield, John; Aiello, Robert; Treadway, Judith L.; Pettersen, John; Minich, Martha L.; Filipski, Kevin J.; Jones, Christopher S.; Tu, Meihua; Aspnes, Gary; Risley, Hud; Bian, Jianwei; Stevens, Benjamin D.; Bourassa, Patricia; D'Aquila, Theresa; Baker, Levenia; Barucci, Nicole; Robertson, Alan S.; Bourbonais, Francis; Derksen, David R.; MacDougall, Margit; Cabrera, Over; Chen, Jing; Lapworth, Amanda Lee; Landro, James A.; Zavadoski, William J.; Atkinson, Karen; Haddish-Berhane, Nahor; Tan, Beijing; Yao, Lili; Kosa, Rachel E.; Varma, Manthena V.; Feng, Bo; Duignan, David B.; El-Kattan, Ayman; Murdande, Sharad; Liu, Shenping; Ammirati, Mark; Knafels, John; Da Silva-Jardine, Paul; Sweet, Laurel; Liras, Spiros; Rolph, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1318-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucokinase is a key regulator of glucose homeostasis, and small mol. allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes.  Systemically acting glucokinase activators (liver and pancreas) have been reported to be efficacious but in many cases present hypoglycemia risk due to activation of the enzyme at low glucose levels in the pancreas, leading to inappropriately excessive insulin secretion.  It was therefore postulated that a liver selective activator may offer effective glycemic control with reduced hypoglycemia risk.  Herein, we report structure-activity studies on a carboxylic acid contg. series of glucokinase activators with preferential activity in hepatocytes vs. pancreatic β-cells.  These activators were designed to have low passive permeability thereby minimizing distribution into extrahepatic tissues; concurrently, they were also optimized as substrates for active liver uptake via members of the org. anion transporting polypeptide (OATP) family.  These studies lead to the identification of 19 as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species.  In preclin. diabetic animals, 19 was found to robustly lower fasting and postprandial glucose with no hypoglycemia, leading to its selection as a clin. development candidate for treating type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMeuV7iNzAXrVg90H21EOLACvtfcHk0lgMojsG4QJEUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Ojur3F&md5=f68a72bcd904abdbb4f096abca0eff6b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fjm2014887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2014887%26sid%3Dliteratum%253Aachs%26aulast%3DPfefferkorn%26aufirst%3DJ.%2BA.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DTreadway%26aufirst%3DJ.%2BL.%26aulast%3DPettersen%26aufirst%3DJ.%26aulast%3DMinich%26aufirst%3DM.%2BL.%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DAspnes%26aufirst%3DG.%26aulast%3DRisley%26aufirst%3DH.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Aquila%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DRobertson%26aufirst%3DA.%2BS.%26aulast%3DBourbonais%26aufirst%3DF.%26aulast%3DDerksen%26aufirst%3DD.%2BR.%26aulast%3DMacdougall%26aufirst%3DM.%26aulast%3DCabrera%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLapworth%26aufirst%3DA.%2BL.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DZavadoski%26aufirst%3DW.%2BJ.%26aulast%3DAtkinson%26aufirst%3DK.%26aulast%3DHaddish-Berhane%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DKosa%26aufirst%3DR.%2BE.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DDuignan%26aufirst%3DD.%2BB.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DMurdande%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DAmmirati%26aufirst%3DM.%26aulast%3DKnafels%26aufirst%3DJ.%26aulast%3DDasilva-Jardine%26aufirst%3DP.%26aulast%3DSweet%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DRolph%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520%2528S%2529-6-%25283-Cyclopentyl-2-%25284-%2528Trifluoromethyl%2529-1H-Imidazol-1-yl%2529Propanamido%2529Nicotinic%2520Acid%2520as%2520a%2520Hepatoselective%2520Glucokinase%2520Activator%2520Clinical%2520Candidate%2520for%2520Treating%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1318%26epage%3D1333%26doi%3D10.1021%2Fjm2014887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzeja, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komorowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Véniant, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Antidiabetic Effects of Glucokinase Regulatory Protein Small-Molecule Disruptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nature12724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature12724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24226772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOmu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=437-440&author=D.+J.+Lloydauthor=D.+J.+St+Jeanauthor=R.+J.+Kurzejaauthor=R.+C.+Wahlauthor=K.+Michelsenauthor=R.+Cupplesauthor=M.+Chenauthor=J.+Wuauthor=G.+Sivitsauthor=J.+Helmeringauthor=R.+Komorowskiauthor=K.+S.+Ashtonauthor=L.+D.+Penningtonauthor=C.+Fotschauthor=M.+Vazirauthor=K.+Chenauthor=S.+Chmaitauthor=J.+Zhangauthor=L.+Liuauthor=M.+H.+Normanauthor=K.+L.+Andrewsauthor=M.+D.+Bartbergerauthor=G.+Vanauthor=E.+J.+Galbreathauthor=S.+L.+Vonderfechtauthor=M.+Wangauthor=S.+R.+Jordanauthor=M.+M.+V%C3%A9niantauthor=C.+Hale&title=Antidiabetic+Effects+of+Glucokinase+Regulatory+Protein+Small-Molecule+Disruptors&doi=10.1038%2Fnature12724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors</span></div><div class="casAuthors">Lloyd, David J.; St. Jean, David J., Jr.; Kurzeja, Robert J. M.; Wahl, Robert C.; Michelsen, Klaus; Cupples, Rod; Chen, Michelle; Wu, John; Sivits, Glenn; Helmering, Joan; Komorowski, Renee; Ashton, Kate S.; Pennington, Lewis D.; Fotsch, Christopher; Vazir, Mukta; Chen, Kui; Chmait, Samer; Zhang, Jiandong; Liu, Longbin; Norman, Mark H.; Andrews, Kristin L.; Bartberger, Michael D.; Van, Gwyneth; Galbreath, Elizabeth J.; Vonderfecht, Steven L.; Wang, Minghan; Jordan, Steven R.; Veniant, Murielle M.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7480</span>),
    <span class="NLM_cas:pages">437-440</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucose homeostasis is a vital and complex process, and its disruption can cause hyperglycemia and type II diabetes mellitus.  Glucokinase (GK), a key enzyme that regulates glucose homeostasis, converts glucose to glucose-6-phosphate in pancreatic β-cells, liver hepatocytes, specific hypothalamic neurons, and gut enterocytes.  In hepatocytes, GK regulates glucose uptake and glycogen synthesis, suppresses glucose prodn., and is subject to the endogenous inhibitor GK regulatory protein (GKRP).  During fasting, GKRP binds, inactivates and sequesters GK in the nucleus, which removes GK from the gluconeogenic process and prevents a futile cycle of glucose phosphorylation.  Compds. that directly hyperactivate GK (GK activators) lower blood glucose levels and are being evaluated clin. as potential therapeutics for the treatment of type II diabetes mellitus.  However, initial reports indicate that an increased risk of hypoglycemia is assocd. with some GK activators.  To mitigate the risk of hypoglycemia, the authors sought to increase GK activity by blocking GKRP.  Here the authors describe the identification of two potent small-mol. GK-GKRP disruptors (AMG-1694 and AMG-3969) that normalized blood glucose levels in several rodent models of diabetes.  These compds. potently reversed the inhibitory effect of GKRP on GK activity and promoted GK translocation both in vitro (isolated hepatocytes) and in vivo (liver).  A co-crystal structure of full-length human GKRP in complex with AMG-1694 revealed a previously unknown binding pocket in GKRP distinct from that of the phosphofructose-binding site.  Furthermore, with AMG-1694 and AMG-3969 (but not GK activators), blood glucose lowering was restricted to diabetic and not normoglycemic animals.  These findings exploit a new cellular mechanism for lowering blood glucose levels with reduced potential for hypoglycemic risk in patients with type II diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo698v-SzzPXLVg90H21EOLACvtfcHk0lgMojsG4QJEUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOmu7%252FL&md5=d26f4006decfda51b73a44d883b11921</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fnature12724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12724%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DKurzeja%26aufirst%3DR.%2BJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DKomorowski%26aufirst%3DR.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DVazir%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DGalbreath%26aufirst%3DE.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DV%25C3%25A9niant%26aufirst%3DM.%2BM.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DAntidiabetic%2520Effects%2520of%2520Glucokinase%2520Regulatory%2520Protein%2520Small-Molecule%2520Disruptors%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D437%26epage%3D440%26doi%3D10.1038%2Fnature12724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschenbach, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscheinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmoll, D.</span></span> <span> </span><span class="NLM_article-title">Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein: Impact of Physiological and Pharmacological Effectors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">31333</span>– <span class="NLM_lpage">31340</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805434200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1074%2Fjbc.M805434200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18809676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCjsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=31333-31340&author=O.+Anderkaauthor=J.+Boykenauthor=U.+Aschenbachauthor=A.+Batzerauthor=O.+Boscheinenauthor=D.+Schmoll&title=Biophysical+Characterization+of+the+Interaction+between+Hepatic+Glucokinase+and+Its+Regulatory+Protein%3A+Impact+of+Physiological+and+Pharmacological+Effectors&doi=10.1074%2Fjbc.M805434200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein: impact of physiological and pharmacological effectors</span></div><div class="casAuthors">Anderka, Oliver; Boyken, Janina; Aschenbach, Ursula; Batzer, Andreas; Boscheinen, Oliver; Schmoll, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">31333-31340</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Glucokinase (GK) is a key enzyme of glucose metab. in liver and pancreatic β-cells, and small mol. activators of GK (GKAs) are under evaluation for the treatment of type 2 diabetes.  In liver, GK activity is controlled by the GK regulatory protein (GKRP), which forms an inhibitory complex with the enzyme.  Here, we performed isothermal titrn. calorimetry (ITC) and surface plasmon resonance (SPR) expts. to characterize GK-GKRP binding and to study the influence that physiol. and pharmacol. effectors of GK have on the protein-protein interaction.  In the presence of fructose-6-phosphate (F6P), GK-GKRP complex formation displayed a strong entropic driving force opposed by a large pos. enthalpy; a neg. change in heat capacity was obsd. (Kd = 45 nM, ΔH = 15.6 kcal/mol, TΔS = 25.7 kcal/mol, ΔCp = -354 cal/mol-1/K-1).  With koff = 1.3 × 10-2 s-1, the complex dissocd. quickly.  The thermodn. profile suggested a largely hydrophobic interaction.  In addn., effects of pH and buffer demonstrated the coupled uptake of one proton and indicated an ionic contribution to binding.  Glucose decreased the binding affinity between GK and GKRP.  This decrease was potentiated by an ATP analog.  Prototypical GKAs of the amino-heteroaryl-amide type bound to GK in a glucose-dependent manner and impaired the assocn. of GK with GKRP.  This mechanism might contribute to the antidiabetic effects of GKAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGaWRtT21jPrVg90H21EOLACvtfcHk0lgMUTBn2jufrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCjsb7N&md5=c12a5ff10469833826f2bc2cd2a4791c</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805434200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805434200%26sid%3Dliteratum%253Aachs%26aulast%3DAnderka%26aufirst%3DO.%26aulast%3DBoyken%26aufirst%3DJ.%26aulast%3DAschenbach%26aufirst%3DU.%26aulast%3DBatzer%26aufirst%3DA.%26aulast%3DBoscheinen%26aufirst%3DO.%26aulast%3DSchmoll%26aufirst%3DD.%26atitle%3DBiophysical%2520Characterization%2520of%2520the%2520Interaction%2520between%2520Hepatic%2520Glucokinase%2520and%2520Its%2520Regulatory%2520Protein%253A%2520Impact%2520of%2520Physiological%2520and%2520Pharmacological%2520Effectors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D31333%26epage%3D31340%26doi%3D10.1074%2Fjbc.M805434200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croghan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzeja, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for <i>in Vivo</i> Proof-of-Concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/jm4016735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=309-324&author=K.+S.+Ashtonauthor=K.+L.+Andrewsauthor=M.+C.+Bryanauthor=J.+Chenauthor=K.+Chenauthor=M.+Chenauthor=S.+Chmaitauthor=M.+Croghanauthor=R.+Cupplesauthor=C.+Fotschauthor=J.+Helmeringauthor=S.+R.+Jordanauthor=R.+J.+Kurzejaauthor=K.+Michelsenauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=G.+Sivitsauthor=G.+Vanauthor=S.+L.+Vonderfechtauthor=R.+C.+Wahlauthor=J.+Zhangauthor=D.+J.+Lloydauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+1.+Discovery+of+a+Novel+Tool+Compound+for+in+Vivo+Proof-of-Concept&doi=10.1021%2Fjm4016735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept</span></div><div class="casAuthors">Ashton, Kate S.; Andrews, Kristin L.; Bryan, Marian C.; Chen, Jie; Chen, Kui; Chen, Michelle; Chmait, Samer; Croghan, Michael; Cupples, Rod; Fotsch, Christopher; Helmering, Joan; Jordan, Steve R.; Kurzeja, Robert J. M.; Michelsen, Klaus; Pennington, Lewis D.; Poon, Steve F.; Sivits, Glenn; Van, Gwyneth; Vonderfecht, Steve L.; Wahl, Robert C.; Zhang, Jiandong; Lloyd, David J.; Hale, Clarence; St. Jean, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">309-324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. activators of glucokinase have shown robust efficacy in both preclin. models and humans.  However, overactivation of glucokinase (GK) can cause excessive glucose turnover, leading to hypoglycemia.  To circumvent this adverse side effect, we chose to modulate GK activity by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP).  Disrupting the GK-GKRP complex results in an increase in the amt. of unbound cytosolic GK without altering the inherent kinetics of the enzyme.  Herein, we report the identification of compds. that efficiently disrupt the GK-GKRP interaction via a previously unknown binding pocket.  Using a structure-based approach, the potency of the initial hit was improved to provide I (AMG-1694).  When dosed in ZDF rats, I showed both a robust pharmacodynamic effect as well as a statistically significant redn. in glucose.  Addnl., hypoglycemia was not obsd. in either the hyperglycemic or normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriLnUgNgMEXrVg90H21EOLACvtfcHk0lgMUTBn2jufrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKjsg%253D%253D&md5=c07363c8a2b60f2e79b94d6e863b2ea5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Fjm4016735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016735%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCroghan%26aufirst%3DM.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DKurzeja%26aufirst%3DR.%2BJ.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DVonderfecht%26aufirst%3DS.%2BL.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25201.%2520Discovery%2520of%2520a%2520Novel%2520Tool%2520Compound%2520for%2520in%2520Vivo%2520Proof-of-Concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D309%26epage%3D324%26doi%3D10.1021%2Fjm4016735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/jm4016747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=325-338&author=D.+J.+St+Jeanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=E.+Galbreathauthor=J.+Helmeringauthor=F.+T.+Hongauthor=S.+R.+Jordanauthor=L.+Liuauthor=R.+K.+Kunzauthor=K.+Michelsenauthor=N.+Nishimuraauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=D.+Reidauthor=G.+Sivitsauthor=M.+M.+Stecauthor=S.+Tadesseauthor=N.+Tamayoauthor=G.+Vanauthor=K.+C.+Yangauthor=J.+Zhangauthor=M.+H.+Normanauthor=C.+Fotschauthor=D.+J.+Lloydauthor=C.+Hale&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+2.+Leveraging+Structure-Based+Drug+Design+to+Identify+Analogues+with+Improved+Pharmacokinetic+Profiles&doi=10.1021%2Fjm4016747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span></div><div class="casAuthors">St. Jean, David J., Jr.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Galbreath, Elizabeth; Helmering, Joan; Hong, Fang-Tsao; Jordan, Steven R.; Liu, Longbin; Kunz, Roxanne K.; Michelsen, Klaus; Nishimura, Nobuko; Pennington, Lewis D.; Poon, Steve F.; Reid, Darren; Sivits, Glenn; Stec, Markian M.; Tadesse, Seifu; Tamayo, Nuria; Van, Gwyneth; Yang, Kevin C.; Zhang, Jiandong; Norman, Mark H.; Fotsch, Christopher; Lloyd, David J.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the previous report, we described the discovery and optimization of novel small mol. disruptors of the GK-GKRP interaction culminating in the identification of I (AMG-1694).  Although this analog possessed excellent in vitro potency and was a useful tool compd. in initial proof-of-concept expts., high metabolic turnover limited its advancement.  Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor, II (AMG-3969).  When administered to db/db mice, this compd. demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent redns. in fed blood glucose levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdKFACRrkebVg90H21EOLACvtfcHk0lhBqMFhD3ObsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D&md5=aebfcbc169a9fbd443badcff47b2b90f</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm4016747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016747%26sid%3Dliteratum%253Aachs%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DGalbreath%26aufirst%3DE.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DReid%26aufirst%3DD.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25202.%2520Leveraging%2520Structure-Based%2520Drug%2520Design%2520to%2520Identify%2520Analogues%2520with%2520Improved%2520Pharmacokinetic%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D325%26epage%3D338%26doi%3D10.1021%2Fjm4016747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5964</span>, <span class="refDoi"> DOI: 10.1021/jm5001979</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001979" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5949-5964&author=F.+T.+Hongauthor=M.+H.+Normanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=C.+Fotschauthor=S.+R.+Jordanauthor=D.+J.+Lloydauthor=G.+Sivitsauthor=S.+Tadesseauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+4.+Exploration+of+a+Novel+Binding+Pocket&doi=10.1021%2Fjm5001979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket</span></div><div class="casAuthors">Hong, Fang-Tsao; Norman, Mark H.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Fotsch, Christopher; Jordan, Steven R.; Lloyd, David J.; Sivits, Glenn; Tadesse, Seifu; Hale, Clarence; St. Jean, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5949-5964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship investigations conducted at the 5-position of the N-pyridine ring of a series of N-arylsulfonyl-N'-2-pyridinyl-piperazines led to the identification of a novel bis-pyridinyl piperazine sulfonamide I that was a potent disruptor of the glucokinase-glucokinase regulatory protein (GK-GKRP) interaction.  Anal. of the x-ray cocrystal of compd. I bound to hGKRP revealed that the 3-pyridine ring moiety occupied a previously unexplored binding pocket within the protein.  Key features of this new binding mode included forming favorable contacts with the top face of the Ala27-Val28-Pro29 ("shelf region") as well as an edge-to-face interaction with the Tyr24 side chain.  Compd. I was potent in both biochem. and cellular assays (IC50 = 0.005 μM and EC50 = 0.205 μM, resp.) and exhibited acceptable pharmacokinetic properties for in vivo evaluation.  When administered to db/db mice (100 mg/kg, po), compd. I demonstrated a robust pharmacodynamic effect and significantly reduced blood glucose levels up to 6 h postdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_rJr3MhD5G7Vg90H21EOLACvtfcHk0lhBqMFhD3ObsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLzP&md5=4c442ed22fb6460d44b956bf11db1a4f</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fjm5001979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001979%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25204.%2520Exploration%2520of%2520a%2520Novel%2520Binding%2520Pocket%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5949%26epage%3D5964%26doi%3D10.1021%2Fjm5001979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization through Conformational Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4482</span>, <span class="refDoi"> DOI: 10.1021/jm5018175</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018175" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4462-4482&author=N.+A.+Tamayoauthor=M.+H.+Normanauthor=M.+D.+Bartbergerauthor=F.+T.+Hongauthor=Y.+Boauthor=L.+Liuauthor=N.+Nishimuraauthor=K.+C.+Yangauthor=S.+Tadesseauthor=C.+Fotschauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=C.+Haleauthor=S.+R.+Jordanauthor=D.+J.+Lloydauthor=G.+Sivitsauthor=G.+Vanauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+5.+A+Novel+Aryl+Sulfone+Series%2C+Optimization+through+Conformational+Analysis&doi=10.1021%2Fjm5018175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis</span></div><div class="casAuthors">Tamayo, Nuria A.; Norman, Mark H.; Bartberger, Michael D.; Hong, Fang-Tsao; Bo, Yunxin; Liu, Longbin; Nishimura, Nobuko; Yang, Kevin C.; Tadesse, Seifu; Fotsch, Christopher; Chen, Jie; Chmait, Samer; Cupples, Rod; Hale, Clarence; Jordan, Steven R.; Lloyd, David J.; Sivits, Glenn; Van, Gwyneth; St. Jean, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4462-4482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The glucokinase-glucokinase regulatory protein (GK-GKRP) complex plays an important role in controlling glucose homeostasis in the liver.  The authors have recently disclosed a series of arylpiperazines as in vitro and in vivo disruptors of the GK-GKRP complex with efficacy in rodent models of type 2 diabetes mellitus (T2DM).  Herein, the authors describe a new class of aryl sulfones as disruptors of the GK-GKRP complex, where the central piperazine scaffold has been replaced by an arom. group.  Conformational anal. and exploration of the structure-activity relationships of this new class of compds. led to the identification of potent GK-GKRP disruptors.  Further optimization of this novel series delivered thiazole sulfone I, which was able to disrupt the GK-GKRP interaction in vitro and in vivo and, by doing so, increases cytoplasmic levels of unbound GK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUs8Kcp1LBDbVg90H21EOLACvtfcHk0lhBqMFhD3ObsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGitLY%253D&md5=ef369fc29c4edcb91d367cf48d9144e8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm5018175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018175%26sid%3Dliteratum%253Aachs%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25205.%2520A%2520Novel%2520Aryl%2520Sulfone%2520Series%252C%2520Optimization%2520through%2520Conformational%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4462%26epage%3D4482%26doi%3D10.1021%2Fjm5018175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, J. K.</span></span> <span> </span><span class="NLM_article-title">Viral Gene Products and Replication of the Human Immunodeficiency Type 1 Virus</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">C1135</span>– <span class="NLM_lpage">C1156</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.1994.266.5.C1135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1152%2Fajpcell.1994.266.5.C1135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8203479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2cXksFCrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=C1135-C1156&author=C.+D.+Morrowauthor=J.+Parkauthor=J.+K.+Wakefield&title=Viral+Gene+Products+and+Replication+of+the+Human+Immunodeficiency+Type+1+Virus&doi=10.1152%2Fajpcell.1994.266.5.C1135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Viral gene products and replication of the human immunodeficiency type 1 virus</span></div><div class="casAuthors">Morrow, Casey D.; Park, Jinseu; Wakefield, John K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">C1135-C1156</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">A review, with 284 refs.  The acquired immunodeficiency syndrome (AIDS) epidemic represents a modern-day plague that has not only resulted in a tragic loss of people from a wide spectrum of society but has reshaped the authors' viewpoints regarding health care, the treatment of infectious diseases, and social issues regarding sexual behavior.  There is little doubt now that the cause of the disease AIDS is a virus known as the human immunodeficiency virus (HIV).  The HIV virus is a member of a large family of viruses termed retroviruses, which have as a hallmark the capacity to convert their RNA genome into a DNA form that then undergoes a process of integration into the host cell chromosome, followed by the expression of the viral genome and translation of viral proteins in the infected cell.  This review describes the organization of the HIV-1 viral genome, the expression of viral proteins, as well as the functions of the accessory viral proteins in HIV replication.  The replication of the viral genome is divided into two phases, the early phase and the late phase.  The early phase consists of the interaction of the virus with the cell surface receptor (CD4 mol. in most cases), the uncoating and conversion of the viral RNA genome into a DNA form, and the integration into the host cell chromosome.  The late phase consists of the expression of the viral proteins from the integrated viral genome, the translation of viral proteins, and the assembly and release of the virus.  Points in the HIV-1 life cycle that are targets for therapeutic intervention are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQBfoIFCt2LVg90H21EOLACvtfcHk0lgTnMY4uHiDDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFCrsbw%253D&md5=8d50b3fe77efd5e898addf14276cf483</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.1994.266.5.C1135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.1994.266.5.C1135%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DC.%2BD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWakefield%26aufirst%3DJ.%2BK.%26atitle%3DViral%2520Gene%2520Products%2520and%2520Replication%2520of%2520the%2520Human%2520Immunodeficiency%2520Type%25201%2520Virus%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1994%26volume%3D266%26spage%3DC1135%26epage%3DC1156%26doi%3D10.1152%2Fajpcell.1994.266.5.C1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/gho/hiv/en/" class="extLink">https://www.who.int/gho/hiv/en/</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fgho%2Fhiv%2Fen%2F+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeni, P.</span></span> <span> </span><span class="NLM_article-title">Update on HAART in HIV</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">S100</span>– <span class="NLM_lpage">S103</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2005.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jhep.2005.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16359748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktl2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=S100-S103&author=P.+Yeni&title=Update+on+HAART+in+HIV&doi=10.1016%2Fj.jhep.2005.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Update on HAART in HIV</span></div><div class="casAuthors">Yeni, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S100-S103</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Highly active antiretroviral combination therapy (HAART) has been responsible for a dramatic decrease in AIDS mortality since 1996, and has changed the clin. profile of HIV infection from a sub-acute lethal to a chronic ambulatory disease.  HAART consists of a double nucleoside (NRTI) backbone plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir pharmacol. enhanced protease inhibitor (PI/r).  Triple NRTI combinations are less potent than 2NRTIs/NNRTI or 2NRTIs/PI/r combinations.  Antiretroviral first-line therapy is rapidly moving towards more convenient and less toxic regimens.  Three double NRTI co-formulations are now available, and the risk of mitochondrial toxicity is low with drugs such as 3TC, FTC and tenofovir.  Similarly, atazanavir, a recently available PI, can be given once daily and is less metabolically toxic than other PIs.  Antiretroviral salvage therapy takes advantage of the development or availability of new drugs, either from existing (tipranavir, TMC 114 as new PIs) or new classes (T20 as a fusion inhibitor), that remain active on many triple-class drug resistant viruses.  More progress is needed in the field of drug discovery, since a significant proportion of patients still die from AIDS with a multi-resistant virus, and since the incidence of primary HIV resistance is increasing in various parts of the world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-v9cXc64aqLVg90H21EOLACvtfcHk0lgTnMY4uHiDDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktl2ksQ%253D%253D&md5=ec6531565d1b68066aa2efc155caa6fa</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DYeni%26aufirst%3DP.%26atitle%3DUpdate%2520on%2520HAART%2520in%2520HIV%26jtitle%3DJ.%2520Hepatol.%26date%3D2006%26volume%3D44%26spage%3DS100%26epage%3DS103%26doi%3D10.1016%2Fj.jhep.2005.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">AIDSinfo</span>, Guidelines for the Use
of Antiretroviral Agents in Adults and Adolescents Living with HIV. <a href="https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/78/specific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection" class="extLink">https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/78/specific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AIDSinfo%2C+Guidelines+for+the+Use%0Aof+Antiretroviral+Agents+in+Adults+and+Adolescents+Living+with+HIV.+https%3A%2F%2Faidsinfo.nih.gov%2Fguidelines%2Fhtml%2F2%2Fpediatric-arv%2F78%2Fspecific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">World Health Organization</span>.  <i>HIV Drug Resistance Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World+Health+Organization&title=HIV+Drug+Resistance+Report+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DHIV%2520Drug%2520Resistance%2520Report%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathyanarayana, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span> <span> </span><span class="NLM_article-title">Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 A Resolution</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1126/science.2686029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.2686029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2686029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFCltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=1149-1152&author=M.+Millerauthor=J.+Schneiderauthor=B.+K.+Sathyanarayanaauthor=M.+V.+Tothauthor=G.+R.+Marshallauthor=L.+Clawsonauthor=L.+Selkauthor=S.+B.+Kentauthor=A.+Wlodawer&title=Structure+of+Complex+of+Synthetic+HIV-1+Protease+with+a+Substrate-Based+Inhibitor+at+2.3+A+Resolution&doi=10.1126%2Fscience.2686029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution</span></div><div class="casAuthors">Miller, Maria; Schneider, Jens; Sathyanarayana, Bangalore K.; Toth, Mihaly V.; Marshall, Garland R.; Clawson, Leigh; Selk, Linda; Kent, Stephen B. H.; Wlodawer, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">4934</span>),
    <span class="NLM_cas:pages">1149-52</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The crystal structure of a complex between a synthetic peptide inhibitor (compd. MVT-101) with the sequence N-acetyl-Thr-Ile-Nle-Ψ[CH2-NH]-Nle-Gln-Arg.amide (Nle, norleucine) with chem. synthesized HIV-1 (human immunodeficiency virus 1) protease was detd. at 2.3 Å resoln. (R factor of 0.176).  Despite the sym. nature of the unliganded enzyme, the asym. inhibitor lies in a single orientation and makes extensive interactions at the interface between the 2 subunits of the homodimeric protein.  Compared with the unliganded enzyme, the protein mol. underwent substantial changes, particularly in an extended region corresponding to the flaps (residues 35-57 in each chain), where backbone movements as large as 7 Å are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsq_wooxyujrVg90H21EOLACvtfcHk0lgTnMY4uHiDDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFCltLk%253D&md5=cf257c6b4ffbcb917329c1846664f966</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1126%2Fscience.2686029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2686029%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DSathyanarayana%26aufirst%3DB.%2BK.%26aulast%3DToth%26aufirst%3DM.%2BV.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26aulast%3DClawson%26aufirst%3DL.%26aulast%3DSelk%26aufirst%3DL.%26aulast%3DKent%26aufirst%3DS.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26atitle%3DStructure%2520of%2520Complex%2520of%2520Synthetic%2520HIV-1%2520Protease%2520with%2520a%2520Substrate-Based%2520Inhibitor%2520at%25202.3%2520A%2520Resolution%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D1149%26epage%3D1152%26doi%3D10.1126%2Fscience.2686029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swain, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span> <span> </span><span class="NLM_article-title">X-Ray Crystallographic Structure of a Complex between a Synthetic Protease of Human Immunodeficiency Virus 1 and a Substrate-Based Hydroxyethylamine Inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">8805</span>– <span class="NLM_lpage">8809</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.22.8805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.87.22.8805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2247451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=8805-8809&author=A.+L.+Swainauthor=M.+M.+Millerauthor=J.+Greenauthor=D.+H.+Richauthor=J.+Schneiderauthor=S.+B.+Kentauthor=A.+Wlodawer&title=X-Ray+Crystallographic+Structure+of+a+Complex+between+a+Synthetic+Protease+of+Human+Immunodeficiency+Virus+1+and+a+Substrate-Based+Hydroxyethylamine+Inhibitor&doi=10.1073%2Fpnas.87.22.8805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor</span></div><div class="casAuthors">Swain, Amy L.; Miller, Maria M.; Green, Jeremy; Rich, Daniel H.; Schneider, Jens; Kent, Stephen B. H.; Wlodawer, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8805-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The crystal of a complex of the chem. synthesized aspartic protease of human immunodeficiency virus 1 (HIV-1) with a heptapeptide-derived inhibitor bound in the active site was detd.  The sequence of the inhibitor JG-365 was Ac-Ser-Leu-Asn-Phe-ψ[CH(OH)CH2N]-Pro-Ile-Val-OMe; the Ki was 0.24 nM.  The hydroxyethylamine moiety, in place of the normal scissile bond of the substrate, is believed to mimic a tetrahedral reaction intermediate.  The structure of the complex was refined to an R factor of 0.146 at 2.4-Å resoln. by using restrained least squares with rms deviations in bond lengths of 0.02 Å and bond angles of 4°.  The bound inhibitor diastereomer had the S configuration at the hydroxyethylamine chiral C atom, and the OH group was positioned between the active site aspartate carboxyl groups within H-bonding distance.  Comparison of this structure with a reduced peptide bond inhibitor-protease complex indicated that these contacts confer the exceptional binding strength of JG-365.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYAMlIk7NhWrVg90H21EOLACvtfcHk0lhbqaf155geeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlyrsr4%253D&md5=a2be842ef3f1d35743271c75f7de903e</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.22.8805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.22.8805%26sid%3Dliteratum%253Aachs%26aulast%3DSwain%26aufirst%3DA.%2BL.%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DRich%26aufirst%3DD.%2BH.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DS.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26atitle%3DX-Ray%2520Crystallographic%2520Structure%2520of%2520a%2520Complex%2520between%2520a%2520Synthetic%2520Protease%2520of%2520Human%2520Immunodeficiency%2520Virus%25201%2520and%2520a%2520Substrate-Based%2520Hydroxyethylamine%2520Inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D8805%26epage%3D8809%26doi%3D10.1073%2Fpnas.87.22.8805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emini, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, I. S.</span></span> <span> </span><span class="NLM_article-title">Active Human Immunodeficiency Virus Protease Is Required for Viral Infectivity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4686</span>– <span class="NLM_lpage">4690</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.13.4686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.85.13.4686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3290901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXltVOmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4686-4690&author=N.+E.+Kohlauthor=E.+A.+Eminiauthor=W.+A.+Schleifauthor=L.+J.+Davisauthor=J.+C.+Heimbachauthor=R.+A.+Dixonauthor=E.+M.+Scolnickauthor=I.+S.+Sigal&title=Active+Human+Immunodeficiency+Virus+Protease+Is+Required+for+Viral+Infectivity&doi=10.1073%2Fpnas.85.13.4686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Active human immunodeficiency virus protease is required for viral infectivity</span></div><div class="casAuthors">Kohl, Nancy E.; Emini, Emilio A.; Schleif, William A.; Davis, Lenora J.; Heimbach, Jill C.; Dixon, Richard A. F.; Scolnick, Edward M.; Sigal, Irving S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4686-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Retroviral proteins are synthesized as polyprotein precursors that undergo proteolytic cleavages to yield the mature viral proteins.  The role of the human immunodeficiency virus (HIV) protease in the viral replication cycle was examd. by use of a site-directed mutation in the protease gene.  The HIV protease gene product was expressed in Escherichia coli and obsd. to cleave HIV gag p55 to gag p24 and gag p17 in vitro.  Substitution of aspartic acid residue 25 (Asp-25) or this protein with an asparagine residue did not affect the expression of the protein, but it eliminated detectable in vitro proteolytic activity against HIV gag p55.  A mutant HIV provirus was constructed that contained the Asn-25 mutation within the protease gene.  SW480 human colon carcinoma cells transfected with the Asn-25 mutant proviral DNA produced virions that contained gag p55 but not gag p24, whereas virions from cells transfected with the wild-type DNA contained both gag p55 and gag p24.  The mutant virions were not able to infect MT-4 lymphoid cells.  In contrast, these cells were highly sensitive to infection by the wild-type virions.  These results demonstrate that the HIV protease is an essential viral enzyme and consequently, an attractive target for anti-HIV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDAYeRHmne27Vg90H21EOLACvtfcHk0lhbqaf155geeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVOmtrY%253D&md5=3f6e11607d70ea93570ef2449b312f22</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.13.4686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.13.4686%26sid%3Dliteratum%253Aachs%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DEmini%26aufirst%3DE.%2BA.%26aulast%3DSchleif%26aufirst%3DW.%2BA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DHeimbach%26aufirst%3DJ.%2BC.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DSigal%26aufirst%3DI.%2BS.%26atitle%3DActive%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Is%2520Required%2520for%2520Viral%2520Infectivity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D4686%26epage%3D4690%26doi%3D10.1073%2Fpnas.85.13.4686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Food and Drug Administration</span>. <a href="http://www.fda.gov/oashi/aids/virals.html" class="extLink">http://www.fda.gov/oashi/aids/virals.html</a> (Accessed May 18, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Food+and+Drug+Administration.+http%3A%2F%2Fwww.fda.gov%2Foashi%2Faids%2Fvirals.html+%28Accessed+May+18%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/jm900492g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900492g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=521-538&author=Y.+Mehellouauthor=E.+De+Clercq&title=Twenty-Six+Years+of+Anti-HIV+Drug+Discovery%3A+Where+Do+We+Stand+and+Where+Do+We+Go%3F&doi=10.1021%2Fjm900492g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?</span></div><div class="casAuthors">Mehellou, Youcef; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">521-538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human immunodeficiency virus (HIV) has now been established as the causative agent of the acquired immunodeficiency syndrome (AIDS) for over 20 years.  During this time an unprecedented success has been achieved in discovering anti-HIV drugs as reflected by the fact that there are now more drugs approved for the treatment of HIV than for all other viral infections taken together.  The currently Food and Drug Administration (FDA) approved anti-HIV drugs can be divided into seven groups: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), coreceptor inhibitors (CRIs), and integrase inhibitors (INIs).  This arsenal of drugs, which is used in combinations, has moved the prognosis of HIV patients from that of high morbidity and mortality to, for many at least, a chronic, manageable but still complex disease.  However, the use of these drugs has been relatively limited by their toxicity, drug resistance development, and more worryingly, the fact that some newly HIV-infected patients carry viruses that are already resistant to the currently approved AIDS treatments.  These issues along with drug-related side effects as well as, in some cases, poor tolerability of these drugs make it apparent that new anti-HIV drugs with acceptable toxicity and resistance profiles and, more importantly, new anti-HIV agents with novel mechanisms of action are clearly needed.  There is no doubt that, since the discovery of HIV 26 years ago, the progress made toward developing effective anti-HIV therapies has superseded that of any other (antiviral) drug discovery initiative.  This unprecedented progress generated an armamentarium of anti-HIV drugs, which target several different stages of the HIV life cycle.  This, therefore, has enabled the use of combination therapy in combating HIV infections.  Although the drugs making up these treatment regimens have proved effective, some problems such as toxicity and resistance development have limited their use and prompted the search for new agents.  The pipeline of anti-HIV drugs is well stocked with drugs that are going to be "next-generation" drugs.  However, as we highlighted in this work, future anti-HIV drug research efforts should also focus on new HIV targets such as HIV proteins and RNase H.  In addn., the development of anti-HIV drugs derived from natural products is an area of research where a lot of efforts should be dedicated in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjZ2YdiQQgbVg90H21EOLACvtfcHk0lhbqaf155geeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltLvL&md5=7b9374af941b187a82bc970b45d71318</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm900492g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900492g%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTwenty-Six%2520Years%2520of%2520Anti-HIV%2520Drug%2520Discovery%253A%2520Where%2520Do%2520We%2520Stand%2520and%2520Where%2520Do%2520We%2520Go%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D521%26epage%3D538%26doi%3D10.1021%2Fjm900492g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boross, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of HIV Protease V82A and L90M Mutants Reveal Changes in the Indinavir-Binding Site</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">1516</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.2004.04060.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1432-1033.2004.04060.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15066177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFeksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=2004&pages=1516-1524&author=B.+Mahalingamauthor=Y.+F.+Wangauthor=P.+I.+Borossauthor=J.+Tozserauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=Crystal+Structures+of+HIV+Protease+V82A+and+L90M+Mutants+Reveal+Changes+in+the+Indinavir-Binding+Site&doi=10.1111%2Fj.1432-1033.2004.04060.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site</span></div><div class="casAuthors">Mahalingam, Bhuvaneshwari; Wang, Yuan-Fang; Boross, Peter I.; Tozser, Jozsef; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1516-1524</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The crystal structures of the wild-type HIV-1 protease (PR) and the two resistant variants, PRV82A and PRL90M, have been detd. in complex with the antiviral drug, indinavir, to gain insight into the mol. basis of drug resistance.  V82A and L90M correspond to an active site mutation and nonactive site mutation, resp.  The inhibition (Ki) of PRV82A and PRL90M was 3.3- and 0.16- fold, resp., relative to the value for PR.  They showed only a modest decrease, of 10-15%, in their kcat/Km values relative to PR.  The crystal structures were refined to resolns. of 1.25-1.4 Å to reveal crit. features assocd. with inhibitor resistance.  PRV82A showed local changes in residues 81-82 at the site of the mutation, while PRL90M showed local changes near Met90 and an addnl. interaction with indinavir.  These structural differences concur with the kinetic data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBAC1vCXX-pLVg90H21EOLACvtfcHk0ljct8OO-gOEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFeksbc%253D&md5=ba374f81e925f41ca6a07b2d95979462</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.2004.04060.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.2004.04060.x%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DTozser%26aufirst%3DJ.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DCrystal%2520Structures%2520of%2520HIV%2520Protease%2520V82A%2520and%2520L90M%2520Mutants%2520Reveal%2520Changes%2520in%2520the%2520Indinavir-Binding%2520Site%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2004%26volume%3D271%26spage%3D1516%26epage%3D1524%26doi%3D10.1111%2Fj.1432-1033.2004.04060.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent HIV-1 Protease Inhibitors Incorporating Sulfoximine Functionality</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5614</span>– <span class="NLM_lpage">5619</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2007.07.095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17822899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5614-5619&author=D.+Luauthor=R.+Vince&title=Discovery+of+Potent+HIV-1+Protease+Inhibitors+Incorporating+Sulfoximine+Functionality&doi=10.1016%2Fj.bmcl.2007.07.095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality</span></div><div class="casAuthors">Lu, Ding; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5614-5619</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on the unique property of sulfoximine and the homodimeric C2 structural symmetry of HIV-1 protease, a novel class of sulfoximine-based pseudosym. HIV-1 protease inhibitors, e.g., I, was designed and synthesized.  The sulfoximine moiety was demonstrated to be important for HIV-1 protease inhibitor potency.  The most active stereoisomer (2S,2'S) displays a potency of 2.5 nM (IC50) against HIV-1 protease and an anti-HIV-1 activity of 408 nM (IC50).  A possible mode of action is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEOJzXk4cU07Vg90H21EOLACvtfcHk0ljct8OO-gOEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisb7I&md5=1da3157fb1ed4ecb89155bba6bb6608d</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.095%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520Potent%2520HIV-1%2520Protease%2520Inhibitors%2520Incorporating%2520Sulfoximine%2520Functionality%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5614%26epage%3D5619%26doi%3D10.1016%2Fj.bmcl.2007.07.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design, Asymmetric Synthesis, and Evaluation of Pseudosymmetric Sulfoximine Inhibitors against HIV-1 Protease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2037</span>– <span class="NLM_lpage">2048</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmc.2010.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20138769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2037-2048&author=D.+Luauthor=Y.+Y.+Shamauthor=R.+Vince&title=Design%2C+Asymmetric+Synthesis%2C+and+Evaluation+of+Pseudosymmetric+Sulfoximine+Inhibitors+against+HIV-1+Protease&doi=10.1016%2Fj.bmc.2010.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease</span></div><div class="casAuthors">Lu, Ding; Sham, Yuk Yin; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2048</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The HIV-1 protease is a validated drug target for the design of antiretroviral drugs to combat AIDS.  We previously established the sulfoximine functionality as a valid transition state mimetic (TSM) in the HIV-1 protease inhibitors (PI) design and have identified a lead pseudosym. compd. with nanomolar enzymic inhibitory activity.  Here, we report the asym. synthesis of this compd. and its application in the synthesis of sulfoximine-based peptidomimetic HIV-1 protease inhibitors.  Mol. modeling revealed the potential mode of binding of the sulfoximine inhibitor as a TSM.  The predicted abs. binding free energies suggested similar inhibitory effect as obsd. in our enzymic inhibitory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeX1toC_hLKLVg90H21EOLACvtfcHk0ljct8OO-gOEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1ajs74%253D&md5=ef9d6d1b014c1c3ee36e5601985115ec</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%252C%2520Asymmetric%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Pseudosymmetric%2520Sulfoximine%2520Inhibitors%2520against%2520HIV-1%2520Protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2037%26epage%3D2048%26doi%3D10.1016%2Fj.bmc.2010.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Sulfoximine Based Inhibitors for HIV-1 Protease</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5406</span>– <span class="NLM_lpage">5410</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2008.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18829317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CqsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5406-5410&author=A.+Razaauthor=Y.+Y.+Shamauthor=R.+Vince&title=Design+and+Synthesis+of+Sulfoximine+Based+Inhibitors+for+HIV-1+Protease&doi=10.1016%2Fj.bmcl.2008.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of sulfoximine based inhibitors for HIV-1 protease</span></div><div class="casAuthors">Raza, Abbas; Sham, Yuk Yin; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5406-5410</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A class of potent sulfoximine inhibitors for HIV-1 protease has been designed and synthesized.  Substitution of the sulfoximine moiety into different parent compds. yields different inhibition effects.  While our previously studied sulfoximine-based inhibitors display potency of 2.5 nM (IC50) against HIV-1 protease, introduction of the sulfoximine moiety into the asym. Indinavir yielded only micromolar inhibition.  Docking studies showed structural variations in their modes of binding which explains this unexpected observation.  The implication of these observations in the development of other sulfoximine inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLbB5oqogTMLVg90H21EOLACvtfcHk0ljct8OO-gOEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CqsrfE&md5=8c9a94592b8128ae74b201806fb2b2ba</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Sulfoximine%2520Based%2520Inhibitors%2520for%2520HIV-1%2520Protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5406%26epage%3D5410%26doi%3D10.1016%2Fj.bmcl.2008.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliakas-Boltz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowdon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonucci, T. K.</span></span> <span> </span><span class="NLM_article-title">Biological and Biochemical Anti-HIV Activity of the Benzothiadiazine Class of Nonnucleoside Reverse Transcriptase Inhibitors</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/0166-3542(94)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2F0166-3542%2894%2990092-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7529014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1994&pages=43-56&author=R.+W.+Buckheitauthor=V.+Fliakas-Boltzauthor=W.+D.+Deckerauthor=J.+L.+Robersonauthor=C.+A.+Pyleauthor=E.+L.+Whiteauthor=B.+J.+Bowdonauthor=J.+B.+McMahonauthor=M.+R.+Boydauthor=J.+P.+Baderauthor=D.+G.+Nickellauthor=H.+Barthauthor=T.+K.+Antonucci&title=Biological+and+Biochemical+Anti-HIV+Activity+of+the+Benzothiadiazine+Class+of+Nonnucleoside+Reverse+Transcriptase+Inhibitors&doi=10.1016%2F0166-3542%2894%2990092-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors</span></div><div class="casAuthors">Buckheit, , Robert W. Jr.; Fliakas-Boltz, Valerie; Decker, W. Don; Roberson, Joseph L.; Pyle, Cathi A.; White, E. Lucile; Bowdon, Bonnie J.; McMahon, James B.; Boyd, Michael R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-56</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">A series of benzothiadiazine derivs. were screened against the human immunodeficiency virus (HIV) and certain structure-activity relationships were defined for anti-HIV activity in this chem. class.  The selected representative NSC 287474 was a highly potent inhibitor of HIV-induced cell killing and HIV replication in a variety of human cell lines, as well as in fresh human peripheral blood lymphocytes and macrophages.  The compd. was active against a panel of biol. diverse lab. and clin. strains of HIV-1, including the AZT-resistant strain G910-6.  However, the agent was inactive against HIV-2, and also against both nevirapine- and pyridinone-resistant strains (N119 and A17) of HIV-1, which are cross-resistant to several structurally diverse nonnucleoside reverse transcriptase inhibitors.  The compd. selectively inhibited HIV-1 reverse transcriptase, but not HIV-2 reverse transcriptase.  Combination of NSC 287474 with AZT synergistically inhibited HIV-1-induced cell killing in vitro.  The compd. did not inhibit the replication of the Rauscher murine leukemia retrovirus or the simian immunodeficiency virus.  The benzothiadiazine class of compds. represents a new active anti-HIV-1 chemotype within the diverse group of nonnucleoside reverse transcriptase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKwxG24h38bVg90H21EOLACvtfcHk0liJyfvNjrZWKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWqtbo%253D&md5=49aa278e2bc36abd873303f70d0f0a3d</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2894%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252894%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DFliakas-Boltz%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DW.%2BD.%26aulast%3DRoberson%26aufirst%3DJ.%2BL.%26aulast%3DPyle%26aufirst%3DC.%2BA.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DBowdon%26aufirst%3DB.%2BJ.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBader%26aufirst%3DJ.%2BP.%26aulast%3DNickell%26aufirst%3DD.%2BG.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DAntonucci%26aufirst%3DT.%2BK.%26atitle%3DBiological%2520and%2520Biochemical%2520Anti-HIV%2520Activity%2520of%2520the%2520Benzothiadiazine%2520Class%2520of%2520Nonnucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D1994%26volume%3D25%26spage%3D43%26epage%3D56%26doi%3D10.1016%2F0166-3542%2894%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Askin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volante, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinkai, I.</span></span> <span> </span><span class="NLM_article-title">Highly Diastereoselective Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptide Isostere Inhibitors of HIV-1 Protease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2773</span>, <span class="refDoi"> DOI: 10.1021/jo00036a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00036a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK38XisFKjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=2771-2773&author=D.+Askinauthor=M.+Wallaceauthor=J.+Vaccaauthor=R.+Reamerauthor=R.+Volanteauthor=I.+Shinkai&title=Highly+Diastereoselective+Alkylations+of+Chiral+Amide+Enolates%3A+New+Routes+to+Hydroxyethylene+Dipeptide+Isostere+Inhibitors+of+HIV-1+Protease&doi=10.1021%2Fjo00036a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Highly diastereoselective alkylations of chiral amide enolates:  new routes to hydroxyethylene dipeptide isostere inhibitors of HIV-1 protease</span></div><div class="casAuthors">Askin, D.; Wallace, M. A.; Vacca, J. P.; Reamer, R. A.; Volante, R. P.; Shinkai, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2771-3</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The non-chelate enforced chiral amide enolate derived from amide I (R = H) and BuLi reacts with MeI at -78° to afford the (2S)-methylated product II in 97% diastereoselectivity.  Similarly, treatment of the lithium enolate with 0.5 equiv of 3-iodo-2-iodomethyl-1-propene affords the double adduct III (X = CH2, R1 = acetonide).  Ozonolysis, redn. and acetonide removal then affords the pseudo-C2-sym. HIV protease inhibitor III (X = H, OH; R1 = H).  Amides I (R = H, 2-morpholinoethoxy, OH, OCH2CH2OH) react with epoxides IV (Boc = Me3CO2C, R2 = Ph, cyclohexyl) upon addn. of 2 or 3 equiv of BuLi to the -78° amide/epoxide soln. in THF, which after warming to -25° affords the (2R) adducts V in an intramol. Lewis acid accelerated one-pot process.  The high diastereoselectivity obsd. in the alkylation of the amide enolates is much greater than predicted from the soln. rotamer ratios of I.  Acetonide cleavage of V then affords the hydroxyethylene dipeptide isosteres VI.  This chem. provides a rapid entry into HIV protease inhibitors derived from the phenylglycine surrogate (-)-cis-(1S,2R)-1-aminoindan-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWd4S3QY_wfLVg90H21EOLACvtfcHk0liJyfvNjrZWKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFKjsrk%253D&md5=bf45cca93d1a4231378baaeede24ccbb</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Fjo00036a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00036a004%26sid%3Dliteratum%253Aachs%26aulast%3DAskin%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DVolante%26aufirst%3DR.%26aulast%3DShinkai%26aufirst%3DI.%26atitle%3DHighly%2520Diastereoselective%2520Alkylations%2520of%2520Chiral%2520Amide%2520Enolates%253A%2520New%2520Routes%2520to%2520Hydroxyethylene%2520Dipeptide%2520Isostere%2520Inhibitors%2520of%2520HIV-1%2520Protease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D2771%26epage%3D2773%26doi%3D10.1021%2Fjo00036a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satzinger, G.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and Commercial Exploitation</span>. <i>Drug News Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1358/dnp.2001.14.4.858403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1358%2Fdnp.2001.14.4.858403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12819791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt12itLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=197-207&author=G.+Satzinger&title=Drug+Discovery+and+Commercial+Exploitation&doi=10.1358%2Fdnp.2001.14.4.858403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and commercial exploitation</span></div><div class="casAuthors">Satzinger, G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  In this report, the author demonstrates the central role of chem. in pharmaceutical research in the past.  Although the modern researcher has a more sophisticated understanding of disease origins and more sophisticated means to new drugs, chem. and ingenuity remain propelling elements of pharmaceutical research in the twenty-first century.  Certainly, long-term experience in com. drug research suggests that prior to launch, the eventual fate of a drug candidate may be less destined by quality and demand than by discrete decision procedures within top management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1GICcHiw07Vg90H21EOLACvtfcHk0liJyfvNjrZWKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt12itLY%253D&md5=42be80826e3aaa60352738a40413adbf</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2001.14.4.858403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2001.14.4.858403%26sid%3Dliteratum%253Aachs%26aulast%3DSatzinger%26aufirst%3DG.%26atitle%3DDrug%2520Discovery%2520and%2520Commercial%2520Exploitation%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2001%26volume%3D14%26spage%3D197%26epage%3D207%26doi%3D10.1358%2Fdnp.2001.14.4.858403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satzinger, G.</span></span> <span> </span><span class="NLM_article-title">Antiviral Pharmaceutical Composition for Treating Lymphocytes</span>. <span class="NLM_patent">US5321024A</span>, Jun, 14 <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+Satzinger&title=Antiviral+Pharmaceutical+Composition+for+Treating+Lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatzinger%26aufirst%3DG.%26atitle%3DAntiviral%2520Pharmaceutical%2520Composition%2520for%2520Treating%2520Lymphocytes%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span> <span> </span><span class="NLM_article-title">Psoriasis: Epidemiology, Clinical Features, and Quality of Life</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">ii18</span>– <span class="NLM_lpage">ii25</span>, <span class="refDoi"> DOI: 10.1136/ard.2004.033217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fard.2004.033217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15708928" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=ii18-ii25&author=R.+G.+B.+Langleyauthor=G.+G.+Kruegerauthor=C.+E.+M.+Griffiths&title=Psoriasis%3A+Epidemiology%2C+Clinical+Features%2C+and+Quality+of+Life&doi=10.1136%2Fard.2004.033217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.033217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.033217%26sid%3Dliteratum%253Aachs%26aulast%3DLangley%26aufirst%3DR.%2BG.%2BB.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26atitle%3DPsoriasis%253A%2520Epidemiology%252C%2520Clinical%2520Features%252C%2520and%2520Quality%2520of%2520Life%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3Dii18%26epage%3Dii25%26doi%3D10.1136%2Fard.2004.033217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynde, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vender, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourcier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, S.</span></span> <span> </span><span class="NLM_article-title">Interleukin 17A: Toward a New Understanding of Psoriasis Pathogenesis</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2013.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaad.2013.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24655820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=141-150&author=C.+W.+Lyndeauthor=Y.+Poulinauthor=R.+Venderauthor=M.+Bourcierauthor=S.+Khalil&title=Interleukin+17A%3A+Toward+a+New+Understanding+of+Psoriasis+Pathogenesis&doi=10.1016%2Fj.jaad.2013.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 17A: Toward a new understanding of psoriasis pathogenesis</span></div><div class="casAuthors">Lynde, Charles W.; Poulin, Yves; Vender, Ronald; Bourcier, Marc; Khalil, Sam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-150</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Mol. and cellular understanding of psoriasis pathogenesis has evolved considerably over the last 30 years beginning in the early 1980s when psoriasis was thought to be a skin disease driven by keratinocyte hyperproliferation.  During the next 20 years, the role of the immune system and T-helper (Th) cells in psoriasis pathogenesis was recognized.  The presence of the interleukin (IL)-12 cytokine in psoriatic lesions led to the postulate that psoriasis is mediated by Th1 cells.  Recent evidence has revealed a role for Th17 cells, and other immune cells, as proximal regulators of psoriatic skin inflammation.  IL-17A, the principal effector cytokine of Th17 cells, stimulates keratinocytes to produce chemokines, cytokines, and other proinflammatory mediators thereby enabling IL-17A to bridge the innate and adaptive immune systems to sustain chronic inflammation.  This model underlies the rationale for inhibiting IL-17A signaling as a potential therapeutic approach to disrupt the psoriatic inflammatory loop.  Several monoclonal antibodies that inhibit the IL-17 pathway are in clin. development.  These agents exhibit promising clin. efficacy and tolerability profiles including immunohistochem. improvement in psoriatic plaques.  Results from clin. trials with IL-17 pathway inhibitors are refining our understanding of psoriasis pathogenesis and may provide a new therapeutic approach for patients with moderate to severe psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaQkyBVZ0zLVg90H21EOLACvtfcHk0ljxCJHiQxzaLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFWltL8%253D&md5=333950541388c2b5e2edd6d1a6c2f7b6</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2013.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2013.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DLynde%26aufirst%3DC.%2BW.%26aulast%3DPoulin%26aufirst%3DY.%26aulast%3DVender%26aufirst%3DR.%26aulast%3DBourcier%26aufirst%3DM.%26aulast%3DKhalil%26aufirst%3DS.%26atitle%3DInterleukin%252017A%253A%2520Toward%2520a%2520New%2520Understanding%2520of%2520Psoriasis%2520Pathogenesis%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2014%26volume%3D71%26spage%3D141%26epage%3D150%26doi%3D10.1016%2Fj.jaad.2013.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span> <span> </span><span class="NLM_article-title">Review of Phase III Trial Data on IL-23 Inhibitors Tildrakizumab and Guselkumab for Psoriasis</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1111/jdv.14451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fjdv.14451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28667777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslalsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1627-1632&author=M.+Aminauthor=K.+Darjiauthor=D.+J.+Noauthor=J.+J.+Wu&title=Review+of+Phase+III+Trial+Data+on+IL-23+Inhibitors+Tildrakizumab+and+Guselkumab+for+Psoriasis&doi=10.1111%2Fjdv.14451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis</span></div><div class="casAuthors">Amin, M.; Darji, K.; No, D. J.; Wu, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1627-1632</span>CODEN:
                <span class="NLM_cas:coden">JEAVEQ</span>;
        ISSN:<span class="NLM_cas:issn">1468-3083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The development of monoclonal antibodies targeting IL-12 and IL-23 has enhanced the therapeutic options available for psoriasis patients.  Recent research suggests that IL-23 alone plays a role in the pathogenesis of psoriasis.  The objective was to review the phase III clin. trial data for the anti-IL-23 agents to evaluate the safety and efficacy profile of each agent.  We reviewed the results of the phase III clin. trials for the anti-IL-23 agents tildrakizumab and guselkumab.  The results of phase III trials on risankizumab have not yet been reported.  By week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was >60% among the most efficacious dose of each agent.  The percentage of patients achieving PASI 90 at week 16 was the primary endpoint for the phase III trials for guselkumab, which was above 70%.  The safety profiles of the agents were comparable, with the most commonly reported adverse events of nasopharyngitis and upper respiratory tract infections.  The anti-IL-23 agents demonstrated a rapid clin. improvement that is similar or superior to the improvement seen with currently marketed IL-17 inhibitors with a favorable short-term safety profile.  The results of the phase III trials support the notion that IL-23 is a potential target in psoriasis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4GdiDmzQSELVg90H21EOLACvtfcHk0ljxCJHiQxzaLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslalsrbJ&md5=c5fae131f60385cfbd1431f7a7cfc0e9</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1111%2Fjdv.14451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjdv.14451%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DM.%26aulast%3DDarji%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DD.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26atitle%3DReview%2520of%2520Phase%2520III%2520Trial%2520Data%2520on%2520IL-23%2520Inhibitors%2520Tildrakizumab%2520and%2520Guselkumab%2520for%2520Psoriasis%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2017%26volume%3D31%26spage%3D1627%26epage%3D1632%26doi%3D10.1111%2Fjdv.14451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arican, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciragil, P.</span></span> <span> </span><span class="NLM_article-title">Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients with Active Psoriasis and Correlation with Disease Severity</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1155/MI.2005.273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1155%2FMI.2005.273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16258194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2MrnvF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=273-279&author=O.+Aricanauthor=M.+Aralauthor=S.+Sasmazauthor=P.+Ciragil&title=Serum+Levels+of+TNF-%CE%B1%2C+IFN-%CE%B3%2C+IL-6%2C+IL-8%2C+IL-12%2C+IL-17%2C+and+IL-18+in+Patients+with+Active+Psoriasis+and+Correlation+with+Disease+Severity&doi=10.1155%2FMI.2005.273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity</span></div><div class="casAuthors">Arican Ozer; Aral Murat; Sasmaz Sezai; Ciragil Pinar</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2005</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-9</span>
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    </div><div class="casAbstract">Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis.  The most often used psoriasis score is the psoriasis area and severity index (PASI).  A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity.  To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis.  The serum levels of cytokines levels were determined with the use of the ELISA method.  All mean values except IL-17 levels of patients were significantly higher than those of controls.  There was a significant correlation between serum levels of IFN-gamma, IL-12, IL-17, and IL-18, and severity of the disease.  Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies.  In this study, serum TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls.  Furthermore, high levels of IFN-gamma, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2CQC8zA6KkCO2kE7krGOBfW6udTcc2eY5ViViZQhjs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrnvF2nug%253D%253D&md5=dea333465f32fd60cdc735d3ae76ff74</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1155%2FMI.2005.273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252FMI.2005.273%26sid%3Dliteratum%253Aachs%26aulast%3DArican%26aufirst%3DO.%26aulast%3DAral%26aufirst%3DM.%26aulast%3DSasmaz%26aufirst%3DS.%26aulast%3DCiragil%26aufirst%3DP.%26atitle%3DSerum%2520Levels%2520of%2520TNF-%25CE%25B1%252C%2520IFN-%25CE%25B3%252C%2520IL-6%252C%2520IL-8%252C%2520IL-12%252C%2520IL-17%252C%2520and%2520IL-18%2520in%2520Patients%2520with%2520Active%2520Psoriasis%2520and%2520Correlation%2520with%2520Disease%2520Severity%26jtitle%3DMediators%2520Inflammation%26date%3D2005%26volume%3D2005%26spage%3D273%26epage%3D279%26doi%3D10.1155%2FMI.2005.273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapies in Psoriasis: A Systematic Review</span>. <i>Cutis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29718027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1MjovFGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=5-9&author=E.+B.+Leeauthor=M.+Aminauthor=T.+Bhutaniauthor=J.+J.+Wu&title=Emerging+Therapies+in+Psoriasis%3A+A+Systematic+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies in psoriasis: a systematic review</span></div><div class="casAuthors">Lee Erica B; Amin Mina; Bhutani Tina; Wu Jashin J</div><div class="citationInfo"><span class="NLM_cas:title">Cutis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">3S</span>),
    <span class="NLM_cas:pages">5-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many new biologics are being studied for use in psoriasis.  In this review, we evaluate and summarize findings about emerging biologic therapies for psoriasis.  We reviewed published data from phase 2 and 3 clinical trials of 2 IL-17 inhibitors (ixekizumab and brodalumab); 3 IL-23 inhibitors (guselkumab, tildrakizumab, and risankizumab); and 1 tumor necrosis factor (TNF) inhibitor (certolizumab pegol).  Janus kinase inhibitors were not included in our review, as they currently are not approved by the US Food and Drug Administration (FDA) and there are no plans to further develop this class for treatment of psoriasis.  Overall, the clinical improvement provided by and the safety profiles of these agents are promising; they may be equal to or more efficacious than available therapeutic options for treating the symptoms of psoriasis.  Long-term studies are still needed, however, to further establish safety and efficacy profiles for these biologic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSaBOzmDoL7IHWj6b1v8uTfW6udTcc2eY5ViViZQhjs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjovFGgtA%253D%253D&md5=e96319a03c6d408033f440696cdc251d</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DAmin%26aufirst%3DM.%26aulast%3DBhutani%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26atitle%3DEmerging%2520Therapies%2520in%2520Psoriasis%253A%2520A%2520Systematic%2520Review%26jtitle%3DCutis%26date%3D2018%26volume%3D101%26spage%3D5%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rendon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäkel, K.</span></span> <span> </span><span class="NLM_article-title">Psoriasis Pathogenesis and Treatment</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1475</span>, <span class="refDoi"> DOI: 10.3390/ijms20061475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3390%2Fijms20061475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1475&author=A.+Rendonauthor=K.+Sch%C3%A4kel&title=Psoriasis+Pathogenesis+and+Treatment&doi=10.3390%2Fijms20061475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis pathogenesis and treatment</span></div><div class="casAuthors">Rendon, Adriana; Schaekel, Knut</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1475</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Research on psoriasis pathogenesis has largely increased knowledge on skin biol. in general.  In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis.  This review discusses the mechanisms involved in the initiation and development of the disease, as well as the therapeutic options that have arisen from the dissection of the inflammatory psoriatic pathways.  Our discussion begins by addressing the inflammatory pathways and key cell types initiating and perpetuating psoriatic inflammation.  Next, we describe the role of genetics, assocd. epigenetic mechanisms, and the interaction of the skin flora in the pathophysiol. of psoriasis.  Finally, we include a comprehensive review of well-established widely available therapies and novel targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeBJo30ie8bbVg90H21EOLACvtfcHk0lgOJl1z97KfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVajsA%253D%253D&md5=40625b4b8d8ae4e2f859798dafc1c8eb</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.3390%2Fijms20061475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061475%26sid%3Dliteratum%253Aachs%26aulast%3DRendon%26aufirst%3DA.%26aulast%3DSch%25C3%25A4kel%26aufirst%3DK.%26atitle%3DPsoriasis%2520Pathogenesis%2520and%2520Treatment%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1475%26doi%3D10.3390%2Fijms20061475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckerandre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarter, J. F.</span></span> <span> </span><span class="NLM_article-title">Identification of Nuclear Receptor mRNAs by RT-PCR Amplification of Conserved Zinc-Finger Motif Sequences</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1993.1976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1006%2Fbbrc.1993.1976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7916608" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=1993&pages=1371-1379&author=M.+Beckerandreauthor=E.+Andreauthor=J.+F.+Delamarter&title=Identification+of+Nuclear+Receptor+mRNAs+by+RT-PCR+Amplification+of+Conserved+Zinc-Finger+Motif+Sequences&doi=10.1006%2Fbbrc.1993.1976"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1993.1976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1993.1976%26sid%3Dliteratum%253Aachs%26aulast%3DBeckerandre%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DE.%26aulast%3DDelamarter%26aufirst%3DJ.%2BF.%26atitle%3DIdentification%2520of%2520Nuclear%2520Receptor%2520mRNAs%2520by%2520RT-PCR%2520Amplification%2520of%2520Conserved%2520Zinc-Finger%2520Motif%2520Sequences%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1993%26volume%3D194%26spage%3D1371%26epage%3D1379%26doi%3D10.1006%2Fbbrc.1993.1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojetin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span> <span> </span><span class="NLM_article-title">REV-ERB and ROR Nuclear Receptors as Drug Targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/nrd4100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd4100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24577401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt12hsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=197-216&author=D.+J.+Kojetinauthor=T.+P.+Burris&title=REV-ERB+and+ROR+Nuclear+Receptors+as+Drug+Targets&doi=10.1038%2Fnrd4100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">REV-ERB and ROR nuclear receptors as drug targets</span></div><div class="casAuthors">Kojetin, Douglas J.; Burris, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The nuclear receptors REV-ERB (consisting of REV-ERBα and REV-ERBβ) and retinoic acid receptor-related orphan receptors (RORs; consisting of RORα, RORβ and RORγ) are involved in many physiol. processes, including regulation of metab., development and immunity as well as the circadian rhythm.  The recent characterization of endogenous ligands for these former orphan nuclear receptors has stimulated the development of synthetic ligands and opened up the possibility of targeting these receptors to treat several diseases, including diabetes, atherosclerosis, autoimmunity and cancer.  This Review focuses on the latest developments in ROR and REV-ERB pharmacol. indicating that these nuclear receptors are druggable targets and that ligands targeting these receptors may be useful in the treatment of several disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorEsJo5WEbmrVg90H21EOLACvtfcHk0lgOJl1z97KfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt12hsL0%253D&md5=156f56d5766fec38440a3c0f2e9c753e</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnrd4100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4100%26sid%3Dliteratum%253Aachs%26aulast%3DKojetin%26aufirst%3DD.%2BJ.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26atitle%3DREV-ERB%2520and%2520ROR%2520Nuclear%2520Receptors%2520as%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D197%26epage%3D216%26doi%3D10.1038%2Fnrd4100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanichamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaire, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenot, J. D.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Mediated Inhibition of RORγ-Dependent Gene Expression and Autoimmune Disease Pathology <i>in Vivo</i></span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1111/imm.12570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fimm.12570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26694902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=399-413&author=D.+Banerjeeauthor=L.+Zhaoauthor=L.+Wuauthor=A.+Palanichamyauthor=A.+Ergunauthor=L.+Pengauthor=C.+Quigleyauthor=S.+Hamannauthor=R.+Dunstanauthor=P.+Cullenauthor=N.+Allaireauthor=K.+Guertinauthor=T.+Wangauthor=J.+Chaoauthor=C.+Lohauthor=J.+D.+Fontenot&title=Small+Molecule+Mediated+Inhibition+of+ROR%CE%B3-Dependent+Gene+Expression+and+Autoimmune+Disease+Pathology+in+Vivo&doi=10.1111%2Fimm.12570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule mediated inhibition of RORγ-dependent gene expression and autoimmune disease pathology in vivo</span></div><div class="casAuthors">Banerjee, Daliya; Zhao, Linlin; Wu, Lan; Palanichamy, Arumugam; Ergun, Ayla; Peng, Liaomin; Quigley, Catherine; Hamann, Stefan; Dunstan, Robert; Cullen, Patrick; Allaire, Norm; Guertin, Kevin; Wang, Tao; Chao, Jianhua; Loh, Christine; Fontenot, Jason D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">399-413</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Retinoic acid receptor-related orphan nuclear receptor γ (RORγ) orchestrates a pro-inflammatory gene expression program in multiple lymphocyte lineages including T helper type 17 (Th17) cells, γδ T cells, innate lymphoid cells and lymphoid tissue inducer cells.  There is compelling evidence that RORγ-expressing cells are relevant targets for therapeutic intervention in the treatment of autoimmune and inflammatory diseases.  Unlike Th17 cells, where RORγ expression is induced under specific pro-inflammatory conditions, γδ T cells and other innate-like immune cells express RORγ in the steady state.  Small mol. mediated disruption of RORγ function in cells with pre-existing RORγ transcriptional complexes represents a significant and challenging pharmacol. hurdle.  We present data demonstrating that a novel, selective and potent small mol. RORγ inhibitor can block the RORγ-dependent gene expression program in both Th17 cells and RORγ-expressing γδ T cells as well as a disease-relevant subset of human RORγ-expressing memory T cells.  Importantly, systemic administration of this inhibitor in vivo limits pathol. in an innate lymphocyte-driven mouse model of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTP37oyCKk3LVg90H21EOLACvtfcHk0lhoV82JafyMUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSqtLo%253D&md5=6b6bfc36bedde9417072422419d19195</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1111%2Fimm.12570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimm.12570%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPalanichamy%26aufirst%3DA.%26aulast%3DErgun%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DQuigley%26aufirst%3DC.%26aulast%3DHamann%26aufirst%3DS.%26aulast%3DDunstan%26aufirst%3DR.%26aulast%3DCullen%26aufirst%3DP.%26aulast%3DAllaire%26aufirst%3DN.%26aulast%3DGuertin%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DLoh%26aufirst%3DC.%26aulast%3DFontenot%26aufirst%3DJ.%2BD.%26atitle%3DSmall%2520Molecule%2520Mediated%2520Inhibition%2520of%2520ROR%25CE%25B3-Dependent%2520Gene%2520Expression%2520and%2520Autoimmune%2520Disease%2520Pathology%2520in%2520Vivo%26jtitle%3DImmunology%26date%3D2016%26volume%3D147%26spage%3D399%26epage%3D413%26doi%3D10.1111%2Fimm.12570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peredo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusq, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viviani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote-Sierra, J.</span></span> <span> </span><span class="NLM_article-title">Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147979</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0147979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26870941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlGltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147979&author=S.+H.+Smithauthor=C.+E.+Peredoauthor=Y.+Takedaauthor=T.+Buiauthor=J.+Neilauthor=D.+Rickardauthor=E.+Millermanauthor=J.+P.+Therrienauthor=E.+Nicodemeauthor=J.+M.+Brusqauthor=V.+Biraultauthor=F.+Vivianiauthor=H.+Hoflandauthor=A.+M.+Jettenauthor=J.+Cote-Sierra&title=Development+of+a+Topical+Treatment+for+Psoriasis+Targeting+ROR%CE%B3%3A+From+Bench+to+Skin&doi=10.1371%2Fjournal.pone.0147979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a topical treatment for psoriasis targeting RORγ: from bench to skin</span></div><div class="casAuthors">Smith, Susan H.; Peredo, Carlos E.; Takeda, Yukimasa; Bui, Thi; Neil, Jessica; Rickard, David; Millerman, Elizabeth; Therrien, Jean-Philippe; Nicodeme, Edwige; Brusq, Jean-Marie; Birault, Veronique; Viviani, Fabrice; Hofland, Hans; Jetten, Anton M.; Cote-Sierra, Javier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147979/1-e0147979/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Psoriasis is a chronic inflammatory skin disorder involving marked immunol. changes.  IL-17-targeting biologics have been successful in reducing the disease burden of psoriasis patients with moderate-to-severe disease.  Unfortunately, the stratum corneum prevents penetration of large mol. wt. proteins, including monoclonal antibodies.  Thus, for the majority of psoriasis patients ineligible for systemic treatments, a small mol. targeting RORγt, the master regulator of IL-17 family cytokines, may represent an alternative topical medicine with biol.-like efficacy.  Methods and Findings: The preclin. studies described in this manuscript bridge the gap from bench to bedside to provide the scientific foundation for a compd. entering clin. trials for patients with mild to moderate psoriasis.  In addn. to several ex vivo reporter assays, primary T cell cultures, and the imiquimod mouse model, we demonstrate efficacy in a newly developed human ex vivo skin assay, where Th17-skewed cytokine expression is induced from skin-resident immune cells.  Importantly, the skin barrier remains intact allowing for the demonstration of topical drug delivery.  With the development of this novel assay, we demonstrate potent compd. activity in the target tissue: human skin.  Finally, target engagement by this small mol. was confirmed in ex vivo lesional psoriatic skin.  Conclusions: Our work describes a progressive series of assays to demonstrate the potential clin. value of a novel RORγ inverse agonist small mol. with high potency and selectivity, which will enter clin. trials in late 2015 for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokk_sPVo8crbVg90H21EOLACvtfcHk0lhoV82JafyMUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlGltLs%253D&md5=75b3d12e090eab85b79fa55312798dd1</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147979%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BH.%26aulast%3DPeredo%26aufirst%3DC.%2BE.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DNeil%26aufirst%3DJ.%26aulast%3DRickard%26aufirst%3DD.%26aulast%3DMillerman%26aufirst%3DE.%26aulast%3DTherrien%26aufirst%3DJ.%2BP.%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DBrusq%26aufirst%3DJ.%2BM.%26aulast%3DBirault%26aufirst%3DV.%26aulast%3DViviani%26aufirst%3DF.%26aulast%3DHofland%26aufirst%3DH.%26aulast%3DJetten%26aufirst%3DA.%2BM.%26aulast%3DCote-Sierra%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520Topical%2520Treatment%2520for%2520Psoriasis%2520Targeting%2520ROR%25CE%25B3%253A%2520From%2520Bench%2520to%2520Skin%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147979%26doi%3D10.1371%2Fjournal.pone.0147979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelhälä, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palatsi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyhrquist, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtimäki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Väyrynen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasanen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiniche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume-Peytavi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauerma, A.</span></span> <span> </span><span class="NLM_article-title">IL-17/Th17 Pathway Is Activated in Acne Lesions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e105238</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0105238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0105238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25153527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cis7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e105238&author=H.+L.+Kelh%C3%A4l%C3%A4author=R.+Palatsiauthor=N.+Fyhrquistauthor=S.+Lehtim%C3%A4kiauthor=J.+P.+V%C3%A4yrynenauthor=M.+Kallioinenauthor=M.+E.+Kubinauthor=D.+Grecoauthor=K.+Tasanenauthor=H.+Aleniusauthor=B.+Bertinoauthor=I.+Carlavanauthor=B.+Mehulauthor=S.+D%C3%A9retauthor=P.+Reinicheauthor=P.+Martelauthor=C.+Martyauthor=U.+Blume-Peytaviauthor=J.+J.+Voegelauthor=A.+Lauerma&title=IL-17%2FTh17+Pathway+Is+Activated+in+Acne+Lesions&doi=10.1371%2Fjournal.pone.0105238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">IL-17/Th17 pathway is activated in acne lesions</span></div><div class="casAuthors">Kelhala, Hanna-Leena; Palatsi, Riitta; Fyhrquist, Nanna; Lehtimaki, Sari; Vayrynen, Juha P.; Kallioinen, Matti; Kubin, Minna E.; Greco, Dario; Tasanen, Kaisa; Alenius, Harri; Bertino, Beatrice; Carlavan, Isabelle; Mehul, Bruno; Deret, Sophie; Reiniche, Pascale; Martel, Philippe; Marty, Carine; Blume-Peytavi, Ulrike; Voegel, Johannes J.; Lauerma, Antti</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e105238/1-e105238/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The mechanisms of inflammation in acne are currently subject of intense investigation.  This study focused on the activation of adaptive and innate immunity in clin. early visible inflamed acne lesions and was performed in two independent patient populations.  Biopsies were collected from lesional and non-lesional skin of acne patients.  Using Affymetrix Genechips, we obsd. significant elevation of the signature cytokines of the Th17 lineage in acne lesions compared to non-lesional skin.  The increased expression of IL-17 was confirmed at the RNA and also protein level with real-time PCR (RT-PCR) and Luminex technol.  Cytokines involved in Th17 lineage differentiation (IL-1β, IL-6, TGF-β, IL23p19) were remarkably induced at the RNA level.  In addn., proinflammatory cytokines and chemokines (TNF-α, IL-8, CSF2 and CCL20), Th1 markers (IL12p40, CXCR3, T-bet, IFN-γ), T regulatory cell markers (Foxp3, IL-10, TGF-β) and IL-17 related antimicrobial peptides (S100A7, S100A9, lipocalin, hBD2, hBD3, hCAP18) were induced.  Importantly, immunohistochem. revealed significantly increased nos. of IL-17A pos. T cells and CD83 dendritic cells in the acne lesions.  In summary our results demonstrate the presence of IL-17A pos. T cells and the activation of Th17-related cytokines in acne lesions, indicating that the Th17 pathway is activated and may play a pivotal role in the disease process, possibly offering new targets of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHJzP1A-XDbVg90H21EOLACvtfcHk0lhoV82JafyMUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cis7zI&md5=cc9b01320f3ef3799b39e0d92286fbe1</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0105238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0105238%26sid%3Dliteratum%253Aachs%26aulast%3DKelh%25C3%25A4l%25C3%25A4%26aufirst%3DH.%2BL.%26aulast%3DPalatsi%26aufirst%3DR.%26aulast%3DFyhrquist%26aufirst%3DN.%26aulast%3DLehtim%25C3%25A4ki%26aufirst%3DS.%26aulast%3DV%25C3%25A4yrynen%26aufirst%3DJ.%2BP.%26aulast%3DKallioinen%26aufirst%3DM.%26aulast%3DKubin%26aufirst%3DM.%2BE.%26aulast%3DGreco%26aufirst%3DD.%26aulast%3DTasanen%26aufirst%3DK.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DBertino%26aufirst%3DB.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DMehul%26aufirst%3DB.%26aulast%3DD%25C3%25A9ret%26aufirst%3DS.%26aulast%3DReiniche%26aufirst%3DP.%26aulast%3DMartel%26aufirst%3DP.%26aulast%3DMarty%26aufirst%3DC.%26aulast%3DBlume-Peytavi%26aufirst%3DU.%26aulast%3DVoegel%26aufirst%3DJ.%2BJ.%26aulast%3DLauerma%26aufirst%3DA.%26atitle%3DIL-17%252FTh17%2520Pathway%2520Is%2520Activated%2520in%2520Acne%2520Lesions%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De105238%26doi%3D10.1371%2Fjournal.pone.0105238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokura, Y.</span></span> <span> </span><span class="NLM_article-title">Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2630</span>, <span class="refDoi"> DOI: 10.1038/jid.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fjid.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18432274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CmsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=2625-2630&author=C.+Kogaauthor=K.+Kabashimaauthor=N.+Shiraishiauthor=M.+Kobayashiauthor=Y.+Tokura&title=Possible+Pathogenic+Role+of+Th17+Cells+for+Atopic+Dermatitis&doi=10.1038%2Fjid.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis</span></div><div class="casAuthors">Koga, Chizuko; Kabashima, Kenji; Shiraishi, Noriko; Kobayashi, Miwa; Tokura, Yoshiki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2625-2630</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The crit. role of IL-17 has recently been reported in a variety of conditions.  Since IL-17 deeply participates in the pathogenesis of psoriasis and keratinocyte prodn. of certain cytokines, the involvement of T helper cell 17 (Th17) in atopic dermatitis (AD) is an issue to be elucidated.  To evaluate the participation of Th17 cells in AD, we successfully detected circulating lymphocytes intracellularly pos. for IL-17 by flow cytometry, and the IL-17+ cell population was found exclusively in CD3+CD4+ T cells.  The percentage of Th17 cells was increased in peripheral blood of AD patients and assocd. with severity of AD.  There was a significant correlation between the percentages of IL-17+ and IFN-γ+ cells, although percentage of Th17 cells was not closely related to Th1/Th2 balance.  Immunohistochem., IL-17+ cells infiltrated in the papillary dermis of atopic eczema more markedly in the acute than chronic lesions.  Finally, IL-17 stimulated keratinocytes to produce GM-CSF, TNF-α, IL-8, CXCL10, and VEGF.  A marked synergistic effect between IL-17 and IL-22 was obsd. on IL-8 prodn.  The no. of Th17 cells is increased in the peripheral blood and acute lesional skin of AD.  Th17 cells may exaggerate atopic eczema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnHI2BHEJfA7Vg90H21EOLACvtfcHk0liP1Z-FCJZtLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CmsLvN&md5=1bf269a34972029c1d496ddfcfbbe701</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fjid.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DC.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DTokura%26aufirst%3DY.%26atitle%3DPossible%2520Pathogenic%2520Role%2520of%2520Th17%2520Cells%2520for%2520Atopic%2520Dermatitis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D2625%26epage%3D2630%26doi%3D10.1038%2Fjid.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buddenkotte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiniche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M.</span></span> <span> </span><span class="NLM_article-title">Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2198</span>– <span class="NLM_lpage">2208</span>, <span class="refDoi"> DOI: 10.1038/jid.2015.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fjid.2015.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25848978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCisr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=2198-2208&author=T.+Buhlauthor=M.+Sulkauthor=P.+Nowakauthor=J.+Buddenkotteauthor=I.+McDonaldauthor=J.+Aubertauthor=I.+Carlavanauthor=S.+D%C3%A9retauthor=P.+Reinicheauthor=M.+Rivierauthor=J.+J.+Voegelauthor=M.+Steinhoff&title=Molecular+and+Morphological+Characterization+of+Inflammatory+Infiltrate+in+Rosacea+Reveals+Activation+of+Th1%2FTh17+Pathways&doi=10.1038%2Fjid.2015.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways</span></div><div class="casAuthors">Buhl, Timo; Sulk, Mathias; Nowak, Pawel; Buddenkotte, Joerg; McDonald, Ian; Aubert, Jerome; Carlavan, Isabelle; Deret, Sophie; Reiniche, Pascale; Rivier, Michel; Voegel, Johannes J.; Steinhoff, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rosacea is a common chronic inflammatory skin disease of unknown etiol.  Our knowledge about an involvement of the adaptive immune system is very limited.  We performed detailed transcriptome anal., quant. real-time reverse-transcriptase-PCR, and quant. immunohistochem. on facial biopsies of rosacea patients, classified according to their clin. subtype.  As controls, we used samples from patients with facial lupus erythematosus and healthy controls.  Our study shows significant activation of the immune system in all subtypes of rosacea, characterizing erythematotelangiectatic rosacea (ETR) already as a disease with significant influx of proinflammatory cells.  The T-cell response is dominated by Th1/Th17-polarized immune cells, as demonstrated by significant upregulation of IFN-γ or IL-17, for example.  Chemokine expression patterns support a Th1/Th17 polarization profile of the T-cell response.  Macrophages and mast cells are increased in all three subtypes of rosacea, whereas neutrophils reach a max. in papulopustular rosacea.  Our studies also provide evidence for the activation of plasma cells with significant antibody prodn. already in ETR, followed by a crescendo pattern toward phymatous rosacea.  In sum, Th1/Th17 polarized inflammation and macrophage infiltration are an underestimated hallmark in all subtypes of rosacea.  Therapies directly targeting the Th1/Th17 pathway are promising candidates in the future treatment of this skin disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47r88Vhv6krVg90H21EOLACvtfcHk0liP1Z-FCJZtLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCisr%252FP&md5=cbcec2f1cdf74a6e0623e02f9c1801c6</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fjid.2015.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2015.141%26sid%3Dliteratum%253Aachs%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DSulk%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DBuddenkotte%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DI.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DD%25C3%25A9ret%26aufirst%3DS.%26aulast%3DReiniche%26aufirst%3DP.%26aulast%3DRivier%26aufirst%3DM.%26aulast%3DVoegel%26aufirst%3DJ.%2BJ.%26aulast%3DSteinhoff%26aufirst%3DM.%26atitle%3DMolecular%2520and%2520Morphological%2520Characterization%2520of%2520Inflammatory%2520Infiltrate%2520in%2520Rosacea%2520Reveals%2520Activation%2520of%2520Th1%252FTh17%2520Pathways%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2015%26volume%3D135%26spage%3D2198%26epage%3D2208%26doi%3D10.1038%2Fjid.2015.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragoulis, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051914-021944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-med-051914-021944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26565676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCqs7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=337-353&author=G.+E.+Fragoulisauthor=S.+Siebertauthor=I.+B.+McInnes&title=Therapeutic+Targeting+of+IL-17+and+IL-23+Cytokines+in+Immune-Mediated+Diseases&doi=10.1146%2Fannurev-med-051914-021944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases</span></div><div class="casAuthors">Fragoulis, George E.; Siebert, Stefan; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">337-353</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">The discovery of the biol. functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases.  Therapeutic agents targeting these cytokines and/or their receptors have now been developed as potential treatment strategies for common immune-mediated diseases.  Anti-IL-17 and anti-IL-12/-23 regimens appear particularly effective in psoriasis, with promising results in spondyloarthropathies also emerging.  Overall, these agents appear well tolerated, with adverse-event rates that are commensurate with those in other biol. treatment programs.  The strategic utility of these new agents, however, remains uncertain, and further studies will be required to det. their place in the context of existing conventional and biol. immune-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5-1bRDtJLJrVg90H21EOLACvtfcHk0liP1Z-FCJZtLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCqs7nN&md5=20a4ead75c89e2e808f55988cb7be7a6</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051914-021944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051914-021944%26sid%3Dliteratum%253Aachs%26aulast%3DFragoulis%26aufirst%3DG.%2BE.%26aulast%3DSiebert%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DTherapeutic%2520Targeting%2520of%2520IL-17%2520and%2520IL-23%2520Cytokines%2520in%2520Immune-Mediated%2520Diseases%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2016%26volume%3D67%26spage%3D337%26epage%3D353%26doi%3D10.1146%2Fannurev-med-051914-021944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span>Identifier:
NCT03004846. <a href="https://clinicaltrials.gov/ct2/show/NCT03004846" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03004846</a> (Accessed Oct
19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03004846.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03004846+%28Accessed+Oct%0A19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrux-Tallau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defoin-Platel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forissier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacini-Rachinel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluchon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatinel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29327456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1aksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=321-337&author=G.+Ouvryauthor=N.+Atrux-Tallauauthor=F.+Bihlauthor=A.+Bonduauthor=C.+Bouix-Peterauthor=I.+Carlavanauthor=O.+Christinauthor=M.+J.+Cuadradoauthor=C.+Defoin-Platelauthor=S.+Deretauthor=D.+Duvertauthor=C.+Feretauthor=M.+Forissierauthor=J.+F.+Fournierauthor=D.+Froudeauthor=F.+Hacini-Rachinelauthor=C.+S.+Harrisauthor=C.+Hervouetauthor=H.+Huguetauthor=G.+Lafitteauthor=A.+P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=B.+Ozelloauthor=C.+Pascauauthor=J.+Pascauauthor=V.+Parnetauthor=G.+Peluchonauthor=R.+Pierreauthor=D.+Piwnicaauthor=C.+Raffinauthor=P.+Rossioauthor=D.+Spiesseauthor=N.+Taquetauthor=E.+Thoreauauthor=R.+Vatinelauthor=E.+Vialauthor=L.+F.+Hennequin&title=Discovery+and+Characterization+of+CD12681%2C+a+Potent+ROR%CE%B3+Inverse+Agonist%2C+Preclinical+Candidate+for+the+Topical+Treatment+of+Psoriasis&doi=10.1002%2Fcmdc.201700758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis</span></div><div class="casAuthors">Ouvry, Gilles; Atrux-Tallau, Nicolas; Bihl, Franck; Bondu, Aline; Bouix-Peter, Claire; Carlavan, Isabelle; Christin, Olivier; Cuadrado, Marie-Josee; Defoin-Platel, Claire; Deret, Sophie; Duvert, Denis; Feret, Christophe; Forissier, Mathieu; Fournier, Jean-Francois; Froude, David; Hacini-Rachinel, Feriel; Harris, Craig Steven; Hervouet, Catherine; Huguet, Helene; Lafitte, Guillaume; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Ozello, Benjamin; Pascau, Coralie; Pascau, Jonathan; Parnet, Veronique; Peluchon, Guillaume; Pierre, Romain; Piwnica, David; Raffin, Catherine; Rossio, Patricia; Spiesse, Delphine; Taquet, Nathalie; Thoreau, Etienne; Vatinel, Rodolphe; Vial, Emmanuel; Hennequin, Laurent Francois</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-337</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a sought-after target in the pharmaceutical industry.  Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases.  These efforts culminated in the discovery of N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-[(tetrahydro-2H-pyran-4-yl)methyl]-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide (CD12681), a potent inverse agonist with in vivo activity in an IL-23-induced mouse skin inflammation model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4rMWerixL7Vg90H21EOLACvtfcHk0lhuZvuFs7eQeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1aksL4%253D&md5=443fc01d790536a34918f1b33f8fdba2</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700758%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DAtrux-Tallau%26aufirst%3DN.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBondu%26aufirst%3DA.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DCuadrado%26aufirst%3DM.%2BJ.%26aulast%3DDefoin-Platel%26aufirst%3DC.%26aulast%3DDeret%26aufirst%3DS.%26aulast%3DDuvert%26aufirst%3DD.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DForissier%26aufirst%3DM.%26aulast%3DFournier%26aufirst%3DJ.%2BF.%26aulast%3DFroude%26aufirst%3DD.%26aulast%3DHacini-Rachinel%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHervouet%26aufirst%3DC.%26aulast%3DHuguet%26aufirst%3DH.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DLuzy%26aufirst%3DA.%2BP.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DOzello%26aufirst%3DB.%26aulast%3DPascau%26aufirst%3DC.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPeluchon%26aufirst%3DG.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DPiwnica%26aufirst%3DD.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRossio%26aufirst%3DP.%26aulast%3DSpiesse%26aufirst%3DD.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DVatinel%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520CD12681%252C%2520a%2520Potent%2520ROR%25CE%25B3%2520Inverse%2520Agonist%252C%2520Preclinical%2520Candidate%2520for%2520the%2520Topical%2520Treatment%2520of%2520Psoriasis%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D321%26epage%3D337%26doi%3D10.1002%2Fcmdc.201700758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantalat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rival, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phenoxyindazoles and Phenylthioindazoles as RORγ Inverse Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5802</span>– <span class="NLM_lpage">5808</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2016.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27815118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslynsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5802-5808&author=G.+Ouvryauthor=C.+Bouix-Peterauthor=F.+Ciesielskiauthor=L.+Chantalatauthor=O.+Christinauthor=C.+Cominoauthor=D.+Duvertauthor=C.+Feretauthor=C.+S.+Harrisauthor=L.+Lamyauthor=A.-P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=J.+Pascauauthor=V.+Parnetauthor=A.+Perrinauthor=R.+Pierreauthor=G.+Polgeauthor=C.+Raffinauthor=Y.+Rivalauthor=N.+Taquetauthor=E.+Thoreauauthor=L.+F.+Hennequin&title=Discovery+of+Phenoxyindazoles+and+Phenylthioindazoles+as+ROR%CE%B3+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2016.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists</span></div><div class="casAuthors">Ouvry, Gilles; Bouix-Peter, Claire; Ciesielski, Fabrice; Chantalat, Laurent; Christin, Olivier; Comino, Catherine; Duvert, Denis; Feret, Christophe; Harris, Craig S.; Lamy, Laurent; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Pascau, Jonathan; Parnet, Veronique; Perrin, Agnes; Pierre, Romain; Polge, Gaelle; Raffin, Catherine; Rival, Yves; Taquet, Nathalie; Thoreau, Etienne; Hennequin, Laurent F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5802-5808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the IL17 pathway and more specifically the nuclear receptor RORγ is thought to be beneficial in multiple skin disorders.  The Letter describes the discovery of phenoxyindazoles and thiophenoxy indazoles as potent RORγ inverse agonists.  Optimization of the potency and efforts to mitigate the phototoxic liability of the series are presented.  Finally, crystn. of the lead compd. revealed that the series bound to an allosteric site of the nuclear receptor.  Such compds. could be useful as tool compds. for understanding the impact of topical treatment on skin disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX7Dguvi_h8LVg90H21EOLACvtfcHk0lhuZvuFs7eQeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslynsr%252FM&md5=cd3aa2c246cfa35c98306096d823dccc</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DChantalat%26aufirst%3DL.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DComino%26aufirst%3DC.%26aulast%3DDuvert%26aufirst%3DD.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DLuzy%26aufirst%3DA.-P.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPerrin%26aufirst%3DA.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DPolge%26aufirst%3DG.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRival%26aufirst%3DY.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520of%2520Phenoxyindazoles%2520and%2520Phenylthioindazoles%2520as%2520ROR%25CE%25B3%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5802%26epage%3D5808%26doi%3D10.1016%2Fj.bmcl.2016.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+Drug+Design%3A+An+Update+on+Recent+Applications+of+Efficiency+Metrics%2C+Strategies+for+Replacing+Problematic+Elements%2C+and+Compounds+in+Nontraditional+Drug+Space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0liPUJABTzozvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Design%253A%2520An%2520Update%2520on%2520Recent%2520Applications%2520of%2520Efficiency%2520Metrics%252C%2520Strategies%2520for%2520Replacing%2520Problematic%2520Elements%252C%2520and%2520Compounds%2520in%2520Nontraditional%2520Drug%2520Space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defoin-Platel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacini-Rachinel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatinel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as Potent RORγ Inverse Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29571573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Omuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1269-1273&author=G.+Ouvryauthor=F.+Bihlauthor=C.+Bouix-Peterauthor=O.+Christinauthor=C.+Defoin-Platelauthor=S.+Deretauthor=C.+Feretauthor=D.+Froudeauthor=F.+Hacini-Rachinelauthor=C.+S.+Harrisauthor=C.+Hervouetauthor=G.+Lafitteauthor=A.-P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=V.+Parnetauthor=C.+Pascauauthor=J.+Pascauauthor=R.+Pierreauthor=C.+Raffinauthor=P.+Rossioauthor=D.+Spiesseauthor=N.+Taquetauthor=E.+Thoreauauthor=R.+Vatinelauthor=E.+Vialauthor=L.+F.+Hennequin&title=Sulfoximines+as+Potent+ROR%CE%B3+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as potent RORγ inverse agonists</span></div><div class="casAuthors">Ouvry, Gilles; Bihl, Franck; Bouix-Peter, Claire; Christin, Olivier; Defoin-Platel, Claire; Deret, Sophie; Feret, Christophe; Froude, David; Hacini-Rachinel, Feriel; Harris, Craig S.; Hervouet, Catherine; Lafitte, Guillaume; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Parnet, Veronique; Pascau, Coralie; Pascau, Jonathan; Pierre, Romain; Raffin, Catherine; Rossio, Patricia; Spiesse, Delphine; Taquet, Nathalie; Thoreau, Etienne; Vatinel, Rodolphe; Vial, Emmanuel; Hennequin, Laurent F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1269-1273</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Progress in the identification of suitable RORγ inverse agonists as clin. candidates has been hampered by the high lipophilicity that seems required for high potency on this nuclear receptor.  In this context, the authors decided to focus on the replacement of the hydroxymethyl group found on known modulators to det. if more polarity could be tolerated in this position.  SAR of the replacement of this moiety is presented in this article leading to the identification of sulfoximine derivs. as potent modulators with pharmacol. activity in the in vivo mouse Imiquimod psoriasis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAQSWLdHKhVbVg90H21EOLACvtfcHk0liPUJABTzozvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Omuro%253D&md5=864629214d833da2bd6cb3e7bdf98f5c</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DDefoin-Platel%26aufirst%3DC.%26aulast%3DDeret%26aufirst%3DS.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DFroude%26aufirst%3DD.%26aulast%3DHacini-Rachinel%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHervouet%26aufirst%3DC.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DLuzy%26aufirst%3DA.-P.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPascau%26aufirst%3DC.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRossio%26aufirst%3DP.%26aulast%3DSpiesse%26aufirst%3DD.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DVatinel%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DSulfoximines%2520as%2520Potent%2520ROR%25CE%25B3%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1269%26epage%3D1273%26doi%3D10.1016%2Fj.bmcl.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, K.</span>; <span class="NLM_string-name">Kanai, T.</span>; <span class="NLM_string-name">Homma, M.</span>; <span class="NLM_string-name">Aratake, S.</span>; <span class="NLM_string-name">Ishimori, T.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-Containing Heterocyclic Compound</span>. <span class="NLM_patent">WO/2014/084330, US/2015/0299214</span>, Jun 5, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Uchida&author=T.+Kanai&author=M.+Homma&author=S.+Aratake&author=T.+Ishimori&title=Nitrogen-Containing+Heterocyclic+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DK.%26atitle%3DNitrogen-Containing%2520Heterocyclic%2520Compound%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span> <span> </span><span class="NLM_article-title">Atopic Dermatitis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)00149-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2815%2900149-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26377142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1109-1122&author=S.+Weidingerauthor=N.+Novak&title=Atopic+Dermatitis&doi=10.1016%2FS0140-6736%2815%2900149-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Novak Natalija</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10023</span>),
    <span class="NLM_cas:pages">1109-1122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (also known as atopic eczema) is a chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions.  Although it most often starts in infancy and affects two of ten children, it is also highly prevalent in adults.  It is the leading non-fatal health burden attributable to skin diseases, inflicts a substantial psychosocial burden on patients and their relatives, and increases the risk of food allergy, asthma, allergic rhinitis, other immune-mediated inflammatory diseases, and mental health disorders.  Originally regarded as a childhood disorder mediated by an imbalance towards a T-helper-2 response and exaggerated IgE responses to allergens, it is now recognised as a lifelong disposition with variable clinical manifestations and expressivity, in which defects of the epidermal barrier are central.  Present prevention and treatment focus on restoration of epidermal barrier function, which is best achieved through the use of emollients.  Topical corticosteroids are still the first-line therapy for acute flares, but they are also used proactively along with topical calcineurin inhibitors to maintain remission.  Non-specific immunosuppressive drugs are used in severe refractory cases, but targeted disease-modifying drugs are being developed.  We need to improve understanding of the heterogeneity of the disease and its subtypes, the role of atopy and autoimmunity, the mechanisms behind disease-associated itch, and the comparative effectiveness and safety of therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09MrRqEXsZufAfW6udTcc2ebT65F5UPQnNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D&md5=02bc2d67207d07d0a6b24f1da996792e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900149-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900149-X%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DNovak%26aufirst%3DN.%26atitle%3DAtopic%2520Dermatitis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1109%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2815%2900149-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, J.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Epidemiology of Childhood Atopic Dermatitis</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1111/all.12270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fall.12270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24417229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2czks1SksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=3-16&author=C.+Flohrauthor=J.+Mann&title=New+Insights+into+the+Epidemiology+of+Childhood+Atopic+Dermatitis&doi=10.1111%2Fall.12270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the epidemiology of childhood atopic dermatitis</span></div><div class="casAuthors">Flohr C; Mann J</div><div class="citationInfo"><span class="NLM_cas:title">Allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a growing desire to explain the worldwide rise in the prevalence of atopic dermatitis (AD).  Trend data on the burden of AD suggest that the picture in the developing world may soon resemble that of wealthier nations, where AD affects over 20% of children.  This, combined with significant variations in prevalence within countries, emphasizes the importance of environmental factors.  Many hypotheses have been explored, from the modulation of immune priming by hygiene, gut microbiota diversity, and exposure to endotoxins through farm animals to the effects of pollution, climate, and diet.  The discovery of the filaggrin skin barrier gene and its importance in AD development and severity has brought the focus on gene-environment interactions and the identification of environmental factors that impact on skin barrier function.  This article reviews our current understanding of the epidemiology of AD, with an emphasis on the findings reported in the international literature over the last 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxkL83eADJYAwxfk_AGB-EfW6udTcc2eY5YJMPH_BTobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czks1SksA%253D%253D&md5=1648100b10d36952cd47bc4ef05ad6b3</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1111%2Fall.12270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.12270%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DC.%26aulast%3DMann%26aufirst%3DJ.%26atitle%3DNew%2520Insights%2520into%2520the%2520Epidemiology%2520of%2520Childhood%2520Atopic%2520Dermatitis%26jtitle%3DAllergy%26date%3D2014%26volume%3D69%26spage%3D3%26epage%3D16%26doi%3D10.1111%2Fall.12270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauerma, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marxhausen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgwick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnik, A.</span></span> <span> </span><span class="NLM_article-title">CCL27-CCR10 Interactions Regulate T Cell-Mediated Skin Inflammation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1038/nm0202-157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnm0202-157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11821900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1equ7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=157-165&author=B.+Homeyauthor=H.+Aleniusauthor=A.+M%C3%BCllerauthor=H.+Sotoauthor=E.+P.+Bowmanauthor=W.+Yuanauthor=L.+McEvoyauthor=A.+I.+Lauermaauthor=T.+Assmannauthor=E.+B%C3%BCnemannauthor=M.+Lehtoauthor=H.+Wolffauthor=D.+Yenauthor=H.+Marxhausenauthor=W.+Toauthor=J.+Sedgwickauthor=T.+Ruzickaauthor=P.+Lehmannauthor=A.+Zlotnik&title=CCL27-CCR10+Interactions+Regulate+T+Cell-Mediated+Skin+Inflammation&doi=10.1038%2Fnm0202-157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">CCL27-CCR10 interactions regulate T cell-mediated skin inflammation</span></div><div class="casAuthors">Homey, Bernhard; Alenius, Harri; Mueller, Anja; Soto, Hortensia; Bowman, Edward P.; Yuan, Wei; McEvoy, Leslie; Lauerma, Antti I.; Assmann, Till; Buenemann, Erich; Lehto, Maili; Wolff, Henrik; Yen, David; Marxhausen, Heather; To, Wayne; Sedgwick, Jonathon; Ruzicka, Thomas; Lehmann, Percy; Zlotnik, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The skin-assocd. chemokine CCL27 (also called CTACK, ALP and ESkine) and its receptor CCR10 (GPR-2) mediate chemotactic responses of skin-homing T cells in vitro.  Here the authors report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10.  Epidermal basal keratinocytes produced CCL27 protein that bound to extracellular matrix, mediated adhesion and was displayed on the surface of dermal endothelial cells.  Tumor necrosis factor-α and interleukin-1β induced CCL27 prodn. whereas the glucocorticosteroid clobetasol propionate suppressed it.  Circulating skin-homing CLA+ T cells, dermal microvascular endothelial cells and fibroblasts expressed CCR10 on their cell surface.  In vivo, intracutaneous CCL27 injection attracted lymphocytes and, conversely, neutralization of CCL27-CCR10 interactions impaired lymphocyte recruitment to the skin leading to the suppression of allergen-induced skin inflammation.  Together, these findings indicate that CCL27-CCR10 interactions have a pivotal role in T cell-mediated skin inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocxf9h8u-iMbVg90H21EOLACvtfcHk0ljnl07GnkpcZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1equ7w%253D&md5=46f0f0377221426254f67dc239b87a05</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fnm0202-157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0202-157%26sid%3Dliteratum%253Aachs%26aulast%3DHomey%26aufirst%3DB.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DBowman%26aufirst%3DE.%2BP.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DLauerma%26aufirst%3DA.%2BI.%26aulast%3DAssmann%26aufirst%3DT.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DE.%26aulast%3DLehto%26aufirst%3DM.%26aulast%3DWolff%26aufirst%3DH.%26aulast%3DYen%26aufirst%3DD.%26aulast%3DMarxhausen%26aufirst%3DH.%26aulast%3DTo%26aufirst%3DW.%26aulast%3DSedgwick%26aufirst%3DJ.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DP.%26aulast%3DZlotnik%26aufirst%3DA.%26atitle%3DCCL27-CCR10%2520Interactions%2520Regulate%2520T%2520Cell-Mediated%2520Skin%2520Inflammation%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D157%26epage%3D165%26doi%3D10.1038%2Fnm0202-157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganzetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliodori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stramazzotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morichetti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, A.</span></span> <span> </span><span class="NLM_article-title">CTACK /CCL27 Expression in Psoriatic Skin and Its Modification after Administration of Etanercept</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2007.08200.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1365-2133.2007.08200.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17916208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2007&pages=1155-1160&author=A.+Campanatiauthor=G.+Goteriauthor=O.+Simonettiauthor=G.+Ganzettiauthor=K.+Giuliodoriauthor=D.+Stramazzottiauthor=D.+Morichettiauthor=M.+L.+Bernardiniauthor=B.+Mannelloauthor=G.+Fabrisauthor=A.+Offidani&title=CTACK+%2FCCL27+Expression+in+Psoriatic+Skin+and+Its+Modification+after+Administration+of+Etanercept&doi=10.1111%2Fj.1365-2133.2007.08200.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept</span></div><div class="casAuthors">Campanati, A.; Goteri, G.; Simonetti, O.; Ganzetti, G.; Giuliodori, K.; Stramazzotti, D.; Morichetti, D.; Bernardini, M. L.; Mannello, B.; Fabris, G.; Offidani, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1155-1160</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor necrosis factor-α upregulates the expression of a cutaneous T cell-attracting chemokine (CTACK/CCL27), that promotes migration of cutaneous lymphocyte-assocd. antigen-pos. lymphocytes into the skin.  The role of CTACK/CCL27 in pathogenesis of psoriasis has recently been documented but no data are available at the present time on its modification in psoriatic cutaneous tissue after administration of etanercept.  Objectives: To evaluate modifications of CTACK/CCL27 expression in skin of patients with psoriasis after administration of etanercept and their relation with disease activity.  Methods: Twenty-two patients with moderate to severe psoriasis underwent clin., histol. and immunohistochem. evaluations of disease activity at baseline and at 12 and 24 wk after starting treatment with etanercept.  Results: All selected patients experienced an improvement of Psoriasis Area and Severity Index (PASI) score (P < 0.001) and Dermatol. Life Quality Index score (P < 0.001) during the treatment.  Skin histol. abnormalities showed statistically significant modifications during treatment (P < 0.001).  Immunohistochem. expression of CTACK/CCL27 decreased significantly (P < 0.001) and its relation with final PASI score was statistically significant (P < 0.05); the pattern of distribution of CTACK/CCL27 immunoreactivity significantly moved from diffuse and predominantly suprabasal to basal (P < 0.001) and the restoration of basal distribution of CTACK/CCL27 was also significantly related to clin. improvement of cutaneous disease (P < 0.001).  Conclusions: Etanercept induces a clin. and histol. improvement of psoriatic disease, promoting a redn. in CTACK/CCL27 cutaneous immunostaining and favoring the restoration of physiol. CTACK/CCL27 epidermal expression.  Moreover, CTACK/CCL27 redn. in cutaneous expression during administration of etanercept could be considered a favorable prognostic marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTvorlITcahLVg90H21EOLACvtfcHk0ljnl07GnkpcZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFakug%253D%253D&md5=5eb2c7b0bd377d64a86d7ba031badee8</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2007.08200.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2007.08200.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampanati%26aufirst%3DA.%26aulast%3DGoteri%26aufirst%3DG.%26aulast%3DSimonetti%26aufirst%3DO.%26aulast%3DGanzetti%26aufirst%3DG.%26aulast%3DGiuliodori%26aufirst%3DK.%26aulast%3DStramazzotti%26aufirst%3DD.%26aulast%3DMorichetti%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%2BL.%26aulast%3DMannello%26aufirst%3DB.%26aulast%3DFabris%26aufirst%3DG.%26aulast%3DOffidani%26aufirst%3DA.%26atitle%3DCTACK%2520%252FCCL27%2520Expression%2520in%2520Psoriatic%2520Skin%2520and%2520Its%2520Modification%2520after%2520Administration%2520of%2520Etanercept%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2007%26volume%3D157%26spage%3D1155%26epage%3D1160%26doi%3D10.1111%2Fj.1365-2133.2007.08200.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hijnen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin-Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel-Koomen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knol, E.</span></span> <span> </span><span class="NLM_article-title">Serum Thymus and Activation-Regulated Chemokine (TARC) and Cutaneous T Cell- Attracting Chemokine (CTACK) Levels in Allergic Diseases: TARC and CTACK Are Disease-Specific Markers for Atopic Dermatitis</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2003.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2003.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14767451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtV2gu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=334-340&author=D.+Hijnenauthor=M.+De+Bruin-Wellerauthor=B.+Oostingauthor=C.+Lebreauthor=E.+De+Jongauthor=C.+Bruijnzeel-Koomenauthor=E.+Knol&title=Serum+Thymus+and+Activation-Regulated+Chemokine+%28TARC%29+and+Cutaneous+T+Cell-+Attracting+Chemokine+%28CTACK%29+Levels+in+Allergic+Diseases%3A+TARC+and+CTACK+Are+Disease-Specific+Markers+for+Atopic+Dermatitis&doi=10.1016%2Fj.jaci.2003.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis</span></div><div class="casAuthors">Hijnen, DirkJan; De Bruin-Weller, Marjolein; Oosting, Bert; Lebre, Cristina; De Jong, Esther; Bruijnzeel-Koomen, Carla; Knol, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">334-340</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tissue infiltration of CD4+ T cells plays an important role in the pathogenesis of allergic diseases.  T-cell trafficking is mediated by specific chemokines and their receptors.  The purpose of this study was to investigate the participation of the chemokines thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) in a large population of patients with allergic diseases.  Serum TARC and CTACK levels were measured in 455 patients with allergic disease.  Patients were characterized as having atopic dermatitis (AD), allergic asthma, allergic rhinitis, or combinations or as healthy control subjects.  Serum TARC and CTACK levels were correlated with disease activity in patients with AD.  Furthermore, in 7 patients with AD, serum TARC and CTACK levels were studied after the start of systemic cyclosporin A treatment.  Finally, TARC and CTACK localization was checked by immunohistochem. in lesional skin biopsy specimens of patients with AD.  Both TARC and CTACK serum levels in patients with AD were significantly higher than those in healthy control subjects and patients with allergic respiratory disease.  Furthermore, serum TARC and CTACK levels significantly correlated with disease activity in patients with AD.  Serum TARC levels paralleled clin. improvement in patients treated with cyclosporin A.  Immunoreactive TARC was found in infiltrating cells and endothelial cells of the dermis but not in epidermal cells.  The serum TARC level is an objective parameter for disease severity specific for AD.  Furthermore, it is a promising tool for treatment monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodafTPjYQjJLVg90H21EOLACvtfcHk0lgc-qLc_Fjt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtV2gu7w%253D&md5=22f31941ce73e1d690841546353e3745</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2003.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2003.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DHijnen%26aufirst%3DD.%26aulast%3DDe%2BBruin-Weller%26aufirst%3DM.%26aulast%3DOosting%26aufirst%3DB.%26aulast%3DLebre%26aufirst%3DC.%26aulast%3DDe%2BJong%26aufirst%3DE.%26aulast%3DBruijnzeel-Koomen%26aufirst%3DC.%26aulast%3DKnol%26aufirst%3DE.%26atitle%3DSerum%2520Thymus%2520and%2520Activation-Regulated%2520Chemokine%2520%2528TARC%2529%2520and%2520Cutaneous%2520T%2520Cell-%2520Attracting%2520Chemokine%2520%2528CTACK%2529%2520Levels%2520in%2520Allergic%2520Diseases%253A%2520TARC%2520and%2520CTACK%2520Are%2520Disease-Specific%2520Markers%2520for%2520Atopic%2520Dermatitis%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2004%26volume%3D113%26spage%3D334%26epage%3D340%26doi%3D10.1016%2Fj.jaci.2003.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group">World Health Organization</span>, Global
Surveillance, Prevention and Control of Chronic Respiratory Diseases:
A Comprehensive Approach. <a href="https://www.who.int/gard/publications/GARD_Manual/en/" class="extLink">https://www.who.int/gard/publications/GARD_Manual/en/</a> (Accessed Feb 12, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization%2C+Global%0ASurveillance%2C+Prevention+and+Control+of+Chronic+Respiratory+Diseases%3A%0AA+Comprehensive+Approach.+https%3A%2F%2Fwww.who.int%2Fgard%2Fpublications%2FGARD_Manual%2Fen%2F+%28Accessed+Feb+12%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Small, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span> <span> </span><span class="NLM_article-title">Allergic Rhinitis</span>. <i>Allergy, Asthma, Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s13223-018-0280-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2Fs13223-018-0280-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30263033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3czjsFGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=51&author=P.+Smallauthor=P.+K.+Keithauthor=H.+Kim&title=Allergic+Rhinitis&doi=10.1186%2Fs13223-018-0280-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Allergic rhinitis</span></div><div class="casAuthors">Small Peter; Keith Paul K; Kim Harold; Kim Harold</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">Suppl 2</span>),
    <span class="NLM_cas:pages">51</span>
        ISSN:<span class="NLM_cas:issn">1710-1484</span>.
    </div><div class="casAbstract">Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis.  It is usually a long-standing condition that often goes undetected in the primary-care setting.  The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing.  A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis.  Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment.  Allergen immunotherapy is an effective immune-modulating treatment that should be recommended if pharmacologic therapy for allergic rhinitis is not effective or is not tolerated, or if chosen by the patient.  This article provides an overview of the pathophysiology, diagnosis, and appropriate management of this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxSes_xqSl_f9pSBfyDvp7fW6udTcc2eZK2eKK05MENbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjsFGgtg%253D%253D&md5=9f153fdd7b19d8952997a3c5e4172a58</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1186%2Fs13223-018-0280-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13223-018-0280-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmall%26aufirst%3DP.%26aulast%3DKeith%26aufirst%3DP.%2BK.%26aulast%3DKim%26aufirst%3DH.%26atitle%3DAllergic%2520Rhinitis%26jtitle%3DAllergy%252C%2520Asthma%252C%2520Clin.%2520Immunol.%26date%3D2018%26volume%3D14%26spage%3D51%26doi%3D10.1186%2Fs13223-018-0280-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span> <span> </span><span class="NLM_article-title">Atopic Dermatitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1056/NEJMra074081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMra074081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18385500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1483-1494&author=T.+Bieber&title=Atopic+Dermatitis&doi=10.1056%2FNEJMra074081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic Dermatitis</span></div><div class="casAuthors">Bieber, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1483-1494</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the epidemiol.,genetics,immunol. mechanisms, clin. implications of atopic dermatitis.  A unifying hypothesis of pathogenesis of atopic dermatitis and its clin. implications were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhSHBOPLfgALVg90H21EOLACvtfcHk0lgc-qLc_Fjt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlSgt7c%253D&md5=9231248a8e723c81eb8f9fdcab103604</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1056%2FNEJMra074081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra074081%26sid%3Dliteratum%253Aachs%26aulast%3DBieber%26aufirst%3DT.%26atitle%3DAtopic%2520Dermatitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1483%26epage%3D1494%26doi%3D10.1056%2FNEJMra074081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochner, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardlaw, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwasser, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roufosse, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleich, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klion, A. D.</span></span> <span> </span><span class="NLM_article-title">Refining the Definition of Hypereosinophilic Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2010.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20639008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3cnotVersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=45-49&author=H.-U.+Simonauthor=M.+E.+Rothenbergauthor=B.+S.+Bochnerauthor=P.+F.+Wellerauthor=A.+J.+Wardlawauthor=M.+E.+Wechslerauthor=L.+J.+Rosenwasserauthor=F.+Roufosseauthor=G.+J.+Gleichauthor=A.+D.+Klion&title=Refining+the+Definition+of+Hypereosinophilic+Syndrome&doi=10.1016%2Fj.jaci.2010.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the definition of hypereosinophilic syndrome</span></div><div class="casAuthors">Simon Hans-Uwe; Rothenberg Marc E; Bochner Bruce S; Weller Peter F; Wardlaw Andrew J; Wechsler Michael E; Rosenwasser Lanny J; Roufosse Florence; Gleich Gerald J; Klion Amy D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic.  Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders.  Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs.  Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBJQRUM96xKUBuFdjgVNKSfW6udTcc2ea50NFNZckoo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnotVersg%253D%253D&md5=ac5a99fa15bfeb23a2f5d7c87a520822</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DH.-U.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DBochner%26aufirst%3DB.%2BS.%26aulast%3DWeller%26aufirst%3DP.%2BF.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26aulast%3DWechsler%26aufirst%3DM.%2BE.%26aulast%3DRosenwasser%26aufirst%3DL.%2BJ.%26aulast%3DRoufosse%26aufirst%3DF.%26aulast%3DGleich%26aufirst%3DG.%2BJ.%26aulast%3DKlion%26aufirst%3DA.%2BD.%26atitle%3DRefining%2520the%2520Definition%2520of%2520Hypereosinophilic%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D126%26spage%3D45%26epage%3D49%26doi%3D10.1016%2Fj.jaci.2010.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, S.G.O</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, P. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, B. Q</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, R. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega Martell, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platts-Mills, T. A.E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span></span> <span> </span><span class="NLM_article-title">Revised Nomenclature for Allergy for Global Use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2003.12.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2003.12.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15131563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2c3kvVeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=832-836&author=S.G.O+Johanssonauthor=T.+Bieberauthor=R.+Dahlauthor=P.+S+Friedmannauthor=B.+Q+Lanierauthor=R.+F+Lockeyauthor=C.+Motalaauthor=J.+A+Ortega+Martellauthor=T.+A.E+Platts-Millsauthor=J.+Ring&title=Revised+Nomenclature+for+Allergy+for+Global+Use%3A+Report+of+the+Nomenclature+Review+Committee+of+the+World+Allergy+Organization%2C+October+2003&doi=10.1016%2Fj.jaci.2003.12.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</span></div><div class="casAuthors">Johansson S G O; Bieber Thomas; Dahl Ronald; Friedmann Peter S; Lanier Bobby Q; Lockey Richard F; Motala Cassim; Ortega Martell Jose A; Platts-Mills Thomas A E; Ring Johannes; Thien Frank; Van Cauwenberge Paul; Williams Hywel C</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">832-6</span>
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    </div><div class="casAbstract">The nomenclature proposed in the October 2003 report of the Nomenclature Review Committee of the World Allergy Organization is an update of the European Academy of Allergology and Clinical Immunology Revised Nomenclature for Allergy Position Statement published in 2001.  The nomenclature can be used independently of target organ or patient age group and is based on the mechanisms that initiate and mediate allergic reactions.  It is assumed that as knowledge about basic causes and mechanisms improves, the nomenclature will need further review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgCRScQzyFpv_I8Jvzw4xCfW6udTcc2ea50NFNZckoo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3kvVeiug%253D%253D&md5=5314fe7754881ef6ea7425c82066b6a8</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2003.12.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2003.12.591%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DS.G.O%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DFriedmann%26aufirst%3DP.%2BS%26aulast%3DLanier%26aufirst%3DB.%2BQ%26aulast%3DLockey%26aufirst%3DR.%2BF%26aulast%3DMotala%26aufirst%3DC.%26aulast%3DOrtega%2BMartell%26aufirst%3DJ.%2BA%26aulast%3DPlatts-Mills%26aufirst%3DT.%2BA.E%26aulast%3DRing%26aufirst%3DJ.%26atitle%3DRevised%2520Nomenclature%2520for%2520Allergy%2520for%2520Global%2520Use%253A%2520Report%2520of%2520the%2520Nomenclature%2520Review%2520Committee%2520of%2520the%2520World%2520Allergy%2520Organization%252C%2520October%25202003%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2004%26volume%3D113%26spage%3D832%26epage%3D836%26doi%3D10.1016%2Fj.jaci.2003.12.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamelmann, E.</span></span> <span> </span><span class="NLM_article-title">The Rationale for Treating Allergic Asthma with Anti-IgE</span>. <i>European Respiratory Review</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1183/09059180.00010401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1183%2F09059180.00010401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=61-66&author=E.+Hamelmann&title=The+Rationale+for+Treating+Allergic+Asthma+with+Anti-IgE&doi=10.1183%2F09059180.00010401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1183%2F09059180.00010401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09059180.00010401%26sid%3Dliteratum%253Aachs%26aulast%3DHamelmann%26aufirst%3DE.%26atitle%3DThe%2520Rationale%2520for%2520Treating%2520Allergic%2520Asthma%2520with%2520Anti-IgE%26jtitle%3DEuropean%2520Respiratory%2520Review%26date%3D2007%26volume%3D16%26spage%3D61%26epage%3D66%26doi%3D10.1183%2F09059180.00010401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hairsine, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matharu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramm, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologically Active Sulfoximides: 5-Hexyl-7-)S-Methylsulfonimidoly) Xanthone-2-Carboxylic Acid, a Potent Antiallergic Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm00190a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00190a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1MXhtlamur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1979&pages=418-424&author=A.+C.+Barnesauthor=P.+W.+Hairsineauthor=S.+S.+Matharuauthor=P.+J.+Rammauthor=J.+B.+Taylor&title=Pharmacologically+Active+Sulfoximides%3A+5-Hexyl-7-%29S-Methylsulfonimidoly%29+Xanthone-2-Carboxylic+Acid%2C+a+Potent+Antiallergic+Agent&doi=10.1021%2Fjm00190a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologically active sulfoximides:  5-hexyl-7-(S-methylsulfonimidoyl)xanthone-2-carboxylic acid, a potent antiallergic agent</span></div><div class="casAuthors">Barnes, Alan C.; Hairsine, Peter W.; Matharu, Saroop S.; Ramm, Peter J.; Taylor, John B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">418-24</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The sulfoximidoxanthones I (X = H, SO(:NH)Me, SO(:NCONH2)Me, etc.; Y = H, C6H13, OC5N11; Z = SO(:NH)Me, CO2H, CO2Me) were prepd. by 2 different routes either from a (methylthio)phenol or a [hexyl(methylthio)phenoxy]isophthalate.  The xanthenecarboxylic acids thus prepd. were evaluated for antiallergic activity and 5-hexyl-7-(S-methylsuylfonimidoyl)xanthone-2-carboxylic acid  [58761-87-8] was the most active.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-lkdudmZKbVg90H21EOLACvtfcHk0li3p-B7KcpqMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhtlamur0%253D&md5=97a75bc329c341f1a0ee9548fd602f61</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fjm00190a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00190a012%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DA.%2BC.%26aulast%3DHairsine%26aufirst%3DP.%2BW.%26aulast%3DMatharu%26aufirst%3DS.%2BS.%26aulast%3DRamm%26aufirst%3DP.%2BJ.%26aulast%3DTaylor%26aufirst%3DJ.%2BB.%26atitle%3DPharmacologically%2520Active%2520Sulfoximides%253A%25205-Hexyl-7-%2529S-Methylsulfonimidoly%2529%2520Xanthone-2-Carboxylic%2520Acid%252C%2520a%2520Potent%2520Antiallergic%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1979%26volume%3D22%26spage%3D418%26epage%3D424%26doi%3D10.1021%2Fjm00190a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, G. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Experimental Immediate Hypersensitivity Reactions by a Novel Xanthone, RU 31156</span>. <i>Arch. Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1978&pages=328-339&author=P.+Millerauthor=G.+W.+James&title=Inhibition+of+Experimental+Immediate+Hypersensitivity+Reactions+by+a+Novel+Xanthone%2C+RU+31156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of experimental immediate hypersensitivity reactions by a novel xanthone, RU 31156</span></div><div class="casAuthors">Miller, P.; James, G. W. L.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">328-39</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">RU 31156 (I)  [66934-53-0] was a potent inhibitor of exptl. immediate hypersensitivity reactions in vivo.  In the IgE-mediated rat passive cutaneous anaphylaxis (PCA) test, I had an ED50 of 0.0046 (0.0037-0.0057) mg/kg which compared with a figure of 1.21 (1.04-1.42) mg/kg for disodium cromoglycate (DSCG), both compds. being administered i.v.  I was also active when administered orally, having an ED50 of 0.19 (0.07-0.30) mg/kg when given 10 min before antigen.  I partially inhibited an IgG-mediated PCA reaction in the rat.  Both I and DSCG inhibited anaphylactic bronchoconstriction in the rat, giving bell-shaped dose-response curves.  From the upward part of the curves, approx. ED30 values of 0.02 and 2.0 mg/kg were obtained for I and DSCG, resp.  Anaphylactic bronchoconstriction in the guinea pig was not affected by I and pinnal anaphylaxis was inhibited only at relatively high doses of 1-10 mg/kg, i.v.  The effects of both histamine and 5-hydroxytryptamine in the mouse pinna were not affected by I.  In PCA expts., I showed self-tachyphylaxis following both i.v. and oral administration.  It also showed cross-tachyphylaxis with DSCG, indicating that these compds. are likely to share a similar mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob5gOPrCwtY7Vg90H21EOLACvtfcHk0lhd1u89sBMCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2qsrY%253D&md5=5967135200f85d0814c03ea1f92541bd</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DG.%2BW.%26atitle%3DInhibition%2520of%2520Experimental%2520Immediate%2520Hypersensitivity%2520Reactions%2520by%2520a%2520Novel%2520Xanthone%252C%2520RU%252031156%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1978%26volume%3D231%26spage%3D328%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-Pyridones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">WO2014029830A1</span>, Feb 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=D.+Fiegen&author=C.+Gnamm&title=Substituted+4-Pyridones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%25204-Pyridones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-Pyridones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">EP2888242B1</span>, Jun 13, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=D.+Fiegen&author=C.+Gnamm&title=Substituted+4-Pyridones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%25204-Pyridones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Anderskewitz, R.</span>; <span class="NLM_string-name">Gnamm, C.</span>; <span class="NLM_string-name">Morschhäuser, G.</span>; <span class="NLM_string-name">Peters, S.</span>; <span class="NLM_string-name">Ries, U. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Bicyclic Dihydropyrimidinones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">WO2016016368A1</span>, Feb 4, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=R.+Anderskewitz&author=C.+Gnamm&author=G.+Morschh%C3%A4user&author=S.+Peters&author=U.+J.+Ries&title=Substituted+Bicyclic+Dihydropyrimidinones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%2520Bicyclic%2520Dihydropyrimidinones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardoel, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zychlinsky, A.</span></span> <span> </span><span class="NLM_article-title">The Balancing Act of Neutrophils</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2014.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chom.2014.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24832448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=526-536&author=B.+W.+Bardoelauthor=E.+F.+Kennyauthor=G.+Sollbergerauthor=A.+Zychlinsky&title=The+Balancing+Act+of+Neutrophils&doi=10.1016%2Fj.chom.2014.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The Balancing Act of Neutrophils</span></div><div class="casAuthors">Bardoel, Bart W.; Kenny, Elaine F.; Sollberger, Gabriel; Zychlinsky, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">526-536</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Neutrophils are endowed with a plethora of toxic mols. that are mobilized in immune responses.  These cells evolved to fight infections, but when deployed at the wrong time and in the wrong place, they cause damage to the host.  Here, we review the generalities of these cells as well as the difficulties encountered when trying to unravel them mechanistically.  We then focus on how neutrophils develop and their function in infection.  We center our attention on human neutrophils and what we learn from clin. immunodeficiencies.  Finally, we use autoimmune disease to illustrate the harmful potential of dysregulated neutrophil responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGVUnRhHq9eLVg90H21EOLACvtfcHk0lhd1u89sBMCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFyntb8%253D&md5=cf22c05b7a54e5d31478ad502611c163</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2014.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2014.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBardoel%26aufirst%3DB.%2BW.%26aulast%3DKenny%26aufirst%3DE.%2BF.%26aulast%3DSollberger%26aufirst%3DG.%26aulast%3DZychlinsky%26aufirst%3DA.%26atitle%3DThe%2520Balancing%2520Act%2520of%2520Neutrophils%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2014%26volume%3D15%26spage%3D526%26epage%3D536%26doi%3D10.1016%2Fj.chom.2014.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korkmaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, F.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fpr.110.002733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21079042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlCh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=726-759&author=B.+Korkmazauthor=M.+S.+Horwitzauthor=D.+E.+Jenneauthor=F.+Gauthier&title=Neutrophil+Elastase%2C+Proteinase+3%2C+and+Cathepsin+G+as+Therapeutic+Targets+in+Human+Diseases&doi=10.1124%2Fpr.110.002733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases</span></div><div class="casAuthors">Korkmaz, Brice; Horwitz, Marshall S.; Jenne, Dieter E.; Gauthier, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">726-759</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Polymorphonuclear neutrophils are the first cells recruited to inflammatory sites and form the earliest line of defense against invading microorganisms.  Neutrophil elastase, proteinase 3, and cathepsin G are three hematopoietic serine proteases stored in large quantities in neutrophil cytoplasmic azurophilic granules.  They act in combination with reactive oxygen species to help degrade engulfed microorganisms inside phagolysosomes.  These proteases are also externalized in an active form during neutrophil activation at inflammatory sites, thus contributing to the regulation of inflammatory and immune responses.  As multifunctional proteases, they also play a regulatory role in noninfectious inflammatory diseases.  Mutations in the ELA2/ELANE gene, encoding neutrophil elastase, are the cause of human congenital neutropenia.  Neutrophil membrane-bound proteinase 3 serves as an autoantigen in Wegener granulomatosis, a systemic autoimmune vasculitis.  All three proteases are affected by mutations of the gene (CTSC) encoding dipeptidyl peptidase I, a protease required for activation of their proform before storage in cytoplasmic granules.  Mutations of CTSC cause Papillon-Lefevre syndrome.  Because of their roles in host defense and disease, elastase, proteinase 3, and cathepsin G are of interest as potential therapeutic targets.  In this review, we describe the physicochem. functions of these proteases, toward a goal of better delineating their role in human diseases and identifying new therapeutic strategies based on the modulation of their bioavailability and activity.  We also describe how non-human primate exptl. models could assist with testing the efficacy of proposed therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWs076oWNwhbVg90H21EOLACvtfcHk0lhd1u89sBMCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlCh&md5=6b7a8706385effb36f5a5789f3866e3e</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002733%26sid%3Dliteratum%253Aachs%26aulast%3DKorkmaz%26aufirst%3DB.%26aulast%3DHorwitz%26aufirst%3DM.%2BS.%26aulast%3DJenne%26aufirst%3DD.%2BE.%26aulast%3DGauthier%26aufirst%3DF.%26atitle%3DNeutrophil%2520Elastase%252C%2520Proteinase%25203%252C%2520and%2520Cathepsin%2520G%2520as%2520Therapeutic%2520Targets%2520in%2520Human%2520Diseases%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D726%26epage%3D759%26doi%3D10.1124%2Fpr.110.002733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadek, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, R. G.</span></span> <span> </span><span class="NLM_article-title">Human Neutrophil Elastase Functions as a Type III Collagen “Collagenase</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(80)80110-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0006-291X%2880%2980110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=6251855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3cXlvVWrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1980&pages=1815-1822&author=J.+E.+Gadekauthor=G.+A.+Fellsauthor=D.+G.+Wrightauthor=R.+G.+Crystal&title=Human+Neutrophil+Elastase+Functions+as+a+Type+III+Collagen+%E2%80%9CCollagenase&doi=10.1016%2FS0006-291X%2880%2980110-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Human neutrophil elastase functions as a type III collagen "collagenase"</span></div><div class="casAuthors">Gadek, James E.; Fells, Gerald A.; Wright, Daniel G.; Crystal, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1815-22</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Under physiol. conditions, human neutrophil elastase cleaves triple helical human type III collagen into specific fragments in a fashion similar to that of a typical collagenase.  In contrast, elastase does not attack the triple helical portion of type I collagen.  However, unlike a classic collagenase, which is a metalloenzyme, the action of elastase on type III collagen is prevented by serine protease inhibitors.  These findings suggest that the concepts of collagenases and elastases must be broadened and that human neutrophil elastase is capable of mediating a broad range of connective tissue destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqoipK_VXUubVg90H21EOLACvtfcHk0lhJLObd8oZr2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlvVWrsLs%253D&md5=6a8fd341b7aac0c433309f89d868bb75</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2880%2980110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252880%252980110-0%26sid%3Dliteratum%253Aachs%26aulast%3DGadek%26aufirst%3DJ.%2BE.%26aulast%3DFells%26aufirst%3DG.%2BA.%26aulast%3DWright%26aufirst%3DD.%2BG.%26aulast%3DCrystal%26aufirst%3DR.%2BG.%26atitle%3DHuman%2520Neutrophil%2520Elastase%2520Functions%2520as%2520a%2520Type%2520III%2520Collagen%2520%25E2%2580%259CCollagenase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1980%26volume%3D95%26spage%3D1815%26epage%3D1822%26doi%3D10.1016%2FS0006-291X%2880%2980110-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polverino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Mayor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Neutrophil Elastase Inhibitors in Lung Diseases</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2017.03.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chest.2017.03.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28442313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtV2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2017&pages=249-262&author=E.+Polverinoauthor=E.+Rosales-Mayorauthor=G.+E.+Daleauthor=K.+Dembowskyauthor=A.+Torres&title=The+Role+of+Neutrophil+Elastase+Inhibitors+in+Lung+Diseases&doi=10.1016%2Fj.chest.2017.03.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Neutrophil Elastase Inhibitors in Lung Diseases</span></div><div class="casAuthors">Polverino Eva; Rosales-Mayor Edmundo; Dale Glenn E; Dembowsky Klaus; Torres Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-262</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In many respiratory diseases characterized by an intense inflammatory response, the balance between proteolytic enzymes (proteases, including elastases) and their inhibitors (proteinases inhibitors) is not neutral.  Excess activity of neutrophil elastase (NE) and similar proteases has been reported to cause tissue damage and to alter the remodeling process in many clinical conditions such as pneumonia, respiratory distress, and acute lung injury (ALI).  Several experimental NE inhibitors have been tested in preclinical and clinical studies of different conditions of inflammatory lung injury such as ALI and pneumonia, with contrasting results.  This study reviews the literature regarding NE inhibitors in the field of respiratory diseases and reflects on possible future developments.  In particular, we highlight potential gaps in the scientific evidence and discuss potential strategies for focusing investigation on antielastases in clinical practice through the selection of targeted populations and proper outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZaNJRtWcfVdts4TFFB11gfW6udTcc2eZwqIlbCxwoWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtV2kug%253D%253D&md5=2ed4829fc520096354dcb155faf11996</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2017.03.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2017.03.056%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DE.%26aulast%3DRosales-Mayor%26aufirst%3DE.%26aulast%3DDale%26aufirst%3DG.%2BE.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DTorres%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Neutrophil%2520Elastase%2520Inhibitors%2520in%2520Lung%2520Diseases%26jtitle%3DChest%26date%3D2017%26volume%3D152%26spage%3D249%26epage%3D262%26doi%3D10.1016%2Fj.chest.2017.03.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Targeting COPD: Advances on Low-Molecular-Weight Inhibitors of Human Neutrophil Elastase</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">E73</span>– <span class="NLM_lpage">E101</span>, <span class="refDoi"> DOI: 10.1002/med.20247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fmed.20247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21681767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=E73-E101&author=S.+D.+Lucasauthor=E.+Costaauthor=R.+C.+Guedesauthor=R.+Moreira&title=Targeting+COPD%3A+Advances+on+Low-Molecular-Weight+Inhibitors+of+Human+Neutrophil+Elastase&doi=10.1002%2Fmed.20247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase</span></div><div class="casAuthors">Lucas, Susana D.; Costa, Elsa; Guedes, Rita C.; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">E73-E101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major increasing health problem and the World Health Organization (WHO) reports COPD as the fifth leading cause of death worldwide.  COPD refers to a condition of inflammation and progressive weakening of the structure of the lung as well as irreversible narrowing of the airways.  Current treatment is only palliative and no available drug halts the progression of the disease.  Human neutrophil elastase (HNE) is a serine protease, which plays a major role in the COPD inflammatory process.  The protease/anti-protease imbalance leads to an excess of extracellular HNE hydrolyzing elastin, the structural protein that confers elasticity to the lung tissue.  Although HNE was identified as a therapeutic target for COPD more than 30 years ago, only Sivelestat (ONO-5046), an HNE inhibitor from Ono Pharmaceutical, has been approved for clin. use.  Nevertheless, Sivelestat is only approved in Japan and its development in the USA was terminated in 2003.  Other inhibitors in pre-clin. or phase I trials were discontinued for various reasons.  Hence, there is an urgent need for low-mol.-wt. synthetic elastase inhibitors and the present review discusses the recent advances on this field covering acylating agents, transition-state inhibitors, mechanism-based inhibitors, relevant natural products, and major patent disclosures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJWyG-jxrWzLVg90H21EOLACvtfcHk0lhJLObd8oZr2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbc%253D&md5=5d8977535c358cd1aaf1e6ea24095e18</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1002%2Fmed.20247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20247%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%2BD.%26aulast%3DCosta%26aufirst%3DE.%26aulast%3DGuedes%26aufirst%3DR.%2BC.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DTargeting%2520COPD%253A%2520Advances%2520on%2520Low-Molecular-Weight%2520Inhibitors%2520of%2520Human%2520Neutrophil%2520Elastase%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3DE73%26epage%3DE101%26doi%3D10.1002%2Fmed.20247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohbayashi, H.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase Inhibitors as Treatment for COPD</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1517/13543784.11.7.965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1517%2F13543784.11.7.965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12084007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Slu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=965-980&author=H.+Ohbayashi&title=Neutrophil+Elastase+Inhibitors+as+Treatment+for+COPD&doi=10.1517%2F13543784.11.7.965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase inhibitors as treatment for COPD</span></div><div class="casAuthors">Ohbayashi, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">965-980</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review. Chronic obstructive pulmonary disease (COPD), characterized by a slowly progressive, irreversible airways limitation, is a major worldwide cause of chronic morbidity and mortality.  The imbalance between human neutrophil elastase and endogenous antiproteases may cause excess human neutrophil elastase in pulmonary tissues, which may be considered a major pathogenic factor in COPD.  Great effort has been devoted to finding a method to restore the balance, resulting in the discovery of two types of potent low-mol.-wt. human neutrophil elastase inhibitors.  In COPD therapy, the human neutrophil elastase inhibitors that have been mainly focused upon include ONO-5046, MR-889, L-694,458, CE-1037, GW-311616 and TEI-8362 as the acyl-enzyme inhibitors, and ONO-6818, AE-3763, FK-706, ICI-200,880, ZD-0892 and ZD-8321 as the transition-state inhibitors.  Various problems that remain to be solved in the clin. use of human neutrophil elastase inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3Vw3Eq2FebVg90H21EOLACvtfcHk0lhMYYcCgVNycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Slu7o%253D&md5=ae3c5080e19b8e00b74ee94f3f38c802</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1517%2F13543784.11.7.965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.11.7.965%26sid%3Dliteratum%253Aachs%26aulast%3DOhbayashi%26aufirst%3DH.%26atitle%3DNeutrophil%2520Elastase%2520Inhibitors%2520as%2520Treatment%2520for%2520COPD%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D965%26epage%3D980%26doi%3D10.1517%2F13543784.11.7.965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miglietta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderazzo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase in Bronchiectasis</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">211</span>, <span class="refDoi"> DOI: 10.1186/s12931-017-0691-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2Fs12931-017-0691-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29258516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKgsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=211&author=A.+Gramegnaauthor=F.+Amatiauthor=L.+Terranovaauthor=G.+Sotgiuauthor=P.+Tarsiaauthor=D.+Migliettaauthor=M.+A.+Calderazzoauthor=S.+Alibertiauthor=F.+Blasi&title=Neutrophil+Elastase+in+Bronchiectasis&doi=10.1186%2Fs12931-017-0691-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase in bronchiectasis</span></div><div class="casAuthors">Gramegna, Andrea; Amati, Francesco; Terranova, Leonardo; Sotgiu, Giovanni; Tarsia, Paolo; Miglietta, Daniela; Calderazzo, Maria Adelaide; Aliberti, Stefano; Blasi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211/1-211/13</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclin. data and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF.  In this context, NE seems to be a predictor of long-term clin. outcomes and a possible target of treatment.  In order to better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence was performed.  Two investigators independently performed the search on PubMed and included studies published up to May 15, 2017 according to predefined criteria.  A final pool of 31 studies was included in the systematic review, with a total of 2679 patients.  For each paper data of interest were extd. and reported in table.  In this review sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and during exacerbations and local or systemic antibiotic treatment.  NE has also been assocd. with risk of exacerbation, time to next exacerbation and all-cause mortality.  This study reviews also the role of NE as a specific target of treatment in bronchiectasis.  Inhibition of NE is at a very early stage and future interventional studies should evaluate safety and efficacy for new mols. and formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVobMcnV9jN7Vg90H21EOLACvtfcHk0lhMYYcCgVNycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKgsLbE&md5=0bc9937bc8fcb93ff4d7d7d0e1d6aff1</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1186%2Fs12931-017-0691-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-017-0691-x%26sid%3Dliteratum%253Aachs%26aulast%3DGramegna%26aufirst%3DA.%26aulast%3DAmati%26aufirst%3DF.%26aulast%3DTerranova%26aufirst%3DL.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DTarsia%26aufirst%3DP.%26aulast%3DMiglietta%26aufirst%3DD.%26aulast%3DCalderazzo%26aufirst%3DM.%2BA.%26aulast%3DAliberti%26aufirst%3DS.%26aulast%3DBlasi%26aufirst%3DF.%26atitle%3DNeutrophil%2520Elastase%2520in%2520Bronchiectasis%26jtitle%3DRespir.%2520Res.%26date%3D2017%26volume%3D18%26spage%3D211%26doi%3D10.1186%2Fs12931-017-0691-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voynow, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span> <span> </span><span class="NLM_article-title">Proteases and Cystic Fibrosis</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.biocel.2008.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18395488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=1238-1245&author=J.+A.+Voynowauthor=B.+M.+Fischerauthor=S.+Zheng&title=Proteases+and+Cystic+Fibrosis&doi=10.1016%2Fj.biocel.2008.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Proteases and cystic fibrosis</span></div><div class="casAuthors">Voynow, Judith A.; Fischer, Bernard M.; Zheng, Shuo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis is the most common, inherited fatal disease in Caucasians.  The major cause of morbidity and mortality is chronic lung disease due to infection and inflammation in the airways leading to bronchiectasis and respiratory failure.  The signature pathol. features of CF lung disease including abnormal mucus obstructing airways, chronic infection with Staphylococcus aureus, Pseudomonas aeruginosa and other gram neg. bacteria, and a robust neutrophil-dominant airway inflammation, are exacerbated by unopposed proteases present at high concns. in the ASL.  There is strong evidence that proteases, particularly neutrophil elastase, contribute to the pathol. of CF by impairing mucociliary clearance, interfering with innate immune functions, and perpetuating neutrophilic inflammation.  The mechanisms employed by proteases to impact airway function in CF will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgb7aa1mlvtrVg90H21EOLACvtfcHk0lhMYYcCgVNycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslGlurg%253D&md5=d7ab94dbe8aaf821f7c1f77e02a47695</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DVoynow%26aufirst%3DJ.%2BA.%26aulast%3DFischer%26aufirst%3DB.%2BM.%26aulast%3DZheng%26aufirst%3DS.%26atitle%3DProteases%2520and%2520Cystic%2520Fibrosis%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D1238%26epage%3D1245%26doi%3D10.1016%2Fj.biocel.2008.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.113.301141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1161%2FCIRCRESAHA.113.301141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24951765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=165-175&author=M.+Rabinovitchauthor=C.+Guignabertauthor=M.+Humbertauthor=M.+R.+Nicolls&title=Inflammation+and+Immunity+in+the+Pathogenesis+of+Pulmonary+Arterial+Hypertension&doi=10.1161%2FCIRCRESAHA.113.301141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Rabinovitch, Marlene; Guignabert, Christophe; Humbert, Marc; Nicolls, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension.  The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed.  Pre-clin. studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed.  In addn., we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development.  We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuJ3RliFVC7Vg90H21EOLACvtfcHk0lhMYYcCgVNycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL&md5=d3a2fe2798a44bdcdf4e5e0f8c71ab99</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.113.301141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.113.301141%26sid%3Dliteratum%253Aachs%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26atitle%3DInflammation%2520and%2520Immunity%2520in%2520the%2520Pathogenesis%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D165%26epage%3D175%26doi%3D10.1161%2FCIRCRESAHA.113.301141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R. A.</span></span> <span> </span><span class="NLM_article-title">Alpha1-Antitrypsin Review</span>. <i>Clinics in Chest Medicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.ccm.2013.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ccm.2013.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24507836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2crmsVKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=39-50&author=R.+A.+Stockley&title=Alpha1-Antitrypsin+Review&doi=10.1016%2Fj.ccm.2013.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Alpha1-antitrypsin review</span></div><div class="casAuthors">Stockley Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alpha1-antitrypsin (AAT) deficiency was first described in 1963 together with its associations with severe early-onset basal panacinar emphysema.  The genetic defects leading to deficiency have been elucidated and the pathophysiologic processes, clinical variation in phenotype, and the role of genetic modifiers have been recognized.  Strategies to increase plasma (and hence tissue) concentrations of AAT have been developed.  The only recognized specific therapeutic strategy is regular infusions of the purified plasma protein, and evidence confirms its efficacy in protecting the lung (at least partially).  Early detection and modification of lifestyle remains crucial to the management of AAT deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWZ0g10qbTe7jnyZkbE8yXfW6udTcc2eZ1rYsIWIA-oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmsVKhsA%253D%253D&md5=6e2d0071ad76060df29f3cf063a2a736</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.ccm.2013.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccm.2013.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DStockley%26aufirst%3DR.%2BA.%26atitle%3DAlpha1-Antitrypsin%2520Review%26jtitle%3DClinics%2520in%2520Chest%2520Medicine%26date%3D2014%26volume%3D35%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ccm.2013.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Utility of the Neutrophil Elastase Inhibitor Sivelestat for the Treatment of Acute Respiratory Distress Syndrome</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S65066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2147%2FTCRM.S65066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25120368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVynu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=621-629&author=N.+Aikawaauthor=Y.+Kawasaki&title=Clinical+Utility+of+the+Neutrophil+Elastase+Inhibitor+Sivelestat+for+the+Treatment+of+Acute+Respiratory+Distress+Syndrome&doi=10.2147%2FTCRM.S65066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome</span></div><div class="casAuthors">Aikawa, Naoki; Kawasaki, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">621-929</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acute respiratory distress syndrome is a serious condition that can arise following direct or indirect lung injury.  It is heterogeneous and has a high mortality rate.  Supportive care is the mainstay of treatment and there is no definitive pharmacol. treatment as yet.  Sivelestat is a neutrophil elastase inhibitor approved in Japan and the Republic of Korea for acute lung injury, including acute respiratory distress syndrome in patients with systemic inflammatory response syndrome.  The aim of this review is to examine the clin. utility of sivelestat in different disease states, using data from nonclin. and clin. studies.  In nonclin. studies, sivelestat appears to show benefit in acute lung injury without inhibiting the host immune defense in cases of infection.  Clin. studies do not yet provide a clear consensus.  Phase III and IV Japanese studies have shown improvements in pulmonary function, length of intensive care unit stay, and mech. ventilation, but a non-Japanese multicenter study did not demonstrate sivelestat to have an effect on ventilator-free days or 28-day all-cause mortality.  Evidence of improvement in various parameters, including duration of stay in intensive care, mech. ventilation, the ratio of partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/F1O2 ratio) ratio, and lung injury scores, has been shown in patients with sepsis or gastric aspiration, and following the surgical treatment of esophageal cancer.  To date, there are no particular concerns regarding adverse events, and the available data do not suggest that sivelestat might worsen infections.  One study has analyzed cost-effectiveness, finding that sivelestat may reduce costs compared with std. care.  The currently available evidence suggests that sivelestat may show some benefit in the treatment of acute lung injury/acute respiratory distress syndrome, although large, randomized controlled trials are needed in specific pathophysiol. conditions to explore these potential benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo39p761ROLC7Vg90H21EOLACvtfcHk0lipeczcMM4WaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVynu7vN&md5=bdb0d303d81992eda4ace23c560ee23d</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S65066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S65066%26sid%3Dliteratum%253Aachs%26aulast%3DAikawa%26aufirst%3DN.%26aulast%3DKawasaki%26aufirst%3DY.%26atitle%3DClinical%2520Utility%2520of%2520the%2520Neutrophil%2520Elastase%2520Inhibitor%2520Sivelestat%2520for%2520the%2520Treatment%2520of%2520Acute%2520Respiratory%2520Distress%2520Syndrome%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2014%26volume%3D10%26spage%3D621%26epage%3D629%26doi%3D10.2147%2FTCRM.S65066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Von Nussbaum, F.</span>; <span class="NLM_string-name">Karthaus, D.</span>; <span class="NLM_string-name">Anlauf, S.</span>; <span class="NLM_string-name">Delbeck, M.</span>; <span class="NLM_string-name">Li, V. M. J.</span>; <span class="NLM_string-name">Meibom, D.</span>; <span class="NLM_string-name">Lustig, K.</span>; <span class="NLM_string-name">Schneider, D.</span></span> <span> </span><span class="NLM_article-title">Sulfonic Amide and Sulfoximine-Substituted Diaryl-Dihydropyrimidinones and Usage Thereof</span>. <span class="NLM_patent">US/2012/0094968</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=F.+Von+Nussbaum&author=D.+Karthaus&author=S.+Anlauf&author=M.+Delbeck&author=V.+M.+J.+Li&author=D.+Meibom&author=K.+Lustig&author=D.+Schneider&title=Sulfonic+Amide+and+Sulfoximine-Substituted+Diaryl-Dihydropyrimidinones+and+Usage+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BNussbaum%26aufirst%3DF.%26atitle%3DSulfonic%2520Amide%2520and%2520Sulfoximine-Substituted%2520Diaryl-Dihydropyrimidinones%2520and%2520Usage%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen-Haertwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosentreter, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span> <span> </span><span class="NLM_article-title">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85–8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201500131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26083237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1163-1173&author=F.+von+Nussbaumauthor=V.+M.+Liauthor=S.+Allerheiligenauthor=S.+Anlaufauthor=L.+B%C3%A4rfackerauthor=M.+Bechemauthor=M.+Delbeckauthor=M.+F.+Fitzgeraldauthor=M.+Gerischauthor=H.+Gielen-Haertwigauthor=H.+Haningauthor=D.+Karthausauthor=D.+Langauthor=K.+Lustigauthor=D.+Meibomauthor=J.+Mittendorfauthor=U.+Rosentreterauthor=M.+Sch%C3%A4ferauthor=S.+Sch%C3%A4ferauthor=J.+Schambergerauthor=L.+A.+Telanauthor=A.+Tersteegen&title=Freezing+the+Bioactive+Conformation+to+Boost+Potency%3A+The+Identification+of+BAY+85%E2%80%938501%2C+a+Selective+and+Potent+Inhibitor+of+Human+Neutrophil+Elastase+for+Pulmonary+Diseases&doi=10.1002%2Fcmdc.201500131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span></div><div class="casAuthors">von Nussbaum, Franz; Li, Volkhart M.-J.; Allerheiligen, Swen; Anlauf, Sonja; Baerfacker, Lars; Bechem, Martin; Delbeck, Martina; Fitzgerald, Mary F.; Gerisch, Michael; Gielen-Haertwig, Heike; Haning, Helmut; Karthaus, Dagmar; Lang, Dieter; Lustig, Klemens; Meibom, Daniel; Mittendorf, Joachim; Rosentreter, Ulrich; Schaefer, Martina; Schaefer, Stefan; Schamberger, Jens; Telan, Leila A.; Tersteegen, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1163-1173</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is a key protease for matrix degrdn.  High HNE activity is obsd. in inflammatory diseases.  Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH).  HNE inhibitors should reestablish the protease-anti-protease balance.  By means of medicinal chem. a novel dihydropyrimidinone lead-structure class was identified.  Further chem. optimization yielded orally active compds. with favorable pharmacokinetics such as the chem. probe BAY-678.  While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned Me sulfone substituent.  An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE.  BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI.  BAY 85-8501 is currently being tested in clin. studies for the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfeHJY2lnE7Vg90H21EOLACvtfcHk0lipeczcMM4WaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N&md5=bb2997077d114dde6769896f50574d3c</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500131%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DAnlauf%26aufirst%3DS.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26aulast%3DBechem%26aufirst%3DM.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DM.%2BF.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DGielen-Haertwig%26aufirst%3DH.%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DKarthaus%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DRosentreter%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DS.%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DTelan%26aufirst%3DL.%2BA.%26aulast%3DTersteegen%26aufirst%3DA.%26atitle%3DFreezing%2520the%2520Bioactive%2520Conformation%2520to%2520Boost%2520Potency%253A%2520The%2520Identification%2520of%2520BAY%252085%25E2%2580%25938501%252C%2520a%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Human%2520Neutrophil%2520Elastase%2520for%2520Pulmonary%2520Diseases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1163%26epage%3D1173%26doi%3D10.1002%2Fcmdc.201500131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagelschmitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span> <span> </span><span class="NLM_article-title">The Novel Elastase Inhibitor BAY 85–8501 Provides a New Approach in the Treatment of Pulmonary Diseases</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=3416&author=J.+Nagelschmitzauthor=D.+Kaufelauthor=S.+Stephanauthor=F.+von+Nussbaumauthor=V.+Liauthor=M.+Delbeckauthor=K.+Lustigauthor=T.+Bandelauthor=H.+Watz&title=The+Novel+Elastase+Inhibitor+BAY+85%E2%80%938501+Provides+a+New+Approach+in+the+Treatment+of+Pulmonary+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagelschmitz%26aufirst%3DJ.%26aulast%3DKaufel%26aufirst%3DD.%26aulast%3DStephan%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DBandel%26aufirst%3DT.%26aulast%3DWatz%26aufirst%3DH.%26atitle%3DThe%2520Novel%2520Elastase%2520Inhibitor%2520BAY%252085%25E2%2580%25938501%2520Provides%2520a%2520New%2520Approach%2520in%2520the%2520Treatment%2520of%2520Pulmonary%2520Diseases%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26spage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span>Identifier:
NCT01818544. <a href="https://clinicaltrials.gov/ct2/show/NCT01818544" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01818544</a> (Accessed Oct
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01818544.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01818544+%28Accessed+Oct%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holick, M. F.</span></span> <span> </span><span class="NLM_article-title">The Photobiology of Vitamin D3 in Man</span>. In  <i>Vitamin D: Basic and Clinical Aspects</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuman, R.</span></span>, Ed. <span class="NLM_publisher-name">Martinus Nijhoff</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1984</span>; pp  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">216</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2F978-1-4613-2839-1_7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&pages=197-216&author=M.+F.+Holickauthor=R.+Kuman&title=Vitamin+D%3A+Basic+and+Clinical+Aspects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1007%2F978-1-4613-2839-1_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4613-2839-1_7%26sid%3Dliteratum%253Aachs%26aulast%3DHolick%26aufirst%3DM.%2BF.%26atitle%3DThe%2520Photobiology%2520of%2520Vitamin%2520D3%2520in%2520Man%26btitle%3DVitamin%2520D%253A%2520Basic%2520and%2520Clinical%2520Aspects%26aulast%3DKuman%26aufirst%3DR.%26pub%3DMartinus%2520Nijhoff%26date%3D1984%26spage%3D197%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bikle, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, S.</span></span> <span> </span><span class="NLM_article-title">Vitamin D, Calcium, and Epidermal Differentiation</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1210/er.14.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1210%2Fer.14.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8491153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3sXksVSqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=3-19&author=D.+D.+Bikleauthor=S.+Pillai&title=Vitamin+D%2C+Calcium%2C+and+Epidermal+Differentiation&doi=10.1210%2Fer.14.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D, calcium, and epidermal differentiation</span></div><div class="casAuthors">Bikle, Daniel D.; Pillai, Sreekumar</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    </div><div class="casAbstract">A review, with 207 refs., on the cutaneous prodn. of 1,25-dihydroxyvitamin D3 and on the regulation of keratinocyte differentiation by Ca and 1,25-dihydroxyvitamin D3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XZhA_FxZsrVg90H21EOLACvtfcHk0li9xsb396KqUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVSqtbo%253D&md5=206ed1b402513bc01578b450b3b04c25</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1210%2Fer.14.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.14.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DBikle%26aufirst%3DD.%2BD.%26aulast%3DPillai%26aufirst%3DS.%26atitle%3DVitamin%2520D%252C%2520Calcium%252C%2520and%2520Epidermal%2520Differentiation%26jtitle%3DEndocr.%2520Rev.%26date%3D1993%26volume%3D14%26spage%3D3%26epage%3D19%26doi%3D10.1210%2Fer.14.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolagas, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousteni, S.</span></span> <span> </span><span class="NLM_article-title">Perspective: Nonreproductive Sites of Action of Reproductive Hormones</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2204</span>, <span class="refDoi"> DOI: 10.1210/endo.142.6.8221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1210%2Fendo.142.6.8221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11356663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFGgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=2200-2204&author=S.+C.+Manolagasauthor=S.+Kousteni&title=Perspective%3A+Nonreproductive+Sites+of+Action+of+Reproductive+Hormones&doi=10.1210%2Fendo.142.6.8221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: nonreproductive sites of action of reproductive hormones</span></div><div class="casAuthors">Manolagas, S. C.; Kousteni, S.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2200-2204</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 59 refs.  Estrogens and androgens, the female and male sex hormones responsible for gender dimorphism and reprodn., play also a very important role in tissues and organs that are not directly involved in procreation.  In fact, withdrawal of the effects of estrogens at menopause from nonreproductive tissues like the skeleton, the cardiovascular system, and the brain, is a major risk factor for the development of osteoporosis, coronary artery disease, stroke, and perhaps neurodegenerative diseases like Alzheimer's.  Continuous exposure of reproductive tissues to estrogen during the postreproductive part of life, is a risk factor for the development of breast, ovarian, and uterine cancer.  During the last decade, there have been significant advances in the understanding of the mechanism of action of sex steroids on the skeleton, the cardiovascular system, and the central nervous system.  The purpose of this perspective is to provide a brief outline of these advances with an emphasis on the emergence of several thematic similarities in the action of sex steroids on nonreproductive tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZuVpHbmjpZ7Vg90H21EOLACvtfcHk0li9xsb396KqUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFGgtbc%253D&md5=1fac1b6a1ebc0fa9f107beb62088f2cf</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1210%2Fendo.142.6.8221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.142.6.8221%26sid%3Dliteratum%253Aachs%26aulast%3DManolagas%26aufirst%3DS.%2BC.%26aulast%3DKousteni%26aufirst%3DS.%26atitle%3DPerspective%253A%2520Nonreproductive%2520Sites%2520of%2520Action%2520of%2520Reproductive%2520Hormones%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26spage%3D2200%26epage%3D2204%26doi%3D10.1210%2Fendo.142.6.8221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glerup, H.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Deficiency and Aging: Implications for General Health and Osteoporosis</span>. <i>Biogerontology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1023/A:1015263514765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1023%2FA%3A1015263514765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12014847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsF2lsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=73-77&author=E.+F.+Eriksenauthor=H.+Glerup&title=Vitamin+D+Deficiency+and+Aging%3A+Implications+for+General+Health+and+Osteoporosis&doi=10.1023%2FA%3A1015263514765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D deficiency and aging: implications for general health and osteoporosis</span></div><div class="casAuthors">Eriksen, Erik Fink; Glerup, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Biogerontology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-77</span>CODEN:
                <span class="NLM_cas:coden">BIOGCN</span>;
        ISSN:<span class="NLM_cas:issn">1389-5729</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Vitamin D deficiency is extremely prevalent in the elderly.  Most often the first symptoms are caused by myopathy with muscle pain, fatigue, muscular weakness and gait disturbances.  More severe deficiency causes osteomalacia with deep bone pain, reduced mineralization of bone matrix and low energy fractures.  Recent data also suggest that hypovitaminosis D increases the risk of cancer of the prostate, colon and breast.  Thus, hypovitaminosis D is assocd. with many diseases assocd. with aging.  In order to diagnose hypovitaminosis D, the assessment of serum levels of 25-hydroxy vitamin D is mandatory.  Screening based on other markers like alk. phosphatase and parathyroid hormone (PTH) will be incomplete.  The treatment of hypovitaminosis D is simple with administration of combined calcium (1 g) and vitamin D supplements (calciferol, at least 800 IU).  Severe cases may demand initial parenteral administration of vitamin D (repeated injections of 300,000 IU 2-3 times with monthly intervals).  More potent analogs are rarely needed.  One should aim at achieving S-25(OH)D values in the range 50-100 nmol/l.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou1cQHHv2EL7Vg90H21EOLACvtfcHk0li9xsb396KqUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsF2lsr0%253D&md5=f9332a098eb399c40958a443d3083740</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015263514765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015263514765%26sid%3Dliteratum%253Aachs%26aulast%3DEriksen%26aufirst%3DE.%2BF.%26aulast%3DGlerup%26aufirst%3DH.%26atitle%3DVitamin%2520D%2520Deficiency%2520and%2520Aging%253A%2520Implications%2520for%2520General%2520Health%2520and%2520Osteoporosis%26jtitle%3DBiogerontology%26date%3D2002%26volume%3D3%26spage%3D73%26epage%3D77%26doi%3D10.1023%2FA%3A1015263514765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span>; <span class="NLM_string-name">Seino, Y.</span></span> <i>Vitamin D and Bone</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=H.+Tanaka&author=Y.+Seino&title=Vitamin+D+and+Bone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DH.%26btitle%3DVitamin%2520D%2520and%2520Bone%26pub%3DAcademic%2520Press%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">The Steroid and Thyroid Hormone Receptor Superfamily</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1126/science.3283939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.3283939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3283939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXktVSqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1988&pages=889-895&author=R.+M.+Evans&title=The+Steroid+and+Thyroid+Hormone+Receptor+Superfamily&doi=10.1126%2Fscience.3283939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">The steroid and thyroid hormone receptor superfamily</span></div><div class="casAuthors">Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">4854</span>),
    <span class="NLM_cas:pages">889-95</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 83 refs., on the activation of the expression of gene networks by steroid and thyroid hormone receptors to coordinate development, differentiation, and physiol. responses to the hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEZIDsZLWoNrVg90H21EOLACvtfcHk0liBE25ndEyRPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktVSqsr4%253D&md5=b1c99cfcc0b115ad743a8ea4e24c88cd</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1126%2Fscience.3283939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3283939%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DThe%2520Steroid%2520and%2520Thyroid%2520Hormone%2520Receptor%2520Superfamily%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D1988%26volume%3D240%26spage%3D889%26epage%3D895%26doi%3D10.1126%2Fscience.3283939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christakos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raval-Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernyj, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Genomic Mechanisms Involved in the Pleiotropic Actions of 1,25-Dihydroxyvitamin D3</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1042/bj3160361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2Fbj3160361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8687373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK28XjvVahsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=1996&pages=361-371&author=S.+Christakosauthor=M.+Raval-Pandyaauthor=R.+P.+Wernyjauthor=W.+Yang&title=Genomic+Mechanisms+Involved+in+the+Pleiotropic+Actions+of+1%2C25-Dihydroxyvitamin+D3&doi=10.1042%2Fbj3160361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3</span></div><div class="casAuthors">Christakos, Sylvia; Raval-Pandya, Mihali; Wernyj, Roman P.; Yang, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">A review, with 169 refs., on the mechanisms involved in the multiple actions of 1,25-dihydroxyvitamin D3, including the genomic actions of the vitamin D receptor (VDR).  The VDR binds to vitamin D-responsive elements (VDREs) in the 5' flanking region of target genes.  It has been suggested that VDR homodimerization can occur upon binding to certain VDREs but that the VDR/retinoid X receptor (RXR) heterodimer is the functional transactivating species.  Other factors reported to be involved in VDR-mediated transcription include chicken ovalbumin upstream promoter (COUP) transcription factor, which is involved in active silencing of transcription, and transcription factor IIB, which has been suggested to play a major role following VDR/RXR heterodimerization.  Newly identified vitamin D-dependent target genes include those for Ca2+/Mg2+-ATPase in the intestine and p21 in the myelomonocytic U937 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptLYvt3Ct4qbVg90H21EOLACvtfcHk0liBE25ndEyRPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVahsb4%253D&md5=fbd55c77e3cf828b1cdadfa46f508ad5</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1042%2Fbj3160361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3160361%26sid%3Dliteratum%253Aachs%26aulast%3DChristakos%26aufirst%3DS.%26aulast%3DRaval-Pandya%26aufirst%3DM.%26aulast%3DWernyj%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DGenomic%2520Mechanisms%2520Involved%2520in%2520the%2520Pleiotropic%2520Actions%2520of%25201%252C25-Dihydroxyvitamin%2520D3%26jtitle%3DBiochem.%2520J.%26date%3D1996%26volume%3D316%26spage%3D361%26epage%3D371%26doi%3D10.1042%2Fbj3160361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramelet, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, J. H.</span></span> <span> </span><span class="NLM_article-title">Remission of Cutaneous T-Cell Lymphoma with Combined Calcitriol and Acitretin</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(94)92122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2894%2992122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7915374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaK2czlt1WgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=1994&pages=686-687&author=L.+E.+Frenchauthor=A.+A.+Rameletauthor=J.+H.+Saurat&title=Remission+of+Cutaneous+T-Cell+Lymphoma+with+Combined+Calcitriol+and+Acitretin&doi=10.1016%2FS0140-6736%2894%2992122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin</span></div><div class="casAuthors">French L E; Ramelet A A; Saurat J H</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">8923</span>),
    <span class="NLM_cas:pages">686-7</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFnOsCWFjUMDUE-swuRqsHfW6udTcc2eYqNa6dFXq7xLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czlt1WgsA%253D%253D&md5=75dfb9b98167c97b213159e8d2a96d2f</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992122-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DL.%2BE.%26aulast%3DRamelet%26aufirst%3DA.%2BA.%26aulast%3DSaurat%26aufirst%3DJ.%2BH.%26atitle%3DRemission%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%2520with%2520Combined%2520Calcitriol%2520and%2520Acitretin%26jtitle%3DLancet%26date%3D1994%26volume%3D344%26spage%3D686%26epage%3D687%26doi%3D10.1016%2FS0140-6736%2894%2992122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">Vitamin D and Analogues</span>. In  <i>Principles of Bone Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilezikian, J. P.</span>; <span class="NLM_string-name">Raisz, L. G.</span>; <span class="NLM_string-name">Martin, T. J.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">1777</span>– <span class="NLM_lpage">1799</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FB978-0-12-373884-4.00087-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=1777-1799&author=G.+Jonesauthor=J.+P.+Bilezikian&author=L.+G.+Raisz&author=T.+J.+Martin&title=Principles+of+Bone+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-373884-4.00087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-373884-4.00087-2%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26atitle%3DVitamin%2520D%2520and%2520Analogues%26btitle%3DPrinciples%2520of%2520Bone%2520Biology%26aulast%3DBilezikian%26aufirst%3DJ.%2BP.%26pub%3DElsevier%2520Academic%2520Press%26date%3D2008%26spage%3D1777%26epage%3D1799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. S.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Signalling Pathways in Cancer: Potential for Anticancer Therapeutics</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1038/nrc2196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrc2196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17721433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=684-700&author=K.+K.+Deebauthor=D.+L.+Trumpauthor=C.+S.+Johnson&title=Vitamin+D+Signalling+Pathways+in+Cancer%3A+Potential+for+Anticancer+Therapeutics&doi=10.1038%2Fnrc2196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D signalling pathways in cancer: potential for anticancer therapeutics</span></div><div class="casAuthors">Deeb, Kristin K.; Trump, Donald L.; Johnson, Candace S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">684-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidemiol. studies indicate that vitamin D insufficiency could have an etiol. role in various human cancers.  Preclin. research indicates that the active metabolite of vitamin D, 1α,25(OH)2D3, also known as calcitriol, or vitamin D analogs might have potential as anticancer agents because their administration has antiproliferative effects, can activate apoptotic pathways and inhibit angiogenesis.  In addn., 1α,25(OH)2D3 potentiates the anticancer effects of many cytotoxic and antiproliferative anticancer agents.  Here, we outline the epidemiol., preclin. and clin. studies that support the development of 1α,25(OH)2D3 and vitamin D analogs as preventative and therapeutic anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55tlJEPhjCrVg90H21EOLACvtfcHk0ljVW9U1lY_0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsb0%253D&md5=a11063de83943ab02e4089c34ccff277</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1038%2Fnrc2196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2196%26sid%3Dliteratum%253Aachs%26aulast%3DDeeb%26aufirst%3DK.%2BK.%26aulast%3DTrump%26aufirst%3DD.%2BL.%26aulast%3DJohnson%26aufirst%3DC.%2BS.%26atitle%3DVitamin%2520D%2520Signalling%2520Pathways%2520in%2520Cancer%253A%2520Potential%2520for%2520Anticancer%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D684%26epage%3D700%26doi%3D10.1038%2Fnrc2196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, R. L.</span></span> <span> </span><span class="NLM_article-title">Ketoconazole Inhibits Self-Induced Metabolism of 1,25-Dihydroxyvitamin D3 and Amplifies 1,25-Dihydroxyvitamin D3 Receptor Up-Regulation in Rat Osteosarcoma Cells</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/0003-9861(89)90240-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2F0003-9861%2889%2990240-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2546501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1MXkslWkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1989&pages=459-465&author=T.+A.+Reinhardtauthor=R.+L.+Horst&title=Ketoconazole+Inhibits+Self-Induced+Metabolism+of+1%2C25-Dihydroxyvitamin+D3+and+Amplifies+1%2C25-Dihydroxyvitamin+D3+Receptor+Up-Regulation+in+Rat+Osteosarcoma+Cells&doi=10.1016%2F0003-9861%2889%2990240-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells</span></div><div class="casAuthors">Reinhardt, T. A.; Horst, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    </div><div class="casAbstract">Ketoconazole (I), an inhibitor of vitamin D 24-hydroxylase was used to study the role of self-induced 1,25-dihydroxyvitamin D3 (1,25-D3) metab. on rat osteosarcoma cellular responsiveness to 1,25-D3.  The 18-h treatment with 1,25-dihydroxy-[26,27-methyl-3H]vitamin D3 (1,25-[3H]D3) increased total 1,25-D3 receptors (VDR) from 60 to 170 fmol/mg protein.  In cells treated with both 1,25-[3H]D3 and I, upregulation of VDR was increased by 40% over that obsd. with cells receiving 1,25-[3H]D3 alone.  I alone had no agonistic activity.  Treatment of cells with 1 nM 1,25-[3H]D3 plus increasing doses of I (0-30 μM) dose dependently increased occupied VDR and total VDR.  This upregulation was assocd. with reduced 1,25-[3H]D3 catabolism.  1,25-[3H]D3-induced upregulation of VDR typically peaked at 14 h and declined thereafter.  I lengthened the time to reach peak VDR upregulation to 20 h.  The ability of I to increase cell responsiveness (VDR upregulation) was the result of both increased and prolonged occupancy of VDR by 1,25-[3H]D3.  The t1/2 of occupied VDR was 2 h in the absence of I and >7 h when I was present.  Self-induced catabolism of 1,25-D3 is apparently an important regulator of VDR occupancy and therefore cellular responsiveness to hormone.  The data also demonstrate the usefulness of I as an inhibitor of vitamin D hydroxylases in intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosX0q3-UI3GrVg90H21EOLACvtfcHk0ljVW9U1lY_0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslWkurk%253D&md5=24130f4b5f35064bf2133d9a2061ca91</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1016%2F0003-9861%2889%2990240-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-9861%252889%252990240-3%26sid%3Dliteratum%253Aachs%26aulast%3DReinhardt%26aufirst%3DT.%2BA.%26aulast%3DHorst%26aufirst%3DR.%2BL.%26atitle%3DKetoconazole%2520Inhibits%2520Self-Induced%2520Metabolism%2520of%25201%252C25-Dihydroxyvitamin%2520D3%2520and%2520Amplifies%25201%252C25-Dihydroxyvitamin%2520D3%2520Receptor%2520Up-Regulation%2520in%2520Rat%2520Osteosarcoma%2520Cells%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1989%26volume%3D272%26spage%3D459%26epage%3D465%26doi%3D10.1016%2F0003-9861%2889%2990240-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilicarslan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, E. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.3.314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fdmd.30.3.314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11854151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhtl2qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=314-318&author=W.+Zhangauthor=Y.+Ramamoorthyauthor=T.+Kilicarslanauthor=H.+Nolteauthor=R.+F.+Tyndaleauthor=E.+M.+Sellers&title=Inhibition+of+Cytochromes+P450+by+Antifungal+Imidazole+Derivatives&doi=10.1124%2Fdmd.30.3.314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytochromes P450 by antifungal imidazole derivatives</span></div><div class="casAuthors">Zhang, Wenjiang; Ramamoorthy, Yamini; Kilicarslan, Tansel; Nolte, Helma; Tyndale, Rachel F.; Sellers, Edward M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-318</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The interactions of a panel of antifungal agents with cytochromes P 450 (P450s), as a means of predicting potential drug-drug interactions, have not yet been investigated.  The objective of this study was to evaluate the specificity and selectivity of five antifungal agents using selective probe reactions for each of the eight major P450s.  The index reactions used were phenacetin O-deethylation (for CYP1A2), coumarin 7-hydroxylation (CYP2A6), diclofenac 4'-hydroxylation (CYP2C9), omeprazole 5-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), 7-ethoxy-4-trifluoromethylcoumarin deethylation (CYP2B6), chlorzoxazone 6-hydroxylation (CYP2E1), and omeprazole sulfonation (CYP3A4).  Five antifungal agents that include an imidazole moiety (clotrimazole, miconazole, sulconazole, tioconazole, and ketoconazole) were examd. in cDNA-expressing microsomes from human lymphoblast cells or human liver microsomes.  All inhibitors studied demonstrated nonselective inhibition of P450s.  Ketoconazole seemed to be the most selective for CYP3A4, although it also inhibited CYP2C9.  High-affinity inhibition was seen for CYP1A2 (sulconazole and tioconazole Ki, 0.4 μM), CYP2B6 (miconazole Ki, 0.05 μM; sulconazole Ki, 0.04 μM), CYP2C19 (miconazole Ki, 0.05 μM; sulconazole Ki, 0.008 μM; tioconazole Ki, 0.04 μM), CYP2C9 (sulconazole Ki, 0.01 μM), CYP2D6 (miconazole Ki, 0.70 μM; sulconazole Ki, 0.40 μM), CYP2E1 (tioconazole Ki, 0.4 μM) and CYP3A4 (clotrimazole Ki, 0.02 μM; miconazole Ki, 0.03 μM; tioconazole Ki, 0.02 μM).  Therefore, this class of compds. is likely to result in significant drug-drug interactions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYP5Jc4ykk47Vg90H21EOLACvtfcHk0ljVW9U1lY_0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhtl2qt7k%253D&md5=a7b9f9e1080415a5ddf524197d913ca9</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.3.314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.3.314%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRamamoorthy%26aufirst%3DY.%26aulast%3DKilicarslan%26aufirst%3DT.%26aulast%3DNolte%26aufirst%3DH.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DInhibition%2520of%2520Cytochromes%2520P450%2520by%2520Antifungal%2520Imidazole%2520Derivatives%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D314%26epage%3D318%26doi%3D10.1124%2Fdmd.30.3.314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. S.</span></span> <span> </span><span class="NLM_article-title">Potent, Low-Calcemic, Selective Inhibitors of CYP24 Hydroxylase: 24-Sulfone Analogs of the Hormone 1alpha,25-Dihydroxyvitamin D3</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>89–90</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.03.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jsbmb.2004.03.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15225738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1aitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89%E2%80%9390&publication_year=2004&pages=5-12&author=G.+H.+Posnerauthor=K.+R.+Crawfordauthor=H.+W.+Yangauthor=M.+Kahramanauthor=H.+B.+Jeonauthor=H.+Liauthor=J.+K.+Leeauthor=B.+C.+Suhauthor=M.+A.+Hatcherauthor=T.+Labonteauthor=A.+Useraauthor=P.+M.+Dolanauthor=T.+W.+Kenslerauthor=S.+Pelegauthor=G.+Jonesauthor=A.+Zhangauthor=B.+Korczakauthor=U.+Sahaauthor=S.+S.+Chuang&title=Potent%2C+Low-Calcemic%2C+Selective+Inhibitors+of+CYP24+Hydroxylase%3A+24-Sulfone+Analogs+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D3&doi=10.1016%2Fj.jsbmb.2004.03.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1α,25-dihydroxyvitamin D3</span></div><div class="casAuthors">Posner, Gary H.; Crawford, Kenneth R.; Yang, Hong Woon; Kahraman, Mehmet; Jeon, Heung Bae; Li, Hongbin; Lee, Jae Kyoo; Suh, Byung Chul; Hatcher, Mark A.; Labonte, Tanzina; Usera, Aimee; Dolan, Patrick M.; Kensler, Thomas W.; Peleg, Sara; Jones, Glenville; Zhang, Anqi; Korczak, Bozena; Saha, Uttam; Chuang, Samuel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">89-90</span>
        (<span class="NLM_cas:issue">1-5</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">: Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The new 24-phenylsulfone I, a low-calcemic analog of the natural hormone 1α,25-dihydroxyvitamin D3, is a potent (IC50 = 28 nM) and highly selective inhibitor of the human 24-hydroxylase enzyme CYP24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt9NmFVhdDa7Vg90H21EOLACvtfcHk0lhvPLskXpT-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1aitL4%253D&md5=2c6e2ce35ff0ff066a2bab0368defb09</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.03.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.03.044%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DCrawford%26aufirst%3DK.%2BR.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DJeon%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DSuh%26aufirst%3DB.%2BC.%26aulast%3DHatcher%26aufirst%3DM.%2BA.%26aulast%3DLabonte%26aufirst%3DT.%26aulast%3DUsera%26aufirst%3DA.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DKorczak%26aufirst%3DB.%26aulast%3DSaha%26aufirst%3DU.%26aulast%3DChuang%26aufirst%3DS.%2BS.%26atitle%3DPotent%252C%2520Low-Calcemic%252C%2520Selective%2520Inhibitors%2520of%2520CYP24%2520Hydroxylase%253A%252024-Sulfone%2520Analogs%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D3%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D89%25E2%2580%259390%26spage%3D5%26epage%3D12%26doi%3D10.1016%2Fj.jsbmb.2004.03.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">Conceptually New Sulfone Analogues of the Hormone 1alpha, 25-Dihydroxyvitamin D(3): Synthesis and Preliminary Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3425</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1021/jm990267c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990267c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXltV2lsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3425-3435&author=G.+H.+Posnerauthor=Q.+Wangauthor=G.+Hanauthor=J.+K.+Leeauthor=K.+Crawfordauthor=S.+Zandauthor=H.+Bremauthor=S.+Pelegauthor=P.+Dolanauthor=T.+W.+Kensler&title=Conceptually+New+Sulfone+Analogues+of+the+Hormone+1alpha%2C+25-Dihydroxyvitamin+D%283%29%3A+Synthesis+and+Preliminary+Biological+Evaluation&doi=10.1021%2Fjm990267c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Conceptually New Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Preliminary Biological Evaluation</span></div><div class="casAuthors">Posner, Gary H.; Wang, Qiang; Han, Gyoonhee; Lee, Jae Kyoo; Crawford, Kenneth; Zand, Sarvenaz; Brem, Henry; Peleg, Sara; Dolan, Patrick; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3425-3435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A conceptually new series of vitamin D3-like nonfluorinated and fluorinated 16-ene side chain tert-Bu sulfones I [X = CH2CH2, 1α-OH, 3β-OH; (CH2)3, 1α-OH, 3β-OH; (CH2)3, 1β-OH, 3α-OH; (CH2CH2CF2), 1α-OH, 3β-OH; (CH2CH2CF2), 1β-OH, 3α-OH; (E)-CH2CH:CH, 1α-OH, 3β-OH; (E)-CH2CH:CH, 1β-OH, 3α-OH; (E)-CH2CH:CF, 1α-OH, 3β-OH; (E)-CH2CH:CF, 1β-OH, 3α-OH] were synthesized.  Even though these novel C,D-ring side chain analogs of the hormone 1α,25-dihydroxyvitamin D3 lack a terminal OH group thought previously to be essential for high biol. activity, they are highly antiproliferative and, in several cases, transcriptionally active in vitro but desirably noncalcemic in vivo.  The side chain sulfone group may be binding to the nVDR as a hydrogen-bond acceptor, in contrast to the hydrogen-bond donor function of the 25-OH group of natural 1,25D3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5HbGa4Pytb7Vg90H21EOLACvtfcHk0lhvPLskXpT-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltV2lsL0%253D&md5=37df7a66f770ad8d5660a20ede562fba</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1021%2Fjm990267c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990267c%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DZand%26aufirst%3DS.%26aulast%3DBrem%26aufirst%3DH.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DConceptually%2520New%2520Sulfone%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C%252025-Dihydroxyvitamin%2520D%25283%2529%253A%2520Synthesis%2520and%2520Preliminary%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3425%26epage%3D3435%26doi%3D10.1021%2Fjm990267c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu-Caldera, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabia, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Etten, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vouros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1alpha,25-Dihydroxyvitamin D(3): Synthesis and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3581</span>– <span class="NLM_lpage">3586</span>, <span class="refDoi"> DOI: 10.1021/jm000215j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000215j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFaqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3581-3586&author=G.+H.+Posnerauthor=K.+Crawfordauthor=M.+L.+Siu-Calderaauthor=G.+S.+Reddyauthor=S.+F.+Sarabiaauthor=D.+Feldmanauthor=E.+van+Ettenauthor=C.+Mathieuauthor=L.+Gennaroauthor=P.+Vourosauthor=S.+Pelegauthor=P.+M.+Dolanauthor=T.+W.+Kensler&title=Conceptually+New+20-epi-22-Oxa+Sulfone+Analogues+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D%283%29%3A+Synthesis+and+Biological+Evaluation&doi=10.1021%2Fjm000215j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Biological Evaluation</span></div><div class="casAuthors">Posner, Gary H.; Crawford, Kenneth; Siu-Caldera, Mei-Ling; Reddy, G. Satyanarayana; Sarabia, Stephen F.; Feldman, David; vanEtten, Evelyne; Mathieu, Chantal; Gennaro, Lynn; Vouros, Paul; Peleg, Sara; Dolan, Patrick M.; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3581-3586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New C,D-ring side-chain-modified sulfone I, with natural 1α,3β-hydroxyl groups but lacking the 25-hydroxyl group characteristic of the natural hormone 1α,25-dihydroxyvitamin D3, was prepd. and characterized.  Novel synthetic features include: (1) chemoselective oxidn. of only a primary silyl ether in a primary-secondary bis-silyl ether intermediate and (2) smooth reductive etherification without interference by a neighboring sulfonyl group.  I, but not its 1β,3α-diastereomer, was powerfully antiproliferative and transcriptionally active in vitro but desirably noncalcemic in vivo.  Although I, designed to resemble Leo Pharmaceutical Co.'s KH-1060 (3), was recognized by catabolic enzymes, the selective biol. profile of I is likely not due to its metabolites that are formed in only minor amts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOUvngld7sQLVg90H21EOLACvtfcHk0lhvPLskXpT-Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFaqt7k%253D&md5=24d1f1753bdaf69bfd4e3967d4efc53a</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1021%2Fjm000215j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000215j%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DSiu-Caldera%26aufirst%3DM.%2BL.%26aulast%3DReddy%26aufirst%3DG.%2BS.%26aulast%3DSarabia%26aufirst%3DS.%2BF.%26aulast%3DFeldman%26aufirst%3DD.%26aulast%3Dvan%2BEtten%26aufirst%3DE.%26aulast%3DMathieu%26aufirst%3DC.%26aulast%3DGennaro%26aufirst%3DL.%26aulast%3DVouros%26aufirst%3DP.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DConceptually%2520New%252020-epi-22-Oxa%2520Sulfone%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D%25283%2529%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3581%26epage%3D3586%26doi%3D10.1021%2Fjm000215j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinishtaj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1alpha,25-Dihydroxyvitamin D(3)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">6854</span>– <span class="NLM_lpage">6863</span>, <span class="refDoi"> DOI: 10.1021/jm040129+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040129%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVansrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6854-6863&author=M.+Kahramanauthor=S.+Sinishtajauthor=P.+M.+Dolanauthor=T.+W.+Kenslerauthor=S.+Pelegauthor=U.+Sahaauthor=S.+S.+Chuangauthor=G.+Bernsteinauthor=B.+Korczakauthor=G.+H.+Posner&title=Potent%2C+Selective+and+Low-Calcemic+Inhibitors+of+CYP24+Hydroxylase%3A+24-Sulfoximine+Analogues+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D%283%29&doi=10.1021%2Fjm040129%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D3</span></div><div class="casAuthors">Kahraman, Mehmet; Sinishtaj, Sandra; Dolan, Patrick M.; Kensler, Thomas W.; Peleg, Sara; Saha, Uttam; Chuang, Samuel S.; Bernstein, Galina; Korczak, Bozena; Posner, Gary H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6854-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A dozen 24-sulfoximine analogs of the hormone 1α,25-dihydroxyvitamin D3 were prepd., differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring.  Although these sulfoximines were not active transcriptionally and were only very weakly antiproliferative, some of them are powerful hydroxylase enzyme inhibitors.  Specifically, 24(S)-NH Ph sulfoximine I is an extremely potent CYP24 inhibitor (IC50 = 7.4 nM) having low calcemic activity.  In addn., this compd. shows high selectivity toward the CYP24 enzyme in comparison to CYP27A1 (IC50 > 1000 nM) and CYP27B (IC50 = 554 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89y_8mOPfOrVg90H21EOLACvtfcHk0ljDQ2CL3zjR2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVansrbP&md5=c1c9be3a2448f5bcfec4ae11d183677a</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1021%2Fjm040129%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040129%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DSinishtaj%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DU.%26aulast%3DChuang%26aufirst%3DS.%2BS.%26aulast%3DBernstein%26aufirst%3DG.%26aulast%3DKorczak%26aufirst%3DB.%26aulast%3DPosner%26aufirst%3DG.%2BH.%26atitle%3DPotent%252C%2520Selective%2520and%2520Low-Calcemic%2520Inhibitors%2520of%2520CYP24%2520Hydroxylase%253A%252024-Sulfoximine%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D%25283%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6854%26epage%3D6863%26doi%3D10.1021%2Fjm040129%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petkovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">CYP24A1 and Kidney Disease</span>. <i>Curr. Opin. Nephrol. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1097/MNH.0b013e3283477a7b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FMNH.0b013e3283477a7b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21610497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntF2ns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=337-344&author=M.+Petkovichauthor=G.+Jones&title=CYP24A1+and+Kidney+Disease&doi=10.1097%2FMNH.0b013e3283477a7b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">CYP24A1 and kidney disease</span></div><div class="casAuthors">Petkovich, Martin; Jones, Glenville</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Nephrology and Hypertension</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">CNHYEM</span>;
        ISSN:<span class="NLM_cas:issn">1062-4821</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Patients with chronic renal disease have elevated serum phosphate levels, elevated fibroblast-like growth factor 23 (FGF-23), and declining vitamin D status.  These changes are related and may be responsible for elevated 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) and dysfunctional vitamin D metab.  This review focuses on the biochem. and pathophysiol. of CYP24A1 and the utility of blocking this enzyme with CYP24A1 inhibitors in chronic kidney disease (CKD) patients.  Recent findings: CYP24A1 is the cytochrome P 450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (25-OHD3) and its hormonal form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], into 24-hydroxylated products targeted for excretion.  The CYP24A1-null phenotype is consistent with the catabolic role of CYP24A1.  A no. of polymorphisms of CYP24A1 have recently been identified.  New data from the uremic rat and humans suggest that dysfunctional vitamin D metab. is due to changes in CYP24A1 expression caused by phosphate and FGF-23 elevations.  Summary: Changes in serum phosphate and FGF-23 levels in the CKD patient increase CYP24A1 expression resulting in decreased vitamin D status.  Vitamin D deficiency may exacerbate defective calcium and phosphate homeostasis causing renal osteodystrophy and contribute to the other complications of renal disease.  These findings argue for increased focus on correcting vitamin D deficiency in CKD patients by blocking CYP24A1 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKFPKp_bEE7Vg90H21EOLACvtfcHk0ljDQ2CL3zjR2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntF2ns7s%253D&md5=54d04f8632227833444db3e1451bffc0</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3283477a7b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3283477a7b%26sid%3Dliteratum%253Aachs%26aulast%3DPetkovich%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%26atitle%3DCYP24A1%2520and%2520Kidney%2520Disease%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2011%26volume%3D20%26spage%3D337%26epage%3D344%26doi%3D10.1097%2FMNH.0b013e3283477a7b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, W. G.</span></span> <span> </span><span class="NLM_article-title">Medical Management of Secondary Hyperparathyroidism in Chronic Renal Failure</span>. <i>Nephrol. Dial. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fndt%2Fgfg1002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFWhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2-8&author=W.+G.+Goodman&title=Medical+Management+of+Secondary+Hyperparathyroidism+in+Chronic+Renal+Failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Medical management of secondary hyperparathyroidism in chronic renal failure</span></div><div class="casAuthors">Goodman, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">iii2-iii8</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Abnormalities in calcium and phosphorus metab. are common, and metabolic bone disease develops often in patients with chronic renal failure (CRF).  Effective clin. management includes measures to control phosphorus retention and prevent hyperphosphatemia, to maintain serum calcium concns. within the normal range and to prevent excess parathyroid hormone (PTH) secretion by the judicious use of vitamin D sterols.  Certain of these interventions appear to increase the risk of soft tissue and vascular calcification in patients with end-stage renal disease (ESRD), changes that may contribute to the development of cardiovascular disease.  Current therapeutic approaches are thus being re-evaluated in an effort to limit these risks.  Despite the importance of controlling phosphorus retention and preventing hyperphosphatemia in patients with CRF, current management strategies often are inadequate, particularly in those ingesting diets contg. adequate amts. of protein.  Results from clin. trials using daily haemodialysis strongly suggest that thrice-weekly haemodialysis regimens are only marginally adequate for achieving weekly phosphorus balance in many patients with ESRD.  The safety of large oral doses of calcium as a phosphate-binding agent in patients with ESRD has also been questioned because excess amts. of calcium that are absorbed from the gastrointestinal tract may lead to ongoing calcium retention in those with little or no residual renal function.  Arterial calcification and cardiac valve calcification are two serious complications that adversely affect cardiovascular hemodynamics.  The use of large, often supraphysiol., doses of calcitriol or other vitamin D sterols to treat secondary hyperparathyroidism may aggravate hypercalcemia and hyperphosphatemia, further increasing the risk of soft tissue and vascular calcification.  Phosphate-binding agents that do not contain calcium, new vitamin D analogs and calcimimetic compds. offer new therapeutic alternatives for managing renal osteodystrophy.  The integration of these novel agents into existing treatment regimens may provide safer and more effective methods for controlling secondary hyperparathyroidism and renal bone disease, while limiting the risks of soft tissue and vascular calcification in patients with CRF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBdqAxyywh7Vg90H21EOLACvtfcHk0ljDQ2CL3zjR2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFWhu7k%253D&md5=54b9720aae84faece1769e7288dc0923</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfg1002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfg1002%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DW.%2BG.%26atitle%3DMedical%2520Management%2520of%2520Secondary%2520Hyperparathyroidism%2520in%2520Chronic%2520Renal%2520Failure%26jtitle%3DNephrol.%2520Dial.%2520Transplant.%26date%3D2003%26volume%3D18%26spage%3D2%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helvig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuerrier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharebov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epps, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petkovich, M.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Analogues Targeting CYP24 in Chronic Kidney Disease</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2010.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jsbmb.2010.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20347976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=13-19&author=G.+H.+Posnerauthor=C.+Helvigauthor=D.+Cuerrierauthor=D.+Collopauthor=A.+Kharebovauthor=K.+Ryderauthor=T.+Eppsauthor=M.+Petkovich&title=Vitamin+D+Analogues+Targeting+CYP24+in+Chronic+Kidney+Disease&doi=10.1016%2Fj.jsbmb.2010.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D analogues targeting CYP24 in chronic kidney disease</span></div><div class="casAuthors">Posner, Gary H.; Helvig, Christian; Cuerrier, Dominic; Collop, Drew; Kharebov, Aza; Ryder, Kara; Epps, Tina; Petkovich, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cytochrome P 450 enzyme 24-hydroxylase (CYP24) plays a crit. role in regulating levels of vitamin D hormone.  Aberrant expression of CYP24 has been implicated in vitamin D insufficiency and resistance to vitamin D therapy.  We have demonstrated amplified CYP24 expression in uremic rats, suggesting that CYP24 has an etiol. role in vitamin D insufficiency commonly assocd. with chronic kidney disease (CKD).  We have designed two new analogs of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), namely CTA 091 and CTA 018/MT 2832, which are potent inhibitors of CYP24.  In vitro studies with CTA 091 show that it enhances the potency of 1α,25(OH)2D3.  In vivo studies demonstrate that CTA 091 decreases serum intact parathyroid hormone (iPTH) levels and increases circulating 1α,25(OH)2D3.  CTA 091 increases both C max and AUC of co-administered 1α,25(OH)2D3.  These studies indicate that CYP24 inhibition can increase cellular responsiveness to vitamin D hormone and potentiate vitamin D therapy.  CTA 018/MT 2832 differs from CTA 091 in that it also has the ability to activate vitamin D receptor-mediated transcription.  CTA 018/MT 2832 effectively suppresses elevated iPTH secretion at doses which do not affect serum calcium or phosphorus levels in a rodent model of CKD.  Studies with both new analogs underscore the potential utility of CYP24 inhibition in the treatment of secondary hyperparathyroidism in CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounHlAlWbmgbVg90H21EOLACvtfcHk0ljDQ2CL3zjR2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVCqtL8%253D&md5=7a102feb2c380d8782137c0bdb043406</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2010.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2010.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DHelvig%26aufirst%3DC.%26aulast%3DCuerrier%26aufirst%3DD.%26aulast%3DCollop%26aufirst%3DD.%26aulast%3DKharebov%26aufirst%3DA.%26aulast%3DRyder%26aufirst%3DK.%26aulast%3DEpps%26aufirst%3DT.%26aulast%3DPetkovich%26aufirst%3DM.%26atitle%3DVitamin%2520D%2520Analogues%2520Targeting%2520CYP24%2520in%2520Chronic%2520Kidney%2520Disease%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D121%26spage%3D13%26epage%3D19%26doi%3D10.1016%2Fj.jsbmb.2010.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagamani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, K.</span></span> <span> </span><span class="NLM_article-title">A Theoretical Insight to Understand the Molecular Mechanism of Dual Target Ligand CTA-018 in the Chronic Kidney Disease Pathogenesis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e0203194</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0203194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0203194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30286109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0203194&author=S.+Nagamaniauthor=K.+Muthusamy&title=A+Theoretical+Insight+to+Understand+the+Molecular+Mechanism+of+Dual+Target+Ligand+CTA-018+in+the+Chronic+Kidney+Disease+Pathogenesis&doi=10.1371%2Fjournal.pone.0203194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis</span></div><div class="casAuthors">Nagamani, Selvaraman; Muthusamy, Karthikeyan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0203194/1-e0203194/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The level of the vitamin D in the bloodstream is regulated by cytochrome P 450 enzyme 24-hydroxylase A1 (CYP24A1).  Over expression of CYP24A1 enzyme is correlated with vitamin D deficiency and resistance to vitamin D therapy.  Chronic kidney disease (CKD) patients are commonly reported with the above said expression variations.  This deregulation could be solved by ligands that act as a vitamin D receptor (VDR) agonists and CYP24A1 antagonists.  Posner et al., (2010) first time reported two new vitamin D analogs namely CTA-091 and CTA-018 to inhibit CYP24A1.  The CTA-018 inhibited CYP24A1 with an IC50 27 ± 6 nM (10 times more potent than the ketoconazole (253 ± 20 nM)).  CTA-018 induced VDR expression (15-fold lower than 1α,25(OH)2D3) and is under phase II clin. trial, whereas CTA-091 was not able to efficiently induce the VDR expression (>2000 nM).  To explore the mol. mechanism, binding specificity of these two vitamin D analogs along with native ligand was extensively studied through in silico approaches.  Through mol. dynamics simulations studies, we shown that the sulfonic group (O = S = O) in the side chain of CTA-018 plays an important role in the regulation of VDR agonistic activity.  The electron lone pairs of the sulfonic group that interacted with His393 lead to be a factor for agonistic mechanism of VDR activity.  Compared to azol-based compds., CTA-018 binds the different sites in the CYP24A1 binding cavity and thus it could be a potent antagonistic for CYP24A1 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5fKsPbaqcxLVg90H21EOLACvtfcHk0lhXqjJ_2i5t8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKhtrc%253D&md5=75588e9163efa5c6a2e3333adccd8b22</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0203194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0203194%26sid%3Dliteratum%253Aachs%26aulast%3DNagamani%26aufirst%3DS.%26aulast%3DMuthusamy%26aufirst%3DK.%26atitle%3DA%2520Theoretical%2520Insight%2520to%2520Understand%2520the%2520Molecular%2520Mechanism%2520of%2520Dual%2520Target%2520Ligand%2520CTA-018%2520in%2520the%2520Chronic%2520Kidney%2520Disease%2520Pathogenesis%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26spage%3De0203194%26doi%3D10.1371%2Fjournal.pone.0203194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group">Press
Release, Mitsubishi Tanabe Pharma Corporation</span>. <a href="https://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC_120601.pdf" class="extLink">https://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC_120601.pdf</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Press%0ARelease%2C+Mitsubishi+Tanabe+Pharma+Corporation.+https%3A%2F%2Fwww.mt-pharma.co.jp%2Fe%2Frelease%2Fnr%2F2012%2Fpdf%2FeMTPC_120601.pdf+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delzell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson-Hughes, B.</span></span> <span> </span><span class="NLM_article-title">The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1002/jbmr.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fjbmr.2269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24771492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2cnntFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=2520-2526&author=N.+C.+Wrightauthor=A.+C.+Lookerauthor=K.+G.+Saagauthor=J.+R.+Curtisauthor=E.+S.+Delzellauthor=S.+Randallauthor=B.+Dawson-Hughes&title=The+Recent+Prevalence+of+Osteoporosis+and+Low+Bone+Mass+in+the+United+States+Based+on+Bone+Mineral+Density+at+the+Femoral+Neck+or+Lumbar+Spine&doi=10.1002%2Fjbmr.2269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine</span></div><div class="casAuthors">Wright Nicole C; Looker Anne C; Saag Kenneth G; Curtis Jeffrey R; Delzell Elizabeth S; Randall Susan; Dawson-Hughes Bess</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2520-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The goal of our study was to estimate the prevalence of osteoporosis and low bone mass based on bone mineral density (BMD) at the femoral neck and the lumbar spine in adults 50 years and older in the United States (US).  We applied prevalence estimates of osteoporosis or low bone mass at the femoral neck or lumbar spine (adjusted by age, sex, and race/ethnicity to the 2010 Census) for the noninstitutionalized population aged 50 years and older from the National Health and Nutrition Examination Survey 2005-2010 to 2010 US Census population counts to determine the total number of older US residents with osteoporosis and low bone mass.  There were more than 99 million adults aged 50 years and older in the US in 2010.  Based on an overall 10.3% prevalence of osteoporosis, we estimated that in 2010, 10.2 million older adults had osteoporosis.  The overall low bone mass prevalence was 43.9%, from which we estimated that 43.4 million older adults had low bone mass.  We estimated that 7.7 million non-Hispanic white, 0.5 million non-Hispanic black, and 0.6 million Mexican American adults had osteoporosis, and another 33.8, 2.9, and 2.0 million had low bone mass, respectively.  When combined, osteoporosis and low bone mass at the femoral neck or lumbar spine affected an estimated 53.6 million older US adults in 2010.  Although most of the individuals with osteoporosis or low bone mass were non-Hispanic white women, a substantial number of men and women from other racial/ethnic groups also had osteoporotic BMD or low bone mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB9ouK8Clo_xBrI9DTGjC0fW6udTcc2ebkluf6cRKt1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnntFGmsA%253D%253D&md5=c2c9f6ac188f871116412e570a636221</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1002%2Fjbmr.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbmr.2269%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DN.%2BC.%26aulast%3DLooker%26aufirst%3DA.%2BC.%26aulast%3DSaag%26aufirst%3DK.%2BG.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DDelzell%26aufirst%3DE.%2BS.%26aulast%3DRandall%26aufirst%3DS.%26aulast%3DDawson-Hughes%26aufirst%3DB.%26atitle%3DThe%2520Recent%2520Prevalence%2520of%2520Osteoporosis%2520and%2520Low%2520Bone%2520Mass%2520in%2520the%2520United%2520States%2520Based%2520on%2520Bone%2520Mineral%2520Density%2520at%2520the%2520Femoral%2520Neck%2520or%2520Lumbar%2520Spine%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2014%26volume%3D29%26spage%3D2520%26epage%3D2526%26doi%3D10.1002%2Fjbmr.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petak, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleerekoper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewiecki, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessah-Pollack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangpricha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimalawansa, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, N. B.</span></span> <span> </span><span class="NLM_article-title">American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016</span>. <i>Endocrine Practice</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.4158/EP161435.GL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4158%2FEP161435.GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27662240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FitVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1-42&author=P.+M.+Camachoauthor=S.+M.+Petakauthor=N.+Binkleyauthor=B.+L.+Clarkeauthor=S.+T.+Harrisauthor=D.+L.+Hurleyauthor=M.+Kleerekoperauthor=E.+M.+Lewieckiauthor=P.+D.+Millerauthor=H.+S.+Narulaauthor=R.+Pessah-Pollackauthor=V.+Tangprichaauthor=S.+J.+Wimalawansaauthor=N.+B.+Watts&title=American+Association+of+Clinical+Endocrinologists+and+American+College+of+Endocrinology+Clinical+Practice+Guidelines+for+the+Diagnosis+and+Treatment+of+Postmenopausal+Osteoporosis+-+2016&doi=10.4158%2FEP161435.GL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016</span></div><div class="casAuthors">Camacho Pauline M; Petak Steven M; Binkley Neil; Clarke Bart L; Harris Steven T; Hurley Daniel L; Kleerekoper Michael; Lewiecki E Michael; Miller Paul D; Narula Harmeet S; Pessah-Pollack Rachel; Tangpricha Vin; Wimalawansa Sunil J; Watts Nelson B</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">Suppl 4</span>),
    <span class="NLM_cas:pages">1-42</span>
        ISSN:<span class="NLM_cas:issn">1530-891X</span>.
    </div><div class="casAbstract">ABBREVIATIONS:  AACE = American Association of Clinical Endocrinologists AFF = atypical femur fracture ASBMR = American Society for Bone and Mineral Research BEL = best evidence level BMD = bone mineral density BTM = bone turnover marker CBC = complete blood count CI = confidence interval DXA = dual-energy X-ray absorptiometry EL = evidence level FDA = U.S.  Food and Drug Administration FLEX = Fracture Intervention Trial (FIT) Long-term Extension FRAX® = Fracture Risk Assessment Tool GFR = glomerular filtration rate GI = gastrointestinal HORIZON = Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly IOF = International Osteoporosis Foundation ISCD = International Society for Clinical Densitometry IU = international units IV = intravenous LSC = least significant change NBHA = National Bone Health Alliance NOF = National Osteoporosis Foundation 25(OH)D = 25-hydroxy vitamin D ONJ = osteonecrosis of the jaw PINP = serum carboxy-terminal propeptide of type I collagen PTH = parathyroid hormone R = recommendation RANK = receptor activator of nuclear factor kappa-B RANKL = receptor activator of nuclear factor kappa-B ligand RCT = randomized controlled trial RR = relative risk S-CTX = serum C-terminal telopeptide SQ = subcutaneous VFA = vertebral fracture assessment WHO = World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhPe6ovOhjlexsqfvU0ziafW6udTcc2ebkluf6cRKt1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FitVehtQ%253D%253D&md5=82fca4af11d47a928d64d6b49505152f</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.4158%2FEP161435.GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4158%252FEP161435.GL%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DP.%2BM.%26aulast%3DPetak%26aufirst%3DS.%2BM.%26aulast%3DBinkley%26aufirst%3DN.%26aulast%3DClarke%26aufirst%3DB.%2BL.%26aulast%3DHarris%26aufirst%3DS.%2BT.%26aulast%3DHurley%26aufirst%3DD.%2BL.%26aulast%3DKleerekoper%26aufirst%3DM.%26aulast%3DLewiecki%26aufirst%3DE.%2BM.%26aulast%3DMiller%26aufirst%3DP.%2BD.%26aulast%3DNarula%26aufirst%3DH.%2BS.%26aulast%3DPessah-Pollack%26aufirst%3DR.%26aulast%3DTangpricha%26aufirst%3DV.%26aulast%3DWimalawansa%26aufirst%3DS.%2BJ.%26aulast%3DWatts%26aufirst%3DN.%2BB.%26atitle%3DAmerican%2520Association%2520of%2520Clinical%2520Endocrinologists%2520and%2520American%2520College%2520of%2520Endocrinology%2520Clinical%2520Practice%2520Guidelines%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Postmenopausal%2520Osteoporosis%2520-%25202016%26jtitle%3DEndocrine%2520Practice%26date%3D2016%26volume%3D22%26spage%3D1%26epage%3D42%26doi%3D10.4158%2FEP161435.GL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beur, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewiecki, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, R.</span></span> <span> </span><span class="NLM_article-title">National Osteoporosis, F. Clinician’s Guide to Prevention and Treatment of Osteoporosis</span>. <i>Osteoporosis Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1007/s00198-014-2794-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00198-014-2794-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25182228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2359-2381&author=F.+Cosmanauthor=S.+J.+de+Beurauthor=M.+S.+LeBoffauthor=E.+M.+Lewieckiauthor=B.+Tannerauthor=S.+Randallauthor=R.+Lindsay&title=National+Osteoporosis%2C+F.+Clinician%E2%80%99s+Guide+to+Prevention+and+Treatment+of+Osteoporosis&doi=10.1007%2Fs00198-014-2794-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Clinician's Guide to Prevention and Treatment of Osteoporosis</span></div><div class="casAuthors">Cosman F; de Beur S J; LeBoff M S; Lewiecki E M; Tanner B; Randall S; Lindsay R</div><div class="citationInfo"><span class="NLM_cas:title">Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2359-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF.  Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQwUgxAQsScgpJitSxOdIlfW6udTcc2ebdQOeHh-O1rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVKitQ%253D%253D&md5=3c4417881ee5308a6ca77adff62a1061</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1007%2Fs00198-014-2794-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00198-014-2794-2%26sid%3Dliteratum%253Aachs%26aulast%3DCosman%26aufirst%3DF.%26aulast%3Dde%2BBeur%26aufirst%3DS.%2BJ.%26aulast%3DLeBoff%26aufirst%3DM.%2BS.%26aulast%3DLewiecki%26aufirst%3DE.%2BM.%26aulast%3DTanner%26aufirst%3DB.%26aulast%3DRandall%26aufirst%3DS.%26aulast%3DLindsay%26aufirst%3DR.%26atitle%3DNational%2520Osteoporosis%252C%2520F.%2520Clinician%25E2%2580%2599s%2520Guide%2520to%2520Prevention%2520and%2520Treatment%2520of%2520Osteoporosis%26jtitle%3DOsteoporosis%2520Int.%26date%3D2014%26volume%3D25%26spage%3D2359%26epage%3D2381%26doi%3D10.1007%2Fs00198-014-2794-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson-Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosteson, A.</span></span> <span> </span><span class="NLM_article-title">Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1359/jbmr.061113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1359%2Fjbmr.061113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17144789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2s7htV2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=465-475&author=R.+Burgeauthor=B.+Dawson-Hughesauthor=D.+H.+Solomonauthor=J.+B.+Wongauthor=A.+Kingauthor=A.+Tosteson&title=Incidence+and+Economic+Burden+of+Osteoporosis-Related+Fractures+in+the+United+States%2C+2005%E2%80%932025&doi=10.1359%2Fjbmr.061113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025</span></div><div class="casAuthors">Burge Russel; Dawson-Hughes Bess; Solomon Daniel H; Wong John B; King Alison; Tosteson Anna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-75</span>
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    </div><div class="casAbstract">UNLABELLED:  This study predicts the burden of incident osteoporosis-related fractures and costs in the United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025.  Total fractures were >2 million, costing nearly $17 billion in 2005.  Men account for >25% of the burden.  Rapid growth in the disease burden is projected among nonwhite populations.  INTRODUCTION:  The aging of the U.S. population will likely lead to greater prevalence of osteoporosis.  Policy makers require precise projections of the disease burden by demographic subgroups and skeletal sites to effectively target osteoporosis intervention and treatment programs.  MATERIALS AND METHODS:  A state transition Markov decision model was used to estimate total incident fractures and costs by age, sex, race/ethnicity, and skeletal site for the U.S. population 50 years of age for 2005-2025.  RESULTS:  More than 2 million incident fractures at a cost of $17 billion are predicted for 2005.  Total costs including prevalent fractures are more than $19 billion.  Men account for 29% of fractures and 25% of costs.  Total incident fractures by skeletal site were vertebral (27%), wrist (19%), hip (14%), pelvic (7%), and other (33%).  Total costs by fracture type were vertebral (6%), hip (72%), wrist (3%), pelvic (5%), and other (14%).  By 2025, annual fractures and costs are projected to rise by almost 50%.  The most rapid growth is estimated for people 65-74 years of age, with an increase>87%.  An increase of nearly 175% is projected for Hispanic and other subpopulations.  CONCLUSIONS:  Osteoporosis prevention, treatment, and education efforts should address all skeletal sites, not just hip and vertebral, and appropriate attention is warranted for men and diverse race/ethnicity subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRQS3mhiTMFENoizSOkG_FfW6udTcc2ebdQOeHh-O1rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7htV2htg%253D%253D&md5=d58ecca501867d9a2498c2a68aa36ce5</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.061113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.061113%26sid%3Dliteratum%253Aachs%26aulast%3DBurge%26aufirst%3DR.%26aulast%3DDawson-Hughes%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DJ.%2BB.%26aulast%3DKing%26aufirst%3DA.%26aulast%3DTosteson%26aufirst%3DA.%26atitle%3DIncidence%2520and%2520Economic%2520Burden%2520of%2520Osteoporosis-Related%2520Fractures%2520in%2520the%2520United%2520States%252C%25202005%25E2%2580%25932025%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2007%26volume%3D22%26spage%3D465%26epage%3D475%26doi%3D10.1359%2Fjbmr.061113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref289"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref289'); return false;" data-citation="" class="refNumLink">289</a></strong><div class="NLM_citation" id="cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raisz, L. G.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of Osteoporosis: Concepts, Conflicts, and Prospects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3318</span>– <span class="NLM_lpage">3325</span>, <span class="refDoi"> DOI: 10.1172/JCI27071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1172%2FJCI27071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16322775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3318-3325&author=L.+G.+Raisz&title=Pathogenesis+of+Osteoporosis%3A+Concepts%2C+Conflicts%2C+and+Prospects&doi=10.1172%2FJCI27071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of osteoporosis: Concepts, conflicts, and prospects</span></div><div class="casAuthors">Raisz, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3318-3325</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures.  This review examines the fundamental pathogenetic mechanisms underlying this disorder, which include: (a) failure to achieve a skeleton of optimal strength during growth and development; (b) excessive bone resorption resulting in loss of bone mass and disruption of architecture; and (c) failure to replace lost bone due to defects in bone formation.  Estrogen deficiency is known to play a crit. role in the development of osteoporosis, while calcium and vitamin D deficiencies and secondary hyperparathyroidism also contribute.  There are multiple mechanisms underlying the regulation of bone remodeling, and these involve not only the osteoblastic and osteoclastic cell lineages but also other marrow cells, in addn. to the interaction of systemic hormones, local cytokines, growth factors, and transcription factors.  Polymorphisms of a large no. of genes have been assocd. with differences in bone mass and fragility.  It is now possible to diagnose osteoporosis, assess fracture risk, and reduce that risk with antiresorptive or other available therapies.  However, new and more effective approaches are likely to emerge from a better understanding of the regulators of bone cell function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr4gmjg9pMWrVg90H21EOLACvtfcHk0lhUNSElKYubJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtLzJ&md5=77de4d8a09119f8178d1277e441e1bff</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1172%2FJCI27071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI27071%26sid%3Dliteratum%253Aachs%26aulast%3DRaisz%26aufirst%3DL.%2BG.%26atitle%3DPathogenesis%2520of%2520Osteoporosis%253A%2520Concepts%252C%2520Conflicts%252C%2520and%2520Prospects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3318%26epage%3D3325%26doi%3D10.1172%2FJCI27071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref290"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref290'); return false;" data-citation="" class="refNumLink">290</a></strong><div class="NLM_citation" id="cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouresmaeili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamarehei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. M.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Overview on Osteoporosis and Its Risk Factors</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2029</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S138000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2147%2FTCRM.S138000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30464484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOht73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=2029-2049&author=F.+Pouresmaeiliauthor=B.+Kamalidehghanauthor=M.+Kamareheiauthor=Y.+M.+Goh&title=A+Comprehensive+Overview+on+Osteoporosis+and+Its+Risk+Factors&doi=10.2147%2FTCRM.S138000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive overview on osteoporosis and its risk factors</span></div><div class="casAuthors">Pouresmaeili, Farkhondeh; Kamalidehghan, Behnam; Kamarehei, Maryam; Goh, Yong Meng</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2029-2049</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Osteoporosis is a bone disorder with remarkable changes in bone biol. material and consequent bone structural distraction, affecting millions of people around the world from different ethnic groups.  Bone fragility is the worse outcome of the disease, which needs long term therapy and medical management, esp. in the elderly.  Many involved genes including environmental factors have been introduced as the disease risk factors so far, of which genes should be considered as effective early diagnosis biomarkers, esp. for the individuals from high-risk families.  In this review, a no. of important criteria involved in osteoporosis are addressed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi7cEIQdi2ELVg90H21EOLACvtfcHk0lgAApS7tfHDnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOht73P&md5=11a1e911dfdd0dca7c5bd19b7ef06600</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S138000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S138000%26sid%3Dliteratum%253Aachs%26aulast%3DPouresmaeili%26aufirst%3DF.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DKamarehei%26aufirst%3DM.%26aulast%3DGoh%26aufirst%3DY.%2BM.%26atitle%3DA%2520Comprehensive%2520Overview%2520on%2520Osteoporosis%2520and%2520Its%2520Risk%2520Factors%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D2029%26epage%3D2049%26doi%3D10.2147%2FTCRM.S138000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref291"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref291'); return false;" data-citation="" class="refNumLink">291</a></strong><div class="NLM_citation" id="cit291"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reginster, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bréart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1007/s00223-011-9499-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00223-011-9499-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21637997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVWis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=91-104&author=R.+Rizzoliauthor=J.+Y.+Reginsterauthor=S.+Boonenauthor=G.+Br%C3%A9artauthor=A.+Diez-Perezauthor=D.+Felsenbergauthor=J.+M.+Kaufmanauthor=J.+A.+Kanisauthor=C.+Cooper&title=Adverse+Reactions+and+Drug-Drug+Interactions+in+the+Management+of+Women+with+Postmenopausal+Osteoporosis&doi=10.1007%2Fs00223-011-9499-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis</span></div><div class="casAuthors">Rizzoli, Rene; Reginster, Jean-Yves; Boonen, Steven; Breart, Gerard; Diez-Perez, Adolfo; Felsenberg, Dieter; Kaufman, Jean-Marc; Kanis, John A.; Cooper, Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-104</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The pharmacol. management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects.  The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis.  We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series.  Bisphosphonates are assocd. with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment.  Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet.  The selective estrogen receptor modulators are assocd. with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke.  Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain.  The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions.  Drug-drug interactions are rare.  Osteoporosis treatments are generally safe and well tolerated, though they are assocd. with a few very rare serious adverse reactions.  While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0zzrjVtMTsLVg90H21EOLACvtfcHk0lgAApS7tfHDnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVWis7g%253D&md5=65258befff9d36b864136a9f58593d4b</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1007%2Fs00223-011-9499-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-011-9499-8%26sid%3Dliteratum%253Aachs%26aulast%3DRizzoli%26aufirst%3DR.%26aulast%3DReginster%26aufirst%3DJ.%2BY.%26aulast%3DBoonen%26aufirst%3DS.%26aulast%3DBr%25C3%25A9art%26aufirst%3DG.%26aulast%3DDiez-Perez%26aufirst%3DA.%26aulast%3DFelsenberg%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DJ.%2BM.%26aulast%3DKanis%26aufirst%3DJ.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26atitle%3DAdverse%2520Reactions%2520and%2520Drug-Drug%2520Interactions%2520in%2520the%2520Management%2520of%2520Women%2520with%2520Postmenopausal%2520Osteoporosis%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2011%26volume%3D89%26spage%3D91%26epage%3D104%26doi%3D10.1007%2Fs00223-011-9499-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref292"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref292'); return false;" data-citation="" class="refNumLink">292</a></strong><div class="NLM_citation" id="cit292"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mödder, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, C. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapeutic Opportunities for Skeletal Restoration</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd3299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd3299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21283108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtleku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=141-156&author=M.+Kawaiauthor=U.+I.+M%C3%B6dderauthor=S.+Khoslaauthor=C.+J.+Rosen&title=Emerging+Therapeutic+Opportunities+for+Skeletal+Restoration&doi=10.1038%2Fnrd3299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic opportunities for skeletal restoration</span></div><div class="casAuthors">Kawai, Masanobu; Modder, Ulrike I.; Khosla, Sundeep; Rosen, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men.  Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective estrogen receptor modulators.  Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without addnl. adverse effects.  The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral d., albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis.  After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiol.  Such novel strategies offer promise not only for reducing age-related bone loss and the assocd. risk of fractures but also for restoring bone mineral d. to healthy levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwYNmm8i-PO7Vg90H21EOLACvtfcHk0lgAApS7tfHDnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtleku7s%253D&md5=40d0087e886fa8ecac176eb08909304e</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1038%2Fnrd3299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3299%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26aulast%3DM%25C3%25B6dder%26aufirst%3DU.%2BI.%26aulast%3DKhosla%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DC.%2BJ.%26atitle%3DEmerging%2520Therapeutic%2520Opportunities%2520for%2520Skeletal%2520Restoration%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D141%26epage%3D156%26doi%3D10.1038%2Fnrd3299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref293"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref293'); return false;" data-citation="" class="refNumLink">293</a></strong><div class="NLM_citation" id="cit293"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieg, D. J.</span></span> <span> </span><span class="NLM_article-title">Signaling through Focal Adhesion Kinase</span>. <i>Prog. Biophys. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1016/S0079-6107(98)00052-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0079-6107%2898%2900052-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10354709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXislaqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1999&pages=435-478&author=D.+D.+Schlaepferauthor=C.+R.+Hauckauthor=D.+J.+Sieg&title=Signaling+through+Focal+Adhesion+Kinase&doi=10.1016%2FS0079-6107%2898%2900052-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling through focal adhesion kinase</span></div><div class="casAuthors">Schlaepfer, David D.; Hauck, Christof R.; Sieg, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Biophysics & Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">435-478</span>CODEN:
                <span class="NLM_cas:coden">PBIMAC</span>;
        ISSN:<span class="NLM_cas:issn">0079-6107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 249 refs.  Integrin receptor binding to extracellular matrix proteins generates intracellular signals via enhanced tyrosine phosphorylation events that are important for cell growth, survival, and migration.  This review will focus on the functions of the focal adhesion kinase (FAK) protein-tyrosine kinase (PTK) and its role in linking integrin receptors to intracellular signaling pathways.  FAK assocs. with several different signaling proteins such as Src-family PTKs, p130Cas, Shc, Grb2, PI 3-kinase, and paxillin.  This enables FAK to function within a network of integrin-stimulated signaling pathways leading to the activation of targets such as the ERK and JNK/mitogen-activated protein kinase pathways.  Focus will be placed on the structural domains and sites of FAK tyrosine phosphorylation important for FAK-mediated signaling events and how these sites are conserved in the FAK-related PTK, Pyk2.  We will review what is known about FAK activation by integrin receptor-mediated events and also non-integrin stimuli.  In addn., we discuss the emergence of a consensus FAK substrate phosphorylation sequence.  Emphasis will also be placed on the role of FAK in generating cell survival signals and the cleavage of FAK during caspase-mediated apoptosis.  An in-depth discussion will be presented of integrin-stimulated signaling events occurring in the FAK knockout fibroblasts (FAK-) and how these cells exhibit deficits in cell migration.  FAK re-expression in the FAK- cells confirms the role of this PTK in the regulation of cell morphol. and in promoting cell migration events.  In addn., these results reinforce the potential role for FAK in promoting an invasive phenotype in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHm5Ujo-_W7Vg90H21EOLACvtfcHk0lhflG0D7nhNyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislaqtbw%253D&md5=5bff0b02efeb62bdbd95f7592ca8ebfa</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1016%2FS0079-6107%2898%2900052-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6107%252898%252900052-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DHauck%26aufirst%3DC.%2BR.%26aulast%3DSieg%26aufirst%3DD.%2BJ.%26atitle%3DSignaling%2520through%2520Focal%2520Adhesion%2520Kinase%26jtitle%3DProg.%2520Biophys.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D71%26spage%3D435%26epage%3D478%26doi%3D10.1016%2FS0079-6107%2898%2900052-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref294"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref294'); return false;" data-citation="" class="refNumLink">294</a></strong><div class="NLM_citation" id="cit294"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hambor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasser, W. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smock, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Proline-Rich Tyrosine Kinase 2 Regulates Osteoprogenitor Cells and Bone Formation, and Offers an Anabolic Treatment Approach for Osteoporosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">10619</span>– <span class="NLM_lpage">10624</span>, <span class="refDoi"> DOI: 10.1073/pnas.0701421104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.0701421104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17537919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Ohtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=10619-10624&author=L.+Buckbinderauthor=D.+T.+Crawfordauthor=H.+Qiauthor=H.+Z.+Keauthor=L.+M.+Olsonauthor=K.+R.+Longauthor=P.+C.+Bonnetteauthor=A.+P.+Baumannauthor=J.+E.+Hamborauthor=W.+A.+Grasserauthor=L.+C.+Panauthor=T.+A.+Owenauthor=M.+J.+Luzzioauthor=C.+A.+Hulfordauthor=D.+F.+Gebhardauthor=V.+M.+Paralkarauthor=H.+A.+Simmonsauthor=J.+C.+Kathauthor=W.+G.+Robertsauthor=S.+L.+Smockauthor=A.+Guzman-Perezauthor=T.+A.+Brownauthor=M.+Li&title=Proline-Rich+Tyrosine+Kinase+2+Regulates+Osteoprogenitor+Cells+and+Bone+Formation%2C+and+Offers+an+Anabolic+Treatment+Approach+for+Osteoporosis&doi=10.1073%2Fpnas.0701421104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis</span></div><div class="casAuthors">Buckbinder, Leonard; Crawford, David T.; Qi, Hong; Ke, Hua Zhu; Olson, Lisa M.; Long, Kelly R.; Bonnette, Peter C.; Baumann, Amy P.; Hambor, John E.; Grasser, William A., III; Pan, Lydia C.; Owen, Thomas A.; Luzzio, Michael J.; Hulford, Catherine A.; Gebhard, David F.; Paralkar, Vishwas M.; Simmons, Hollis A.; Kath, John C.; Roberts, W. Gregory; Smock, Steven L.; Guzman-Perez, Angel; Brown, Thomas A.; Li, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10619-10624</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bone is accrued and maintained primarily through the coupled actions of bone-forming osteoblasts and bone-resorbing osteoclasts.  Cumulative in vitro studies indicated that proline-rich tyrosine kinase 2 (PYK2) is a pos. mediator of osteoclast function and activity.  However, our investigation of PYK2-/- mice did not reveal evidence supporting an essential function for PYK2 in osteoclasts either in vivo or in culture.  We find that PYK2-/- mice have high bone mass resulting from an unexpected increase in bone formation.  Consistent with the in vivo findings, mouse bone marrow cultures show that PYK2 deficiency enhances differentiation and activity of osteoprogenitor cells, as does expressing a PYK2-specific short hairpin RNA or dominantly interfering proteins in human mesenchymal stem cells.  Furthermore, the daily administration of a small-mol. PYK2 inhibitor increases bone formation and protects against bone loss in ovariectomized rats, an established preclin. model of postmenopausal osteoporosis.  In summary, we find that PYK2 regulates the differentiation of early osteoprogenitor cells across species and that inhibitors of the PYK2 have potential as a bone anabolic approach for the treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENpFzA2DSTrVg90H21EOLACvtfcHk0lhflG0D7nhNyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Ohtro%253D&md5=6327da043a470ce6c932d1f09c23fee8</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0701421104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0701421104%26sid%3Dliteratum%253Aachs%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DOlson%26aufirst%3DL.%2BM.%26aulast%3DLong%26aufirst%3DK.%2BR.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBaumann%26aufirst%3DA.%2BP.%26aulast%3DHambor%26aufirst%3DJ.%2BE.%26aulast%3DGrasser%26aufirst%3DW.%2BA.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DSimmons%26aufirst%3DH.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DSmock%26aufirst%3DS.%2BL.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DProline-Rich%2520Tyrosine%2520Kinase%25202%2520Regulates%2520Osteoprogenitor%2520Cells%2520and%2520Bone%2520Formation%252C%2520and%2520Offers%2520an%2520Anabolic%2520Treatment%2520Approach%2520for%2520Osteoporosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D10619%26epage%3D10624%26doi%3D10.1073%2Fpnas.0701421104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref295"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref295'); return false;" data-citation="" class="refNumLink">295</a></strong><div class="NLM_citation" id="cit295"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lakkakorpi, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodan, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, L. T.</span></span> <span> </span><span class="NLM_article-title">Stable Association of PYK2 and p130Cas in Osteoclasts and Their Co-Localization in the Sealing Zone</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">4900</span>– <span class="NLM_lpage">4907</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.8.4900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1074%2Fjbc.274.8.4900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9988732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=4900-4907&author=P.+T.+Lakkakorpiauthor=I.+Nakamuraauthor=R.+M.+Nagyauthor=J.+T.+Parsonsauthor=G.+A.+Rodanauthor=L.+T.+Duong&title=Stable+Association+of+PYK2+and+p130Cas+in+Osteoclasts+and+Their+Co-Localization+in+the+Sealing+Zone&doi=10.1074%2Fjbc.274.8.4900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit295R"><div class="casContent"><span class="casTitleNuber">295</span><div class="casTitle"><span class="NLM_cas:atitle">Stable association of PYK2 and p130Cas in osteoclasts and their co-localization in the sealing zone</span></div><div class="casAuthors">Lakkakorpi, Paivi T.; Nakamura, Ichiro; Nagy, Rose M.; Parsons, J. Thomas; Rodan, Gideon A.; Duong, Le T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4900-4907</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone resorption is initiated by osteoclast attachment to the mineralized matrix, cytoskeletal reorganization, cellular polarization, and the formation of the sealing zone.  The present study examines the interaction between PYK2 and p130Cas (Crk-assocd. substrate), suggested to be part of the signaling pathway initiated by osteoclast adhesion.  Using murine osteoclast-like cells (OCLs) and their mononuclear precursors (pOCs), generated in a co-culture of bone marrow and osteoblastic MB1.8 cells, we show that: (1) p130Cas is tyrosine-phosphorylated upon adhesion of pOCs to vitronectin or ligation of β3 integrins; (2) p130Cas colocalizes with PYK2 and the cytoskeletal proteins F-actin, vinculin, and paxillin in the podosomal-rich ring-like structures of OCLs plated on glass and in the sealing zone in actively resorbing OCLs on bone; (3) p130Cas and PYK2 form a stable complex in pOCs, independent of tyrosine phosphorylation of either mol., and this complex is present in Src (-/-) OCLs, in which neither protein is phosphorylated or assocd. with the osteoclast adhesion structure; (4) the assocn. of p130Cas and PYK2 is mediated by the SH3 domain of p130Cas and the C-terminal domain of PYK2.  These findings suggest that p130Cas and its assocn. with PYK2 may play an important role in the adhesion-dependent signaling that leads to cytoskeletal reorganization and formation of the sealing zone during osteoclast activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOWxlVAIkq9rVg90H21EOLACvtfcHk0lhflG0D7nhNyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSls7o%253D&md5=582b7fb186a1ec2fb9e59c28e1e6333e</span></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.8.4900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.8.4900%26sid%3Dliteratum%253Aachs%26aulast%3DLakkakorpi%26aufirst%3DP.%2BT.%26aulast%3DNakamura%26aufirst%3DI.%26aulast%3DNagy%26aufirst%3DR.%2BM.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26aulast%3DRodan%26aufirst%3DG.%2BA.%26aulast%3DDuong%26aufirst%3DL.%2BT.%26atitle%3DStable%2520Association%2520of%2520PYK2%2520and%2520p130Cas%2520in%2520Osteoclasts%2520and%2520Their%2520Co-Localization%2520in%2520the%2520Sealing%2520Zone%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D4900%26epage%3D4907%26doi%3D10.1074%2Fjbc.274.8.4900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref296"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref296'); return false;" data-citation="" class="refNumLink">296</a></strong><div class="NLM_citation" id="cit296"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlynn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span> <span> </span><span class="NLM_article-title">Sulfoximine-Substituted Trifluoromethylpyrimidine Analogs as Inhibitors of Proline-Rich Tyrosine Kinase 2 (PYK2) Show Reduced hERG Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3253</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2009.04.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19428251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3253-3258&author=D.+P.+Walkerauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=J.-C.+Liauthor=D.+W.+Kungauthor=P.+C.+Bonnetteauthor=A.+Baumannauthor=L.+Buckbinderauthor=J.+A.+Houserauthor=J.+Boerauthor=A.+Mistryauthor=S.+Hanauthor=L.+Xing&title=Sulfoximine-Substituted+Trifluoromethylpyrimidine+Analogs+as+Inhibitors+of+Proline-Rich+Tyrosine+Kinase+2+%28PYK2%29+Show+Reduced+hERG+Activity&doi=10.1016%2Fj.bmcl.2009.04.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit296R"><div class="casContent"><span class="casTitleNuber">296</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity</span></div><div class="casAuthors">Walker, Daniel P.; Zawistoski, Michael P.; McGlynn, Molly A.; Li, Jian-Cheng; Kung, Daniel W.; Bonnette, Peter C.; Baumann, Amy; Buckbinder, Leonard; Houser, Janet A.; Boer, Jason; Mistry, Anil; Han, Seungil; Guzman-Perez, Li Xing and Angel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3253-3258</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described.  These compds. were prepd. as surrogates of the corresponding sulfone compd. I.  Sulfone I was an attractive PYK2 lead compd.; however, subsequent studies detd. this compd. possessed high dofetilide binding, which is an early indicator of cardiovascular safety.  Surprisingly, the corresponding sulfoximine analogs displayed significantly lower dofetilide binding, which, for one example, translated to lower activity in a patch clamp hERG K+ ion channel screen.  In addn., the compd. shows good oral exposure in a rat pharmacokinetic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5iWLOkqSmarVg90H21EOLACvtfcHk0lg4GfR9I7lEhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eksb4%253D&md5=5981d4a1e1dfac8e37acb22585742f6e</span></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.093%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBaumann%26aufirst%3DA.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DHouser%26aufirst%3DJ.%2BA.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DL.%26atitle%3DSulfoximine-Substituted%2520Trifluoromethylpyrimidine%2520Analogs%2520as%2520Inhibitors%2520of%2520Proline-Rich%2520Tyrosine%2520Kinase%25202%2520%2528PYK2%2529%2520Show%2520Reduced%2520hERG%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3253%26epage%3D3258%26doi%3D10.1016%2Fj.bmcl.2009.04.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref297"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref297'); return false;" data-citation="" class="refNumLink">297</a></strong><div class="NLM_citation" id="cit297"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, N.</span></span> <span> </span><span class="NLM_article-title">Triggers, Targets and Treatments for Thrombosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>451</i></span>,  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">918</span>, <span class="refDoi"> DOI: 10.1038/nature06797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature06797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18288180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1ynsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2008&pages=914-918&author=N.+Mackman&title=Triggers%2C+Targets+and+Treatments+for+Thrombosis&doi=10.1038%2Fnature06797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit297R"><div class="casContent"><span class="casTitleNuber">297</span><div class="casTitle"><span class="NLM_cas:atitle">Triggers, targets and treatments for thrombosis</span></div><div class="casAuthors">Mackman, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">451</span>
        (<span class="NLM_cas:issue">7181</span>),
    <span class="NLM_cas:pages">914-918</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thrombosis - localized clotting of the blood - can occur in the arterial or the venous circulation and has a major medical impact.  Acute arterial thrombosis is the proximal cause of most cases of myocardial infarction (heart attack) and of about 80% of strokes, collectively the most common cause of death in the developed world.  Venous thromboembolism is the third leading cause of cardiovascular-assocd. death.  The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood.  Understanding these processes is crucial for developing safer and more effective antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxKva6uiDjA7Vg90H21EOLACvtfcHk0lg4GfR9I7lEhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1ynsb8%253D&md5=dad98f180f1d7416433bb6d993178ec5</span></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=10.1038%2Fnature06797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06797%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DN.%26atitle%3DTriggers%252C%2520Targets%2520and%2520Treatments%2520for%2520Thrombosis%26jtitle%3DNature%26date%3D2008%26volume%3D451%26spage%3D914%26epage%3D918%26doi%3D10.1038%2Fnature06797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref298"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref298'); return false;" data-citation="" class="refNumLink">298</a></strong><div class="NLM_citation" id="cit298"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makaryus, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. F.</span></span> <span> </span><span class="NLM_article-title">Oral Anticoagulants in the Management of Venous Thromboembolism</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2013.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrcardio.2013.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23689703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=397-409&author=J.+N.+Makaryusauthor=J.+L.+Halperinauthor=J.+F.+Lau&title=Oral+Anticoagulants+in+the+Management+of+Venous+Thromboembolism&doi=10.1038%2Fnrcardio.2013.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit298R"><div class="casContent"><span class="casTitleNuber">298</span><div class="casTitle"><span class="NLM_cas:atitle">Oral anticoagulants in the management of venous thromboembolism</span></div><div class="casAuthors">Makaryus, John N.; Halperin, Jonathan L.; Lau, Joe F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite advances in diagnosis, prevention, and management, venous thromboembolism (VTE) remains a common cause of morbidity and mortality.  For decades, antithrombotic therapy for prevention and treatment of VTE was limited to parenteral agents related to heparin and oral vitamin K antagonists (VKAs).  Both classes of anticoagulants are effective, but have limitations, including considerable variability in dose-response, narrow therapeutic margins between the risks of thrombosis and bleeding, and the need to monitor anticoagulation intensity.  Over the past decade, the introduction of new oral anticoagulants that specifically inhibit coagulation factors IIa (thrombin) or Xa has changed practice in a variety of clin. situations, including VTE prophylaxis and treatment.  In this Review, we outline the use of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the prevention and treatment of VTE, and discuss practical considerations for choosing the appropriate drug for each patient.  Although the introduction of novel anticoagulant drugs is promising, selecting the optimum strategy for an individual patient requires an understanding of the specific circumstances assocd. with thrombus formation and the pharmacol. properties of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ3bQp-WZ4zrVg90H21EOLACvtfcHk0lg4GfR9I7lEhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSiu7fO&md5=86593dfa9e696e7716cabab22632ebf5</span></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2013.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2013.73%26sid%3Dliteratum%253Aachs%26aulast%3DMakaryus%26aufirst%3DJ.%2BN.%26aulast%3DHalperin%26aufirst%3DJ.%2BL.%26aulast%3DLau%26aufirst%3DJ.%2BF.%26atitle%3DOral%2520Anticoagulants%2520in%2520the%2520Management%2520of%2520Venous%2520Thromboembolism%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2013%26volume%3D10%26spage%3D397%26epage%3D409%26doi%3D10.1038%2Fnrcardio.2013.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref299"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref299'); return false;" data-citation="" class="refNumLink">299</a></strong><div class="NLM_citation" id="cit299"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span> <span> </span><span class="NLM_article-title">Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2012.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrcardio.2012.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22371104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=385-391&author=K.+P.+Cabralauthor=J.+Ansell&title=Oral+Direct+Factor+Xa+Inhibitors+for+Stroke+Prevention+in+Atrial+Fibrillation&doi=10.1038%2Fnrcardio.2012.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit299R"><div class="casContent"><span class="casTitleNuber">299</span><div class="casTitle"><span class="NLM_cas:atitle">Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation</span></div><div class="casAuthors">Cabral, Katherine P.; Ansell, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-391</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Oral direct factor Xa inhibitors, particularly apixaban and rivaroxaban, are novel and promising alternatives to warfarin for stroke prevention in patients with atrial fibrillation.  Drs Cabral and Ansell review the data from clin. trials of these drugs, and also discuss the challenges of reversing their anticoagulant effects, interactions with other medications, patient compliance, and therapeutic monitoring.  Safe and effective stroke prevention in atrial fibrillation (AF) is crucial as the no. of patients with this condition continues to increase.  Several novel oral anticoagulants are being developed as replacements for warfarin for this indication.  Direct factor Xa inhibitors comprise the largest class of oral anticoagulants in development; the inhibition of factor Xa is recognized to be a promising target for therapeutic anticoagulation, partly because of its location in the coagulation cascade.  Apixaban, betrixaban, edoxaban, and rivaroxaban are small-mol., selective inhibitors that directly and reversibly bind to the active site of factor Xa.  Their pharmacokinetic and pharmacodynamic profiles vary, which might allow patient-specific therapy.  Several of these agents have been tested in clin. trials for various indications, including AF, with favorable results.  In particular, apixaban and rivaroxaban have shown superiority and noninferiority, resp., to warfarin in phase III clin. trials for stroke prevention in AF.  These agents have also been shown to be safe in terms of bleeding risk.  Despite these advantages, factor Xa inhibitors have several characteristics, such as potential interactions with other drugs (inhibitors of cytochrome P 450 and P-glycoprotein) and the inability to reverse their anticoagulant effects, as well as concerns about poor patient compliance, which must be considered when initiating patients on a novel factor Xa inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmYeFmP0LN47Vg90H21EOLACvtfcHk0lg4GfR9I7lEhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGmsbs%253D&md5=9b438e79ebc3d2f4a3a7f79117b61a1f</span></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2012.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2012.19%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DK.%2BP.%26aulast%3DAnsell%26aufirst%3DJ.%26atitle%3DOral%2520Direct%2520Factor%2520Xa%2520Inhibitors%2520for%2520Stroke%2520Prevention%2520in%2520Atrial%2520Fibrillation%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2012%26volume%3D9%26spage%3D385%26epage%3D391%26doi%3D10.1038%2Fnrcardio.2012.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref300"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref300'); return false;" data-citation="" class="refNumLink">300</a></strong><div class="NLM_citation" id="cit300"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J. W.</span></span> <span> </span><span class="NLM_article-title">Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-062209-095159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-med-062209-095159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21226611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVWht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=41-57&author=B.+I.+Erikssonauthor=D.+J.+Quinlanauthor=J.+W.+Eikelboom&title=Novel+Oral+Factor+Xa+and+Thrombin+Inhibitors+in+the+Management+of+Thromboembolism&doi=10.1146%2Fannurev-med-062209-095159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism</span></div><div class="casAuthors">Eriksson, Bengt I.; Quinlan, Daniel J.; Eikelboom, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-57</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The last decade has seen the evaluation of several new oral anticoagulants that directly target thrombin or activated factor X (FXa).  All demonstrate a rapid onset of action, a low potential for food and drug interactions, and a predictable anticoagulant effect that obviates the need for routine coagulation monitoring.  Those agents at the most advanced stages of clin. development are a direct thrombin inhibitor, dabigatran, and direct FXa inhibitors, rivaroxaban and apixaban.  Dabigatran and rivaroxaban are approved in more than 70 countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty, and apixaban is being considered for approval by regulatory agencies for this indication.  Dabigatran was shown in a large phase III trial to be more effective and safer than warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and has recently been approved for this indication.  Edoxaban, an oral FXa inhibitor, is also being evaluated in phase III clin. trials.  This review summarizes the pharmacol., clin. trial results, and future role of the new oral anticoagulants in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdVM7dFkKODrVg90H21EOLACvtfcHk0ljSuU4js9kTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVWht78%253D&md5=95143da0d76c5c7607cba9931e3011ef</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-062209-095159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-062209-095159%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DB.%2BI.%26aulast%3DQuinlan%26aufirst%3DD.%2BJ.%26aulast%3DEikelboom%26aufirst%3DJ.%2BW.%26atitle%3DNovel%2520Oral%2520Factor%2520Xa%2520and%2520Thrombin%2520Inhibitors%2520in%2520the%2520Management%2520of%2520Thromboembolism%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2011%26volume%3D62%26spage%3D41%26epage%3D57%26doi%3D10.1146%2Fannurev-med-062209-095159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref301"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref301'); return false;" data-citation="" class="refNumLink">301</a></strong><div class="NLM_citation" id="cit301"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaugule, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarag, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sairam, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship of Potent, Selective and Orally Active Anthranilamide-Based Factor Xa Inhibitors: Application of Weakly Basic Sulfoximine Group as Novel S4 Binding Element</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2012.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23124211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOrsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=136-152&author=V.+Pandyaauthor=M.+Jainauthor=G.+Chakrabartiauthor=H.+Soniauthor=B.+Parmarauthor=B.+Chauguleauthor=J.+Patelauthor=T.+Jaragauthor=J.+Joshiauthor=N.+Joshiauthor=A.+Rathauthor=V.+Unadkatauthor=B.+Sharmaauthor=H.+Ajaniauthor=J.+Kumarauthor=K.+V.+Sairamauthor=H.+Patelauthor=P.+Patel&title=Synthesis+and+Structure-Activity+Relationship+of+Potent%2C+Selective+and+Orally+Active+Anthranilamide-Based+Factor+Xa+Inhibitors%3A+Application+of+Weakly+Basic+Sulfoximine+Group+as+Novel+S4+Binding+Element&doi=10.1016%2Fj.ejmech.2012.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit301R"><div class="casContent"><span class="casTitleNuber">301</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element</span></div><div class="casAuthors">Pandya, Vrajesh; Jain, Mukul; Chakrabarti, Ganes; Soni, Hitesh; Parmar, Bhavesh; Chaugule, Balaji; Patel, Jigar; Jarag, Tushar; Joshi, Jignesh; Joshi, Nirav; Rath, Akshyaya; Unadkat, Vishal; Sharma, Bhavesh; Ajani, Haresh; Kumar, Jeevan; Sairam, Kalapatapu V. V. M.; Patel, Harilal; Patel, Pankaj</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">136-152</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of potent and efficacious factor Xa inhibitors contg. a sulfoximine moiety as a novel S4 binding element in an anthranilamide chemotype has been identified.  Lead optimization at this novel P4 group led to many potent factor Xa inhibitors with excellent anticoagulant activity in human plasma.  Selected compds. were dosed orally in rats and checked for their ex vivo prothrombin time prolonging activity, which resulted in identification of compd. 5-chloro-N-(5-chloropyridin-2-yl)-2-(4-(N-(2-(diethylamino)acetyl)-S-methylsulfonimidoyl)benzamido)benzamide (I).  The detailed pharmacokinetic evaluation and subsequent metab. study of I suggested the presence of an active metabolite.  The compd. I and its active metabolite II demonstrated excellent in vivo efficacy in both arterial and venous thrombosis model in rats and were found to be highly selective against related serine proteases.  Based on this promising profile, compd. I was selected for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquQcyT3ufGirVg90H21EOLACvtfcHk0ljSuU4js9kTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOrsrrI&md5=cdc06710c5029dc63ba9ce427d367ea4</span></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DPandya%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DChakrabarti%26aufirst%3DG.%26aulast%3DSoni%26aufirst%3DH.%26aulast%3DParmar%26aufirst%3DB.%26aulast%3DChaugule%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DJarag%26aufirst%3DT.%26aulast%3DJoshi%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DN.%26aulast%3DRath%26aufirst%3DA.%26aulast%3DUnadkat%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DJ.%26aulast%3DSairam%26aufirst%3DK.%2BV.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPatel%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Anthranilamide-Based%2520Factor%2520Xa%2520Inhibitors%253A%2520Application%2520of%2520Weakly%2520Basic%2520Sulfoximine%2520Group%2520as%2520Novel%2520S4%2520Binding%2520Element%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D136%26epage%3D152%26doi%3D10.1016%2Fj.ejmech.2012.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref302"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref302'); return false;" data-citation="" class="refNumLink">302</a></strong><div class="NLM_citation" id="cit302"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.cell.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31564456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=312-339&author=J.+M.+Longauthor=D.+M.+Holtzman&title=Alzheimer+Disease%3A+An+Update+on+Pathobiology+and+Treatment+Strategies&doi=10.1016%2Fj.cell.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit302R"><div class="casContent"><span class="casTitleNuber">302</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span></div><div class="casAuthors">Long, Justin M.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-339</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiol.  The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathol. criteria for AD diagnosis.  However, a no. of recent fundamental discoveries highlight important pathol. roles for other crit. cellular and mol. processes.  Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clin. trials have failed to demonstrate benefits.  Here, we review recent advances in our understanding of AD pathobiol. and discuss current treatment strategies, highlighting recent clin. trials and opportunities for developing future disease-modifying therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIdXAv0NNRFbVg90H21EOLACvtfcHk0ljSuU4js9kTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN&md5=b68edceb2c7ebe4515efded93c9281c3</span></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DAlzheimer%2520Disease%253A%2520An%2520Update%2520on%2520Pathobiology%2520and%2520Treatment%2520Strategies%26jtitle%3DCell%26date%3D2019%26volume%3D179%26spage%3D312%26epage%3D339%26doi%3D10.1016%2Fj.cell.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref303"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref303'); return false;" data-citation="" class="refNumLink">303</a></strong><div class="NLM_citation" id="cit303"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blennow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlawish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masliah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, N.</span></span> <span> </span><span class="NLM_article-title">NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2018.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jalz.2018.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29653606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1MjisFaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=535-562&author=C.+R.+Jackauthor=D.+A.+Bennettauthor=K.+Blennowauthor=M.+C.+Carrilloauthor=B.+Dunnauthor=S.+B.+Haeberleinauthor=D.+M.+Holtzmanauthor=W.+Jagustauthor=F.+Jessenauthor=J.+Karlawishauthor=E.+Liuauthor=J.+L.+Molinuevoauthor=T.+Montineauthor=C.+Phelpsauthor=K.+P.+Rankinauthor=C.+C.+Roweauthor=P.+Scheltensauthor=E.+Siemersauthor=H.+M.+Snyderauthor=R.+Sperlingauthor=C.+Elliottauthor=E.+Masliahauthor=L.+Ryanauthor=N.+Silverberg&title=NIA-AA+Research+Framework%3A+Toward+a+Biological+Definition+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.jalz.2018.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit303R"><div class="casContent"><span class="casTitleNuber">303</span><div class="casTitle"><span class="NLM_cas:atitle">NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</span></div><div class="casAuthors">Jack Clifford R Jr; Bennett David A; Blennow Kaj; Carrillo Maria C; Snyder Heather M; Dunn Billy; Haeberlein Samantha Budd; Holtzman David M; Jagust William; Jessen Frank; Karlawish Jason; Liu Enchi; Molinuevo Jose Luis; Montine Thomas; Phelps Creighton; Rankin Katherine P; Rowe Christopher C; Scheltens Philip; Siemers Eric; Sperling Reisa</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-562</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease.  Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines.  This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care.  In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers.  The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct.  The research framework focuses on the diagnosis of AD with biomarkers in living persons.  Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)].  This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures.  The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available.  We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures.  However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme.  It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms.  We appreciate the concern that this biomarker-based research framework has the potential to be misused.  Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice.  Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers.  There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document).  Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study.  Importantly, this framework should be examined in diverse populations.  Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia.  We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia.  This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1xBNMNLsPJUH3Rlp_k91zfW6udTcc2ebqnDkm8gMJMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjisFaltA%253D%253D&md5=f19a7f80d1357920644fa33bd7493fc0</span></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2018.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2018.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BA.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DDunn%26aufirst%3DB.%26aulast%3DHaeberlein%26aufirst%3DS.%2BB.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DJagust%26aufirst%3DW.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DKarlawish%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DMontine%26aufirst%3DT.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DRankin%26aufirst%3DK.%2BP.%26aulast%3DRowe%26aufirst%3DC.%2BC.%26aulast%3DScheltens%26aufirst%3DP.%26aulast%3DSiemers%26aufirst%3DE.%26aulast%3DSnyder%26aufirst%3DH.%2BM.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DC.%26aulast%3DMasliah%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DL.%26aulast%3DSilverberg%26aufirst%3DN.%26atitle%3DNIA-AA%2520Research%2520Framework%253A%2520Toward%2520a%2520Biological%2520Definition%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2018%26volume%3D14%26spage%3D535%26epage%3D562%26doi%3D10.1016%2Fj.jalz.2018.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref304"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref304'); return false;" data-citation="" class="refNumLink">304</a></strong><div class="NLM_citation" id="cit304"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duyckaerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delatour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potier, M. C.</span></span> <span> </span><span class="NLM_article-title">Classification and Basic Pathology of Alzheimer Disease</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1007/s00401-009-0532-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00401-009-0532-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19381658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1ahu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2009&pages=5-36&author=C.+Duyckaertsauthor=B.+Delatourauthor=M.+C.+Potier&title=Classification+and+Basic+Pathology+of+Alzheimer+Disease&doi=10.1007%2Fs00401-009-0532-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">Classification and basic pathology of Alzheimer disease</span></div><div class="casAuthors">Duyckaerts, Charles; Delatour, Benoit; Potier, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-36</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The lesions of Alzheimer disease include accumulation of proteins, losses of neurons and synapses, and alterations related to reactive processes.  Extracellular Aβ accumulation occurs in the parenchyma as diffuse, focal or stellate deposits.  It may involve the vessel walls of arteries, veins and capillaries.  The cases in which the capillary vessel walls are affected have a higher probability of having one or two apoε 4 alleles.  Parenchymal as well as vascular Aβ deposition follows a stepwise progression.  Tau accumulation, probably the best histopathol. correlate of the clin. symptoms, takes three aspects: in the cell body of the neuron as neurofibrillary tangle, in the dendrites as neuropil threads, and in the axons forming the senile plaque neuritic corona.  The progression of tau pathol. is stepwise and stereotyped from the entorhinal cortex, through the hippocampus, to the isocortex.  The neuronal loss is heterogeneous and area-specific.  Its mechanism is still discussed.  The timing of the synaptic loss, probably linked to Aβ peptide itself, maybe as oligomers, is also controversial.  Various clinico-pathol. types of Alzheimer disease have been described, according to the type of the lesions (plaque only and tangle predominant), the type of onset (focal onset), the cause (genetic or sporadic) and the assocd. lesions (Lewy bodies, vascular lesions, hippocampal sclerosis, TDP-43 inclusions and argyrophilic grain disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV9FKh5BL9WLVg90H21EOLACvtfcHk0lgvfjh_Qld2og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1ahu70%253D&md5=df9d40a78355a4ef31e76fcf91a5bfdc</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.1007%2Fs00401-009-0532-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-009-0532-1%26sid%3Dliteratum%253Aachs%26aulast%3DDuyckaerts%26aufirst%3DC.%26aulast%3DDelatour%26aufirst%3DB.%26aulast%3DPotier%26aufirst%3DM.%2BC.%26atitle%3DClassification%2520and%2520Basic%2520Pathology%2520of%2520Alzheimer%2520Disease%26jtitle%3DActa%2520Neuropathol.%26date%3D2009%26volume%3D118%26spage%3D5%26epage%3D36%26doi%3D10.1007%2Fs00401-009-0532-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref305"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref305'); return false;" data-citation="" class="refNumLink">305</a></strong><div class="NLM_citation" id="cit305"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span> <span> </span><span class="NLM_article-title">BACE1 (β-secretase) Inhibitors for the Treatment of Alzheimer’s disease</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6765</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1039/C3CS60460H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC3CS60460H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24691405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6765-6813&author=A.+K.+Ghoshauthor=H.+L.+Osswald&title=BACE1+%28%CE%B2-secretase%29+Inhibitors+for+the+Treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC3CS60460H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit305R"><div class="casContent"><span class="casTitleNuber">305</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6765-6813</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease.  BACE1 is an aspartic protease which functions in the first step of the pathway leading to the prodn. and deposition of amyloid-β peptide (Aβ).  Its gene deletion showed only mild phenotypes.  BACE1 inhibition has direct implications in the Alzheimer's disease pathol. without largely affecting viability.  However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists.  Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed.  These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.  Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics.  In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compds. that have been shown to reduce brain Aβ, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri59_pgGAbxLVg90H21EOLACvtfcHk0lgvfjh_Qld2og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ&md5=dab445bf7efb6fdc0c80e032d3bb0071</span></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=10.1039%2FC3CS60460H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3CS60460H%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26atitle%3DBACE1%2520%2528%25CE%25B2-secretase%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6765%26epage%3D6813%26doi%3D10.1039%2FC3CS60460H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref306"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref306'); return false;" data-citation="" class="refNumLink">306</a></strong><div class="NLM_citation" id="cit306"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Peters, J. U.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Schnider, C.</span>; <span class="NLM_string-name">Wermuth, R.</span>; <span class="NLM_string-name">Woltering, T.</span></span> <span> </span><span class="NLM_article-title">5-Aryl-1-Imino-1-Oxo-[1,2,4]Thiadiazines</span>. <span class="NLM_patent">WO/2015/091595</span>, Jun 25, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+Guba&author=W.+Haap&author=A.+Kuglstatter&author=J.+U.+Peters&author=U.+Obst+Sander&author=C.+Schnider&author=R.+Wermuth&author=T.+Woltering&title=5-Aryl-1-Imino-1-Oxo-%5B1%2C2%2C4%5DThiadiazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit306&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuba%26aufirst%3DW.%26atitle%3D5-Aryl-1-Imino-1-Oxo-%255B1%252C2%252C4%255DThiadiazines%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref307"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref307'); return false;" data-citation="" class="refNumLink">307</a></strong><div class="NLM_citation" id="cit307"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, B.</span>; <span class="NLM_string-name">Dolente, C.</span>; <span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Peters, J. U.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Woltering, T.</span>; <span class="NLM_string-name">Schnider, C.</span>; <span class="NLM_string-name">Wermuth, R.</span></span> <span> </span><span class="NLM_article-title">Pyridyl-Triazabicycles</span>. <span class="NLM_patent">WO/2016/012422</span>, Jan 28, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=B.+Bartels&author=C.+Dolente&author=W.+Guba&author=W.+Haap&author=A.+Kuglstatter&author=U.+Obst+Sander&author=J.+U.+Peters&author=M.+Rogers-Evans&author=T.+Woltering&author=C.+Schnider&author=R.+Wermuth&title=Pyridyl-Triazabicycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit307&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DB.%26atitle%3DPyridyl-Triazabicycles%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref308"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref308'); return false;" data-citation="" class="refNumLink">308</a></strong><div class="NLM_citation" id="cit308"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anselm, L.</span>; <span class="NLM_string-name">Bartels, B.</span>; <span class="NLM_string-name">Dolente, C.</span>; <span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Peters, J.-U.</span>; <span class="NLM_string-name">Woltering, T.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span></span> <span> </span><span class="NLM_article-title">2,2,2-Trifluoroethyl-Thiadiazines</span>. <span class="NLM_patent">WO/2016/023927</span>, Feb 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Anselm&author=B.+Bartels&author=C.+Dolente&author=W.+Guba&author=W.+Haap&author=J.-U.+Peters&author=T.+Woltering&author=U.+Obst+Sander&author=M.+Rogers-Evans&title=2%2C2%2C2-Trifluoroethyl-Thiadiazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit308&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnselm%26aufirst%3DL.%26atitle%3D2%252C2%252C2-Trifluoroethyl-Thiadiazines%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref309"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref309'); return false;" data-citation="" class="refNumLink">309</a></strong><div class="NLM_citation" id="cit309"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solfrizzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sardone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccininni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stallone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seripa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logroscino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">BACE Inhibitors in Clinical Development for the Treatment of Alzheimer’s Disease</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1080/14737175.2018.1531706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1080%2F14737175.2018.1531706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30277096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSjtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=847-857&author=F.+Panzaauthor=M.+Lozuponeauthor=V.+Solfrizziauthor=R.+Sardoneauthor=C.+Piccininniauthor=V.+Dibelloauthor=R.+Stalloneauthor=G.+Giannelliauthor=A.+Bellomoauthor=A.+Grecoauthor=A.+Danieleauthor=D.+Seripaauthor=G.+Logroscinoauthor=B.+P.+Imbimbo&title=BACE+Inhibitors+in+Clinical+Development+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1080%2F14737175.2018.1531706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit309R"><div class="casContent"><span class="casTitleNuber">309</span><div class="casTitle"><span class="NLM_cas:atitle">BACE inhibitors in clinical development for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Panza, Francesco; Lozupone, Madia; Solfrizzi, Vincenzo; Sardone, Rodolfo; Piccininni, Carla; Dibello, Vittorio; Stallone, Roberta; Giannelli, Gianluigi; Bellomo, Antonello; Greco, Antonio; Daniele, Antonio; Seripa, Davide; Logroscino, Giancarlo; Imbimbo, Bruno P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">847-857</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Introduction: The amyloid hypothesis of Alzheimer's disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and sol. aggregates represent the major pathol. event of the disease.  Several anti-Aβ small org. mols., monoclonal antibodies and antigens were developed to interfere with Aβ prodn. and clearance, including β-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymic step of Aβ formation.  All these approaches, including BACE inhibitors, have failed in large randomized clin. trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD.  Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compds. in Phase III RCTs.  Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clin., or functional benefit in large RCTs.  BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates.  Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD.  This may indicate that blocking the formation of nascent Aβ is not useful in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquBOgMVQQBdbVg90H21EOLACvtfcHk0lj2hJVpPDTV4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSjtbbF&md5=fcbe8aa1c2a43ce6e0bace2759ddfe49</span></div><a href="/servlet/linkout?suffix=cit309&amp;dbid=16384&amp;doi=10.1080%2F14737175.2018.1531706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2018.1531706%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DSolfrizzi%26aufirst%3DV.%26aulast%3DSardone%26aufirst%3DR.%26aulast%3DPiccininni%26aufirst%3DC.%26aulast%3DDibello%26aufirst%3DV.%26aulast%3DStallone%26aufirst%3DR.%26aulast%3DGiannelli%26aufirst%3DG.%26aulast%3DBellomo%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DDaniele%26aufirst%3DA.%26aulast%3DSeripa%26aufirst%3DD.%26aulast%3DLogroscino%26aufirst%3DG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DBACE%2520Inhibitors%2520in%2520Clinical%2520Development%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2018%26volume%3D18%26spage%3D847%26epage%3D857%26doi%3D10.1080%2F14737175.2018.1531706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref310"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref310'); return false;" data-citation="" class="refNumLink">310</a></strong><div class="NLM_citation" id="cit310"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span> <span> </span><span class="NLM_article-title">The Growing Landscape of Lysine Acetylation Links Metabolism and Cell Signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrm3841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm3841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25053359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ktbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=536-550&author=C.+Choudharyauthor=B.+T.+Weinertauthor=Y.+Nishidaauthor=E.+Verdinauthor=M.+Mann&title=The+Growing+Landscape+of+Lysine+Acetylation+Links+Metabolism+and+Cell+Signalling&doi=10.1038%2Fnrm3841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit310R"><div class="casContent"><span class="casTitleNuber">310</span><div class="casTitle"><span class="NLM_cas:atitle">The growing landscape of lysine acetylation links metabolism and cell signaling</span></div><div class="casAuthors">Choudhary, Chunaram; Weinert, Brian T.; Nishida, Yuya; Verdin, Eric; Mann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">536-550</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lys residue acetylation is a conserved protein post-translational modification that links acetyl-CoA metab. and cellular signaling.  Recent advances in the identification and quantification of Lys residue acetylation by mass spectrometry have increased the understanding of Lys acetylation, implicating it in many biol. processes through the regulation of protein interactions, activity, and localization.  In addn., proteins are frequently modified by other types of acylations, such as formylation, butyrylation, propionylation, succinylation, malonylation, myristoylation, glutarylation, and crotonylation.  The intricate link between Lys acylation and cellular metab. has been clarified by the occurrence of several such metabolite-sensitive acylations and their selective removal by sirtuin deacylases.  These emerging findings point to new functions for different Lys acylations and deacylating enzymes and also highlight the mechanisms by which acetylation regulates various cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFJb5kUjj7arVg90H21EOLACvtfcHk0lj2hJVpPDTV4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ktbrN&md5=89703cd65c2cebe4a1474cf40f6d0be7</span></div><a href="/servlet/linkout?suffix=cit310&amp;dbid=16384&amp;doi=10.1038%2Fnrm3841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3841%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DWeinert%26aufirst%3DB.%2BT.%26aulast%3DNishida%26aufirst%3DY.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DMann%26aufirst%3DM.%26atitle%3DThe%2520Growing%2520Landscape%2520of%2520Lysine%2520Acetylation%2520Links%2520Metabolism%2520and%2520Cell%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D536%26epage%3D550%26doi%3D10.1038%2Fnrm3841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref311"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref311'); return false;" data-citation="" class="refNumLink">311</a></strong><div class="NLM_citation" id="cit311"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Bromodomains: A New Target Class for drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0030-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs41573-019-0030-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31273347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=609-628&author=A.+G.+Cochranauthor=A.+R.+Coneryauthor=R.+J.+Sims&title=Bromodomains%3A+A+New+Target+Class+for+drug+Development&doi=10.1038%2Fs41573-019-0030-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit311R"><div class="casContent"><span class="casTitleNuber">311</span><div class="casTitle"><span class="NLM_cas:atitle">Bromodomains: a new target class for drug development</span></div><div class="casAuthors">Cochran, Andrea G.; Conery, Andrew R.; Sims, III, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-mol. targets.  This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chem. probe discovery to understand the biol. potential of new agents that targeted bromodomains.  The original examples, inhibitors of the bromodomain and extra-terminal (BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compds. have since advanced to human clin. trials.  Here, we review the current state of BET inhibitor biol. in relation to clin. development, and we discuss the next wave of bromodomain inhibitors with clin. potential in oncol. and non-oncol. indications.  The lessons learned from BET inhibitor programs should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6QwxqowW9NbVg90H21EOLACvtfcHk0lj2hJVpPDTV4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL&md5=88e56eec8edeb7c325d28156ec131ed8</span></div><a href="/servlet/linkout?suffix=cit311&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomains%253A%2520A%2520New%2520Target%2520Class%2520for%2520drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D609%26epage%3D628%26doi%3D10.1038%2Fs41573-019-0030-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref312"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref312'); return false;" data-citation="" class="refNumLink">312</a></strong><div class="NLM_citation" id="cit312"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit312R"><div class="casContent"><span class="casTitleNuber">312</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0lj-7hcl_tj8xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit312&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref313"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref313'); return false;" data-citation="" class="refNumLink">313</a></strong><div class="NLM_citation" id="cit313"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marazzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coste, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lora, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarakhovsky, A.</span></span> <span> </span><span class="NLM_article-title">Suppression of Inflammation by a Synthetic Histone Mimic</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1038/nature09589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature09589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21068722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1119-1123&author=E.+Nicodemeauthor=K.+L.+Jeffreyauthor=U.+Schaeferauthor=S.+Beinkeauthor=S.+Dewellauthor=C.-W.+Chungauthor=R.+Chandwaniauthor=I.+Marazziauthor=P.+Wilsonauthor=H.+Costeauthor=J.+Whiteauthor=J.+Kirilovskyauthor=C.+M.+Riceauthor=J.+M.+Loraauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=A.+Tarakhovsky&title=Suppression+of+Inflammation+by+a+Synthetic+Histone+Mimic&doi=10.1038%2Fnature09589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit313R"><div class="casContent"><span class="casTitleNuber">313</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of inflammation by a synthetic histone mimic</span></div><div class="casAuthors">Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe; Beinke, Soren; Dewell, Scott; Chung, Chun-wa; Chandwani, Rohit; Marazzi, Ivan; Wilson, Paul; Coste, Herve; White, Julia; Kirilovsky, Jorge; Rice, Charles M.; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin; Tarakhovsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression.  This response, although vital for immune defense, is frequently deleterious to the host due to the exaggerated prodn. of inflammatory proteins.  The scope of inflammatory responses reflects the activation state of signaling proteins upstream of inflammatory genes as well as signal-induced assembly of nuclear chromatin complexes that support mRNA expression.  Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a crit. step in the regulation of gene expression.  Here we present a novel pharmacol. approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins.  We describe a synthetic compd. (I-BET) that by mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis.  Our findings suggest that synthetic compds. specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxc3_PNaiuKLVg90H21EOLACvtfcHk0lj-7hcl_tj8xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP&md5=0dfccd9d01b87859512bf591e1c5a93c</span></div><a href="/servlet/linkout?suffix=cit313&amp;dbid=16384&amp;doi=10.1038%2Fnature09589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09589%26sid%3Dliteratum%253Aachs%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DJeffrey%26aufirst%3DK.%2BL.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DBeinke%26aufirst%3DS.%26aulast%3DDewell%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DChandwani%26aufirst%3DR.%26aulast%3DMarazzi%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DP.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTarakhovsky%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Inflammation%2520by%2520a%2520Synthetic%2520Histone%2520Mimic%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1119%26epage%3D1123%26doi%3D10.1038%2Fnature09589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref314"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref314'); return false;" data-citation="" class="refNumLink">314</a></strong><div class="NLM_citation" id="cit314"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K.</span></span> <span> </span><span class="NLM_article-title">Bromodomain Protein Inhibition: A Novel Therapeutic Strategy in Rheumatic Diseases</span>. <i>RMD Open</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e000744</span>, <span class="refDoi"> DOI: 10.1136/rmdopen-2018-000744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref314/cit314&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Frmdopen-2018-000744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref314/cit314&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30564450" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=e000744&author=K.+Klein&title=Bromodomain+Protein+Inhibition%3A+A+Novel+Therapeutic+Strategy+in+Rheumatic+Diseases&doi=10.1136%2Frmdopen-2018-000744"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit314&amp;dbid=16384&amp;doi=10.1136%2Frmdopen-2018-000744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Frmdopen-2018-000744%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DK.%26atitle%3DBromodomain%2520Protein%2520Inhibition%253A%2520A%2520Novel%2520Therapeutic%2520Strategy%2520in%2520Rheumatic%2520Diseases%26jtitle%3DRMD%2520Open%26date%3D2018%26volume%3D4%26spage%3De000744%26doi%3D10.1136%2Frmdopen-2018-000744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref315"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref315'); return false;" data-citation="" class="refNumLink">315</a></strong><div class="NLM_citation" id="cit315"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altenburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöbel, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goßen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderliek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschmieder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Altenburgauthor=M.+Fringsauthor=J.-H.+Sch%C3%B6belauthor=J.+Go%C3%9Fenauthor=K.+Pannenauthor=K.+Vanderliekauthor=G.+Rossettiauthor=S.+Koschmiederauthor=N.+Chatainauthor=C.+Bolm&title=Chiral+Analogues+of+PFI-1+as+BET+Inhibitors+and+Their+Functional+Role+in+Myeloid+Malignancies&doi=10.1021%2Facsmedchemlett.9b00625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit315&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00625%26sid%3Dliteratum%253Aachs%26aulast%3DAltenburg%26aufirst%3DB.%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DSch%25C3%25B6bel%26aufirst%3DJ.-H.%26aulast%3DGo%25C3%259Fen%26aufirst%3DJ.%26aulast%3DPannen%26aufirst%3DK.%26aulast%3DVanderliek%26aufirst%3DK.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DKoschmieder%26aufirst%3DS.%26aulast%3DChatain%26aufirst%3DN.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DChiral%2520Analogues%2520of%2520PFI-1%2520as%2520BET%2520Inhibitors%2520and%2520Their%2520Functional%2520Role%2520in%2520Myeloid%2520Malignancies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.9b00625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288'],'ref289':['cit289'],'ref290':['cit290'],'ref291':['cit291'],'ref292':['cit292'],'ref293':['cit293'],'ref294':['cit294'],'ref295':['cit295'],'ref296':['cit296'],'ref297':['cit297'],'ref298':['cit298'],'ref299':['cit299'],'ref300':['cit300'],'ref301':['cit301'],'ref302':['cit302'],'ref303':['cit303'],'ref304':['cit304'],'ref305':['cit305'],'ref306':['cit306'],'ref307':['cit307'],'ref308':['cit308'],'ref309':['cit309'],'ref310':['cit310'],'ref311':['cit311'],'ref312':['cit312'],'ref313':['cit313'],'ref314':['cit314'],'ref315':['cit315']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yu Tang, <span class="NLM_string-name hlFld-ContribAuthor">Scott J. Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Enantioselective Synthesis of Pyridyl Sulfoximines. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (24)
                                     , 9230-9235. <a href="https://doi.org/10.1021/jacs.1c04431" title="DOI URL">https://doi.org/10.1021/jacs.1c04431</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c04431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c04431%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCatalytic%252BEnantioselective%252BSynthesis%252Bof%252BPyridyl%252BSulfoximines%26aulast%3DTang%26aufirst%3DYu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D28042021%26date%3D14062021%26volume%3D143%26issue%3D24%26spage%3D9230%26epage%3D9235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gregory B. Craven, Edward L. Briggs, Charlotte M. Zammit, Alexander McDermott, Stephanie Greed, Dominic P. Affron, Charlotte Leinfellner, Hannah R. Cudmore, Ruth R. Tweedy, Renzo Luisi, James A. Bull, <span class="NLM_string-name hlFld-ContribAuthor">Alan Armstrong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (11)
                                     , 7403-7424. <a href="https://doi.org/10.1021/acs.joc.1c00373" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00373%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BConfigurational%252BAssignment%252Bof%252BVinyl%252BSulfoximines%252Band%252BSulfonimidamides%26aulast%3DCraven%26aufirst%3DGregory%2BB.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D15022021%26date%3D18052021%26volume%3D86%26issue%3D11%26spage%3D7403%26epage%3D7424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Renè Hommelsheim, Heliana Michaela Núñez Ponce, Khai-Nghi Truong, Kari Rissanen, <span class="NLM_string-name hlFld-ContribAuthor">Carsten Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">2-Sulfoximidoyl Acetic Acids from Multicomponent Petasis Reactions and Their Use as Building Blocks in Syntheses of Sulfoximine Benzodiazepine Analogues. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (9)
                                     , 3415-3420. <a href="https://doi.org/10.1021/acs.orglett.1c00874" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00874%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D2-Sulfoximidoyl%252BAcetic%252BAcids%252Bfrom%252BMulticomponent%252BPetasis%252BReactions%252Band%252BTheir%252BUse%252Bas%252BBuilding%252BBlocks%252Bin%252BSyntheses%252Bof%252BSulfoximine%252BBenzodiazepine%252BAnalogues%26aulast%3DHommelsheim%26aufirst%3DRen%25C3%25A8%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13032021%26date%3D08042021%26volume%3D23%26issue%3D9%26spage%3D3415%26epage%3D3420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anže Zupanc, <span class="NLM_string-name hlFld-ContribAuthor">Marjan Jereb</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of N-Iodo Sulfoximines from Sulfides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (8)
                                     , 5991-6000. <a href="https://doi.org/10.1021/acs.joc.1c00292" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00292%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BN-Iodo%252BSulfoximines%252Bfrom%252BSulfides%26aulast%3DZupanc%26aufirst%3DAn%25C5%25BEe%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05022021%26date%3D25032021%26volume%3D86%26issue%3D8%26spage%3D5991%26epage%3D6000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng Shi, Yongliang Tu, Chenyang Wang, Deshen Kong, Ding Ma, <span class="NLM_string-name hlFld-ContribAuthor">Carsten Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Benzothiadiazine-1-oxides by Rhodium-Catalyzed C−H Amidation/Cyclization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (22)
                                     , 8842-8845. <a href="https://doi.org/10.1021/acs.orglett.0c03212" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03212</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03212%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BBenzothiadiazine-1-oxides%252Bby%252BRhodium-Catalyzed%252BC%2525E2%252588%252592H%252BAmidation%25252FCyclization%26aulast%3DShi%26aufirst%3DPeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24092020%26date%3D10112020%26volume%3D22%26issue%3D22%26spage%3D8842%26epage%3D8845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chenyang Wang, Ding Ma, Yongliang Tu, <span class="NLM_string-name hlFld-ContribAuthor">Carsten Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Hypervalent Iodine Reagents in Visible Light-Promoted α-Ketoacylations of Sulfoximines with Aryl Alkynes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (22)
                                     , 8937-8940. <a href="https://doi.org/10.1021/acs.orglett.0c03338" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03338%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DUse%252Bof%252BHypervalent%252BIodine%252BReagents%252Bin%252BVisible%252BLight-Promoted%252B%2525CE%2525B1-Ketoacylations%252Bof%252BSulfoximines%252Bwith%252BAryl%252BAlkynes%26aulast%3DWang%26aufirst%3DChenyang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06102020%26date%3D30102020%26volume%3D22%26issue%3D22%26spage%3D8937%26epage%3D8940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Tilby</span>, <span class="hlFld-ContribAuthor ">Michael C.  Willis</span>. </span><span class="cited-content_cbyCitation_article-title">How do we address neglected sulfur pharmacophores in drug discovery?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>, 1-5. <a href="https://doi.org/10.1080/17460441.2021.1948008" title="DOI URL">https://doi.org/10.1080/17460441.2021.1948008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1948008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1948008%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DHow%252Bdo%252Bwe%252Baddress%252Bneglected%252Bsulfur%252Bpharmacophores%252Bin%252Bdrug%252Bdiscovery%25253F%26aulast%3DTilby%26aufirst%3DMichael%2BJ.%26date%3D2021%26date%3D2021%26volume%3D16%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas Q.  Davies</span>, <span class="hlFld-ContribAuthor ">Michael C.  Willis</span>. </span><span class="cited-content_cbyCitation_article-title">Rediscovering Sulfinylamines as Reagents for Organic Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (35)
                                     , 8918-8927. <a href="https://doi.org/10.1002/chem.202100321" title="DOI URL">https://doi.org/10.1002/chem.202100321</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202100321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202100321%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DRediscovering%252BSulfinylamines%252Bas%252BReagents%252Bfor%252BOrganic%252BSynthesis%26aulast%3DDavies%26aufirst%3DThomas%2BQ.%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D35%26spage%3D8918%26epage%3D8927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ankita  Isor</span>, <span class="hlFld-ContribAuthor ">Renè  Hommelsheim</span>, <span class="hlFld-ContribAuthor ">Grant W.  Cone</span>, <span class="hlFld-ContribAuthor ">Marcus  Frings</span>, <span class="hlFld-ContribAuthor ">John T.  Petroff</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>, <span class="hlFld-ContribAuthor ">Ryan D.  McCulla</span>. </span><span class="cited-content_cbyCitation_article-title">Photochemistry of
              N
              ‐Phenyl Dibenzothiophene Sulfoximine
              †. </span><span class="cited-content_cbyCitation_journal-name">Photochemistry and Photobiology</span><span> <strong>2021,</strong> <em>131 </em><a href="https://doi.org/10.1111/php.13456" title="DOI URL">https://doi.org/10.1111/php.13456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/php.13456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fphp.13456%26sid%3Dliteratum%253Aachs%26jtitle%3DPhotochemistry%2520and%2520Photobiology%26atitle%3DPhotochemistry%252Bof%252BN%252B%2525E2%252580%252590Phenyl%252BDibenzothiophene%252BSulfoximine%252B%2525E2%252580%2525A0%26aulast%3DIsor%26aufirst%3DAnkita%26date%3D2021%26date%3D2021%26volume%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Shi</span>, <span class="hlFld-ContribAuthor ">Yongliang  Tu</span>, <span class="hlFld-ContribAuthor ">Duo  Zhang</span>, <span class="hlFld-ContribAuthor ">Chenyang  Wang</span>, <span class="hlFld-ContribAuthor ">Khai‐Nghi  Truong</span>, <span class="hlFld-ContribAuthor ">Kari  Rissanen</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Regio‐ and Stereoselective Chloro Sulfoximidations of Terminal Aryl Alkynes Enabled by Copper Catalysis and Visible Light. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (10)
                                     , 2552-2556. <a href="https://doi.org/10.1002/adsc.202100162" title="DOI URL">https://doi.org/10.1002/adsc.202100162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100162%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DRegio%2525E2%252580%252590%252Band%252BStereoselective%252BChloro%252BSulfoximidations%252Bof%252BTerminal%252BAryl%252BAlkynes%252BEnabled%252Bby%252BCopper%252BCatalysis%252Band%252BVisible%252BLight%26aulast%3DShi%26aufirst%3DPeng%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D10%26spage%3D2552%26epage%3D2556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nasser  Amri</span>, <span class="hlFld-ContribAuthor ">Thomas  Wirth</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Electrochemical Synthesis of Organosulfur Compounds. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2021,</strong> <em>76 </em><a href="https://doi.org/10.1002/tcr.202100064" title="DOI URL">https://doi.org/10.1002/tcr.202100064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.202100064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.202100064%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BElectrochemical%252BSynthesis%252Bof%252BOrganosulfur%252BCompounds%26aulast%3DAmri%26aufirst%3DNasser%26date%3D2021%26date%3D2021%26volume%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Rong</span>, <span class="hlFld-ContribAuthor ">Chuanfa  Ni</span>, <span class="hlFld-ContribAuthor ">Yucheng  Gu</span>, <span class="hlFld-ContribAuthor ">Jinbo  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Enantiopure Benzo Fused Cyclic Sulfoximines Through Stereoselective [3+2] Cycloaddition between
              N
              ‐
              tert
              ‐Butanesulfinyl [(2‐Pyridyl)sulfonyl]‐difluoromethyl Ketimines and Arynes. </span><span class="cited-content_cbyCitation_journal-name">Helvetica Chimica Acta</span><span> <strong>2021,</strong> <em>104 </em>
                                    (4)
                                     <a href="https://doi.org/10.1002/hlca.202100019" title="DOI URL">https://doi.org/10.1002/hlca.202100019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hlca.202100019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhlca.202100019%26sid%3Dliteratum%253Aachs%26jtitle%3DHelvetica%2520Chimica%2520Acta%26atitle%3DSynthesis%252Bof%252BEnantiopure%252BBenzo%252BFused%252BCyclic%252BSulfoximines%252BThrough%252BStereoselective%252B%25255B3%25252B2%25255D%252BCycloaddition%252Bbetween%252BN%252B%2525E2%252580%252590%252Btert%252B%2525E2%252580%252590Butanesulfinyl%252B%25255B%2525282%2525E2%252580%252590Pyridyl%252529sulfonyl%25255D%2525E2%252580%252590difluoromethyl%252BKetimines%252Band%252BArynes%26aulast%3DRong%26aufirst%3DJian%26date%3D2021%26date%3D2021%26volume%3D104%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajasekar Reddy  Annapureddy</span>, <span class="hlFld-ContribAuthor ">Finn  Burg</span>, <span class="hlFld-ContribAuthor ">Johannes  Gramüller</span>, <span class="hlFld-ContribAuthor ">Tino P.  Golub</span>, <span class="hlFld-ContribAuthor ">Christian  Merten</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Huber</span>, <span class="hlFld-ContribAuthor ">Thorsten  Bach</span>. </span><span class="cited-content_cbyCitation_article-title">Silver‐Catalyzed Enantioselective Sulfimidation Mediated by Hydrogen Bonding Interactions. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (14)
                                     , 7999-8005. <a href="https://doi.org/10.1002/ange.202016561" title="DOI URL">https://doi.org/10.1002/ange.202016561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202016561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202016561%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DSilver%2525E2%252580%252590Catalyzed%252BEnantioselective%252BSulfimidation%252BMediated%252Bby%252BHydrogen%252BBonding%252BInteractions%26aulast%3DAnnapureddy%26aufirst%3DRajasekar%2BReddy%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D14%26spage%3D7999%26epage%3D8005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajasekar Reddy  Annapureddy</span>, <span class="hlFld-ContribAuthor ">Finn  Burg</span>, <span class="hlFld-ContribAuthor ">Johannes  Gramüller</span>, <span class="hlFld-ContribAuthor ">Tino P.  Golub</span>, <span class="hlFld-ContribAuthor ">Christian  Merten</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Huber</span>, <span class="hlFld-ContribAuthor ">Thorsten  Bach</span>. </span><span class="cited-content_cbyCitation_article-title">Silver‐Catalyzed Enantioselective Sulfimidation Mediated by Hydrogen Bonding Interactions. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (14)
                                     , 7920-7926. <a href="https://doi.org/10.1002/anie.202016561" title="DOI URL">https://doi.org/10.1002/anie.202016561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202016561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202016561%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DSilver%2525E2%252580%252590Catalyzed%252BEnantioselective%252BSulfimidation%252BMediated%252Bby%252BHydrogen%252BBonding%252BInteractions%26aulast%3DAnnapureddy%26aufirst%3DRajasekar%2BReddy%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D14%26spage%3D7920%26epage%3D7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding  Ma</span>, <span class="hlFld-ContribAuthor ">Chenyang  Wang</span>, <span class="hlFld-ContribAuthor ">Deshen  Kong</span>, <span class="hlFld-ContribAuthor ">Yongliang  Tu</span>, <span class="hlFld-ContribAuthor ">Peng  Shi</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium‐Catalyzed Carbonylation in the Synthesis of
              N
              ‐Ynonylsulfoximines. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (5)
                                     , 1330-1334. <a href="https://doi.org/10.1002/adsc.202001440" title="DOI URL">https://doi.org/10.1002/adsc.202001440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001440%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DPalladium%2525E2%252580%252590Catalyzed%252BCarbonylation%252Bin%252Bthe%252BSynthesis%252Bof%252BN%252B%2525E2%252580%252590Ynonylsulfoximines%26aulast%3DMa%26aufirst%3DDing%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D5%26spage%3D1330%26epage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan‐Hendrik  Schöbel</span>, <span class="hlFld-ContribAuthor ">Philipp  Elbers</span>, <span class="hlFld-ContribAuthor ">Khai‐Nghi  Truong</span>, <span class="hlFld-ContribAuthor ">Kari  Rissanen</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">1,2‐Benzothiazine Derivatives from Sulfonimidamides by Metal‐Catalyzed Annulation Reactions in Solution and under Solvent‐Free Mechanochemical Conditions. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (5)
                                     , 1322-1329. <a href="https://doi.org/10.1002/adsc.202001505" title="DOI URL">https://doi.org/10.1002/adsc.202001505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001505%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3D1%25252C2%2525E2%252580%252590Benzothiazine%252BDerivatives%252Bfrom%252BSulfonimidamides%252Bby%252BMetal%2525E2%252580%252590Catalyzed%252BAnnulation%252BReactions%252Bin%252BSolution%252Band%252Bunder%252BSolvent%2525E2%252580%252590Free%252BMechanochemical%252BConditions%26aulast%3DSch%25C3%25B6bel%26aufirst%3DJan%25E2%2580%2590Hendrik%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D5%26spage%3D1322%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenyang  Wang</span>, <span class="hlFld-ContribAuthor ">Han  Wang</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfoximines with
              α
              ‐Ketoester Functionalities at Nitrogen from Cyanoacetates and Air. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (3)
                                     , 747-750. <a href="https://doi.org/10.1002/adsc.202001264" title="DOI URL">https://doi.org/10.1002/adsc.202001264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001264%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSulfoximines%252Bwith%252B%2525CE%2525B1%252B%2525E2%252580%252590Ketoester%252BFunctionalities%252Bat%252BNitrogen%252Bfrom%252BCyanoacetates%252Band%252BAir%26aulast%3DWang%26aufirst%3DChenyang%26date%3D2021%26date%3D2020%26volume%3D363%26issue%3D3%26spage%3D747%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenyang  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Shi</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">Visible light-promoted
              N
              H-halogenation of sulfoximines with dichloromethane or dibromomethane. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>6 </em><a href="https://doi.org/10.1039/D1QO00382H" title="DOI URL">https://doi.org/10.1039/D1QO00382H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00382H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00382H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DVisible%252Blight-promoted%252BN%252BH-halogenation%252Bof%252Bsulfoximines%252Bwith%252Bdichloromethane%252Bor%252Bdibromomethane%26aulast%3DWang%26aufirst%3DChenyang%26date%3D2021%26date%3D2021%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barry M.  Trost</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Jiao</span>, <span class="hlFld-ContribAuthor ">Hadi  Gholami</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-catalyzed asymmetric allylic alkylation (AAA) with alkyl sulfones as nucleophiles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>96 </em><a href="https://doi.org/10.1039/D1SC02599F" title="DOI URL">https://doi.org/10.1039/D1SC02599F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC02599F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC02599F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DPalladium-catalyzed%252Basymmetric%252Ballylic%252Balkylation%252B%252528AAA%252529%252Bwith%252Balkyl%252Bsulfones%252Bas%252Bnucleophiles%26aulast%3DTrost%26aufirst%3DBarry%2BM.%26date%3D2021%26date%3D2021%26volume%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K.  Natarajan</span>, <span class="hlFld-ContribAuthor ">C. P.  Irfana Jesin</span>, <span class="hlFld-ContribAuthor ">A.  Antony Haritha Mercy</span>, <span class="hlFld-ContribAuthor ">Ganesh Chandra  Nandi</span>. </span><span class="cited-content_cbyCitation_article-title">A metal-free Petasis reaction towards the synthesis of
              N
              -(α-substituted)alkyl sulfoximines/sulfonimidamides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>6 </em><a href="https://doi.org/10.1039/D1OB01181B" title="DOI URL">https://doi.org/10.1039/D1OB01181B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB01181B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB01181B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bmetal-free%252BPetasis%252Breaction%252Btowards%252Bthe%252Bsynthesis%252Bof%252BN%252B-%252528%2525CE%2525B1-substituted%252529alkyl%252Bsulfoximines%25252Fsulfonimidamides%26aulast%3DNatarajan%26aufirst%3DK.%26date%3D2021%26date%3D2021%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Schumacher</span>, <span class="hlFld-ContribAuthor ">Hannah  Fergen</span>, <span class="hlFld-ContribAuthor ">Rakesh  Puttreddy</span>, <span class="hlFld-ContribAuthor ">Khai-Nghi  Truong</span>, <span class="hlFld-ContribAuthor ">Torsten  Rinesch</span>, <span class="hlFld-ContribAuthor ">Kari  Rissanen</span>, <span class="hlFld-ContribAuthor ">Carsten  Bolm</span>. </span><span class="cited-content_cbyCitation_article-title">N
              -(2,3,5,6-Tetrafluoropyridyl)sulfoximines: synthesis, X-ray crystallography, and halogen bonding. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (23)
                                     , 3896-3906. <a href="https://doi.org/10.1039/D0QO01139H" title="DOI URL">https://doi.org/10.1039/D0QO01139H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01139H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01139H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DN%252B-%2525282%25252C3%25252C5%25252C6-Tetrafluoropyridyl%252529sulfoximines%25253A%252Bsynthesis%25252C%252BX-ray%252Bcrystallography%25252C%252Band%252Bhalogen%252Bbonding%26aulast%3DSchumacher%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D23%26spage%3D3896%26epage%3D3906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of selected boron-containing biologically active compounds.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5−8)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) General structure of sulfur-containing functional groups. (B) General properties of sulfoximines. (C) General properties of sulfonimidamides.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9−15)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the numbers of publications per decade containing the keyword “sulfoximine” (blue bars) and of reactions per decade containing a sulfoximine substructure (red bars) according to SciFinder (accessed July 17, 2020).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of methionine sulfoximine (<b>10</b>), buthionine sulfoximine (<b>11</b>), and sulfoxaflor (<b>12</b>).<a onclick="showRef(event, 'ref36 ref42'); return false;" href="javascript:void(0);" class="ref ref36 ref42">(36,42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of selected tool compounds (<b>13</b>–<b>26</b>) investigated by Gnamm and co-workers.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of matched molecular pairs <b>27</b>–<b>38</b> investigated by Sirvent and Lücking.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of matched molecular pairs <b>39</b>–<b>44</b> investigated in several studies.<a onclick="showRef(event, 'ref58 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref60">(58,60)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Chemical structures and biological data of some pan-CDK inhibitors <b>45</b>–<b>48</b>. (B) Chemical structures and biological data of some CDK9-selective inhibitors <b>49</b>–<b>53</b>.<a onclick="showRef(event, 'ref15 ref74 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref15 ref74 ref77 ref78">(15,74,77,78)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures and key properties of ATR inhibitors AZ20 (<b>54</b>) and AZD6738 (<b>55</b>) and its metabolites <b>56</b> and <b>57</b>.<a onclick="showRef(event, 'ref98 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref98 ref99 ref100">(98−100)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0025.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Proposed Mechanism for the Oxidative Deimination of AZD6738 (<b>55</b>) (Stereochemistry Not Shown)<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of sulfoximine-based ASNS inhibitors <b>59</b>–<b>61</b>.<a onclick="showRef(event, 'ref119 ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121">(119−121)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structures of celecoxib (<b>62</b>) and rofecoxib (<b>63</b>). (B) Overview of sulfoximine-based COX-2 inhibitors <b>64</b>–<b>68</b>.<a onclick="showRef(event, 'ref128 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref128 ref129 ref130">(128−130)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Chemical structures and IC<sub>50</sub> values of the parent carbohydrate-based thiochroman <b>69</b> and its sulfoximine analogues <b>70a</b>/<b>b</b>. (B) chemical structure and IC<sub>50</sub> value of the most potent sulfoximine-triazole hybrid <b>71</b>.<a onclick="showRef(event, 'ref146 ref147 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref149 ref150">(146,147,149,150)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0013.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. (A) Oxazolidinone-based sulfoximines (<b>72</b>) as antibacterial agents. (B) <i>N</i>-Trifluoromethylthiolated sulfoximines and sulfonimidamides (<b>73</b>–<b>79</b>) as antitubercular agents.<a onclick="showRef(event, 'ref163 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref163 ref165 ref166">(163,165,166)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures and IC<sub>50</sub> values of DPP-4 inhibitors (<b>80</b>–<b>83</b>) investigated by Merck, Sharp, and Dohme, sitagliptin (<b>84</b>), and linagliptin (<b>85</b>).<a onclick="showRef(event, 'ref176 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref176 ref177 ref178">(176−178)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0015.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (A) Chemical structures and EC<sub>50</sub> values of sulfonimidamide-based AMPK activators (<b>86</b> and <b>87</b>) investigated by Boehringer Ingelheim. (B) Chemical structures and key properties of selected GK-GKRP disruptors (<b>88</b>–<b>93</b>) investigated by Amgen.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0016.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Chemical structures and IC<sub>50</sub> values of indinavir (<b>94</b>) and L700417 (<b>95</b>). (B) Comparison of tetrahedral transition state and tetrahedral transition state mimetics. (C) Chemical structures and IC<sub>50</sub> values of the most potent sulfoximine-based antiretroviral agents.<a onclick="showRef(event, 'ref206 ref207 ref208 ref209 ref210'); return false;" href="javascript:void(0);" class="ref ref206 ref207 ref208 ref209 ref210">(206−210)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0017.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) Chemical structures and IC<sub>50</sub> values of inverse agonists of RORγ <b>100</b> and <b>101</b> investigated by Nestlé Skin Health. (B) Chemical structures of sulfonimidamide-based CCR10 antagonists <b>102</b>–<b>104</b> investigated by Kyowa Hakko Kirin Co., Ltd..<a onclick="showRef(event, 'ref222 ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref222 ref231 ref232">(222,231,232)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0018.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (A) Chemical structures and ED<sub>50</sub> values of disodium chromoglycate (DSCG, <b>105</b>), sulfoximine <b>106</b>, and sudedanox (<b>107</b>). (B) chemical (core) structures and IC<sub>50</sub> values of sulfoximine-based hNE inhibitors (<b>108</b>–<b>111</b>).<a onclick="showRef(event, 'ref244 ref246 ref247 ref248'); return false;" href="javascript:void(0);" class="ref ref244 ref246 ref247 ref248">(244,246−248)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0019.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures and biological activities of the known CYP24 hydroxylase inhibitor ketoconazole (<b>112</b>), calcitriol (<b>113</b>), and its analogues <b>114</b>–<b>116</b> with CYP24 hydroxylase inhibitory activity.<a onclick="showRef(event, 'ref274 ref276 ref277 ref278 ref279'); return false;" href="javascript:void(0);" class="ref ref274 ref276 ref277 ref278 ref279">(274,276−279)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0020.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures and key properties of investigated PYK2 inhibitors <b>117</b>–<b>120</b>.<a onclick="showRef(event, 'ref296'); return false;" href="javascript:void(0);" class="ref ref296">(296)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0021.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of betrixaban (<b>121</b>) and sulfoximine-based factor Xa inhibitors (<b>122</b>–<b>125</b>).<a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">(301)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0022.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures and IC<sub>50</sub> values of selected sulfonimidamide-based β-secretase inhibitors <b>126</b>–<b>130</b>.<a onclick="showRef(event, 'ref306 ref307 ref308'); return false;" href="javascript:void(0);" class="ref ref306 ref307 ref308">(306−308)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0023.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. (A) Chemical structures and IC<sub>50</sub> values of JQ-1 (<b>131</b>) and GSK525762A (<b>132</b>). (B) Chemical structure of the parent PFI-1 (<b>133</b>), the most potent sulfoximine (<i>S</i>)-<b>134</b>, and the most potent sulfondiimide <b>135</b>.<a onclick="showRef(event, 'ref312 ref313 ref315'); return false;" href="javascript:void(0);" class="ref ref312 ref313 ref315">(312,313,315)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/medium/jm0c00960_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0024.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Overview and status of biologically active sulfoximines that entered clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00960/20201203/images/large/jm0c00960_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00960&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 315 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <i>Bioisosteres in Medicinal Chemistry</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Weinheim</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2F9783527654307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+Brown&title=Bioisosteres+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2F9783527654307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527654307%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DN.%26btitle%3DBioisosteres%2520in%2520Medicinal%2520Chemistry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallqvist, A.</span></span> <span> </span><span class="NLM_article-title">Classification of Scaffold-Hopping Approaches</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.drudis.2011.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22056715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=310-324&author=H.+Sunauthor=G.+Tawaauthor=A.+Wallqvist&title=Classification+of+Scaffold-Hopping+Approaches&doi=10.1016%2Fj.drudis.2011.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of scaffold-hopping approaches</span></div><div class="casAuthors">Sun, Hongmao; Tawa, Gregory; Wallqvist, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">310-324</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The general goal of drug discovery is to identify novel compds. that are active against a preselected biol. target with acceptable pharmacol. properties defined by marketed drugs.  Scaffold hopping has been widely applied by medicinal chemists to discover equipotent compds. with novel backbones that have improved properties.  In this article we classify scaffold hopping into four major categories, namely heterocycle replacements, ring opening or closure, peptidomimetics and topol.-based hopping.  We review the structural diversity of original and final scaffolds with respect to each category.  We discuss the advantages and limitations of small, medium and large-step scaffold hopping.  Finally, we summarize software that is frequently used to facilitate different kinds of scaffold-hopping methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAONaJ8Be0x7Vg90H21EOLACvtfcHk0lg7NGezjH-vJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFyrt7k%253D&md5=5f1143cc255c81b88ea4f83ac9f8efc6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqvist%26aufirst%3DA.%26atitle%3DClassification%2520of%2520Scaffold-Hopping%2520Approaches%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D310%26epage%3D324%26doi%3D10.1016%2Fj.drudis.2011.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutchukian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilyeva, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindvall, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span> <span> </span><span class="NLM_article-title">Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e48476</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0048476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0048476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23185259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVagsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e48476&author=P.+S.+Kutchukianauthor=N.+Y.+Vasilyevaauthor=J.+Xuauthor=M.+K.+Lindvallauthor=M.+P.+Dillonauthor=M.+Glickauthor=J.+D.+Coleyauthor=N.+Brooijmans&title=Inside+the+Mind+of+a+Medicinal+Chemist%3A+The+Role+of+Human+Bias+in+Compound+Prioritization+during+Drug+Discovery&doi=10.1371%2Fjournal.pone.0048476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery</span></div><div class="casAuthors">Kutchukian, Peter S.; Vasilyeva, Nadya Y.; Xu, Jordan; Lindvall, Mika K.; Dillon, Michael P.; Glick, Meir; Coley, John D.; Brooijmans, Natasja</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e48476</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Medicinal chemists' "intuition" is crit. for success in modern drug discovery.  Early in the discovery process, chemists select a subset of compds. for further research, often from many viable candidates.  These decisions det. the success of a discovery campaign, and ultimately what kind of drugs are developed and marketed to the public.  Surprisingly little is known about the cognitive aspects of chemists' decision-making when they prioritize compds.  We investigate (1) how and to what extent chemists simplify the problem of identifying promising compds., (2) whether chemists agree with each other about the criteria used for such decisions, and (3) how accurately chemists report the criteria they use for these decisions.  Chemists were surveyed and asked to select chem. fragments that they would be willing to develop into a lead compd. from a set of ∼4,000 available fragments.  Based on each chemist's selections, computational classifiers were built to model each chemist's selection strategy.  Results suggest that chemists greatly simplified the problem, typically using only 1-2 of many possible parameters when making their selections.  Although chemists tended to use the same parameters to select compds., differing value preferences for these parameters led to an overall lack of consensus in compd. selections.  Moreover, what little agreement there was among the chemists was largely in what fragments were undesirable.  Furthermore, chemists were often unaware of the parameters (such as compd. size) which were statistically significant in their selections, and overestimated the no. of parameters they employed.  A crit. evaluation of the problem space faced by medicinal chemists and cognitive models of categorization were esp. useful in understanding the low consensus between chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2xkFnkLMFbVg90H21EOLACvtfcHk0linyRwtMEelsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVagsr3N&md5=a94653786832db485777a60e05dbb848</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048476%26sid%3Dliteratum%253Aachs%26aulast%3DKutchukian%26aufirst%3DP.%2BS.%26aulast%3DVasilyeva%26aufirst%3DN.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLindvall%26aufirst%3DM.%2BK.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DColey%26aufirst%3DJ.%2BD.%26aulast%3DBrooijmans%26aufirst%3DN.%26atitle%3DInside%2520the%2520Mind%2520of%2520a%2520Medicinal%2520Chemist%253A%2520The%2520Role%2520of%2520Human%2520Bias%2520in%2520Compound%2520Prioritization%2520during%2520Drug%2520Discovery%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De48476%26doi%3D10.1371%2Fjournal.pone.0048476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the Medicinal Chemistry Synthetic Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd.2018.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30140018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=709-727&author=J.+Bostr%C3%B6mauthor=D.+G.+Brownauthor=R.+J.+Youngauthor=G.+M.+Keser%C3%BC&title=Expanding+the+Medicinal+Chemistry+Synthetic+Toolbox&doi=10.1038%2Fnrd.2018.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinal chemistry synthetic toolbox</span></div><div class="casAuthors">Bostrom Jonas; Brown Dean G; Young Robert J; Keseru Gyorgy M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The key objectives of medicinal chemistry are to efficiently design and synthesize bioactive compounds that have the potential to become safe and efficacious drugs.  Most medicinal chemistry programmes rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemistry reactions.  Analysis of the role of synthetic organic chemistry in subsequent hit and lead optimization efforts suggests that only a few reactions dominate.  Thus, the uptake of new synthetic methodologies in drug discovery is limited.  Starting from the known limitations of reaction parameters, synthesis design tools, synthetic strategies and innovative chemistries, here we highlight opportunities for the expansion of the medicinal chemists' synthetic toolbox.  More intense crosstalk between synthetic and medicinal chemists in industry and academia should enable enhanced impact of new methodologies in future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8c_ueHSwcYMcDoIzZtNkfW6udTcc2ebdP1hjwi5hpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D&md5=d87e988602808139597576ced56faa88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.116%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DExpanding%2520the%2520Medicinal%2520Chemistry%2520Synthetic%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D709%26epage%3D727%26doi%3D10.1038%2Fnrd.2018.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dessain, S.</span>; <span class="NLM_string-name">Fishman, S. E.</span></span> <i>Preserving the Promise: Improving the Culture of Biotech Investment</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Dessain&author=S.+E.+Fishman&title=Preserving+the+Promise%3A+Improving+the+Culture+of+Biotech+Investment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDessain%26aufirst%3DS.%26btitle%3DPreserving%2520the%2520Promise%253A%2520Improving%2520the%2520Culture%2520of%2520Biotech%2520Investment%26pub%3DAcademic%2520Press%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span> <span> </span><span class="NLM_article-title">An Upcoming Drug for Onychomycosis: Tavaborole</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.171870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4103%2F0976-500X.171870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26816482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC28nltV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=236-239&author=N.+Sharmaauthor=D.+Sharma&title=An+Upcoming+Drug+for+Onychomycosis%3A+Tavaborole&doi=10.4103%2F0976-500X.171870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">An upcoming drug for onychomycosis: Tavaborole</span></div><div class="casAuthors">Sharma Neha; Sharma Dhruva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">236-9</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">Fungal infection of the nail as well as nail bed is termed as 'onychomycosis'.  It is caused by dermatophytes, non-dermatophytic fungal species and yeasts like Candida albicans.  It is traditionally treated by topical antifungals, systemic agents like ketoconazole, griseofulvin, itraconazole, fluconazole, etc.  Chemical avulsion or surgical removal of nail can also be tried to treat this disease.  In spite of all these treatment options available, podiatrists were always in search of an ideal drug molecule with lesser side effects and which may improve the patient compliance.  This exhaustive search led to the discovery of a better antifungal agent, known as "Tavaborole." A systematic literature search was carried out using databases such as PubMed, Cochrane Reviews, Google Scholar, etc.  Detailed information about onychomycosis and tavaborole was gathered.  Tavaborole is the first oxaborole antifungal agent approved by FDA in July 2014.  It is marketed under the trade name "Kerydin." It acts by inhibiting protein synthesis in the fungus.  It inhibits an enzyme known as cytosolic leucyl-transfer RNA synthetase, or LeuRS, which plays a key role in fungal essential protein synthesis.  Dermatitis at the site of topical application, erythema, exfoliation and ingrowing toe nail has been reported in 1% of subjects.  Tavaborole may offer a promising role in the treatment of onychomycosis and may compell podiatrists to offer its use in onychomycosis.  The present study describes about chemical nature, mechanism of action and two completed phase 3 clinical trial findings of Tavaborole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT31to254tzSUg6wdEZmT2rfW6udTcc2ebdP1hjwi5hpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nltV2hug%253D%253D&md5=65f0361466ec28d85a354341c13fa39b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.171870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.171870%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DD.%26atitle%3DAn%2520Upcoming%2520Drug%2520for%2520Onychomycosis%253A%2520Tavaborole%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2015%26volume%3D6%26spage%3D236%26epage%3D239%26doi%3D10.4103%2F0976-500X.171870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wring, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenks, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowling, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaukel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarlett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scandale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span> <span> </span><span class="NLM_article-title">SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1151</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pntd.0001151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21738803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=e1151&author=R.+T.+Jacobsauthor=B.+Nareauthor=S.+A.+Wringauthor=M.+D.+Orrauthor=D.+Chenauthor=J.+M.+Sligarauthor=M.+X.+Jenksauthor=R.+A.+Noeauthor=T.+S.+Bowlingauthor=L.+T.+Mercerauthor=C.+Rewertsauthor=E.+Gaukelauthor=J.+Owensauthor=R.+Parhamauthor=R.+Randolphauthor=B.+Beaudetauthor=C.+J.+Bacchiauthor=N.+Yarlettauthor=J.+J.+Plattnerauthor=Y.+Freundauthor=C.+Dingauthor=T.+Akamaauthor=Y.+K.+Zhangauthor=R.+Brunauthor=M.+Kaiserauthor=I.+Scandaleauthor=R.+Don&title=SCYX-7158%2C+an+Orally-Active+Benzoxaborole+for+the+Treatment+of+Stage+2+Human+African+Trypanosomiasis&doi=10.1371%2Fjournal.pntd.0001151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 Human African trypanosomiasis</span></div><div class="casAuthors">Jacobs, Robert T.; Nare, Bakela; Wring, Stephen A.; Orr, Matthew D.; Chen, Daitao; Sligar, Jessica M.; Jenks, Matthew X.; Noe, Robert A.; Bowling, Tana S.; Mercer, Luke T.; Rewerts, Cindy; Gaukel, Eric; Owens, Jennifer; Parham, Robin; Randolph, Ryan; Beaudet, Beth; Bacchi, Cyrus J.; Yarlett, Nigel; Plattner, Jacob J.; Freund, Yvonne; Ding, Charles; Akama, Tsutomu; Zhang, Y.-K.; Brun, Reto; Kaiser, Marcel; Scandale, Ivan; Don, Robert</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1151</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals.  An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods.  We have discovered and optimized a novel class of small-mol. boron-contg. compds., benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT.  Methodol./Principal Findings: A drug discovery project employing integrated biol. screening, medicinal chem. and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2 murine HAT models and has physicochem. and in vitro absorption, distribution, metab., elimination and toxicol. (ADMET) properties consistent with the compd. being orally available, metabolically stable and CNS permeable.  In a murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD × 7 days).  In vivo pharmacokinetic characterization of SCYX-7158 demonstrates that the compd. is highly bioavailable in rodents and non-human primates, has low i.v. plasma clearance and has a 24-h elimination half-life and a vol. of distribution that indicate good tissue distribution.  Most importantly, in rodents brain exposure of SCYX-7158 is high, with Cmax>10 μg/mL and AUC0-24 hr>100 μg*h/mL following a 25 mg/kg oral dose.  Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to achieve therapeutically relevant concns. in this compartment.  Conclusions/Significance: The biol. and pharmacokinetic properties of SCYX-7158 suggest that this compd. will be efficacious and safe to treat stage 2 HAT.  SCYX-7158 has been selected to enter preclin. studies, with expected progression to phase 1 clin. trials in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdyaAga5lprVg90H21EOLACvtfcHk0ljiijORLI3gcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlOgsLY%253D&md5=a54f2d57149e6714c7f6acf5f5280a7d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0001151%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%2BT.%26aulast%3DNare%26aufirst%3DB.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DOrr%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSligar%26aufirst%3DJ.%2BM.%26aulast%3DJenks%26aufirst%3DM.%2BX.%26aulast%3DNoe%26aufirst%3DR.%2BA.%26aulast%3DBowling%26aufirst%3DT.%2BS.%26aulast%3DMercer%26aufirst%3DL.%2BT.%26aulast%3DRewerts%26aufirst%3DC.%26aulast%3DGaukel%26aufirst%3DE.%26aulast%3DOwens%26aufirst%3DJ.%26aulast%3DParham%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DR.%26aulast%3DBeaudet%26aufirst%3DB.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26aulast%3DYarlett%26aufirst%3DN.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DScandale%26aufirst%3DI.%26aulast%3DDon%26aufirst%3DR.%26atitle%3DSCYX-7158%252C%2520an%2520Orally-Active%2520Benzoxaborole%2520for%2520the%2520Treatment%2520of%2520Stage%25202%2520Human%2520African%2520Trypanosomiasis%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2011%26volume%3D5%26spage%3De1151%26doi%3D10.1371%2Fjournal.pntd.0001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totrov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomovskaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsivkovski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abendroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loutit, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, M. N.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3682</span>– <span class="NLM_lpage">3692</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3682-3692&author=S.+J.+Heckerauthor=K.+R.+Reddyauthor=M.+Totrovauthor=G.+C.+Hirstauthor=O.+Lomovskayaauthor=D.+C.+Griffithauthor=P.+Kingauthor=R.+Tsivkovskiauthor=D.+Sunauthor=M.+Sabetauthor=Z.+Taraziauthor=M.+C.+Cliftonauthor=K.+Atkinsauthor=A.+Raymondauthor=K.+T.+Pottsauthor=J.+Abendrothauthor=S.+H.+Boyerauthor=J.+S.+Loutitauthor=E.+E.+Morganauthor=S.+Dursoauthor=M.+N.+Dudley&title=Discovery+of+a+Cyclic+Boronic+Acid+%CE%B2-Lactamase+Inhibitor+%28RPX7009%29+with+Utility+vs+Class+A+Serine+Carbapenemases&doi=10.1021%2Facs.jmedchem.5b00127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases</span></div><div class="casAuthors">Hecker, Scott J.; Reddy, K. Raja; Totrov, Maxim; Hirst, Gavin C.; Lomovskaya, Olga; Griffith, David C.; King, Paula; Tsivkovski, Ruslan; Sun, Dongxu; Sabet, Mojgan; Tarazi, Ziad; Clifton, Matthew C.; Atkins, Kateri; Raymond, Amy; Potts, Kristy T.; Abendroth, Jan; Boyer, Serge H.; Loutit, Jeffrey S.; Morgan, Elizabeth E.; Durso, Stephanie; Dudley, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3682-3692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing dissemination of carbapenemases in Gram-neg. bacteria has threatened the clin. usefulness of the β-lactam class of antimicrobials.  A program was initiated to discover a new series of serine β-lactamase inhibitors contg. a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials.  Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases.  Promising candidate mols. were synthesized and evaluated in biochem. and whole-cell assays.  Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases.  Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.  Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXpE5YX_dRNLVg90H21EOLACvtfcHk0ljNa9FJt4w9Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gs7g%253D&md5=965fbf2b42f2e1b38eccc3b23dfa374f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00127%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTotrov%26aufirst%3DM.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26aulast%3DLomovskaya%26aufirst%3DO.%26aulast%3DGriffith%26aufirst%3DD.%2BC.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DTsivkovski%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DSabet%26aufirst%3DM.%26aulast%3DTarazi%26aufirst%3DZ.%26aulast%3DClifton%26aufirst%3DM.%2BC.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DRaymond%26aufirst%3DA.%26aulast%3DPotts%26aufirst%3DK.%2BT.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BH.%26aulast%3DLoutit%26aufirst%3DJ.%2BS.%26aulast%3DMorgan%26aufirst%3DE.%2BE.%26aulast%3DDurso%26aufirst%3DS.%26aulast%3DDudley%26aufirst%3DM.%2BN.%26atitle%3DDiscovery%2520of%2520a%2520Cyclic%2520Boronic%2520Acid%2520%25CE%25B2-Lactamase%2520Inhibitor%2520%2528RPX7009%2529%2520with%2520Utility%2520vs%2520Class%2520A%2520Serine%2520Carbapenemases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3682%26epage%3D3692%26doi%3D10.1021%2Facs.jmedchem.5b00127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reggelin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zur, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: Structures, Properties and Synthetic Applications</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2000</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1055/s-2000-6217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1055%2Fs-2000-6217" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2000&publication_year=2000&pages=1-64&author=M.+Reggelinauthor=C.+Zur&title=Sulfoximines%3A+Structures%2C+Properties+and+Synthetic+Applications&doi=10.1055%2Fs-2000-6217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6217%26sid%3Dliteratum%253Aachs%26aulast%3DReggelin%26aufirst%3DM.%26aulast%3DZur%26aufirst%3DC.%26atitle%3DSulfoximines%253A%2520Structures%252C%2520Properties%2520and%2520Synthetic%2520Applications%26jtitle%3DSynthesis%26date%3D2000%26volume%3D2000%26spage%3D1%26epage%3D64%26doi%3D10.1055%2Fs-2000-6217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. R.</span></span> <span> </span><span class="NLM_article-title">Applications of Sulfoximines in Synthesis</span>. <i>Chem. Informationsdienst</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1002/chin.198548352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fchin.198548352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1985&pages=3-10&author=C.+R.+Johnson&title=Applications+of+Sulfoximines+in+Synthesis&doi=10.1002%2Fchin.198548352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fchin.198548352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchin.198548352%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26atitle%3DApplications%2520of%2520Sulfoximines%2520in%2520Synthesis%26jtitle%3DChem.%2520Informationsdienst%26date%3D1985%26volume%3D16%26spage%3D3%26epage%3D10%26doi%3D10.1002%2Fchin.198548352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9399</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1002/anie.201302209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201302209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9399-9408&author=U.+L%C3%BCcking&title=Sulfoximines%3A+A+Neglected+Opportunity+in+Medicinal+Chemistry&doi=10.1002%2Fanie.201302209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: A Neglected Opportunity in Medicinal Chemistry</span></div><div class="casAuthors">Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9399-9408</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Innovation has frequently been described as the key to drug discovery.  However, in the daily routine, medicinal chemists often tend to stick to the functional groups and structural elements they know and love.  Blockbuster cancer drug Velcade (bortezomib), for example, was rejected by more than 50 companies, supposedly because of its unusual boronic acid function (as often repeated: "only a moron would put boron in a drug!").  Similarly, in the discovery process of the pan-CDK inhibitor BAY 1000394, the unconventional proposal to introduce a sulfoximine group into the lead series also led to sneers and raised eyebrows, since sulfoximines have seldom been used in medicinal chem.  However, it was the introduction of the sulfoximine group that finally allowed the fundamental issues of the project to be overcome, culminating in the identification of the clin. sulfoximine pan-CDK inhibitor BAY 1000394.  This Minireview provides an overview of a widely neglected opportunity in medicinal chem.-the sulfoximine group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcpeepAANfbVg90H21EOLACvtfcHk0ljfKfn-n0C3ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CrsrvI&md5=6850d8d77b1141d9d9344410822c00c3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302209%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DSulfoximines%253A%2520A%2520Neglected%2520Opportunity%2520in%2520Medicinal%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9399%26epage%3D9408%26doi%3D10.1002%2Fanie.201302209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordwell, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branca, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanier, N. R.</span></span> <span> </span><span class="NLM_article-title">Acidities of Sulfoximines and Related Oxosulfonium Cations. Cyclopropyl Effects and Structures of Alpha-Sulfonyl-Type Carbanions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3884</span>– <span class="NLM_lpage">3889</span>, <span class="refDoi"> DOI: 10.1021/jo01307a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01307a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3cXlvVGmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=3884-3889&author=F.+G.+Bordwellauthor=J.+C.+Brancaauthor=C.+R.+Johnsonauthor=N.+R.+Vanier&title=Acidities+of+Sulfoximines+and+Related+Oxosulfonium+Cations.+Cyclopropyl+Effects+and+Structures+of+Alpha-Sulfonyl-Type+Carbanions&doi=10.1021%2Fjo01307a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Acidities of sulfoximines and related oxosulfonium cations.  Cyclopropyl effects and structures of α-sulfonyl-type carbanions</span></div><div class="casAuthors">Bordwell, Frederick G.; Branca, John C.; Johnson, Carl R.; Vanier, Noel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3884-9</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">PhS(O)(:N+Me2)Me was more acidic than PhS(O)(:NMe)Me, by about 19 pKa units.  The latter is about equal in acidity to PhS(O)Me and about 5 pKa units less acidic than PhSO2Me.  I [R = PhS(O):NMe2, MeC6H4S(O):N+Me2, PhS(O):NSO2Ph] were 4-7 pKa units less acidic than their acyclic Me analogs, MeR due to a demand on the part of sulfone-type groups for p character in the cyclopropyl carbanions of their conjugate bases.  Evidence is presented to show that RCH2- [R = R1SO2, R1S(O)(:NR1), R1SO, Ph2PO, (R1O)2PO] are planar or nearly planar.  Acidity data indicate that the preferential generation of chiral, rather than achiral, planar α-sulfonyl carbanions is a consequence of a preferred kinetics path rather than an inherent greater thermodn. stability.  Factors controlling the stereoselective generation and reactions of carbanions are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiGPX1NRoDYLVg90H21EOLACvtfcHk0ljfKfn-n0C3ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlvVGmsLY%253D&md5=cb49c609c7a76a1ed24d115c2540f60b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo01307a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01307a030%26sid%3Dliteratum%253Aachs%26aulast%3DBordwell%26aufirst%3DF.%2BG.%26aulast%3DBranca%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26aulast%3DVanier%26aufirst%3DN.%2BR.%26atitle%3DAcidities%2520of%2520Sulfoximines%2520and%2520Related%2520Oxosulfonium%2520Cations.%2520Cyclopropyl%2520Effects%2520and%2520Structures%2520of%2520Alpha-Sulfonyl-Type%2520Carbanions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D3884%26epage%3D3889%26doi%3D10.1021%2Fjo01307a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides: Synthesis and Applications in Preparative Organic Chemistry</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2976</span>– <span class="NLM_lpage">3001</span>, <span class="refDoi"> DOI: 10.1002/adsc.201800273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fadsc.201800273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=2976-3001&author=G.+C.+Nandiauthor=P.+I.+Arvidsson&title=Sulfonimidamides%3A+Synthesis+and+Applications+in+Preparative+Organic+Chemistry&doi=10.1002%2Fadsc.201800273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides: Synthesis and Applications in Preparative Organic Chemistry</span></div><div class="casAuthors">Nandi, Ganesh Chandra; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2976-3001</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  During the last one and half decades, chemists within vastly different areas of science have witnessed a rising interest in chem. matters incorporating the sulfonimidamide functional group.  New synthetic routes to sulfonimidamides have been reported, and the utility of these products has been demonstrated in synthetic, medicinal, agrochem., and material science applications.  In this review, we described the synthesis of sulfonimidamide and their applications in synthetic org. chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr23MHhVOyTLbVg90H21EOLACvtfcHk0ljfKfn-n0C3ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgur7M&md5=116efc3e7ea9fa58a7d7459c8af9063d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201800273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201800273%26sid%3Dliteratum%253Aachs%26aulast%3DNandi%26aufirst%3DG.%2BC.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%253A%2520Synthesis%2520and%2520Applications%2520in%2520Preparative%2520Organic%2520Chemistry%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2018%26volume%3D360%26spage%3D2976%26epage%3D3001%26doi%3D10.1002%2Fadsc.201800273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgDaLaO7K--AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Neglected Sulfur(vi) Pharmacophores in Drug Discovery: Exploration of Novel Chemical Space by the Interplay of Drug Design and Method Development</span>. <i>Org. Chem. Front.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1319</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.1039/C8QO01233D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC8QO01233D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslemtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1319-1324&author=U.+L%C3%BCcking&title=Neglected+Sulfur%28vi%29+Pharmacophores+in+Drug+Discovery%3A+Exploration+of+Novel+Chemical+Space+by+the+Interplay+of+Drug+Design+and+Method+Development&doi=10.1039%2FC8QO01233D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected sulfur(VI) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development</span></div><div class="casAuthors">Luecking, U.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Chemistry Frontiers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1319-1324</span>CODEN:
                <span class="NLM_cas:coden">OCFRA8</span>;
        ISSN:<span class="NLM_cas:issn">2052-4129</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Historically, sulfoximines, sulfondiimines and sulfonimidamides have been neglected pharmacophores in drug discovery even though they offer very interesting properties.  This highlight shares the key learnings of various lead optimization approaches at Bayer AG that have successfully utilized these neglected sulfur(VI) functional groups to deliver multiple clin. candidates.  In this context, the key synthetic methods utilized for the synthetic prepn. of these unusual compds. will be outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcX6XF4X_NJbVg90H21EOLACvtfcHk0lgDaLaO7K--AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslemtL8%253D&md5=eae9b5efca8d68f3d8ab46e8fe29be99</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2FC8QO01233D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8QO01233D%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNeglected%2520Sulfur%2528vi%2529%2520Pharmacophores%2520in%2520Drug%2520Discovery%253A%2520Exploration%2520of%2520Novel%2520Chemical%2520Space%2520by%2520the%2520Interplay%2520of%2520Drug%2520Design%2520and%2520Method%2520Development%26jtitle%3DOrg.%2520Chem.%2520Front.%26date%3D2019%26volume%3D6%26spage%3D1319%26epage%3D1324%26doi%3D10.1039%2FC8QO01233D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">6391</span>– <span class="NLM_lpage">6399</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b00844</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b00844" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosFaku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=6391-6399&author=M.+Zenzolaauthor=R.+Doranauthor=R.+Luisiauthor=J.+A.+Bull&title=Synthesis+of+Sulfoximine+Carbamates+by+Rhodium-Catalyzed+Nitrene+Transfer+of+Carbamates+to+Sulfoxides&doi=10.1021%2Facs.joc.5b00844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides</span></div><div class="casAuthors">Zenzola, Marina; Doran, Robert; Luisi, Renzo; Bull, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6391-6399</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sulfoximines are of considerable interest for incorporation into medicinal compds.  A convenient synthesis of N-protected sulfoximines is achieved, under mild conditions, by rhodium-catalyzed transfer of carbamates to sulfoxides.  The first examples of 4-membered thietane-oximines are prepd.  Sulfoximines bearing Boc and Cbz groups are stable to further cross coupling reactions, and readily deprotected.  This method may facilitate the prepn. of NH-sulfoximines providing improved (global) deprotection strategies, which is illustrated in the synthesis of methionine sulfoxide (MSO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptKhE9GKYkx7Vg90H21EOLACvtfcHk0lgYX2a-KhOtUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosFaku78%253D&md5=7c1584e0c90c9fe9da756cbc95efd44f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b00844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b00844%26sid%3Dliteratum%253Aachs%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DDoran%26aufirst%3DR.%26aulast%3DLuisi%26aufirst%3DR.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520Sulfoximine%2520Carbamates%2520by%2520Rhodium-Catalyzed%2520Nitrene%2520Transfer%2520of%2520Carbamates%2520to%2520Sulfoxides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D6391%26epage%3D6399%26doi%3D10.1021%2Facs.joc.5b00844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span> <span> </span><span class="NLM_article-title">Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7203</span>– <span class="NLM_lpage">7207</span>, <span class="refDoi"> DOI: 10.1002/anie.201602320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201602320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFehsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=7203-7207&author=M.+Zenzolaauthor=R.+Doranauthor=L.+Degennaroauthor=R.+Luisiauthor=J.+A.+Bull&title=Transfer+of+Electrophilic+NH+Using+Convenient+Sources+of+Ammonia%3A+Direct+Synthesis+of+NH+Sulfoximines+from+Sulfoxides&doi=10.1002%2Fanie.201602320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides</span></div><div class="casAuthors">Zenzola, Marina; Doran, Robert; Degennaro, Leonardo; Luisi, Renzo; Bull, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7203-7207</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new system for NH transfer is developed for the prepn. of sulfoximines, which are emerging as valuable motifs for drug discovery.  The protocol employs readily available sources of nitrogen without the requirement for either preactivation or for metal catalysts.  Mixing ammonium salts with diacetoxyiodobenzene directly converts sulfoxides into sulfoximines.  This report describes the first example of using of ammonia sources with diacetoxyiodobenzene to generate an electrophilic nitrogen center.  Control and mechanistic studies suggest a short-lived electrophilic intermediate, which is likely to be PhINH or PhIN+.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbS6BCDLgzLLVg90H21EOLACvtfcHk0lgYX2a-KhOtUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFehsro%253D&md5=5374bfd2d888f59a68acca77e2e6eac8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201602320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201602320%26sid%3Dliteratum%253Aachs%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DDoran%26aufirst%3DR.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DLuisi%26aufirst%3DR.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26atitle%3DTransfer%2520of%2520Electrophilic%2520NH%2520Using%2520Convenient%2520Sources%2520of%2520Ammonia%253A%2520Direct%2520Synthesis%2520of%2520NH%2520Sulfoximines%2520from%2520Sulfoxides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D7203%26epage%3D7207%26doi%3D10.1002%2Fanie.201602320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tota, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John-Campbell, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanazzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of NH-Sulfoximines from Sulfides by Chemoselective One-Pot N- and O-Transfers</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1039/C6CC08891K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC6CC08891K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2gs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=348-351&author=A.+Totaauthor=M.+Zenzolaauthor=S.+J.+Chawnerauthor=S.+S.+John-Campbellauthor=C.+Carlucciauthor=G.+Romanazziauthor=L.+Degennaroauthor=J.+A.+Bullauthor=R.+Luisi&title=Synthesis+of+NH-Sulfoximines+from+Sulfides+by+Chemoselective+One-Pot+N-+and+O-Transfers&doi=10.1039%2FC6CC08891K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of NH-sulfoximines from sulfides by chemoselective one-pot N- and O-transfers</span></div><div class="casAuthors">Tota, Arianna; Zenzola, Marina; Chawner, Stephen J.; John-Campbell, Sahra St; Carlucci, Claudia; Romanazzi, Giuseppe; Degennaro, Leonardo; Bull, James A.; Luisi, Renzo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-351</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Direct synthesis of NH-sulfoximines from sulfides were achieved through O and NH transfer in the same reaction, occurring with complete selectivity.  The reaction was mediated by bisacetoxyiodobenzene under simple conditions and employs inexpensive N-sources.  Preliminary studies indicated that NH-transfer was likely to be first, followed by oxidn., but the reaction proceedes successfully in either order.  A wide range of functional groups and biol. relevant compds. were tolerated.  The use of AcO15NH4 affords 15N-labeled compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj0BQ01T3hNbVg90H21EOLACvtfcHk0lgYX2a-KhOtUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2gs7vE&md5=fd5d9d3e50c2d117b670fffb5db5808b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FC6CC08891K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC08891K%26sid%3Dliteratum%253Aachs%26aulast%3DTota%26aufirst%3DA.%26aulast%3DZenzola%26aufirst%3DM.%26aulast%3DChawner%26aufirst%3DS.%2BJ.%26aulast%3DJohn-Campbell%26aufirst%3DS.%2BS.%26aulast%3DCarlucci%26aufirst%3DC.%26aulast%3DRomanazzi%26aufirst%3DG.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DBull%26aufirst%3DJ.%2BA.%26aulast%3DLuisi%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520NH-Sulfoximines%2520from%2520Sulfides%2520by%2520Chemoselective%2520One-Pot%2520N-%2520and%2520O-Transfers%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D348%26epage%3D351%26doi%3D10.1039%2FC6CC08891K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaabouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthelemy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glachet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagousset, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pégot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, V.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Aryl- and Alkyl S-Perfluoroalkylated NH-Sulfoximines from Sulfides</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">17006</span>– <span class="NLM_lpage">17010</span>, <span class="refDoi"> DOI: 10.1002/chem.201805055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fchem.201805055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30300956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=17006-17010&author=S.+Chaabouniauthor=J.+F.+Lohierauthor=A.+L.+Barthelemyauthor=T.+Glachetauthor=E.+Anselmiauthor=G.+Dagoussetauthor=P.+Diterauthor=B.+P%C3%A9gotauthor=E.+Magnierauthor=V.+Reboul&title=One-Pot+Synthesis+of+Aryl-+and+Alkyl+S-Perfluoroalkylated+NH-Sulfoximines+from+Sulfides&doi=10.1002%2Fchem.201805055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Aryl- and Alkyl S-Perfluoroalkylated NH-Sulfoximines from Sulfides</span></div><div class="casAuthors">Chaabouni, Slim; Lohier, Jean-Francois; Barthelemy, Anne-Laure; Glachet, Thomas; Anselmi, Elsa; Dagousset, Guillaume; Diter, Patrick; Pegot, Bruce; Magnier, Emmanuel; Reboul, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">64</span>),
    <span class="NLM_cas:pages">17006-17010</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Perfluoroalkyl and fluoroalkyl sulfoximines such as 4-MeOC6H4S(:O)(:NH)R (R = F3C, BrF2C, F2HC) were prepd. in one or two steps from the corresponding sulfide by reaction with ammonium carbamate mediated by phenyliodine diacetate in 2,2,2-trifluoroethanol followed (in some cases) by hydrolysis of N-acetylsulfoximines.  The conditions were used for fluoromethyl, dichlorofluoromethyl, difluoromethyl, bromodifluoromethyl, trifluoromethyl, and nonafluorobutyl sulfides.  A nitridosulfur intermediate in the prepn. of 4-MeOC6H4S(:O)(:NH)CHF2 was detected by 19F NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohYhnqP7mOqLVg90H21EOLACvtfcHk0lj6YS4yj4WgZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWqsrvO&md5=30dc245218c49ed98c2d1f8c4b940c5f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fchem.201805055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201805055%26sid%3Dliteratum%253Aachs%26aulast%3DChaabouni%26aufirst%3DS.%26aulast%3DLohier%26aufirst%3DJ.%2BF.%26aulast%3DBarthelemy%26aufirst%3DA.%2BL.%26aulast%3DGlachet%26aufirst%3DT.%26aulast%3DAnselmi%26aufirst%3DE.%26aulast%3DDagousset%26aufirst%3DG.%26aulast%3DDiter%26aufirst%3DP.%26aulast%3DP%25C3%25A9got%26aufirst%3DB.%26aulast%3DMagnier%26aufirst%3DE.%26aulast%3DReboul%26aufirst%3DV.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Aryl-%2520and%2520Alkyl%2520S-Perfluoroalkylated%2520NH-Sulfoximines%2520from%2520Sulfides%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D17006%26epage%3D17010%26doi%3D10.1002%2Fchem.201805055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luisi, R.</span></span> <span> </span><span class="NLM_article-title">Straightforward Strategies for the Preparation of NH-Sulfoximines: A Serendipitous Story</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2525</span>– <span class="NLM_lpage">2538</span>, <span class="refDoi"> DOI: 10.1055/s-0036-1590874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1055%2Fs-0036-1590874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGktr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2525-2538&author=J.+A.+Bullauthor=L.+Degennaroauthor=R.+Luisi&title=Straightforward+Strategies+for+the+Preparation+of+NH-Sulfoximines%3A+A+Serendipitous+Story&doi=10.1055%2Fs-0036-1590874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Straightforward Strategies for the Preparation of NH-Sulfoximines: A Serendipitous Story</span></div><div class="casAuthors">Bull, James A.; Degennaro, Leonardo; Luisi, Renzo</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2525-2538</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Sulfoximines are emerging as valuable new isosteres for use in medicinal chem., with the potential to modulate physicochem. properties.  Recent developments in synthetic strategies have made the unprotected 'free' NH-sulfoximine group more readily available, facilitating further study.  This account reviews approaches to NH-sulfoximines, with a focus on the authors' contribution to the field.  Starting from the development of catalytic strategies involving transition metals, more sustainable metal-free processes were discovered.  In particular, the use of hypervalent iodine reagents to mediate NH-transfer to sulfoxides is described, along with an assessment of the substrate scope.  Furthermore, a one-pot strategy to convert sulfides directly into NH-sulfoximines is discussed, with N- and O-transfer occurring under the reaction conditions.  Mechanistic evidence for the new procedures is included as well as relevant synthetic applications that further exemplify the potential of these approaches.  Topics discussed include: strategies to form NH-sulfoximines involving transition-metal catalysts; metal-free strategies to prep. NH-sulfoximines; mechanistic evidence for the direct synthesis of NH-sulfoximines from sulfoxides and sulfides; and further applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiXvIO62R7C7Vg90H21EOLACvtfcHk0lj6YS4yj4WgZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGktr3K&md5=4691f2fff7a0a87a9f3945da04f88c98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1055%2Fs-0036-1590874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0036-1590874%26sid%3Dliteratum%253Aachs%26aulast%3DBull%26aufirst%3DJ.%2BA.%26aulast%3DDegennaro%26aufirst%3DL.%26aulast%3DLuisi%26aufirst%3DR.%26atitle%3DStraightforward%2520Strategies%2520for%2520the%2520Preparation%2520of%2520NH-Sulfoximines%253A%2520A%2520Serendipitous%2520Story%26jtitle%3DSynlett%26date%3D2017%26volume%3D28%26spage%3D2525%26epage%3D2538%26doi%3D10.1055%2Fs-0036-1590874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lohier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glachet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzag, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaumont, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, V.</span></span> <span> </span><span class="NLM_article-title">Mechanistic Investigation of the NH-Sulfoximination of Sulfide. Evidence for λ6-Sulfanenitrile Intermediates</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2064</span>– <span class="NLM_lpage">2067</span>, <span class="refDoi"> DOI: 10.1039/C6CC09940H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC6CC09940H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28133647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=2064-2067&author=J.+F.+Lohierauthor=T.+Glachetauthor=H.+Marzagauthor=A.+C.+Gaumontauthor=V.+Reboul&title=Mechanistic+Investigation+of+the+NH-Sulfoximination+of+Sulfide.+Evidence+for+%CE%BB6-Sulfanenitrile+Intermediates&doi=10.1039%2FC6CC09940H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic investigation of the NH-sulfoximination of sulfide. Evidence for λ6-sulfanenitrile intermediates</span></div><div class="casAuthors">Lohier, Jean-Francois; Glachet, Thomas; Marzag, Hamid; Gaumont, Annie-Claude; Reboul, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2064-2067</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report a new procedure for the prepn. of NH-sulfoximines from sulfides using PIDA as an oxidant and ammonium carbamate as the ammonia source.  Excellent yields were obtained with a wide range of sulfides.  The formation of acetoxy- and methoxy-λ6-sulfanenitrile as intermediates was proposed, both of which were converted to the NH-sulfoximine by the action of the solvent.  The structure of these intermediates was confirmed by 1H, 13C and 15N NMR and HRMS anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rt5nwaunPbVg90H21EOLACvtfcHk0lgdqKuG_xYBmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSnsL8%253D&md5=71625d993d0c7f648d07ed50639e265e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC6CC09940H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC09940H%26sid%3Dliteratum%253Aachs%26aulast%3DLohier%26aufirst%3DJ.%2BF.%26aulast%3DGlachet%26aufirst%3DT.%26aulast%3DMarzag%26aufirst%3DH.%26aulast%3DGaumont%26aufirst%3DA.%2BC.%26aulast%3DReboul%26aufirst%3DV.%26atitle%3DMechanistic%2520Investigation%2520of%2520the%2520NH-Sulfoximination%2520of%2520Sulfide.%2520Evidence%2520for%2520%25CE%25BB6-Sulfanenitrile%2520Intermediates%26jtitle%3DChem.%2520Commun.%26date%3D2017%26volume%3D53%26spage%3D2064%26epage%3D2067%26doi%3D10.1039%2FC6CC09940H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Chiral Sulfoximines via the S-Arylation of Sulfinamides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">19263</span>– <span class="NLM_lpage">19268</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b11298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b11298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=19263-19268&author=Y.+Aotaauthor=T.+Kanoauthor=K.+Maruoka&title=Asymmetric+Synthesis+of+Chiral+Sulfoximines+via+the+S-Arylation+of+Sulfinamides&doi=10.1021%2Fjacs.9b11298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric synthesis of chiral sulfoximines via the S-arylation of sulfinamides</span></div><div class="casAuthors">Aota, Yusuke; Kano, Taichi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">19263-19268</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optically active sulfoximines are a promising substructure in me-dicinal chem.  However, a methodol. for prepg. chiral sulfoximines in a stereoselective manner has been underdeveloped.  Herein, an asym. synthesis of chiral sulfoximines having an aryl group by the newly developed sulfur-selective arylation of easily accessible chiral sulfinamides is reported.  The utility of the pre-sent method is demonstrated by the asym. synthesis of a key intermediate of a COX-2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2nOBzRq3-7Vg90H21EOLACvtfcHk0lgdqKuG_xYBmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmtL%252FE&md5=fd46b1ede617df78a1a3ccc8f113a2c5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b11298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b11298%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Chiral%2520Sulfoximines%2520via%2520the%2520S-Arylation%2520of%2520Sulfinamides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D19263%26epage%3D19268%26doi%3D10.1021%2Fjacs.9b11298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis of Chiral Sulfoximines through the S-Alkylation of Sulfinamides</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17661</span>– <span class="NLM_lpage">17665</span>, <span class="refDoi"> DOI: 10.1002/anie.201911021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201911021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=17661-17665&author=Y.+Aotaauthor=T.+Kanoauthor=K.+Maruoka&title=Asymmetric+Synthesis+of+Chiral+Sulfoximines+through+the+S-Alkylation+of+Sulfinamides&doi=10.1002%2Fanie.201911021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis of Chiral Sulfoximines through the S-Alkylation of Sulfinamides</span></div><div class="casAuthors">Aota, Yusuke; Kano, Taichi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17661-17665</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Innovation in drug discovery critically depends on the development of new bioisosteric groups.  Chiral sulfoximines, which contain a tetrasubstituted sulfur atom that bears one nitrogen, one oxygen, and two different carbon substituents, represent an emerging chiral bioisostere in medicinal chem.  Chiral sulfoximines are conventionally prepd. by a stereospecific nitrene transfer reaction to chiral sulfoxides; however, the no. of readily available chiral sulfoxides remains limited.  Herein, we report the asym. synthesis of a class of hitherto difficult-to-access chiral sulfoximines with two structurally similar alkyl chains.  Our synthetic approach is based on the sulfur-selective alkylation of easily accessible chiral sulfinamides with com. available reagents under simple and safe conditions.  This stereospecific S-alkylation offers a general and scalable approach to the asym. synthesis of chiral sulfoximines, which represent important substructures in bioactive mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0_RGMof7wbVg90H21EOLACvtfcHk0lgdqKuG_xYBmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValurnO&md5=ab5e5707d7fd5ad82ba7a198bd2904c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fanie.201911021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201911021%26sid%3Dliteratum%253Aachs%26aulast%3DAota%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DAsymmetric%2520Synthesis%2520of%2520Chiral%2520Sulfoximines%2520through%2520the%2520S-Alkylation%2520of%2520Sulfinamides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D17661%26epage%3D17665%26doi%3D10.1002%2Fanie.201911021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines from a Medicinal Chemist’s Perspective: Physicochemical and <i>in Vitro</i> Parameters Relevant for Drug Discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2016.09.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27821325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=225-245&author=M.+Fringsauthor=C.+Bolmauthor=A.+Blumauthor=C.+Gnamm&title=Sulfoximines+from+a+Medicinal+Chemist%E2%80%99s+Perspective%3A+Physicochemical+and+in+Vitro+Parameters+Relevant+for+Drug+Discovery&doi=10.1016%2Fj.ejmech.2016.09.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery</span></div><div class="casAuthors">Frings, Marcus; Bolm, Carsten; Blum, Andreas; Gnamm, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-245</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored variants of the common sulfone or sulfonamide motif.  In this study, we report the physicochem. and in vitro properties of sulfoximines and compare them with related analogs and isosteres.  Furthermore, we present a matched mol. pair anal. of compds. from drug discovery projects within Boehringer Ingelheim.  We demonstrate that the sulfoximine moiety is a chem. stable, comparatively polar and weakly basic functional group, often leading to favorable aq. soly., permeability and metabolic stability.  Moreover, their addnl. vectors at nitrogen enable simple chem. modifications and thus facilitate exploration and fine-tuning of the mol. properties.  We conclude that sulfoximines and their congeners do not exhibit any intrinsic flaw but significantly enrich the toolbox of medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu0FlXXURKybVg90H21EOLACvtfcHk0lgEDYxDOYJy3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVahsbfK&md5=8a7939f22425f46ad9eb87fcddd29099</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.091%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DBolm%26aufirst%3DC.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DGnamm%26aufirst%3DC.%26atitle%3DSulfoximines%2520from%2520a%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%253A%2520Physicochemical%2520and%2520in%2520Vitro%2520Parameters%2520Relevant%2520for%2520Drug%2520Discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D126%26spage%3D225%26epage%3D245%26doi%3D10.1016%2Fj.ejmech.2016.09.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chinthakindi, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naicker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides in Medicinal and Agricultural Chemistry</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4100</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1002/anie.201610456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fanie.201610456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlynu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=4100-4109&author=P.+K.+Chinthakindiauthor=T.+Naickerauthor=N.+Thotaauthor=T.+Govenderauthor=H.+G.+Krugerauthor=P.+I.+Arvidsson&title=Sulfonimidamides+in+Medicinal+and+Agricultural+Chemistry&doi=10.1002%2Fanie.201610456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides in Medicinal and Agricultural Chemistry</span></div><div class="casAuthors">Chinthakindi, Praveen K.; Naicker, Tricia; Thota, Niranjan; Govender, Thavendran; Kruger, Hendrik G.; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4100-4109</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The synthesis and evaluation of structural analogs and isosteres are of central importance in medicinal and agricultural chem.  The sulfonamide functional group represents one of the most important amide isosteres in contemporary drug design, and about 500 such compds. have overcome both the pharmacol. and regulatory hurdles that precede studies in humans.  The mono aza analogs of sulfonamides, i.e., sulfonimidamides, are rapidly gaining popularity as a novel functional group among synthetic chemists involved in the design of biol. active compds. for both pharmaceutical and agrochem. applications.  Herein, we review these recent developments to showcase the promise of this functional group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zj9KqdepKbVg90H21EOLACvtfcHk0lgEDYxDOYJy3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlynu7k%253D&md5=3460c3a7c17bd914174be7c81d645fb0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201610456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201610456%26sid%3Dliteratum%253Aachs%26aulast%3DChinthakindi%26aufirst%3DP.%2BK.%26aulast%3DNaicker%26aufirst%3DT.%26aulast%3DThota%26aufirst%3DN.%26aulast%3DGovender%26aufirst%3DT.%26aulast%3DKruger%26aufirst%3DH.%2BG.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%2520in%2520Medicinal%2520and%2520Agricultural%2520Chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D4100%26epage%3D4109%26doi%3D10.1002%2Fanie.201610456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bizet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfur Imidations: Access to Sulfimides and Sulfoximines</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3378</span>– <span class="NLM_lpage">3390</span>, <span class="refDoi"> DOI: 10.1039/C5CS00208G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC5CS00208G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25941981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=3378-3390&author=V.+Bizetauthor=C.+M.+Hendriksauthor=C.+Bolm&title=Sulfur+Imidations%3A+Access+to+Sulfimides+and+Sulfoximines&doi=10.1039%2FC5CS00208G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfur imidations: access to sulfimides and sulfoximines</span></div><div class="casAuthors">Bizet, Vincent; Hendriks, Christine M. M.; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3378-3390</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Being mono-aza analogs of sulfoxides and sulfones, sulfimides and sulfoximines, resp., are important compds. in asym. synthesis, crop protection and medicinal chem. various methods were developed for their prepn.  For their prepn. various methods were developed.  In the search for the optimal synthetic approach for a given target compd., several parameters have to be considered which also include safety issues and availability of starting materials.  An overview of sulfur imidation methods, classified by imidating agents and compds. with a related behavior were reviewed.  The aim of this survey was to provide a practical ''tool box'' for the synthetic chemist by mapping the advantages and disadvantages assocd. with the use of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLkp3i4O2QrVg90H21EOLACvtfcHk0lgEDYxDOYJy3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yisrw%253D&md5=f783729be2df3166e6e3b09c3b6d311f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC5CS00208G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00208G%26sid%3Dliteratum%253Aachs%26aulast%3DBizet%26aufirst%3DV.%26aulast%3DHendriks%26aufirst%3DC.%2BM.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfur%2520Imidations%253A%2520Access%2520to%2520Sulfimides%2520and%2520Sulfoximines%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D3378%26epage%3D3390%26doi%3D10.1039%2FC5CS00208G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Fluorinated Sulfoximines: Preparation, Reactions and Applications</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">4437</span>– <span class="NLM_lpage">4451</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201402086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fejoc.201402086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=4437-4451&author=X.+Shenauthor=J.+Hu&title=Fluorinated+Sulfoximines%3A+Preparation%2C+Reactions+and+Applications&doi=10.1002%2Fejoc.201402086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorinated Sulfoximines: Preparation, Reactions and Applications</span></div><div class="casAuthors">Shen, Xiao; Hu, Jinbo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4437-4451</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The selective incorporation of fluorine atoms or fluorinated groups into org. mols. has become a hot research topic in modern org. chem.  However, selective and efficient synthesis of organofluorine compds. greatly depends on the development of powerful fluorination or fluoroalkylation reagents and reactions.  In this context, the past decade has witnessed rapid research progress in the development of α-fluoro sulfoximines as versatile fluoroalkylation reagents.  Many efficient nucleophilic, electrophilic and radical fluoroalkylation reactions based on α-fluoro sulfoximine reagents have been developed; among these, several chiral sulfoximine reagents were successfully used in the synthesis of enantiomerically enriched organofluorine compds.  It was found that α-fluoro sulfoximines show unique chem. behavior characteristics (such as difluorocarbene and fluoroalkyl radical reactivity) significantly different from those of their non-fluorinated counterparts.  In addn. to the rapid development of fluorinated sulfoximines in org. synthesis, research into their application in materials science has also attracted increasing attention.  Sulfoximines are important bioactive substances, and more recently the synthesis and application of fluorinated sulfoximines has attracted much attention in life sciences and the pharmaceutical industry.  In this microreview the authors summarize the prepn., reactions and applications of fluorinated sulfoximines (mainly α-fluoro sulfoximines).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVRzT5ZgNCtbVg90H21EOLACvtfcHk0lgEDYxDOYJy3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVGitbs%253D&md5=dbff1f6ff4aa7f4947708b693bb7199b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201402086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201402086%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DFluorinated%2520Sulfoximines%253A%2520Preparation%252C%2520Reactions%2520and%2520Applications%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2014%26volume%3D2014%26spage%3D4437%26epage%3D4451%26doi%3D10.1002%2Fejoc.201402086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Building Block Approach for the Synthesis of Sulfoximines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5348</span>– <span class="NLM_lpage">5351</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b02678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b02678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=5348-5351&author=A.+D.+Steinkampauthor=S.+Wiezorekauthor=F.+Brosgeauthor=C.+Bolm&title=Building+Block+Approach+for+the+Synthesis+of+Sulfoximines&doi=10.1021%2Facs.orglett.6b02678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Building Block Approach for the Synthesis of Sulfoximines</span></div><div class="casAuthors">Steinkamp, Anne-Dorothee; Wiezorek, Stefan; Brosge, Felix; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5348-5351</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A cross-coupling strategy for the prepn. of novel sulfoximines via preformed sulfoximidoyl-contg. building blocks has been developed.  It allows obtaining a wide range of products in good yields under mild reaction conditions, and it can be applied in late-stage functionalizations, as demonstrated by the synthesis of a sulfoximine-based analog of a recently reported potent valosine-contg. protein inhibitor, I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUr7J5CfXcnbVg90H21EOLACvtfcHk0lhhzjh7iViIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtLfO&md5=c7580aa3d515cffd7bc65ef24f105733</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b02678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b02678%26sid%3Dliteratum%253Aachs%26aulast%3DSteinkamp%26aufirst%3DA.%2BD.%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DBrosge%26aufirst%3DF.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DBuilding%2520Block%2520Approach%2520for%2520the%2520Synthesis%2520of%2520Sulfoximines%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D5348%26epage%3D5351%26doi%3D10.1021%2Facs.orglett.6b02678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines: Synthesis and Catalytic Applications</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1246/cl.2004.482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1246%2Fcl.2004.482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFemu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=482-487&author=H.+Okamuraauthor=C.+Bolm&title=Sulfoximines%3A+Synthesis+and+Catalytic+Applications&doi=10.1246%2Fcl.2004.482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines: Synthesis and catalytic applications</span></div><div class="casAuthors">Okamura, Hiroaki; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">482-487</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Chiral sulfoximines have a stereogenic center at the sulfur atom and their use in asym. synthesis is well established.  Recently, sulfoximines have been recognized as an interesting new class of chiral ligands, which can be applied in various asym. metal catalyzes.  This review summarizes the latest progress in synthetic methods towards sulfoximines and the application of chiral derivs. in catalytic asym. reactions.  A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVmt7dFHJS7Vg90H21EOLACvtfcHk0lhhzjh7iViIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFemu78%253D&md5=bf4314a99485e415de467c7f68967bf4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1246%2Fcl.2004.482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2004.482%26sid%3Dliteratum%253Aachs%26aulast%3DOkamura%26aufirst%3DH.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfoximines%253A%2520Synthesis%2520and%2520Catalytic%2520Applications%26jtitle%3DChem.%2520Lett.%26date%3D2004%26volume%3D33%26spage%3D482%26epage%3D487%26doi%3D10.1246%2Fcl.2004.482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barthelemy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnier, E.</span></span> <span> </span><span class="NLM_article-title">Recent Trends in Perfluorinated Sulfoximines</span>. <i>C. R. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/j.crci.2018.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.crci.2018.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFeqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2018&pages=711-722&author=A.+L.+Barthelemyauthor=E.+Magnier&title=Recent+Trends+in+Perfluorinated+Sulfoximines&doi=10.1016%2Fj.crci.2018.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent trends in perfluorinated sulfoximines</span></div><div class="casAuthors">Barthelemy, Anne-Laure; Magnier, Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">Comptes Rendus Chimie</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">CRCOCR</span>;
        ISSN:<span class="NLM_cas:issn">1631-0748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  This short review summarizes the recent works in S-perfluoroalkylated sulfoximines.  This review will consequently focus on an overview of the new trends in this research area, since 2014.  The structural diversification of the skeleton of sulfoximines via N-functionalization or ortho-lithiation, their applications in catalytic and organocatalytic systems, their use as perfluoroalkylating reagents, and their potential as biol. active mols. have been discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNJS4hcrHvzrVg90H21EOLACvtfcHk0lhhzjh7iViIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFeqsrk%253D&md5=2a101a7000e27b2c1d0c0be6431fa969</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.crci.2018.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.crci.2018.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DBarthelemy%26aufirst%3DA.%2BL.%26aulast%3DMagnier%26aufirst%3DE.%26atitle%3DRecent%2520Trends%2520in%2520Perfluorinated%2520Sulfoximines%26jtitle%3DC.%2520R.%2520Chim.%26date%3D2018%26volume%3D21%26spage%3D711%26epage%3D722%26doi%3D10.1016%2Fj.crci.2018.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomé, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Chiral Sulfoximine-Based Thioureas and Their Application in Asymmetric Organocatalysis</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.3762/bjoc.8.164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3762%2Fbjoc.8.164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23019479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWrs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=1443-1451&author=M.+Fringsauthor=I.+Thom%C3%A9author=C.+Bolm&title=Synthesis+of+Chiral+Sulfoximine-Based+Thioureas+and+Their+Application+in+Asymmetric+Organocatalysis&doi=10.3762%2Fbjoc.8.164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of chiral sulfoximine-based thioureas and their application in asymmetric organocatalysis</span></div><div class="casAuthors">Frings, Marcus; Thome, Isabelle; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1443-1451, No. 164</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">For the first time, chiral sulfoximine derivs. have been applied as asym. organocatalysts.  In combination with a thiourea-type backbone the sulfonimidoyl moiety leads to organocatalysts showing good reactivity in the catalytic desymmetrization of a cyclic meso-anhydride and moderate enantioselectivity in the catalytic asym. Biginelli reaction.  Straightforward synthetic routes provide the newly designed thiourea-sulfoximine catalysts in high overall yields without affecting the stereohomogeneity of the sulfur-contg. core fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFfuM-KD5frVg90H21EOLACvtfcHk0lhFSvtUmc9mdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWrs7rE&md5=44bbd7d1d1331311126d34603e067bd8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.8.164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.8.164%26sid%3Dliteratum%253Aachs%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DThom%25C3%25A9%26aufirst%3DI.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520Chiral%2520Sulfoximine-Based%2520Thioureas%2520and%2520Their%2520Application%2520in%2520Asymmetric%2520Organocatalysis%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D8%26spage%3D1443%26epage%3D1451%26doi%3D10.3762%2Fbjoc.8.164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span> <span> </span><span class="NLM_article-title">Action of Nitrogen Trichloride on Proteins: Progress in the Isolation of the Toxic Factor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1949</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1038/163675a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2F163675a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18120748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaH1MXktFGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1949&pages=675-676&author=H.+R.+Bentleyauthor=E.+E.+McDermottauthor=J.+Paceauthor=J.+K.+Whiteheadauthor=T.+Moran&title=Action+of+Nitrogen+Trichloride+on+Proteins%3A+Progress+in+the+Isolation+of+the+Toxic+Factor&doi=10.1038%2F163675a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Action of nitrogen trichloride on proteins. Progress in the isolation of the toxic factor</span></div><div class="casAuthors">Bentley, H. R.; McDermott, E. E.; Pace, J.; Whitehead, J. K.; Moran, T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1949</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">675-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Finely powd. zein (treated with NCl3 at a level of 5.5 mg./g. by absorption from a mixt. of NCl3 vapor and Cl2 dild. with moist air) was digested with pancreatin.  Dialysis through Cellophane sepd. the toxic factor in the dialyzate, which was then extd. successively with H2O-satd. BuOH at 80° and then with phenol in the cold.  The phenol-sol. material was hydrolyzed by boiling under reflux for 3 hrs. with 8 N HCl (the bulk of excess HCl removed by repeated evapn. in vacuo and the residue redissolved in H2O), again repeatedly extd. with hot BuOH and decolorized with charcoal.  The aq. phase contg. the toxic factor after BuOH extn. was brought to 95% acetone concn. when the toxic factor was distributed between the gummy ppt. and the sol. fraction.  The ppt., redissolved in H2O, was electrodialyzed in a 3-compartment cell and the material from the middle compartment was then applied to a resin column (Zeo-Karb 215).  On elution with NH3 (0.15 N) the amino acids appear in the effluent in the same order as that described by Partridge (Chemistry & Industry 1949, 27) the toxic factor being eluted in a broad band following proline and extending to the point of the NH3 "break through."  When examd. on paper chromatograms, the material of the toxic band was found to contain several ninhydrin-reacting substances; proline, a substance A (probably methionine) with an RF value of 0.75, and unidentified substances giving a group of purple spots of RF values in the range of 0.1-0.3 (Whatman No. 4 paper run with phenol).  These substances of low RF values were impurities and not identified with the toxic factor; feeding expts. showed them to be nontoxic.  Hydrolysis of the toxic material did not yield new ninhydrin-reacting substances; consequently, it was considered that the toxic factor was not a peptide unless it was present in amt. below the sensitivity of the ninhydrin test.  The toxicity of the most concd. material represented a 2500-fold increase on that of the original treated zein; the toxic dose is 2 mg. and 5 g., resp., when tested on 1-kg. rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGit5KlK9v8rVg90H21EOLACvtfcHk0lhFSvtUmc9mdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH1MXktFGqtg%253D%253D&md5=e35b639d96d205381eb78d3460c76f08</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2F163675a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F163675a0%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DH.%2BR.%26aulast%3DMcDermott%26aufirst%3DE.%2BE.%26aulast%3DPace%26aufirst%3DJ.%26aulast%3DWhitehead%26aufirst%3DJ.%2BK.%26aulast%3DMoran%26aufirst%3DT.%26atitle%3DAction%2520of%2520Nitrogen%2520Trichloride%2520on%2520Proteins%253A%2520Progress%2520in%2520the%2520Isolation%2520of%2520the%2520Toxic%2520Factor%26jtitle%3DNature%26date%3D1949%26volume%3D163%26spage%3D675%26epage%3D676%26doi%3D10.1038%2F163675a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">Dist and Canine Hysteria; Experimental Production by Treated Flour</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1946</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1136/bmj.2.4484.885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fbmj.2.4484.885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20278492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaH2s%252FktVSjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1946&pages=885-887&author=E.+Mellanby&title=Dist+and+Canine+Hysteria%3B+Experimental+Production+by+Treated+Flour&doi=10.1136%2Fbmj.2.4484.885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dist and canine hysteria; experimental production by treated flour</span></div><div class="casAuthors">MELLANBY E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1946</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4484</span>),
    <span class="NLM_cas:pages">885-7</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvQ1qqyubszJWtyewyzkyLfW6udTcc2eYCkJENrDfTZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH2s%252FktVSjtA%253D%253D&md5=1734ca5f1208114f45b0d40e623d2a86</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1136%2Fbmj.2.4484.885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.2.4484.885%26sid%3Dliteratum%253Aachs%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DDist%2520and%2520Canine%2520Hysteria%253B%2520Experimental%2520Production%2520by%2520Treated%2520Flour%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1946%26volume%3D2%26spage%3D885%26epage%3D887%26doi%3D10.1136%2Fbmj.2.4484.885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">Further Observations on the Production of Canine Hysteria by Flour Treated with Nitrogen Trichloride (Agene Process)</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1947</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1136/bmj.2.4520.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fbmj.2.4520.288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20257560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaH2s%252FhvFSktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1947&pages=288-289&author=E.+Mellanby&title=Further+Observations+on+the+Production+of+Canine+Hysteria+by+Flour+Treated+with+Nitrogen+Trichloride+%28Agene+Process%29&doi=10.1136%2Fbmj.2.4520.288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Further observations on the production of canine hysteria by flour treated with nitrogen trichloride (agene process)</span></div><div class="casAuthors">MELLANBY E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1947</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4520</span>),
    <span class="NLM_cas:pages">288</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgtJH1gKZ31EEksK8CslK8fW6udTcc2eYCkJENrDfTZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaH2s%252FhvFSktg%253D%253D&md5=56667154a76d451488b8b0a3597813a5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fbmj.2.4520.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.2.4520.288%26sid%3Dliteratum%253Aachs%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DFurther%2520Observations%2520on%2520the%2520Production%2520of%2520Canine%2520Hysteria%2520by%2520Flour%2520Treated%2520with%2520Nitrogen%2520Trichloride%2520%2528Agene%2520Process%2529%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1947%26volume%3D2%26spage%3D288%26epage%3D289%26doi%3D10.1136%2Fbmj.2.4520.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Work, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellanby, E.</span></span> <span> </span><span class="NLM_article-title">The Isolation of a Toxic Substance from Agenized Wheat Flour</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1951</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1042/bj0480106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2Fbj0480106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14820791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaG3MXislOrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1951&pages=106-113&author=P.+N.+Campbellauthor=T.+S.+Workauthor=E.+Mellanby&title=The+Isolation+of+a+Toxic+Substance+from+Agenized+Wheat+Flour&doi=10.1042%2Fbj0480106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a toxic substance from agenized wheat flour</span></div><div class="casAuthors">Campbell, P. N.; Work, T. S.; Mellanby, E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106-13</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">cf. C.A. 44, 6044g.  Digestion of agenized gluten with pepsin and trypsin converted about 80% of the N into dialyzable substances but the latter were as toxic as the nondialyzable portion.  The toxic substance must, therefore, be an integral part of the protein.  Acid hydrolysis destroyed about 30% of toxicity and the amino N/total N was increased from 0.25 to 0.60, thus decreasing the av. mol. wt.  Electrodialysis achieved considerable purification of the toxic substance since 36% of the amino N was removed as glutamic and about 10% as basic amino acids.  Removal of aromatic amino acids by charcoal was a necessary preliminary to fractionation on a Zeo-Karb 215 column.  The toxic substance was found in this column immediately following the proline fraction, the max. toxicity being confined to a relatively small fraction.  γ-Aminobutyric acid was isolated by paper chromatography (46.7 mg. thrice recrystd., m.p. 193°, from 1800 g. gluten) and identified as such.  Since it does not occur in untreated gluten, this amino acid must be regarded as being formed under the action of NCl3, but it is not the toxic agent.  Further fractionation was made on a column of powd. paper (complete fractionation achieved with 1000 g. paper pulp to 100 mg. N).  Extensive expts. lead to the conclusion that the toxic substance is a deriv. of methionine, although methionine peptides treated with NCl3 did not produce the toxic substance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwj1kzS3-N7Vg90H21EOLACvtfcHk0liWfrhEZym6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3MXislOrtQ%253D%253D&md5=c026c5e997a922c5e246b0a8defca4fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1042%2Fbj0480106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj0480106%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DP.%2BN.%26aulast%3DWork%26aufirst%3DT.%2BS.%26aulast%3DMellanby%26aufirst%3DE.%26atitle%3DThe%2520Isolation%2520of%2520a%2520Toxic%2520Substance%2520from%2520Agenized%2520Wheat%2520Flour%26jtitle%3DBiochem.%2520J.%26date%3D1951%26volume%3D48%26spage%3D106%26epage%3D113%26doi%3D10.1042%2Fbj0480106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Potent and Specific Inhibition of Glutathione Synthesis by Buthionine Sulfoximine (S-n-Butyl Homocysteine Sulfoximine)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">7558</span>– <span class="NLM_lpage">7560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=38242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1MXlvVOhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=7558-7560&author=O.+W.+Griffithauthor=A.+Meister&title=Potent+and+Specific+Inhibition+of+Glutathione+Synthesis+by+Buthionine+Sulfoximine+%28S-n-Butyl+Homocysteine+Sulfoximine%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)</span></div><div class="casAuthors">Griffith, Owen W.; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7558-60</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">DL-Buthionine-SR-sulfoximine)  [5072-26-4] inhibited γ-glutamylcysteine synthetase  [9023-64-7] ∼20 times more effectively that did DL-prothionine-SR-sulfoximine  [70085-86-8] and ≥100 times more effectively than L-methionine-SR-sulfoximine  [15985-39-4].  The S-alkyl moiety of the sulfoximine apparently binds at the enzyme site that normally binds the acceptor amino acid.  Thus, the affinity of the enzyme for the S-Et, S-n-Pr, and S-n-Bu sulfoximines increases in a manner which is parallel to those of the corresponding isosteric acceptor amino acid substrates, i.e. glycine, alanine, and α-aminobutyrate.  Buthionine sulfoximine did not inhibit glutamine synthetase  [9023-70-5], detectably, nor did it produce convulsions when injected into mice.  Injection of buthionine sulfoximine into mice decreased the level of glutathione  [70-18-8] in the kidney to a greater extent (<20% of the control level) than found previously after giving prothionine sulfoximine.  α-Methyl-DL-buthionine-SR-sulfoximine  [71806-54-7] was also prepd. and was almost as effective as buthionine sulfoximine, this compd. would not be expected to undergo substantial degradative metab.  Buthionine sulfoximine and α-Me buthionine sulfoximine may be useful agents for inhibition of glutathione synthesis in various exptl. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV-FKkR0surVg90H21EOLACvtfcHk0liWfrhEZym6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlvVOhu70%253D&md5=60a87fed5e007d1c70204b879fec3383</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DO.%2BW.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DPotent%2520and%2520Specific%2520Inhibition%2520of%2520Glutathione%2520Synthesis%2520by%2520Buthionine%2520Sulfoximine%2520%2528S-n-Butyl%2520Homocysteine%2520Sulfoximine%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D7558%26epage%3D7560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Identification of L-Methionine S-Sulfoximine as the Diastereoisomer of L-Methionine SR-Sulfoximine that Inhibits Glutamine Synthetase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2681</span>– <span class="NLM_lpage">2685</span>, <span class="refDoi"> DOI: 10.1021/bi00834a066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00834a066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaF1MXktlKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1969&pages=2681-2685&author=J.+M.+Manningauthor=S.+Mooreauthor=W.+B.+Roweauthor=A.+Meister&title=Identification+of+L-Methionine+S-Sulfoximine+as+the+Diastereoisomer+of+L-Methionine+SR-Sulfoximine+that+Inhibits+Glutamine+Synthetase&doi=10.1021%2Fbi00834a066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of L-methionine S-sulfoximine as the diastereoisomer of L-methionine SR-sulfoximine that inhibits glutamine synthetase</span></div><div class="casAuthors">Manning, James M.; Moore, Stanford; Rowe, William Bruce; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2681-5</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The diastereoisomers of L-methionine SR-sulfoximine phosphate have been sepd. as the corresponding α-N-L-leucyl derivs. by ion-exchange chromatog. on an amino acid analyzer.  The diastereoisomers of L-methionine SR-sulfoximine and L-methionine SR-sulfoxide can be sepd. without derivatization.  Chromatographic study of the L-methionine sulfoximine phosphate obtained from sheep brain glutamine synthetase inhibited by treatment with L-methionine SR-sulfoximine, ATP, and Mg2+ showed the presence of only 1 diastereoisomer.  Studies with prepns. of L-methionine S-sulfoximine and L-methionine R-sulfoximine indicate that only the former diastereoisomer is phosphorylated and inhibits the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcEBp15neEeLVg90H21EOLACvtfcHk0liWfrhEZym6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXktlKjtbo%253D&md5=c6fb76051344971ca0dcf9e8252d52d1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi00834a066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00834a066%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DRowe%26aufirst%3DW.%2BB.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520L-Methionine%2520S-Sulfoximine%2520as%2520the%2520Diastereoisomer%2520of%2520L-Methionine%2520SR-Sulfoximine%2520that%2520Inhibits%2520Glutamine%2520Synthetase%26jtitle%3DBiochemistry%26date%3D1969%26volume%3D8%26spage%3D2681%26epage%3D2685%26doi%3D10.1021%2Fbi00834a066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of γ-Glutamylcysteine Synthetase by L-Methionine-S-sulfoximine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">6684</span>– <span class="NLM_lpage">6690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=4147652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE3sXlsVers78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1973&pages=6684-6690&author=P.+G.+Richmanauthor=M.+Orlowskiauthor=A.+Meister&title=Inhibition+of+%CE%B3-Glutamylcysteine+Synthetase+by+L-Methionine-S-sulfoximine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of γ-glutamylcysteine synthetase by L-methionine-S-sulfoximine</span></div><div class="casAuthors">Richman, Paul G.; Orlowski, Marian; Meister, Alton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6684-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Methionine sulfoximine was an effective inhibitor of γ-glutamylcysteine synthetase.  The data indicated that methionine sulfoximine bound to the glutamate site of the enzyme and that, in the presence of ATP and metal ions (Mg2+ or Mn2+ it was converted to methionine sulfoximine phosphate.  Of the 4 stereoisomers of methionine sulfoximine, only L-methionine-S-sulfoximine inhibited the enzyme; this is the same stereoisomer which inhibits glutamine synthetase and which causes convulsions in mice.  Chem. synthesized L-methionine sulfoximine phosphate inhibited the enzyme in the presence of Mg2+ or Mn2+.  These findings indicated that the mechanism of inhibition of γ-glutamylcysteine synthetase by methionine sulfoximine was similar to that by which this compd. was previously shown to inhibit glutamine synthetase.  However, methionine sulfoximine phosphate was less tightly bound to γ-glutamylcysteine synthetase than to glutamine synthetase; thus, under certain conditions methionine sulfoximine phosphate can be released from inhibited γ-glutamylcysteine synthetase with restoration of catalytic activity.  The findings were in accord with the view that enzyme-bound γ-glutamyl phosphate was an intermediate in the reaction catalyzed by γ-glutamylcysteine synthetase, and that phosphorylation of methionine sulfoximine by the enzyme reflected the phosphorylation step of the normal catalytic reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHwgmWByORorVg90H21EOLACvtfcHk0lhHYfl50j4QDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXlsVers78%253D&md5=44297b3f3856849740ccbab5eb60405e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DP.%2BG.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DMeister%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520%25CE%25B3-Glutamylcysteine%2520Synthetase%2520by%2520L-Methionine-S-sulfoximine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1973%26volume%3D248%26spage%3D6684%26epage%3D6690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, J. K.</span></span> <span> </span><span class="NLM_article-title">Action of Nitrogen Trichloride on Proteins: A Synthesis of the Toxic Factor from Methionine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1950</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">735</span>, <span class="refDoi"> DOI: 10.1038/165735b0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2F165735b0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15416824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaG3cXjvVOqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1950&pages=735&author=H.+R.+Bentleyauthor=E.+E.+McDermottauthor=J.+K.+Whitehead&title=Action+of+Nitrogen+Trichloride+on+Proteins%3A+A+Synthesis+of+the+Toxic+Factor+from+Methionine&doi=10.1038%2F165735b0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Action of nitrogen trichloride on proteins-synthesis of the toxic factor from methionine</span></div><div class="casAuthors">Bentley, H. R.; McDermott, E. E.; Whitehead, J. K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1950</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">735</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">cf. C.A. 43, 7523e; 44, 181c.  A cryst. compd. identical with the toxic factor of agenized zein or wheat gluten was synthesized from DL-methionine sulfoxide and NH3 (Schmidt reaction).  Its structure, HO2CCH(NH2)CH2CH2S++Me-(O-)(N-H), was proved by comparison with the factor isolated from NCl3-treated cereal, by using paper chromatog. and rabbit toxicity tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEplW5BF_qQ7Vg90H21EOLACvtfcHk0lhHYfl50j4QDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3cXjvVOqsQ%253D%253D&md5=e7cebe3ee6b522534a1e027322cc49c8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2F165735b0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F165735b0%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DH.%2BR.%26aulast%3DMcDermott%26aufirst%3DE.%2BE.%26aulast%3DWhitehead%26aufirst%3DJ.%2BK.%26atitle%3DAction%2520of%2520Nitrogen%2520Trichloride%2520on%2520Proteins%253A%2520A%2520Synthesis%2520of%2520the%2520Toxic%2520Factor%2520from%2520Methionine%26jtitle%3DNature%26date%3D1950%26volume%3D165%26spage%3D735%26doi%3D10.1038%2F165735b0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, H. H.</span></span> <span> </span><span class="NLM_article-title">L-S,R-Buthionine Sulfoximine: Historical Development and Clinical Issues</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>111–112</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(97)00164-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0009-2797%2897%2900164-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9679558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXitlSksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111%E2%80%93112&publication_year=1998&pages=239-254&author=H.+H.+Bailey&title=L-S%2CR-Buthionine+Sulfoximine%3A+Historical+Development+and+Clinical+Issues&doi=10.1016%2FS0009-2797%2897%2900164-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">L-S,R-buthionine sulfoximine: historical development and clinical issues</span></div><div class="casAuthors">Bailey, Howard H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">111-112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-254</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 39 refs.  L-S,R-buthionine sulfoximine (L-S,R BSO) is a potent specific inhibitor of γ-glutamylcysteine synthetase, the rate-limiting step in glutathione (GSH) biosynthesis.  GSH is an important component of tumor drug resistance based on a strong assocn. and recent transfection studies.  Depletion of intracellular GSH by BSO significantly enhances the cytotoxicity of many cytotoxic agents, principally alkylating agents and platinating compds. but also irradn. and anthracyclines.  Phase I clin. trials of BSO + melphalan (L-PAM) have been carried out and obsd. little toxicity with BSO alone and increased myelosuppression with BSO + L-PAM.  Consistent and profound (<10% of control) GSH depletion was obsd. in serial detns. of tumor GSH levels in patients receiving continuous infusion (CI) BSO.  Evidence of clin. activity has been obsd. in patients with alkylating or platinating agent-refractory tumors.  Phase II evaluation of CI BSO with L-PAM is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEjK5eJejBWbVg90H21EOLACvtfcHk0lhHYfl50j4QDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlSksbk%253D&md5=10a1d55d64a05b6d5d82d2e375825b91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2897%2900164-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252897%252900164-6%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DH.%2BH.%26atitle%3DL-S%252CR-Buthionine%2520Sulfoximine%253A%2520Historical%2520Development%2520and%2520Clinical%2520Issues%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1998%26volume%3D111%25E2%2580%2593112%26spage%3D239%26epage%3D254%26doi%3D10.1016%2FS0009-2797%2897%2900164-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Breijo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monserrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez-Rubio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Laviada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Moreno, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Román, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisbert, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guijarro, L. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of Azathioprine Plus Buthionine Sulfoximine in the Treatment of Human Hepatocarcinoma and Colon Carcinoma</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3899</span>– <span class="NLM_lpage">3911</span>, <span class="refDoi"> DOI: 10.3748/wjg.v17.i34.3899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3748%2Fwjg.v17.i34.3899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22025878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyqtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3899-3911&author=B.+Hern%C3%A1ndez-Breijoauthor=J.+Monserratauthor=S.+Ram%C3%ADrez-Rubioauthor=E.+P.+Cuevasauthor=D.+Varaauthor=I.+D%C3%ADaz-Laviadaauthor=M.+D.+Fern%C3%A1ndez-Morenoauthor=I.+D.+Rom%C3%A1nauthor=J.+P.+Gisbertauthor=L.+G.+Guijarro&title=Preclinical+Evaluation+of+Azathioprine+Plus+Buthionine+Sulfoximine+in+the+Treatment+of+Human+Hepatocarcinoma+and+Colon+Carcinoma&doi=10.3748%2Fwjg.v17.i34.3899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma</span></div><div class="casAuthors">Hernandez-Breijo, Borja; Monserrat, Jorge; Ramirez-Rubio, Sara; Cuevas, Eva P.; Vara, Diana; Diaz-Laviada, Ines; Fernandez-Moreno, M. Dolores; Roman, Irene D.; Gisbert, Javier P.; Guijarro, Luis G.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3899-3911</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">To evaluate the efficacy and the safety of azathioprine (AZA) and buthionine sulfoximine (BSO) by localized application into HepG2 tumor in vivo.  Different hepatoma and colon carcinoma cell lines (HepG2, HuH7, Chang liver, LoVo, RKO, SW-48, SW-480) were grown in minimal essential medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic soln. and maintained in a humidified 37°C incubator with 5% CO2.  These cells were pretreated with BSO for 24 h and then with AZA for different times.  We examd. the effects of this combination on some proteins and on cellular death.  We also studied the efficacy and the safety of AZA (6 mg/kg per day) and BSO (90 mg/kg per day) in HepG2 tumor growth in vivo using athymic mice.  We measured safety by serol. markers such as amino-transferases and creatine kinase.  The in vitro studies revealed a new mechanism of action for the AZA plus BSO combination in the cancer cells compared with other thiopurines (6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine and 6-methylthioguanine) in combination with BSO.  The cytotoxic effect of AZA plus BSO in HepG2 cells resulted from necroptosis induction in a mitochondrial-dependent manner.  From kinetic studies we suggest that glutathione (GSH) depletion stimulates c-Jun amino-terminal kinase and Bax translocation in HepG2 cells with subsequent deregulation of mitochondria (cytochrome c release, loss of membrane potential), and proteolysis activation leading to loss of membrane integrity, release of lactate dehydrogenase and DNA degrdn.  Some of this biochem. and cellular changes could be reversed by N-acetylcysteine (a GSH replenisher).  In vivo studies showed that HepG2 tumor growth was inhibited when AZA was combined with BSO.  Our studies suggest that a combination of AZA plus BSO could be useful for localized treatment of hepatocellular carcinoma as in the currently used transarterial chemoembolization method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa0uPLZFLPLVg90H21EOLACvtfcHk0lgFwwfcjJqcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyqtLjP&md5=8d6ebb1b52dbda23b3f811eced5e98b6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v17.i34.3899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v17.i34.3899%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez-Breijo%26aufirst%3DB.%26aulast%3DMonserrat%26aufirst%3DJ.%26aulast%3DRam%25C3%25ADrez-Rubio%26aufirst%3DS.%26aulast%3DCuevas%26aufirst%3DE.%2BP.%26aulast%3DVara%26aufirst%3DD.%26aulast%3DD%25C3%25ADaz-Laviada%26aufirst%3DI.%26aulast%3DFern%25C3%25A1ndez-Moreno%26aufirst%3DM.%2BD.%26aulast%3DRom%25C3%25A1n%26aufirst%3DI.%2BD.%26aulast%3DGisbert%26aufirst%3DJ.%2BP.%26aulast%3DGuijarro%26aufirst%3DL.%2BG.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Azathioprine%2520Plus%2520Buthionine%2520Sulfoximine%2520in%2520the%2520Treatment%2520of%2520Human%2520Hepatocarcinoma%2520and%2520Colon%2520Carcinoma%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2011%26volume%3D17%26spage%3D3899%26epage%3D3911%26doi%3D10.3748%2Fwjg.v17.i34.3899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renga, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBoer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Sulfoxaflor, a Novel Insecticide Targeting Sap-Feeding Pests</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2950</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1021/jf102765x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf102765x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=2950-2957&author=Y.+Zhuauthor=M.+R.+Losoauthor=G.+B.+Watsonauthor=T.+C.+Sparksauthor=R.+B.+Rogersauthor=J.+X.+Huangauthor=B.+C.+Gerwickauthor=J.+M.+Babcockauthor=D.+Kelleyauthor=V.+B.+Hegdeauthor=B.+M.+Nugentauthor=J.+M.+Rengaauthor=I.+Denholmauthor=K.+Gormanauthor=G.+J.+DeBoerauthor=J.+Haslerauthor=T.+Meadeauthor=J.+D.+Thomas&title=Discovery+and+Characterization+of+Sulfoxaflor%2C+a+Novel+Insecticide+Targeting+Sap-Feeding+Pests&doi=10.1021%2Fjf102765x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Sulfoxaflor, a Novel Insecticide Targeting Sap-Feeding Pests</span></div><div class="casAuthors">Zhu, Yuan-Ming; Loso, Michael R.; Watson, Gerald. B.; Sparks, Thomas C.; Rogers, Richard B.; Huang, Jim X.; Gerwick, B. Clifford; Babcock, Jonathan M.; Kelley, Donald; Hegde, Vidyadhar B.; Nugent, Benjamin M.; Renga, James M.; Denholm, Ian; Gorman, Kevin; DeBoer, Gerrit J.; Hasler, James; Meade, Thomas; Thomas, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2950-2957</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of sulfoxaflor [N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-λ4-sulfanylidene] cyanamide] resulted from an investigation of the sulfoximine functional group as a novel bioactive scaffold for insecticidal activity and a subsequent extensive structure-activity relationship study.  Sulfoxaflor, the first product from this new class (the sulfoximines) of insect control agents, exhibits broad-spectrum efficacy against many sap-feeding insect pests, including aphids, whiteflies, hoppers, and Lygus, with levels of activity that are comparable to those of other classes of insecticides targeting sap-feeding insects, including the neonicotinoids.  However, no cross-resistance has been obsd. between sulfoxaflor and neonicotinoids such as imidacloprid, apparently the result of differences in susceptibility to oxidative metab.  Available data are consistent with sulfoxaflor acting via the insect nicotinic receptor in a complex manner.  These observations reflect the unique structure of the sulfoximines compared with neonicotinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHh1N6zSdO7bVg90H21EOLACvtfcHk0lgFwwfcjJqcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzJ&md5=1fb0ba843a6cd43cb8b3a451cef00afd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjf102765x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf102765x%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DRogers%26aufirst%3DR.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DGerwick%26aufirst%3DB.%2BC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DKelley%26aufirst%3DD.%26aulast%3DHegde%26aufirst%3DV.%2BB.%26aulast%3DNugent%26aufirst%3DB.%2BM.%26aulast%3DRenga%26aufirst%3DJ.%2BM.%26aulast%3DDenholm%26aufirst%3DI.%26aulast%3DGorman%26aufirst%3DK.%26aulast%3DDeBoer%26aufirst%3DG.%2BJ.%26aulast%3DHasler%26aufirst%3DJ.%26aulast%3DMeade%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Sulfoxaflor%252C%2520a%2520Novel%2520Insecticide%2520Targeting%2520Sap-Feeding%2520Pests%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2011%26volume%3D59%26spage%3D2950%26epage%3D2957%26doi%3D10.1021%2Fjf102765x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Insecticides: Targets, Selectivity, Resistance, and Secondary Effects</span>. <i>Annu. Rev. Entomol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1146/annurev-ento-120811-153645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-ento-120811-153645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23317040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=99-117&author=J.+E.+Casidaauthor=K.+A.+Durkin&title=Neuroactive+Insecticides%3A+Targets%2C+Selectivity%2C+Resistance%2C+and+Secondary+Effects&doi=10.1146%2Fannurev-ento-120811-153645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive insecticides: targets, selectivity, resistance, and secondary effects</span></div><div class="casAuthors">Casida, John E.; Durkin, Kathleen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Entomology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-117</span>CODEN:
                <span class="NLM_cas:coden">ARENAA</span>;
        ISSN:<span class="NLM_cas:issn">0066-4170</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neuroactive insecticides are the principal means of protecting crops, people, livestock, and pets from pest insect attack and disease transmission.  Currently, the four major nerve targets are acetylcholinesterase for organophosphates and methylcarbamates, the nicotinic acetylcholine receptor for neonicotinoids, the γ-aminobutyric acid receptor/chloride channel for polychlorocyclohexanes and fiproles, and the voltage-gated sodium channel for pyrethroids and dichlorodiphenyltrichloroethane.  Species selectivity and acquired resistance are attributable in part to structural differences in binding subsites, receptor subunit interfaces, or transmembrane regions.  Addnl. targets are sites in the sodium channel (indoxacarb and metaflumizone), the glutamate-gated chloride channel (avermectins), the octopamine receptor (amitraz metabolite), and the calcium-activated calcium channel (diamides).  Secondary toxic effects in mammals from off-target serine hydrolase inhibition include organophosphate-induced delayed neuropathy and disruption of the cannabinoid system.  Possible assocns. between pesticides and Parkinson's and Alzheimer's diseases are proposed but not established based on epidemiol. observations and mechanistic considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98rRbt7XflbVg90H21EOLACvtfcHk0lgFwwfcjJqcBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVWjtrk%253D&md5=ad091517bf34bf0b36ab3bbf25b8525c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1146%2Fannurev-ento-120811-153645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-ento-120811-153645%26sid%3Dliteratum%253Aachs%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26atitle%3DNeuroactive%2520Insecticides%253A%2520Targets%252C%2520Selectivity%252C%2520Resistance%252C%2520and%2520Secondary%2520Effects%26jtitle%3DAnnu.%2520Rev.%2520Entomol.%26date%3D2013%26volume%3D58%26spage%3D99%26epage%3D117%26doi%3D10.1146%2Fannurev-ento-120811-153645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span> <span> </span><span class="NLM_article-title">Sulfoxaflor and the Sulfoximine Insecticides: Chemistry, Mode of Action and Basis for Efficacy on Resistant Insects</span>. <i>Pestic. Biochem. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.pestbp.2013.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.pestbp.2013.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25149228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1-7&author=T.+C.+Sparksauthor=G.+B.+Watsonauthor=M.+R.+Losoauthor=C.+Gengauthor=J.+M.+Babcockauthor=J.+D.+Thomas&title=Sulfoxaflor+and+the+Sulfoximine+Insecticides%3A+Chemistry%2C+Mode+of+Action+and+Basis+for+Efficacy+on+Resistant+Insects&doi=10.1016%2Fj.pestbp.2013.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoxaflor and the sulfoximine insecticides: Chemistry, mode of action and basis for efficacy on resistant insects</span></div><div class="casAuthors">Sparks, Thomas C.; Watson, Gerald B.; Loso, Michael R.; Geng, Chaoxian; Babcock, Jon M.; Thomas, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Biochemistry and Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">PCBPBS</span>;
        ISSN:<span class="NLM_cas:issn">0048-3575</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The sulfoximines, as exemplified by sulfoxaflor ([N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-λ4-sulfanylidene]cyanamide) represent a new class of insecticides.  Sulfoxaflor exhibits a high degree of efficacy against a wide range of sap-feeding insects, including those resistant to neonicotinoids and other insecticides.  Sulfoxaflor is an agonist at insect nicotinic acetylcholine receptors (nAChRs) and functions in a manner distinct from other insecticides acting at nAChRs.  The sulfoximines also exhibit structure activity relationships (SAR) that are different from other nAChR agonists such as the neonicotinoids.  This review summarizes the sulfoximine SAR, mode of action and the biochem. underlying the obsd. efficacy on resistant insect pests, with a particular focus on sulfoxaflor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Fm-KpdpakrVg90H21EOLACvtfcHk0liDze2F-FffLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgt7vE&md5=92a0bbcdffbab995170c24526dae2811</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.pestbp.2013.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pestbp.2013.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26atitle%3DSulfoxaflor%2520and%2520the%2520Sulfoximine%2520Insecticides%253A%2520Chemistry%252C%2520Mode%2520of%2520Action%2520and%2520Basis%2520for%2520Efficacy%2520on%2520Resistant%2520Insects%26jtitle%3DPestic.%2520Biochem.%2520Physiol.%26date%3D2013%26volume%3D107%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.pestbp.2013.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Longhurst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denholm, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span> <span> </span><span class="NLM_article-title">Cross-Resistance Relationships of the Sulfoximine Insecticide Sulfoxaflor with Neonicotinoids and Other Insecticides in the Whiteflies <i>Bemisia tabaci</i> and <i>Trialeurodes vaporariorum</i></span>. <i>Pest Manage. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/ps.3439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fps.3439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23203347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCktLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=809-813&author=C.+Longhurstauthor=J.+M.+Babcockauthor=I.+Denholmauthor=K.+Gormanauthor=J.+D.+Thomasauthor=T.+C.+Sparks&title=Cross-Resistance+Relationships+of+the+Sulfoximine+Insecticide+Sulfoxaflor+with+Neonicotinoids+and+Other+Insecticides+in+the+Whiteflies+Bemisia+tabaci+and+Trialeurodes+vaporariorum&doi=10.1002%2Fps.3439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-resistance relationships of the sulfoximine insecticide sulfoxaflor with neonicotinoids and other insecticides in the whiteflies Bemisia tabaci and Trialeurodes vaporariorum</span></div><div class="casAuthors">Longhurst, Christopher; Babcock, Jonathan M.; Denholm, Ian; Gorman, Kevin; Thomas, James D.; Sparks, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Pest Management Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">809-813</span>CODEN:
                <span class="NLM_cas:coden">PMSCFC</span>;
        ISSN:<span class="NLM_cas:issn">1526-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Agrochem. compds. effective against insect pests such as the whiteflies Bemisia tabaci and Trialeurodes vaporariorum which often show resistance to a range of insecticidal modes of action (MOA) have particular value in insect pest resistance management programs.  The sulfoximine insecticides are chem. unique as the first group to incorporate a sulfoximine functional group.  Sulfoxaflor is the first sulfoximine compd. under com. development for the control of sap-feeding insects.  The sulfoxaflor cross-resistance relations were studied by comparing the responses of field-collected strains and insecticide-susceptible lab. strains of B. tabaci and T. vaporariorum.  Sulfoxaflor, imidacloprid, acetamiprid, deltamethrin, thiamethoxam, profenofos, and dinotefuran insecticides were used in the assays.  Sulfoxaflor had very low (<3-fold) resistance ratios (RR) when tested against B. tabaci strains that had RR up to 1000-fold to imidacloprid and cross-resistance to other neonicotinoid insecticides.  Sulfoxaflor showed no cross-resistance in a B. tabaci strain with resistance to pyrethroid (deltamethrin) and organophosphate (profenophos) insecticides.  No cross-resistance was obsd. between sulfoxaflor and imidacloprid in T. vaporariorum.  One population of the 3 field strains tested showed slightly decrease susceptibility to sufloxaflor with RR = 4.17.  This same population had RR >23.8-fold for imidacloprid relative to the susceptible population.  Despite sharing the target site with neonicotinoids (nicotinic acetylcholine receptor), the sulfoxaflor activity was largely unaffected by existing neonicotinoid resistance in B. tabaci and T. vaporariorum.  Neonicotinoid resistance mechanisms in these whitefly species are primarily based on enhanced detoxification of insecticides.  This lack of cross-resistance indicates that sulfoxaflor can be a valuable tool for the management of sap-feeding insect pests already resistant to established insecticide groups.  © 2012 Society of Chem. Industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYzFNkSuWVbVg90H21EOLACvtfcHk0liDze2F-FffLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCktLfP&md5=857d94f1fcb98705635dfa13df41d748</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fps.3439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fps.3439%26sid%3Dliteratum%253Aachs%26aulast%3DLonghurst%26aufirst%3DC.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DDenholm%26aufirst%3DI.%26aulast%3DGorman%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26atitle%3DCross-Resistance%2520Relationships%2520of%2520the%2520Sulfoximine%2520Insecticide%2520Sulfoxaflor%2520with%2520Neonicotinoids%2520and%2520Other%2520Insecticides%2520in%2520the%2520Whiteflies%2520Bemisia%2520tabaci%2520and%2520Trialeurodes%2520vaporariorum%26jtitle%3DPest%2520Manage.%2520Sci.%26date%3D2013%26volume%3D69%26spage%3D809%26epage%3D813%26doi%3D10.1002%2Fps.3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Insecticide Resistance Action Committee</span>. <a href="http://www.irac-online.org" class="extLink">http://www.irac-online.org</a> (Accessed July 12, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Insecticide+Resistance+Action+Committee.+http%3A%2F%2Fwww.irac-online.org+%28Accessed+July+12%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolting, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Biological Characterization of Sulfoxaflor, a Novel Insecticide</span>. <i>Pest Manage. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1002/ps.2069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fps.2069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21308958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=328-334&author=J.+M.+Babcockauthor=C.+B.+Gerwickauthor=J.+X.+Huangauthor=M.+R.+Losoauthor=G.+Nakamuraauthor=S.+P.+Noltingauthor=R.+B.+Rogersauthor=T.+C.+Sparksauthor=J.+Thomasauthor=G.+B.+Watsonauthor=Y.+Zhu&title=Biological+Characterization+of+Sulfoxaflor%2C+a+Novel+Insecticide&doi=10.1002%2Fps.2069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of sulfoxaflor, a novel insecticide</span></div><div class="casAuthors">Babcock, Jonathan M.; Gerwick, Clifford B.; Huang, Jim X.; Loso, Michael R.; Nakamura, Genta; Nolting, Steven P.; Rogers, Richard B.; Sparks, Thomas C.; Thomas, James; Watson, Gerald B.; Zhu, Yuan-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Pest Management Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-334</span>CODEN:
                <span class="NLM_cas:coden">PMSCFC</span>;
        ISSN:<span class="NLM_cas:issn">1526-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The commercialization of new insecticides is important for ensuring that multiple effective product choices are available.  In particular, new insecticides that exhibit high potency and lack insecticidal cross-resistance are particularly useful in insecticide resistance management (IRM) programs.  Sulfoxaflor possesses these characteristics and is the first compd. under development from the novel sulfoxamine class of insecticides.  Results: In the lab., sulfoxaflor demonstrated high levels of insecticidal potency against a broad range of sap-feeding insect species.  The potency of sulfoxaflor was comparable with that of com. products, including neonicotinoids, for the control of a wide range of aphids, whiteflies (Homoptera) and true bugs (Heteroptera).  Sulfoxaflor performed equally well in the lab. against both insecticide-susceptible and insecticide-resistant populations of sweetpotato whitefly, Bemisia tabaci Gennadius, and brown planthopper, Nilaparvata lugens (Stal), including populations resistant to the neonicotinoid insecticide imidacloprid.  These lab. efficacy trends were confirmed in field trials from multiple geogs. and crops, and in populations of insects with histories of repeated exposure to insecticides.  In particular, a sulfoxaflor use rate of 25 g ha-1 against cotton aphid (Aphis gossypii Glover) outperformed acetamiprid (25 g ha-1) and dicrotophos (560 g ha-1).  Sulfoxaflor (50 g ha-1) provided a control of sweetpotato whitefly equiv. to that of acetamiprid (75 g ha-1) and imidacloprid (50 g ha-1) and better than that of thiamethoxam (50 g ha-1).  Conclusion: The novel chem. of sulfoxaflor, its unique biol. spectrum of activity and its lack of cross-resistance highlight the potential of sulfoxaflor as an important new tool for the control of sap-feeding insect pests.  Copyright © 2010 Society of Chem. Industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hJPxMY9l2rVg90H21EOLACvtfcHk0liDze2F-FffLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yltbg%253D&md5=6dda9d2ece173d9940b769395008c576</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fps.2069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fps.2069%26sid%3Dliteratum%253Aachs%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DGerwick%26aufirst%3DC.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DNakamura%26aufirst%3DG.%26aulast%3DNolting%26aufirst%3DS.%2BP.%26aulast%3DRogers%26aufirst%3DR.%2BB.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DBiological%2520Characterization%2520of%2520Sulfoxaflor%252C%2520a%2520Novel%2520Insecticide%26jtitle%3DPest%2520Manage.%2520Sci.%26date%3D2011%26volume%3D67%26spage%3D328%26epage%3D334%26doi%3D10.1002%2Fps.2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letherer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, T. C.</span></span> <span> </span><span class="NLM_article-title">Novel Nicotinic Action of the Sulfoximine Insecticide Sulfoxaflor</span>. <i>Insect Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ibmb.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ibmb.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21296156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslKls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=432-439&author=G.+B.+Watsonauthor=M.+R.+Losoauthor=J.+M.+Babcockauthor=J.+M.+Haslerauthor=T.+J.+Lethererauthor=C.+D.+Youngauthor=Y.+Zhuauthor=J.+E.+Casidaauthor=T.+C.+Sparks&title=Novel+Nicotinic+Action+of+the+Sulfoximine+Insecticide+Sulfoxaflor&doi=10.1016%2Fj.ibmb.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Novel nicotinic action of the sulfoximine insecticide sulfoxaflor</span></div><div class="casAuthors">Watson, Gerald B.; Loso, Michael R.; Babcock, Jonathan M.; Hasler, James M.; Letherer, Theodore J.; Young, Cathy D.; Zhu, Yuanming; Casida, John E.; Sparks, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Insect Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">432-439</span>CODEN:
                <span class="NLM_cas:coden">IBMBES</span>;
        ISSN:<span class="NLM_cas:issn">0965-1748</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The novel sulfoximine insecticide sulfoxaflor is as potent or more effective than the neonicotinoids for toxicity to green peach aphids (GPA, Myzus persicae).  The action of sulfoxaflor was characterized at insect nicotinic acetylcholine receptors (nAChRs) using electrophysiol. and radioligand binding techniques.  When tested for agonist properties on Drosophila melanogaster Dα2 nAChR subunit co-expressed in Xenopus laevis oocytes with the chicken β2 subunit, sulfoxaflor elicited very high amplitude (efficacy) currents.  Sulfoximine analogs of sulfoxaflor were also agonists on Dα2/β2 nAChRs, but none produced maximal currents equiv. to sulfoxaflor nor were any as toxic to GPAs.  Addnl., except for clothianidin, none of the neonicotinoids produced maximal currents as large as those produced by sulfoxaflor.  These data suggest that the potent insecticidal activity of sulfoxaflor may be due to its very high efficacy at nAChRs.  In contrast, sulfoxaflor displaced [3H]imidacloprid (IMI) from GPA nAChR membrane prepns. with weak affinity compared to most of the neonicotinoids examd.  The nature of the interaction of sulfoxaflor with nAChRs apparently differs from that of IMI and other neonicotinoids, and when coupled with other known characteristics (novel chem. structure, lack of cross-resistance, and metabolic stability), indicate that sulfoxaflor represents a significant new insecticide option for the control of sap-feeding insects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtziFh6WNRm7Vg90H21EOLACvtfcHk0ljW8MZCgMEDsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslKls70%253D&md5=dd9a5d0273f164707d90c667f7143630</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ibmb.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ibmb.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DG.%2BB.%26aulast%3DLoso%26aufirst%3DM.%2BR.%26aulast%3DBabcock%26aufirst%3DJ.%2BM.%26aulast%3DHasler%26aufirst%3DJ.%2BM.%26aulast%3DLetherer%26aufirst%3DT.%2BJ.%26aulast%3DYoung%26aufirst%3DC.%2BD.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26aulast%3DSparks%26aufirst%3DT.%2BC.%26atitle%3DNovel%2520Nicotinic%2520Action%2520of%2520the%2520Sulfoximine%2520Insecticide%2520Sulfoxaflor%26jtitle%3DInsect%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D41%26spage%3D432%26epage%3D439%26doi%3D10.1016%2Fj.ibmb.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siviter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbeater, E.</span></span> <span> </span><span class="NLM_article-title">Sulfoxaflor Exposure Reduces Bumblebee Reproductive Success</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0430-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs41586-018-0430-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30111837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2018&pages=109-112&author=H.+Siviterauthor=M.+J.+F.+Brownauthor=E.+Leadbeater&title=Sulfoxaflor+Exposure+Reduces+Bumblebee+Reproductive+Success&doi=10.1038%2Fs41586-018-0430-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoxaflor exposure reduces bumblebee reproductive success</span></div><div class="casAuthors">Siviter, Harry; Brown, Mark J. F.; Leadbeater, Ellouise</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">7721</span>),
    <span class="NLM_cas:pages">109-112</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Intensive agriculture currently relies on pesticides to maximize crop yield1,2.  Neonicotinoids are the most widely used insecticides globally3, but increasing evidence of neg. impacts on important pollinators4-9 and other non-target organisms10 has led to legislative reassessment and created demand for the development of alternative products.  Sulfoximine-based insecticides are the most likely successor11, and are either licensed for use or under consideration for licensing in several worldwide markets3, including within the European Union12, where certain neonicotinoids (imidacloprid, clothianidin and thiamethoxam) are now banned from agricultural use outside of permanent greenhouse structures.  There is an urgent need to pre-emptively evaluate the potential sub-lethal effects of sulfoximine-based pesticides on pollinators11, because such effects are rarely detected by std. ecotoxicol. assessments, but can have major impacts at larger ecol. scales13-15.  Chronic exposure to the sulfoximine-based insecticide sulfoxaflor, at dosages consistent with potential post-spray field exposure, has severe sub-lethal effects on bumblebee (Bombus terrestris) colonies.  Field-based colonies that were exposed to sulfoxaflor during the early growth phase produced significantly fewer workers than unexposed controls, and ultimately produced fewer reproductive offspring.  Differences between the life-history trajectories of treated and control colonies first became apparent when individuals exposed as larvae began to emerge, suggesting that direct or indirect effects on a small cohort may have cumulative long-term consequences for colony fitness.  The authors' results caution against the use of sulfoximines as a direct replacement for neonicotinoids.  To avoid continuing cycles of novel pesticide release and removal, with concomitant impacts on the environment, a broad evidence base needs to be assessed prior to the development of policy and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkMsnr51RgoLVg90H21EOLACvtfcHk0ljW8MZCgMEDsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahsbrI&md5=559b39bf3adf2478d80d663105f68ad6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0430-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0430-6%26sid%3Dliteratum%253Aachs%26aulast%3DSiviter%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BF.%26aulast%3DLeadbeater%26aufirst%3DE.%26atitle%3DSulfoxaflor%2520Exposure%2520Reduces%2520Bumblebee%2520Reproductive%2520Success%26jtitle%3DNature%26date%3D2018%26volume%3D561%26spage%3D109%26epage%3D112%26doi%3D10.1038%2Fs41586-018-0430-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siviter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pull, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbeater, E.</span></span> <span> </span><span class="NLM_article-title">No Evidence for Negative Impacts of Acute Sulfoxaflor Exposure on Bee Olfactory Conditioning or Working Memory</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e7208</span>, <span class="refDoi"> DOI: 10.7717/peerj.7208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.7717%2Fpeerj.7208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31423353" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=e7208&author=H.+Siviterauthor=A.+Scottauthor=G.+Pasquierauthor=C.+D.+Pullauthor=M.+J.+F.+Brownauthor=E.+Leadbeater&title=No+Evidence+for+Negative+Impacts+of+Acute+Sulfoxaflor+Exposure+on+Bee+Olfactory+Conditioning+or+Working+Memory&doi=10.7717%2Fpeerj.7208"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.7208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.7208%26sid%3Dliteratum%253Aachs%26aulast%3DSiviter%26aufirst%3DH.%26aulast%3DScott%26aufirst%3DA.%26aulast%3DPasquier%26aufirst%3DG.%26aulast%3DPull%26aufirst%3DC.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BF.%26aulast%3DLeadbeater%26aufirst%3DE.%26atitle%3DNo%2520Evidence%2520for%2520Negative%2520Impacts%2520of%2520Acute%2520Sulfoxaflor%2520Exposure%2520on%2520Bee%2520Olfactory%2520Conditioning%2520or%2520Working%2520Memory%26jtitle%3DPeerJ%26date%3D2019%26volume%3D7%26spage%3De7208%26doi%3D10.7717%2Fpeerj.7208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, C.</span></span> <span> </span><span class="NLM_article-title">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ci900450m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900450m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=339-348&author=J.+Hussainauthor=C.+Rea&title=Computationally+Efficient+Algorithm+to+Identify+Matched+Molecular+Pairs+%28MMPs%29+in+Large+Data+Sets&doi=10.1021%2Fci900450m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span></div><div class="casAuthors">Hussain, Jameed; Rea, Ceara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern drug discovery organizations generate large vols. of SAR data.  A promising methodol. that can be used to mine this chem. data to identify novel structure-activity relationships is the matched mol. pair (MMP) methodol.  However, before the full potential of the MMP methodol. can be utilized, a MMP identification method that is capable of identifying all MMPs in large chem. data sets on modest computational hardware is required.  In this paper we report an algorithm that is capable of systematically generating all MMPs in chem. data sets.  Addnl., the algorithm is computationally efficient enough to be applied on large data sets.  As an example the algorithm was used to identify the MMPs in the ∼300k NIH MLSMR set.  The algorithm identified ∼5.3 million matched mol. pairs in the set.  These pairs cover ∼2.6 million unique mol. transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0rN8jaKSjrVg90H21EOLACvtfcHk0ljW8MZCgMEDsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D&md5=23964abebc23274f5c36c319bee52bab</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fci900450m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900450m%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DRea%26aufirst%3DC.%26atitle%3DComputationally%2520Efficient%2520Algorithm%2520to%2520Identify%2520Matched%2520Molecular%2520Pairs%2520%2528MMPs%2529%2520in%2520Large%2520Data%2520Sets%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D339%26epage%3D348%26doi%3D10.1021%2Fci900450m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirvent, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span> <span> </span><span class="NLM_article-title">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28221724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=487-501&author=J.+A.+Sirventauthor=U.+L%C3%BCcking&title=Novel+Pieces+for+the+Emerging+Picture+of+Sulfoximines+in+Drug+Discovery%3A+Synthesis+and+Evaluation+of+Sulfoximine+Analogues+of+Marketed+Drugs+and+Advanced+Clinical+Candidates&doi=10.1002%2Fcmdc.201700044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates</span></div><div class="casAuthors">Sirvent, Juan Alberto; Luecking, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">487-501</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late.  In particular, the clin. kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention.  While the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chem.-relevant properties of sulfoximines.  Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogs of marketed drugs and advanced clin. candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5kfVM3I45LVg90H21EOLACvtfcHk0lidGjekjg1N0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1Sltbo%253D&md5=5b4589d7af32c8984d4fd3027c31c168</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700044%26sid%3Dliteratum%253Aachs%26aulast%3DSirvent%26aufirst%3DJ.%2BA.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DNovel%2520Pieces%2520for%2520the%2520Emerging%2520Picture%2520of%2520Sulfoximines%2520in%2520Drug%2520Discovery%253A%2520Synthesis%2520and%2520Evaluation%2520of%2520Sulfoximine%2520Analogues%2520of%2520Marketed%2520Drugs%2520and%2520Advanced%2520Clinical%2520Candidates%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D487%26epage%3D501%26doi%3D10.1002%2Fcmdc.201700044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G. M.</span></span> <span> </span><span class="NLM_article-title">Nonleadlikeness and Leadlikeness in Biochemical Screening</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/S1359644602025722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS1359644602025722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12565011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252Fls1SjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=86-96&author=G.+M.+Rishton&title=Nonleadlikeness+and+Leadlikeness+in+Biochemical+Screening&doi=10.1016%2FS1359644602025722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Nonleadlikeness and leadlikeness in biochemical screening</span></div><div class="casAuthors">Rishton Gilbert M</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">86-96</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Biochemical assays have largely supplanted functional biological assays as drug screening tools in the early stages of drug discovery.  The de-selection of compounds that are 'nonleadlike' binders (and bonders) and the proactive selection of those compounds that are 'leadlike' in their binding to the target are vital components of the screening effort.  The physiochemical properties of leadlikeness and the surprising differences between those properties and the now classical definitions of druglikeness are becoming apparent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFoWSt5LTTmsrRqEXsZufAfW6udTcc2eZaIqaFYb0lOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252Fls1SjtQ%253D%253D&md5=5e34cece6f751fa727f949c3526aa95c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS1359644602025722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359644602025722%26sid%3Dliteratum%253Aachs%26aulast%3DRishton%26aufirst%3DG.%2BM.%26atitle%3DNonleadlikeness%2520and%2520Leadlikeness%2520in%2520Biochemical%2520Screening%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D86%26epage%3D96%26doi%3D10.1016%2FS1359644602025722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lidGjekjg1N0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Kinase Inhibitors: An Analysis of FDA-Approved Drugs</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.drudis.2015.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26210956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=5-10&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=Small-Molecule+Kinase+Inhibitors%3A+An+Analysis+of+FDA-Approved+Drugs&doi=10.1016%2Fj.drudis.2015.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule kinase inhibitors: an analysis of FDA-approved drugs</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-10</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising targeted therapeutics.  Here, we assess the key structural and physicochem. properties, target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors.  Our anal. showed that >30% of approved SMKIs have a mol. wt. (MW) exceeding 500 and all have a total ring count of between three and five.  The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable.  Although previous SMKI research was concd. on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new targets, mechanistic types, and therapeutic indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZrY68ZOI2xLVg90H21EOLACvtfcHk0lgU4TyDA6V2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73P&md5=228524fa464393053ecbfac19e994929</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSmall-Molecule%2520Kinase%2520Inhibitors%253A%2520An%2520Analysis%2520of%2520FDA-Approved%2520Drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D5%26epage%3D10%26doi%3D10.1016%2Fj.drudis.2015.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties that Influence the Oral Bioavailability of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2615</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+Properties+that+Influence+the+Oral+Bioavailability+of+Drug+Candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lgU4TyDA6V2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520Properties%2520that%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreft, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschmies, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casebier, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comery, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamantidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingboe, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubrak, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnenberg-Reines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woller, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, J. S.</span></span> <span> </span><span class="NLM_article-title">(S)-N-(5-Chlorothiophene-2-Sulfonyl)-β,β-Diethylalaninol a Notch-1-Sparing γ-Secretase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.11.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2008.11.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19097890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=926-929&author=D.+C.+Coleauthor=J.+R.+Stockauthor=A.+F.+Kreftauthor=M.+Antaneauthor=S.+H.+Aschmiesauthor=K.+P.+Atchisonauthor=D.+S.+Casebierauthor=T.+A.+Comeryauthor=G.+Diamantidisauthor=J.+W.+Ellingboeauthor=B.+L.+Harrisonauthor=Y.+Huauthor=M.+Jinauthor=D.+M.+Kubrakauthor=P.+Luauthor=C.+W.+Mannauthor=R.+L.+Martoneauthor=W.+J.+Mooreauthor=A.+Oganesianauthor=D.+R.+Riddellauthor=J.+Sonnenberg-Reinesauthor=S.+C.+Sunauthor=E.+Wagnerauthor=Z.+Wangauthor=K.+R.+Wollerauthor=Z.+Xuauthor=H.+Zhouauthor=J.+S.+Jacobsen&title=%28S%29-N-%285-Chlorothiophene-2-Sulfonyl%29-%CE%B2%2C%CE%B2-Diethylalaninol+a+Notch-1-Sparing+%CE%B3-Secretase+Inhibitor&doi=10.1016%2Fj.bmcl.2008.11.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor</span></div><div class="casAuthors">Cole, Derek C.; Stock, Joseph R.; Kreft, Anthony F.; Antane, Madelene; Aschmies, Suzan H.; Atchison, Kevin P.; Casebier, David S.; Comery, Thomas A.; Diamantidis, George; Ellingboe, John W.; Harrison, Boyd L.; Hu, Yun; Jin, Mei; Kubrak, Dennis M.; Lu, Peimin; Mann, Charles W.; Martone, Robert L.; Moore, William J.; Oganesian, Aram; Riddell, David R.; Sonnenberg-Reines, June; Sun, Shaiu-Ching; Wagner, Erik; Wang, Zheng; Woller, Kevin R.; Xu, Zheng; Zhou, Hua; Jacobsen, J. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-929</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Accumulation of beta-amyloid (Aβ), produced by the proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretase, is widely believed to be assocd. with Alzheimer's disease (AD).  Research around the high-throughput screening hit (S)-4-chlorophenylsulfonyl isoleucinol led to the identification of the Notch-1-sparing (9.5-fold) γ-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-β,β-diethylalaninol 7.b.2 (Aβ40/42 EC50 = 28 nM), which is efficacious in redn. of Aβ prodn. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdqzZ7gfiP7Vg90H21EOLACvtfcHk0lhmOK7Fp9KEww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itLk%253D&md5=64713282284d9577a317dfcf737a5ec7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.116%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DD.%2BC.%26aulast%3DStock%26aufirst%3DJ.%2BR.%26aulast%3DKreft%26aufirst%3DA.%2BF.%26aulast%3DAntane%26aufirst%3DM.%26aulast%3DAschmies%26aufirst%3DS.%2BH.%26aulast%3DAtchison%26aufirst%3DK.%2BP.%26aulast%3DCasebier%26aufirst%3DD.%2BS.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DDiamantidis%26aufirst%3DG.%26aulast%3DEllingboe%26aufirst%3DJ.%2BW.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DM.%26aulast%3DKubrak%26aufirst%3DD.%2BM.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DC.%2BW.%26aulast%3DMartone%26aufirst%3DR.%2BL.%26aulast%3DMoore%26aufirst%3DW.%2BJ.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DSonnenberg-Reines%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DWagner%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWoller%26aufirst%3DK.%2BR.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DJacobsen%26aufirst%3DJ.%2BS.%26atitle%3D%2528S%2529-N-%25285-Chlorothiophene-2-Sulfonyl%2529-%25CE%25B2%252C%25CE%25B2-Diethylalaninol%2520a%2520Notch-1-Sparing%2520%25CE%25B3-Secretase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D926%26epage%3D929%26doi%3D10.1016%2Fj.bmcl.2008.11.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehgelmeble, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotticci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundkvist, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, <i>in Vitro</i>, and <i>in Vivo</i> Studies with γ-Secretase Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201200014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22307979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=396-399&author=F.+Sehgelmebleauthor=J.+Jansonauthor=C.+Rayauthor=S.+Rosqvistauthor=S.+Gustavssonauthor=L.+I.+Nilssonauthor=A.+Minidisauthor=J.+Holenzauthor=D.+Rotticciauthor=J.+Lundkvistauthor=P.+I.+Arvidsson&title=Sulfonimidamides+as+Sulfonamides+Bioisosteres%3A+Rational+Evaluation+through+Synthetic%2C+in+Vitro%2C+and+in+Vivo+Studies+with+%CE%B3-Secretase+Inhibitors&doi=10.1002%2Fcmdc.201200014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, in Vitro, and in Vivo Studies with γ-Secretase Inhibitors</span></div><div class="casAuthors">Sehgelmeble, Fernando; Janson, Juliette; Ray, Colin; Rosqvist, Susanne; Gustavsson, Susanne; Nilsson, Linda I.; Minidis, Alexander; Holenz, Joerg; Rotticci, Didier; Lundkvist, Johan; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">396-399</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel sulfonimidamide analogs were prepd., as potential sulfonamides bioisosteres, and their γ-secretase inhibiting activity tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7JaMdVVAfKrVg90H21EOLACvtfcHk0lhmOK7Fp9KEww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSit7c%253D&md5=2a806cd471c27d5a949db37a26e596d8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200014%26sid%3Dliteratum%253Aachs%26aulast%3DSehgelmeble%26aufirst%3DF.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DC.%26aulast%3DRosqvist%26aufirst%3DS.%26aulast%3DGustavsson%26aufirst%3DS.%26aulast%3DNilsson%26aufirst%3DL.%2BI.%26aulast%3DMinidis%26aufirst%3DA.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DRotticci%26aufirst%3DD.%26aulast%3DLundkvist%26aufirst%3DJ.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DSulfonimidamides%2520as%2520Sulfonamides%2520Bioisosteres%253A%2520Rational%2520Evaluation%2520through%2520Synthetic%252C%2520in%2520Vitro%252C%2520and%2520in%2520Vivo%2520Studies%2520with%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D396%26epage%3D399%26doi%3D10.1002%2Fcmdc.201200014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fietkau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375</span>. <i>Skin Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1159/000453042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1159%2F000453042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2017&pages=281-290&author=A.+D.+Steinkampauthor=L.+Schmittauthor=X.+Chenauthor=K.+Fietkauauthor=R.+Heiseauthor=J.+M.+Baronauthor=C.+Bolm&title=Synthesis+of+a+Sulfonimidamide-Based+Analog+of+Tasisulam+and+Its+Biological+Evaluation+in+the+Melanoma+Cell+Lines+SKMel23+and+A375&doi=10.1159%2F000453042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1159%2F000453042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000453042%26sid%3Dliteratum%253Aachs%26aulast%3DSteinkamp%26aufirst%3DA.%2BD.%26aulast%3DSchmitt%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFietkau%26aufirst%3DK.%26aulast%3DHeise%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520a%2520Sulfonimidamide-Based%2520Analog%2520of%2520Tasisulam%2520and%2520Its%2520Biological%2520Evaluation%2520in%2520the%2520Melanoma%2520Cell%2520Lines%2520SKMel23%2520and%2520A375%26jtitle%3DSkin%2520Pharmacol.%2520Physiol.%26date%3D2017%26volume%3D29%26spage%3D281%26epage%3D290%26doi%3D10.1159%2F000453042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lglHjQLFYorTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Considine, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Dios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durst, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferritto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giera, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin
Cabrejas, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richett, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span> <span> </span><span class="NLM_article-title">Acyl Sulfonamide Anti-Proliferatives: Benzene Substituent Structure–Activity Relationships for a Novel Class of Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">5367</span>– <span class="NLM_lpage">5380</span>, <span class="refDoi"> DOI: 10.1021/jm030594r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030594r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsleis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=5367-5380&author=K.+L.+Lobbauthor=P.+A.+Hipskindauthor=J.+A.+Aikinsauthor=E.+Alvarezauthor=Y.-Y.+Cheungauthor=E.+L.+Considineauthor=A.+De+Diosauthor=G.+L.+Durstauthor=R.+Ferrittoauthor=C.+S.+Grossmanauthor=D.+D.+Gieraauthor=B.+A.+Hollisterauthor=Z.+Huangauthor=P.+W.+Iversenauthor=K.+L.+Lawauthor=T.+Liauthor=H.+S.+Linauthor=B.+Lopezauthor=J.+E.+Lopezauthor=L.+M.+Martin%0ACabrejasauthor=D.+J.+McCannauthor=V.+Moleroauthor=J.+E.+Reillyauthor=M.+E.+Richettauthor=C.+Shihauthor=B.+Teicherauthor=J.+H.+Wikelauthor=W.+T.+Whiteauthor=M.+M.+Mader&title=Acyl+Sulfonamide+Anti-Proliferatives%3A+Benzene+Substituent+Structure%E2%80%93Activity+Relationships+for+a+Novel+Class+of+Antitumor+Agents&doi=10.1021%2Fjm030594r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl Sulfonamide Anti-Proliferatives: Benzene Substituent Structure-Activity Relationships for a Novel Class of Antitumor Agents</span></div><div class="casAuthors">Lobb, Karen L.; Hipskind, Philip A.; Aikins, James A.; Alvarez, Enrique; Cheung, Yiu-Yin; Considine, Eileen L.; De Dios, Alfonso; Durst, Gregory L.; Ferritto, Rafael; Grossman, Cora Sue; Giera, Deborah D.; Hollister, Beth A.; Huang, Zhongping; Iversen, Philip W.; Law, Kevin L.; Li, Tiechao; Lin, Ho-Shen; Lopez, Beatriz; Lopez, Jose E.; Cabrejas, Luisa M. Martin; McCann, Denis J.; Molero, Victoriano; Reilly, John E.; Richett, Michael E.; Shih, Chuan; Teicher, Beverly; Wikel, James H.; White, Wesley T.; Mader, Mary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5367-5380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related diaryl acylsulfonamides were recently reported as potent antitumor agents against a broad spectrum of human tumor xenografts (colon, lung, breast, ovary, and prostate) in nude mice.  Esp. intriguing was their activity against colorectal cancer xenografts.  In this paper, rapid parallel synthesis along with traditional medicinal chem. techniques were used to quickly delineate the structure-activity relationships of the substitution patterns in both Ph rings of the acylsufonamide anti-proliferative scaffold.  Although the mol. target of the compds. remains unclear, we detd. that the vascular endothelial growth factor-dependent human umbilical vein endothelial cells assay in combination with a soft agar disk diffusion assay allowed for optimization of potency in the series.  The pharmacokinetic properties and in vivo activity in an HCT116 xenograft model are reported for representative compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeCysoz5N61bVg90H21EOLACvtfcHk0lj0XW9Zl3cQNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsleis7Y%253D&md5=e10193988e21a4cecf4040e5e8ad996e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm030594r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030594r%26sid%3Dliteratum%253Aachs%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DAikins%26aufirst%3DJ.%2BA.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DY.-Y.%26aulast%3DConsidine%26aufirst%3DE.%2BL.%26aulast%3DDe%2BDios%26aufirst%3DA.%26aulast%3DDurst%26aufirst%3DG.%2BL.%26aulast%3DFerritto%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DC.%2BS.%26aulast%3DGiera%26aufirst%3DD.%2BD.%26aulast%3DHollister%26aufirst%3DB.%2BA.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DLaw%26aufirst%3DK.%2BL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DH.%2BS.%26aulast%3DLopez%26aufirst%3DB.%26aulast%3DLopez%26aufirst%3DJ.%2BE.%26aulast%3DMartin%2BCabrejas%26aufirst%3DL.%2BM.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26aulast%3DMolero%26aufirst%3DV.%26aulast%3DReilly%26aufirst%3DJ.%2BE.%26aulast%3DRichett%26aufirst%3DM.%2BE.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DWikel%26aufirst%3DJ.%2BH.%26aulast%3DWhite%26aufirst%3DW.%2BT.%26aulast%3DMader%26aufirst%3DM.%2BM.%26atitle%3DAcyl%2520Sulfonamide%2520Anti-Proliferatives%253A%2520Benzene%2520Substituent%2520Structure%25E2%2580%2593Activity%2520Relationships%2520for%2520a%2520Novel%2520Class%2520of%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D5367%26epage%3D5380%26doi%3D10.1021%2Fjm030594r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scagliotti, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Pawel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermisch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alwis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eschbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manegold, C.</span></span> <span> </span><span class="NLM_article-title">Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients with Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3182519d79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FJTO.0b013e3182519d79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22588156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1053-1057&author=G.+V.+Scagliottiauthor=R.+Ilariaauthor=S.+Novelloauthor=J.+von+Pawelauthor=J.+R.+Fischerauthor=S.+Ermischauthor=D.+P.+de+Alwisauthor=J.+Andrewsauthor=M.+Reckauthor=L.+Crinoauthor=C.+Eschbachauthor=C.+Manegold&title=Tasisulam+Sodium+%28LY573636+Sodium%29+as+Third-Line+Treatment+in+Patients+with+Unresectable%2C+Metastatic+Non%E2%80%93Small-Cell+Lung+Cancer%3A+A+Phase-II+Study&doi=10.1097%2FJTO.0b013e3182519d79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: A phase-II study</span></div><div class="casAuthors">Scagliotti, Giorgio V.; Ilaria, Robert, Jr.; Novello, Silvia; von Pawel, J.; Fischer, Juergen R.; Ermisch, Sabine; de Alwis, Dinesh P.; Andrews, Joan; Reck, Martin; Crino, Lucio; Eschbach, Corinna; Manegold, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Tasisulam sodium (hereafter referred to as tasisulam) is a novel anticancer compd. that induces apoptosis and exhibits antiangiogenesis activity in a broad range of cancer models, including non-small-cell lung cancer (NSCLC).  Methods: Tasisulam was administered as a 2-h infusion every 21 days as third-line treatment in patients with advanced (stage IIIB/IV) NSCLC.  Results: Thirty-two patients received a Cmax target dose of 420 μg/mL.  Median time to progression was 3.12 mo, median progression-free survival was 2.69 mo, and median overall survival was 8.48 mo.  There were no objective responses; 43.8% of patients achieved stable disease.  A high rate of grade-4 hematol. toxicity in the first 30 patients led to exploration of a lower Cmax target dose of 380 μg/mL.  The rate of grade-4 hematol. toxicity (thrombocytopenia and/or neutropenia) at the 380-μg/mL dose (n = 20) was 20% vs. 34% at the 420-μg/mL dose.  Conclusions: Tasisulam has only modest activity as a third-line treatment of patients with unresectable/metastatic NSCLC.  The high rate of grade-4 hematol. toxicity obsd. with this highly albumin-bound compd. in this patient population provided challenges for fixed Cmax-based dosing.  Alternative dosing methods, including varying the Cmax target dose by predose albumin, are under investigation in other studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-A4REc-NTRbVg90H21EOLACvtfcHk0lhREZQvUHDfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShtbnF&md5=f4612b2e4144ba59a4ba1288e0bfd1b3</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182519d79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182519d79%26sid%3Dliteratum%253Aachs%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DIlaria%26aufirst%3DR.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DJ.%2BR.%26aulast%3DErmisch%26aufirst%3DS.%26aulast%3Dde%2BAlwis%26aufirst%3DD.%2BP.%26aulast%3DAndrews%26aufirst%3DJ.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DEschbach%26aufirst%3DC.%26aulast%3DManegold%26aufirst%3DC.%26atitle%3DTasisulam%2520Sodium%2520%2528LY573636%2520Sodium%2529%2520as%2520Third-Line%2520Treatment%2520in%2520Patients%2520with%2520Unresectable%252C%2520Metastatic%2520Non%25E2%2580%2593Small-Cell%2520Lung%2520Cancer%253A%2520A%2520Phase-II%2520Study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1053%26epage%3D1057%26doi%3D10.1097%2FJTO.0b013e3182519d79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jotte, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becerra, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conkling, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert-Vizcarrondo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">An Innovative, Multi-Arm, Complete Phase 1b Study of the Novel Anti-Cancer Agent Tasisulam in Patients with Advanced Solid Tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0160-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs10637-014-0160-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25260842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KgsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=148-158&author=R.+M.+Jotteauthor=D.+D.+Von+Hoffauthor=F.+Braitehauthor=C.+R.+Becerraauthor=D.+A.+Richardsauthor=D.+A.+Smithauthor=L.+Garboauthor=J.+Stephensonauthor=P.+R.+Conklingauthor=F.+Robert-Vizcarrondoauthor=J.+Chenauthor=P.+K.+Turnerauthor=K.+H.+Chowauthor=D.+F.+Taiauthor=R.+Ilaria&title=An+Innovative%2C+Multi-Arm%2C+Complete+Phase+1b+Study+of+the+Novel+Anti-Cancer+Agent+Tasisulam+in+Patients+with+Advanced+Solid+Tumors&doi=10.1007%2Fs10637-014-0160-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors</span></div><div class="casAuthors">Jotte, Robert M.; Von Hoff, Daniel D.; Braiteh, Fadi; Becerra, Carlos R.; Richards, Donald A.; Smith, David A.; Garbo, Lawrence; Stephenson, Joe; Conkling, Paul R.; Robert-Vizcarrondo, Francisco; Chen, Jian; Turner, P. Kellie; Chow, Kay Hoong; Tai, D. Fritz; Ilaria, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-158</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacol., combined with std. chemotherapies in patients with advanced solid tumors, with the ultimate goal of accelerating drug development.  Methods: Patients received escalating doses of tasisulam (3 + 3 schema; target Cmax 300-400 μg/mL) every 28 days plus 1,000 mg/m2 gemcitabine HCl (days 1 and 15), 60 mg/m2 docetaxel, 200 mg/m2/day temozolomide, 75 mg/m2 cisplatin, or 150 mg/day erlotinib.  Following dose-escalation, patients were enrolled into specific tumor subtype arms, chosen based on the established activity of the std. agent.  Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-cor. exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib).  Results: A total of 234 patients were enrolled.  The safety profile of tasisulam with std. chemotherapies was sufficient to allow enrollment into the dose-confirmation phase in all arms.  The primary dose-limiting toxicities were hematol. (thrombocytopenia and neutropenia).  The most common grade ≥3 drug-related treatment-emergent adverse event was neutropenia, with the highest incidence in the docetaxel arm.  Conclusions: The multi-arm design allowed the efficient detn. of the max. tolerated dose of tasisulam across multiple combinations, and a preliminary characterization of pharmacokinetics, safety, and potential efficacy.  Although enrollment into all planned groups was not completed due to termination of compd. development, these data support the feasibility of this approach for accelerated cancer drug development, even for drugs with complex pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FP30ceoed7Vg90H21EOLACvtfcHk0lhREZQvUHDfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KgsbnI&md5=255ef33e89c87b0d8557c2d737a59342</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0160-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0160-z%26sid%3Dliteratum%253Aachs%26aulast%3DJotte%26aufirst%3DR.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DBraiteh%26aufirst%3DF.%26aulast%3DBecerra%26aufirst%3DC.%2BR.%26aulast%3DRichards%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DGarbo%26aufirst%3DL.%26aulast%3DStephenson%26aufirst%3DJ.%26aulast%3DConkling%26aufirst%3DP.%2BR.%26aulast%3DRobert-Vizcarrondo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTurner%26aufirst%3DP.%2BK.%26aulast%3DChow%26aufirst%3DK.%2BH.%26aulast%3DTai%26aufirst%3DD.%2BF.%26aulast%3DIlaria%26aufirst%3DR.%26atitle%3DAn%2520Innovative%252C%2520Multi-Arm%252C%2520Complete%2520Phase%25201b%2520Study%2520of%2520the%2520Novel%2520Anti-Cancer%2520Agent%2520Tasisulam%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D148%26epage%3D158%26doi%3D10.1007%2Fs10637-014-0160-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilaria, R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahka-Kemppinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Open-Label Clinical Trial of Tasisulam Sodium versus Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">2016</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1002/cncr.28635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcncr.28635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24676877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWktr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2016-2024&author=O.+Hamidauthor=R.+Ilariaauthor=C.+Garbeauthor=P.+Wolterauthor=M.+Maioauthor=T.+E.+Hutsonauthor=A.+Aranceauthor=P.+Loriganauthor=J.+Leeauthor=A.+Hauschildauthor=P.+Mohrauthor=M.+Hahka-Kemppinenauthor=C.+Kaiserauthor=P.+K.+Turnerauthor=I.+Contiauthor=J.+J.+Grob&title=A+Randomized%2C+Open-Label+Clinical+Trial+of+Tasisulam+Sodium+versus+Paclitaxel+as+Second-Line+Treatment+in+Patients+with+Metastatic+Melanoma&doi=10.1002%2Fcncr.28635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma</span></div><div class="casAuthors">Hamid, Omid; Ilaria, Robert, Jr.; Garbe, Claus; Wolter, Pascal; Maio, Michele; Hutson, Thomas E.; Arance, Ana; Lorigan, Paul; Lee, Jeeyun; Hauschild, Axel; Mohr, Peter; Hahka-Kemppinen, Marjo; Kaiser, Christopher; Turner, P. Kellie; Conti, Ilaria; Grob, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2016-2024</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.  METHODS : In this open-label phase 3 study, patients with AJCC stage IV melanoma received tasisulam (targeting an albumin-cor. exposure of 1200-6400 h (hour).μg/mL on day 1) or paclitaxel (80 mg/m2 on days 1, 8, and 15) every 28 days as second-line treatment.  RESULTS : The study was placed on clin. hold after randomization of 336 patients when a safety review indicated an imbalance of possibly drug-related deaths in the tasisulam arm.  Efficacy results for tasisulam vs. paclitaxel revealed a response rate of 3.0% vs. 4.8%, a median progression-free survival of 1.94 mo vs. 2.14 mo (P = .048), and a median overall survival of 6.77 mo vs. 9.36 mo (P = .121).  The most common drug-related grade ≥3 lab. toxicities (graded according to Common Terminol. for Adverse Events [version 3.0]) were thrombocytopenia (18.9%) for patients treated with tasisulam and neutropenia/leukopenia (8.7%) among those receiving paclitaxel.  There were 13 possibly related deaths reported to occur on the study, with the majority occurring during cycle 2 in the setting of grade 4 myelosuppression, all in the tasisulam arm.  Investigation of the unexpectedly high rate of hematol. toxicity revealed a subset of patients with low tasisulam clearance, leading to drug accumulation and high albumin-cor. exposure in cycle 2.  CONCLUSIONS : Although the study was stopped early because of safety issues in the tasisulam arm, tasisulam was considered unlikely to be superior to paclitaxel, and paclitaxel activity in the second-line treatment of melanoma was much lower than expected.  The toxicity imbalance was attributed to an unexpectedly low tasisulam clearance in a subset of patients, underscoring the importance of pharmacokinetic monitoring of compds. with complex dosing, even in late-phase studies.  Cancer 2014;120:2016-2024. © 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHr_f6DAfpzbVg90H21EOLACvtfcHk0lhREZQvUHDfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWktr3E&md5=96830e138ca2b73dfc47dffdb56c121e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28635%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DIlaria%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHahka-Kemppinen%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DTurner%26aufirst%3DP.%2BK.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Randomized%252C%2520Open-Label%2520Clinical%2520Trial%2520of%2520Tasisulam%2520Sodium%2520versus%2520Paclitaxel%2520as%2520Second-Line%2520Treatment%2520in%2520Patients%2520with%2520Metastatic%2520Melanoma%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D2016%26epage%3D2024%26doi%3D10.1002%2Fcncr.28635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassanpour, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehghani, M.</span></span> <span> </span><span class="NLM_article-title">Review of Cancer from Perspective of Molecular</span>. <i>Journal of Cancer Research and Practice</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.jcrpr.2017.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jcrpr.2017.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=127-129&author=S.+H.+Hassanpourauthor=M.+Dehghani&title=Review+of+Cancer+from+Perspective+of+Molecular&doi=10.1016%2Fj.jcrpr.2017.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.jcrpr.2017.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcrpr.2017.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHassanpour%26aufirst%3DS.%2BH.%26aulast%3DDehghani%26aufirst%3DM.%26atitle%3DReview%2520of%2520Cancer%2520from%2520Perspective%2520of%2520Molecular%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Practice%26date%3D2017%26volume%3D4%26spage%3D127%26epage%3D129%26doi%3D10.1016%2Fj.jcrpr.2017.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Protein Kinase Inhibitors Including Palbociclib as Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.phrs.2016.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26995305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=249-275&author=R.+Roskoski&title=Cyclin-Dependent+Protein+Kinase+Inhibitors+Including+Palbociclib+as+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2016.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-275</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle progression.  The levels of the cell cycle CDKs are generally const. and their activities are controlled by cyclins, proteins whose levels oscillate during each cell cycle.  Addnl. CDK family members were subsequently discovered that play significant roles in a wide range of activities including the control of gene transcription, metab., and neuronal function.  In response to mitogenic stimuli, cells in the G1 phase of the cell cycle produce cyclins of the D type that activate CDK4/6.  These activated enzymes catalyze the monophosphorylation of the retinoblastoma protein.  Then CDK2-cyclin E catalyzes the hyperphosphorylation of Rb that promotes the release and activation of the E2F transcription factors, which in turn lead to the generation of several proteins required for cell cycle progression.  As a result, cells pass through the G1-restriction point and are committed to complete cell division.  CDK2-cyclin A, CDK1-cyclin A, and CDK1-cyclin B are required for S, G2, and M-phase progression.  Increased cyclin or CDK expression or decreased levels of endogenous CDK inhibitors such as INK4 or CIP/KIP have been obsd. in various cancers.  In contrast to the mutational activation of EGFR, Kit, or B-Raf in the pathogenesis of malignancies, mutations in the CDKs that cause cancers are rare.  Owing to their role in cell proliferation, CDKs represent natural targets for anticancer therapies.  Abemaciclib (LY2835219), ribociclib (Lee011), and palbociclib (Ibrance or PD0332991) target CDK4/6 with IC50 values in the low nanomolar range.  Palbociclib and other CDK inhibitors bind in the cleft between the small and large lobes of the CDKs and inhibit the binding of ATP.  Like ATP, palbociclib forms hydrogen bonds with residues in the hinge segment of the cleft.  Like the adenine base of ATP, palbociclib interacts with catalytic spine residues CS6 and CS7.  CDK antagonists are in clin. trials for the treatment of a variety of malignancies.  Significantly, palbociclib has been approved by the FDA for the treatment of hormone-receptor pos./human epidermal growth factor receptor-2 neg. breast cancer in conjunction with letrozole as a first-line therapy and with fulvestrant as a second-line treatment.  As inhibitors of the cell cycle, it is not surprising that one of their most common toxicities is myelosuppression with decreased neutrophil prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol0On7HAFtl7Vg90H21EOLACvtfcHk0lhQlOm5C_iKcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D&md5=0356807b16735e3903706eac10635bc7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DCyclin-Dependent%2520Protein%2520Kinase%2520Inhibitors%2520Including%2520Palbociclib%2520as%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D107%26spage%3D249%26epage%3D275%26doi%3D10.1016%2Fj.phrs.2016.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Kinases as Therapeutic Targets for Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+Cycle+Kinases+as+Therapeutic+Targets+for+Cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0lhQlOm5C_iKcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520Cycle%2520Kinases%2520as%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-Dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lhQlOm5C_iKcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-Dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26115571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVeis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+S%C3%A1nchez-Mart%C3%ADnezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Gelbert, Lawrence M.; Lallena, Maria Jose; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3420-3435</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sustained proliferative capacity is a hallmark of cancer.  In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate crit. checkpoints.  CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point.  This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compds. under clin. evaluation.  Chem. structures, structure activity relationships, and relevant preclin. properties will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwE7MEzEetPbVg90H21EOLACvtfcHk0liZWajQtFo0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVeis7fN&md5=d4451fdbfd0ef0b08165105b9c8a38dc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinomas by Inducing Apoptosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1674</span>– <span class="NLM_lpage">1681</span>, <span class="refDoi"> DOI: 10.1172/JCI3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+Novel+Cyclin-Dependent+Kinase+Inhibitor%2C+Suppresses+the+Growth+of+Head+and+Neck+Squamous+Cell+Carcinomas+by+Inducing+Apoptosis&doi=10.1172%2FJCI3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0liZWajQtFo0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520Novel%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%252C%2520Suppresses%2520the%2520Growth%2520of%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinomas%2520by%2520Inducing%2520Apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2FJCI3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcros, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulinoux, J. P.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.t01-2-00527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9030781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=527-536&author=L.+Meijerauthor=A.+Borgneauthor=O.+Mulnerauthor=J.+P.+Chongauthor=J.+J.+Blowauthor=N.+Inagakiauthor=M.+Inagakiauthor=J.+G.+Delcrosauthor=J.+P.+Moulinoux&title=Biochemical+and+Cellular+Effects+of+Roscovitine%2C+a+Potent+and+Selective+Inhibitor+of+the+Cyclin-Dependent+Kinases+cdc2%2C+cdk2+and+cdk5&doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5</span></div><div class="casAuthors">Meijer, Laurent; Borgne, Annie; Mulner, Odile; Chong, James P. J.; Blow, J. Julian; Inagaki, Naoyuki; Inagaki, Masaki; Delcros, Jean Guy; Moulinoux, Jacques Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (cdk) play an essential role in the intracellular control of the cell division cycle (cdc).  These kinases and their regulators are frequently deregulated in human tumors.  Enzymic screening has recently led to the discovery of specific inhibitors of cyclin-dependent kinases, such as butyrolactone I, flavopiridol and the purine olomoucine.  Among a series of C2, N6,N9-substituted adenines tested on purified cdc2/cyclin B, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (roscovitine) displays high efficiency and high selectivity towards some cyclin-dependent kinases.  The kinase specificity of roscovitine was investigated with 25 highly purified kinases (including protein kinase A, G and C isoforms, myosin light-chain kinase, casein kinase 2, insulin receptor tyrosine kinase, c-src, v-abl).  Most kinases are not significantly inhibited by roscovitine.  Cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 only are substantially inhibited (IC50 values of 0.65, 0.7, 0.7 and 0.2 μM, resp.).  Cdk4/cyclin D1 and cdk6/cyclin D2 are very poorly inhibited by roscovitine (IC50>100 μM).  Extracellular regulated kinases erk1 and erk2 are inhibited with an IC50 of 34 μM and 14 μM, resp.  Roscovitine reversibly arrests starfish oocytes and sea urchin embryos in late prophase.  Roscovitine inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg exts.  It blocks progesterone-induced oocyte maturation of Xenopus oocytes and in vivo phosphorylation of the elongation factor eEF-1.  Roscovitine inhibits the proliferation of mammalian cell lines with an av. IC50 of 16 μM.  In the presence of roscovitine L1210 cells arrest in G1 and accumulate in G2.  In vivo phosphorylation of vimentin on Ser55 by cdc2/cyclin B is inhibited by roscovitine.  Through its unique selectivity for some cyclin-dependent kinases, roscovitine provides a useful anti-mitotic reagent for cell cycle studies and may prove interesting to control cells with deregulated cdc2, cdk2 or cdk5 kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO61Tu2_0pWLVg90H21EOLACvtfcHk0liZWajQtFo0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVWiu7g%253D&md5=d55100def53ac8811e485d9d34c46b79</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.t01-2-00527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.t01-2-00527.x%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBorgne%26aufirst%3DA.%26aulast%3DMulner%26aufirst%3DO.%26aulast%3DChong%26aufirst%3DJ.%2BP.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DDelcros%26aufirst%3DJ.%2BG.%26aulast%3DMoulinoux%26aufirst%3DJ.%2BP.%26atitle%3DBiochemical%2520and%2520Cellular%2520Effects%2520of%2520Roscovitine%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520the%2520Cyclin-Dependent%2520Kinases%2520cdc2%252C%2520cdk2%2520and%2520cdk5%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D527%26epage%3D536%26doi%3D10.1111%2Fj.1432-1033.1997.t01-2-00527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cicenas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorokinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankunas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meskinyte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankevicius, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupinis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valius, M.</span></span> <span> </span><span class="NLM_article-title">Roscovitine in Cancer and Other Diseases</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26207228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12it7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=135&author=J.+Cicenasauthor=K.+Kalyanauthor=A.+Sorokinasauthor=E.+Stankunasauthor=J.+Levyauthor=I.+Meskinyteauthor=V.+Stankeviciusauthor=A.+Kaupinisauthor=M.+Valius&title=Roscovitine+in+Cancer+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Roscovitine in cancer and other diseases</span></div><div class="casAuthors">Cicenas, Jonas; Kalyan, Karthik; Sorokinas, Aleksandras; Stankunas, Edvinas; Levy, Josh; Meskinyte, Ingrida; Stankevicius, Vaidotas; Kaupinis, Algirdas; Valius, Mindaugas</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">135/1-135/12</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small mol. that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site.  It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6.  Roscovitine is widely used as a biol. tool in cell cycle, cancer, apoptosis and neurobiol. studies.  Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis.  This review focuses on the use of roscovitine in the disease model as well as clin. model research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5_9cy7XHJtrVg90H21EOLACvtfcHk0lhqcN05J0Jypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12it7rM&md5=452d3346e3361d657d3f4b5884b99db8</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DKalyan%26aufirst%3DK.%26aulast%3DSorokinas%26aufirst%3DA.%26aulast%3DStankunas%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DMeskinyte%26aufirst%3DI.%26aulast%3DStankevicius%26aufirst%3DV.%26aulast%3DKaupinis%26aufirst%3DA.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DRoscovitine%2520in%2520Cancer%2520and%2520Other%2520Diseases%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26spage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lhqcN05J0Jypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detjen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Coy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosslet, K.</span></span> <span> </span><span class="NLM_article-title">Molecular and Pharmacodynamic Characteristics of the Novel Multi-Target Tumor Growth Inhibitor ZK 304709</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2006.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.biopha.2006.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16887322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=269-272&author=G.+Siemeisterauthor=U.+Lueckingauthor=C.+Wagnerauthor=K.+Detjenauthor=C.+Mc+Coyauthor=K.+Bosslet&title=Molecular+and+Pharmacodynamic+Characteristics+of+the+Novel+Multi-Target+Tumor+Growth+Inhibitor+ZK+304709&doi=10.1016%2Fj.biopha.2006.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709</span></div><div class="casAuthors">Siemeister, G.; Luecking, U.; Wagner, C.; Detjen, K.; Mc Coy, C.; Bosslet, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">269-272</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier SAS</span>)
        </div><div class="casAbstract">Loss of cell cycle control and tumor-induced neovascularization are major drivers of human tumor growth.  The multi-target tumor growth inhibitor ZK 304709 is a nanomolar inhibitor of cyclin-dependent kinases 1, 2, 4, 7 and 9, as well as vascular endothelial growth factor receptor tyrosine kinase 1-3 and of platelet-derived growth factor receptor β tyrosine kinase.  The multi-targeted mode of action of ZK 304709 acting on cell cycle and angiogenesis resulted in superior efficacy compared to std. chemotherapeutic compds. both in s.c. human tumor xenografts as well as orthotopic human pancreatic carcinoma models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgwXX1ZRgTYLVg90H21EOLACvtfcHk0lhqcN05J0Jypw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWms7Y%253D&md5=6d8b6528242d0e9d5a2462229c61aac4</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2006.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2006.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DDetjen%26aufirst%3DK.%26aulast%3DMc%2BCoy%26aufirst%3DC.%26aulast%3DBosslet%26aufirst%3DK.%26atitle%3DMolecular%2520and%2520Pharmacodynamic%2520Characteristics%2520of%2520the%2520Novel%2520Multi-Target%2520Tumor%2520Growth%2520Inhibitor%2520ZK%2520304709%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2006%26volume%3D60%26spage%3D269%26epage%3D272%26doi%3D10.1016%2Fj.biopha.2006.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detjen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedenmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, J.</span></span> <span> </span><span class="NLM_article-title">Open-Label, Non-Randomised, Inter-Individual Dose Escalation of ZK 304709 with the Evaluation of Safety, Tolerability, Pharmacokinetics, Oral Bioavailability and Orientating Efficacy after Daily Administration in Patients with Advanced Cancer (7 d Treatment and 14 d Recovery)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2162</span>– <span class="NLM_lpage">2168</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2008.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejca.2008.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18653327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sis73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=2162-2168&author=J.+S.+Grahamauthor=R.+Plummerauthor=C.+McCoyauthor=K.+Kowalauthor=H.+Wiesingerauthor=K.+Detjenauthor=H.+Calvertauthor=B.+Wiedenmannauthor=J.+Cassidy&title=Open-Label%2C+Non-Randomised%2C+Inter-Individual+Dose+Escalation+of+ZK+304709+with+the+Evaluation+of+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+Oral+Bioavailability+and+Orientating+Efficacy+after+Daily+Administration+in+Patients+with+Advanced+Cancer+%287+d+Treatment+and+14+d+Recovery%29&doi=10.1016%2Fj.ejca.2008.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)</span></div><div class="casAuthors">Graham, Janet S.; Plummer, Ruth; McCoy, Candice; Kowal, Kristin; Wiesinger, Herbert; Detjen, Katharina; Calvert, Hilary; Wiedenmann, Bertram; Cassidy, Jim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2162-2168</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The primary objectives of this study were to det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ZK 304709, a novel multi-targeted growth inhibitor (MTGI), in man.  Secondary end-points included safety evaluation, tolerability, pharmacokinetic profiling and assessment of response using std. and novel surrogate pharmacodynamic end-points.  Patients (n = 40) with advanced solid malignancies were treated with ZK 304709, administered orally once daily for 7 d with 14 d recovery.  Doses were escalated in sequential cohorts of three patients with expansion to 6-7 patients should a dose-limiting toxicity occur.  ZK 304709 was safely administered up to 360 mg.  However, above 90 mg blood concns. increased only slightly.  As this dose was not deemed likely to result in meaningful pharmacol. or clin. activity, the trial was stopped before the MTD was ascertained.  It was therefore not possible to make a reliable assessment of efficacy or pharmacodynamic end-points.  Due to the lack of further increment in blood concns. above a dose of 90 mg, which was felt from previous animal studies to be unlikely to result in meaningful pharmacol. or clin. activity, this study was stopped early.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQcjQ5EPkn7Vg90H21EOLACvtfcHk0lg6Rxn5BlSxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sis73I&md5=cf889c430e869cbcb528a89f2bab793e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2008.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2008.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DDetjen%26aufirst%3DK.%26aulast%3DCalvert%26aufirst%3DH.%26aulast%3DWiedenmann%26aufirst%3DB.%26aulast%3DCassidy%26aufirst%3DJ.%26atitle%3DOpen-Label%252C%2520Non-Randomised%252C%2520Inter-Individual%2520Dose%2520Escalation%2520of%2520ZK%2520304709%2520with%2520the%2520Evaluation%2520of%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520Oral%2520Bioavailability%2520and%2520Orientating%2520Efficacy%2520after%2520Daily%2520Administration%2520in%2520Patients%2520with%2520Advanced%2520Cancer%2520%25287%2520d%2520Treatment%2520and%252014%2520d%2520Recovery%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D2162%26epage%3D2168%26doi%3D10.1016%2Fj.ejca.2008.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bono, J.</span></span> <span> </span><span class="NLM_article-title">A Phase I Dose Escalation Study of the Pharmacokinetics and Tolerability of ZK 304709, an Oral Multi-Targeted Growth Inhibitor (MTGI), in Patients with Advanced Solid Tumours</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-0968-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00280-009-0968-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19280191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=425-429&author=E.+N.+Scottauthor=A.+L.+Thomasauthor=L.+R.+Molifeauthor=S.+Ahmedauthor=S.+Blagdenauthor=P.+C.+Fongauthor=K.+Kowalauthor=C.+McCoyauthor=H.+Wiesingerauthor=W.+Stewardauthor=J.+De+Bono&title=A+Phase+I+Dose+Escalation+Study+of+the+Pharmacokinetics+and+Tolerability+of+ZK+304709%2C+an+Oral+Multi-Targeted+Growth+Inhibitor+%28MTGI%29%2C+in+Patients+with+Advanced+Solid+Tumours&doi=10.1007%2Fs00280-009-0968-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours</span></div><div class="casAuthors">Scott, Edwina N.; Thomas, Anne L.; Molife, L. Rhoda; Ahmed, Samreen; Blagden, Sarah; Fong, Peter C.; Kowal, Kristin; McCoy, Candice; Wiesinger, Herbert; Steward, Will; De Bono, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">425-429</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery.  Methods: Patients with solid tumors resistant to std. treatments were enrolled in an accelerated titrn. design.  Results: Thirty-seven patients received ZK 304709 from 15 to 285 mg daily.  The most common drug-related adverse events were vomiting, diarrhea and fatigue.  Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses.  Thirteen patients had stable disease as best response as per RECIST criteria.  Conclusions: There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not detd.  This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHmxGlOkQx7Vg90H21EOLACvtfcHk0lg6Rxn5BlSxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1agurk%253D&md5=fe0e50036e3fc15838425c5f52e30426</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-0968-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-0968-y%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DE.%2BN.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DKowal%26aufirst%3DK.%26aulast%3DMcCoy%26aufirst%3DC.%26aulast%3DWiesinger%26aufirst%3DH.%26aulast%3DSteward%26aufirst%3DW.%26aulast%3DDe%2BBono%26aufirst%3DJ.%26atitle%3DA%2520Phase%2520I%2520Dose%2520Escalation%2520Study%2520of%2520the%2520Pharmacokinetics%2520and%2520Tolerability%2520of%2520ZK%2520304709%252C%2520an%2520Oral%2520Multi-Targeted%2520Growth%2520Inhibitor%2520%2528MTGI%2529%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26spage%3D425%26epage%3D429%26doi%3D10.1007%2Fs00280-009-0968-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span> <span> </span><span class="NLM_article-title">The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-Hydroxy-1-Methylpropyl]Oxy}-5-(Trifluoromethyl)Pyrimidin-2-yl]Amino}Phenyl)Sulfoximide (BAY 1000394) for the Treatment of Cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1085</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201300096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23671017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFemsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1067-1085&author=U.+L%C3%BCckingauthor=R.+Jautelatauthor=M.+Kr%C3%BCgerauthor=T.+Brumbyauthor=P.+Lienauauthor=M.+Sch%C3%A4ferauthor=H.+Briemauthor=J.+Schulzeauthor=A.+Hillischauthor=A.+Reichelauthor=A.+M.+Wengnerauthor=G.+Siemeister&title=The+Lab+Oddity+Prevails%3A+Discovery+of+Pan-CDK+Inhibitor+%28R%29-S-Cyclopropyl-S-%284-%7B%5B4-%7B%5B%281R%2C2R%29-2-Hydroxy-1-Methylpropyl%5DOxy%7D-5-%28Trifluoromethyl%29Pyrimidin-2-yl%5DAmino%7DPhenyl%29Sulfoximide+%28BAY+1000394%29+for+the+Treatment+of+Cancer&doi=10.1002%2Fcmdc.201300096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Jautelat, Rolf; Krueger, Martin; Brumby, Thomas; Lienau, Philip; Schaefer, Martina; Briem, Hans; Schulze, Julia; Hillisch, Alexander; Reichel, Andreas; Wengner, Antje Margret; Siemeister, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-1085</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK 304709 (I), a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclin. profile.  Nevertheless, I failed in phase I studies due to dose-limited absorption and high inter-patient variability, which was attributed to limited aq. soly. and off-target activity against carbonic anhydrases.  Further lead optimization efforts to address the off-target activity profile finally resulted in the introduction of a sulfoximine group, which is still a rather unusual approach in medicinal chem.  However, the sulfoximine series of compds. quickly revealed very interesting properties, culminating in the identification of the nanomolar pan-CDK inhibitor BAY 1000394 (II), which is currently being investigated in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMw3zOAyohGbVg90H21EOLACvtfcHk0lg6Rxn5BlSxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFemsbo%253D&md5=28b7bc5cb05381908f19d099460d925e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300096%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DBrumby%26aufirst%3DT.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DSchulze%26aufirst%3DJ.%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26atitle%3DThe%2520Lab%2520Oddity%2520Prevails%253A%2520Discovery%2520of%2520Pan-CDK%2520Inhibitor%2520%2528R%2529-S-Cyclopropyl-S-%25284-%257B%255B4-%257B%255B%25281R%252C2R%2529-2-Hydroxy-1-Methylpropyl%255DOxy%257D-5-%2528Trifluoromethyl%2529Pyrimidin-2-yl%255DAmino%257DPhenyl%2529Sulfoximide%2520%2528BAY%25201000394%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1067%26epage%3D1085%26doi%3D10.1002%2Fcmdc.201300096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bömer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rühter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&author=U.+L%C3%BCckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+B%C3%B6merauthor=M.+Sch%C3%A4ferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+R%C3%BChterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+Atuveciclib+%28BAY+1143572%29%2C+the+First+Highly+Selective%2C+Clinical+PTEFb%2FCDK9+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0lizdkZ2tm6J3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DB%25C3%25B6mer%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DR%25C3%25BChter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Atuveciclib%2520%2528BAY%25201143572%2529%252C%2520the%2520First%2520Highly%2520Selective%252C%2520Clinical%2520PTEFb%252FCDK9%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&author=G.+Siemeisterauthor=U.+L%C3%BCckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+1000394%2C+a+Novel+Cyclin-Dependent+Kinase+Inhibitor%2C+with+Potent+Antitumor+Activity+in+Mono-+and+in+Combination+Treatment+upon+Oral+Application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0lizdkZ2tm6J3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%25201000394%252C%2520a%2520Novel%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%252C%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Mono-%2520and%2520in%2520Combination%2520Treatment%2520upon%2520Oral%2520Application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span>Identifier:
NCT02522910. <a href="https://clinicaltrials.gov/ct2/show/NCT02522910" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02522910</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02522910.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02522910+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dy, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span> <span> </span><span class="NLM_article-title">Phase Ib/II Study of the Pan-Cyclin-Dependent Kinase Inhibitor Roniciclib in Combination with Chemotherapy in Patients with Extensive-Disease Small-Cell Lung Cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.lungcan.2018.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30089585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2018&pages=14-21&author=B.+C.+Choauthor=G.+K.+Dyauthor=R.+Govindanauthor=D.+W.+Kimauthor=N.+A.+Pennellauthor=G.+Zalcmanauthor=B.+Besseauthor=J.+H.+Kimauthor=G.+Kocaauthor=P.+Rajagopalanauthor=S.+Langerauthor=M.+Ockerauthor=H.+Nogaiauthor=F.+Barlesi&title=Phase+Ib%2FII+Study+of+the+Pan-Cyclin-Dependent+Kinase+Inhibitor+Roniciclib+in+Combination+with+Chemotherapy+in+Patients+with+Extensive-Disease+Small-Cell+Lung+Cancer&doi=10.1016%2Fj.lungcan.2018.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer</span></div><div class="casAuthors">Cho Byoung Chul; Dy Grace K; Govindan Ramaswamy; Kim Dong-Wan; Pennell Nathan A; Zalcman Gerard; Besse Benjamin; Kim Joo-Hang; Koca Goekben; Ocker Matthias; Nogai Hendrik; Rajagopalan Prabhu; Langer Simon; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).  PATIENTS AND METHODS:  In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule.  Cisplatin 75 mg/m(2) or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m(2) on days 1-3, of 21-day cycles.  Phase Ib used a dose-escalation design to define the MTD for phase II.  Pharmacokinetics were assessed.  RESULTS:  Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]).  The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP.  Common adverse events were nausea (90.7%) and vomiting (69.8%).  Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5-1 h), with a 30-40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics.  The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).  CONCLUSION:  Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy.  An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS891qx-r3xr-b6AVA-44PTfW6udTcc2ebSnVd4__RO47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7mt1yrtg%253D%253D&md5=ec4e685886d5caf2a6db31b0364cdc2b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPennell%26aufirst%3DN.%2BA.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKoca%26aufirst%3DG.%26aulast%3DRajagopalan%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DNogai%26aufirst%3DH.%26aulast%3DBarlesi%26aufirst%3DF.%26atitle%3DPhase%2520Ib%252FII%2520Study%2520of%2520the%2520Pan-Cyclin-Dependent%2520Kinase%2520Inhibitor%2520Roniciclib%2520in%2520Combination%2520with%2520Chemotherapy%2520in%2520Patients%2520with%2520Extensive-Disease%2520Small-Cell%2520Lung%2520Cancer%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D123%26spage%3D14%26epage%3D21%26doi%3D10.1016%2Fj.lungcan.2018.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span>Identifier:
NCT01188252. <a href="https://clinicaltrials.gov/ct2/show/NCT01188252" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01188252</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01188252.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01188252+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span> <span> </span><span class="NLM_article-title">CYCLINg through Transcription: Posttranslational Modifications of P-TEFb Regulate Transcription Elongation</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.4161/cc.9.9.11346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4161%2Fcc.9.9.11346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20436276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12itrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1697-1705&author=S.+Choauthor=S.+Schroederauthor=M.+Ott&title=CYCLINg+through+Transcription%3A+Posttranslational+Modifications+of+P-TEFb+Regulate+Transcription+Elongation&doi=10.4161%2Fcc.9.9.11346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">CYCLINg through transcription: Posttranslational modifications of P-TEFb regulate transcription elongation</span></div><div class="casAuthors">Cho, Sungyoo; Schroeder, Sebastian; Ott, Melanie</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The cyclin T/CDK9 complex, also called pos. transcription elongation factor b (P-TEFb) phosphorylates the C-terminal domain of the large fragment of the RNA polymerase II.  This action is a hallmark of the transition from transcription initiation to elongation.  P-TEFb is itself modified by phosphorylation and ubiquitination.  Recently, the core components of P-TEFb, cyclin T1 and CDK9, were identified as novel substrates of histone acetyltransferases.  Here, we review how posttranslational modifications regulate the activity of the P-TEFb complex and discuss how acetylation of the complex optimizes transcription elongation in the context of other posttranslational modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewigj-ZyWYLVg90H21EOLACvtfcHk0ljEXZwo_hb-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12itrrN&md5=740e639378f047ae7f2a5c59fcdca72b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.9.11346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.9.11346%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DOtt%26aufirst%3DM.%26atitle%3DCYCLINg%2520through%2520Transcription%253A%2520Posttranslational%2520Modifications%2520of%2520P-TEFb%2520Regulate%2520Transcription%2520Elongation%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D1697%26epage%3D1705%26doi%3D10.4161%2Fcc.9.9.11346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, R.</span></span> <span> </span><span class="NLM_article-title">Perspective of Cyclin-Dependent Kinase 9 (CDK9) as a Drug Target</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2883</span>– <span class="NLM_lpage">2890</span>, <span class="refDoi"> DOI: 10.2174/138161212800672750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F138161212800672750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22571657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFaltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2883-2890&author=V.+Krystofauthor=S.+Baumliauthor=R.+F%C3%BCrst&title=Perspective+of+Cyclin-Dependent+Kinase+9+%28CDK9%29+as+a+Drug+Target&doi=10.2174%2F138161212800672750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target</span></div><div class="casAuthors">Krystof, Vladimir; Baumli, Sonja; Furst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2883-2890</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review,.  The deregulation of cyclin-dependent kinases (CDKs) has been assocd. with many cancer types and has evoked an interest in chem. inhibitors with possible therapeutic benefit.  While most known inhibitors display broad selectivity toward multiple CDKs, recent work highlights CDK9 as the crit. target responsible for the anticancer activity of clin. evaluated drugs.  Here, the authors discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 toward applications in cancer therapy.  The authors also highlight the role of CDK9 in inflammatory processes and diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppF9ic2C9FM7Vg90H21EOLACvtfcHk0ljEXZwo_hb-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFaltrw%253D&md5=27c49385a4c0fab8b0ce6bfbef49cc5b</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F138161212800672750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672750%26sid%3Dliteratum%253Aachs%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DPerspective%2520of%2520Cyclin-Dependent%2520Kinase%25209%2520%2528CDK9%2529%2520as%2520a%2520Drug%2520Target%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2883%26epage%3D2890%26doi%3D10.2174%2F138161212800672750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Overview of CDK9 as a Target in Cancer Research</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+Target+in+Cancer+Research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0ljEXZwo_hb-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520Target%2520in%2520Cancer%2520Research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span>Identifier:
NCT02345382. <a href="https://clinicaltrials.gov/ct2/show/NCT02345382" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02345382</a> (Accessed Sep
29, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02345382.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02345382+%28Accessed+Sep%0A29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span>Identifier:
NCT01938638. <a href="https://clinicaltrials.gov/ct2/show/NCT01938638" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01938638</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01938638.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01938638+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Bömer, U.</span></span> <span> </span><span class="NLM_article-title">Disubstituted 5-Fluoro Pyrimidine Derivatives Containing a Sulfondiimine Group</span>. <span class="NLM_patent">WO/2015/150273</span>, Oct 8, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=U.+L%C3%BCcking&author=A.+Scholz&author=P.+Lienau&author=G.+Siemeister&author=R.+Bohlmann&author=U.+B%C3%B6mer&title=Disubstituted+5-Fluoro+Pyrimidine+Derivatives+Containing+a+Sulfondiimine+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26atitle%3DDisubstituted%25205-Fluoro%2520Pyrimidine%2520Derivatives%2520Containing%2520a%2520Sulfondiimine%2520Group%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span>Identifier:
NCT02745743. <a href="https://clinicaltrials.gov/ct2/show/NCT02745743" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02745743</a> (Accessed Sep
29, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02745743.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02745743+%28Accessed+Sep%0A29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span>Identifier:
NCT02635672. <a href="https://www.clinicaltrials.gov/ct2/show/NCT02635672" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02635672</a> (Accessed Sep 26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02635672.+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02635672+%28Accessed+Sep+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the DNA Damage Response in Cancer</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.molcel.2015.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26590714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyqtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=547-560&author=M.+J.+O%E2%80%99Connor&title=Targeting+the+DNA+Damage+Response+in+Cancer&doi=10.1016%2Fj.molcel.2015.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Damage Response in Cancer</span></div><div class="casAuthors">O'Connor, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-560</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">An underlying hallmark of cancers is their genomic instability, which is assocd. with a greater propensity to accumulate DNA damage.  Historical treatment of cancer by radiotherapy and DNA-damaging chemotherapy is based on this principle, yet it is accompanied by significant collateral damage to normal tissue and unwanted side effects.  Targeted therapy based on inhibiting the DNA damage response (DDR) in cancers offers the potential for a greater therapeutic window by tailoring treatment to patients with tumors lacking specific DDR functions.  The recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tumors harboring BRCA1 or BRCA2 mutations, represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles' heel.  This review highlights the different concepts behind targeting DDR in cancer and how this can provide significant opportunities for DDR-based therapies in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWZ64MrshabrVg90H21EOLACvtfcHk0lgN8rIYOcBDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyqtbvI&md5=b3f0d737d3e7dbf1f404b3f7658ab271</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520the%2520DNA%2520Damage%2520Response%2520in%2520Cancer%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D60%26spage%3D547%26epage%3D560%26doi%3D10.1016%2Fj.molcel.2015.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span> <span> </span><span class="NLM_article-title">DNA REPAIR. Drugging DNA Repair</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1179</span>, <span class="refDoi"> DOI: 10.1126/science.aab0958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.aab0958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27257245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFWnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&pages=1178-1179&author=S.+P.+Jacksonauthor=T.+Helleday&title=DNA+REPAIR.+Drugging+DNA+Repair&doi=10.1126%2Fscience.aab0958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging DNA repair</span></div><div class="casAuthors">Jackson, Stephen P.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">6290</span>),
    <span class="NLM_cas:pages">1178-1179</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCagmHvG64VrVg90H21EOLACvtfcHk0lgN8rIYOcBDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFWnsbc%253D&md5=d5ee2615d0034d26060761f921791a70</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab0958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab0958%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DDNA%2520REPAIR.%2520Drugging%2520DNA%2520Repair%26jtitle%3DScience%26date%3D2016%26volume%3D352%26spage%3D1178%26epage%3D1179%26doi%3D10.1126%2Fscience.aab0958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfettini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Cell Death by Mitotic Catastrophe: A Molecular Definition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fsj.onc.1207528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15077146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFKmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=2825-2837&author=M.+Castedoauthor=J.+L.+Perfettiniauthor=T.+Roumierauthor=K.+Andreauauthor=R.+Medemaauthor=G.+Kroemer&title=Cell+Death+by+Mitotic+Catastrophe%3A+A+Molecular+Definition&doi=10.1038%2Fsj.onc.1207528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death by mitotic catastrophe: a molecular definition</span></div><div class="casAuthors">Castedo, Maria; Perfettini, Jean-Luc; Roumier, Thomas; Andreau, Karine; Medema, Rene; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2825-2837</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The current literature is devoid of a clearcut definition of mitotic catastrophe, a type of cell death that occurs during mitosis.  Here, we propose that mitotic catastrophe results from a combination of deficient cell-cycle checkpoints (in particular the DNA structure checkpoints and the spindle assembly checkpoint) and cellular damage.  Failure to arrest the cell cycle before or at mitosis triggers an attempt of aberrant chromosome segregation, which culminates in the activation of the apoptotic default pathway and cellular demise.  Cell death occurring during the metaphase/anaphase transition is characterized by the activation of caspase-2 (which can be activated in response to DNA damage) and/or mitochondrial membrane permeabilization with the release of cell death effectors such as apoptosis-inducing factor and the caspase-9 and-3 activator cytochrome c.  Although the morphol. aspect of apoptosis may be incomplete, these alterations constitute the biochem. hallmarks of apoptosis.  Cells that fail to execute an apoptotic program in response to mitotic failure are likely to divide asym. in the next round of cell division, with the consequent generation of aneuploid cells.  This implies that disabling of the apoptotic program may actually favor chromosomal instability, through the suppression of mitotic catastrophe.  Mitotic catastrophe thus may be conceived as a mol. device that prevents aneuploidization, which may participate in oncogenesis.  Mitotic catastrophe is controlled by numerous mol. players, in particular, cell-cycle-specific kinases (such as the cyclin B1-dependent kinase Cdk1, polo-like kinases and Aurora kinases), cell-cycle checkpoint proteins, survivin, p53, caspases and members of the Bcl-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aIJ_tZK95bVg90H21EOLACvtfcHk0lgN8rIYOcBDPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFKmsLo%253D&md5=3b32e733e56e6e9b682fd44b38050d9e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207528%26sid%3Dliteratum%253Aachs%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DPerfettini%26aufirst%3DJ.%2BL.%26aulast%3DRoumier%26aufirst%3DT.%26aulast%3DAndreau%26aufirst%3DK.%26aulast%3DMedema%26aufirst%3DR.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCell%2520Death%2520by%2520Mitotic%2520Catastrophe%253A%2520A%2520Molecular%2520Definition%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D2825%26epage%3D2837%26doi%3D10.1038%2Fsj.onc.1207528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Mitotic Catastrophe: A Mechanism for Avoiding Genomic Instability</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1038/nrm3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21527953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=385-392&author=I.+Vitaleauthor=L.+Galluzziauthor=M.+Castedoauthor=G.+Kroemer&title=Mitotic+Catastrophe%3A+A+Mechanism+for+Avoiding+Genomic+Instability&doi=10.1038%2Fnrm3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic catastrophe: a mechanism for avoiding genomic instability</span></div><div class="casAuthors">Vitale, Ilio; Galluzzi, Lorenzo; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-392</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The improper distribution of chromosomes during mitosis compromises cellular functions and can reduce cellular fitness or contribute to malignant transformation.  As a countermeasure, higher eukaryotes have developed strategies for eliminating mitosis-incompetent cells, one of which is mitotic catastrophe.  Mitotic catastrophe is driven by a complex and poorly understood signalling cascade but, from a functional perspective, it can be defined as an oncosuppressive mechanism that precedes (and is distinct from) apoptosis, necrosis or senescence.  Accordingly, the disruption of mitotic catastrophe ppts. tumorigenesis and cancer progression, and its induction constitutes a therapeutic endpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_SWBPBcc957Vg90H21EOLACvtfcHk0lgxn52-11O4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D&md5=1af21f749fca1bf75d526c38a75df61b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrm3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3115%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMitotic%2520Catastrophe%253A%2520A%2520Mechanism%2520for%2520Avoiding%2520Genomic%2520Instability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D385%26epage%3D392%26doi%3D10.1038%2Fnrm3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sancar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsey-Boltz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unsal-Kaçmaz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev.biochem.73.011303.073723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15189136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=39-85&author=A.+Sancarauthor=L.+A.+Lindsey-Boltzauthor=K.+Unsal-Ka%C3%A7mazauthor=S.+Linn&title=Molecular+Mechanisms+of+Mammalian+DNA+Repair+and+the+DNA+Damage+Checkpoints&doi=10.1146%2Fannurev.biochem.73.011303.073723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints</span></div><div class="casAuthors">Sancar, Aziz; Lindsey-Boltz, Laura A.; Uensal-Kacmaz, Keziban; Linn, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-85</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  DNA damage is a relatively common event in the life of a cell and may lead to mutation, cancer, and cellular or organismic death.  Damage to DNA induces several cellular responses that enable the cell either to eliminate or cope with the damage or to activate a programmed cell death process, presumably to eliminate cells with potentially catastrophic mutations.  These DNA damage response reactions include: (a) removal of DNA damage and restoration of the continuity of the DNA duplex; (b) activation of a DNA damage checkpoint, which arrests cell cycle progression so as to allow for repair and prevention of the transmission of damaged or incompletely replicated chromosomes: (c) transcriptional response, which causes changes in the transcription profile that may be beneficial to the cell; and (d) apoptosis, which eliminates heavily damaged or seriously deregulated cells.  DNA repair mechanisms include direct repair, base excision repair, nucleotide excision repair, double-strand break repair, and cross-link repair.  The DNA damage checkpoints employ damage sensor proteins, such as ATM, ATR, the Rad17-RFC complex, and the 9-1-1 complex, to detect DNA damage and to initiate signal transduction cascades that employ Chk1 and Chk2 Ser/Thr kinases and Cdc25 phosphatases.  The signal transducers activate p53 and inactivate cyclin-dependent kinases to inhibit cell cycle progression from G1 to S (the G1/S checkpoint), DNA replication (the intra-S checkpoint), or G2 to mitosis (the G2/M checkpoint).  In this review the mol. mechanisms of DNA repair and the DNA damage checkpoints in mammalian cells are analyzed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_p5BqBCbTf7Vg90H21EOLACvtfcHk0lgxn52-11O4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsrk%253D&md5=63f88da9f19d721af81defffba832615</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073723%26sid%3Dliteratum%253Aachs%26aulast%3DSancar%26aufirst%3DA.%26aulast%3DLindsey-Boltz%26aufirst%3DL.%2BA.%26aulast%3DUnsal-Ka%25C3%25A7maz%26aufirst%3DK.%26aulast%3DLinn%26aufirst%3DS.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Mammalian%2520DNA%2520Repair%2520and%2520the%2520DNA%2520Damage%2520Checkpoints%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D39%26epage%3D85%26doi%3D10.1146%2Fannurev.biochem.73.011303.073723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazinski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span> <span> </span><span class="NLM_article-title">Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway</span>. <i>Annu. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1146/annurev-genet-121415-121658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-genet-121415-121658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27617969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFensbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=155-173&author=S.+A.+Yazinskiauthor=L.+Zou&title=Functions%2C+Regulation%2C+and+Therapeutic+Implications+of+the+ATR+Checkpoint+Pathway&doi=10.1146%2Fannurev-genet-121415-121658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway</span></div><div class="casAuthors">Yazinski, Stephanie A.; Zou, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-173</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">The ATR (ATM and rad3-related) pathway is crucial for proliferation, responding to DNA replication stress and DNA damage.  This crit. signaling pathway is carefully orchestrated through a multistep process requiring initial priming of ATR prior to damage, recruitment of ATR to DNA damage lesions, activation of ATR signaling, and, finally, modulation of ATR activity through a variety of post-translational modifications.  Following activation, ATR functions in several vital cellular processes, including suppression of replication origin firing, promotion of deoxynucleotide synthesis and replication fork restart, prevention of double-stranded DNA break formation, and avoidance of replication catastrophe and mitotic catastrophe.  In many cancers, tumor cells have increased dependence on ATR signaling for survival, making ATR a promising target for cancer therapy.  Tumor cells compromised in DNA repair pathways or DNA damage checkpoints, cells reliant on homologous recombination, and cells with increased replication stress are particularly sensitive to ATR inhibition.  Understanding ATR signaling and modulation is essential to unraveling which tumors have increased dependence on ATR signaling as well as how the ATR pathway can best be exploited for targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqftgE3FgvtQLVg90H21EOLACvtfcHk0lgxn52-11O4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFensbfJ&md5=d05c2ace8255cabbaaa2c82c5c31784c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1146%2Fannurev-genet-121415-121658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-genet-121415-121658%26sid%3Dliteratum%253Aachs%26aulast%3DYazinski%26aufirst%3DS.%2BA.%26aulast%3DZou%26aufirst%3DL.%26atitle%3DFunctions%252C%2520Regulation%252C%2520and%2520Therapeutic%2520Implications%2520of%2520the%2520ATR%2520Checkpoint%2520Pathway%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D50%26spage%3D155%26epage%3D173%26doi%3D10.1146%2Fannurev-genet-121415-121658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span> <span> </span><span class="NLM_article-title">ATR: An Essential Regulator of Genome Integrity</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1038/nrm2450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm2450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18594563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosl2rsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=616-627&author=K.+A.+Cimprichauthor=D.+Cortez&title=ATR%3A+An+Essential+Regulator+of+Genome+Integrity&doi=10.1038%2Fnrm2450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">ATR: an essential regulator of genome integrity</span></div><div class="casAuthors">Cimprich, Karlene A.; Cortez, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">616-627</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genome maintenance is a const. concern for cells, and a coordinated response to DNA damage is required to maintain cellular viability and prevent disease.  The ataxia-telangiectasia mutated (ATM) and ATM and RAD3-related (ATR) protein kinases act as master regulators of the DNA-damage response by signaling to control cell-cycle transitions, DNA replication, DNA repair and apoptosis.  Recent studies have provided new insights into the mechanisms that control ATR activation, have helped to explain the overlapping but non-redundant activities of ATR and ATM in DNA-damage signaling, and have clarified the crucial functions of ATR in maintaining genome integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQNdqvNUR2-bVg90H21EOLACvtfcHk0lhghqw9JI6Peg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosl2rsb0%253D&md5=6257723ff4145b2aca32ca0707499ade</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrm2450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2450%26sid%3Dliteratum%253Aachs%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26aulast%3DCortez%26aufirst%3DD.%26atitle%3DATR%253A%2520An%2520Essential%2520Regulator%2520of%2520Genome%2520Integrity%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D616%26epage%3D627%26doi%3D10.1038%2Fnrm2450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fillery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thommes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6[1-(Methylsulfonyl)Cyclopropyl]Pyrim idin-2-yl}-1H-Indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy <i>in Vivo</i> Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2125</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6%5B1-%28Methylsulfonyl%29Cyclopropyl%5DPyrim+idin-2-yl%7D-1H-Indole+%28AZ20%29%3A+A+Potent+and+Selective+Inhibitor+of+ATR+Protein+Kinase+with+Monotherapy+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity</span></div><div class="casAuthors">Foote, Kevin M.; Blades, Kevin; Cronin, Anna; Fillery, Shaun; Guichard, Sylvie S.; Hassall, Lorraine; Hickson, Ian; Jacq, Xavier; Jewsbury, Philip J.; McGuire, Thomas M.; Nissink, J. Willem M.; Odedra, Rajesh; Page, Ken; Perkins, Paula; Suleman, Abid; Tam, Kin; Thommes, Pia; Broadhurst, Rebecca; Wood, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2125-2138</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways.  We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition.  Optimization from a high quality screening hit within tight SAR space led to compd. I (AZ20) which inhibits ATR immunopptd. from HeLa nuclear exts. with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.  Compd. I potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses.  At well tolerated doses I leads to significant growth inhibition of LoVo xenografts grown in nude mice.  Compd. I is a useful compd. to explore ATR pharmacol. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpY5_RVxXl9LVg90H21EOLACvtfcHk0lhghqw9JI6Peg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsr0%253D&md5=60d2f6fe78e2b82695198b9cba930ae7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6%255B1-%2528Methylsulfonyl%2529Cyclopropyl%255DPyrim%2520idin-2-yl%257D-1H-Indole%2520%2528AZ20%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520ATR%2520Protein%2520Kinase%2520with%2520Monotherapy%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foote, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odedra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9889</span>– <span class="NLM_lpage">9907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9889-9907&author=K.+M.+Footeauthor=J.+W.+M.+Nissinkauthor=T.+McGuireauthor=P.+Turnerauthor=S.+Guichardauthor=J.+W.+T.+Yatesauthor=A.+Lauauthor=K.+Bladesauthor=D.+Heathcoteauthor=R.+Odedraauthor=G.+Wilkinsonauthor=Z.+Wilsonauthor=C.+M.+Woodauthor=P.+J.+Jewsbury&title=Discovery+and+Characterization+of+AZD6738%2C+a+Potent+Inhibitor+of+Ataxia+Telangiectasia+Mutated+and+Rad3+Related+%28ATR%29+Kinase+with+Application+as+an+Anticancer+Agent&doi=10.1021%2Facs.jmedchem.8b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent</span></div><div class="casAuthors">Foote, Kevin M.; Nissink, J. Willem M.; McGuire, Thomas; Turner, Paul; Guichard, Sylvie; Yates, James W. T.; Lau, Alan; Blades, Kevin; Heathcote, Dan; Odedra, Rajesh; Wilkinson, Gary; Wilson, Zena; Wood, Christine M.; Jewsbury, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9889-9907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and assocd. DNA double-strand breaks.  Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clin. response by increasing replication stress.  Here the authors describe the development of the clin. candidate II (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclin. physicochem. and pharmacokinetic (PK) characteristics.  Compd. II was developed improving aq. soly. and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor I (AZ20).  The clin. candidate II has favorable human PK suitable for once or twice daily dosing and achieves biol. effective exposure at moderate doses.  Compd. II is currently being tested in multiple phase I/II trials as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr419z5SGLz_LVg90H21EOLACvtfcHk0lhghqw9JI6Peg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu77F&md5=992b9a9669f1e58926d3e7e4d4e816ba</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01187%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DMcGuire%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DP.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DJ.%2BW.%2BT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DC.%2BM.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520AZD6738%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Ataxia%2520Telangiectasia%2520Mutated%2520and%2520Rad3%2520Related%2520%2528ATR%2529%2520Kinase%2520with%2520Application%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9889%26epage%3D9907%26doi%3D10.1021%2Facs.jmedchem.8b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Conversion and Degradation Pathways of Sulfoximines</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5408</span>– <span class="NLM_lpage">5423</span>, <span class="refDoi"> DOI: 10.1039/C9CS00483A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC9CS00483A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31535112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSgu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=5408-5423&author=S.+Wiezorekauthor=P.+Lamersauthor=C.+Bolm&title=Conversion+and+Degradation+Pathways+of+Sulfoximines&doi=10.1039%2FC9CS00483A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion and degradation pathways of sulfoximines</span></div><div class="casAuthors">Wiezorek, Stefan; Lamers, Philip; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5408-5423</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In recent years, sulfoximines have received significant attention in both academia and industry.  This development has been reinforced by the introduction of new methods for prepg. and efficiently accessing key sulfur-based reagents allowing further functionalizations.  For all fields and in particular those related to pharmaceutical and agrochem. applications, the knowledge of potential degrdn. pathways of sulfoximines is vital.  Being aware of possible metabolites minimises the risks of late stage failures.  In this review, we describe chem. transformations in the lab. leading to sulfoximine degrdns.  Those include reductive and oxidative pathways as well as C-S bond cleavage reactions.  In a wide frame the intention of this summary is to provide a better understanding of decompn.-like reactions of sulfoximines thereby enabling a more focussed search and anal. of byproducts and potential metabolites in biorelevant systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe95QU-R9QSbVg90H21EOLACvtfcHk0ljpU_24aqAu0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSgu7vF&md5=d61b3464fcdf0b7966eaee26297e970a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1039%2FC9CS00483A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CS00483A%26sid%3Dliteratum%253Aachs%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DLamers%26aufirst%3DP.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DConversion%2520and%2520Degradation%2520Pathways%2520of%2520Sulfoximines%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D5408%26epage%3D5423%26doi%3D10.1039%2FC9CS00483A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span>Identifier:
NCT02264678. <a href="https://clinicaltrials.gov/ct2/show/NCT02264678" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02264678</a> (Accessed Dec
10, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02264678.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02264678+%28Accessed+Dec%0A10%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span>Identifier:
NCT02630199. <a href="https://clinicaltrials.gov/ct2/show/NCT02630199" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02630199</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02630199.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02630199+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span>Identifier:
NCT02223923. <a href="https://clinicaltrials.gov/ct2/show/NCT02223923" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02223923</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT02223923.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02223923+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span>Identifier:
NCT03462342. <a href="https://clinicaltrials.gov/ct2/show/NCT03462342" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03462342</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03462342.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03462342+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span>Identifier:
NCT03330847. <a href="https://clinicaltrials.gov/ct2/show/NCT03330847" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03330847</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03330847.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03330847+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span>Identifier:
NCT03328273. <a href="https://clinicaltrials.gov/ct2/show/NCT03328273" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03328273</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03328273.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03328273+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span>Identifier:
NCT03334617. <a href="https://clinicaltrials.gov/ct2/show/NCT03334617" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03334617</a> (Accessed Sep
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03334617.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03334617+%28Accessed+Sep%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, C. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartkamp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiezorek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkamp, A.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as ATR Inhibitors: Analogs of VE-821</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2659</span>– <span class="NLM_lpage">2662</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2017.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28479198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2659-2662&author=C.+M.+M.+Hendriksauthor=J.+Hartkampauthor=S.+Wiezorekauthor=A.-D.+Steinkampauthor=G.+Rossettiauthor=B.+L%C3%BCscherauthor=C.+Bolm&title=Sulfoximines+as+ATR+Inhibitors%3A+Analogs+of+VE-821&doi=10.1016%2Fj.bmcl.2017.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as ATR inhibitors: Analogs of VE-821</span></div><div class="casAuthors">Hendriks, Christine M. M.; Hartkamp, Joerg; Wiezorek, Stefan; Steinkamp, Anne-Dorothee; Rossetti, Giulia; Luescher, Bernhard; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2659-2662</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATM- and Rad3-related (ATR) kinases play a key role in DNA repair processes and thus ATR is an attractive target for cancer therapy.  Here the authors designed and synthesized sulfilimidoyl- and sulfoximidoyl-substituted analogs of the sulfone VE-821, a reported ATR inhibitor.  The properties of these analogs have been investigated by calcg. physicochem. parameters and studying their potential to specifically inhibit ATR in cells.  Prolonged inhibition of ATR by the analogs in a Burkitt lymphoma cell line resulted in enhanced DNA damage and a substantial amt. of apoptosis.  Together the authors' findings suggest that the sulfilimidoyl- and sulfoximidoyl-substituted analogs are efficient ATR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod6PEFPAEFrLVg90H21EOLACvtfcHk0ljpU_24aqAu0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFamsbk%253D&md5=0f008f6e8bffd2543fbf90fa8eb9f3cf</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DC.%2BM.%2BM.%26aulast%3DHartkamp%26aufirst%3DJ.%26aulast%3DWiezorek%26aufirst%3DS.%26aulast%3DSteinkamp%26aufirst%3DA.-D.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DSulfoximines%2520as%2520ATR%2520Inhibitors%253A%2520Analogs%2520of%2520VE-821%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2659%26epage%3D2662%26doi%3D10.1016%2Fj.bmcl.2017.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markandu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarfe, G.</span></span> <span> </span><span class="NLM_article-title">CYP-Mediated Sulfoximine Deimination of AZD6738</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.077776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fdmd.117.077776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28835442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=1133-1138&author=B.+C.+Jonesauthor=R.+Markanduauthor=C.+Guauthor=G.+Scarfe&title=CYP-Mediated+Sulfoximine+Deimination+of+AZD6738&doi=10.1124%2Fdmd.117.077776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">CYP-mediated sulfoximine deimination of AZD6738</span></div><div class="casAuthors">Jones, Barry C.; Markandu, Roshini; Gu, Chungang; Scarfe, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1133-1138</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In hepatic S9 and human liver microsomes (HLMs) the sulfoximine moiety of the ATR inhibitor AZD6738 is metabolized to its corresponding sulfoxide (AZ8982) and sulfone (AZ0002).  The initial deimination to AZ8982 is nominally a reductive reaction, but in HLMs it required both NADPH and oxygen and also was inhibited by 1-aminobenzotriazole at a concn. of 1 mM.  Studies conducted in a panel of 11 members of the cytochrome P 450 (P 450) family (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 CYP2J2, CYP3A4, and CYP3A5) confirmed that deimination was an oxidative process that was mediated largely by CYP2C8 with some CYP2J2 involvement, whereas the subsequent oxidn. to sulfone was carried out largely by CYP2J2, CYP3A4, and CYP3A5.  There was no measureable metab. in flavin-contg. monooxygenase (FMO) enzymes FMO3, FMO5 or NADPH cytochrome C reductase.  Studies using Silensomes, a com. available HLM in which specific members of the P 450 family have been inhibited by selective mechanism-based inhibitors, showed that when CYP2C8 was inhibited, the rate of deimination was reduced by 95%, suggesting that CYP2J2 is only playing a minor role in HLMs.  When CYP3A4 was inhibited, the rate increased by 58% due to the inhibition of the subsequent sulfone formation.  Correlation studies conducted in HLM samples from different individuals confirmed the role of CYP2C8 in the deimination over CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.  Hence, although nominally a redn., the deimination of AZD6738 to its sulfoxide metabolite AZ8982 is an oxidn. mediated by CYP2C8, and this metabolite is subsequently oxidized to the sulfone (AZ0002) largely by CYP3A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkjsC18qUf7Vg90H21EOLACvtfcHk0ljpU_24aqAu0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlehtrw%253D&md5=37babaa5f98d9aba9fe0788c3ccc290b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.077776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.077776%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMarkandu%26aufirst%3DR.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DScarfe%26aufirst%3DG.%26atitle%3DCYP-Mediated%2520Sulfoximine%2520Deimination%2520of%2520AZD6738%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D1133%26epage%3D1138%26doi%3D10.1124%2Fdmd.117.077776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">National Cancer Institute</span>. <a href="https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq#section/all" class="extLink">https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq#section/all</a> (Accessed Sep 19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Cancer+Institute.+https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fleukemia%2Fpatient%2Fchild-all-treatment-pdq%23section%2Fall+%28Accessed+Sep+19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greaves, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullighan, C. G.</span></span> <span> </span><span class="NLM_article-title">Acute Lymphoblastic Leukaemia</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1955</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)62187-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2812%2962187-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23523389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3svovFWisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=1943-1955&author=H.+Inabaauthor=M.+Greavesauthor=C.+G.+Mullighan&title=Acute+Lymphoblastic+Leukaemia&doi=10.1016%2FS0140-6736%2812%2962187-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Acute lymphoblastic leukaemia</span></div><div class="casAuthors">Inaba Hiroto; Greaves Mel; Mullighan Charles G</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">9881</span>),
    <span class="NLM_cas:pages">1943-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age.  Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles.  Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.  However, innovative approaches are needed to further improve survival while reducing adverse effects.  Prognosis remains poor in infants and adults.  Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvyNMEVGJXbeWhZTslLrfffW6udTcc2eakUs9TUT4prrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svovFWisA%253D%253D&md5=6a13740d2abd2b597f6e4f09a97b22cf</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2962187-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252962187-4%26sid%3Dliteratum%253Aachs%26aulast%3DInaba%26aufirst%3DH.%26aulast%3DGreaves%26aufirst%3DM.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DAcute%2520Lymphoblastic%2520Leukaemia%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D1943%26epage%3D1955%26doi%3D10.1016%2FS0140-6736%2812%2962187-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update</span>. <i>Blood Cancer Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e577</span>, <span class="refDoi"> DOI: 10.1038/bcj.2017.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fbcj.2017.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28665419" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e577&author=T.+Terwilligerauthor=M.+Abdul-Hay&title=Acute+Lymphoblastic+Leukemia%3A+A+Comprehensive+Review+and+2017+Update&doi=10.1038%2Fbcj.2017.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2017.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2017.53%26sid%3Dliteratum%253Aachs%26aulast%3DTerwilliger%26aufirst%3DT.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DAcute%2520Lymphoblastic%2520Leukemia%253A%2520A%2520Comprehensive%2520Review%2520and%25202017%2520Update%26jtitle%3DBlood%2520Cancer%2520Journal%26date%3D2017%26volume%3D7%26spage%3De577%26doi%3D10.1038%2Fbcj.2017.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunger, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruchel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goekbuget, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrappe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pui, C. H.</span></span> <span> </span><span class="NLM_article-title">L-Asparaginase Treatment in Acute Lymphoblastic Leukemia: A Focus on <i>Erwinia</i> Asparaginase</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1002/cncr.25489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcncr.25489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20824725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=238-249&author=R.+Pietersauthor=S.+P.+Hungerauthor=J.+Boosauthor=C.+Rizzariauthor=L.+Silvermanauthor=A.+Baruchelauthor=N.+Goekbugetauthor=M.+Schrappeauthor=C.+H.+Pui&title=L-Asparaginase+Treatment+in+Acute+Lymphoblastic+Leukemia%3A+A+Focus+on+Erwinia+Asparaginase&doi=10.1002%2Fcncr.25489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase</span></div><div class="casAuthors">Pieters, Rob; Hunger, Stephen P.; Boos, Joachim; Rizzari, Carmelo; Silverman, Lewis; Baruchel, Andre; Goekbuget, Nicola; Schrappe, Martin; Pui, Ching-Hon</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">238-249</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols.  Extensive clin. data have shown that intensive asparaginase treatment improves clin. outcomes in childhood ALL.  Three asparaginase prepns. are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG-asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase.  Clin. hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases.  Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL.  Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible.  Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols.  Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues.  This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2cX8iktXNrbVg90H21EOLACvtfcHk0liyOV6y4LbPDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yrsbs%253D&md5=3fe58f228c57c343666031618da60e07</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25489%26sid%3Dliteratum%253Aachs%26aulast%3DPieters%26aufirst%3DR.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DBoos%26aufirst%3DJ.%26aulast%3DRizzari%26aufirst%3DC.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBaruchel%26aufirst%3DA.%26aulast%3DGoekbuget%26aufirst%3DN.%26aulast%3DSchrappe%26aufirst%3DM.%26aulast%3DPui%26aufirst%3DC.%2BH.%26atitle%3DL-Asparaginase%2520Treatment%2520in%2520Acute%2520Lymphoblastic%2520Leukemia%253A%2520A%2520Focus%2520on%2520Erwinia%2520Asparaginase%26jtitle%3DCancer%26date%3D2011%26volume%3D117%26spage%3D238%26epage%3D249%26doi%3D10.1002%2Fcncr.25489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aghaiypour, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubkowski, J.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Activity and Substrate Specificity of <i>Erwinia chrysanthemi</i> L-Asparaginase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">5655</span>– <span class="NLM_lpage">5664</span>, <span class="refDoi"> DOI: 10.1021/bi0029595</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0029595" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislKhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=5655-5664&author=K.+Aghaiypourauthor=A.+Wlodawerauthor=J.+Lubkowski&title=Structural+Basis+for+the+Activity+and+Substrate+Specificity+of+Erwinia+chrysanthemi+L-Asparaginase&doi=10.1021%2Fbi0029595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase</span></div><div class="casAuthors">Aghaiypour, Khosrow; Wlodawer, Alexander; Lubkowski, Jacek</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5655-5664</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bacterial L-asparaginases, enzymes that catalyze the hydrolysis of L-asparagine to aspartic acid, have been used for over 30 yr as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.  Other substrates of asparaginases include L-glutamine, D-asparagine, and succinic acid monoamide.  Here, the authors present high-resoln. crystal structures of the complexes of E. chrysanthemi L-asparaginase (ErA) with the products of such reactions that also can serve as substrates, namely L-glutamic acid (L-Glu), D-aspartic acid (D-Asp), and succinic acid (Suc).  Comparison of the 4 independent active sites within each complex indicated unique and specific binding of the ligand mols.; the mode of binding was also similar between complexes.  The lack of the α-NH3+ group in Suc, compared to L-Asp, did not affect the binding mode.  The side-chain of L-Glu, larger than that of L-Asp, caused several structural distortions in the ErA active side.  The active site flexible loop (residues 15-33) did not exhibit a stable conformation, resulting in suboptimal orientation of the nucleophile, Thr-15.  Addnl., the δ-COO- plane of L-Glu was approx. perpendicular to the plane of γ-COO- in L-Asp bound to the asparaginase active site.  The binding of D-Asp to the ErA active site was very distinctive compared to the other ligands, suggesting that the low activity of ErA against D-Asp could be mainly attributed to the low kcat value.  A comparison of the amino acid sequence and the crystal structure of ErA with those of other bacterial L-asparaginases showed that the presence of 2 active site residues, Glu-63 and Ser-254, may correlate with significant glutaminase activity, whereas their substitution by Gln and Asn, resp., may lead to minimal L-glutaminase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlJZYG4GKFGbVg90H21EOLACvtfcHk0liyOV6y4LbPDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislKhsr4%253D&md5=a4dab6f94a3c0f771012c92afc56cfd9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fbi0029595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0029595%26sid%3Dliteratum%253Aachs%26aulast%3DAghaiypour%26aufirst%3DK.%26aulast%3DWlodawer%26aufirst%3DA.%26aulast%3DLubkowski%26aufirst%3DJ.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Activity%2520and%2520Substrate%2520Specificity%2520of%2520Erwinia%2520chrysanthemi%2520L-Asparaginase%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D5655%26epage%3D5664%26doi%3D10.1021%2Fbi0029595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kislitsin, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranova, I.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Structures of L-Asparaginase from <i>Erwinia carotovora</i> Complexed with Aspartate and Glutamate</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1107/S0907444907065766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1107%2FS0907444907065766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18323619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVaqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=248-256&author=O.+Kravchenkoauthor=Y.+A.+Kislitsinauthor=A.+Popovauthor=S.+Nikonovauthor=I.+Kuranova&title=Three-Dimensional+Structures+of+L-Asparaginase+from+Erwinia+carotovora+Complexed+with+Aspartate+and+Glutamate&doi=10.1107%2FS0907444907065766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structures of L-asparaginase from Erwinia carotovora complexed with aspartate and glutamate</span></div><div class="casAuthors">Kravchenko, O. V.; Kislitsin, Yu. A.; Popov, A. N.; Nikonov, S. V.; Kuranova, I. P.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-256</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The crystal structures of E. carotovora L-asparaginase (I) complexed with L-aspartate and L-glutamate were detd. at 1.9 and 2.2 Å, resp., using the mol.-replacement method and were refined to R factors of ∼21% in both cases.  The positions of the ligands in the active site were located.  A comparison of the new structures with the known structures of Escherichia coli I and Erwinia chrysanthemi I was performed.  It was found that the arrangement of the ligands practically coincided in all 3 enzymes.  The peculiarities of the quaternary structure of the enzyme, the possible role of water mols. in enzyme action, and the conformational changes during the catalyzed reaction were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWUGWrq1vkbVg90H21EOLACvtfcHk0ljlC6K16goHlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVaqtr0%253D&md5=1f8ffba849dbbea806b99dee1d74cbb6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1107%2FS0907444907065766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444907065766%26sid%3Dliteratum%253Aachs%26aulast%3DKravchenko%26aufirst%3DO.%26aulast%3DKislitsin%26aufirst%3DY.%2BA.%26aulast%3DPopov%26aufirst%3DA.%26aulast%3DNikonov%26aufirst%3DS.%26aulast%3DKuranova%26aufirst%3DI.%26atitle%3DThree-Dimensional%2520Structures%2520of%2520L-Asparaginase%2520from%2520Erwinia%2520carotovora%2520Complexed%2520with%2520Aspartate%2520and%2520Glutamate%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D248%26epage%3D256%26doi%3D10.1107%2FS0907444907065766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syrigou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makrilia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K. N.</span></span> <span> </span><span class="NLM_article-title">Hypersensitivity Reactions to Antineoplastic Agents: An Overview</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1097/CAD.0b013e32831961b3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FCAD.0b013e32831961b3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19342995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=1-6&author=E.+Syrigouauthor=N.+Makriliaauthor=I.+Kotiauthor=M.+W.+Saifauthor=K.+N.+Syrigos&title=Hypersensitivity+Reactions+to+Antineoplastic+Agents%3A+An+Overview&doi=10.1097%2FCAD.0b013e32831961b3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Hypersensitivity reactions to antineoplastic agents: an overview</span></div><div class="casAuthors">Syrigou, Ekaterini; Makrilia, Nektaria; Koti, Ioanna; Saif, Muhammad W.; Syrigos, Kostas N.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Hypersensitivity reactions to antineoplastic agents are defined as unexpected reactions with signs and symptoms inconsistent with known toxicity of antineoplastic drugs.  These reactions are uncommon and usually assocd. with certain antineoplastic categories, such as taxanes, platinum-contg. compds., epipodofyllotoxins, asparaginase, procarbazine and, more rarely, with doxorubicin and 6-mercaptopurine.  The mechanisms that are responsible for hypersensitivity reactions are unclear and vary between agents.  Symptoms of these reactions range from mild skin rashes to more severe reactions, such as arthralgia, respiratory arrest or even death in some cases.  Once hypersensitivity reactions are obsd., basic principles that allow their management and possible continuance and completion of the regimen should be followed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS-9pc34PLDbVg90H21EOLACvtfcHk0ljlC6K16goHlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVajsA%253D%253D&md5=a5c5dde4b31ba5836a1669c1797196d6</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e32831961b3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e32831961b3%26sid%3Dliteratum%253Aachs%26aulast%3DSyrigou%26aufirst%3DE.%26aulast%3DMakrilia%26aufirst%3DN.%26aulast%3DKoti%26aufirst%3DI.%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DSyrigos%26aufirst%3DK.%2BN.%26atitle%3DHypersensitivity%2520Reactions%2520to%2520Antineoplastic%2520Agents%253A%2520An%2520Overview%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2009%26volume%3D20%26spage%3D1%26epage%3D6%26doi%3D10.1097%2FCAD.0b013e32831961b3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asselin, B. L.</span></span> <span> </span><span class="NLM_article-title">The Three Asparaginases. Comparative Pharmacology and Optimal Use in Childhood Leukemia</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1007/978-1-4615-4811-9_69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2F978-1-4615-4811-9_69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10500842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3cXis1Ciurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=1999&pages=621-629&author=B.+L.+Asselin&title=The+Three+Asparaginases.+Comparative+Pharmacology+and+Optimal+Use+in+Childhood+Leukemia&doi=10.1007%2F978-1-4615-4811-9_69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia</span></div><div class="casAuthors">Asselin, Barbara L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">Drug Resistance in Leukemia and Lymphoma III</span>),
    <span class="NLM_cas:pages">621-629</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">Asparaginase (ASP) is a std. component of the antileukemia armamentarium.  There are currently 3 prepns. of asparaginase available: (1) E. coli (ASP, Elspar); (2) the enzyme derived from Erwinia chrysanthemi (ERW, Erwinase); (3) pegaspargase (PEG, Oncaspar), the E. coli enzyme modified by covalent attachment of polyethylene glycol.  This report describes the findings of 3 pharmacol. end points: ASP enzyme activity in patients' sera, depletion of asparagine and the development of anti-ASP antibodies.  Pharmacokinetics and pharmacodynamic studies in a group of naive children with newly diagnosed ALL demonstrate a significant difference in apparent half-life (1.24 days E. coli vs. 0.65 ERW vs. 5.73 PEG; p < 0.001) and days of asparagine depletion (14-23 E. coli vs. 7-15 ERW vs. 26-34 PEG; p < 0.01) for the 3 different prepns.  Data from Pediatric Oncol. Group (POG) Protocol #8866 show that high antibody levels correlated with rapid ASP clearance and a significantly lower response rate (NR = 26% vs. CR + PR+64%).  The pharmacol. characteristics of ASP in terms of clearance of enzyme activity and ability to deplete serum asparagine was dependent upon the nature of the enzyme and are significantly altered in patients who develop anti-ASP antibodies regardless of their clin. status.  In addn., these data demonstrate that ASP pharmacokinetics are directly related to its anti-leukemic effect.  In order to maximize the therapeutic benefits of ASP, the optimal dose and schedule of treatment should be detd. based on pharmacol. testing rather than by clin. alone.  Future studies will focus on the role of "silent hypersensitivity" as a mechanism of resistance to ASP and strategies to maximize the therapeutic efficacy of ASP as part of ALL therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNqT1YeegAbVg90H21EOLACvtfcHk0ljlC6K16goHlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXis1Ciurk%253D&md5=3e09955abd379f80c34dda98578a9fdb</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4811-9_69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-4811-9_69%26sid%3Dliteratum%253Aachs%26aulast%3DAsselin%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Three%2520Asparaginases.%2520Comparative%2520Pharmacology%2520and%2520Optimal%2520Use%2520in%2520Childhood%2520Leukemia%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D1999%26volume%3D457%26spage%3D621%26epage%3D629%26doi%3D10.1007%2F978-1-4615-4811-9_69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pui, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandlund, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaste, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubnitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onciu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kun, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handgretinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Relling, M. V.</span></span> <span> </span><span class="NLM_article-title">Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2741</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0900386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa0900386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19553647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1eit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2730-2741&author=C.+H.+Puiauthor=D.+Campanaauthor=D.+Peiauthor=W.+P.+Bowmanauthor=J.+T.+Sandlundauthor=S.+C.+Kasteauthor=R.+C.+Ribeiroauthor=J.+E.+Rubnitzauthor=S.+C.+Raimondiauthor=M.+Onciuauthor=E.+Coustan-Smithauthor=L.+E.+Kunauthor=S.+Jehaauthor=C.+Chengauthor=S.+C.+Howardauthor=V.+Simmonsauthor=A.+Baylesauthor=M.+L.+Metzgerauthor=J.+M.+Boyettauthor=W.+Leungauthor=R.+Handgretingerauthor=J.+R.+Downingauthor=W.+E.+Evansauthor=M.+V.+Relling&title=Treating+Childhood+Acute+Lymphoblastic+Leukemia+without+Cranial+Irradiation&doi=10.1056%2FNEJMoa0900386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Treating childhood acute lymphoblastic leukemia without cranial irradiation</span></div><div class="casAuthors">Pui, Ching-Hon; Campana, Dario; Pei, Deqing; Bowman, W. Paul; Sandlund, John T.; Kaste, Sue C.; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Raimondi, Sausana C.; Onciu, Mihaela; Coustan-Smith, Elaine; Kun, Larry E.; Jeha, Sima; Cheng, Cheng; Howard, Scott C.; Simmons, Vickey; Bayles, Amy; Metzger, Monika L.; Boyett, James M.; Leung, Wing; Handgretinger, Rupert; Downing, James R.; Evans, William E.; Relling, Mary V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2730-2741</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Prophylactic cranial irradn. has been a std. treatment with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.  METHODS We conducted a clin. trials to test whether prophylactic cranial irradn. could be omitted from treatment in all children with newly diagnosed ALL.  A total of 498 patients who could be evaluated were enrolled.  Treatment intensity was based on presenting features and the level of minimal residual disease after remission-induction treatment.  The duration of continuous complete remission in the 71 patients who previously would have received prophylactic cranial irradn. was compared with that of 56 historical controls who received it.  RESULTS The 5-yr event-free and overall survival probabilities for all 498 patients were 85.6% (95% confidence interval [CI], 79.9 to 91.3) and 93.5% (95% CI, 89.8 to 07.2), resp.  The 5-yr cumulative risk of isolated CNS relapse was 2.7% (95% CI, 1.1 to 4.3), and that of any CNS relapse (including isolated relapse and combined relapse) was 3.9% (95% CI, 1.9 to 5.9).  The 71 patients had significantly longer continuous complete remission than the 56 historical controls (P = 0.04).  All 11 patients with isolated CNS relapse remained in second remission for 0.4 to 5.5 years.  CNS leukemia (CNS-3 status) or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease (≥1%) after 6 wk of remission induction were significantly assocd. with poorer event-free survival.  Risk factors for CNS relapse included the genetic abnormality t(1;19)(TCF3-PBX1), any CNS involvement at diagnosis, and T-cell immunophenotype.  CONCLUSIONS With effective risk-adjusted chemotherapy, prophylactic cranial irradn. can be safely omitted from the treatment of childhood ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9PfSfNhQRRbVg90H21EOLACvtfcHk0lgPi7kcDEiIJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1eit78%253D&md5=3c815f963c3edd10df1686b3a6ef1b81</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900386%26sid%3Dliteratum%253Aachs%26aulast%3DPui%26aufirst%3DC.%2BH.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DBowman%26aufirst%3DW.%2BP.%26aulast%3DSandlund%26aufirst%3DJ.%2BT.%26aulast%3DKaste%26aufirst%3DS.%2BC.%26aulast%3DRibeiro%26aufirst%3DR.%2BC.%26aulast%3DRubnitz%26aufirst%3DJ.%2BE.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DOnciu%26aufirst%3DM.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DKun%26aufirst%3DL.%2BE.%26aulast%3DJeha%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DHoward%26aufirst%3DS.%2BC.%26aulast%3DSimmons%26aufirst%3DV.%26aulast%3DBayles%26aufirst%3DA.%26aulast%3DMetzger%26aufirst%3DM.%2BL.%26aulast%3DBoyett%26aufirst%3DJ.%2BM.%26aulast%3DLeung%26aufirst%3DW.%26aulast%3DHandgretinger%26aufirst%3DR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DRelling%26aufirst%3DM.%2BV.%26atitle%3DTreating%2520Childhood%2520Acute%2520Lymphoblastic%2520Leukemia%2520without%2520Cranial%2520Irradiation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2730%26epage%3D2741%26doi%3D10.1056%2FNEJMoa0900386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, J. i.</span></span> <span> </span><span class="NLM_article-title">A Potent Transition-State Analogue Inhibitor of <i>Escherichia coli</i> Asparagine Synthetase A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">5799</span>– <span class="NLM_lpage">5800</span>, <span class="refDoi"> DOI: 10.1021/ja990851a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja990851a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVKhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=1999&pages=5799-5800&author=M.+Koizumiauthor=J.+Hiratakeauthor=T.+Nakatsuauthor=H.+Katoauthor=J.+i.+Oda&title=A+Potent+Transition-State+Analogue+Inhibitor+of+Escherichia+coli+Asparagine+Synthetase+A&doi=10.1021%2Fja990851a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Transition-State Analogue Inhibitor of Escherichia coli Asparagine Synthetase A</span></div><div class="casAuthors">Koizumi, Mitsuteru; Hiratake, Jun; Nakatsu, Toru; Kato, Hiroaki; Oda, Jun'ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5799-5800</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">L-Asparagine synthetase [L-aspartate: ammonia ligase (AMP-forming) EC 6.3.1.1] (AS-A) from Escherichia coli is typical of ammonia-dependent asparagine synthetases and catalyzes the formation of L-Asn from L-Asp and ammonia with concomitant hydrolysis of ATP to AMP and pyrophosphate.  Asparagine synthetase is a potential target for cancer chemotherapy because asparagine depletion caused by the administration of L-asparaginase is a currently implemented protocol for the treatment of acute lymphoblastic leukemia.  It is therefore highly desirable to obtain good inhibitors of AS-A not only for use as a probe to define the detailed reaction mechanisms of asparagine synthetases but also for generating a lead for chemotherapeutic agents targeted toward the inhibition of asparagine biosynthesis.  For these purposes transition-state analogs are far more suitable than substrate analogs or intermediate mimics.  We now describe the synthesis and characterization of an N-adenylated S-methyl-L-cysteine sulfoximine as a transition-state analog.  This compd. serves as an extremely potent slow-binding inhibitor of E. coli AS-A with an overall inhibition const. of 67 nM.  An X-ray crystal structure of the enzyme-inhibitor complex reveals several key amino acid residues responsible for catalysis as well as residues responsible for substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2H0NO9uyK6rVg90H21EOLACvtfcHk0lgPi7kcDEiIJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVKhsbg%253D&md5=5a02295d58c673efc9e0b683017f8724</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fja990851a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja990851a%26sid%3Dliteratum%253Aachs%26aulast%3DKoizumi%26aufirst%3DM.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DNakatsu%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DJ.%2Bi.%26atitle%3DA%2520Potent%2520Transition-State%2520Analogue%2520Inhibitor%2520of%2520Escherichia%2520coli%2520Asparagine%2520Synthetase%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1999%26volume%3D121%26spage%3D5799%26epage%3D5800%26doi%3D10.1021%2Fja990851a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koroniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of Human Asparagine Synthetase Suppresses Proliferation of an L-Asparaginase-Resistant Leukemia Cell Line</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chembiol.2006.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17185229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1339-1347&author=J.+A.+Gutierrezauthor=Y.+X.+Panauthor=L.+Koroniakauthor=J.+Hiratakeauthor=M.+S.+Kilbergauthor=N.+G.+J.+Richards&title=An+Inhibitor+of+Human+Asparagine+Synthetase+Suppresses+Proliferation+of+an+L-Asparaginase-Resistant+Leukemia+Cell+Line&doi=10.1016%2Fj.chembiol.2006.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line</span></div><div class="casAuthors">Gutierrez, Jemy A.; Pan, Yuan-Xiang; Koroniak, Lukasz; Hiratake, Jun; Kilberg, Michael S.; Richards, Nigel G. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1339-1347</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Drug resistance in lymphoblastic and myeloblastic leukemia cells is poorly understood, with several lines of evidence suggesting that resistance can be correlated with upregulation of human asparagine synthetase (hASNS) expression, although this hypothesis is controversial.  New tools are needed to investigate this clin. important question, including potent hASNS inhibitors.  In vitro expts. show an adenylated sulfoximine to be a slow-onset, tight-binding inhibitor of hASNS with nanomolar affinity.  This binding affinity represents a 10-fold improvement over that reported for the only other well-characterized hASNS inhibitor.  The adenylated sulfoximine has a cytostatic effect on L-asparaginase-resistant MOLT-4 cells cultured in the presence of L-asparaginase, an enzyme that depletes L-asparagine in the growth medium.  These observations represent direct evidence that potent hASNS inhibitors may prove to be effective agents for the clin. treatment of acute lymphoblastic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEX4MJhrzHLVg90H21EOLACvtfcHk0lgPi7kcDEiIJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CjsQ%253D%253D&md5=084645b1658ca32681db4fee11925159</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DJ.%2BA.%26aulast%3DPan%26aufirst%3DY.%2BX.%26aulast%3DKoroniak%26aufirst%3DL.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DKilberg%26aufirst%3DM.%2BS.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DAn%2520Inhibitor%2520of%2520Human%2520Asparagine%2520Synthetase%2520Suppresses%2520Proliferation%2520of%2520an%2520L-Asparaginase-Resistant%2520Leukemia%2520Cell%2520Line%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1339%26epage%3D1347%26doi%3D10.1016%2Fj.chembiol.2006.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otokawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegazy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiratake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">A Sulfoximine-Based Inhibitor of Human Asparagine Synthetase Kills L-Asparaginase-Resistant Leukemia Cells</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5915</span>– <span class="NLM_lpage">5927</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.07.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmc.2012.07.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22951255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OjsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=5915-5927&author=H.+Ikeuchiauthor=Y.-M.+Ahnauthor=T.+Otokawaauthor=B.+Watanabeauthor=L.+Hegazyauthor=J.+Hiratakeauthor=N.+G.+J.+Richards&title=A+Sulfoximine-Based+Inhibitor+of+Human+Asparagine+Synthetase+Kills+L-Asparaginase-Resistant+Leukemia+Cells&doi=10.1016%2Fj.bmc.2012.07.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells</span></div><div class="casAuthors">Ikeuchi, Hideyuki; Ahn, Yong-Mo; Otokawa, Takuya; Watanabe, Bunta; Hegazy, Lamees; Hiratake, Jun; Richards, Nigel G. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5915-5927</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An adenylated sulfoximine transition-state analog 1, which inhibits human asparagine synthetase (hASNS) with nanomolar potency, has been reported to suppress the proliferation of an l-asparagine amidohydrolase (ASNase)-resistant MOLT-4 leukemia cell line (MOLT-4R) when l-asparagine is depleted in the medium.  We now report the synthesis and biol. activity of two new sulfoximine analogs of 1 that have been studied as part of systematic efforts to identify compds. with improved cell permeability and/or metabolic stability.  One of these new analogs, an amino sulfoximine 5 having no net charge at cellular pH, is a better hASNS inhibitor (KI* = 8 nM) than 1 and suppresses proliferation of MOLT-4R cells at 10-fold lower concn. (IC50 = 0.1 mM).  More importantly, and in contrast to the lead compd. 1, the presence of sulfoximine 5 at concns. above 0.25 mM causes the death of MOLT-4R cells even when ASNase is absent in the culture medium.  The amino sulfoximine 5 exhibits different dose-response behavior when incubated with an ASNase-sensitive MOLT-4 cell line (MOLT-4S), supporting the hypothesis that sulfoximine 5 exerts its effect by inhibiting hASNS in the cell.  Our work provides further evidence for the idea that hASNS represents a chemotherapeutic target for the treatment of leukemia, and perhaps other cancers, including those of the prostate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfnqk-3n-4ULVg90H21EOLACvtfcHk0ljGnxVfee35FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OjsbzK&md5=8e2b3e66218778e9b9e74e78fec55faa</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.07.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.07.047%26sid%3Dliteratum%253Aachs%26aulast%3DIkeuchi%26aufirst%3DH.%26aulast%3DAhn%26aufirst%3DY.-M.%26aulast%3DOtokawa%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DB.%26aulast%3DHegazy%26aufirst%3DL.%26aulast%3DHiratake%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DA%2520Sulfoximine-Based%2520Inhibitor%2520of%2520Human%2520Asparagine%2520Synthetase%2520Kills%2520L-Asparaginase-Resistant%2520Leukemia%2520Cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D5915%26epage%3D5927%26doi%3D10.1016%2Fj.bmc.2012.07.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radadiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordin, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Márquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coricello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomanbhoy, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G. J.</span></span> <span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of Human Asparagine Synthetase Enables Analysis of Inhibitor Binding and Selectivity</span>. <i>Commun. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">345</span>, <span class="refDoi"> DOI: 10.1038/s42003-019-0587-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs42003-019-0587-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31552298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=345&author=W.+Zhuauthor=A.+Radadiyaauthor=C.+Bissonauthor=S.+Wenzelauthor=B.+E.+Nordinauthor=F.+Mart%C3%ADnez-M%C3%A1rquezauthor=T.+Imasakiauthor=S.+E.+Sedelnikovaauthor=A.+Coricelloauthor=P.+Baumannauthor=A.+H.+Berryauthor=T.+K.+Nomanbhoyauthor=J.+W.+Kozarichauthor=Y.+Jinauthor=D.+W.+Riceauthor=Y.+Takagiauthor=N.+G.+J.+Richards&title=High-Resolution+Crystal+Structure+of+Human+Asparagine+Synthetase+Enables+Analysis+of+Inhibitor+Binding+and+Selectivity&doi=10.1038%2Fs42003-019-0587-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of human asparagine synthetase enables analysis of inhibitor binding and selectivity</span></div><div class="casAuthors">Zhu Wen; Radadiya Ashish; Coricello Adriana; Baumann Patrick; Jin Yi; Richards Nigel G J; Zhu Wen; Bisson Claudine; Bisson Claudine; Sedelnikova Svetlana E; Rice David W; Wenzel Sabine; Martinez-Marquez Francisco; Imasaki Tsuyoshi; Takagi Yuichiro; Nordin Brian E; Nomanbhoy Tyzoon K; Kozarich John W; Nordin Brian E; Imasaki Tsuyoshi; Berry Alexandria H; Richards Nigel G J</div><div class="citationInfo"><span class="NLM_cas:title">Communications biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">345</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Expression of human asparagine synthetase (ASNS) promotes metastatic progression and tumor cell invasiveness in colorectal and breast cancer, presumably by altering cellular levels of L-asparagine.  Human ASNS is therefore emerging as a bona fide drug target for cancer therapy.  Here we show that a slow-onset, tight binding inhibitor, which exhibits nanomolar affinity for human ASNS in vitro, exhibits excellent selectivity at 10 μM concentration in HCT-116 cell lysates with almost no off-target binding.  The high-resolution (1.85 ÅA) crystal structure of human ASNS has enabled us to identify a cluster of negatively charged side chains in the synthetase domain that plays a key role in inhibitor binding.  Comparing this structure with those of evolutionarily related AMP-forming enzymes provides insights into intermolecular interactions that give rise to the observed binding selectivity.  Our findings demonstrate the feasibility of developing second generation human ASNS inhibitors as lead compounds for the discovery of drugs against metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTJXPyXuaAyIxhnOQkIHOxfW6udTcc2eYfLKWGXW4sMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVOhtQ%253D%253D&md5=170f03110a151e50197375386f54d189</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fs42003-019-0587-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs42003-019-0587-z%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DRadadiya%26aufirst%3DA.%26aulast%3DBisson%26aufirst%3DC.%26aulast%3DWenzel%26aufirst%3DS.%26aulast%3DNordin%26aufirst%3DB.%2BE.%26aulast%3DMart%25C3%25ADnez-M%25C3%25A1rquez%26aufirst%3DF.%26aulast%3DImasaki%26aufirst%3DT.%26aulast%3DSedelnikova%26aufirst%3DS.%2BE.%26aulast%3DCoricello%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DA.%2BH.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DRice%26aufirst%3DD.%2BW.%26aulast%3DTakagi%26aufirst%3DY.%26aulast%3DRichards%26aufirst%3DN.%2BG.%2BJ.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520Human%2520Asparagine%2520Synthetase%2520Enables%2520Analysis%2520of%2520Inhibitor%2520Binding%2520and%2520Selectivity%26jtitle%3DCommun.%2520Biol.%26date%3D2019%26volume%3D2%26spage%3D345%26doi%3D10.1038%2Fs42003-019-0587-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase 2 Inhibitors: Discovery, Selectivity and the Future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(99)01385-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0165-6147%2899%2901385-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10542447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXns1yltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=465-469&author=L.+J.+Marnettauthor=A.+S.+Kalgutkar&title=Cyclooxygenase+2+Inhibitors%3A+Discovery%2C+Selectivity+and+the+Future&doi=10.1016%2FS0165-6147%2899%2901385-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase 2 inhibitors: discovery, selectivity and the future</span></div><div class="casAuthors">Marnett, Lawrence J.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">465-469</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 52 refs.  The recent marketing of two selective cyclooxygenase 2 (COX-2) inhibitors climaxes the first phase of an exciting and fast-paced effort to exploit a novel mol. target for nonsteroidal anti-inflammatory drugs (NSAIDs).  Much has been written in the lay and scientific press about the potential of COX-2 inhibitors as anti-inflammatory and analgesic agents that lack the gastrointestinal side-effects of traditional NSAIDs.  Although research on COX-2 inhibitors has focussed mainly on inflammation and pain, exptl. and epidemiol. data suggest that COX-2 inhibitors could be used in the treatment or prevention of a broader range of diseases.  In this review, some key points and unresolved issues related to the discovery of COX-2 inhibitors, the kinetic and structural basis for their selectivity, and possible complications in their development and use will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc42Ho_aiYKLVg90H21EOLACvtfcHk0ljGnxVfee35FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1yltr8%253D&md5=dfd4f9ae3e7015f0be283c5672a1fefd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2899%2901385-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252899%252901385-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DCyclooxygenase%25202%2520Inhibitors%253A%2520Discovery%252C%2520Selectivity%2520and%2520the%2520Future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1999%26volume%3D20%26spage%3D465%26epage%3D469%26doi%3D10.1016%2FS0165-6147%2899%2901385-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mardini, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs</span>. <i>Mol. Interventions</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14993336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1ersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=30-38&author=I.+A.+Mardiniauthor=G.+A.+FitzGerald&title=Selective+Inhibitors+of+Cyclooxygenase-2%3A+A+Growing+Class+of+Anti-Inflammatory+Drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugs</span></div><div class="casAuthors">Mardini, Issam A.; FitzGerald, Garret A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Interventions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">MIONAR</span>;
        ISSN:<span class="NLM_cas:issn">1534-0384</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review, with 55 refs., on the selective inhibitors of cyclooxygenase (COX)-2, which have been hailed as powerful addns. to the armamentarium of nonsteroidal anti-inflammatory drugs, covers the exptl. verification of COX inhibitor selectivity; COX-2 hypothesis; and implications of selective COX inhibitors in cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3DOFyqXG47Vg90H21EOLACvtfcHk0ljHTjV7yf7HhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1ersr8%253D&md5=80c3d9b889268a24f9b0563d4427f70a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMardini%26aufirst%3DI.%2BA.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DSelective%2520Inhibitors%2520of%2520Cyclooxygenase-2%253A%2520A%2520Growing%2520Class%2520of%2520Anti-Inflammatory%2520Drugs%26jtitle%3DMol.%2520Interventions%26date%3D2001%26volume%3D1%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Design of Selective Inhibitors of Cyclooxygenase-2 as Nonulcerogenic Anti-Inflammatory Agents</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1016/S1367-5931(98)80124-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS1367-5931%2898%2980124-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9736921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFWnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1998&pages=482-490&author=L.+J.+Marnettauthor=A.+S.+Kalgutkar&title=Design+of+Selective+Inhibitors+of+Cyclooxygenase-2+as+Nonulcerogenic+Anti-Inflammatory+Agents&doi=10.1016%2FS1367-5931%2898%2980124-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents</span></div><div class="casAuthors">Marnett, Lawrence J.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">A review is given with 61 refs.  The discovery of a 2nd isoform of cyclooxygenase (cyclooxygenase-2) that is expressed in inflammatory cells and the central nervous system, but not in the gastric mucosa, offers the possibility of developing antiinflammatory and analgesic agents that lack the gastrointestinal side effects of currently available nonsteroidal antiinflammatory drugs.  Lead compds. from several different structural classes were identified and shown to be slow, tight-binding inhibitors that express their selectivity for cyclooxygenase-2 in the time-dependent step.  The detn. of structures of enzyme-inhibitor co-crystals along with site-directed mutagenesis expts. reveal the mol. basis for selectivity of some, but not all, inhibitors.  Preclin. and clin. studies suggest cyclooxygenase-2 inhibitors are highly promising new agents for the treatment of pain and inflammation, and for the prevention of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1iROc_OE4ybVg90H21EOLACvtfcHk0ljHTjV7yf7HhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFWnsrw%253D&md5=a85635956cadcadcd19fad063979437e</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2898%2980124-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252898%252980124-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDesign%2520of%2520Selective%2520Inhibitors%2520of%2520Cyclooxygenase-2%2520as%2520Nonulcerogenic%2520Anti-Inflammatory%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D1998%26volume%3D2%26spage%3D482%26epage%3D490%26doi%3D10.1016%2FS1367-5931%2898%2980124-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. S.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase Inhibitors: Scope of Their Use and Development in Cancer Chemotherapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1002/med.20182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fmed.20182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19967720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12ktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=161-201&author=M.+N.+Khanauthor=Y.+S.+Lee&title=Cyclooxygenase+Inhibitors%3A+Scope+of+Their+Use+and+Development+in+Cancer+Chemotherapy&doi=10.1002%2Fmed.20182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy</span></div><div class="casAuthors">Khan, Mohammed Naseer A.; Lee, Yong Sup</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-201</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The traditional nonsteroidal anti-inflammatory drugs (NSAIDs) exert their effect by inhibition of cyclooxygenase-1 (COX-1) as well as COX-2 enzymes.  As COX-1 is responsible for maintaining normal biol. functions, the nonselective inhibition of these enzymes caused side effects including gastrointestinal (GI) problems.  Recently developed selective COX-2 inhibitors could reduce these adverse effects, but the evidence of cardiovascular side effects including an increased risk of myocardial infarction began to emerge, and some of the COX-2 inhibitors were eventually withdrawn from the market and this led to the downfall of this research.  So, the discovery of novel COX-2 inhibitors with their safety profile became the biggest challenge in pharmaceutical research.  However, recent mechanistic and clin. studies revolutionized this area by indicating the fact that COX-2 is involved in apoptosis resistance, angiogenesis, and tumor progression.  Epidemiol. data suggest that selective COX-2 inhibitors might prevent the development of cancers.  Moreover, COX-2 is overexpressed in many cancers thus making it an attractive therapeutic target for the prevention and treatment of a no. of malignancies.  The purpose of this review is to focus on the medicinal chem. aspects of COX-2 inhibitors in cancer chemotherapy and recent reports on these inhibitors as anticancer agents.  We attempted to cover only the COX inhibitors that showed anticancer activity, although a no. of potent COX-2 inhibitors have been reported without their anticancer effects.  Furthermore, structure-activity relationships (SAR) of different classes of compds. for COX-2 inhibition as well as anticancer activity, and their future applications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqumWKRUpyajbVg90H21EOLACvtfcHk0ljHTjV7yf7HhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12ktLg%253D&md5=5523a7b7f4611af41007f71317fedc91</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fmed.20182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20182%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DM.%2BN.%26aulast%3DLee%26aufirst%3DY.%2BS.%26atitle%3DCyclooxygenase%2520Inhibitors%253A%2520Scope%2520of%2520Their%2520Use%2520and%2520Development%2520in%2520Cancer%2520Chemotherapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D161%26epage%3D201%26doi%3D10.1002%2Fmed.20182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grösch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1093/jnci/djj206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjnci%2Fdjj206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16757698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD28zktl2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=736-747&author=S.+Gr%C3%B6schauthor=T.+J.+Maierauthor=S.+Schiffmannauthor=G.+Geisslinger&title=Cyclooxygenase-2+%28COX-2%29%E2%80%93Independent+Anticarcinogenic+Effects+of+Selective+COX-2+Inhibitors&doi=10.1093%2Fjnci%2Fdjj206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors</span></div><div class="casAuthors">Grosch Sabine; Maier Thorsten Jurgen; Schiffmann Susanne; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer.  One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues.  Overexpression of COX-2 increases cell proliferation and inhibits apoptosis.  However, selective COX-2 inhibitors can also act through COX-independent mechanisms.  In this review, we describe the COX-2-independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors.  We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmpLQT5sXhncSzjBFCN0BJfW6udTcc2eawoG3L8c1pELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zktl2qsw%253D%253D&md5=11649e472d380b2480f709534c82013e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjj206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjj206%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25B6sch%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DT.%2BJ.%26aulast%3DSchiffmann%26aufirst%3DS.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DCyclooxygenase-2%2520%2528COX-2%2529%25E2%2580%2593Independent%2520Anticarcinogenic%2520Effects%2520of%2520Selective%2520COX-2%2520Inhibitors%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2006%26volume%3D98%26spage%3D736%26epage%3D747%26doi%3D10.1093%2Fjnci%2Fdjj206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dannhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, W.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase Inhibitors – Current Status and Future Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(01)01197-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0223-5234%2801%2901197-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11311743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtF2gtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2001&pages=109-126&author=G.+Dannhardtauthor=W.+Kiefer&title=Cyclooxygenase+Inhibitors+%E2%80%93+Current+Status+and+Future+Prospects&doi=10.1016%2FS0223-5234%2801%2901197-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors - current status and future prospects</span></div><div class="casAuthors">Dannhardt, Gerd; Kiefer, Werner</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-126</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review with 118 refs.  Prostaglandins are formed from arachidonic acid by the action of cyclooxygenase and subsequent downstream synthetases.  Two closely related forms of the cyclooxygenase have been identified which are now known as COX-1 and COX-2.  Both isoenzymes transform arachidonic acid to prostaglandins, but differ in their distribution and their physiol. roles.  Meanwhile, the responsible genes and their regulation have been clarified.  COX-1, the pre-dominantly constitutive form of the enzyme, is expressed throughout the body and performs a no. of homeostatic functions such as maintaining normal gastric mucosa and influencing renal blood flow and platelet aggregation.  In contrast, the inducible form is expressed in response to inflammatory and other physiol. stimuli and growth factors, and is involved in the prodn. of the prostaglandins that mediate pain and support the inflammatory process.  All the classic NSAIDs inhibit both COX-1 and COX-2 at std. anti-inflammatory doses.  The beneficial anti-inflammatory and analgesic effects are based on the inhibition of COX-2, but the gastrointestinal toxicity and the mild bleeding diathesis are a result of the concurrent inhibition of COX-1.  Agents that inhibit COX-2 while sparing COX-1 represent a new attractive therapeutic development and could represent a major advance in the treatment of rheumatoid arthritis and osteoarthritis.  Apart from its involvement in inflammatory processes, COX-2 seems to play a role in angiogenesis, colon cancer and Alzheimer's disease, based on the fact that it is expressed during these diseases.  The benefits of specific and selective COX-2 inhibitors are currently under discussion and offer a new perspective for a further use of COX-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SuyNXVrw77Vg90H21EOLACvtfcHk0lhKAX3wq2YXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtF2gtL8%253D&md5=21a93f7148930ac5c21e689d29109b97</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2801%2901197-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252801%252901197-7%26sid%3Dliteratum%253Aachs%26aulast%3DDannhardt%26aufirst%3DG.%26aulast%3DKiefer%26aufirst%3DW.%26atitle%3DCyclooxygenase%2520Inhibitors%2520%25E2%2580%2593%2520Current%2520Status%2520and%2520Future%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2001%26volume%3D36%26spage%3D109%26epage%3D126%26doi%3D10.1016%2FS0223-5234%2801%2901197-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Bioactive Sulfoximines: Syntheses and Properties of Vioxx® Analogs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4890</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2011.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21752640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Smtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4888-4890&author=S.+J.+Parkauthor=H.+Buschmannauthor=C.+Bolm&title=Bioactive+Sulfoximines%3A+Syntheses+and+Properties+of+Vioxx%C2%AE+Analogs&doi=10.1016%2Fj.bmcl.2011.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive sulfoximines: Syntheses and properties of Vioxx analogs</span></div><div class="casAuthors">Park, Seong Jun; Buschmann, Helmut; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4888-4890</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The syntheses and biol. profiles of sulfoximine-based Vioxx analogs, I and II, are described.  Interesting data have been obtained for arylsulfoximine I, which shows a selective COX-2 inhibition (albeit not as strong as Vioxx itself) exhibiting reduced hERG activity compare to the parent sulfone Vioxx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrelQluvcnRcbVg90H21EOLACvtfcHk0lhKAX3wq2YXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Smtr0%253D&md5=233cc524860fca1691793ad0487b36a4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DBioactive%2520Sulfoximines%253A%2520Syntheses%2520and%2520Properties%2520of%2520Vioxx%25C2%25AE%2520Analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4888%26epage%3D4890%26doi%3D10.1016%2Fj.bmcl.2011.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baars, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mersmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amann, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redelstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">N-Cyano Sulfoximines: COX Inhibition, Anticancer Activity, Cellular Toxicity, and Mutagenicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201200403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23225780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslymsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=217-220&author=S.+J.+Parkauthor=H.+Baarsauthor=S.+Mersmannauthor=H.+Buschmannauthor=J.+M.+Baronauthor=P.+M.+Amannauthor=K.+Czajaauthor=H.+Hollertauthor=K.+Bluhmauthor=R.+Redelsteinauthor=C.+Bolm&title=N-Cyano+Sulfoximines%3A+COX+Inhibition%2C+Anticancer+Activity%2C+Cellular+Toxicity%2C+and+Mutagenicity&doi=10.1002%2Fcmdc.201200403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cyano Sulfoximines: COX Inhibition, Anticancer Activity, Cellular Toxicity, and Mutagenicity</span></div><div class="casAuthors">Park, Seong Jun; Baars, Hannah; Mersmann, Stefanie; Buschmann, Helmut; Baron, Jens Malte; Amann, Philipp M.; Czaja, Katharina; Hollert, Henner; Bluhm, Kerstin; Redelstein, Regine; Bolm, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-220</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The COX inhibition, anticancer activity, cellular toxicity, and mutagenicity of N-cyano sulfoximines, e.g. I, is reported.  I was prepd. by metal-free oxidative imination of the corresponding sulfide with cyanogen amine as the nitrogen source followed by oxidn. with m-chloroperoxybenzoic acid.  I significantly affected the growth of non-small-cell lung cancer and melanoma cell lines.  The examd. N-cyano sulfoximines showed no significant toxicity towards HaCaT skin cells.  No mutagenic potential could be found for N-cyanosulfoximine I using the Ames fluctuation assay.  I showed potent COX-2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLfOT_LApsKLVg90H21EOLACvtfcHk0lhKAX3wq2YXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslymsbzF&md5=351ebaa6eecd1fa86af43888e1c5b2b9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200403%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DBaars%26aufirst%3DH.%26aulast%3DMersmann%26aufirst%3DS.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DAmann%26aufirst%3DP.%2BM.%26aulast%3DCzaja%26aufirst%3DK.%26aulast%3DHollert%26aufirst%3DH.%26aulast%3DBluhm%26aufirst%3DK.%26aulast%3DRedelstein%26aufirst%3DR.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DN-Cyano%2520Sulfoximines%253A%2520COX%2520Inhibition%252C%2520Anticancer%2520Activity%252C%2520Cellular%2520Toxicity%252C%2520and%2520Mutagenicity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D217%26epage%3D220%26doi%3D10.1002%2Fcmdc.201200403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">World
Health Organization</span>, World Malaria Report
2018. <a href="https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf?ua=1" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf?ua=1</a> (Accessed May 31, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World%0AHealth+Organization%2C+World+Malaria+Report%0A2018.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F275867%2F9789241565653-eng.pdf%3Fua%3D1+%28Accessed+May+31%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gething, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battle, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shackelford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulikoff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. S.</span></span> <span> </span><span class="NLM_article-title">Mapping <i>Plasmodium falciparum</i> Mortality in Africa between 1990 and 2015</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2435</span>– <span class="NLM_lpage">2445</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1606701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa1606701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27723434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2svns1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2435-2445&author=P.+W.+Gethingauthor=D.+C.+Caseyauthor=D.+J.+Weissauthor=D.+Bisanzioauthor=S.+Bhattauthor=E.+Cameronauthor=K.+E.+Battleauthor=U.+Dalrympleauthor=J.+Rozierauthor=P.+C.+Raoauthor=M.+J.+Kutzauthor=R.+M.+Barberauthor=C.+Huynhauthor=K.+A.+Shackelfordauthor=M.+M.+Coatesauthor=G.+Nguyenauthor=M.+S.+Fraserauthor=R.+Kulikoffauthor=H.+Wangauthor=M.+Naghaviauthor=D.+L.+Smithauthor=C.+J.+L.+Murrayauthor=S.+I.+Hayauthor=S.+S.+Lim&title=Mapping+Plasmodium+falciparum+Mortality+in+Africa+between+1990+and+2015&doi=10.1056%2FNEJMoa1606701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping Plasmodium falciparum Mortality in Africa between 1990 and 2015</span></div><div class="casAuthors">Gething Peter W; Casey Daniel C; Weiss Daniel J; Bisanzio Donal; Bhatt Samir; Cameron Ewan; Battle Katherine E; Dalrymple Ursula; Rozier Jennifer; Rao Puja C; Kutz Michael J; Barber Ryan M; Huynh Chantal; Shackelford Katya A; Coates Matthew M; Nguyen Grant; Fraser Maya S; Kulikoff Rachel; Wang Haidong; Naghavi Mohsen; Smith David L; Murray Christopher J L; Hay Simon I; Lim Stephen S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2435-2445</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Malaria control has not been routinely informed by the assessment of subnational variation in malaria deaths.  We combined data from the Malaria Atlas Project and the Global Burden of Disease Study to estimate malaria mortality across sub-Saharan Africa on a grid of 5 km(2) from 1990 through 2015.  METHODS:  We estimated malaria mortality using a spatiotemporal modeling framework of geolocated data (i.e., with known latitude and longitude) on the clinical incidence of malaria, coverage of antimalarial drug treatment, case fatality rate, and population distribution according to age.  RESULTS:  Across sub-Saharan Africa during the past 15 years, we estimated that there was an overall decrease of 57% (95% uncertainty interval, 46 to 65) in the rate of malaria deaths, from 12.5 (95% uncertainty interval, 8.3 to 17.0) per 10,000 population in 2000 to 5.4 (95% uncertainty interval, 3.4 to 7.9) in 2015.  This led to an overall decrease of 37% (95% uncertainty interval, 36 to 39) in the number of malaria deaths annually, from 1,007,000 (95% uncertainty interval, 666,000 to 1,376,000) to 631,000 (95% uncertainty interval, 394,000 to 914,000).  The share of malaria deaths among children younger than 5 years of age ranged from more than 80% at a rate of death of more than 25 per 10,000 to less than 40% at rates below 1 per 10,000.  Areas with high malaria mortality (>10 per 10,000) and low coverage (<50%) of insecticide-treated bed nets and antimalarial drugs included much of Nigeria, Angola, and Cameroon and parts of the Central African Republic, Congo, Guinea, and Equatorial Guinea.  CONCLUSIONS:  We estimated that there was an overall decrease of 57% in the rate of death from malaria across sub-Saharan Africa over the past 15 years and identified several countries in which high rates of death were associated with low coverage of antimalarial treatment and prevention programs. (Funded by the Bill and Melinda Gates Foundation and others.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5crYzD3IVsdK0qsdY6Nc1fW6udTcc2eaqZcSbd3p5dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svns1ymtA%253D%253D&md5=c103e5b72e3641e186204a4b94667c52</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1606701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1606701%26sid%3Dliteratum%253Aachs%26aulast%3DGething%26aufirst%3DP.%2BW.%26aulast%3DCasey%26aufirst%3DD.%2BC.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DBisanzio%26aufirst%3DD.%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DCameron%26aufirst%3DE.%26aulast%3DBattle%26aufirst%3DK.%2BE.%26aulast%3DDalrymple%26aufirst%3DU.%26aulast%3DRozier%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DP.%2BC.%26aulast%3DKutz%26aufirst%3DM.%2BJ.%26aulast%3DBarber%26aufirst%3DR.%2BM.%26aulast%3DHuynh%26aufirst%3DC.%26aulast%3DShackelford%26aufirst%3DK.%2BA.%26aulast%3DCoates%26aufirst%3DM.%2BM.%26aulast%3DNguyen%26aufirst%3DG.%26aulast%3DFraser%26aufirst%3DM.%2BS.%26aulast%3DKulikoff%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNaghavi%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26aulast%3DHay%26aufirst%3DS.%2BI.%26aulast%3DLim%26aufirst%3DS.%2BS.%26atitle%3DMapping%2520Plasmodium%2520falciparum%2520Mortality%2520in%2520Africa%2520between%25201990%2520and%25202015%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2435%26epage%3D2445%26doi%3D10.1056%2FNEJMoa1606701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del Prado, G. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cea, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinilla, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, I. A.</span></span> <span> </span><span class="NLM_article-title">Malaria in Developing Countries</span>. <i>J. Infect. Dev. Countries</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.3855/jidc.4610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3855%2Fjidc.4610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24423706" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1-4&author=G.+R.+L.+Del+Pradoauthor=C.+H.+Garc%C3%ADaauthor=L.+M.+Ceaauthor=V.+F.+Espinillaauthor=M.+F.+Morenoauthor=A.+M%C3%A1rquezauthor=M.+J.+Poloauthor=I.+A.+Garc%C3%ADa&title=Malaria+in+Developing+Countries&doi=10.3855%2Fjidc.4610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.3855%2Fjidc.4610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3855%252Fjidc.4610%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BPrado%26aufirst%3DG.%2BR.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DC.%2BH.%26aulast%3DCea%26aufirst%3DL.%2BM.%26aulast%3DEspinilla%26aufirst%3DV.%2BF.%26aulast%3DMoreno%26aufirst%3DM.%2BF.%26aulast%3DM%25C3%25A1rquez%26aufirst%3DA.%26aulast%3DPolo%26aufirst%3DM.%2BJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DI.%2BA.%26atitle%3DMalaria%2520in%2520Developing%2520Countries%26jtitle%3DJ.%2520Infect.%2520Dev.%2520Countries%26date%3D2014%26volume%3D8%26spage%3D1%26epage%3D4%26doi%3D10.3855%2Fjidc.4610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogstad, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herwaldt, B. L.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Agents: Mechanisms of Action</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1128/AAC.32.6.793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1128%2FAAC.32.6.793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3046479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXksVOltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=793-798&author=P.+H.+Schlesingerauthor=D.+J.+Krogstadauthor=B.+L.+Herwaldt&title=Antimalarial+Agents%3A+Mechanisms+of+Action&doi=10.1128%2FAAC.32.6.793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial agents:  Mechanisms of action</span></div><div class="casAuthors">Schlesinger, Paul H.; Krogstad, Donald J.; Herwaldt, Barbara L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">793-8</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">A review with 75 refs. examg. the antimalarial mechanisms of action of mefloquine, chloroquine, quinine, quinidine, sulfonamides, dihydrofolate reductase inhibitors, protein synthesis inhibitors, 8-aminoquinolines, and investigational drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp20U0Ba4nP_7Vg90H21EOLACvtfcHk0lgLA26jTI3RNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXksVOltr0%253D&md5=ef40c5b563fe7200005354e3b72efa35</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1128%2FAAC.32.6.793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.32.6.793%26sid%3Dliteratum%253Aachs%26aulast%3DSchlesinger%26aufirst%3DP.%2BH.%26aulast%3DKrogstad%26aufirst%3DD.%2BJ.%26aulast%3DHerwaldt%26aufirst%3DB.%2BL.%26atitle%3DAntimalarial%2520Agents%253A%2520Mechanisms%2520of%2520Action%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1988%26volume%3D32%26spage%3D793%26epage%3D798%26doi%3D10.1128%2FAAC.32.6.793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warhurst, D. C.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Drugs: Mode of Action and Resistance</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1093/jac/18.Supplement_B.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjac%2F18.Supplement_B.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3793663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL2sXnvVWisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1986&pages=51-59&author=D.+C.+Warhurst&title=Antimalarial+Drugs%3A+Mode+of+Action+and+Resistance&doi=10.1093%2Fjac%2F18.Supplement_B.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drugs:  mode of action and resistance</span></div><div class="casAuthors">Warhurst, D. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Suppl. B</span>),
    <span class="NLM_cas:pages">51-9</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    </div><div class="casAbstract">A review with 44 refs.  By virtue of their chem. structure and their activity on different stages of the malaria life cycle, it is possible to classify currently used antimalarial drugs into 3 groups.  These are the antimetabolites, the 8-aminoquinolines, and the blood-schizontocides.  In addn., it is possible to recognize another group, antibacterial antibiotics with antimalarial activity.  The relation of these mechanisms to resistance is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbySnrM8a0PrVg90H21EOLACvtfcHk0lgLA26jTI3RNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXnvVWisg%253D%253D&md5=a2242afbdaa515ff90c0a4f7c39b0929</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F18.Supplement_B.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F18.Supplement_B.51%26sid%3Dliteratum%253Aachs%26aulast%3DWarhurst%26aufirst%3DD.%2BC.%26atitle%3DAntimalarial%2520Drugs%253A%2520Mode%2520of%2520Action%2520and%2520Resistance%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1986%26volume%3D18%26spage%3D51%26epage%3D59%26doi%3D10.1093%2Fjac%2F18.Supplement_B.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">The Molecular Mechanism of Action of Artemisinin--the Debate Continues</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.3390/molecules15031705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3390%2Fmolecules15031705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20336009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ygurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1705-1721&author=P.+M.+O%E2%80%99Neillauthor=V.+E.+Bartonauthor=S.+A.+Ward&title=The+Molecular+Mechanism+of+Action+of+Artemisinin%2D%2Dthe+Debate+Continues&doi=10.3390%2Fmolecules15031705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanism of action of artemisinin - the debate continues</span></div><div class="casAuthors">O'Neill, Paul M.; Barton, Victoria E.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1705-1721</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Despite international efforts to 'roll back malaria' the 2008 World Malaria Report revealed the disease still affects approx. 3 billion people in 109 countries; 45 within the WHO African region.  The latest report however does provide some 'cautious optimism'; more than one-third of malarious countries have documented >50% redns. in malaria cases in 2008 compared to 2000.  The goal of the Member States at the World Health Assembly and 'Roll Back Malaria' (RBM) partnership is to reduce the nos. of malaria cases and deaths recorded in 2000 by 50% or more by the end of 2010.  Although malaria is preventable it is most prevalent in poorer countries where prevention is difficult and prophylaxis is generally not an option.  The burden of disease has increased by the emergence of multi drug resistant (MDR) parasites which threatens the use of established and cost effective antimalarial agents.  After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitemia and quick resoln. of symptoms.  Since artemisinin and its derivs. are eliminated rapidly, artemisinin combination therapies (ACT's) are now recommended to delay resistance mechanisms.  In spite of these precautionary measures reduced susceptibility of parasites to the artemisinin-based component of ACT's has developed at the Thai-Cambodian border, a historical 'hot spot' for MDR parasite evolution and emergence.  This development raises serious concerns for the future of the artemisinins and this is not helped by controversy related to the mode of action.  Although a no. of potential targets were proposed the actual mechanism of action remains ambiguous.  Interestingly, artemisinins have also shown potent and broad anticancer properties in cell lines and animal models and are becoming established as anti-schistosomal agents.  In this review we will discuss the recent evidence explaining bioactivation and potential mol. targets in the chemotherapy of malaria and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtgBcY1E6K97Vg90H21EOLACvtfcHk0ljafCnM4UPh2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ygurY%253D&md5=be4d50f93ea4c66578d5043f164dab31</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.3390%2Fmolecules15031705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules15031705%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DBarton%26aufirst%3DV.%2BE.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DThe%2520Molecular%2520Mechanism%2520of%2520Action%2520of%2520Artemisinin--the%2520Debate%2520Continues%26jtitle%3DMolecules%26date%3D2010%26volume%3D15%26spage%3D1705%26epage%3D1721%26doi%3D10.3390%2Fmolecules15031705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Divo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Oxygen- and Time-Dependent Effects of Antibiotics and Selected Mitochondrial Inhibitors on <i>Plasmodium falciparum</i> in Culture</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1128/AAC.27.1.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1128%2FAAC.27.1.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3885844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL2MXht1ylsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1985&pages=21-27&author=A.+A.+Divoauthor=T.+G.+Gearyauthor=J.+B.+Jensen&title=Oxygen-+and+Time-Dependent+Effects+of+Antibiotics+and+Selected+Mitochondrial+Inhibitors+on+Plasmodium+falciparum+in+Culture&doi=10.1128%2FAAC.27.1.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture</span></div><div class="casAuthors">Divo, Alan A.; Geary, Timothy G.; Jensen, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-7</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Several antibiotics which inhibit protein synthesis on 70 S ribosomes, including clindamycin, pirlimycin, 4'-pentyl-N-demethyl clindamycin, 4 tetracyclines, chloramphenicol, thiamphenicol, and erythromycin, had antimalarial effects against P. falciparum in culture which were greatly influenced by the duration of the drug exposure and by O tension.  In 96-h incubations, potency was increased by a ≤106-fold over the 1st 48-h period and by ≤104-fold in 15% O vs. 1% O.  Two aminoglycosides, kanamycin and tobramycin, had no antimalarial activity.  Rifampin and nalidixic acid, which inhibit nucleic acid synthesis, were not similar to the 70 S inhibitors.  The mitochondrial inhibitors, Janus Green, rhodamine 123, antimycin A1, and 8-methylamino-8-desmethyl riboflavin, had activities which were influenced by the duration of exposure and O tension.  Quinoline-contg. antimalarial agents, ionophores, and other antimalarial drugs were influenced to a minor extent by the duration of exposure, but were not affected by O tension.  Apparently, antimalarial 70 S ribosome-specific protein synthesis inhibitors are toxic to the parasites by acting on the mitochondrion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j0MWx_kSf7Vg90H21EOLACvtfcHk0ljafCnM4UPh2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1ylsbc%253D&md5=7065aa3f037be5ae9140b32fa82f6db5</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1128%2FAAC.27.1.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.27.1.21%26sid%3Dliteratum%253Aachs%26aulast%3DDivo%26aufirst%3DA.%2BA.%26aulast%3DGeary%26aufirst%3DT.%2BG.%26aulast%3DJensen%26aufirst%3DJ.%2BB.%26atitle%3DOxygen-%2520and%2520Time-Dependent%2520Effects%2520of%2520Antibiotics%2520and%2520Selected%2520Mitochondrial%2520Inhibitors%2520on%2520Plasmodium%2520falciparum%2520in%2520Culture%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1985%26volume%3D27%26spage%3D21%26epage%3D27%26doi%3D10.1128%2FAAC.27.1.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geary, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. B.</span></span> <span> </span><span class="NLM_article-title">Effects of Antibiotics on <i>Plasmodium falciparum in Vitro</i></span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1983.32.221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4269%2Fajtmh.1983.32.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=6340539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3sXitFaksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1983&pages=221-225&author=T.+G.+Gearyauthor=J.+B.+Jensen&title=Effects+of+Antibiotics+on+Plasmodium+falciparum+in+Vitro&doi=10.4269%2Fajtmh.1983.32.221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of antibiotics on Plasmodium falciparum in vitro</span></div><div class="casAuthors">Geary, Timothy G.; Jensen, James B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-5</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">Twelve antibiotics were tested against P. falciparum in vitro; they included cycloheximide, streptomycin, erythromycin, tetracycline, chloramphenicol, clindamycin, actinomycin D, rifampin, nalidixic acid, penicillin G, chlorhexidine, and isoniazid.  Inhibitory effects obtained at various drug concns. in vitro were compared to drug levels reported to be effective against bacteria in vivo.  Several antibacterial drugs, including erythromycin, chloramphenicol, clindamycin, rifampin, and tetracycline demonstrated significant antiparasitic effects at concns. within or near those obsd. during therapy in vivo; the potency of erythromycin and tetracycline was greater at 96 h of exposure than at 48 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZKlMzKHBq2rVg90H21EOLACvtfcHk0ljafCnM4UPh2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitFaksLY%253D&md5=67abd6f30316e36873be77579a5bdb3b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1983.32.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1983.32.221%26sid%3Dliteratum%253Aachs%26aulast%3DGeary%26aufirst%3DT.%2BG.%26aulast%3DJensen%26aufirst%3DJ.%2BB.%26atitle%3DEffects%2520of%2520Antibiotics%2520on%2520Plasmodium%2520falciparum%2520in%2520Vitro%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1983%26volume%3D32%26spage%3D221%26epage%3D225%26doi%3D10.4269%2Fajtmh.1983.32.221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enserink, M.</span></span> <span> </span><span class="NLM_article-title">Combating Malaria. Malaria Treatment: ACT Two</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1126/science.318.5850.560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.318.5850.560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17962536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Cmtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=560-563&author=M.+Enserink&title=Combating+Malaria.+Malaria+Treatment%3A+ACT+Two&doi=10.1126%2Fscience.318.5850.560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Malaria Treatment: ACT Two</span></div><div class="casAuthors">Enserink, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5850</span>),
    <span class="NLM_cas:pages">560-561, 563</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An influx of money and a new generation of drugs called artemisinin-based combination therapies (ACTs) are raising optimism that malaria's toll can be reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIojWvbthNvrVg90H21EOLACvtfcHk0lgPrlwpq0DBNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Cmtb7N&md5=2a528406da0d202db45a30c1d00ca523</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1126%2Fscience.318.5850.560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.318.5850.560%26sid%3Dliteratum%253Aachs%26aulast%3DEnserink%26aufirst%3DM.%26atitle%3DCombating%2520Malaria.%2520Malaria%2520Treatment%253A%2520ACT%2520Two%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D560%26epage%3D563%26doi%3D10.1126%2Fscience.318.5850.560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutabingwa, T. K.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-Based Combination Therapies (ACTs): Best Hope for Malaria Treatment but Inaccessible to the Needy!</span>. <i>Acta Trop.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.actatropica.2005.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.actatropica.2005.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16098946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=305-315&author=T.+K.+Mutabingwa&title=Artemisinin-Based+Combination+Therapies+%28ACTs%29%3A+Best+Hope+for+Malaria+Treatment+but+Inaccessible+to+the+Needy%21&doi=10.1016%2Fj.actatropica.2005.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!</span></div><div class="casAuthors">Mutabingwa, T. K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Tropica</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">ACTRAQ</span>;
        ISSN:<span class="NLM_cas:issn">0001-706X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Artemisinin-based combination therapies (ACTs) are the best anti-malarial drugs available now.  Artemisinin enhances efficacy and has the potential of lowering the rate at which resistance emerges and spreads.  Under low transmission intensity, ACTs have an addnl. public health benefit of reducing the overall malaria transmission and studies are urgently needed to investigate modalities of attaining similar benefits under high transmission.  Despite being recommended by WHO since 2001, overall deployment of ACT has been slow.  Limiting factors are high cost, limited knowledge and public awareness on the concept of combination therapy (CT) and ACT in particular, limited knowledge on safety of ACTs in pregnancy, operational issue such as inappropriate drug use, lack of suitable drug formulations, lack of post-marketing surveillance (PMS) systems, and the imbalance between demand and supply.  Through concerted efforts of multilateral organizations, the local scientific community with involvement of policy-makers progress has been on several fonts leading to improved ACT uptake rates in the last 2 years.  Of 43 countries that had adopted ACT by Feb. 2005, 18 (42%) adopted the policy in 2004.  Preference to co-formulated Coartem has led to a surge in its demand with consequent shortage.  Alternative ways for increased prodn. of ACTs are urgently needed otherwise most policies will remain adopted on paper.  Despite limitations, opportunities are opening up for effective malaria control.  Insecticides, insecticide-treated nets (ITNs) and ACTs are proven efficacious controls available that should be accessed by many.  Substantial funding is now available for biomedical malaria research and for policy implementation.  While the Global Fund is the financial engine behind the scaling up of ACT uptake, delays in cash flow after grant approval has led to many countries adopting ACT in 2004 but only few (nine) implementing it.  Clear policies on granted funds and minimal politics within funding agencies might improve the situation.  Increased interest in drug development together with the public and private sector partnership have led to new anti-malarials, some less expensive and therefore affordable by poor malaria endemic countries.  Dihydroartemisinin-piperaquine (Artekin) has a cost advantage over other ACTs (US$$ 1 for an adult treatment) making it a potential best candidate for deployment in Africa.  Part of available funds should be invested into capacity building and strengthening (personnel, resources and infrastructure) of institutions in malaria endemic countries.  This will create enabling environment and a crit. mass of scientists and public health experts to spearhead ACT policy implementation.  Active involvement of scientists from malaria endemic countries in recent International Scientific Forums like the Malaria in Pregnancy Working Group and the Consortium on ACT Implementation is the best way forward to emulate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjXH1lCc038LVg90H21EOLACvtfcHk0lgPrlwpq0DBNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1emtbk%253D&md5=b0ebba6b642d70fd50e18f046c8aab1d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.actatropica.2005.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actatropica.2005.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DMutabingwa%26aufirst%3DT.%2BK.%26atitle%3DArtemisinin-Based%2520Combination%2520Therapies%2520%2528ACTs%2529%253A%2520Best%2520Hope%2520for%2520Malaria%2520Treatment%2520but%2520Inaccessible%2520to%2520the%2520Needy%2521%26jtitle%3DActa%2520Trop.%26date%3D2005%26volume%3D95%26spage%3D305%26epage%3D315%26doi%3D10.1016%2Fj.actatropica.2005.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-Based Combination Treatment of Falciparum Malaria</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2007.77.181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4269%2Fajtmh.2007.77.181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18165491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1anuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2007&pages=181-192&author=F.+Nostenauthor=N.+J.+White&title=Artemisinin-Based+Combination+Treatment+of+Falciparum+Malaria&doi=10.4269%2Fajtmh.2007.77.181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-based combination treatment of falciparum malaria</span></div><div class="casAuthors">Nosten, Francois; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6, Suppl.</span>),
    <span class="NLM_cas:pages">181-192</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">A review.  Artemisinin-based combination treatments (ACTs) are now generally accepted as the best treatments for uncomplicated falciparum malaria.  They are rapidly and reliably effective.  Efficacy is detd. by the drug partnering the artemisinin deriv. and, for artesunate-mefloquine, artemether-lumefantrine, and dihydroartemisinin-piperaquine, this usually exceeds 95%.  Artesunate-sulfadoxine-pyrimethamine and artesunate-amodiaquine are effective in some areas, but in other areas resistance to the partner precludes their use.  There is still uncertainty over the safety of artemisinin derivs. in the first trimester of pregnancy, when they should not be used unless there are no effective alternatives.  Otherwise, except for occasional hypersensitivity reactions, the artemisinin derivs. are safe and remarkably well tolerated.  The adverse effect profiles of the artemisinin-based combination treatments are detd. by the partner drug.  Most malaria endemic countries have now adopted artemisinin-based combination treatments as first-line treatment of falciparum malaria, but in most of these only a minority of the patients that need artemisinin-based combination treatments actually receive them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBFIreJy8VF7Vg90H21EOLACvtfcHk0lgPrlwpq0DBNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1anuro%253D&md5=1fea5377a810d40f4797d7bd985c9990</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2007.77.181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2007.77.181%26sid%3Dliteratum%253Aachs%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin-Based%2520Combination%2520Treatment%2520of%2520Falciparum%2520Malaria%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2007%26volume%3D77%26spage%3D181%26epage%3D192%26doi%3D10.4269%2Fajtmh.2007.77.181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieten, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bélard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vugt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M. P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Artemisinin Combination Therapy (ACT) for Non-Falciparum Malaria: A Systematic Review</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">463</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-13-463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1475-2875-13-463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25428624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Klur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=463&author=B.+J.+Visserauthor=R.+W.+Wietenauthor=D.+Kroonauthor=I.+M.+Nagelauthor=S.+B%C3%A9lardauthor=M.+van+Vugtauthor=M.+P.+Grobusch&title=Efficacy+and+Safety+of+Artemisinin+Combination+Therapy+%28ACT%29+for+Non-Falciparum+Malaria%3A+A+Systematic+Review&doi=10.1186%2F1475-2875-13-463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review</span></div><div class="casAuthors">Visser, Benjamin J.; Wieten, Rosanne W.; Kroon, Danielle; Nagel, Ingeborg M.; Belard, Sabine; van Vugt, Michele; Grobusch, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Malaria Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">463/1-463/31, 31 pp.</span>CODEN:
                <span class="NLM_cas:coden">MJAOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-2875</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Artemisinin combination therapy (ACT) is recommended as first-line treatment for uncomplicated Plasmodium falciparum malaria, whereas chloroquine is still commonly used for the treatment of non-falciparum species (Plasmodium vivax, Plasmodium ovale and Plasmodium malariae).  A more simplified, more uniform treatment approach across all malaria species is worthwhile to be considered both in endemic areas and for malaria as an imported condition alike.  Methods: A PROSPERO-registered systematic review to det. the efficacy and safety of ACT for the treatment of non-falciparum malaria was conducted, following PRISMA guidelines.  Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies published up to Nov. 2014.  Results: The literature search identified 986 reports; 40 publications were found eligible for inclusion, all of them on non-falciparum malaria in endemic areas.  Most evidence was available for P. vivax (n = 35).  Five clin. trials in total were identified evaluating ACT for P. ovale, P. malariae and Plasmodium knowlesi.  Most ACT presentations have high efficacy against P. vivax parasites; artemisinin-based combinations have shorter parasite and fever clearance times compared to chloroquine.  ACT is as effective as chloroquine in preventing recurrent parasitemia before day 28.  Artemisinin-based combinations with long half-lives show significantly fewer recurrent parasitemia up to day 63.  The limited evidence available supports both the use of chloroquine and an ACT for P. ovale and P. malariae.  ACT seems to be preferable for optimal treatment of P. knowlesi.  Conclusion: ACT is at least equiv. to chloroquine in effectively treating non-falciparum malaria.  These findings may facilitate development of simplified protocols for treating all forms of malaria with ACT, including returning travellers.  Obtaining comprehensive efficacy and safety data on ACT use for non-falciparum species particularly for P. ovale, P. malariae and P. knowlesi should be a research priority.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpjHp8bYXMILVg90H21EOLACvtfcHk0lgPrlwpq0DBNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Klur4%253D&md5=2df58218346d276a01098d41ae9946f0</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-13-463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-13-463%26sid%3Dliteratum%253Aachs%26aulast%3DVisser%26aufirst%3DB.%2BJ.%26aulast%3DWieten%26aufirst%3DR.%2BW.%26aulast%3DKroon%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DI.%2BM.%26aulast%3DB%25C3%25A9lard%26aufirst%3DS.%26aulast%3Dvan%2BVugt%26aufirst%3DM.%26aulast%3DGrobusch%26aufirst%3DM.%2BP.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Artemisinin%2520Combination%2520Therapy%2520%2528ACT%2529%2520for%2520Non-Falciparum%2520Malaria%253A%2520A%2520Systematic%2520Review%26jtitle%3DMalar.%2520J.%26date%3D2014%26volume%3D13%26spage%3D463%26doi%3D10.1186%2F1475-2875-13-463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möhrle, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeuvray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, T. N.</span></span> <span> </span><span class="NLM_article-title">Designing the Next Generation of Medicines for Malaria Control and Eradication</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-12-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1475-2875-12-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23742293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3sjgsVSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=187&author=J.+N.+Burrowsauthor=R.+H.+van+Huijsduijnenauthor=J.+J.+M%C3%B6hrleauthor=C.+Oeuvrayauthor=T.+N.+Wells&title=Designing+the+Next+Generation+of+Medicines+for+Malaria+Control+and+Eradication&doi=10.1186%2F1475-2875-12-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Designing the next generation of medicines for malaria control and eradication</span></div><div class="casAuthors">Burrows Jeremy N; van Huijsduijnen Rob Hooft; Mohrle Jorg J; Oeuvray Claude; Wells Timothy N C</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the fight against malaria new medicines are an essential weapon.  For the parts of the world where the current gold standard artemisinin combination therapies are active, significant improvements can still be made: for example combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or improved stability under field conditions.  For those parts of the world where the existing combinations show less than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a secondary role.  For new medicines to be optimal in malaria control they must also be able to reduce transmission and prevent relapse of dormant forms: additional constraints on a combination medicine.  In the absence of a highly effective vaccine, new medicines are also needed to protect patient populations.  In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested.  In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles).  MMV presents now a suggested framework for combining the new candidates to produce the new medicines.  Sustained investment over the next decade in discovery and development of new molecules is essential to enable the long-term delivery of the medicines needed to combat malaria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjy7sj0k3cHtFxYDaSSP8XfW6udTcc2eaXMuX74EEEtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjgsVSisA%253D%253D&md5=c4283af83b04bc217f40528dde196e23</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-12-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-12-187%26sid%3Dliteratum%253Aachs%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3Dvan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DM%25C3%25B6hrle%26aufirst%3DJ.%2BJ.%26aulast%3DOeuvray%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DT.%2BN.%26atitle%3DDesigning%2520the%2520Next%2520Generation%2520of%2520Medicines%2520for%2520Malaria%2520Control%2520and%2520Eradication%26jtitle%3DMalar.%2520J.%26date%3D2013%26volume%3D12%26spage%3D187%26doi%3D10.1186%2F1475-2875-12-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhorda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovannaroth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pukrittayakamee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jittamala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutasmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchatsoonthorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runcharoen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hien, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy-Nhien, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thanh, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Htut, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aye, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokuolu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaosebikan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folaranmi, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayxay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanthavong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hongvanthong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyamboko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanello, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshefu, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valecha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashraheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peshu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faiz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacInnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeeyapant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheah, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakulthaew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intharabut, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihokhern, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunasol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegg, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowe, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1314981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMoa1314981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25075834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=411-423&author=E.+A.+Ashleyauthor=M.+Dhordaauthor=R.+M.+Fairhurstauthor=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=J.+M.+Andersonauthor=S.+Maoauthor=B.+Samauthor=C.+Sophaauthor=C.+M.+Chuorauthor=C.+Nguonauthor=S.+Sovannarothauthor=S.+Pukrittayakameeauthor=P.+Jittamalaauthor=K.+Chotivanichauthor=K.+Chutasmitauthor=C.+Suchatsoonthornauthor=R.+Runcharoenauthor=T.+T.+Hienauthor=N.+T.+Thuy-Nhienauthor=N.+V.+Thanhauthor=N.+H.+Phuauthor=Y.+Htutauthor=K.+T.+Hanauthor=K.+H.+Ayeauthor=O.+A.+Mokuoluauthor=R.+R.+Olaosebikanauthor=O.+O.+Folaranmiauthor=M.+Mayxayauthor=M.+Khanthavongauthor=B.+Hongvanthongauthor=P.+N.+Newtonauthor=M.+A.+Onyambokoauthor=C.+I.+Fanelloauthor=A.+K.+Tshefuauthor=N.+Mishraauthor=N.+Valechaauthor=A.+P.+Phyoauthor=F.+Nostenauthor=P.+Yiauthor=R.+Tripuraauthor=S.+Borrmannauthor=M.+Bashraheilauthor=J.+Peshuauthor=M.+A.+Faizauthor=A.+Ghoseauthor=M.+A.+Hossainauthor=R.+Samadauthor=M.+R.+Rahmanauthor=M.+M.+Hasanauthor=A.+Islamauthor=O.+Miottoauthor=R.+Amatoauthor=B.+MacInnisauthor=J.+Stalkerauthor=D.+P.+Kwiatkowskiauthor=Z.+Bozdechauthor=A.+Jeeyapantauthor=P.+Y.+Cheahauthor=T.+Sakulthaewauthor=J.+Chalkauthor=B.+Intharabutauthor=K.+Silamutauthor=S.+J.+Leeauthor=B.+Vihokhernauthor=C.+Kunasolauthor=M.+Imwongauthor=J.+Tarningauthor=W.+J.+Taylorauthor=S.+Yeungauthor=C.+J.+Woodrowauthor=J.+A.+Fleggauthor=D.+Dasauthor=J.+Smithauthor=M.+Venkatesanauthor=C.+V.+Ploweauthor=K.+Stepniewskaauthor=P.+J.+Guerinauthor=A.+M.+Dondorpauthor=N.+P.+Dayauthor=N.+J.+White&title=Spread+of+Artemisinin+Resistance+in+Plasmodium+falciparum+Malaria&doi=10.1056%2FNEJMoa1314981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Spread of artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Ashley, E. A.; Dhorda, M.; Fairhurst, R. M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J. M.; Mao, S.; Sam, B.; Sopha, C.; Chuor, C. M.; Nguon, C.; Sovannaroth, S.; Pukrittayakamee, S.; Jittamala, P.; Chotivanich, K.; Chutasmit, K.; Suchatsoonthorn, C.; Runcharoen, R.; Hien, T. T.; Thuy-Nhien, N. T.; Thanh, N. V.; Phu, N. H.; Htut, Y.; Han, K.-T.; Aye, K. H.; Mokuolu, O. A.; Olaosebikan, R. R.; Folaranmi, O. O.; Mayxay, M.; Khanthavong, M.; Hongvanthong, B.; Newton, P. N.; Onyamboko, M. A.; Fanello, C. I.; Tshefu, A. K.; Mishra, N.; Valecha, N.; Phyo, A. P.; Nosten, F.; Yi, P.; Tripura, R.; Borrmann, S.; Bashraheil, M.; Peshu, J.; Faiz, M. A.; Ghose, A.; Hossain, M. A.; Samad, R.; Rahman, M. R.; Hasan, M. M.; Islam, A.; Miotto, O.; Amato, R.; MacInnis, B.; Stalker, J.; Kwiatkowski, D. P.; Bozdech, Z.; Jeeyapant, A.; Cheah, P. Y.; Sakulthaew, T.; Chalk, J.; Intharabut, B.; Silamut, K.; Lee, S. J.; Vihokhern, B.; Kunasol, C.; Imwong, M.; Tarning, J.; Taylor, W. J.; Yeung, S.; Woodrow, C. J.; Flegg, J. A.; Das, D.; Smith, J.; Venkatesan, M.; Plowe, C. V.; Stepniewska, K.; Guerin, P. J.; Dondorp, A. M.; Day, N. P.; White, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-423, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria.  Mapping the geog. extent of resistance is essential for planning containment and elimination strategies.  Methods: Between May 2011 and Apr. 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa).  Patients received artesunate, administered orally at a daily dose of either 2 mg per kg of body wt. per day or 4 mg per kg, for 3 days, followed by a std. 3-day course of artemisinin-based combination therapy.  Parasite counts in peripheral-blood samples were measured every 6 h, and the parasite clearance half-lives were detd.  Results: The median parasite clearance half-lives ranged from 1.9 h in the Democratic Republic of Congo to 7.0 h at the Thailand-Cambodia border.  Slowly clearing infections (parasite clearance half-life >5 h), strongly assocd. with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from Southern Vietnam to central Myanmar.  The incidence of pre-treatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission.  In Western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was assocd. with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days.  Conclusions: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is assocd. with mutations in kelch13.  Prolonged courses of artemisinin- based combination therapies are currently efficacious in areas where std. 3-day treatments are failing. (Funded by the U.K. Department of International Development and others).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7aJ4A3O4W8rVg90H21EOLACvtfcHk0liyQEtAlOzKLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ers7jF&md5=bb2f2a4d554ba6a1f4c605868be43f6e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1314981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1314981%26sid%3Dliteratum%253Aachs%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DDhorda%26aufirst%3DM.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DNguon%26aufirst%3DC.%26aulast%3DSovannaroth%26aufirst%3DS.%26aulast%3DPukrittayakamee%26aufirst%3DS.%26aulast%3DJittamala%26aufirst%3DP.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DChutasmit%26aufirst%3DK.%26aulast%3DSuchatsoonthorn%26aufirst%3DC.%26aulast%3DRuncharoen%26aufirst%3DR.%26aulast%3DHien%26aufirst%3DT.%2BT.%26aulast%3DThuy-Nhien%26aufirst%3DN.%2BT.%26aulast%3DThanh%26aufirst%3DN.%2BV.%26aulast%3DPhu%26aufirst%3DN.%2BH.%26aulast%3DHtut%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DK.%2BT.%26aulast%3DAye%26aufirst%3DK.%2BH.%26aulast%3DMokuolu%26aufirst%3DO.%2BA.%26aulast%3DOlaosebikan%26aufirst%3DR.%2BR.%26aulast%3DFolaranmi%26aufirst%3DO.%2BO.%26aulast%3DMayxay%26aufirst%3DM.%26aulast%3DKhanthavong%26aufirst%3DM.%26aulast%3DHongvanthong%26aufirst%3DB.%26aulast%3DNewton%26aufirst%3DP.%2BN.%26aulast%3DOnyamboko%26aufirst%3DM.%2BA.%26aulast%3DFanello%26aufirst%3DC.%2BI.%26aulast%3DTshefu%26aufirst%3DA.%2BK.%26aulast%3DMishra%26aufirst%3DN.%26aulast%3DValecha%26aufirst%3DN.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DTripura%26aufirst%3DR.%26aulast%3DBorrmann%26aufirst%3DS.%26aulast%3DBashraheil%26aufirst%3DM.%26aulast%3DPeshu%26aufirst%3DJ.%26aulast%3DFaiz%26aufirst%3DM.%2BA.%26aulast%3DGhose%26aufirst%3DA.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26aulast%3DSamad%26aufirst%3DR.%26aulast%3DRahman%26aufirst%3DM.%2BR.%26aulast%3DHasan%26aufirst%3DM.%2BM.%26aulast%3DIslam%26aufirst%3DA.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DMacInnis%26aufirst%3DB.%26aulast%3DStalker%26aufirst%3DJ.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BP.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DJeeyapant%26aufirst%3DA.%26aulast%3DCheah%26aufirst%3DP.%2BY.%26aulast%3DSakulthaew%26aufirst%3DT.%26aulast%3DChalk%26aufirst%3DJ.%26aulast%3DIntharabut%26aufirst%3DB.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DVihokhern%26aufirst%3DB.%26aulast%3DKunasol%26aufirst%3DC.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DW.%2BJ.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DWoodrow%26aufirst%3DC.%2BJ.%26aulast%3DFlegg%26aufirst%3DJ.%2BA.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DVenkatesan%26aufirst%3DM.%26aulast%3DPlowe%26aufirst%3DC.%2BV.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DGuerin%26aufirst%3DP.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DSpread%2520of%2520Artemisinin%2520Resistance%2520in%2520Plasmodium%2520falciparum%2520Malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D411%26epage%3D423%26doi%3D10.1056%2FNEJMoa1314981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spitzmüller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span> <span> </span><span class="NLM_article-title">Prediction of the <i>P. falciparum</i> Target Space Relevant to Malaria Drug Discovery</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1003257</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1003257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pcbi.1003257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24146604" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003257&author=A.+Spitzm%C3%BCllerauthor=J.+Mestres&title=Prediction+of+the+P.+falciparum+Target+Space+Relevant+to+Malaria+Drug+Discovery&doi=10.1371%2Fjournal.pcbi.1003257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1003257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1003257%26sid%3Dliteratum%253Aachs%26aulast%3DSpitzm%25C3%25BCller%26aufirst%3DA.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520the%2520P.%2520falciparum%2520Target%2520Space%2520Relevant%2520to%2520Malaria%2520Drug%2520Discovery%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3De1003257%26doi%3D10.1371%2Fjournal.pcbi.1003257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshapo, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makolo, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammon, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, C.</span></span> <span> </span><span class="NLM_article-title">Preparation and Antimalarial Activity of a Novel Class of Carbohydrate-Derived, Fused Thiochromans</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2014.09.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25255435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=197-202&author=H.+H.+Kinfeauthor=P.+T.+Moshapoauthor=F.+L.+Makoloauthor=D.+W.+Gammonauthor=M.+Ehlersauthor=C.+Schmuck&title=Preparation+and+Antimalarial+Activity+of+a+Novel+Class+of+Carbohydrate-Derived%2C+Fused+Thiochromans&doi=10.1016%2Fj.ejmech.2014.09.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and antimalarial activity of a novel class of carbohydrate-derived, fused thiochromans</span></div><div class="casAuthors">Kinfe, Henok H.; Moshapo, Paseka T.; Makolo, Felix L.; Gammon, David W.; Ehlers, Martin; Schmuck, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-202</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel class of fused thiochroman derivs., e.g. I, has been prepd. by an efficient and versatile synthetic procedure involving nucleophilic displacement of the side-chain iodo substituent in 2-deoxy-2-C-iodomethyl glucosides by thiophenolate ions, and subsequent intramol. C-glycoside formation.  A range of arom. substituents is tolerated, and the subsequent facile selective oxidn. of the sulfur to the sulfoxide or sulfone level expands the range and mol. diversity of the series of compds.  A selection of the sulfoxide and sulfone derivs. bearing lipophilic substituents on the arom. portion were found to have antimalarial activities in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIi49vLzOoGbVg90H21EOLACvtfcHk0lij15In3h8XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrt7nN&md5=c39335e29430e6a5d73404dba889364e</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.060%26sid%3Dliteratum%253Aachs%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26aulast%3DMoshapo%26aufirst%3DP.%2BT.%26aulast%3DMakolo%26aufirst%3DF.%2BL.%26aulast%3DGammon%26aufirst%3DD.%2BW.%26aulast%3DEhlers%26aufirst%3DM.%26aulast%3DSchmuck%26aufirst%3DC.%26atitle%3DPreparation%2520and%2520Antimalarial%2520Activity%2520of%2520a%2520Novel%2520Class%2520of%2520Carbohydrate-Derived%252C%2520Fused%2520Thiochromans%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D197%26epage%3D202%26doi%3D10.1016%2Fj.ejmech.2014.09.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madumo, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshapo, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Effects of Lipophilicity, Protecting Group and Stereochemistry on the Antimalarial Activity of Carbohydrate-Derived Thiochromans</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1007/s00044-017-2105-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00044-017-2105-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=817-833&author=G.+K.+Madumoauthor=P.+T.+Moshapoauthor=H.+H.+Kinfe&title=Effects+of+Lipophilicity%2C+Protecting+Group+and+Stereochemistry+on+the+Antimalarial+Activity+of+Carbohydrate-Derived+Thiochromans&doi=10.1007%2Fs00044-017-2105-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of lipophilicity, protecting group and stereochemistry on the antimalarial activity of carbohydrate-derived thiochromans</span></div><div class="casAuthors">Madumo, Gilbert K.; Moshapo, Paseka T.; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">817-833</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A series of novel carbohydrate-derived thiochromans has been successfully synthesized in order to investigate the influence of alkyl substituents on the arom. ring of the thiophenol moiety in addn. to the effect of protecting groups and stereochem. on the sugar component of the target mols.  Results from the evaluation of the thiochromans for their antimalarial activity against the chloroquine-sensitive (3D7) strain of Plasmodium falciparum suggest that the presence of short chain alkyl substituents, a benzyl ether protecting group and equatorial orientation of the C-4 substituent on the sugar moiety are crucial structural features that impart high antimalarial activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomk2u731mMbVg90H21EOLACvtfcHk0lij15In3h8XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Ghsw%253D%253D&md5=239ce3dee7885d89800a1fa468630c69</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1007%2Fs00044-017-2105-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-017-2105-5%26sid%3Dliteratum%253Aachs%26aulast%3DMadumo%26aufirst%3DG.%2BK.%26aulast%3DMoshapo%26aufirst%3DP.%2BT.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DEffects%2520of%2520Lipophilicity%252C%2520Protecting%2520Group%2520and%2520Stereochemistry%2520on%2520the%2520Antimalarial%2520Activity%2520of%2520Carbohydrate-Derived%2520Thiochromans%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2018%26volume%3D27%26spage%3D817%26epage%3D833%26doi%3D10.1007%2Fs00044-017-2105-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span> <span> </span><span class="NLM_article-title">Azide-Alkyne Cycloaddition En Route to 1H-1,2,3-Triazole-Tethered 7-Chloroquinoline-Isatin Chimeras: Synthesis and Antimalarial Evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">590</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23434528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=590-596&author=R.+Rajauthor=P.+Singhauthor=P.+Singhauthor=J.+Gutauthor=P.+J.+Rosenthalauthor=V.+Kumar&title=Azide-Alkyne+Cycloaddition+En+Route+to+1H-1%2C2%2C3-Triazole-Tethered+7-Chloroquinoline-Isatin+Chimeras%3A+Synthesis+and+Antimalarial+Evaluation&doi=10.1016%2Fj.ejmech.2013.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Azide-alkyne cycloaddition en route to 1H-1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: Synthesis and antimalarial evaluation</span></div><div class="casAuthors">Raj, Raghu; Singh, Pardeep; Singh, Parvesh; Gut, Jiri; Rosenthal, Philip J.; Kumar, Vipan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">590-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We describe the synthesis and antimalarial activities of 1H-1,2,3-triazole tethered 7-chloroquinoline-isatin hybrids.  Activity against cultured parasites was dependent on the C-5 substituent of the isatin ring as well as the alkyl chain length between the isatin and 7-chloroquinoline moieties.  Compd. I displayed the best activity among the test compds., with IC50 value of 1.21 μM against cultured W2-strain Plasmodium falciparum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpffhW2sdt177Vg90H21EOLACvtfcHk0lij15In3h8XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSrtL8%253D&md5=9442940ccbcff64cb989f9c2e1942960</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DRaj%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DJ.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DKumar%26aufirst%3DV.%26atitle%3DAzide-Alkyne%2520Cycloaddition%2520En%2520Route%2520to%25201H-1%252C2%252C3-Triazole-Tethered%25207-Chloroquinoline-Isatin%2520Chimeras%253A%2520Synthesis%2520and%2520Antimalarial%2520Evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D590%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2013.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chizema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabasa, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoppe, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Antiplasmodial Evaluation of a Series of Novel Sulfoximine Analogues of Carbohydrate-Based Thiochromans</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fcbdd.13408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30264436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=254-261&author=M.+Chizemaauthor=T.+F.+Mabasaauthor=H.+C.+Hoppeauthor=H.+H.+Kinfe&title=Design%2C+Synthesis%2C+and+Antiplasmodial+Evaluation+of+a+Series+of+Novel+Sulfoximine+Analogues+of+Carbohydrate-Based+Thiochromans&doi=10.1111%2Fcbdd.13408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and antiplasmodial evaluation of a series of novel sulfoximine analogues of carbohydrate-based thiochromans</span></div><div class="casAuthors">Chizema, Munashe; Mabasa, Tommy F.; Hoppe, Heinrich C.; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">254-261</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sulfone/sulfoxide-contg. carbohydrate derived thiochromans were found to be highly active antiplasmodial agents.  However, the inability of the sulfone/sulfoxide functional groups for further derivatization and manipulation limited the potential for further exploration.  In this study, based on the interesting and important physicochem. properties, as well as amenability of sulfoximines (isosters of sulfones) for further derivatization, a series of novel sulfoximine-type carbohydrate-derived thiochroman derivs. have been successfully synthesized, characterized, and evaluated for their antiplasmodial activity.  Although the replacement of the sulfone functional group with a sulfoximine unit improved the antiplasmodial activity of the scaffolds, the activity was highly dependent on the configuration of the stereogenic center at the sulfur atom.  Moreover, anal. of the crystal structures of the sulfoximine analogs revealed that the bond between the sulfur and nitrogen atoms of the sulfoximine functional group is not a true double bond but rather a polarized single bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNHAtIBj2mjbVg90H21EOLACvtfcHk0lgnG5zhaOk9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eitbbK&md5=43bf6df41241087c21879dd4c824ae11</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13408%26sid%3Dliteratum%253Aachs%26aulast%3DChizema%26aufirst%3DM.%26aulast%3DMabasa%26aufirst%3DT.%2BF.%26aulast%3DHoppe%26aufirst%3DH.%2BC.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Antiplasmodial%2520Evaluation%2520of%2520a%2520Series%2520of%2520Novel%2520Sulfoximine%2520Analogues%2520of%2520Carbohydrate-Based%2520Thiochromans%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2019%26volume%3D93%26spage%3D254%26epage%3D261%26doi%3D10.1111%2Fcbdd.13408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mabasa, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laming, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinfe, H. H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-Triazole Hybrids as Potential Antimalarial Prototypes</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/1573406415666190206232308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F1573406415666190206232308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30727905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWrsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=685-692&author=T.+F.+Mabasaauthor=B.+Aweauthor=D.+Lamingauthor=H.+H.+Kinfe&title=Design%2C+Synthesis+and+Antiplasmodial+Evaluation+of+Sulfoximine-Triazole+Hybrids+as+Potential+Antimalarial+Prototypes&doi=10.2174%2F1573406415666190206232308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antiplasmodial Evaluation of Sulfoximine-triazole Hybrids as Potential Antimalarial Prototypes</span></div><div class="casAuthors">Mabasa, Tommy F.; Awe, Babatunde; Laming, Dustin; Kinfe, Henok H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-692</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Malaria, caused by the deadly Plasmodium falciparum strain, claims the lives of millions of people annually.  The emergence of drug-resistant strains of P. falciparum to the artemisinin-based combination therapy (ACT), the last line of defense against malaria, is worrisome and urges for the development of new chemo-types with a new mode of action.  In the search of new antimalarial agents, hybrids of triazoles and other known antimalarial drugs have been reported to possess better activity than either of the parent compds. administered individually.  In the hope of developing new antimalarial prototypes, we propose the design, synthesis and antimalarial evaluation of novel sulfoximine-triazole hybrids owing to their interesting biol. and physiol. properties.  Propargylation of the NH moiety of the sulfoximine followed by copper-catalyzed click chem. with benzyl azide was envisaged to provide the target sulfoximine-triazole hybrids.  Results: Five novel sulfoximine-triazole hybrids possessing various substituents on the sulfoximine moiety have been successfully synthesized and evaluated for their antiplasmodial and cytotoxicity activities.  The results revealed that the co-presence of the sulfoximine and triazole moieties along with a lipophilic alkyl substituent on the sulfur atom impart significant activity.  Sulfoximine-triazole hybrids could be used as a prototype for the synthesis of new derivs. with better antiplasmodial activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_-OKIT2I9nrVg90H21EOLACvtfcHk0lgnG5zhaOk9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWrsr3K&md5=8f8929bf534e9fb76aff0012a474b30c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.2174%2F1573406415666190206232308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406415666190206232308%26sid%3Dliteratum%253Aachs%26aulast%3DMabasa%26aufirst%3DT.%2BF.%26aulast%3DAwe%26aufirst%3DB.%26aulast%3DLaming%26aufirst%3DD.%26aulast%3DKinfe%26aufirst%3DH.%2BH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antiplasmodial%2520Evaluation%2520of%2520Sulfoximine-Triazole%2520Hybrids%2520as%2520Potential%2520Antimalarial%2520Prototypes%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D685%26epage%3D692%26doi%3D10.2174%2F1573406415666190206232308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawat, D. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 4-Aminoquinoline-1,2,3-Triazole and 4-Aminoquinoline-1,2,3-Triazole-1,3,5-Triazine Hybrids as Potential Antimalarial Agents</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1111/j.1747-0285.2011.01115.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1747-0285.2011.01115.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21457474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVamtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2011&pages=124-136&author=S.+Manoharauthor=S.+I.+Khanauthor=D.+S.+Rawat&title=Synthesis+of+4-Aminoquinoline-1%2C2%2C3-Triazole+and+4-Aminoquinoline-1%2C2%2C3-Triazole-1%2C3%2C5-Triazine+Hybrids+as+Potential+Antimalarial+Agents&doi=10.1111%2Fj.1747-0285.2011.01115.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents</span></div><div class="casAuthors">Manohar, Sunny; Khan, Shabane I.; Rawat, Diwan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">124-136</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The authors report the synthesis of a series of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole-1,3,5-triazine hybrids and evaluation of their antimalarial activity against D6 and W2 strains of Plasmodium falciparum.  To study the structure-activity relationship of substituted 4-aminoquinoline-based hybrids, 34 structurally diverse compds. were synthesized and tested against D6 and W2 strains of P. falciparum.  Some of the compds. showed promising antimalarial activity without toxicity against Vero cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod4ZoiSw8UKrVg90H21EOLACvtfcHk0lgnG5zhaOk9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVamtLY%253D&md5=bbe9769364f7966cadf8f212e6d6b2b2</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2011.01115.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2011.01115.x%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DRawat%26aufirst%3DD.%2BS.%26atitle%3DSynthesis%2520of%25204-Aminoquinoline-1%252C2%252C3-Triazole%2520and%25204-Aminoquinoline-1%252C2%252C3-Triazole-1%252C3%252C5-Triazine%2520Hybrids%2520as%2520Potential%2520Antimalarial%2520Agents%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2011%26volume%3D78%26spage%3D124%26epage%3D136%26doi%3D10.1111%2Fj.1747-0285.2011.01115.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandão, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arantes, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Paula, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Nascimento, M. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dos Santos, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Rocha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, A. B.</span></span> <span> </span><span class="NLM_article-title">7-Chloroquinolinotriazoles: Synthesis by the Azide–Alkyne Cycloaddition Click Chemistry, Antimalarial Activity, Cytotoxicity and SAR Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24469080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=295-309&author=G.+R.+Pereiraauthor=G.+C.+Brand%C3%A3oauthor=L.+M.+Arantesauthor=H.+A.+de+Oliveiraauthor=R.+C.+de+Paulaauthor=M.+F.+A.+do+Nascimentoauthor=F.+M.+dos+Santosauthor=R.+K.+da+Rochaauthor=J.+C.+D.+Lopesauthor=A.+B.+de+Oliveira&title=7-Chloroquinolinotriazoles%3A+Synthesis+by+the+Azide%E2%80%93Alkyne+Cycloaddition+Click+Chemistry%2C+Antimalarial+Activity%2C+Cytotoxicity+and+SAR+Studies&doi=10.1016%2Fj.ejmech.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">7-Chloroquinolinotriazoles: Synthesis by the azide-alkyne cycloaddition click chemistry, antimalarial activity, cytotoxicity and SAR studies</span></div><div class="casAuthors">Pereira, Guilherme R.; Brandao, Geraldo Celio; Arantes, Lucas M.; de Oliveira, Haliton A., Jr.; de Paula, Renata Cristina; do Nascimento, Maria Fernanda A.; dos Santos, Fabio M.; da Rocha, Ramon K.; Lopes, Julio Cesar D.; Braga de Oliveira, Alaide</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Twenty-seven 7-chloroquinolinotriazole derivs. with different substituents in the triazole moiety were synthesized via copper-catalyzed cycloaddn. (CuAAC) click chem. between 4-azido-7-chloroquinoline and several alkynes.  All the synthetic compds. were evaluated for their in vitro activity against Plasmodium falciparum (W2) and cytotoxicity to Hep G2A16 cells.  All the products disclosed low cytotoxicity (CC50 > 100 μM) and five of them have shown moderate antimalarial activity (IC50 from 9.6 to 40.9 μM).  As chloroquine analogs, it was expected that these compds. might inhibit the heme polymn. and SAR studies were performed aiming to explain their antimalarial profile.  New structural variations can be designed on the basis of the results obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53hpmXI1iX7Vg90H21EOLACvtfcHk0lgRI4lxzOFMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSisbw%253D&md5=10ae802353f6cfcffc7c1d13f00a38dc</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DG.%2BR.%26aulast%3DBrand%25C3%25A3o%26aufirst%3DG.%2BC.%26aulast%3DArantes%26aufirst%3DL.%2BM.%26aulast%3Dde%2BOliveira%26aufirst%3DH.%2BA.%26aulast%3Dde%2BPaula%26aufirst%3DR.%2BC.%26aulast%3Ddo%2BNascimento%26aufirst%3DM.%2BF.%2BA.%26aulast%3Ddos%2BSantos%26aufirst%3DF.%2BM.%26aulast%3Dda%2BRocha%26aufirst%3DR.%2BK.%26aulast%3DLopes%26aufirst%3DJ.%2BC.%2BD.%26aulast%3Dde%2BOliveira%26aufirst%3DA.%2BB.%26atitle%3D7-Chloroquinolinotriazoles%253A%2520Synthesis%2520by%2520the%2520Azide%25E2%2580%2593Alkyne%2520Cycloaddition%2520Click%2520Chemistry%252C%2520Antimalarial%2520Activity%252C%2520Cytotoxicity%2520and%2520SAR%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D295%26epage%3D309%26doi%3D10.1016%2Fj.ejmech.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackie, M. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Triazole-Linked 2-Trichloromethylquinazolines and Exploration of Their Efficacy against <i>P. falciparum</i></span>. <i>S. Afr. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWhsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=231-236&author=A.+R.+Hamannauthor=C.+de+Kockauthor=P.+J.+Smithauthor=W.+A.+van+Otterloauthor=M.+A.+Blackie&title=Synthesis+of+Triazole-Linked+2-Trichloromethylquinazolines+and+Exploration+of+Their+Efficacy+against+P.+falciparum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of triazole-linked 2-trichloromethylquinazolines and exploration of their efficacy against P. falciparum</span></div><div class="casAuthors">Hamann, Anton R.; de Kock, Carmen; Smith, Peter J.; van Otterlo, Willem A. L.; Blackie, Margaret A. L.</div><div class="citationInfo"><span class="NLM_cas:title">South African Journal of Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-236</span>CODEN:
                <span class="NLM_cas:coden">SAJCDG</span>;
        ISSN:<span class="NLM_cas:issn">0379-4350</span>.
    
            (<span class="NLM_cas:orgname">South African Chemical Institute</span>)
        </div><div class="casAbstract">Using 2-trichloromethyl quinazoline as scaffold, seven novel triazole-linked compds., e.g., I, have been synthesized using CuAAC chem.  The in vitro biol. activity of four of the compds. on the Plasmodium falciparum chloroquine-sensitive strain NF54 was then detd.  The compds. which were tested showed moderate activity with 1.45 μM as the lowest inhibitory concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQdm2_Ypj3DrVg90H21EOLACvtfcHk0lgRI4lxzOFMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWhsbjP&md5=1a40c96644a315308a1eba349240c24c</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DA.%2BR.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%26aulast%3DBlackie%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%2520of%2520Triazole-Linked%25202-Trichloromethylquinazolines%2520and%2520Exploration%2520of%2520Their%2520Efficacy%2520against%2520P.%2520falciparum%26jtitle%3DS.%2520Afr.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D231%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Otterlo, W. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackie, M. A. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Triazole-Linked Mefloquine Derivatives: Biological Evaluation against <i>Plasmodium falciparum</i></span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5466</span>– <span class="NLM_lpage">5469</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2014.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25455485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5466-5469&author=A.+R.+Hamannauthor=C.+de+Kockauthor=P.+J.+Smithauthor=W.+A.+L.+van+Otterloauthor=M.+A.+L.+Blackie&title=Synthesis+of+Novel+Triazole-Linked+Mefloquine+Derivatives%3A+Biological+Evaluation+against+Plasmodium+falciparum&doi=10.1016%2Fj.bmcl.2014.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel triazole-linked mefloquine derivatives: Biological evaluation against Plasmodium falciparum</span></div><div class="casAuthors">Hamann, Anton R.; de Kock, Carmen; Smith, Peter J.; van Otterlo, Willem A. L.; Blackie, Margaret A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5466-5469</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using 2,8-bis(trifluoromethyl)quinoline, the pharmacophore of mefloquine, as scaffold, eleven novel triazole-linked compds. of formula I [R = substituted piperazinyl; dicyclohexylamino, tert-butylamino, etc.] have been synthesized by the application of CuAAC chem.  The in vitro biol. activity of the compds. on the Plasmodium falciparum chloroquine-sensitive strain NF54 was then detd.  The compds. all showed IC50 values in the low μM range with I (R = 2-adamantylamino) exhibiting the best activity with an IC50 value of 1.00 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvdaQuprF1cbVg90H21EOLACvtfcHk0lgRI4lxzOFMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtrrP&md5=04751be9552f0e1fffb4481cb9dc5537</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DA.%2BR.%26aulast%3Dde%2BKock%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DP.%2BJ.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DBlackie%26aufirst%3DM.%2BA.%2BL.%26atitle%3DSynthesis%2520of%2520Novel%2520Triazole-Linked%2520Mefloquine%2520Derivatives%253A%2520Biological%2520Evaluation%2520against%2520Plasmodium%2520falciparum%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5466%26epage%3D5469%26doi%3D10.1016%2Fj.bmcl.2014.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. d. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, F. P.</span></span> <span> </span><span class="NLM_article-title">1-Phenyl-1H- and 2-Phenyl-2H-1,2,3-Triazol Derivatives: Design, Synthesis and Inhibitory Effect on Alpha-Glycosidases</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2013.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24487194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2jt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=461-476&author=D.+Gonzagaauthor=M.+R.+Sengerauthor=F.+d.+C.+da+Silvaauthor=V.+F.+Ferreiraauthor=F.+P.+Silva&title=1-Phenyl-1H-+and+2-Phenyl-2H-1%2C2%2C3-Triazol+Derivatives%3A+Design%2C+Synthesis+and+Inhibitory+Effect+on+Alpha-Glycosidases&doi=10.1016%2Fj.ejmech.2013.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: Design, synthesis and inhibitory effect on alpha-glycosidases</span></div><div class="casAuthors">Gonzaga, Daniel; Senger, Mario Roberto; de Carvalho da Silva, Fernando; Ferreira, Vitor Francisco; Silva, Floriano Paes, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Due to aging and increasingly overweight human population, the incidence of non-insulin dependent diabetes mellitus (NIDDM or Type 2 DM) is increasing considerably.  Therefore, searching for new α-glycosidase inhibitors (GIs) capable of slowing down carbohydrate assimilation by humans is an important strategy towards control of NIDDM.  In this report, the authors disclose the search for new easily accessible synthetic triazoles as antidiabetic compds.  Two series of non-glycoside triazoles were synthesized (series A and B) and screened against Saccharomyces cerevisiae (baker's yeast) α-glucosidase (MAL12) and porcine pancreatic α-amylase activity (PPA).  Of the 60 compds. tested at 500 μM, were considered hits (≥60% inhibition) six triazoles against MAL12 and three against PPA, with the inhibition reaching up to 99.4% on MAL12 and 88.6% on PPA.  The IC50 values were calcd. for both enzymes and ranged from 54 to 482 μM for MAL12 and 145 to 282 μM for PPA.  These results demonstrated the potential activity of simple and non-glycosidic triazoles as an important novel class of GIs for the development of drugs to treat Type 2 DM.  The synthesis of the target compds. was achieved by an azide-alkyne 1,3-dipolar cycloaddn., alkenylation, formylation method.  The title compds. thus formed included 1-phenyl-1H-1,2,3-triazole-4-methanol, 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-methanol 4-acetate (ester), 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-methanol 4-benzoate (ester), 1-phenyl-1H-1,2,3-triazole-4-carboxaldehyde (aldehyde), 4-ethenyl-1-phenyl-1H-1,2,3-triazole (alkene) and related substances, such as hydrazones, isomers, 2-phenyl-2H-1,2,3-triazole-4-methanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphOl3bKI2aDrVg90H21EOLACvtfcHk0li5reTC8IR-mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2jt7k%253D&md5=b4113eac48f12d8df99b2d6fe726d74d</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DGonzaga%26aufirst%3DD.%26aulast%3DSenger%26aufirst%3DM.%2BR.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2Bd.%2BC.%26aulast%3DFerreira%26aufirst%3DV.%2BF.%26aulast%3DSilva%26aufirst%3DF.%2BP.%26atitle%3D1-Phenyl-1H-%2520and%25202-Phenyl-2H-1%252C2%252C3-Triazol%2520Derivatives%253A%2520Design%252C%2520Synthesis%2520and%2520Inhibitory%2520Effect%2520on%2520Alpha-Glycosidases%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D461%26epage%3D476%26doi%3D10.1016%2Fj.ejmech.2013.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klnfe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belay, Y. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Thiosemicarbazone–Triazole Hybrid Compounds Antimalarial Agents</span>. <i>S. Afr. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">135</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=130-135&author=H.+Klnfeauthor=Y.+H.+Belay&title=Synthesis+and+Biological+Evaluation+of+Novel+Thiosemicarbazone%E2%80%93Triazole+Hybrid+Compounds+Antimalarial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlnfe%26aufirst%3DH.%26aulast%3DBelay%26aufirst%3DY.%2BH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Thiosemicarbazone%25E2%2580%2593Triazole%2520Hybrid%2520Compounds%2520Antimalarial%2520Agents%26jtitle%3DS.%2520Afr.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D130%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J.</span></span> <span> </span><span class="NLM_article-title">Where Have All the Antibiotics Gone?</span>. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1155/2006/707296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1155%2F2006%2F707296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18382641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD1c3isVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=287-290&author=J.+Davies&title=Where+Have+All+the+Antibiotics+Gone%3F&doi=10.1155%2F2006%2F707296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Where have All the Antibiotics Gone?</span></div><div class="casAuthors">Davies Julian</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">287-90</span>
        ISSN:<span class="NLM_cas:issn">1712-9532</span>.
    </div><div class="casAbstract">The discovery of antibiotics some 60 years ago was anticipated to herald the end of infectious diseases.  However, microbial evolution and genetic jugglery have dispelled this notion; the constant increase in the appearance of resistant strains has not been matched by the introduction of new therapeutic agents.  On the contrary, the dire need for novel antibiotics has coincided with a reduction in antibiotic discovery programs in the pharmaceutical industry.  As a result, the treatment of microbial diseases has reached a point where many infections are essentially untreatable by the antimicrobial agents currently available.  At the present time, numerous initiatives are being undertaken by physicians and by governments in an attempt to redress this situation.  In addition, alternative approaches to antibiotics for the treatment of infectious diseases are being explored intensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS39oRQPOIHnrmQt-ICR3qNfW6udTcc2eZYpfSpGCI3QLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3isVSltw%253D%253D&md5=ba2232e1cf5d7068573fe957cfda85cd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1155%2F2006%2F707296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2006%252F707296%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DJ.%26atitle%3DWhere%2520Have%2520All%2520the%2520Antibiotics%2520Gone%253F%26jtitle%3DCanadian%2520Journal%2520of%2520Infectious%2520Diseases%2520%2526%2520Medical%2520Microbiology%26date%3D2006%26volume%3D17%26spage%3D287%26epage%3D290%26doi%3D10.1155%2F2006%2F707296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Centers for Disease Control and Prevention</span>. <a href="https://www.cdc.gov/drugresistance/about.html" class="extLink">https://www.cdc.gov/drugresistance/about.html</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Centers+for+Disease+Control+and+Prevention.+https%3A%2F%2Fwww.cdc.gov%2Fdrugresistance%2Fabout.html+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance" class="extLink">https://www.who.int/en/news-room/fact-sheets/detail/antibiotic-resistance</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fen%2Fnews-room%2Ffact-sheets%2Fdetail%2Fantibiotic-resistance+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reygaert, W. C.</span></span> <span> </span><span class="NLM_article-title">An Overview of the Antimicrobial Resistance Mechanisms of Bacteria</span>. <i>AIMS Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.3934/microbiol.2018.3.482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3934%2Fmicrobiol.2018.3.482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31294229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslShur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=482-501&author=W.+C.+Reygaert&title=An+Overview+of+the+Antimicrobial+Resistance+Mechanisms+of+Bacteria&doi=10.3934%2Fmicrobiol.2018.3.482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the antimicrobial resistance mechanisms of bacteria</span></div><div class="casAuthors">Reygaert, Wanda C.</div><div class="citationInfo"><span class="NLM_cas:title">AIMS Microbiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">482-501</span>CODEN:
                <span class="NLM_cas:coden">AMIIDH</span>;
        ISSN:<span class="NLM_cas:issn">2471-1888</span>.
    
            (<span class="NLM_cas:orgname">AIMS Press</span>)
        </div><div class="casAbstract">Resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide.  When antibiotics were first introduced in the 1900's, it was thought that we had won the war against microorganisms.  It was soon discovered however, that the microorganisms were capable of developing resistance to any of the drugs that were used.  Apparently most pathogenic microorganisms have the capability of developing resistance to at least some antimicrobial agents.  The main mechanisms of resistance are: limiting uptake of a drug, modification of a drug target, inactivation of a drug, and active efflux of a drug.  These mechanisms may be native to the microorganisms, or acquired from other microorganisms.  Understanding more about these mechanisms should hopefully lead to better treatment options for infective diseases, and development of antimicrobial drugs that can withstand the microorganisms attempts to become resistant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-z_mr8zG27Vg90H21EOLACvtfcHk0li5reTC8IR-mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslShur7F&md5=36fabb687fa636cb2e85c272508db088</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.3934%2Fmicrobiol.2018.3.482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3934%252Fmicrobiol.2018.3.482%26sid%3Dliteratum%253Aachs%26aulast%3DReygaert%26aufirst%3DW.%2BC.%26atitle%3DAn%2520Overview%2520of%2520the%2520Antimicrobial%2520Resistance%2520Mechanisms%2520of%2520Bacteria%26jtitle%3DAIMS%2520Microbiol.%26date%3D2018%26volume%3D4%26spage%3D482%26epage%3D501%26doi%3D10.3934%2Fmicrobiol.2018.3.482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeli, Y.</span></span> <span> </span><span class="NLM_article-title">The Negative Impact of Antibiotic Resistance</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.cmi.2015.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.cmi.2015.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26706614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC28rkvFaktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=416-422&author=N.+D.+Friedmanauthor=E.+Temkinauthor=Y.+Carmeli&title=The+Negative+Impact+of+Antibiotic+Resistance&doi=10.1016%2Fj.cmi.2015.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The negative impact of antibiotic resistance</span></div><div class="casAuthors">Friedman N D; Temkin E; Carmeli Y</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibacterial therapy is one of the most important medical developments of the twentieth century; however, the spread of resistance in healthcare settings and in the community threatens the enormous gains made by the availability of antibiotic therapy.  Infections caused by resistant bacteria lead to up to two-fold higher rates of adverse outcomes compared with similar infections caused by susceptible strains.  These adverse outcomes may be clinical or economic and reflect primarily the failure or delay of antibiotic treatment.  The magnitude of these adverse outcomes will be more pronounced as disease severity, strain virulence, or host vulnerability increases.  The negative impacts of antibacterial resistance can be measured at the patient level by increased morbidity and mortality, at the healthcare level by increased resource utilization, higher costs and reduced hospital activity and at the society level by antibiotic treatment guidelines favouring increasingly broad-spectrum empiric therapy.  In this review we will discuss the negative impact of antibiotic resistance on patients, the healthcare system and society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgWHlR74U1QVVwdslNBF-tfW6udTcc2eZe6UCvH1wCU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rkvFaktg%253D%253D&md5=0e374fdb882ce959b3ec4241649b9545</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.cmi.2015.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmi.2015.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DN.%2BD.%26aulast%3DTemkin%26aufirst%3DE.%26aulast%3DCarmeli%26aufirst%3DY.%26atitle%3DThe%2520Negative%2520Impact%2520of%2520Antibiotic%2520Resistance%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2016%26volume%3D22%26spage%3D416%26epage%3D422%26doi%3D10.1016%2Fj.cmi.2015.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaplewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piddock, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of New Antibacterial Drugs: Learning from Experience?</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1452</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1093/jac/dky019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fjac%2Fdky019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29438542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvFensrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1452-1459&author=N.+Jacksonauthor=L.+Czaplewskiauthor=L.+J.+V.+Piddock&title=Discovery+and+Development+of+New+Antibacterial+Drugs%3A+Learning+from+Experience%3F&doi=10.1093%2Fjac%2Fdky019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of new antibacterial drugs: learning from experience?</span></div><div class="casAuthors">Jackson, Nicole; Czaplewski, Lloyd; Piddock, Laura J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1452-1459</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Antibiotic (antibacterial) resistance is a serious global problem and the need for new treatments is urgent.  The current antibiotic discovery model is not delivering new agents at a rate that is sufficient to combat present levels of antibiotic resistance.  This has led to fears of the arrival of a 'post-antibiotic era'.  Scientific difficulties, an unfavorable regulatory climate, multiple company mergers and the low financial returns assocd. with antibiotic drug development have led to the withdrawal of many pharmaceutical companies from the field.  The regulatory climate has now begun to improve, but major scientific hurdles still impede the discovery and development of novel antibacterial agents.  To facilitate discovery activities there must be increased understanding of the scientific problems experienced by pharmaceutical companies.  This must be coupled with addressing the current antibiotic resistance crisis so that compds. and ultimately drugs are delivered to treat the most urgent clin. challenges.  By understanding the causes of the failures and successes of the pharmaceutical industry's research history, duplication of discovery programs will be reduced, increasing the productivity of the antibiotic drug discovery pipeline by academia and small companies.  The most important scientific issues to address are getting mols. into the Gram-neg. bacterial cell and avoiding their efflux.  Hence screening programs should focus their efforts on whole bacterial cells rather than cell-free systems.  Despite falling out of favor with pharmaceutical companies, natural product research still holds promise for providing new mols. as a basis for discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuEyGokOC1LLVg90H21EOLACvtfcHk0ljKhP7uesjlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvFensrg%253D&md5=b238daaabc100b0bf57d64ef63772917</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky019%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DN.%26aulast%3DCzaplewski%26aufirst%3DL.%26aulast%3DPiddock%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520New%2520Antibacterial%2520Drugs%253A%2520Learning%2520from%2520Experience%253F%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1452%26epage%3D1459%26doi%3D10.1093%2Fjac%2Fdky019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hester, J. B. J.</span>; <span class="NLM_string-name">Alexander, D. L.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones Having a Sulfoximine Functionality and Their Use as Antimicrobial Agents</span>. <span class="NLM_patent">WO2001046185A1</span>, Jun 28, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.+B.+J.+Hester&author=D.+L.+Alexander&title=Oxazolidinones+Having+a+Sulfoximine+Functionality+and+Their+Use+as+Antimicrobial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHester%26aufirst%3DJ.%2BB.%2BJ.%26atitle%3DOxazolidinones%2520Having%2520a%2520Sulfoximine%2520Functionality%2520and%2520Their%2520Use%2520as%2520Antimicrobial%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremillion, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span> <span> </span><span class="NLM_article-title">Effect of Neutrophil Elastase Inhibitor (Sivelestat Sodium) in the Treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis</span>. <i>Intern. Med. (Tokyo, Jpn.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2423</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.49.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2169%2Finternalmedicine.49.4010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21088343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2423-2432&author=K.+Iwataauthor=A.+Doiauthor=G.+Ohjiauthor=H.+Okaauthor=Y.+Obaauthor=K.+Takimotoauthor=W.+Igarashiauthor=D.+H.+Gremillionauthor=T.+Shimada&title=Effect+of+Neutrophil+Elastase+Inhibitor+%28Sivelestat+Sodium%29+in+the+Treatment+of+Acute+Lung+Injury+%28ALI%29+and+Acute+Respiratory+Distress+Syndrome+%28ARDS%29%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.2169%2Finternalmedicine.49.4010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis</span></div><div class="casAuthors">Iwata Kentaro; Doi Asako; Ohji Goh; Oka Hideaki; Oba Yuichiro; Takimoto Kohei; Igarashi Wataru; Gremillion David H; Shimada Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2423-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury.  However, the clinical efficacy of the medication has not been convincingly demonstrated.  METHODS:  We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome.  Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies.  Authors were contacted if necessary.  ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE.  The primary outcome was mortality within 28-30 days after randomization.  Relative risks were pooled with the random effect model.  RESULTS:  8 trials were included in the analysis.  There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26).  Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28).  There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO(2)/FiO(2) ratio (0.30, 0.05 to 0.56).  Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias.  CONCLUSION:  Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRv_-Z2qP_xPh3YQQtAhNufW6udTcc2eZe6UCvH1wCU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D&md5=12473c878a1d894ff1847afb7a655f04</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.49.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.49.4010%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DA.%26aulast%3DOhji%26aufirst%3DG.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DOba%26aufirst%3DY.%26aulast%3DTakimoto%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DW.%26aulast%3DGremillion%26aufirst%3DD.%2BH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DEffect%2520of%2520Neutrophil%2520Elastase%2520Inhibitor%2520%2528Sivelestat%2520Sodium%2529%2520in%2520the%2520Treatment%2520of%2520Acute%2520Lung%2520Injury%2520%2528ALI%2529%2520and%2520Acute%2520Respiratory%2520Distress%2520Syndrome%2520%2528ARDS%2529%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DIntern.%2520Med.%2520%2528Tokyo%252C%2520Jpn.%2529%26date%3D2010%26volume%3D49%26spage%3D2423%26epage%3D2432%26doi%3D10.2169%2Finternalmedicine.49.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajbongshi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuturgoon, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somboro, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naicker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvidsson, P. I.</span></span> <span> </span><span class="NLM_article-title">N-Trifluoromethylthiolated Sulfonimidamides and Sulfoximines: Anti-Microbial, Anti-Mycobacterial, and Cytotoxic Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1461</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKju7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1457-1461&author=N.+Thotaauthor=P.+Makamauthor=K.+K.+Rajbongshiauthor=S.+Nagiahauthor=N.+S.+Abdulauthor=A.+A.+Chuturgoonauthor=A.+Kaushikauthor=G.+Lamichhaneauthor=A.+M.+Somboroauthor=H.+G.+Krugerauthor=T.+Govenderauthor=T.+Naickerauthor=P.+I.+Arvidsson&title=N-Trifluoromethylthiolated+Sulfonimidamides+and+Sulfoximines%3A+Anti-Microbial%2C+Anti-Mycobacterial%2C+and+Cytotoxic+Activity&doi=10.1021%2Facsmedchemlett.9b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">N-Trifluoromethylthiolated Sulfonimidamides and Sulfoximines: Anti-microbial, Anti-mycobacterial, and Cytotoxic Activity</span></div><div class="casAuthors">Thota, Niranjan; Makam, Parameshwar; Rajbongshi, Kamal K.; Nagiah, Savania; Abdul, Naeem Sheik; Chuturgoon, Anil A.; Kaushik, Amit; Lamichhane, Gyanu; Somboro, Anou M.; Kruger, Hendrik G.; Govender, Thavendran; Naicker, Tricia; Arvidsson, Per I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1457-1461</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We demonstrate the expanded utility of a recently described N-trifluoromethylthiolation protocol to sulfonimidamide contg. substances.  The novel N-trifluoromethylthio sulfonimidamide derivs. thus obtained were evaluated for antibacterial activity against Mycobacterium tuberculosis and Mycobacterium abscessus and Gram + Ve (Streptococcus aureus, Bacillus subtilis), and Gram - Ve (Escherichia coli, Pseudomonas aeruginosa) bacteria.  Two compds. (I and II) showed high antimycobacterial activity with MIC value of 4-8 μg/mL; i.e. comparable to WHO recommended 1st line antibiotic for TB infection ethambutol.  The same compds. were also cytotoxic in HepG2 cells (I IC50 = 15 and II 65 μg/mL).  A structure activity relation, using matched pair anal., gave the unexpected conclusion that the trifluoromethylthio moiety was responsible for the cellular and bacterial toxicity.  Given the increasing use of the trifluoromethylthio group in contemporary medicinal chem., this observation calls for considerations before implementation of the functionality in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4EAHBZr3I-rVg90H21EOLACvtfcHk0lhCaa3GV-d0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKju7bF&md5=42018042a1e12ba323bd22356c6c2595</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00285%26sid%3Dliteratum%253Aachs%26aulast%3DThota%26aufirst%3DN.%26aulast%3DMakam%26aufirst%3DP.%26aulast%3DRajbongshi%26aufirst%3DK.%2BK.%26aulast%3DNagiah%26aufirst%3DS.%26aulast%3DAbdul%26aufirst%3DN.%2BS.%26aulast%3DChuturgoon%26aufirst%3DA.%2BA.%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DSomboro%26aufirst%3DA.%2BM.%26aulast%3DKruger%26aufirst%3DH.%2BG.%26aulast%3DGovender%26aufirst%3DT.%26aulast%3DNaicker%26aufirst%3DT.%26aulast%3DArvidsson%26aufirst%3DP.%2BI.%26atitle%3DN-Trifluoromethylthiolated%2520Sulfonimidamides%2520and%2520Sulfoximines%253A%2520Anti-Microbial%252C%2520Anti-Mycobacterial%252C%2520and%2520Cytotoxic%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1457%26epage%3D1461%26doi%3D10.1021%2Facsmedchemlett.9b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalakas, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udwadia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Management of Drug-Resistant Tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31882-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2819%2931882-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31526739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=953-966&author=C.+Langeauthor=K.+Dhedaauthor=D.+Chesovauthor=A.+M.+Mandalakasauthor=Z.+Udwadiaauthor=C.+R.+Horsburgh&title=Management+of+Drug-Resistant+Tuberculosis&doi=10.1016%2FS0140-6736%2819%2931882-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Management of drug-resistant tuberculosis</span></div><div class="casAuthors">Lange, Christoph; Dheda, Keertan; Chesov, Dumitru; Mandalakas, Anna Maria; Udwadia, Zarir; Horsburgh, C. Robert Jr</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10202</span>),
    <span class="NLM_cas:pages">953-966</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-resistant tuberculosis is a major public health concern in many countries.  Over the past decade, the no. of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase.  Globally, 4·6% of patients with tuberculosis have multidrug-resistant tuberculosis, but in some areas, like Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, this proportion exceeds 25%.  Treatment for patients with multidrug-resistant tuberculosis is prolonged (ie, 9-24 mo) and patients with multidrug-resistant tuberculosis have less favorable outcomes than those treated for drug-susceptible tuberculosis.  Individualised multidrug-resistant tuberculosis treatment with novel (eg, bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcomes.  Some clin. trials are evaluating 6-mo regimens to simplify management and improve outcomes of patients with multidrug-resistant tuberculosis.  Here we review optimal diagnostic and treatment strategies for patients with drug-resistant tuberculosis and their contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGregCFW97a6-rVg90H21EOLACvtfcHk0lhCaa3GV-d0Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShurnM&md5=c6ff64bf9bbcdef8f48354b3c87f07c4</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931882-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931882-3%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DChesov%26aufirst%3DD.%26aulast%3DMandalakas%26aufirst%3DA.%2BM.%26aulast%3DUdwadia%26aufirst%3DZ.%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26atitle%3DManagement%2520of%2520Drug-Resistant%2520Tuberculosis%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D953%26epage%3D966%26doi%3D10.1016%2FS0140-6736%2819%2931882-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">International Diabetes Federation</span>. <a href="https://diabetesatlas.org/en/resources" class="extLink">https://diabetesatlas.org/en/resources</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International+Diabetes+Federation.+https%3A%2F%2Fdiabetesatlas.org%2Fen%2Fresources+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F. B.</span></span> <span> </span><span class="NLM_article-title">The Global Implications of Diabetes and Cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60886-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2814%2960886-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24910221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgs1KntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2014&pages=1947-1948&author=Y.+Shiauthor=F.+B.+Hu&title=The+Global+Implications+of+Diabetes+and+Cancer&doi=10.1016%2FS0140-6736%2814%2960886-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">The global implications of diabetes and cancer</span></div><div class="casAuthors">Shi Yuankai; Hu Frank B</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">9933</span>),
    <span class="NLM_cas:pages">1947-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWtmcQeIqOz-R_TJajKxJDfW6udTcc2eZJIm0dMDFx7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgs1KntA%253D%253D&md5=5f6ae34cb370a60ee4b2ad9fa3376ceb</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960886-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960886-2%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DF.%2BB.%26atitle%3DThe%2520Global%2520Implications%2520of%2520Diabetes%2520and%2520Cancer%26jtitle%3DLancet%26date%3D2014%26volume%3D383%26spage%3D1947%26epage%3D1948%26doi%3D10.1016%2FS0140-6736%2814%2960886-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeFronzo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrannini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groop, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, R.</span></span> <span> </span><span class="NLM_article-title">Type 2 Diabetes Mellitus</span>. <i>Nature Reviews Disease Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15019</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrdp.2015.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27189025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1Smsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15019&author=R.+A.+DeFronzoauthor=E.+Ferranniniauthor=L.+Groopauthor=R.+R.+Henryauthor=W.+H.+Hermanauthor=J.+J.+Holstauthor=F.+B.+Huauthor=C.+R.+Kahnauthor=I.+Razauthor=G.+I.+Shulmanauthor=D.+C.+Simonsonauthor=M.+A.+Testaauthor=R.+Weiss&title=Type+2+Diabetes+Mellitus&doi=10.1038%2Fnrdp.2015.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 diabetes mellitus</span></div><div class="casAuthors">DeFronzo Ralph A; Ferrannini Ele; Groop Leif; Henry Robert R; Herman William H; Holst Jens Juul; Hu Frank B; Kahn C Ronald; Raz Itamar; Shulman Gerald I; Simonson Donald C; Testa Marcia A; Weiss Ram</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15019</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 diabetes mellitus (T2DM) is an expanding global health problem, closely linked to the epidemic of obesity.  Individuals with T2DM are at high risk for both microvascular complications (including retinopathy, nephropathy and neuropathy) and macrovascular complications (such as cardiovascular comorbidities), owing to hyperglycaemia and individual components of the insulin resistance (metabolic) syndrome.  Environmental factors (for example, obesity, an unhealthy diet and physical inactivity) and genetic factors contribute to the multiple pathophysiological disturbances that are responsible for impaired glucose homeostasis in T2DM.  Insulin resistance and impaired insulin secretion remain the core defects in T2DM, but at least six other pathophysiological abnormalities contribute to the dysregulation of glucose metabolism.  The multiple pathogenetic disturbances present in T2DM dictate that multiple antidiabetic agents, used in combination, will be required to maintain normoglycaemia.  The treatment must not only be effective and safe but also improve the quality of life.  Several novel medications are in development, but the greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.  For an illustrated summary of this Primer, visit: http://go.nature.com/V2eGfN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp7RmPT9C1jpPq5LRczm8ffW6udTcc2eZJIm0dMDFx7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1Smsw%253D%253D&md5=e373d9ca912e9365d8b3fb6571b9ad13</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.19%26sid%3Dliteratum%253Aachs%26aulast%3DDeFronzo%26aufirst%3DR.%2BA.%26aulast%3DFerrannini%26aufirst%3DE.%26aulast%3DGroop%26aufirst%3DL.%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DHerman%26aufirst%3DW.%2BH.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DHu%26aufirst%3DF.%2BB.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DRaz%26aufirst%3DI.%26aulast%3DShulman%26aufirst%3DG.%2BI.%26aulast%3DSimonson%26aufirst%3DD.%2BC.%26aulast%3DTesta%26aufirst%3DM.%2BA.%26aulast%3DWeiss%26aufirst%3DR.%26atitle%3DType%25202%2520Diabetes%2520Mellitus%26jtitle%3DNature%2520Reviews%2520Disease%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15019%26doi%3D10.1038%2Fnrdp.2015.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verspohl, E. J.</span></span> <span> </span><span class="NLM_article-title">Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/pr.110.003319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fpr.110.003319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22407617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=188-237&author=E.+J.+Verspohl&title=Novel+Pharmacological+Approaches+to+the+Treatment+of+Type+2+Diabetes&doi=10.1124%2Fpr.110.003319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Novel pharmacological approaches to the treatment of type 2 diabetes</span></div><div class="casAuthors">Verspohl, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-237</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The huge increase in type 2 diabetes is a burden worldwide.  Many marketed compds. do not address relevant aspects of the disease; they may already compensate for defects in insulin secretion and insulin action, but loss of secreting cells (β-cell destruction), hyperglucagonemia, gastric emptying, enzyme activation/inhibition in insulin-sensitive cells, substitution or antagonizing of physiol. hormones and pathways, finally leading to secondary complications of diabetes, are not sufficiently addressed.  In addn., side effects for established therapies such as hypoglycemias and wt. gain have to be diminished.  At present, nearly 1000 compds. have been described, and approx. 180 of these are going to be developed (already in clin. studies), some of them directly influencing enzyme activity, influencing pathophysiol. pathways, and some using G-protein-coupled receptors.  In addn., immunol. approaches and antisense strategies are going to be developed.  Many compds. are derived from physiol. compds. (hormones) aiming at improving their kinetics and selectivity, and others are chem. compds. that were obtained by screening for a newly identified target in the physiol. or pathophysiol. machinery.  In some areas, great progress is obsd. (e.g., incretin area); in others, no great progress is obvious (e.g., glucokinase activators), and other areas are not recommended for further research.  For all scientific areas, conclusions with respect to their impact on diabetes are given.  Potential targets for which no chem. compd. has yet been identified as a ligand (agonist or antagonist) are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSgTyKdbrIarVg90H21EOLACvtfcHk0lj7qTr6N6kXXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslKksbs%253D&md5=75a2134cceb893d4190ca720d38f2505</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003319%26sid%3Dliteratum%253Aachs%26aulast%3DVerspohl%26aufirst%3DE.%2BJ.%26atitle%3DNovel%2520Pharmacological%2520Approaches%2520to%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DPharmacol.%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D188%26epage%3D237%26doi%3D10.1124%2Fpr.110.003319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalabalik, J.</span></span> <span> </span><span class="NLM_article-title">Management of Type-2 Diabetes Mellitus in Adults: Focus on Individualizing Non-Insulin Therapies</span>. <i>P & T</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">696</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23319847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3s3psFCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=687-696&author=L.+Brunettiauthor=J.+Kalabalik&title=Management+of+Type-2+Diabetes+Mellitus+in+Adults%3A+Focus+on+Individualizing+Non-Insulin+Therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies</span></div><div class="casAuthors">Brunetti Luigi; Kalabalik Julie</div><div class="citationInfo"><span class="NLM_cas:title">P & T : a peer-reviewed journal for formulary management</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">687-96</span>
        ISSN:<span class="NLM_cas:issn">1052-1372</span>.
    </div><div class="casAbstract">Successful management of hyperglycemia may involve glucose and non-glucose therapies, non-drug approaches, and non-insulin agents.  Treatment should be tailored to each patient, with an emphasis on safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfXBjPdvtDn8rRqEXsZufAfW6udTcc2eZrFMM9xXWKE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3psFCqtw%253D%253D&md5=d3d50d32a418b43ef3a797fd2ce3077b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrunetti%26aufirst%3DL.%26aulast%3DKalabalik%26aufirst%3DJ.%26atitle%3DManagement%2520of%2520Type-2%2520Diabetes%2520Mellitus%2520in%2520Adults%253A%2520Focus%2520on%2520Individualizing%2520Non-Insulin%2520Therapies%26jtitle%3DP%2520%2526%2520T%26date%3D2012%26volume%3D37%26spage%3D687%26epage%3D696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, C. F.</span></span> <span> </span><span class="NLM_article-title">Peptide Degradation and the Role of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.peptides.2017.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.peptides.2017.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29412814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2018&pages=150-157&author=C.+F.+Deacon&title=Peptide+Degradation+and+the+Role+of+DPP-4+Inhibitors+in+the+Treatment+of+Type+2+Diabetes&doi=10.1016%2Fj.peptides.2017.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes</span></div><div class="casAuthors">Deacon, Carolyn F.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-157</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Dipeptidyl peptidase-4 (DPP-4) inhibitors are now a widely used, safe and efficacious class of antidiabetic drugs, which were developed prospectively using a rational drug design approach based on a thorough understanding of the endocrinol. and degrdn. of glucagon-like peptide-1 (GLP-1).  GLP-1 is an intestinal hormone with potent insulinotropic and glucagonostatic effects and can normalize blood glucose levels in patients with type 2 diabetes, but the native peptide is not therapeutically useful because of its inherent metabolic instability.  Using the GLP-1/DPP-4 system and type 2 diabetes as an example, this review summarises how knowledge of a peptide's biol. effects coupled with an understanding of the pathways involved in its metabolic clearance can be exploited in a rational, step-by-step manner to develop a therapeutic agent, which is effective and well tolerated, and any side effects are minor and largely predictable.  Other peptides with metabolic effects which can also be degraded by DPP-4 will be reviewed, and their potential role as addnl. mediators of the effects of DPP-4 inhibitors will be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAu3aVseiELVg90H21EOLACvtfcHk0lj7qTr6N6kXXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFyisrk%253D&md5=0c8421485e0f6790aad8ce89267ef9a1</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.peptides.2017.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.peptides.2017.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26atitle%3DPeptide%2520Degradation%2520and%2520the%2520Role%2520of%2520DPP-4%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DPeptides%26date%3D2018%26volume%3D100%26spage%3D150%26epage%3D157%26doi%3D10.1016%2Fj.peptides.2017.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, C. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demuth, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pospisilik, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, R.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl Peptidase IV Inhibitors: How Do They Work as New Antidiabetic Agents?</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.regpep.2004.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.regpep.2004.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15780435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVajsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=159-165&author=C.+H.+S.+McIntoshauthor=H.-U.+Demuthauthor=J.+A.+Pospisilikauthor=R.+Pederson&title=Dipeptidyl+Peptidase+IV+Inhibitors%3A+How+Do+They+Work+as+New+Antidiabetic+Agents%3F&doi=10.1016%2Fj.regpep.2004.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?</span></div><div class="casAuthors">McIntosh, Christopher H. S.; Demuth, Hans-Ulrich; Pospisilik, J. Andrew; Pederson, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A no. of new approaches to diabetes therapy are currently undergoing clin. trials, including those involving stimulation of the pancreatic β-cell with the gut-derived insulinotropic hormones (incretins), GIP and GLP-1.  The current review focuses on an approach based on the inhibition of dipeptidyl peptidase IV (DP IV), the major enzyme responsible for degrading the incretins in vivo.  The rationale for this approach was that blockade of incretin degrdn. would increase their physiol. actions, including the stimulation of insulin secretion and inhibition of gastric emptying.  It is now clear that both GIP and GLP-1 also have powerful effects on β-cell differentiation, mitogenesis and survival.  By potentiating these pleiotropic actions of the incretins, DP IV inhibition can therefore preserve β-cell mass and improve secretory function in diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrub2GeHyCJMrVg90H21EOLACvtfcHk0ljab3vCXxYADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVajsLo%253D&md5=72f1cca0efcad5c0bd2bf67b1bed8f65</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2004.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2004.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntosh%26aufirst%3DC.%2BH.%2BS.%26aulast%3DDemuth%26aufirst%3DH.-U.%26aulast%3DPospisilik%26aufirst%3DJ.%2BA.%26aulast%3DPederson%26aufirst%3DR.%26atitle%3DDipeptidyl%2520Peptidase%2520IV%2520Inhibitors%253A%2520How%2520Do%2520They%2520Work%2520as%2520New%2520Antidiabetic%2520Agents%253F%26jtitle%3DRegul.%2520Pept.%26date%3D2005%26volume%3D128%26spage%3D159%26epage%3D165%26doi%3D10.1016%2Fj.regpep.2004.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behme, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupré, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. J.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide 1 Improved Glycemic Control in Type 1 Diabetes</span>. <i>BMC Endocr. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/1472-6823-3-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2F1472-6823-3-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12697069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnt12qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=3&author=M.+T.+Behmeauthor=J.+Dupr%C3%A9author=T.+J.+McDonald&title=Glucagon-Like+Peptide+1+Improved+Glycemic+Control+in+Type+1+Diabetes&doi=10.1186%2F1472-6823-3-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1 improved glycemic control in type 1 diabetes</span></div><div class="casAuthors">Behme Margaret T; Dupre John; McDonald Thomas J</div><div class="citationInfo"><span class="NLM_cas:title">BMC endocrine disorders</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying.  We examined the potential of GLP-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion.  METHODS: Dose-finding studies were carried out to establish mid range doses for delay of gastric emptying indicated by postponement of pancreatic polypeptide responses after meals.  The selected dose of 0.63 micrograms/kg GLP-1 was administered before breakfast and lunch in 8-hour studies in hospital to establish the efficacy and safety of GLP-1.  In outside-hospital studies, GLP-1 or vehicle was self-administered double-blind before meals with usual insulin for five consecutive days by five males and three females with well-controlled C-peptide-negative type 1 diabetes.  Capillary blood glucose values were self-monitored before meals, at 30 and 60 min after breakfast and supper, and at bedtime.  Breakfast tests with GLP-1 were conducted on the day before and on the day after 5-day studies.  Paired t-tests and ANOVA were used for statistical analysis.  RESULTS: In 8-hour studies time-averaged incremental (delta) areas under the curves(AUC) for plasma glucose through 8 hours were decreased by GLP-1 compared to vehicle (3.2 PlusMinus; 0.9, mean PlusMinus; se, vs 5.4 PlusMinus; 0.8 mmol/l, p <.05), and for pancreatic polypeptide, an indicator of gastric emptying, through 30 min after meals (4.0 PlusMinus; 3.1 vs 37 PlusMinus; 9.6 pmol/l, p <.05) with no adverse effects.  Incremental glucagon levels through 60 min after meals were depressed by GLP-1 compared to vehicle (-3.7 PlusMinus; 2.5 vs 3.1 PlusMinus; 1.9 ng/l, p <.04).  In 5-day studies, AUC for capillary blood glucose levels were lower with GLP-1 than with vehicle (-0.64 PlusMinus; 0.33 vs 0.34 PlusMinus; 0.26 mmol/l, p <.05).  No assisted episode of hypoglycaemia or change in insulin dosage occurred.  Breakfast tests on the days immediately before and after 5-day trials showed no change in the effects of GLP-1.  CONCLUSION: We have demonstrated that subcutaneous GLP-1 can improve glucose control in type 1 diabetes without adverse effects when self-administered before meals with usual insulin during established intensive insulin treatment programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpyQ38jGmgUvx2phytoz6_fW6udTcc2eb4hJ6nQHagYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnt12qtw%253D%253D&md5=21aa6485e764d1208c1d04fc1c6f1295</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1186%2F1472-6823-3-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6823-3-3%26sid%3Dliteratum%253Aachs%26aulast%3DBehme%26aufirst%3DM.%2BT.%26aulast%3DDupr%25C3%25A9%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DT.%2BJ.%26atitle%3DGlucagon-Like%2520Peptide%25201%2520Improved%2520Glycemic%2520Control%2520in%2520Type%25201%2520Diabetes%26jtitle%3DBMC%2520Endocr.%2520Disord.%26date%3D2003%26volume%3D3%26spage%3D3%26doi%3D10.1186%2F1472-6823-3-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behme, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hramiak, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. J.</span></span> <span> </span><span class="NLM_article-title">Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.2337/diabetes.44.6.626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdiab.44.6.626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7789625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1antLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1995&pages=626-630&author=J.+Dupreauthor=M.+T.+Behmeauthor=I.+M.+Hramiakauthor=P.+McFarlaneauthor=M.+P.+Williamsonauthor=P.+Zabelauthor=T.+J.+McDonald&title=Glucagon-Like+Peptide+I+Reduces+Postprandial+Glycemic+Excursions+in+IDDM&doi=10.2337%2Fdiabetes.44.6.626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM</span></div><div class="casAuthors">Dupre, John; Behme, Margaret T.; Hramiak, Irene M.; McFarlane, Philip; Williamson, M. Paul; Zabel, Pamela; McDonald, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-30</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Effects of human glucagon-like peptide I (GLP-I)(7-36)amide were examd. in volunteers having insulin-dependent diabetes mellitus (IDDM) with residual C-peptide (CP) secretion (7 men and 1 woman; age, 31 yr; body mass index, 24.7 kg/m2; duration of diabetes, 3.2 yr; insulin dose, 0.41 U/kg/day; meal-stimulated CP, 1.0 nmol/L).  After a mixed meal (Sustacal, 30 kJ/kg), i.v. injection of GLP-I, 1.2 pmol/kg/min through 120 min, virtually abolished increments of plasma glucose, CP, pancreatic polypeptide (PP), and glucagon concns., with no significant effect on plasma gastrin levels during the infusions.  At reduced dosage (0.75 pmol/kg/min), GLP-I had lesser effects on plasma glucose and CP levels.  On cessation of i.v. GLP-I infusions after the meals, plasma glucose, CP, PP, and glucagon concns. rebounded toward control levels by 180 min, and the response of plasma gastrin was prolonged.  These rebound responses are consistent with intestinal delivery of food retained in the stomach on escape from inhibition of gastric emptying by GLP-I.  Infusion of 1.2 pmol/kg/min GLP-I with 20 g glucose (10% dextrose in water) injected i.v. over 60 min enhanced plasma responses of immunoreactive CP; the mean incremental areas under concn. curves (0-60 min) increased 6-fold, but the glycemic excursion was not affected.  Thus, in CP-pos. IDDM, pharmacol. doses of GLP-I reduce glycemic excursions after meals by a mechanism(s) not dependent on stimulation of insulin secretion, presumably involving delayed gastric emptying.  This effect of the peptide on blood glucose levels after meals may have therapeutic implications in both IDDM and non-insulin-dependent diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl20unSla1kbVg90H21EOLACvtfcHk0ljab3vCXxYADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1antLg%253D&md5=7eeddb1e7266a365e0ef806828db46f9</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.2337%2Fdiab.44.6.626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.44.6.626%26sid%3Dliteratum%253Aachs%26aulast%3DDupre%26aufirst%3DJ.%26aulast%3DBehme%26aufirst%3DM.%2BT.%26aulast%3DHramiak%26aufirst%3DI.%2BM.%26aulast%3DMcFarlane%26aufirst%3DP.%26aulast%3DWilliamson%26aufirst%3DM.%2BP.%26aulast%3DZabel%26aufirst%3DP.%26aulast%3DMcDonald%26aufirst%3DT.%2BJ.%26atitle%3DGlucagon-Like%2520Peptide%2520I%2520Reduces%2520Postprandial%2520Glycemic%2520Excursions%2520in%2520IDDM%26jtitle%3DDiabetes%26date%3D1995%26volume%3D44%26spage%3D626%26epage%3D630%26doi%3D10.2337%2Fdiabetes.44.6.626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biftu, T.</span>; <span class="NLM_string-name">Khan, T.</span>; <span class="NLM_string-name">Treating, A.</span></span> <span> </span><span class="NLM_article-title">Diabetes with Dipeptidyl Peptidase-IV Inhibitors</span>. <span class="NLM_patent">WO/2014/018355, US/2015/0175609</span>, Jan 30, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Biftu&author=T.+Khan&author=A.+Treating&title=Diabetes+with+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26atitle%3DDiabetes%2520with%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karasik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzeff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. P.</span></span> <span> </span><span class="NLM_article-title">Sitagliptin, a DPP-4 Inhibitor for the Treatment of Patients with Type 2 Diabetes: A Review of Recent Clinical Trials</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1185/030079908X261069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1185%2F030079908X261069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18182122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlahsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2008&pages=489-496&author=A.+Karasikauthor=P.+Aschnerauthor=H.+Katzeffauthor=M.+J.+Daviesauthor=P.+P.+Stein&title=Sitagliptin%2C+a+DPP-4+Inhibitor+for+the+Treatment+of+Patients+with+Type+2+Diabetes%3A+A+Review+of+Recent+Clinical+Trials&doi=10.1185%2F030079908X261069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials</span></div><div class="casAuthors">Karasik, Avraham; Aschner, Pablo; Katzeff, Harvey; Davies, Michael J.; Stein, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antihyperglycemic agents that enhance the body's ability to regulate blood glucose by increasing the active levels of incretins, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).  There are numerous DPP-4 inhibitors in development with sitagliptin as the first approved agent for the treatment of patients with type 2 diabetes.  Objective: The purpose of this review is to provide an overview of the clin. trial results with sitagliptin.  Methods: Clin. trials published between Jan. 2005 (first sitagliptin publication) and Nov. 2007 were included in this review.  Medline was searched using the search terms: MK-0431 or sitagliptin.  Findings: Sitagliptin, an oral, once-daily, and highly selective DPP-4 inhibitor, has been evaluated in clin. trials as monotherapy, as add-on therapy, or as initial combination therapy with metformin.  Sitagliptin provided effective fasting and postprandial glycemic control in a wide range of patients with type 2 diabetes.  Markers of β-cell function (HOMA-β and proinsulin/insulin ratio) were improved with sitagliptin treatment.  In these clin. trials, sitagliptin was generally well tolerated with an overall incidence of adverse experiences comparable to placebo, a low risk of hypoglycemia or gastrointestinal adverse experiences, and a neutral effect on body wt.  The findings presented in this review are limited to the specific patient population enrolled in each clin. trial and for durations for up to 1 yr.  Future clin. studies should evaluate whether this class of agents has the potential to delay progression and/or prevent type 2 diabetes.  Conclusions: Sitagliptin has been shown to be effective and well-tolerated in various treatment regimens and may be considered for both initial therapy and as add-on therapy for patients with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC59qTagO1NrVg90H21EOLACvtfcHk0ljab3vCXxYADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlahsrg%253D&md5=c8a6a7b3d6b8cdff8cba2d8245a6ec50</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1185%2F030079908X261069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F030079908X261069%26sid%3Dliteratum%253Aachs%26aulast%3DKarasik%26aufirst%3DA.%26aulast%3DAschner%26aufirst%3DP.%26aulast%3DKatzeff%26aufirst%3DH.%26aulast%3DDavies%26aufirst%3DM.%2BJ.%26aulast%3DStein%26aufirst%3DP.%2BP.%26atitle%3DSitagliptin%252C%2520a%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Type%25202%2520Diabetes%253A%2520A%2520Review%2520of%2520Recent%2520Clinical%2520Trials%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2008%26volume%3D24%26spage%3D489%26epage%3D496%26doi%3D10.1185%2F030079908X261069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfrengle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span> <span> </span><span class="NLM_article-title">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-Ynyl-3-Methyl-1-(4-Methyl-Quinazolin-2-Ylmethyl)-3,7-Dihydropurine-2,6-Dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1021/jm701280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6450-6453&author=M.+Eckhardtauthor=E.+Langkopfauthor=M.+Markauthor=M.+Tadayyonauthor=L.+Thomasauthor=H.+Narauthor=W.+Pfrengleauthor=B.+Guthauthor=R.+Lotzauthor=P.+Siegerauthor=H.+Fuchsauthor=F.+Himmelsbach&title=8-%283-%28R%29-Aminopiperidin-1-yl%29-7-but-2-Ynyl-3-Methyl-1-%284-Methyl-Quinazolin-2-Ylmethyl%29-3%2C7-Dihydropurine-2%2C6-Dione+%28BI+1356%29%2C+a+Highly+Potent%2C+Selective%2C+Long-Acting%2C+and+Orally+Bioavailable+DPP-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm701280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Eckhardt, Matthias; Langkopf, Elke; Mark, Michael; Tadayyon, Moh; Thomas, Leo; Nar, Herbert; Pfrengle, Waldemar; Guth, Brian; Lotz, Ralf; Sieger, Peter; Fuchs, Holger; Himmelsbach, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chem. class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated.  Systematic structural variations have led to 1 (BI 1356, I), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species.  1 Is currently undergoing clin. phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVyDZtAZGjgLVg90H21EOLACvtfcHk0lj6uL397RB33g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ&md5=442ec88b800d899cc7a1f1528e1af4fa</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Fjm701280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701280z%26sid%3Dliteratum%253Aachs%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DLangkopf%26aufirst%3DE.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPfrengle%26aufirst%3DW.%26aulast%3DGuth%26aufirst%3DB.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DHimmelsbach%26aufirst%3DF.%26atitle%3D8-%25283-%2528R%2529-Aminopiperidin-1-yl%2529-7-but-2-Ynyl-3-Methyl-1-%25284-Methyl-Quinazolin-2-Ylmethyl%2529-3%252C7-Dihydropurine-2%252C6-Dione%2520%2528BI%25201356%2529%252C%2520a%2520Highly%2520Potent%252C%2520Selective%252C%2520Long-Acting%252C%2520and%2520Orally%2520Bioavailable%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6450%26epage%3D6453%26doi%3D10.1021%2Fjm701280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, S. A.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase: A Target for Drugs Both Ancient and Modern</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chembiol.2012.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23102217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1222-1236&author=D.+G.+Hardieauthor=F.+A.+Rossauthor=S.+A.+Hawley&title=AMP-Activated+Protein+Kinase%3A+A+Target+for+Drugs+Both+Ancient+and+Modern&doi=10.1016%2Fj.chembiol.2012.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern</span></div><div class="casAuthors">Hardie, D. Grahame; Ross, Fiona A.; Hawley, Simon A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1222-1236</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status.  It is activated, by a mechanism requiring the tumor suppressor LKB1, by metabolic stresses that increase cellular ADP:ATP and/or AMP:ATP ratios.  Once activated, it switches on catabolic pathways that generate ATP, while switching off biosynthetic pathways and cell-cycle progress.  These effects suggest that AMPK activators might be useful for treatment and/or prevention of type 2 diabetes and cancer.  Indeed, AMPK is activated by the drugs metformin and salicylate, the latter being the major breakdown product of aspirin.  Metformin is widely used to treat diabetes, while there is epidemiol. evidence that both metformin and aspirin provide protection against cancer.  We review the mechanisms of AMPK activation by these and other drugs, and by natural products derived from traditional herbal medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIhWqL6rSH0bVg90H21EOLACvtfcHk0lj6uL397RB33g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hsbfF&md5=b1a6cd59d2ef144bc91abb772a4674cc</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DHardie%26aufirst%3DD.%2BG.%26aulast%3DRoss%26aufirst%3DF.%2BA.%26aulast%3DHawley%26aufirst%3DS.%2BA.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%253A%2520A%2520Target%2520for%2520Drugs%2520Both%2520Ancient%2520and%2520Modern%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1222%26epage%3D1236%26doi%3D10.1016%2Fj.chembiol.2012.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungaro, P.</span></span> <span> </span><span class="NLM_article-title">AMP-Activated Protein Kinase: A Target for Old Drugs against Diabetes and Cancer</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bcp.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23747347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVehtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=339-350&author=G.+L.+Russoauthor=M.+Russoauthor=P.+Ungaro&title=AMP-Activated+Protein+Kinase%3A+A+Target+for+Old+Drugs+against+Diabetes+and+Cancer&doi=10.1016%2Fj.bcp.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase: A target for old drugs against diabetes and cancer</span></div><div class="casAuthors">Russo, Gian Luigi; Russo, Maria; Ungaro, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-350</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The AMP-activated protein kinase (AMPK) is considered a key checkpoint to ensure energy balance in both cells and organisms.  AMPK is an αβγ heterotrimer controlled by allosteric regulation by AMP, ADP and ATP, auto-inhibitory features and phosphorylation, with the threonine-172 phosphorylation on the catalytic α-subunit by LKB1, CaMKKβ or Tak1 being essential for its fully activation.  AMPK acts as a protective response to energy stress in numerous systems, but it is also a key player in diabetes and related metabolic diseases and cancer.  Pharmacol. activation of AMPK by metformin or other compds. holds a considerable potential to reverse the metabolic abnormalities assocd. with type 2 diabetes.  In cancer, correction of the dysregulated metabolic pathway LKB1/AMPK/mTORC1 can lower the Warburg effect, suggesting AMPK as a potential target for cancer prevention and/or treatment.  In this commentary, the authors review recent findings that support the role and function of AMPK in normal and pathol. conditions.  The authors also discuss how the activation of AMPK by naturally occurring compds. could help to prevent the development of numerous chronic diseases contributing in such a way to the well-being of aging population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgRcW2jWm9prVg90H21EOLACvtfcHk0lj6uL397RB33g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVehtbnN&md5=4abcc8123a8c48c4f15a3963e97cd390</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DG.%2BL.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DUngaro%26aufirst%3DP.%26atitle%3DAMP-Activated%2520Protein%2520Kinase%253A%2520A%2520Target%2520for%2520Old%2520Drugs%2520against%2520Diabetes%2520and%2520Cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D339%26epage%3D350%26doi%3D10.1016%2Fj.bcp.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span>; <span class="NLM_string-name">Blum, A.</span></span> <span> </span><span class="NLM_article-title">Azabenzimidazole Derivatives</span>. <span class="NLM_patent">US20160039846A1</span>, Feb 11, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Langkopf&author=A.+Blum&title=Azabenzimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLangkopf%26aufirst%3DE.%26atitle%3DAzabenzimidazole%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 3. Structure-Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N’-Arylpiperazine Series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3094</span>– <span class="NLM_lpage">3116</span>, <span class="refDoi"> DOI: 10.1021/jm5000497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5000497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjvVOns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3094-3116&author=N.+Nishimuraauthor=M.+H.+Normanauthor=L.+Liuauthor=K.+C.+Yangauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=S.+Chmaitauthor=J.+Chenauthor=R.+Cupplesauthor=C.+Fotschauthor=J.+Helmeringauthor=S.+R.+Jordanauthor=R.+K.+Kunzauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=A.+Siegmundauthor=G.+Sivitsauthor=D.+J.+Lloydauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+3.+Structure-Activity+Relationships+within+the+Aryl+Carbinol+Region+of+the+N-Arylsulfonamido-N%E2%80%99-Arylpiperazine+Series&doi=10.1021%2Fjm5000497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 3. Structure-Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N'-arylpiperazine Series</span></div><div class="casAuthors">Nishimura, Nobuko; Norman, Mark H.; Liu, Longbin; Yang, Kevin C.; Ashton, Kate S.; Bartberger, Michael D.; Chmait, Samer; Chen, Jie; Cupples, Rod; Fotsch, Christopher; Helmering, Joan; Jordan, Steven R.; Kunz, Roxanne K.; Pennington, Lewis D.; Poon, Steve F.; Siegmund, Aaron; Sivits, Glenn; Lloyd, David J.; Hale, Clarence; St. Jean, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3094-3116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small mol. to its endogenous inhibitor, glucokinase regulatory protein (GKRP).  These initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol (I, AMG-3969), a compd. that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals.  Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series.  Guided by the X-ray cocrystal structure of compd. I bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region.  Among them, sulfoximine and pyridinyl derivs. II and III possessed excellent potency as well as favorable PK properties.  When dosed orally in db/db mice, both compds. significantly lowered fed blood glucose levels (up to 58%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq--wNW0LMFO7Vg90H21EOLACvtfcHk0lgmhFRqEebf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjvVOns7o%253D&md5=8ca40e15429af254f75f8304aa5a0fa2</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fjm5000497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5000497%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25203.%2520Structure-Activity%2520Relationships%2520within%2520the%2520Aryl%2520Carbinol%2520Region%2520of%2520the%2520N-Arylsulfonamido-N%25E2%2580%2599-Arylpiperazine%2520Series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3094%26epage%3D3116%26doi%3D10.1021%2Fjm5000497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agius, L.</span></span> <span> </span><span class="NLM_article-title">Glucokinase and Molecular Aspects of Liver Glycogen Metabolism</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1042/BJ20080595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2FBJ20080595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18651836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2008&pages=1-18&author=L.+Agius&title=Glucokinase+and+Molecular+Aspects+of+Liver+Glycogen+Metabolism&doi=10.1042%2FBJ20080595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase and molecular aspects of liver glycogen metabolism</span></div><div class="casAuthors">Agius, Loranne</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-18</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Conversion of glucose into glycogen is a major pathway that contributes to the removal of glucose from the portal vein by the liver in the postprandial state.  It is regulated in part by the increase in blood-glucose concn. in the portal vein, which activates glucokinase, the first enzyme in the pathway, causing an increase in the concn. of glucose 6-P (glucose 6-phosphate), which modulates the phosphorylation state of downstream enzymes by acting synergistically with other allosteric effectors.  Glucokinase is regulated by a hierarchy of transcriptional and post-transcriptional mechanisms that are only partially understood.  In the fasted state, glucokinase is in part sequestered in the nucleus in an inactive state, complexed to a specific regulatory protein, GKRP (glucokinase regulatory protein).  This reserve pool is rapidly mobilized to the cytoplasm in the postprandial state in response to an elevated concn. of glucose.  The translocation of glucokinase between the nucleus and cytoplasm is modulated by various metabolic and hormonal conditions.  The elevated glucose 6-P concn., consequent to glucokinase activation, has a synergistic effect with glucose in promoting dephosphorylation (inactivation) of glycogen phosphorylase and inducing dephosphorylation (activation) of glycogen synthase.  The latter involves both a direct ligand-induced conformational change and depletion of the phosphorylated form of glycogen phosphorylase, which is a potent allosteric inhibitor of glycogen synthase phosphatase activity assocd. with the glycogen-targeting protein, GL [hepatic glycogen-targeting subunit of PP-1 (protein phosphatase-1) encoded by PPP1R3B].  Defects in both the activation of glucokinase and in the dephosphorylation of glycogen phosphorylase are potential contributing factors to the dysregulation of hepatic glucose metab. in Type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY34FiWICqI7Vg90H21EOLACvtfcHk0lgmhFRqEebf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCisbs%253D&md5=3dcd4b879731094f020a0eaf797ba49d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1042%2FBJ20080595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080595%26sid%3Dliteratum%253Aachs%26aulast%3DAgius%26aufirst%3DL.%26atitle%3DGlucokinase%2520and%2520Molecular%2520Aspects%2520of%2520Liver%2520Glycogen%2520Metabolism%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D414%26spage%3D1%26epage%3D18%26doi%3D10.1042%2FBJ20080595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">Glucokinase as Glucose Sensor and Metabolic Signal Generator in Pancreatic β-Cells and Hepatocytes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.2337/diab.39.6.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdiab.39.6.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2189759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3cXktlOqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1990&pages=647-652&author=F.+M.+Matschinsky&title=Glucokinase+as+Glucose+Sensor+and+Metabolic+Signal+Generator+in+Pancreatic+%CE%B2-Cells+and+Hepatocytes&doi=10.2337%2Fdiab.39.6.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-52</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    </div><div class="casAbstract">A review, with 31 refs., on evidence for a pivotal role of glucokinase as glucose sensor of the pancreatic β-cells.  Glucokinase explains the capacity, hexose specificity, affinities, sigmoidicity, and anomeric preference of pancreatic islet glycolysis, and because stimulation of glucose metab. is a prerequisite of glucose stimulation of insulin release, glucokinase also explains many characteristics of this β-cell function.  Tissue-specific regulation corresponds with observations that liver and pancreatic β-cell glucokinase are structurally distinct.  Glucokinase could play a glucose-sensor role in hepatocytes as well, and certain forms of diabetes mellitus might be due to glucokinase deficiencies in pancreatic β-cells, hepatocytes, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdI-s6D2kzbVg90H21EOLACvtfcHk0lgmhFRqEebf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktlOqtbY%253D&md5=a267592dce249b83fda5f9573ec2f0d6</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.2337%2Fdiab.39.6.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.39.6.647%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGlucokinase%2520as%2520Glucose%2520Sensor%2520and%2520Metabolic%2520Signal%2520Generator%2520in%2520Pancreatic%2520%25CE%25B2-Cells%2520and%2520Hepatocytes%26jtitle%3DDiabetes%26date%3D1990%26volume%3D39%26spage%3D647%26epage%3D652%26doi%3D10.2337%2Fdiab.39.6.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">Glucokinase, Glucose Homeostasis, and Diabetes Mellitus</span>. <i>Curr. Diabetes Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1007/s11892-005-0005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs11892-005-0005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15929862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSkt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=171-176&author=F.+M.+Matschinsky&title=Glucokinase%2C+Glucose+Homeostasis%2C+and+Diabetes+Mellitus&doi=10.1007%2Fs11892-005-0005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase, glucose homeostasis, and diabetes mellitus</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Current Science Inc.</span>)
        </div><div class="casAbstract">A review.  The enzyme glucokinase (GK) regulates the rate of glucose metab. in many tissues, including liver, the pancreatic β cells, certain neurons, enteroendocrine cells, and the pituitary, serving as a glucose sensor in many of these.  Thus, GK plays a crit. role in glucose homeostasis.  Spontaneous mutants of GK in humans result in autosomal-dominant hypo- and hyperglycemia syndromes described as "GK disease.".  GK activator drugs have been discovered that lower blood glucose in normal and diabetic animals and promise to be useful in the treatment of type 2 diabetes mellitus.  There is no question that the GK mol. and related issues will continue to be a fruitful topic for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Z-ncpR-k3rVg90H21EOLACvtfcHk0ljDNWln3zdTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSkt7jJ&md5=84049ae306771ea998694d62309e02a4</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1007%2Fs11892-005-0005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-005-0005-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGlucokinase%252C%2520Glucose%2520Homeostasis%252C%2520and%2520Diabetes%2520Mellitus%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2005%26volume%3D5%26spage%3D171%26epage%3D176%26doi%3D10.1007%2Fs11892-005-0005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelent, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doliba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderkooi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsby, J.</span></span> <span> </span><span class="NLM_article-title">Glucokinase Activators for Diabetes Therapy: May 2010 Status Report</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S236</span>– <span class="NLM_lpage">S243</span>, <span class="refDoi"> DOI: 10.2337/dc11-s236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2337%2Fdc11-s236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21525462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlKksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=S236-S243&author=F.+M.+Matschinskyauthor=B.+Zelentauthor=N.+Dolibaauthor=C.+Liauthor=J.+M.+Vanderkooiauthor=A.+Najiauthor=R.+Sarabuauthor=J.+Grimsby&title=Glucokinase+Activators+for+Diabetes+Therapy%3A+May+2010+Status+Report&doi=10.2337%2Fdc11-s236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Glucokinase activators for diabetes therapy: May 2010 status report</span></div><div class="casAuthors">Matschinsky, Franz M.; Zelent, Bogumil; Doliba, Nicolai; Li, Changhong; Vanderkooi, Jane M.; Naji, Ali; Sarabu, Ramakanth; Grimsby, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S236-S243</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review on the essential aspect of the role of glucokinase (GK) in glucose homeostasis, of the biochem. pharmacol. of GK activator (GKA), and of the current status of GKA research and development and therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoGPdUYzBgUbVg90H21EOLACvtfcHk0ljDNWln3zdTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlKksL8%253D&md5=ef51e1f08da702fea401c70f27db21ff</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.2337%2Fdc11-s236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-s236%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26aulast%3DZelent%26aufirst%3DB.%26aulast%3DDoliba%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DVanderkooi%26aufirst%3DJ.%2BM.%26aulast%3DNaji%26aufirst%3DA.%26aulast%3DSarabu%26aufirst%3DR.%26aulast%3DGrimsby%26aufirst%3DJ.%26atitle%3DGlucokinase%2520Activators%2520for%2520Diabetes%2520Therapy%253A%2520May%25202010%2520Status%2520Report%26jtitle%3DDiabetes%2520Care%26date%3D2011%26volume%3D34%26spage%3DS236%26epage%3DS243%26doi%3D10.2337%2Fdc11-s236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lather, V.</span></span> <span> </span><span class="NLM_article-title">Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.2174/1389557514666140722082713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2174%2F1389557514666140722082713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25052034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=585-602&author=A.+S.+Grewalauthor=B.+S.+Sekhonauthor=V.+Lather&title=Recent+Updates+on+Glucokinase+Activators+for+the+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.2174%2F1389557514666140722082713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Grewal, Ajmer Singh; Sekhon, Bhupinder Singh; Lather, Viney</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">585-602</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory actions in pancreatic β-cells and liver hepatocytes.  Conversion of glucose to glucose-6-phosphate by GK promotes glycogen synthesis in liver hepatocytes, and insulin release in the pancreatic β-cells.  Small mols. called glucokinase activators (GKAs) which bind to an allosteric activator site of the GK enzyme have indeed been discovered and developed, and thus hold great promise as new, effective and safe antidiabetic agents.  GKAs enhance the catalytic activity of GK and promising clin. trials in humans demonstrated that they are highly useful in the treatment of type 2 diabetes mellitus.  Most of the reported GKAs include amide derivs. like benzamides, acrylamides, carboxamides, acetamides and acrylamides.  Examples include Piragliatin, AZD1656, AZD6370, R1440 GKA2, GKA 50, YH GKA, PSN 010, and LY2121260.  Recent findings on GKAs including lead compds. and overview of current hypothesis on mechanism of GK activation along with summary of the recently published patents as well as the GKAs of natural origin are reported in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosQe6QzxAtg7Vg90H21EOLACvtfcHk0ljDNWln3zdTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgsrfL&md5=7cc627f098582d93f7bd43431759adb8</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.2174%2F1389557514666140722082713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557514666140722082713%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DA.%2BS.%26aulast%3DSekhon%26aufirst%3DB.%2BS.%26aulast%3DLather%26aufirst%3DV.%26atitle%3DRecent%2520Updates%2520on%2520Glucokinase%2520Activators%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D585%26epage%3D602%26doi%3D10.2174%2F1389557514666140722082713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfefferkorn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treadway, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Aquila, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbonais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derksen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdougall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrera, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapworth, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landro, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavadoski, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddish-Berhane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duignan, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammirati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (S)-6-(3-Cyclopentyl-2-(4-(Trifluoromethyl)-1H-Imidazol-1-yl)Propanamido)Nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1021/jm2014887</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2014887" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Ojur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1318-1333&author=J.+A.+Pfefferkornauthor=A.+Guzman-Perezauthor=J.+Litchfieldauthor=R.+Aielloauthor=J.+L.+Treadwayauthor=J.+Pettersenauthor=M.+L.+Minichauthor=K.+J.+Filipskiauthor=C.+S.+Jonesauthor=M.+Tuauthor=G.+Aspnesauthor=H.+Risleyauthor=J.+Bianauthor=B.+D.+Stevensauthor=P.+Bourassaauthor=T.+D%E2%80%99Aquilaauthor=L.+Bakerauthor=N.+Barucciauthor=A.+S.+Robertsonauthor=F.+Bourbonaisauthor=D.+R.+Derksenauthor=M.+Macdougallauthor=O.+Cabreraauthor=J.+Chenauthor=A.+L.+Lapworthauthor=J.+A.+Landroauthor=W.+J.+Zavadoskiauthor=K.+Atkinsonauthor=N.+Haddish-Berhaneauthor=B.+Tanauthor=L.+Yaoauthor=R.+E.+Kosaauthor=M.+V.+Varmaauthor=B.+Fengauthor=D.+B.+Duignanauthor=A.+El-Kattanauthor=S.+Murdandeauthor=S.+Liuauthor=M.+Ammiratiauthor=J.+Knafelsauthor=P.+Dasilva-Jardineauthor=L.+Sweetauthor=S.+Lirasauthor=T.+P.+Rolph&title=Discovery+of+%28S%29-6-%283-Cyclopentyl-2-%284-%28Trifluoromethyl%29-1H-Imidazol-1-yl%29Propanamido%29Nicotinic+Acid+as+a+Hepatoselective+Glucokinase+Activator+Clinical+Candidate+for+Treating+Type+2+Diabetes+Mellitus&doi=10.1021%2Fjm2014887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus</span></div><div class="casAuthors">Pfefferkorn, Jeffrey A.; Guzman-Perez, Angel; Litchfield, John; Aiello, Robert; Treadway, Judith L.; Pettersen, John; Minich, Martha L.; Filipski, Kevin J.; Jones, Christopher S.; Tu, Meihua; Aspnes, Gary; Risley, Hud; Bian, Jianwei; Stevens, Benjamin D.; Bourassa, Patricia; D'Aquila, Theresa; Baker, Levenia; Barucci, Nicole; Robertson, Alan S.; Bourbonais, Francis; Derksen, David R.; MacDougall, Margit; Cabrera, Over; Chen, Jing; Lapworth, Amanda Lee; Landro, James A.; Zavadoski, William J.; Atkinson, Karen; Haddish-Berhane, Nahor; Tan, Beijing; Yao, Lili; Kosa, Rachel E.; Varma, Manthena V.; Feng, Bo; Duignan, David B.; El-Kattan, Ayman; Murdande, Sharad; Liu, Shenping; Ammirati, Mark; Knafels, John; Da Silva-Jardine, Paul; Sweet, Laurel; Liras, Spiros; Rolph, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1318-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucokinase is a key regulator of glucose homeostasis, and small mol. allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes.  Systemically acting glucokinase activators (liver and pancreas) have been reported to be efficacious but in many cases present hypoglycemia risk due to activation of the enzyme at low glucose levels in the pancreas, leading to inappropriately excessive insulin secretion.  It was therefore postulated that a liver selective activator may offer effective glycemic control with reduced hypoglycemia risk.  Herein, we report structure-activity studies on a carboxylic acid contg. series of glucokinase activators with preferential activity in hepatocytes vs. pancreatic β-cells.  These activators were designed to have low passive permeability thereby minimizing distribution into extrahepatic tissues; concurrently, they were also optimized as substrates for active liver uptake via members of the org. anion transporting polypeptide (OATP) family.  These studies lead to the identification of 19 as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species.  In preclin. diabetic animals, 19 was found to robustly lower fasting and postprandial glucose with no hypoglycemia, leading to its selection as a clin. development candidate for treating type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMeuV7iNzAXrVg90H21EOLACvtfcHk0lilB7VslpnPAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Ojur3F&md5=f68a72bcd904abdbb4f096abca0eff6b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fjm2014887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2014887%26sid%3Dliteratum%253Aachs%26aulast%3DPfefferkorn%26aufirst%3DJ.%2BA.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DAiello%26aufirst%3DR.%26aulast%3DTreadway%26aufirst%3DJ.%2BL.%26aulast%3DPettersen%26aufirst%3DJ.%26aulast%3DMinich%26aufirst%3DM.%2BL.%26aulast%3DFilipski%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DAspnes%26aufirst%3DG.%26aulast%3DRisley%26aufirst%3DH.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DBourassa%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Aquila%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DL.%26aulast%3DBarucci%26aufirst%3DN.%26aulast%3DRobertson%26aufirst%3DA.%2BS.%26aulast%3DBourbonais%26aufirst%3DF.%26aulast%3DDerksen%26aufirst%3DD.%2BR.%26aulast%3DMacdougall%26aufirst%3DM.%26aulast%3DCabrera%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLapworth%26aufirst%3DA.%2BL.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DZavadoski%26aufirst%3DW.%2BJ.%26aulast%3DAtkinson%26aufirst%3DK.%26aulast%3DHaddish-Berhane%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DB.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DKosa%26aufirst%3DR.%2BE.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DDuignan%26aufirst%3DD.%2BB.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DMurdande%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DAmmirati%26aufirst%3DM.%26aulast%3DKnafels%26aufirst%3DJ.%26aulast%3DDasilva-Jardine%26aufirst%3DP.%26aulast%3DSweet%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DRolph%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520%2528S%2529-6-%25283-Cyclopentyl-2-%25284-%2528Trifluoromethyl%2529-1H-Imidazol-1-yl%2529Propanamido%2529Nicotinic%2520Acid%2520as%2520a%2520Hepatoselective%2520Glucokinase%2520Activator%2520Clinical%2520Candidate%2520for%2520Treating%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1318%26epage%3D1333%26doi%3D10.1021%2Fjm2014887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzeja, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komorowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Véniant, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Antidiabetic Effects of Glucokinase Regulatory Protein Small-Molecule Disruptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nature12724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature12724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24226772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOmu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=437-440&author=D.+J.+Lloydauthor=D.+J.+St+Jeanauthor=R.+J.+Kurzejaauthor=R.+C.+Wahlauthor=K.+Michelsenauthor=R.+Cupplesauthor=M.+Chenauthor=J.+Wuauthor=G.+Sivitsauthor=J.+Helmeringauthor=R.+Komorowskiauthor=K.+S.+Ashtonauthor=L.+D.+Penningtonauthor=C.+Fotschauthor=M.+Vazirauthor=K.+Chenauthor=S.+Chmaitauthor=J.+Zhangauthor=L.+Liuauthor=M.+H.+Normanauthor=K.+L.+Andrewsauthor=M.+D.+Bartbergerauthor=G.+Vanauthor=E.+J.+Galbreathauthor=S.+L.+Vonderfechtauthor=M.+Wangauthor=S.+R.+Jordanauthor=M.+M.+V%C3%A9niantauthor=C.+Hale&title=Antidiabetic+Effects+of+Glucokinase+Regulatory+Protein+Small-Molecule+Disruptors&doi=10.1038%2Fnature12724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors</span></div><div class="casAuthors">Lloyd, David J.; St. Jean, David J., Jr.; Kurzeja, Robert J. M.; Wahl, Robert C.; Michelsen, Klaus; Cupples, Rod; Chen, Michelle; Wu, John; Sivits, Glenn; Helmering, Joan; Komorowski, Renee; Ashton, Kate S.; Pennington, Lewis D.; Fotsch, Christopher; Vazir, Mukta; Chen, Kui; Chmait, Samer; Zhang, Jiandong; Liu, Longbin; Norman, Mark H.; Andrews, Kristin L.; Bartberger, Michael D.; Van, Gwyneth; Galbreath, Elizabeth J.; Vonderfecht, Steven L.; Wang, Minghan; Jordan, Steven R.; Veniant, Murielle M.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7480</span>),
    <span class="NLM_cas:pages">437-440</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucose homeostasis is a vital and complex process, and its disruption can cause hyperglycemia and type II diabetes mellitus.  Glucokinase (GK), a key enzyme that regulates glucose homeostasis, converts glucose to glucose-6-phosphate in pancreatic β-cells, liver hepatocytes, specific hypothalamic neurons, and gut enterocytes.  In hepatocytes, GK regulates glucose uptake and glycogen synthesis, suppresses glucose prodn., and is subject to the endogenous inhibitor GK regulatory protein (GKRP).  During fasting, GKRP binds, inactivates and sequesters GK in the nucleus, which removes GK from the gluconeogenic process and prevents a futile cycle of glucose phosphorylation.  Compds. that directly hyperactivate GK (GK activators) lower blood glucose levels and are being evaluated clin. as potential therapeutics for the treatment of type II diabetes mellitus.  However, initial reports indicate that an increased risk of hypoglycemia is assocd. with some GK activators.  To mitigate the risk of hypoglycemia, the authors sought to increase GK activity by blocking GKRP.  Here the authors describe the identification of two potent small-mol. GK-GKRP disruptors (AMG-1694 and AMG-3969) that normalized blood glucose levels in several rodent models of diabetes.  These compds. potently reversed the inhibitory effect of GKRP on GK activity and promoted GK translocation both in vitro (isolated hepatocytes) and in vivo (liver).  A co-crystal structure of full-length human GKRP in complex with AMG-1694 revealed a previously unknown binding pocket in GKRP distinct from that of the phosphofructose-binding site.  Furthermore, with AMG-1694 and AMG-3969 (but not GK activators), blood glucose lowering was restricted to diabetic and not normoglycemic animals.  These findings exploit a new cellular mechanism for lowering blood glucose levels with reduced potential for hypoglycemic risk in patients with type II diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo698v-SzzPXLVg90H21EOLACvtfcHk0lilB7VslpnPAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOmu7%252FL&md5=d26f4006decfda51b73a44d883b11921</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fnature12724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12724%26sid%3Dliteratum%253Aachs%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DKurzeja%26aufirst%3DR.%2BJ.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DKomorowski%26aufirst%3DR.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DVazir%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DGalbreath%26aufirst%3DE.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DV%25C3%25A9niant%26aufirst%3DM.%2BM.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DAntidiabetic%2520Effects%2520of%2520Glucokinase%2520Regulatory%2520Protein%2520Small-Molecule%2520Disruptors%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D437%26epage%3D440%26doi%3D10.1038%2Fnature12724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschenbach, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscheinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmoll, D.</span></span> <span> </span><span class="NLM_article-title">Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein: Impact of Physiological and Pharmacological Effectors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">31333</span>– <span class="NLM_lpage">31340</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805434200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1074%2Fjbc.M805434200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18809676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCjsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=31333-31340&author=O.+Anderkaauthor=J.+Boykenauthor=U.+Aschenbachauthor=A.+Batzerauthor=O.+Boscheinenauthor=D.+Schmoll&title=Biophysical+Characterization+of+the+Interaction+between+Hepatic+Glucokinase+and+Its+Regulatory+Protein%3A+Impact+of+Physiological+and+Pharmacological+Effectors&doi=10.1074%2Fjbc.M805434200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein: impact of physiological and pharmacological effectors</span></div><div class="casAuthors">Anderka, Oliver; Boyken, Janina; Aschenbach, Ursula; Batzer, Andreas; Boscheinen, Oliver; Schmoll, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">31333-31340</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Glucokinase (GK) is a key enzyme of glucose metab. in liver and pancreatic β-cells, and small mol. activators of GK (GKAs) are under evaluation for the treatment of type 2 diabetes.  In liver, GK activity is controlled by the GK regulatory protein (GKRP), which forms an inhibitory complex with the enzyme.  Here, we performed isothermal titrn. calorimetry (ITC) and surface plasmon resonance (SPR) expts. to characterize GK-GKRP binding and to study the influence that physiol. and pharmacol. effectors of GK have on the protein-protein interaction.  In the presence of fructose-6-phosphate (F6P), GK-GKRP complex formation displayed a strong entropic driving force opposed by a large pos. enthalpy; a neg. change in heat capacity was obsd. (Kd = 45 nM, ΔH = 15.6 kcal/mol, TΔS = 25.7 kcal/mol, ΔCp = -354 cal/mol-1/K-1).  With koff = 1.3 × 10-2 s-1, the complex dissocd. quickly.  The thermodn. profile suggested a largely hydrophobic interaction.  In addn., effects of pH and buffer demonstrated the coupled uptake of one proton and indicated an ionic contribution to binding.  Glucose decreased the binding affinity between GK and GKRP.  This decrease was potentiated by an ATP analog.  Prototypical GKAs of the amino-heteroaryl-amide type bound to GK in a glucose-dependent manner and impaired the assocn. of GK with GKRP.  This mechanism might contribute to the antidiabetic effects of GKAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGaWRtT21jPrVg90H21EOLACvtfcHk0ljiIs_-q4GRlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCjsb7N&md5=c12a5ff10469833826f2bc2cd2a4791c</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805434200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805434200%26sid%3Dliteratum%253Aachs%26aulast%3DAnderka%26aufirst%3DO.%26aulast%3DBoyken%26aufirst%3DJ.%26aulast%3DAschenbach%26aufirst%3DU.%26aulast%3DBatzer%26aufirst%3DA.%26aulast%3DBoscheinen%26aufirst%3DO.%26aulast%3DSchmoll%26aufirst%3DD.%26atitle%3DBiophysical%2520Characterization%2520of%2520the%2520Interaction%2520between%2520Hepatic%2520Glucokinase%2520and%2520Its%2520Regulatory%2520Protein%253A%2520Impact%2520of%2520Physiological%2520and%2520Pharmacological%2520Effectors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D31333%26epage%3D31340%26doi%3D10.1074%2Fjbc.M805434200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croghan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzeja, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonderfecht, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for <i>in Vivo</i> Proof-of-Concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/jm4016735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=309-324&author=K.+S.+Ashtonauthor=K.+L.+Andrewsauthor=M.+C.+Bryanauthor=J.+Chenauthor=K.+Chenauthor=M.+Chenauthor=S.+Chmaitauthor=M.+Croghanauthor=R.+Cupplesauthor=C.+Fotschauthor=J.+Helmeringauthor=S.+R.+Jordanauthor=R.+J.+Kurzejaauthor=K.+Michelsenauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=G.+Sivitsauthor=G.+Vanauthor=S.+L.+Vonderfechtauthor=R.+C.+Wahlauthor=J.+Zhangauthor=D.+J.+Lloydauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+1.+Discovery+of+a+Novel+Tool+Compound+for+in+Vivo+Proof-of-Concept&doi=10.1021%2Fjm4016735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept</span></div><div class="casAuthors">Ashton, Kate S.; Andrews, Kristin L.; Bryan, Marian C.; Chen, Jie; Chen, Kui; Chen, Michelle; Chmait, Samer; Croghan, Michael; Cupples, Rod; Fotsch, Christopher; Helmering, Joan; Jordan, Steve R.; Kurzeja, Robert J. M.; Michelsen, Klaus; Pennington, Lewis D.; Poon, Steve F.; Sivits, Glenn; Van, Gwyneth; Vonderfecht, Steve L.; Wahl, Robert C.; Zhang, Jiandong; Lloyd, David J.; Hale, Clarence; St. Jean, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">309-324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. activators of glucokinase have shown robust efficacy in both preclin. models and humans.  However, overactivation of glucokinase (GK) can cause excessive glucose turnover, leading to hypoglycemia.  To circumvent this adverse side effect, we chose to modulate GK activity by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP).  Disrupting the GK-GKRP complex results in an increase in the amt. of unbound cytosolic GK without altering the inherent kinetics of the enzyme.  Herein, we report the identification of compds. that efficiently disrupt the GK-GKRP interaction via a previously unknown binding pocket.  Using a structure-based approach, the potency of the initial hit was improved to provide I (AMG-1694).  When dosed in ZDF rats, I showed both a robust pharmacodynamic effect as well as a statistically significant redn. in glucose.  Addnl., hypoglycemia was not obsd. in either the hyperglycemic or normal rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriLnUgNgMEXrVg90H21EOLACvtfcHk0ljiIs_-q4GRlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKjsg%253D%253D&md5=c07363c8a2b60f2e79b94d6e863b2ea5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Fjm4016735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016735%26sid%3Dliteratum%253Aachs%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCroghan%26aufirst%3DM.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DKurzeja%26aufirst%3DR.%2BJ.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DVonderfecht%26aufirst%3DS.%2BL.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25201.%2520Discovery%2520of%2520a%2520Novel%2520Tool%2520Compound%2520for%2520in%2520Vivo%2520Proof-of-Concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D309%26epage%3D324%26doi%3D10.1021%2Fjm4016735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/jm4016747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=325-338&author=D.+J.+St+Jeanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=E.+Galbreathauthor=J.+Helmeringauthor=F.+T.+Hongauthor=S.+R.+Jordanauthor=L.+Liuauthor=R.+K.+Kunzauthor=K.+Michelsenauthor=N.+Nishimuraauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=D.+Reidauthor=G.+Sivitsauthor=M.+M.+Stecauthor=S.+Tadesseauthor=N.+Tamayoauthor=G.+Vanauthor=K.+C.+Yangauthor=J.+Zhangauthor=M.+H.+Normanauthor=C.+Fotschauthor=D.+J.+Lloydauthor=C.+Hale&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+2.+Leveraging+Structure-Based+Drug+Design+to+Identify+Analogues+with+Improved+Pharmacokinetic+Profiles&doi=10.1021%2Fjm4016747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span></div><div class="casAuthors">St. Jean, David J., Jr.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Galbreath, Elizabeth; Helmering, Joan; Hong, Fang-Tsao; Jordan, Steven R.; Liu, Longbin; Kunz, Roxanne K.; Michelsen, Klaus; Nishimura, Nobuko; Pennington, Lewis D.; Poon, Steve F.; Reid, Darren; Sivits, Glenn; Stec, Markian M.; Tadesse, Seifu; Tamayo, Nuria; Van, Gwyneth; Yang, Kevin C.; Zhang, Jiandong; Norman, Mark H.; Fotsch, Christopher; Lloyd, David J.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the previous report, we described the discovery and optimization of novel small mol. disruptors of the GK-GKRP interaction culminating in the identification of I (AMG-1694).  Although this analog possessed excellent in vitro potency and was a useful tool compd. in initial proof-of-concept expts., high metabolic turnover limited its advancement.  Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor, II (AMG-3969).  When administered to db/db mice, this compd. demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent redns. in fed blood glucose levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdKFACRrkebVg90H21EOLACvtfcHk0ljiIs_-q4GRlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D&md5=aebfcbc169a9fbd443badcff47b2b90f</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm4016747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016747%26sid%3Dliteratum%253Aachs%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DGalbreath%26aufirst%3DE.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DReid%26aufirst%3DD.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25202.%2520Leveraging%2520Structure-Based%2520Drug%2520Design%2520to%2520Identify%2520Analogues%2520with%2520Improved%2520Pharmacokinetic%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D325%26epage%3D338%26doi%3D10.1021%2Fjm4016747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5964</span>, <span class="refDoi"> DOI: 10.1021/jm5001979</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001979" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5949-5964&author=F.+T.+Hongauthor=M.+H.+Normanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=C.+Fotschauthor=S.+R.+Jordanauthor=D.+J.+Lloydauthor=G.+Sivitsauthor=S.+Tadesseauthor=C.+Haleauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+4.+Exploration+of+a+Novel+Binding+Pocket&doi=10.1021%2Fjm5001979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket</span></div><div class="casAuthors">Hong, Fang-Tsao; Norman, Mark H.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Fotsch, Christopher; Jordan, Steven R.; Lloyd, David J.; Sivits, Glenn; Tadesse, Seifu; Hale, Clarence; St. Jean, David J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5949-5964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship investigations conducted at the 5-position of the N-pyridine ring of a series of N-arylsulfonyl-N'-2-pyridinyl-piperazines led to the identification of a novel bis-pyridinyl piperazine sulfonamide I that was a potent disruptor of the glucokinase-glucokinase regulatory protein (GK-GKRP) interaction.  Anal. of the x-ray cocrystal of compd. I bound to hGKRP revealed that the 3-pyridine ring moiety occupied a previously unexplored binding pocket within the protein.  Key features of this new binding mode included forming favorable contacts with the top face of the Ala27-Val28-Pro29 ("shelf region") as well as an edge-to-face interaction with the Tyr24 side chain.  Compd. I was potent in both biochem. and cellular assays (IC50 = 0.005 μM and EC50 = 0.205 μM, resp.) and exhibited acceptable pharmacokinetic properties for in vivo evaluation.  When administered to db/db mice (100 mg/kg, po), compd. I demonstrated a robust pharmacodynamic effect and significantly reduced blood glucose levels up to 6 h postdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_rJr3MhD5G7Vg90H21EOLACvtfcHk0ljWhbsi0UjzQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtLzP&md5=4c442ed22fb6460d44b956bf11db1a4f</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Fjm5001979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001979%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25204.%2520Exploration%2520of%2520a%2520Novel%2520Binding%2520Pocket%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5949%26epage%3D5964%26doi%3D10.1021%2Fjm5001979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Jean, D. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization through Conformational Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4482</span>, <span class="refDoi"> DOI: 10.1021/jm5018175</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018175" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4462-4482&author=N.+A.+Tamayoauthor=M.+H.+Normanauthor=M.+D.+Bartbergerauthor=F.+T.+Hongauthor=Y.+Boauthor=L.+Liuauthor=N.+Nishimuraauthor=K.+C.+Yangauthor=S.+Tadesseauthor=C.+Fotschauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=C.+Haleauthor=S.+R.+Jordanauthor=D.+J.+Lloydauthor=G.+Sivitsauthor=G.+Vanauthor=D.+J.+St+Jean&title=Small+Molecule+Disruptors+of+the+Glucokinase-Glucokinase+Regulatory+Protein+Interaction%3A+5.+A+Novel+Aryl+Sulfone+Series%2C+Optimization+through+Conformational+Analysis&doi=10.1021%2Fjm5018175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis</span></div><div class="casAuthors">Tamayo, Nuria A.; Norman, Mark H.; Bartberger, Michael D.; Hong, Fang-Tsao; Bo, Yunxin; Liu, Longbin; Nishimura, Nobuko; Yang, Kevin C.; Tadesse, Seifu; Fotsch, Christopher; Chen, Jie; Chmait, Samer; Cupples, Rod; Hale, Clarence; Jordan, Steven R.; Lloyd, David J.; Sivits, Glenn; Van, Gwyneth; St. Jean, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4462-4482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The glucokinase-glucokinase regulatory protein (GK-GKRP) complex plays an important role in controlling glucose homeostasis in the liver.  The authors have recently disclosed a series of arylpiperazines as in vitro and in vivo disruptors of the GK-GKRP complex with efficacy in rodent models of type 2 diabetes mellitus (T2DM).  Herein, the authors describe a new class of aryl sulfones as disruptors of the GK-GKRP complex, where the central piperazine scaffold has been replaced by an arom. group.  Conformational anal. and exploration of the structure-activity relationships of this new class of compds. led to the identification of potent GK-GKRP disruptors.  Further optimization of this novel series delivered thiazole sulfone I, which was able to disrupt the GK-GKRP interaction in vitro and in vivo and, by doing so, increases cytoplasmic levels of unbound GK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUs8Kcp1LBDbVg90H21EOLACvtfcHk0ljWhbsi0UjzQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGitLY%253D&md5=ef369fc29c4edcb91d367cf48d9144e8</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1021%2Fjm5018175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018175%26sid%3Dliteratum%253Aachs%26aulast%3DTamayo%26aufirst%3DN.%2BA.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DSt%2BJean%26aufirst%3DD.%2BJ.%26atitle%3DSmall%2520Molecule%2520Disruptors%2520of%2520the%2520Glucokinase-Glucokinase%2520Regulatory%2520Protein%2520Interaction%253A%25205.%2520A%2520Novel%2520Aryl%2520Sulfone%2520Series%252C%2520Optimization%2520through%2520Conformational%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4462%26epage%3D4482%26doi%3D10.1021%2Fjm5018175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, J. K.</span></span> <span> </span><span class="NLM_article-title">Viral Gene Products and Replication of the Human Immunodeficiency Type 1 Virus</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">C1135</span>– <span class="NLM_lpage">C1156</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.1994.266.5.C1135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1152%2Fajpcell.1994.266.5.C1135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8203479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2cXksFCrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=C1135-C1156&author=C.+D.+Morrowauthor=J.+Parkauthor=J.+K.+Wakefield&title=Viral+Gene+Products+and+Replication+of+the+Human+Immunodeficiency+Type+1+Virus&doi=10.1152%2Fajpcell.1994.266.5.C1135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Viral gene products and replication of the human immunodeficiency type 1 virus</span></div><div class="casAuthors">Morrow, Casey D.; Park, Jinseu; Wakefield, John K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">C1135-C1156</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">A review, with 284 refs.  The acquired immunodeficiency syndrome (AIDS) epidemic represents a modern-day plague that has not only resulted in a tragic loss of people from a wide spectrum of society but has reshaped the authors' viewpoints regarding health care, the treatment of infectious diseases, and social issues regarding sexual behavior.  There is little doubt now that the cause of the disease AIDS is a virus known as the human immunodeficiency virus (HIV).  The HIV virus is a member of a large family of viruses termed retroviruses, which have as a hallmark the capacity to convert their RNA genome into a DNA form that then undergoes a process of integration into the host cell chromosome, followed by the expression of the viral genome and translation of viral proteins in the infected cell.  This review describes the organization of the HIV-1 viral genome, the expression of viral proteins, as well as the functions of the accessory viral proteins in HIV replication.  The replication of the viral genome is divided into two phases, the early phase and the late phase.  The early phase consists of the interaction of the virus with the cell surface receptor (CD4 mol. in most cases), the uncoating and conversion of the viral RNA genome into a DNA form, and the integration into the host cell chromosome.  The late phase consists of the expression of the viral proteins from the integrated viral genome, the translation of viral proteins, and the assembly and release of the virus.  Points in the HIV-1 life cycle that are targets for therapeutic intervention are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYQBfoIFCt2LVg90H21EOLACvtfcHk0ljbFSeDmhA2YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFCrsbw%253D&md5=8d50b3fe77efd5e898addf14276cf483</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.1994.266.5.C1135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.1994.266.5.C1135%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DC.%2BD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWakefield%26aufirst%3DJ.%2BK.%26atitle%3DViral%2520Gene%2520Products%2520and%2520Replication%2520of%2520the%2520Human%2520Immunodeficiency%2520Type%25201%2520Virus%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1994%26volume%3D266%26spage%3DC1135%26epage%3DC1156%26doi%3D10.1152%2Fajpcell.1994.266.5.C1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/gho/hiv/en/" class="extLink">https://www.who.int/gho/hiv/en/</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fgho%2Fhiv%2Fen%2F+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeni, P.</span></span> <span> </span><span class="NLM_article-title">Update on HAART in HIV</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">S100</span>– <span class="NLM_lpage">S103</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2005.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jhep.2005.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16359748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD28Xktl2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2006&pages=S100-S103&author=P.+Yeni&title=Update+on+HAART+in+HIV&doi=10.1016%2Fj.jhep.2005.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Update on HAART in HIV</span></div><div class="casAuthors">Yeni, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S100-S103</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Highly active antiretroviral combination therapy (HAART) has been responsible for a dramatic decrease in AIDS mortality since 1996, and has changed the clin. profile of HIV infection from a sub-acute lethal to a chronic ambulatory disease.  HAART consists of a double nucleoside (NRTI) backbone plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir pharmacol. enhanced protease inhibitor (PI/r).  Triple NRTI combinations are less potent than 2NRTIs/NNRTI or 2NRTIs/PI/r combinations.  Antiretroviral first-line therapy is rapidly moving towards more convenient and less toxic regimens.  Three double NRTI co-formulations are now available, and the risk of mitochondrial toxicity is low with drugs such as 3TC, FTC and tenofovir.  Similarly, atazanavir, a recently available PI, can be given once daily and is less metabolically toxic than other PIs.  Antiretroviral salvage therapy takes advantage of the development or availability of new drugs, either from existing (tipranavir, TMC 114 as new PIs) or new classes (T20 as a fusion inhibitor), that remain active on many triple-class drug resistant viruses.  More progress is needed in the field of drug discovery, since a significant proportion of patients still die from AIDS with a multi-resistant virus, and since the incidence of primary HIV resistance is increasing in various parts of the world.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-v9cXc64aqLVg90H21EOLACvtfcHk0ljbFSeDmhA2YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xktl2ksQ%253D%253D&md5=ec6531565d1b68066aa2efc155caa6fa</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DYeni%26aufirst%3DP.%26atitle%3DUpdate%2520on%2520HAART%2520in%2520HIV%26jtitle%3DJ.%2520Hepatol.%26date%3D2006%26volume%3D44%26spage%3DS100%26epage%3DS103%26doi%3D10.1016%2Fj.jhep.2005.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">AIDSinfo</span>, Guidelines for the Use
of Antiretroviral Agents in Adults and Adolescents Living with HIV. <a href="https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/78/specific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection" class="extLink">https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/78/specific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AIDSinfo%2C+Guidelines+for+the+Use%0Aof+Antiretroviral+Agents+in+Adults+and+Adolescents+Living+with+HIV.+https%3A%2F%2Faidsinfo.nih.gov%2Fguidelines%2Fhtml%2F2%2Fpediatric-arv%2F78%2Fspecific-issues-in-antiretroviral-therapy-for-adolescents-living-with-hiv-infection+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">World Health Organization</span>.  <i>HIV Drug Resistance Report 2017</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=World+Health+Organization&title=HIV+Drug+Resistance+Report+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DHIV%2520Drug%2520Resistance%2520Report%25202017%26pub%3DWorld%2520Health%250AOrganization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathyanarayana, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span> <span> </span><span class="NLM_article-title">Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 A Resolution</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1126/science.2686029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.2686029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2686029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFCltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=1149-1152&author=M.+Millerauthor=J.+Schneiderauthor=B.+K.+Sathyanarayanaauthor=M.+V.+Tothauthor=G.+R.+Marshallauthor=L.+Clawsonauthor=L.+Selkauthor=S.+B.+Kentauthor=A.+Wlodawer&title=Structure+of+Complex+of+Synthetic+HIV-1+Protease+with+a+Substrate-Based+Inhibitor+at+2.3+A+Resolution&doi=10.1126%2Fscience.2686029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution</span></div><div class="casAuthors">Miller, Maria; Schneider, Jens; Sathyanarayana, Bangalore K.; Toth, Mihaly V.; Marshall, Garland R.; Clawson, Leigh; Selk, Linda; Kent, Stephen B. H.; Wlodawer, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">4934</span>),
    <span class="NLM_cas:pages">1149-52</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The crystal structure of a complex between a synthetic peptide inhibitor (compd. MVT-101) with the sequence N-acetyl-Thr-Ile-Nle-Ψ[CH2-NH]-Nle-Gln-Arg.amide (Nle, norleucine) with chem. synthesized HIV-1 (human immunodeficiency virus 1) protease was detd. at 2.3 Å resoln. (R factor of 0.176).  Despite the sym. nature of the unliganded enzyme, the asym. inhibitor lies in a single orientation and makes extensive interactions at the interface between the 2 subunits of the homodimeric protein.  Compared with the unliganded enzyme, the protein mol. underwent substantial changes, particularly in an extended region corresponding to the flaps (residues 35-57 in each chain), where backbone movements as large as 7 Å are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsq_wooxyujrVg90H21EOLACvtfcHk0ljbFSeDmhA2YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFCltLk%253D&md5=cf257c6b4ffbcb917329c1846664f966</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1126%2Fscience.2686029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2686029%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DSathyanarayana%26aufirst%3DB.%2BK.%26aulast%3DToth%26aufirst%3DM.%2BV.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26aulast%3DClawson%26aufirst%3DL.%26aulast%3DSelk%26aufirst%3DL.%26aulast%3DKent%26aufirst%3DS.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26atitle%3DStructure%2520of%2520Complex%2520of%2520Synthetic%2520HIV-1%2520Protease%2520with%2520a%2520Substrate-Based%2520Inhibitor%2520at%25202.3%2520A%2520Resolution%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D1149%26epage%3D1152%26doi%3D10.1126%2Fscience.2686029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swain, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span> <span> </span><span class="NLM_article-title">X-Ray Crystallographic Structure of a Complex between a Synthetic Protease of Human Immunodeficiency Virus 1 and a Substrate-Based Hydroxyethylamine Inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">8805</span>– <span class="NLM_lpage">8809</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.22.8805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.87.22.8805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2247451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=8805-8809&author=A.+L.+Swainauthor=M.+M.+Millerauthor=J.+Greenauthor=D.+H.+Richauthor=J.+Schneiderauthor=S.+B.+Kentauthor=A.+Wlodawer&title=X-Ray+Crystallographic+Structure+of+a+Complex+between+a+Synthetic+Protease+of+Human+Immunodeficiency+Virus+1+and+a+Substrate-Based+Hydroxyethylamine+Inhibitor&doi=10.1073%2Fpnas.87.22.8805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor</span></div><div class="casAuthors">Swain, Amy L.; Miller, Maria M.; Green, Jeremy; Rich, Daniel H.; Schneider, Jens; Kent, Stephen B. H.; Wlodawer, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8805-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The crystal of a complex of the chem. synthesized aspartic protease of human immunodeficiency virus 1 (HIV-1) with a heptapeptide-derived inhibitor bound in the active site was detd.  The sequence of the inhibitor JG-365 was Ac-Ser-Leu-Asn-Phe-ψ[CH(OH)CH2N]-Pro-Ile-Val-OMe; the Ki was 0.24 nM.  The hydroxyethylamine moiety, in place of the normal scissile bond of the substrate, is believed to mimic a tetrahedral reaction intermediate.  The structure of the complex was refined to an R factor of 0.146 at 2.4-Å resoln. by using restrained least squares with rms deviations in bond lengths of 0.02 Å and bond angles of 4°.  The bound inhibitor diastereomer had the S configuration at the hydroxyethylamine chiral C atom, and the OH group was positioned between the active site aspartate carboxyl groups within H-bonding distance.  Comparison of this structure with a reduced peptide bond inhibitor-protease complex indicated that these contacts confer the exceptional binding strength of JG-365.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYAMlIk7NhWrVg90H21EOLACvtfcHk0lipaZW6ydXICA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlyrsr4%253D&md5=a2be842ef3f1d35743271c75f7de903e</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.22.8805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.22.8805%26sid%3Dliteratum%253Aachs%26aulast%3DSwain%26aufirst%3DA.%2BL.%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DRich%26aufirst%3DD.%2BH.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DS.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26atitle%3DX-Ray%2520Crystallographic%2520Structure%2520of%2520a%2520Complex%2520between%2520a%2520Synthetic%2520Protease%2520of%2520Human%2520Immunodeficiency%2520Virus%25201%2520and%2520a%2520Substrate-Based%2520Hydroxyethylamine%2520Inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D8805%26epage%3D8809%26doi%3D10.1073%2Fpnas.87.22.8805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emini, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolnick, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal, I. S.</span></span> <span> </span><span class="NLM_article-title">Active Human Immunodeficiency Virus Protease Is Required for Viral Infectivity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">4686</span>– <span class="NLM_lpage">4690</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.13.4686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.85.13.4686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3290901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXltVOmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4686-4690&author=N.+E.+Kohlauthor=E.+A.+Eminiauthor=W.+A.+Schleifauthor=L.+J.+Davisauthor=J.+C.+Heimbachauthor=R.+A.+Dixonauthor=E.+M.+Scolnickauthor=I.+S.+Sigal&title=Active+Human+Immunodeficiency+Virus+Protease+Is+Required+for+Viral+Infectivity&doi=10.1073%2Fpnas.85.13.4686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Active human immunodeficiency virus protease is required for viral infectivity</span></div><div class="casAuthors">Kohl, Nancy E.; Emini, Emilio A.; Schleif, William A.; Davis, Lenora J.; Heimbach, Jill C.; Dixon, Richard A. F.; Scolnick, Edward M.; Sigal, Irving S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4686-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Retroviral proteins are synthesized as polyprotein precursors that undergo proteolytic cleavages to yield the mature viral proteins.  The role of the human immunodeficiency virus (HIV) protease in the viral replication cycle was examd. by use of a site-directed mutation in the protease gene.  The HIV protease gene product was expressed in Escherichia coli and obsd. to cleave HIV gag p55 to gag p24 and gag p17 in vitro.  Substitution of aspartic acid residue 25 (Asp-25) or this protein with an asparagine residue did not affect the expression of the protein, but it eliminated detectable in vitro proteolytic activity against HIV gag p55.  A mutant HIV provirus was constructed that contained the Asn-25 mutation within the protease gene.  SW480 human colon carcinoma cells transfected with the Asn-25 mutant proviral DNA produced virions that contained gag p55 but not gag p24, whereas virions from cells transfected with the wild-type DNA contained both gag p55 and gag p24.  The mutant virions were not able to infect MT-4 lymphoid cells.  In contrast, these cells were highly sensitive to infection by the wild-type virions.  These results demonstrate that the HIV protease is an essential viral enzyme and consequently, an attractive target for anti-HIV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDAYeRHmne27Vg90H21EOLACvtfcHk0lipaZW6ydXICA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVOmtrY%253D&md5=3f6e11607d70ea93570ef2449b312f22</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.13.4686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.13.4686%26sid%3Dliteratum%253Aachs%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DEmini%26aufirst%3DE.%2BA.%26aulast%3DSchleif%26aufirst%3DW.%2BA.%26aulast%3DDavis%26aufirst%3DL.%2BJ.%26aulast%3DHeimbach%26aufirst%3DJ.%2BC.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DSigal%26aufirst%3DI.%2BS.%26atitle%3DActive%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Is%2520Required%2520for%2520Viral%2520Infectivity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26spage%3D4686%26epage%3D4690%26doi%3D10.1073%2Fpnas.85.13.4686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Food and Drug Administration</span>. <a href="http://www.fda.gov/oashi/aids/virals.html" class="extLink">http://www.fda.gov/oashi/aids/virals.html</a> (Accessed May 18, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Food+and+Drug+Administration.+http%3A%2F%2Fwww.fda.gov%2Foashi%2Faids%2Fvirals.html+%28Accessed+May+18%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/jm900492g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900492g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=521-538&author=Y.+Mehellouauthor=E.+De+Clercq&title=Twenty-Six+Years+of+Anti-HIV+Drug+Discovery%3A+Where+Do+We+Stand+and+Where+Do+We+Go%3F&doi=10.1021%2Fjm900492g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?</span></div><div class="casAuthors">Mehellou, Youcef; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">521-538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human immunodeficiency virus (HIV) has now been established as the causative agent of the acquired immunodeficiency syndrome (AIDS) for over 20 years.  During this time an unprecedented success has been achieved in discovering anti-HIV drugs as reflected by the fact that there are now more drugs approved for the treatment of HIV than for all other viral infections taken together.  The currently Food and Drug Administration (FDA) approved anti-HIV drugs can be divided into seven groups: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), coreceptor inhibitors (CRIs), and integrase inhibitors (INIs).  This arsenal of drugs, which is used in combinations, has moved the prognosis of HIV patients from that of high morbidity and mortality to, for many at least, a chronic, manageable but still complex disease.  However, the use of these drugs has been relatively limited by their toxicity, drug resistance development, and more worryingly, the fact that some newly HIV-infected patients carry viruses that are already resistant to the currently approved AIDS treatments.  These issues along with drug-related side effects as well as, in some cases, poor tolerability of these drugs make it apparent that new anti-HIV drugs with acceptable toxicity and resistance profiles and, more importantly, new anti-HIV agents with novel mechanisms of action are clearly needed.  There is no doubt that, since the discovery of HIV 26 years ago, the progress made toward developing effective anti-HIV therapies has superseded that of any other (antiviral) drug discovery initiative.  This unprecedented progress generated an armamentarium of anti-HIV drugs, which target several different stages of the HIV life cycle.  This, therefore, has enabled the use of combination therapy in combating HIV infections.  Although the drugs making up these treatment regimens have proved effective, some problems such as toxicity and resistance development have limited their use and prompted the search for new agents.  The pipeline of anti-HIV drugs is well stocked with drugs that are going to be "next-generation" drugs.  However, as we highlighted in this work, future anti-HIV drug research efforts should also focus on new HIV targets such as HIV proteins and RNase H.  In addn., the development of anti-HIV drugs derived from natural products is an area of research where a lot of efforts should be dedicated in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjZ2YdiQQgbVg90H21EOLACvtfcHk0lipaZW6ydXICA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2ltLvL&md5=7b9374af941b187a82bc970b45d71318</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm900492g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900492g%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTwenty-Six%2520Years%2520of%2520Anti-HIV%2520Drug%2520Discovery%253A%2520Where%2520Do%2520We%2520Stand%2520and%2520Where%2520Do%2520We%2520Go%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D521%26epage%3D538%26doi%3D10.1021%2Fjm900492g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boross, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of HIV Protease V82A and L90M Mutants Reveal Changes in the Indinavir-Binding Site</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">1516</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.2004.04060.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1432-1033.2004.04060.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15066177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFeksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=2004&pages=1516-1524&author=B.+Mahalingamauthor=Y.+F.+Wangauthor=P.+I.+Borossauthor=J.+Tozserauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=Crystal+Structures+of+HIV+Protease+V82A+and+L90M+Mutants+Reveal+Changes+in+the+Indinavir-Binding+Site&doi=10.1111%2Fj.1432-1033.2004.04060.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site</span></div><div class="casAuthors">Mahalingam, Bhuvaneshwari; Wang, Yuan-Fang; Boross, Peter I.; Tozser, Jozsef; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1516-1524</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The crystal structures of the wild-type HIV-1 protease (PR) and the two resistant variants, PRV82A and PRL90M, have been detd. in complex with the antiviral drug, indinavir, to gain insight into the mol. basis of drug resistance.  V82A and L90M correspond to an active site mutation and nonactive site mutation, resp.  The inhibition (Ki) of PRV82A and PRL90M was 3.3- and 0.16- fold, resp., relative to the value for PR.  They showed only a modest decrease, of 10-15%, in their kcat/Km values relative to PR.  The crystal structures were refined to resolns. of 1.25-1.4 Å to reveal crit. features assocd. with inhibitor resistance.  PRV82A showed local changes in residues 81-82 at the site of the mutation, while PRL90M showed local changes near Met90 and an addnl. interaction with indinavir.  These structural differences concur with the kinetic data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBAC1vCXX-pLVg90H21EOLACvtfcHk0liPcbiAU0q6zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFeksbc%253D&md5=ba374f81e925f41ca6a07b2d95979462</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.2004.04060.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.2004.04060.x%26sid%3Dliteratum%253Aachs%26aulast%3DMahalingam%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DTozser%26aufirst%3DJ.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DCrystal%2520Structures%2520of%2520HIV%2520Protease%2520V82A%2520and%2520L90M%2520Mutants%2520Reveal%2520Changes%2520in%2520the%2520Indinavir-Binding%2520Site%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2004%26volume%3D271%26spage%3D1516%26epage%3D1524%26doi%3D10.1111%2Fj.1432-1033.2004.04060.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent HIV-1 Protease Inhibitors Incorporating Sulfoximine Functionality</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5614</span>– <span class="NLM_lpage">5619</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2007.07.095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17822899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5614-5619&author=D.+Luauthor=R.+Vince&title=Discovery+of+Potent+HIV-1+Protease+Inhibitors+Incorporating+Sulfoximine+Functionality&doi=10.1016%2Fj.bmcl.2007.07.095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality</span></div><div class="casAuthors">Lu, Ding; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5614-5619</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on the unique property of sulfoximine and the homodimeric C2 structural symmetry of HIV-1 protease, a novel class of sulfoximine-based pseudosym. HIV-1 protease inhibitors, e.g., I, was designed and synthesized.  The sulfoximine moiety was demonstrated to be important for HIV-1 protease inhibitor potency.  The most active stereoisomer (2S,2'S) displays a potency of 2.5 nM (IC50) against HIV-1 protease and an anti-HIV-1 activity of 408 nM (IC50).  A possible mode of action is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEOJzXk4cU07Vg90H21EOLACvtfcHk0liPcbiAU0q6zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisb7I&md5=1da3157fb1ed4ecb89155bba6bb6608d</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.095%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520Potent%2520HIV-1%2520Protease%2520Inhibitors%2520Incorporating%2520Sulfoximine%2520Functionality%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5614%26epage%3D5619%26doi%3D10.1016%2Fj.bmcl.2007.07.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design, Asymmetric Synthesis, and Evaluation of Pseudosymmetric Sulfoximine Inhibitors against HIV-1 Protease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2037</span>– <span class="NLM_lpage">2048</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmc.2010.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20138769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2037-2048&author=D.+Luauthor=Y.+Y.+Shamauthor=R.+Vince&title=Design%2C+Asymmetric+Synthesis%2C+and+Evaluation+of+Pseudosymmetric+Sulfoximine+Inhibitors+against+HIV-1+Protease&doi=10.1016%2Fj.bmc.2010.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease</span></div><div class="casAuthors">Lu, Ding; Sham, Yuk Yin; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2037-2048</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The HIV-1 protease is a validated drug target for the design of antiretroviral drugs to combat AIDS.  We previously established the sulfoximine functionality as a valid transition state mimetic (TSM) in the HIV-1 protease inhibitors (PI) design and have identified a lead pseudosym. compd. with nanomolar enzymic inhibitory activity.  Here, we report the asym. synthesis of this compd. and its application in the synthesis of sulfoximine-based peptidomimetic HIV-1 protease inhibitors.  Mol. modeling revealed the potential mode of binding of the sulfoximine inhibitor as a TSM.  The predicted abs. binding free energies suggested similar inhibitory effect as obsd. in our enzymic inhibitory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeX1toC_hLKLVg90H21EOLACvtfcHk0liPcbiAU0q6zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1ajs74%253D&md5=ef9d6d1b014c1c3ee36e5601985115ec</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%252C%2520Asymmetric%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Pseudosymmetric%2520Sulfoximine%2520Inhibitors%2520against%2520HIV-1%2520Protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2037%26epage%3D2048%26doi%3D10.1016%2Fj.bmc.2010.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Sulfoximine Based Inhibitors for HIV-1 Protease</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5406</span>– <span class="NLM_lpage">5410</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2008.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18829317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CqsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5406-5410&author=A.+Razaauthor=Y.+Y.+Shamauthor=R.+Vince&title=Design+and+Synthesis+of+Sulfoximine+Based+Inhibitors+for+HIV-1+Protease&doi=10.1016%2Fj.bmcl.2008.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of sulfoximine based inhibitors for HIV-1 protease</span></div><div class="casAuthors">Raza, Abbas; Sham, Yuk Yin; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5406-5410</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A class of potent sulfoximine inhibitors for HIV-1 protease has been designed and synthesized.  Substitution of the sulfoximine moiety into different parent compds. yields different inhibition effects.  While our previously studied sulfoximine-based inhibitors display potency of 2.5 nM (IC50) against HIV-1 protease, introduction of the sulfoximine moiety into the asym. Indinavir yielded only micromolar inhibition.  Docking studies showed structural variations in their modes of binding which explains this unexpected observation.  The implication of these observations in the development of other sulfoximine inhibitors is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLbB5oqogTMLVg90H21EOLACvtfcHk0liPcbiAU0q6zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CqsrfE&md5=8c9a94592b8128ae74b201806fb2b2ba</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Sulfoximine%2520Based%2520Inhibitors%2520for%2520HIV-1%2520Protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5406%26epage%3D5410%26doi%3D10.1016%2Fj.bmcl.2008.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliakas-Boltz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowdon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonucci, T. K.</span></span> <span> </span><span class="NLM_article-title">Biological and Biochemical Anti-HIV Activity of the Benzothiadiazine Class of Nonnucleoside Reverse Transcriptase Inhibitors</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/0166-3542(94)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2F0166-3542%2894%2990092-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7529014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1994&pages=43-56&author=R.+W.+Buckheitauthor=V.+Fliakas-Boltzauthor=W.+D.+Deckerauthor=J.+L.+Robersonauthor=C.+A.+Pyleauthor=E.+L.+Whiteauthor=B.+J.+Bowdonauthor=J.+B.+McMahonauthor=M.+R.+Boydauthor=J.+P.+Baderauthor=D.+G.+Nickellauthor=H.+Barthauthor=T.+K.+Antonucci&title=Biological+and+Biochemical+Anti-HIV+Activity+of+the+Benzothiadiazine+Class+of+Nonnucleoside+Reverse+Transcriptase+Inhibitors&doi=10.1016%2F0166-3542%2894%2990092-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors</span></div><div class="casAuthors">Buckheit, , Robert W. Jr.; Fliakas-Boltz, Valerie; Decker, W. Don; Roberson, Joseph L.; Pyle, Cathi A.; White, E. Lucile; Bowdon, Bonnie J.; McMahon, James B.; Boyd, Michael R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-56</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">A series of benzothiadiazine derivs. were screened against the human immunodeficiency virus (HIV) and certain structure-activity relationships were defined for anti-HIV activity in this chem. class.  The selected representative NSC 287474 was a highly potent inhibitor of HIV-induced cell killing and HIV replication in a variety of human cell lines, as well as in fresh human peripheral blood lymphocytes and macrophages.  The compd. was active against a panel of biol. diverse lab. and clin. strains of HIV-1, including the AZT-resistant strain G910-6.  However, the agent was inactive against HIV-2, and also against both nevirapine- and pyridinone-resistant strains (N119 and A17) of HIV-1, which are cross-resistant to several structurally diverse nonnucleoside reverse transcriptase inhibitors.  The compd. selectively inhibited HIV-1 reverse transcriptase, but not HIV-2 reverse transcriptase.  Combination of NSC 287474 with AZT synergistically inhibited HIV-1-induced cell killing in vitro.  The compd. did not inhibit the replication of the Rauscher murine leukemia retrovirus or the simian immunodeficiency virus.  The benzothiadiazine class of compds. represents a new active anti-HIV-1 chemotype within the diverse group of nonnucleoside reverse transcriptase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKwxG24h38bVg90H21EOLACvtfcHk0ljwGwS-GwR4Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWqtbo%253D&md5=49aa278e2bc36abd873303f70d0f0a3d</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2894%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252894%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DFliakas-Boltz%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DW.%2BD.%26aulast%3DRoberson%26aufirst%3DJ.%2BL.%26aulast%3DPyle%26aufirst%3DC.%2BA.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DBowdon%26aufirst%3DB.%2BJ.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBader%26aufirst%3DJ.%2BP.%26aulast%3DNickell%26aufirst%3DD.%2BG.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DAntonucci%26aufirst%3DT.%2BK.%26atitle%3DBiological%2520and%2520Biochemical%2520Anti-HIV%2520Activity%2520of%2520the%2520Benzothiadiazine%2520Class%2520of%2520Nonnucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D1994%26volume%3D25%26spage%3D43%26epage%3D56%26doi%3D10.1016%2F0166-3542%2894%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Askin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volante, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinkai, I.</span></span> <span> </span><span class="NLM_article-title">Highly Diastereoselective Alkylations of Chiral Amide Enolates: New Routes to Hydroxyethylene Dipeptide Isostere Inhibitors of HIV-1 Protease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2773</span>, <span class="refDoi"> DOI: 10.1021/jo00036a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00036a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK38XisFKjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=2771-2773&author=D.+Askinauthor=M.+Wallaceauthor=J.+Vaccaauthor=R.+Reamerauthor=R.+Volanteauthor=I.+Shinkai&title=Highly+Diastereoselective+Alkylations+of+Chiral+Amide+Enolates%3A+New+Routes+to+Hydroxyethylene+Dipeptide+Isostere+Inhibitors+of+HIV-1+Protease&doi=10.1021%2Fjo00036a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Highly diastereoselective alkylations of chiral amide enolates:  new routes to hydroxyethylene dipeptide isostere inhibitors of HIV-1 protease</span></div><div class="casAuthors">Askin, D.; Wallace, M. A.; Vacca, J. P.; Reamer, R. A.; Volante, R. P.; Shinkai, I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2771-3</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The non-chelate enforced chiral amide enolate derived from amide I (R = H) and BuLi reacts with MeI at -78° to afford the (2S)-methylated product II in 97% diastereoselectivity.  Similarly, treatment of the lithium enolate with 0.5 equiv of 3-iodo-2-iodomethyl-1-propene affords the double adduct III (X = CH2, R1 = acetonide).  Ozonolysis, redn. and acetonide removal then affords the pseudo-C2-sym. HIV protease inhibitor III (X = H, OH; R1 = H).  Amides I (R = H, 2-morpholinoethoxy, OH, OCH2CH2OH) react with epoxides IV (Boc = Me3CO2C, R2 = Ph, cyclohexyl) upon addn. of 2 or 3 equiv of BuLi to the -78° amide/epoxide soln. in THF, which after warming to -25° affords the (2R) adducts V in an intramol. Lewis acid accelerated one-pot process.  The high diastereoselectivity obsd. in the alkylation of the amide enolates is much greater than predicted from the soln. rotamer ratios of I.  Acetonide cleavage of V then affords the hydroxyethylene dipeptide isosteres VI.  This chem. provides a rapid entry into HIV protease inhibitors derived from the phenylglycine surrogate (-)-cis-(1S,2R)-1-aminoindan-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWd4S3QY_wfLVg90H21EOLACvtfcHk0ljwGwS-GwR4Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFKjsrk%253D&md5=bf45cca93d1a4231378baaeede24ccbb</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Fjo00036a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00036a004%26sid%3Dliteratum%253Aachs%26aulast%3DAskin%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DVolante%26aufirst%3DR.%26aulast%3DShinkai%26aufirst%3DI.%26atitle%3DHighly%2520Diastereoselective%2520Alkylations%2520of%2520Chiral%2520Amide%2520Enolates%253A%2520New%2520Routes%2520to%2520Hydroxyethylene%2520Dipeptide%2520Isostere%2520Inhibitors%2520of%2520HIV-1%2520Protease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D2771%26epage%3D2773%26doi%3D10.1021%2Fjo00036a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satzinger, G.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and Commercial Exploitation</span>. <i>Drug News Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1358/dnp.2001.14.4.858403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1358%2Fdnp.2001.14.4.858403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12819791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt12itLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=197-207&author=G.+Satzinger&title=Drug+Discovery+and+Commercial+Exploitation&doi=10.1358%2Fdnp.2001.14.4.858403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and commercial exploitation</span></div><div class="casAuthors">Satzinger, G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  In this report, the author demonstrates the central role of chem. in pharmaceutical research in the past.  Although the modern researcher has a more sophisticated understanding of disease origins and more sophisticated means to new drugs, chem. and ingenuity remain propelling elements of pharmaceutical research in the twenty-first century.  Certainly, long-term experience in com. drug research suggests that prior to launch, the eventual fate of a drug candidate may be less destined by quality and demand than by discrete decision procedures within top management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1GICcHiw07Vg90H21EOLACvtfcHk0ljwGwS-GwR4Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt12itLY%253D&md5=42be80826e3aaa60352738a40413adbf</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2001.14.4.858403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2001.14.4.858403%26sid%3Dliteratum%253Aachs%26aulast%3DSatzinger%26aufirst%3DG.%26atitle%3DDrug%2520Discovery%2520and%2520Commercial%2520Exploitation%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2001%26volume%3D14%26spage%3D197%26epage%3D207%26doi%3D10.1358%2Fdnp.2001.14.4.858403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satzinger, G.</span></span> <span> </span><span class="NLM_article-title">Antiviral Pharmaceutical Composition for Treating Lymphocytes</span>. <span class="NLM_patent">US5321024A</span>, Jun, 14 <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=G.+Satzinger&title=Antiviral+Pharmaceutical+Composition+for+Treating+Lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatzinger%26aufirst%3DG.%26atitle%3DAntiviral%2520Pharmaceutical%2520Composition%2520for%2520Treating%2520Lymphocytes%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span> <span> </span><span class="NLM_article-title">Psoriasis: Epidemiology, Clinical Features, and Quality of Life</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">ii18</span>– <span class="NLM_lpage">ii25</span>, <span class="refDoi"> DOI: 10.1136/ard.2004.033217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Fard.2004.033217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15708928" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=ii18-ii25&author=R.+G.+B.+Langleyauthor=G.+G.+Kruegerauthor=C.+E.+M.+Griffiths&title=Psoriasis%3A+Epidemiology%2C+Clinical+Features%2C+and+Quality+of+Life&doi=10.1136%2Fard.2004.033217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.033217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.033217%26sid%3Dliteratum%253Aachs%26aulast%3DLangley%26aufirst%3DR.%2BG.%2BB.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26atitle%3DPsoriasis%253A%2520Epidemiology%252C%2520Clinical%2520Features%252C%2520and%2520Quality%2520of%2520Life%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3Dii18%26epage%3Dii25%26doi%3D10.1136%2Fard.2004.033217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynde, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vender, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourcier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, S.</span></span> <span> </span><span class="NLM_article-title">Interleukin 17A: Toward a New Understanding of Psoriasis Pathogenesis</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2013.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaad.2013.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24655820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=141-150&author=C.+W.+Lyndeauthor=Y.+Poulinauthor=R.+Venderauthor=M.+Bourcierauthor=S.+Khalil&title=Interleukin+17A%3A+Toward+a+New+Understanding+of+Psoriasis+Pathogenesis&doi=10.1016%2Fj.jaad.2013.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 17A: Toward a new understanding of psoriasis pathogenesis</span></div><div class="casAuthors">Lynde, Charles W.; Poulin, Yves; Vender, Ronald; Bourcier, Marc; Khalil, Sam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-150</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Mol. and cellular understanding of psoriasis pathogenesis has evolved considerably over the last 30 years beginning in the early 1980s when psoriasis was thought to be a skin disease driven by keratinocyte hyperproliferation.  During the next 20 years, the role of the immune system and T-helper (Th) cells in psoriasis pathogenesis was recognized.  The presence of the interleukin (IL)-12 cytokine in psoriatic lesions led to the postulate that psoriasis is mediated by Th1 cells.  Recent evidence has revealed a role for Th17 cells, and other immune cells, as proximal regulators of psoriatic skin inflammation.  IL-17A, the principal effector cytokine of Th17 cells, stimulates keratinocytes to produce chemokines, cytokines, and other proinflammatory mediators thereby enabling IL-17A to bridge the innate and adaptive immune systems to sustain chronic inflammation.  This model underlies the rationale for inhibiting IL-17A signaling as a potential therapeutic approach to disrupt the psoriatic inflammatory loop.  Several monoclonal antibodies that inhibit the IL-17 pathway are in clin. development.  These agents exhibit promising clin. efficacy and tolerability profiles including immunohistochem. improvement in psoriatic plaques.  Results from clin. trials with IL-17 pathway inhibitors are refining our understanding of psoriasis pathogenesis and may provide a new therapeutic approach for patients with moderate to severe psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaQkyBVZ0zLVg90H21EOLACvtfcHk0li1Ho83jUfqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFWltL8%253D&md5=333950541388c2b5e2edd6d1a6c2f7b6</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2013.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2013.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DLynde%26aufirst%3DC.%2BW.%26aulast%3DPoulin%26aufirst%3DY.%26aulast%3DVender%26aufirst%3DR.%26aulast%3DBourcier%26aufirst%3DM.%26aulast%3DKhalil%26aufirst%3DS.%26atitle%3DInterleukin%252017A%253A%2520Toward%2520a%2520New%2520Understanding%2520of%2520Psoriasis%2520Pathogenesis%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2014%26volume%3D71%26spage%3D141%26epage%3D150%26doi%3D10.1016%2Fj.jaad.2013.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span> <span> </span><span class="NLM_article-title">Review of Phase III Trial Data on IL-23 Inhibitors Tildrakizumab and Guselkumab for Psoriasis</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1111/jdv.14451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fjdv.14451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28667777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslalsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1627-1632&author=M.+Aminauthor=K.+Darjiauthor=D.+J.+Noauthor=J.+J.+Wu&title=Review+of+Phase+III+Trial+Data+on+IL-23+Inhibitors+Tildrakizumab+and+Guselkumab+for+Psoriasis&doi=10.1111%2Fjdv.14451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis</span></div><div class="casAuthors">Amin, M.; Darji, K.; No, D. J.; Wu, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1627-1632</span>CODEN:
                <span class="NLM_cas:coden">JEAVEQ</span>;
        ISSN:<span class="NLM_cas:issn">1468-3083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The development of monoclonal antibodies targeting IL-12 and IL-23 has enhanced the therapeutic options available for psoriasis patients.  Recent research suggests that IL-23 alone plays a role in the pathogenesis of psoriasis.  The objective was to review the phase III clin. trial data for the anti-IL-23 agents to evaluate the safety and efficacy profile of each agent.  We reviewed the results of the phase III clin. trials for the anti-IL-23 agents tildrakizumab and guselkumab.  The results of phase III trials on risankizumab have not yet been reported.  By week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was >60% among the most efficacious dose of each agent.  The percentage of patients achieving PASI 90 at week 16 was the primary endpoint for the phase III trials for guselkumab, which was above 70%.  The safety profiles of the agents were comparable, with the most commonly reported adverse events of nasopharyngitis and upper respiratory tract infections.  The anti-IL-23 agents demonstrated a rapid clin. improvement that is similar or superior to the improvement seen with currently marketed IL-17 inhibitors with a favorable short-term safety profile.  The results of the phase III trials support the notion that IL-23 is a potential target in psoriasis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4GdiDmzQSELVg90H21EOLACvtfcHk0li1Ho83jUfqqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslalsrbJ&md5=c5fae131f60385cfbd1431f7a7cfc0e9</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1111%2Fjdv.14451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjdv.14451%26sid%3Dliteratum%253Aachs%26aulast%3DAmin%26aufirst%3DM.%26aulast%3DDarji%26aufirst%3DK.%26aulast%3DNo%26aufirst%3DD.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26atitle%3DReview%2520of%2520Phase%2520III%2520Trial%2520Data%2520on%2520IL-23%2520Inhibitors%2520Tildrakizumab%2520and%2520Guselkumab%2520for%2520Psoriasis%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2017%26volume%3D31%26spage%3D1627%26epage%3D1632%26doi%3D10.1111%2Fjdv.14451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arican, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasmaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciragil, P.</span></span> <span> </span><span class="NLM_article-title">Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients with Active Psoriasis and Correlation with Disease Severity</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1155/MI.2005.273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1155%2FMI.2005.273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16258194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2MrnvF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=273-279&author=O.+Aricanauthor=M.+Aralauthor=S.+Sasmazauthor=P.+Ciragil&title=Serum+Levels+of+TNF-%CE%B1%2C+IFN-%CE%B3%2C+IL-6%2C+IL-8%2C+IL-12%2C+IL-17%2C+and+IL-18+in+Patients+with+Active+Psoriasis+and+Correlation+with+Disease+Severity&doi=10.1155%2FMI.2005.273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity</span></div><div class="casAuthors">Arican Ozer; Aral Murat; Sasmaz Sezai; Ciragil Pinar</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2005</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">273-9</span>
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    </div><div class="casAbstract">Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis.  The most often used psoriasis score is the psoriasis area and severity index (PASI).  A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity.  To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis.  The serum levels of cytokines levels were determined with the use of the ELISA method.  All mean values except IL-17 levels of patients were significantly higher than those of controls.  There was a significant correlation between serum levels of IFN-gamma, IL-12, IL-17, and IL-18, and severity of the disease.  Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies.  In this study, serum TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls.  Furthermore, high levels of IFN-gamma, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2CQC8zA6KkCO2kE7krGOBfW6udTcc2ebNGr2sHhj6vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrnvF2nug%253D%253D&md5=dea333465f32fd60cdc735d3ae76ff74</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1155%2FMI.2005.273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252FMI.2005.273%26sid%3Dliteratum%253Aachs%26aulast%3DArican%26aufirst%3DO.%26aulast%3DAral%26aufirst%3DM.%26aulast%3DSasmaz%26aufirst%3DS.%26aulast%3DCiragil%26aufirst%3DP.%26atitle%3DSerum%2520Levels%2520of%2520TNF-%25CE%25B1%252C%2520IFN-%25CE%25B3%252C%2520IL-6%252C%2520IL-8%252C%2520IL-12%252C%2520IL-17%252C%2520and%2520IL-18%2520in%2520Patients%2520with%2520Active%2520Psoriasis%2520and%2520Correlation%2520with%2520Disease%2520Severity%26jtitle%3DMediators%2520Inflammation%26date%3D2005%26volume%3D2005%26spage%3D273%26epage%3D279%26doi%3D10.1155%2FMI.2005.273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapies in Psoriasis: A Systematic Review</span>. <i>Cutis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29718027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1MjovFGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=5-9&author=E.+B.+Leeauthor=M.+Aminauthor=T.+Bhutaniauthor=J.+J.+Wu&title=Emerging+Therapies+in+Psoriasis%3A+A+Systematic+Review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies in psoriasis: a systematic review</span></div><div class="casAuthors">Lee Erica B; Amin Mina; Bhutani Tina; Wu Jashin J</div><div class="citationInfo"><span class="NLM_cas:title">Cutis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">3S</span>),
    <span class="NLM_cas:pages">5-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many new biologics are being studied for use in psoriasis.  In this review, we evaluate and summarize findings about emerging biologic therapies for psoriasis.  We reviewed published data from phase 2 and 3 clinical trials of 2 IL-17 inhibitors (ixekizumab and brodalumab); 3 IL-23 inhibitors (guselkumab, tildrakizumab, and risankizumab); and 1 tumor necrosis factor (TNF) inhibitor (certolizumab pegol).  Janus kinase inhibitors were not included in our review, as they currently are not approved by the US Food and Drug Administration (FDA) and there are no plans to further develop this class for treatment of psoriasis.  Overall, the clinical improvement provided by and the safety profiles of these agents are promising; they may be equal to or more efficacious than available therapeutic options for treating the symptoms of psoriasis.  Long-term studies are still needed, however, to further establish safety and efficacy profiles for these biologic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSaBOzmDoL7IHWj6b1v8uTfW6udTcc2eZOOTte0ya8-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjovFGgtA%253D%253D&md5=e96319a03c6d408033f440696cdc251d</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DAmin%26aufirst%3DM.%26aulast%3DBhutani%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BJ.%26atitle%3DEmerging%2520Therapies%2520in%2520Psoriasis%253A%2520A%2520Systematic%2520Review%26jtitle%3DCutis%26date%3D2018%26volume%3D101%26spage%3D5%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rendon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäkel, K.</span></span> <span> </span><span class="NLM_article-title">Psoriasis Pathogenesis and Treatment</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1475</span>, <span class="refDoi"> DOI: 10.3390/ijms20061475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.3390%2Fijms20061475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1475&author=A.+Rendonauthor=K.+Sch%C3%A4kel&title=Psoriasis+Pathogenesis+and+Treatment&doi=10.3390%2Fijms20061475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis pathogenesis and treatment</span></div><div class="casAuthors">Rendon, Adriana; Schaekel, Knut</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1475</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Research on psoriasis pathogenesis has largely increased knowledge on skin biol. in general.  In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis.  This review discusses the mechanisms involved in the initiation and development of the disease, as well as the therapeutic options that have arisen from the dissection of the inflammatory psoriatic pathways.  Our discussion begins by addressing the inflammatory pathways and key cell types initiating and perpetuating psoriatic inflammation.  Next, we describe the role of genetics, assocd. epigenetic mechanisms, and the interaction of the skin flora in the pathophysiol. of psoriasis.  Finally, we include a comprehensive review of well-established widely available therapies and novel targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeBJo30ie8bbVg90H21EOLACvtfcHk0ljpS2L0JQoovw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVajsA%253D%253D&md5=40625b4b8d8ae4e2f859798dafc1c8eb</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.3390%2Fijms20061475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061475%26sid%3Dliteratum%253Aachs%26aulast%3DRendon%26aufirst%3DA.%26aulast%3DSch%25C3%25A4kel%26aufirst%3DK.%26atitle%3DPsoriasis%2520Pathogenesis%2520and%2520Treatment%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1475%26doi%3D10.3390%2Fijms20061475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckerandre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarter, J. F.</span></span> <span> </span><span class="NLM_article-title">Identification of Nuclear Receptor mRNAs by RT-PCR Amplification of Conserved Zinc-Finger Motif Sequences</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1993.1976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1006%2Fbbrc.1993.1976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7916608" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=1993&pages=1371-1379&author=M.+Beckerandreauthor=E.+Andreauthor=J.+F.+Delamarter&title=Identification+of+Nuclear+Receptor+mRNAs+by+RT-PCR+Amplification+of+Conserved+Zinc-Finger+Motif+Sequences&doi=10.1006%2Fbbrc.1993.1976"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1993.1976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1993.1976%26sid%3Dliteratum%253Aachs%26aulast%3DBeckerandre%26aufirst%3DM.%26aulast%3DAndre%26aufirst%3DE.%26aulast%3DDelamarter%26aufirst%3DJ.%2BF.%26atitle%3DIdentification%2520of%2520Nuclear%2520Receptor%2520mRNAs%2520by%2520RT-PCR%2520Amplification%2520of%2520Conserved%2520Zinc-Finger%2520Motif%2520Sequences%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1993%26volume%3D194%26spage%3D1371%26epage%3D1379%26doi%3D10.1006%2Fbbrc.1993.1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kojetin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, T. P.</span></span> <span> </span><span class="NLM_article-title">REV-ERB and ROR Nuclear Receptors as Drug Targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/nrd4100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd4100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24577401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt12hsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=197-216&author=D.+J.+Kojetinauthor=T.+P.+Burris&title=REV-ERB+and+ROR+Nuclear+Receptors+as+Drug+Targets&doi=10.1038%2Fnrd4100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">REV-ERB and ROR nuclear receptors as drug targets</span></div><div class="casAuthors">Kojetin, Douglas J.; Burris, Thomas P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The nuclear receptors REV-ERB (consisting of REV-ERBα and REV-ERBβ) and retinoic acid receptor-related orphan receptors (RORs; consisting of RORα, RORβ and RORγ) are involved in many physiol. processes, including regulation of metab., development and immunity as well as the circadian rhythm.  The recent characterization of endogenous ligands for these former orphan nuclear receptors has stimulated the development of synthetic ligands and opened up the possibility of targeting these receptors to treat several diseases, including diabetes, atherosclerosis, autoimmunity and cancer.  This Review focuses on the latest developments in ROR and REV-ERB pharmacol. indicating that these nuclear receptors are druggable targets and that ligands targeting these receptors may be useful in the treatment of several disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorEsJo5WEbmrVg90H21EOLACvtfcHk0ljpS2L0JQoovw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt12hsL0%253D&md5=156f56d5766fec38440a3c0f2e9c753e</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1038%2Fnrd4100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4100%26sid%3Dliteratum%253Aachs%26aulast%3DKojetin%26aufirst%3DD.%2BJ.%26aulast%3DBurris%26aufirst%3DT.%2BP.%26atitle%3DREV-ERB%2520and%2520ROR%2520Nuclear%2520Receptors%2520as%2520Drug%2520Targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D197%26epage%3D216%26doi%3D10.1038%2Fnrd4100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanichamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ergun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaire, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenot, J. D.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Mediated Inhibition of RORγ-Dependent Gene Expression and Autoimmune Disease Pathology <i>in Vivo</i></span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1111/imm.12570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fimm.12570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26694902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2016&pages=399-413&author=D.+Banerjeeauthor=L.+Zhaoauthor=L.+Wuauthor=A.+Palanichamyauthor=A.+Ergunauthor=L.+Pengauthor=C.+Quigleyauthor=S.+Hamannauthor=R.+Dunstanauthor=P.+Cullenauthor=N.+Allaireauthor=K.+Guertinauthor=T.+Wangauthor=J.+Chaoauthor=C.+Lohauthor=J.+D.+Fontenot&title=Small+Molecule+Mediated+Inhibition+of+ROR%CE%B3-Dependent+Gene+Expression+and+Autoimmune+Disease+Pathology+in+Vivo&doi=10.1111%2Fimm.12570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule mediated inhibition of RORγ-dependent gene expression and autoimmune disease pathology in vivo</span></div><div class="casAuthors">Banerjee, Daliya; Zhao, Linlin; Wu, Lan; Palanichamy, Arumugam; Ergun, Ayla; Peng, Liaomin; Quigley, Catherine; Hamann, Stefan; Dunstan, Robert; Cullen, Patrick; Allaire, Norm; Guertin, Kevin; Wang, Tao; Chao, Jianhua; Loh, Christine; Fontenot, Jason D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">399-413</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Retinoic acid receptor-related orphan nuclear receptor γ (RORγ) orchestrates a pro-inflammatory gene expression program in multiple lymphocyte lineages including T helper type 17 (Th17) cells, γδ T cells, innate lymphoid cells and lymphoid tissue inducer cells.  There is compelling evidence that RORγ-expressing cells are relevant targets for therapeutic intervention in the treatment of autoimmune and inflammatory diseases.  Unlike Th17 cells, where RORγ expression is induced under specific pro-inflammatory conditions, γδ T cells and other innate-like immune cells express RORγ in the steady state.  Small mol. mediated disruption of RORγ function in cells with pre-existing RORγ transcriptional complexes represents a significant and challenging pharmacol. hurdle.  We present data demonstrating that a novel, selective and potent small mol. RORγ inhibitor can block the RORγ-dependent gene expression program in both Th17 cells and RORγ-expressing γδ T cells as well as a disease-relevant subset of human RORγ-expressing memory T cells.  Importantly, systemic administration of this inhibitor in vivo limits pathol. in an innate lymphocyte-driven mouse model of psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTP37oyCKk3LVg90H21EOLACvtfcHk0lgeibsNMKKTSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSqtLo%253D&md5=6b6bfc36bedde9417072422419d19195</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1111%2Fimm.12570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimm.12570%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPalanichamy%26aufirst%3DA.%26aulast%3DErgun%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DQuigley%26aufirst%3DC.%26aulast%3DHamann%26aufirst%3DS.%26aulast%3DDunstan%26aufirst%3DR.%26aulast%3DCullen%26aufirst%3DP.%26aulast%3DAllaire%26aufirst%3DN.%26aulast%3DGuertin%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DLoh%26aufirst%3DC.%26aulast%3DFontenot%26aufirst%3DJ.%2BD.%26atitle%3DSmall%2520Molecule%2520Mediated%2520Inhibition%2520of%2520ROR%25CE%25B3-Dependent%2520Gene%2520Expression%2520and%2520Autoimmune%2520Disease%2520Pathology%2520in%2520Vivo%26jtitle%3DImmunology%26date%3D2016%26volume%3D147%26spage%3D399%26epage%3D413%26doi%3D10.1111%2Fimm.12570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peredo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brusq, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viviani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote-Sierra, J.</span></span> <span> </span><span class="NLM_article-title">Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147979</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0147979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26870941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XotlGltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147979&author=S.+H.+Smithauthor=C.+E.+Peredoauthor=Y.+Takedaauthor=T.+Buiauthor=J.+Neilauthor=D.+Rickardauthor=E.+Millermanauthor=J.+P.+Therrienauthor=E.+Nicodemeauthor=J.+M.+Brusqauthor=V.+Biraultauthor=F.+Vivianiauthor=H.+Hoflandauthor=A.+M.+Jettenauthor=J.+Cote-Sierra&title=Development+of+a+Topical+Treatment+for+Psoriasis+Targeting+ROR%CE%B3%3A+From+Bench+to+Skin&doi=10.1371%2Fjournal.pone.0147979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a topical treatment for psoriasis targeting RORγ: from bench to skin</span></div><div class="casAuthors">Smith, Susan H.; Peredo, Carlos E.; Takeda, Yukimasa; Bui, Thi; Neil, Jessica; Rickard, David; Millerman, Elizabeth; Therrien, Jean-Philippe; Nicodeme, Edwige; Brusq, Jean-Marie; Birault, Veronique; Viviani, Fabrice; Hofland, Hans; Jetten, Anton M.; Cote-Sierra, Javier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147979/1-e0147979/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Psoriasis is a chronic inflammatory skin disorder involving marked immunol. changes.  IL-17-targeting biologics have been successful in reducing the disease burden of psoriasis patients with moderate-to-severe disease.  Unfortunately, the stratum corneum prevents penetration of large mol. wt. proteins, including monoclonal antibodies.  Thus, for the majority of psoriasis patients ineligible for systemic treatments, a small mol. targeting RORγt, the master regulator of IL-17 family cytokines, may represent an alternative topical medicine with biol.-like efficacy.  Methods and Findings: The preclin. studies described in this manuscript bridge the gap from bench to bedside to provide the scientific foundation for a compd. entering clin. trials for patients with mild to moderate psoriasis.  In addn. to several ex vivo reporter assays, primary T cell cultures, and the imiquimod mouse model, we demonstrate efficacy in a newly developed human ex vivo skin assay, where Th17-skewed cytokine expression is induced from skin-resident immune cells.  Importantly, the skin barrier remains intact allowing for the demonstration of topical drug delivery.  With the development of this novel assay, we demonstrate potent compd. activity in the target tissue: human skin.  Finally, target engagement by this small mol. was confirmed in ex vivo lesional psoriatic skin.  Conclusions: Our work describes a progressive series of assays to demonstrate the potential clin. value of a novel RORγ inverse agonist small mol. with high potency and selectivity, which will enter clin. trials in late 2015 for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokk_sPVo8crbVg90H21EOLACvtfcHk0lgeibsNMKKTSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotlGltLs%253D&md5=75b3d12e090eab85b79fa55312798dd1</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147979%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BH.%26aulast%3DPeredo%26aufirst%3DC.%2BE.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DNeil%26aufirst%3DJ.%26aulast%3DRickard%26aufirst%3DD.%26aulast%3DMillerman%26aufirst%3DE.%26aulast%3DTherrien%26aufirst%3DJ.%2BP.%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DBrusq%26aufirst%3DJ.%2BM.%26aulast%3DBirault%26aufirst%3DV.%26aulast%3DViviani%26aufirst%3DF.%26aulast%3DHofland%26aufirst%3DH.%26aulast%3DJetten%26aufirst%3DA.%2BM.%26aulast%3DCote-Sierra%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520Topical%2520Treatment%2520for%2520Psoriasis%2520Targeting%2520ROR%25CE%25B3%253A%2520From%2520Bench%2520to%2520Skin%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147979%26doi%3D10.1371%2Fjournal.pone.0147979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelhälä, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palatsi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyhrquist, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtimäki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Väyrynen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasanen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiniche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume-Peytavi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauerma, A.</span></span> <span> </span><span class="NLM_article-title">IL-17/Th17 Pathway Is Activated in Acne Lesions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e105238</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0105238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0105238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25153527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cis7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e105238&author=H.+L.+Kelh%C3%A4l%C3%A4author=R.+Palatsiauthor=N.+Fyhrquistauthor=S.+Lehtim%C3%A4kiauthor=J.+P.+V%C3%A4yrynenauthor=M.+Kallioinenauthor=M.+E.+Kubinauthor=D.+Grecoauthor=K.+Tasanenauthor=H.+Aleniusauthor=B.+Bertinoauthor=I.+Carlavanauthor=B.+Mehulauthor=S.+D%C3%A9retauthor=P.+Reinicheauthor=P.+Martelauthor=C.+Martyauthor=U.+Blume-Peytaviauthor=J.+J.+Voegelauthor=A.+Lauerma&title=IL-17%2FTh17+Pathway+Is+Activated+in+Acne+Lesions&doi=10.1371%2Fjournal.pone.0105238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">IL-17/Th17 pathway is activated in acne lesions</span></div><div class="casAuthors">Kelhala, Hanna-Leena; Palatsi, Riitta; Fyhrquist, Nanna; Lehtimaki, Sari; Vayrynen, Juha P.; Kallioinen, Matti; Kubin, Minna E.; Greco, Dario; Tasanen, Kaisa; Alenius, Harri; Bertino, Beatrice; Carlavan, Isabelle; Mehul, Bruno; Deret, Sophie; Reiniche, Pascale; Martel, Philippe; Marty, Carine; Blume-Peytavi, Ulrike; Voegel, Johannes J.; Lauerma, Antti</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e105238/1-e105238/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The mechanisms of inflammation in acne are currently subject of intense investigation.  This study focused on the activation of adaptive and innate immunity in clin. early visible inflamed acne lesions and was performed in two independent patient populations.  Biopsies were collected from lesional and non-lesional skin of acne patients.  Using Affymetrix Genechips, we obsd. significant elevation of the signature cytokines of the Th17 lineage in acne lesions compared to non-lesional skin.  The increased expression of IL-17 was confirmed at the RNA and also protein level with real-time PCR (RT-PCR) and Luminex technol.  Cytokines involved in Th17 lineage differentiation (IL-1β, IL-6, TGF-β, IL23p19) were remarkably induced at the RNA level.  In addn., proinflammatory cytokines and chemokines (TNF-α, IL-8, CSF2 and CCL20), Th1 markers (IL12p40, CXCR3, T-bet, IFN-γ), T regulatory cell markers (Foxp3, IL-10, TGF-β) and IL-17 related antimicrobial peptides (S100A7, S100A9, lipocalin, hBD2, hBD3, hCAP18) were induced.  Importantly, immunohistochem. revealed significantly increased nos. of IL-17A pos. T cells and CD83 dendritic cells in the acne lesions.  In summary our results demonstrate the presence of IL-17A pos. T cells and the activation of Th17-related cytokines in acne lesions, indicating that the Th17 pathway is activated and may play a pivotal role in the disease process, possibly offering new targets of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHJzP1A-XDbVg90H21EOLACvtfcHk0li9PXLJbdqVOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cis7zI&md5=cc9b01320f3ef3799b39e0d92286fbe1</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0105238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0105238%26sid%3Dliteratum%253Aachs%26aulast%3DKelh%25C3%25A4l%25C3%25A4%26aufirst%3DH.%2BL.%26aulast%3DPalatsi%26aufirst%3DR.%26aulast%3DFyhrquist%26aufirst%3DN.%26aulast%3DLehtim%25C3%25A4ki%26aufirst%3DS.%26aulast%3DV%25C3%25A4yrynen%26aufirst%3DJ.%2BP.%26aulast%3DKallioinen%26aufirst%3DM.%26aulast%3DKubin%26aufirst%3DM.%2BE.%26aulast%3DGreco%26aufirst%3DD.%26aulast%3DTasanen%26aufirst%3DK.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DBertino%26aufirst%3DB.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DMehul%26aufirst%3DB.%26aulast%3DD%25C3%25A9ret%26aufirst%3DS.%26aulast%3DReiniche%26aufirst%3DP.%26aulast%3DMartel%26aufirst%3DP.%26aulast%3DMarty%26aufirst%3DC.%26aulast%3DBlume-Peytavi%26aufirst%3DU.%26aulast%3DVoegel%26aufirst%3DJ.%2BJ.%26aulast%3DLauerma%26aufirst%3DA.%26atitle%3DIL-17%252FTh17%2520Pathway%2520Is%2520Activated%2520in%2520Acne%2520Lesions%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De105238%26doi%3D10.1371%2Fjournal.pone.0105238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokura, Y.</span></span> <span> </span><span class="NLM_article-title">Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2630</span>, <span class="refDoi"> DOI: 10.1038/jid.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fjid.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18432274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CmsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=2625-2630&author=C.+Kogaauthor=K.+Kabashimaauthor=N.+Shiraishiauthor=M.+Kobayashiauthor=Y.+Tokura&title=Possible+Pathogenic+Role+of+Th17+Cells+for+Atopic+Dermatitis&doi=10.1038%2Fjid.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis</span></div><div class="casAuthors">Koga, Chizuko; Kabashima, Kenji; Shiraishi, Noriko; Kobayashi, Miwa; Tokura, Yoshiki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2625-2630</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The crit. role of IL-17 has recently been reported in a variety of conditions.  Since IL-17 deeply participates in the pathogenesis of psoriasis and keratinocyte prodn. of certain cytokines, the involvement of T helper cell 17 (Th17) in atopic dermatitis (AD) is an issue to be elucidated.  To evaluate the participation of Th17 cells in AD, we successfully detected circulating lymphocytes intracellularly pos. for IL-17 by flow cytometry, and the IL-17+ cell population was found exclusively in CD3+CD4+ T cells.  The percentage of Th17 cells was increased in peripheral blood of AD patients and assocd. with severity of AD.  There was a significant correlation between the percentages of IL-17+ and IFN-γ+ cells, although percentage of Th17 cells was not closely related to Th1/Th2 balance.  Immunohistochem., IL-17+ cells infiltrated in the papillary dermis of atopic eczema more markedly in the acute than chronic lesions.  Finally, IL-17 stimulated keratinocytes to produce GM-CSF, TNF-α, IL-8, CXCL10, and VEGF.  A marked synergistic effect between IL-17 and IL-22 was obsd. on IL-8 prodn.  The no. of Th17 cells is increased in the peripheral blood and acute lesional skin of AD.  Th17 cells may exaggerate atopic eczema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnHI2BHEJfA7Vg90H21EOLACvtfcHk0li9PXLJbdqVOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CmsLvN&md5=1bf269a34972029c1d496ddfcfbbe701</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1038%2Fjid.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DC.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DTokura%26aufirst%3DY.%26atitle%3DPossible%2520Pathogenic%2520Role%2520of%2520Th17%2520Cells%2520for%2520Atopic%2520Dermatitis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D2625%26epage%3D2630%26doi%3D10.1038%2Fjid.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buddenkotte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Déret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiniche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, M.</span></span> <span> </span><span class="NLM_article-title">Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2198</span>– <span class="NLM_lpage">2208</span>, <span class="refDoi"> DOI: 10.1038/jid.2015.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fjid.2015.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25848978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCisr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=2198-2208&author=T.+Buhlauthor=M.+Sulkauthor=P.+Nowakauthor=J.+Buddenkotteauthor=I.+McDonaldauthor=J.+Aubertauthor=I.+Carlavanauthor=S.+D%C3%A9retauthor=P.+Reinicheauthor=M.+Rivierauthor=J.+J.+Voegelauthor=M.+Steinhoff&title=Molecular+and+Morphological+Characterization+of+Inflammatory+Infiltrate+in+Rosacea+Reveals+Activation+of+Th1%2FTh17+Pathways&doi=10.1038%2Fjid.2015.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways</span></div><div class="casAuthors">Buhl, Timo; Sulk, Mathias; Nowak, Pawel; Buddenkotte, Joerg; McDonald, Ian; Aubert, Jerome; Carlavan, Isabelle; Deret, Sophie; Reiniche, Pascale; Rivier, Michel; Voegel, Johannes J.; Steinhoff, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rosacea is a common chronic inflammatory skin disease of unknown etiol.  Our knowledge about an involvement of the adaptive immune system is very limited.  We performed detailed transcriptome anal., quant. real-time reverse-transcriptase-PCR, and quant. immunohistochem. on facial biopsies of rosacea patients, classified according to their clin. subtype.  As controls, we used samples from patients with facial lupus erythematosus and healthy controls.  Our study shows significant activation of the immune system in all subtypes of rosacea, characterizing erythematotelangiectatic rosacea (ETR) already as a disease with significant influx of proinflammatory cells.  The T-cell response is dominated by Th1/Th17-polarized immune cells, as demonstrated by significant upregulation of IFN-γ or IL-17, for example.  Chemokine expression patterns support a Th1/Th17 polarization profile of the T-cell response.  Macrophages and mast cells are increased in all three subtypes of rosacea, whereas neutrophils reach a max. in papulopustular rosacea.  Our studies also provide evidence for the activation of plasma cells with significant antibody prodn. already in ETR, followed by a crescendo pattern toward phymatous rosacea.  In sum, Th1/Th17 polarized inflammation and macrophage infiltration are an underestimated hallmark in all subtypes of rosacea.  Therapies directly targeting the Th1/Th17 pathway are promising candidates in the future treatment of this skin disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47r88Vhv6krVg90H21EOLACvtfcHk0ljvBI2hl_oN9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCisr%252FP&md5=cbcec2f1cdf74a6e0623e02f9c1801c6</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fjid.2015.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2015.141%26sid%3Dliteratum%253Aachs%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DSulk%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DP.%26aulast%3DBuddenkotte%26aufirst%3DJ.%26aulast%3DMcDonald%26aufirst%3DI.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DD%25C3%25A9ret%26aufirst%3DS.%26aulast%3DReiniche%26aufirst%3DP.%26aulast%3DRivier%26aufirst%3DM.%26aulast%3DVoegel%26aufirst%3DJ.%2BJ.%26aulast%3DSteinhoff%26aufirst%3DM.%26atitle%3DMolecular%2520and%2520Morphological%2520Characterization%2520of%2520Inflammatory%2520Infiltrate%2520in%2520Rosacea%2520Reveals%2520Activation%2520of%2520Th1%252FTh17%2520Pathways%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2015%26volume%3D135%26spage%3D2198%26epage%3D2208%26doi%3D10.1038%2Fjid.2015.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragoulis, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-051914-021944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-med-051914-021944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26565676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVCqs7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=337-353&author=G.+E.+Fragoulisauthor=S.+Siebertauthor=I.+B.+McInnes&title=Therapeutic+Targeting+of+IL-17+and+IL-23+Cytokines+in+Immune-Mediated+Diseases&doi=10.1146%2Fannurev-med-051914-021944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases</span></div><div class="casAuthors">Fragoulis, George E.; Siebert, Stefan; McInnes, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">337-353</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">The discovery of the biol. functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases.  Therapeutic agents targeting these cytokines and/or their receptors have now been developed as potential treatment strategies for common immune-mediated diseases.  Anti-IL-17 and anti-IL-12/-23 regimens appear particularly effective in psoriasis, with promising results in spondyloarthropathies also emerging.  Overall, these agents appear well tolerated, with adverse-event rates that are commensurate with those in other biol. treatment programs.  The strategic utility of these new agents, however, remains uncertain, and further studies will be required to det. their place in the context of existing conventional and biol. immune-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5-1bRDtJLJrVg90H21EOLACvtfcHk0ljvBI2hl_oN9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVCqs7nN&md5=20a4ead75c89e2e808f55988cb7be7a6</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051914-021944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051914-021944%26sid%3Dliteratum%253Aachs%26aulast%3DFragoulis%26aufirst%3DG.%2BE.%26aulast%3DSiebert%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DTherapeutic%2520Targeting%2520of%2520IL-17%2520and%2520IL-23%2520Cytokines%2520in%2520Immune-Mediated%2520Diseases%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2016%26volume%3D67%26spage%3D337%26epage%3D353%26doi%3D10.1146%2Fannurev-med-051914-021944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span>Identifier:
NCT03004846. <a href="https://clinicaltrials.gov/ct2/show/NCT03004846" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03004846</a> (Accessed Oct
19, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT03004846.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03004846+%28Accessed+Oct%0A19%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrux-Tallau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlavan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defoin-Platel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forissier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacini-Rachinel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluchon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatinel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201700758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29327456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1aksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=321-337&author=G.+Ouvryauthor=N.+Atrux-Tallauauthor=F.+Bihlauthor=A.+Bonduauthor=C.+Bouix-Peterauthor=I.+Carlavanauthor=O.+Christinauthor=M.+J.+Cuadradoauthor=C.+Defoin-Platelauthor=S.+Deretauthor=D.+Duvertauthor=C.+Feretauthor=M.+Forissierauthor=J.+F.+Fournierauthor=D.+Froudeauthor=F.+Hacini-Rachinelauthor=C.+S.+Harrisauthor=C.+Hervouetauthor=H.+Huguetauthor=G.+Lafitteauthor=A.+P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=B.+Ozelloauthor=C.+Pascauauthor=J.+Pascauauthor=V.+Parnetauthor=G.+Peluchonauthor=R.+Pierreauthor=D.+Piwnicaauthor=C.+Raffinauthor=P.+Rossioauthor=D.+Spiesseauthor=N.+Taquetauthor=E.+Thoreauauthor=R.+Vatinelauthor=E.+Vialauthor=L.+F.+Hennequin&title=Discovery+and+Characterization+of+CD12681%2C+a+Potent+ROR%CE%B3+Inverse+Agonist%2C+Preclinical+Candidate+for+the+Topical+Treatment+of+Psoriasis&doi=10.1002%2Fcmdc.201700758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis</span></div><div class="casAuthors">Ouvry, Gilles; Atrux-Tallau, Nicolas; Bihl, Franck; Bondu, Aline; Bouix-Peter, Claire; Carlavan, Isabelle; Christin, Olivier; Cuadrado, Marie-Josee; Defoin-Platel, Claire; Deret, Sophie; Duvert, Denis; Feret, Christophe; Forissier, Mathieu; Fournier, Jean-Francois; Froude, David; Hacini-Rachinel, Feriel; Harris, Craig Steven; Hervouet, Catherine; Huguet, Helene; Lafitte, Guillaume; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Ozello, Benjamin; Pascau, Coralie; Pascau, Jonathan; Parnet, Veronique; Peluchon, Guillaume; Pierre, Romain; Piwnica, David; Raffin, Catherine; Rossio, Patricia; Spiesse, Delphine; Taquet, Nathalie; Thoreau, Etienne; Vatinel, Rodolphe; Vial, Emmanuel; Hennequin, Laurent Francois</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-337</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a sought-after target in the pharmaceutical industry.  Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases.  These efforts culminated in the discovery of N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-[(tetrahydro-2H-pyran-4-yl)methyl]-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide (CD12681), a potent inverse agonist with in vivo activity in an IL-23-induced mouse skin inflammation model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4rMWerixL7Vg90H21EOLACvtfcHk0lg9COIjK0Q84w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1aksL4%253D&md5=443fc01d790536a34918f1b33f8fdba2</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700758%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DAtrux-Tallau%26aufirst%3DN.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBondu%26aufirst%3DA.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DCarlavan%26aufirst%3DI.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DCuadrado%26aufirst%3DM.%2BJ.%26aulast%3DDefoin-Platel%26aufirst%3DC.%26aulast%3DDeret%26aufirst%3DS.%26aulast%3DDuvert%26aufirst%3DD.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DForissier%26aufirst%3DM.%26aulast%3DFournier%26aufirst%3DJ.%2BF.%26aulast%3DFroude%26aufirst%3DD.%26aulast%3DHacini-Rachinel%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHervouet%26aufirst%3DC.%26aulast%3DHuguet%26aufirst%3DH.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DLuzy%26aufirst%3DA.%2BP.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DOzello%26aufirst%3DB.%26aulast%3DPascau%26aufirst%3DC.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPeluchon%26aufirst%3DG.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DPiwnica%26aufirst%3DD.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRossio%26aufirst%3DP.%26aulast%3DSpiesse%26aufirst%3DD.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DVatinel%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520CD12681%252C%2520a%2520Potent%2520ROR%25CE%25B3%2520Inverse%2520Agonist%252C%2520Preclinical%2520Candidate%2520for%2520the%2520Topical%2520Treatment%2520of%2520Psoriasis%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D321%26epage%3D337%26doi%3D10.1002%2Fcmdc.201700758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantalat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rival, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phenoxyindazoles and Phenylthioindazoles as RORγ Inverse Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5802</span>– <span class="NLM_lpage">5808</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2016.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27815118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslynsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5802-5808&author=G.+Ouvryauthor=C.+Bouix-Peterauthor=F.+Ciesielskiauthor=L.+Chantalatauthor=O.+Christinauthor=C.+Cominoauthor=D.+Duvertauthor=C.+Feretauthor=C.+S.+Harrisauthor=L.+Lamyauthor=A.-P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=J.+Pascauauthor=V.+Parnetauthor=A.+Perrinauthor=R.+Pierreauthor=G.+Polgeauthor=C.+Raffinauthor=Y.+Rivalauthor=N.+Taquetauthor=E.+Thoreauauthor=L.+F.+Hennequin&title=Discovery+of+Phenoxyindazoles+and+Phenylthioindazoles+as+ROR%CE%B3+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2016.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists</span></div><div class="casAuthors">Ouvry, Gilles; Bouix-Peter, Claire; Ciesielski, Fabrice; Chantalat, Laurent; Christin, Olivier; Comino, Catherine; Duvert, Denis; Feret, Christophe; Harris, Craig S.; Lamy, Laurent; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Pascau, Jonathan; Parnet, Veronique; Perrin, Agnes; Pierre, Romain; Polge, Gaelle; Raffin, Catherine; Rival, Yves; Taquet, Nathalie; Thoreau, Etienne; Hennequin, Laurent F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5802-5808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the IL17 pathway and more specifically the nuclear receptor RORγ is thought to be beneficial in multiple skin disorders.  The Letter describes the discovery of phenoxyindazoles and thiophenoxy indazoles as potent RORγ inverse agonists.  Optimization of the potency and efforts to mitigate the phototoxic liability of the series are presented.  Finally, crystn. of the lead compd. revealed that the series bound to an allosteric site of the nuclear receptor.  Such compds. could be useful as tool compds. for understanding the impact of topical treatment on skin disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX7Dguvi_h8LVg90H21EOLACvtfcHk0liIaIcHE9M-Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslynsr%252FM&md5=cd3aa2c246cfa35c98306096d823dccc</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DChantalat%26aufirst%3DL.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DComino%26aufirst%3DC.%26aulast%3DDuvert%26aufirst%3DD.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DLuzy%26aufirst%3DA.-P.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPerrin%26aufirst%3DA.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DPolge%26aufirst%3DG.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRival%26aufirst%3DY.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520of%2520Phenoxyindazoles%2520and%2520Phenylthioindazoles%2520as%2520ROR%25CE%25B3%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5802%26epage%3D5808%26doi%3D10.1016%2Fj.bmcl.2016.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+Drug+Design%3A+An+Update+on+Recent+Applications+of+Efficiency+Metrics%2C+Strategies+for+Replacing+Problematic+Elements%2C+and+Compounds+in+Nontraditional+Drug+Space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0liIaIcHE9M-Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Design%253A%2520An%2520Update%2520on%2520Recent%2520Applications%2520of%2520Efficiency%2520Metrics%252C%2520Strategies%2520for%2520Replacing%2520Problematic%2520Elements%252C%2520and%2520Compounds%2520in%2520Nontraditional%2520Drug%2520Space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouvry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defoin-Platel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froude, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hacini-Rachinel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzy, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taquet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatinel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as Potent RORγ Inverse Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29571573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Omuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1269-1273&author=G.+Ouvryauthor=F.+Bihlauthor=C.+Bouix-Peterauthor=O.+Christinauthor=C.+Defoin-Platelauthor=S.+Deretauthor=C.+Feretauthor=D.+Froudeauthor=F.+Hacini-Rachinelauthor=C.+S.+Harrisauthor=C.+Hervouetauthor=G.+Lafitteauthor=A.-P.+Luzyauthor=B.+Musickiauthor=D.+Orfilaauthor=V.+Parnetauthor=C.+Pascauauthor=J.+Pascauauthor=R.+Pierreauthor=C.+Raffinauthor=P.+Rossioauthor=D.+Spiesseauthor=N.+Taquetauthor=E.+Thoreauauthor=R.+Vatinelauthor=E.+Vialauthor=L.+F.+Hennequin&title=Sulfoximines+as+Potent+ROR%CE%B3+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as potent RORγ inverse agonists</span></div><div class="casAuthors">Ouvry, Gilles; Bihl, Franck; Bouix-Peter, Claire; Christin, Olivier; Defoin-Platel, Claire; Deret, Sophie; Feret, Christophe; Froude, David; Hacini-Rachinel, Feriel; Harris, Craig S.; Hervouet, Catherine; Lafitte, Guillaume; Luzy, Anne-Pascale; Musicki, Branislav; Orfila, Danielle; Parnet, Veronique; Pascau, Coralie; Pascau, Jonathan; Pierre, Romain; Raffin, Catherine; Rossio, Patricia; Spiesse, Delphine; Taquet, Nathalie; Thoreau, Etienne; Vatinel, Rodolphe; Vial, Emmanuel; Hennequin, Laurent F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1269-1273</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Progress in the identification of suitable RORγ inverse agonists as clin. candidates has been hampered by the high lipophilicity that seems required for high potency on this nuclear receptor.  In this context, the authors decided to focus on the replacement of the hydroxymethyl group found on known modulators to det. if more polarity could be tolerated in this position.  SAR of the replacement of this moiety is presented in this article leading to the identification of sulfoximine derivs. as potent modulators with pharmacol. activity in the in vivo mouse Imiquimod psoriasis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAQSWLdHKhVbVg90H21EOLACvtfcHk0liZ6fkvsPViUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Omuro%253D&md5=864629214d833da2bd6cb3e7bdf98f5c</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DOuvry%26aufirst%3DG.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DChristin%26aufirst%3DO.%26aulast%3DDefoin-Platel%26aufirst%3DC.%26aulast%3DDeret%26aufirst%3DS.%26aulast%3DFeret%26aufirst%3DC.%26aulast%3DFroude%26aufirst%3DD.%26aulast%3DHacini-Rachinel%26aufirst%3DF.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHervouet%26aufirst%3DC.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DLuzy%26aufirst%3DA.-P.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DOrfila%26aufirst%3DD.%26aulast%3DParnet%26aufirst%3DV.%26aulast%3DPascau%26aufirst%3DC.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DPierre%26aufirst%3DR.%26aulast%3DRaffin%26aufirst%3DC.%26aulast%3DRossio%26aufirst%3DP.%26aulast%3DSpiesse%26aufirst%3DD.%26aulast%3DTaquet%26aufirst%3DN.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DVatinel%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DE.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26atitle%3DSulfoximines%2520as%2520Potent%2520ROR%25CE%25B3%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1269%26epage%3D1273%26doi%3D10.1016%2Fj.bmcl.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, K.</span>; <span class="NLM_string-name">Kanai, T.</span>; <span class="NLM_string-name">Homma, M.</span>; <span class="NLM_string-name">Aratake, S.</span>; <span class="NLM_string-name">Ishimori, T.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-Containing Heterocyclic Compound</span>. <span class="NLM_patent">WO/2014/084330, US/2015/0299214</span>, Jun 5, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Uchida&author=T.+Kanai&author=M.+Homma&author=S.+Aratake&author=T.+Ishimori&title=Nitrogen-Containing+Heterocyclic+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DK.%26atitle%3DNitrogen-Containing%2520Heterocyclic%2520Compound%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span> <span> </span><span class="NLM_article-title">Atopic Dermatitis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)00149-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2815%2900149-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26377142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1109-1122&author=S.+Weidingerauthor=N.+Novak&title=Atopic+Dermatitis&doi=10.1016%2FS0140-6736%2815%2900149-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Novak Natalija</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10023</span>),
    <span class="NLM_cas:pages">1109-1122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (also known as atopic eczema) is a chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions.  Although it most often starts in infancy and affects two of ten children, it is also highly prevalent in adults.  It is the leading non-fatal health burden attributable to skin diseases, inflicts a substantial psychosocial burden on patients and their relatives, and increases the risk of food allergy, asthma, allergic rhinitis, other immune-mediated inflammatory diseases, and mental health disorders.  Originally regarded as a childhood disorder mediated by an imbalance towards a T-helper-2 response and exaggerated IgE responses to allergens, it is now recognised as a lifelong disposition with variable clinical manifestations and expressivity, in which defects of the epidermal barrier are central.  Present prevention and treatment focus on restoration of epidermal barrier function, which is best achieved through the use of emollients.  Topical corticosteroids are still the first-line therapy for acute flares, but they are also used proactively along with topical calcineurin inhibitors to maintain remission.  Non-specific immunosuppressive drugs are used in severe refractory cases, but targeted disease-modifying drugs are being developed.  We need to improve understanding of the heterogeneity of the disease and its subtypes, the role of atopy and autoimmunity, the mechanisms behind disease-associated itch, and the comparative effectiveness and safety of therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09MrRqEXsZufAfW6udTcc2ebXYO71fWs6Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D&md5=02bc2d67207d07d0a6b24f1da996792e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900149-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900149-X%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DNovak%26aufirst%3DN.%26atitle%3DAtopic%2520Dermatitis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1109%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2815%2900149-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, J.</span></span> <span> </span><span class="NLM_article-title">New Insights into the Epidemiology of Childhood Atopic Dermatitis</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1111/all.12270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fall.12270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24417229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2czks1SksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=3-16&author=C.+Flohrauthor=J.+Mann&title=New+Insights+into+the+Epidemiology+of+Childhood+Atopic+Dermatitis&doi=10.1111%2Fall.12270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the epidemiology of childhood atopic dermatitis</span></div><div class="casAuthors">Flohr C; Mann J</div><div class="citationInfo"><span class="NLM_cas:title">Allergy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a growing desire to explain the worldwide rise in the prevalence of atopic dermatitis (AD).  Trend data on the burden of AD suggest that the picture in the developing world may soon resemble that of wealthier nations, where AD affects over 20% of children.  This, combined with significant variations in prevalence within countries, emphasizes the importance of environmental factors.  Many hypotheses have been explored, from the modulation of immune priming by hygiene, gut microbiota diversity, and exposure to endotoxins through farm animals to the effects of pollution, climate, and diet.  The discovery of the filaggrin skin barrier gene and its importance in AD development and severity has brought the focus on gene-environment interactions and the identification of environmental factors that impact on skin barrier function.  This article reviews our current understanding of the epidemiology of AD, with an emphasis on the findings reported in the international literature over the last 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxkL83eADJYAwxfk_AGB-EfW6udTcc2ebXYO71fWs6Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czks1SksA%253D%253D&md5=1648100b10d36952cd47bc4ef05ad6b3</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1111%2Fall.12270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.12270%26sid%3Dliteratum%253Aachs%26aulast%3DFlohr%26aufirst%3DC.%26aulast%3DMann%26aufirst%3DJ.%26atitle%3DNew%2520Insights%2520into%2520the%2520Epidemiology%2520of%2520Childhood%2520Atopic%2520Dermatitis%26jtitle%3DAllergy%26date%3D2014%26volume%3D69%26spage%3D3%26epage%3D16%26doi%3D10.1111%2Fall.12270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alenius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauerma, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marxhausen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgwick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnik, A.</span></span> <span> </span><span class="NLM_article-title">CCL27-CCR10 Interactions Regulate T Cell-Mediated Skin Inflammation</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1038/nm0202-157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnm0202-157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11821900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1equ7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=157-165&author=B.+Homeyauthor=H.+Aleniusauthor=A.+M%C3%BCllerauthor=H.+Sotoauthor=E.+P.+Bowmanauthor=W.+Yuanauthor=L.+McEvoyauthor=A.+I.+Lauermaauthor=T.+Assmannauthor=E.+B%C3%BCnemannauthor=M.+Lehtoauthor=H.+Wolffauthor=D.+Yenauthor=H.+Marxhausenauthor=W.+Toauthor=J.+Sedgwickauthor=T.+Ruzickaauthor=P.+Lehmannauthor=A.+Zlotnik&title=CCL27-CCR10+Interactions+Regulate+T+Cell-Mediated+Skin+Inflammation&doi=10.1038%2Fnm0202-157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">CCL27-CCR10 interactions regulate T cell-mediated skin inflammation</span></div><div class="casAuthors">Homey, Bernhard; Alenius, Harri; Mueller, Anja; Soto, Hortensia; Bowman, Edward P.; Yuan, Wei; McEvoy, Leslie; Lauerma, Antti I.; Assmann, Till; Buenemann, Erich; Lehto, Maili; Wolff, Henrik; Yen, David; Marxhausen, Heather; To, Wayne; Sedgwick, Jonathon; Ruzicka, Thomas; Lehmann, Percy; Zlotnik, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The skin-assocd. chemokine CCL27 (also called CTACK, ALP and ESkine) and its receptor CCR10 (GPR-2) mediate chemotactic responses of skin-homing T cells in vitro.  Here the authors report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10.  Epidermal basal keratinocytes produced CCL27 protein that bound to extracellular matrix, mediated adhesion and was displayed on the surface of dermal endothelial cells.  Tumor necrosis factor-α and interleukin-1β induced CCL27 prodn. whereas the glucocorticosteroid clobetasol propionate suppressed it.  Circulating skin-homing CLA+ T cells, dermal microvascular endothelial cells and fibroblasts expressed CCR10 on their cell surface.  In vivo, intracutaneous CCL27 injection attracted lymphocytes and, conversely, neutralization of CCL27-CCR10 interactions impaired lymphocyte recruitment to the skin leading to the suppression of allergen-induced skin inflammation.  Together, these findings indicate that CCL27-CCR10 interactions have a pivotal role in T cell-mediated skin inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocxf9h8u-iMbVg90H21EOLACvtfcHk0ljvd2MbNxAT1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1equ7w%253D&md5=46f0f0377221426254f67dc239b87a05</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fnm0202-157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0202-157%26sid%3Dliteratum%253Aachs%26aulast%3DHomey%26aufirst%3DB.%26aulast%3DAlenius%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DBowman%26aufirst%3DE.%2BP.%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DLauerma%26aufirst%3DA.%2BI.%26aulast%3DAssmann%26aufirst%3DT.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DE.%26aulast%3DLehto%26aufirst%3DM.%26aulast%3DWolff%26aufirst%3DH.%26aulast%3DYen%26aufirst%3DD.%26aulast%3DMarxhausen%26aufirst%3DH.%26aulast%3DTo%26aufirst%3DW.%26aulast%3DSedgwick%26aufirst%3DJ.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DLehmann%26aufirst%3DP.%26aulast%3DZlotnik%26aufirst%3DA.%26atitle%3DCCL27-CCR10%2520Interactions%2520Regulate%2520T%2520Cell-Mediated%2520Skin%2520Inflammation%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D157%26epage%3D165%26doi%3D10.1038%2Fnm0202-157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campanati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganzetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliodori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stramazzotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morichetti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, A.</span></span> <span> </span><span class="NLM_article-title">CTACK /CCL27 Expression in Psoriatic Skin and Its Modification after Administration of Etanercept</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2007.08200.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1111%2Fj.1365-2133.2007.08200.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17916208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2007&pages=1155-1160&author=A.+Campanatiauthor=G.+Goteriauthor=O.+Simonettiauthor=G.+Ganzettiauthor=K.+Giuliodoriauthor=D.+Stramazzottiauthor=D.+Morichettiauthor=M.+L.+Bernardiniauthor=B.+Mannelloauthor=G.+Fabrisauthor=A.+Offidani&title=CTACK+%2FCCL27+Expression+in+Psoriatic+Skin+and+Its+Modification+after+Administration+of+Etanercept&doi=10.1111%2Fj.1365-2133.2007.08200.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept</span></div><div class="casAuthors">Campanati, A.; Goteri, G.; Simonetti, O.; Ganzetti, G.; Giuliodori, K.; Stramazzotti, D.; Morichetti, D.; Bernardini, M. L.; Mannello, B.; Fabris, G.; Offidani, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1155-1160</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Background: Tumor necrosis factor-α upregulates the expression of a cutaneous T cell-attracting chemokine (CTACK/CCL27), that promotes migration of cutaneous lymphocyte-assocd. antigen-pos. lymphocytes into the skin.  The role of CTACK/CCL27 in pathogenesis of psoriasis has recently been documented but no data are available at the present time on its modification in psoriatic cutaneous tissue after administration of etanercept.  Objectives: To evaluate modifications of CTACK/CCL27 expression in skin of patients with psoriasis after administration of etanercept and their relation with disease activity.  Methods: Twenty-two patients with moderate to severe psoriasis underwent clin., histol. and immunohistochem. evaluations of disease activity at baseline and at 12 and 24 wk after starting treatment with etanercept.  Results: All selected patients experienced an improvement of Psoriasis Area and Severity Index (PASI) score (P < 0.001) and Dermatol. Life Quality Index score (P < 0.001) during the treatment.  Skin histol. abnormalities showed statistically significant modifications during treatment (P < 0.001).  Immunohistochem. expression of CTACK/CCL27 decreased significantly (P < 0.001) and its relation with final PASI score was statistically significant (P < 0.05); the pattern of distribution of CTACK/CCL27 immunoreactivity significantly moved from diffuse and predominantly suprabasal to basal (P < 0.001) and the restoration of basal distribution of CTACK/CCL27 was also significantly related to clin. improvement of cutaneous disease (P < 0.001).  Conclusions: Etanercept induces a clin. and histol. improvement of psoriatic disease, promoting a redn. in CTACK/CCL27 cutaneous immunostaining and favoring the restoration of physiol. CTACK/CCL27 epidermal expression.  Moreover, CTACK/CCL27 redn. in cutaneous expression during administration of etanercept could be considered a favorable prognostic marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTvorlITcahLVg90H21EOLACvtfcHk0ljvd2MbNxAT1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFakug%253D%253D&md5=5eb2c7b0bd377d64a86d7ba031badee8</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2007.08200.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2007.08200.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampanati%26aufirst%3DA.%26aulast%3DGoteri%26aufirst%3DG.%26aulast%3DSimonetti%26aufirst%3DO.%26aulast%3DGanzetti%26aufirst%3DG.%26aulast%3DGiuliodori%26aufirst%3DK.%26aulast%3DStramazzotti%26aufirst%3DD.%26aulast%3DMorichetti%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DM.%2BL.%26aulast%3DMannello%26aufirst%3DB.%26aulast%3DFabris%26aufirst%3DG.%26aulast%3DOffidani%26aufirst%3DA.%26atitle%3DCTACK%2520%252FCCL27%2520Expression%2520in%2520Psoriatic%2520Skin%2520and%2520Its%2520Modification%2520after%2520Administration%2520of%2520Etanercept%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2007%26volume%3D157%26spage%3D1155%26epage%3D1160%26doi%3D10.1111%2Fj.1365-2133.2007.08200.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hijnen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin-Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel-Koomen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knol, E.</span></span> <span> </span><span class="NLM_article-title">Serum Thymus and Activation-Regulated Chemokine (TARC) and Cutaneous T Cell- Attracting Chemokine (CTACK) Levels in Allergic Diseases: TARC and CTACK Are Disease-Specific Markers for Atopic Dermatitis</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2003.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2003.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=14767451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtV2gu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=334-340&author=D.+Hijnenauthor=M.+De+Bruin-Wellerauthor=B.+Oostingauthor=C.+Lebreauthor=E.+De+Jongauthor=C.+Bruijnzeel-Koomenauthor=E.+Knol&title=Serum+Thymus+and+Activation-Regulated+Chemokine+%28TARC%29+and+Cutaneous+T+Cell-+Attracting+Chemokine+%28CTACK%29+Levels+in+Allergic+Diseases%3A+TARC+and+CTACK+Are+Disease-Specific+Markers+for+Atopic+Dermatitis&doi=10.1016%2Fj.jaci.2003.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis</span></div><div class="casAuthors">Hijnen, DirkJan; De Bruin-Weller, Marjolein; Oosting, Bert; Lebre, Cristina; De Jong, Esther; Bruijnzeel-Koomen, Carla; Knol, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">334-340</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Tissue infiltration of CD4+ T cells plays an important role in the pathogenesis of allergic diseases.  T-cell trafficking is mediated by specific chemokines and their receptors.  The purpose of this study was to investigate the participation of the chemokines thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) in a large population of patients with allergic diseases.  Serum TARC and CTACK levels were measured in 455 patients with allergic disease.  Patients were characterized as having atopic dermatitis (AD), allergic asthma, allergic rhinitis, or combinations or as healthy control subjects.  Serum TARC and CTACK levels were correlated with disease activity in patients with AD.  Furthermore, in 7 patients with AD, serum TARC and CTACK levels were studied after the start of systemic cyclosporin A treatment.  Finally, TARC and CTACK localization was checked by immunohistochem. in lesional skin biopsy specimens of patients with AD.  Both TARC and CTACK serum levels in patients with AD were significantly higher than those in healthy control subjects and patients with allergic respiratory disease.  Furthermore, serum TARC and CTACK levels significantly correlated with disease activity in patients with AD.  Serum TARC levels paralleled clin. improvement in patients treated with cyclosporin A.  Immunoreactive TARC was found in infiltrating cells and endothelial cells of the dermis but not in epidermal cells.  The serum TARC level is an objective parameter for disease severity specific for AD.  Furthermore, it is a promising tool for treatment monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodafTPjYQjJLVg90H21EOLACvtfcHk0ljvd2MbNxAT1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtV2gu7w%253D&md5=22f31941ce73e1d690841546353e3745</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2003.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2003.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DHijnen%26aufirst%3DD.%26aulast%3DDe%2BBruin-Weller%26aufirst%3DM.%26aulast%3DOosting%26aufirst%3DB.%26aulast%3DLebre%26aufirst%3DC.%26aulast%3DDe%2BJong%26aufirst%3DE.%26aulast%3DBruijnzeel-Koomen%26aufirst%3DC.%26aulast%3DKnol%26aufirst%3DE.%26atitle%3DSerum%2520Thymus%2520and%2520Activation-Regulated%2520Chemokine%2520%2528TARC%2529%2520and%2520Cutaneous%2520T%2520Cell-%2520Attracting%2520Chemokine%2520%2528CTACK%2529%2520Levels%2520in%2520Allergic%2520Diseases%253A%2520TARC%2520and%2520CTACK%2520Are%2520Disease-Specific%2520Markers%2520for%2520Atopic%2520Dermatitis%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2004%26volume%3D113%26spage%3D334%26epage%3D340%26doi%3D10.1016%2Fj.jaci.2003.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group">World Health Organization</span>, Global
Surveillance, Prevention and Control of Chronic Respiratory Diseases:
A Comprehensive Approach. <a href="https://www.who.int/gard/publications/GARD_Manual/en/" class="extLink">https://www.who.int/gard/publications/GARD_Manual/en/</a> (Accessed Feb 12, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization%2C+Global%0ASurveillance%2C+Prevention+and+Control+of+Chronic+Respiratory+Diseases%3A%0AA+Comprehensive+Approach.+https%3A%2F%2Fwww.who.int%2Fgard%2Fpublications%2FGARD_Manual%2Fen%2F+%28Accessed+Feb+12%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Small, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span> <span> </span><span class="NLM_article-title">Allergic Rhinitis</span>. <i>Allergy, Asthma, Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s13223-018-0280-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2Fs13223-018-0280-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30263033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BB3czjsFGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=51&author=P.+Smallauthor=P.+K.+Keithauthor=H.+Kim&title=Allergic+Rhinitis&doi=10.1186%2Fs13223-018-0280-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Allergic rhinitis</span></div><div class="casAuthors">Small Peter; Keith Paul K; Kim Harold; Kim Harold</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">Suppl 2</span>),
    <span class="NLM_cas:pages">51</span>
        ISSN:<span class="NLM_cas:issn">1710-1484</span>.
    </div><div class="casAbstract">Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis.  It is usually a long-standing condition that often goes undetected in the primary-care setting.  The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing.  A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis.  Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment.  Allergen immunotherapy is an effective immune-modulating treatment that should be recommended if pharmacologic therapy for allergic rhinitis is not effective or is not tolerated, or if chosen by the patient.  This article provides an overview of the pathophysiology, diagnosis, and appropriate management of this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxSes_xqSl_f9pSBfyDvp7fW6udTcc2eZXJ4kYmoL21bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjsFGgtg%253D%253D&md5=9f153fdd7b19d8952997a3c5e4172a58</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1186%2Fs13223-018-0280-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13223-018-0280-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmall%26aufirst%3DP.%26aulast%3DKeith%26aufirst%3DP.%2BK.%26aulast%3DKim%26aufirst%3DH.%26atitle%3DAllergic%2520Rhinitis%26jtitle%3DAllergy%252C%2520Asthma%252C%2520Clin.%2520Immunol.%26date%3D2018%26volume%3D14%26spage%3D51%26doi%3D10.1186%2Fs13223-018-0280-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span> <span> </span><span class="NLM_article-title">Atopic Dermatitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1056/NEJMra074081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1056%2FNEJMra074081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18385500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1483-1494&author=T.+Bieber&title=Atopic+Dermatitis&doi=10.1056%2FNEJMra074081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic Dermatitis</span></div><div class="casAuthors">Bieber, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1483-1494</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the epidemiol.,genetics,immunol. mechanisms, clin. implications of atopic dermatitis.  A unifying hypothesis of pathogenesis of atopic dermatitis and its clin. implications were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhSHBOPLfgALVg90H21EOLACvtfcHk0lh9uTxWn1Bg9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlSgt7c%253D&md5=9231248a8e723c81eb8f9fdcab103604</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1056%2FNEJMra074081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra074081%26sid%3Dliteratum%253Aachs%26aulast%3DBieber%26aufirst%3DT.%26atitle%3DAtopic%2520Dermatitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1483%26epage%3D1494%26doi%3D10.1056%2FNEJMra074081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochner, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardlaw, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wechsler, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwasser, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roufosse, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleich, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klion, A. D.</span></span> <span> </span><span class="NLM_article-title">Refining the Definition of Hypereosinophilic Syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2010.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20639008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC3cnotVersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=45-49&author=H.-U.+Simonauthor=M.+E.+Rothenbergauthor=B.+S.+Bochnerauthor=P.+F.+Wellerauthor=A.+J.+Wardlawauthor=M.+E.+Wechslerauthor=L.+J.+Rosenwasserauthor=F.+Roufosseauthor=G.+J.+Gleichauthor=A.+D.+Klion&title=Refining+the+Definition+of+Hypereosinophilic+Syndrome&doi=10.1016%2Fj.jaci.2010.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the definition of hypereosinophilic syndrome</span></div><div class="casAuthors">Simon Hans-Uwe; Rothenberg Marc E; Bochner Bruce S; Weller Peter F; Wardlaw Andrew J; Wechsler Michael E; Rosenwasser Lanny J; Roufosse Florence; Gleich Gerald J; Klion Amy D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic.  Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders.  Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs.  Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBJQRUM96xKUBuFdjgVNKSfW6udTcc2eZXJ4kYmoL21bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnotVersg%253D%253D&md5=ac5a99fa15bfeb23a2f5d7c87a520822</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DH.-U.%26aulast%3DRothenberg%26aufirst%3DM.%2BE.%26aulast%3DBochner%26aufirst%3DB.%2BS.%26aulast%3DWeller%26aufirst%3DP.%2BF.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26aulast%3DWechsler%26aufirst%3DM.%2BE.%26aulast%3DRosenwasser%26aufirst%3DL.%2BJ.%26aulast%3DRoufosse%26aufirst%3DF.%26aulast%3DGleich%26aufirst%3DG.%2BJ.%26aulast%3DKlion%26aufirst%3DA.%2BD.%26atitle%3DRefining%2520the%2520Definition%2520of%2520Hypereosinophilic%2520Syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2010%26volume%3D126%26spage%3D45%26epage%3D49%26doi%3D10.1016%2Fj.jaci.2010.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, S.G.O</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, P. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, B. Q</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, R. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega Martell, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platts-Mills, T. A.E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span></span> <span> </span><span class="NLM_article-title">Revised Nomenclature for Allergy for Global Use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2003.12.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jaci.2003.12.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15131563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2c3kvVeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=832-836&author=S.G.O+Johanssonauthor=T.+Bieberauthor=R.+Dahlauthor=P.+S+Friedmannauthor=B.+Q+Lanierauthor=R.+F+Lockeyauthor=C.+Motalaauthor=J.+A+Ortega+Martellauthor=T.+A.E+Platts-Millsauthor=J.+Ring&title=Revised+Nomenclature+for+Allergy+for+Global+Use%3A+Report+of+the+Nomenclature+Review+Committee+of+the+World+Allergy+Organization%2C+October+2003&doi=10.1016%2Fj.jaci.2003.12.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003</span></div><div class="casAuthors">Johansson S G O; Bieber Thomas; Dahl Ronald; Friedmann Peter S; Lanier Bobby Q; Lockey Richard F; Motala Cassim; Ortega Martell Jose A; Platts-Mills Thomas A E; Ring Johannes; Thien Frank; Van Cauwenberge Paul; Williams Hywel C</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">832-6</span>
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    </div><div class="casAbstract">The nomenclature proposed in the October 2003 report of the Nomenclature Review Committee of the World Allergy Organization is an update of the European Academy of Allergology and Clinical Immunology Revised Nomenclature for Allergy Position Statement published in 2001.  The nomenclature can be used independently of target organ or patient age group and is based on the mechanisms that initiate and mediate allergic reactions.  It is assumed that as knowledge about basic causes and mechanisms improves, the nomenclature will need further review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgCRScQzyFpv_I8Jvzw4xCfW6udTcc2ebKLYZIw_pF57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3kvVeiug%253D%253D&md5=5314fe7754881ef6ea7425c82066b6a8</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2003.12.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2003.12.591%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DS.G.O%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DFriedmann%26aufirst%3DP.%2BS%26aulast%3DLanier%26aufirst%3DB.%2BQ%26aulast%3DLockey%26aufirst%3DR.%2BF%26aulast%3DMotala%26aufirst%3DC.%26aulast%3DOrtega%2BMartell%26aufirst%3DJ.%2BA%26aulast%3DPlatts-Mills%26aufirst%3DT.%2BA.E%26aulast%3DRing%26aufirst%3DJ.%26atitle%3DRevised%2520Nomenclature%2520for%2520Allergy%2520for%2520Global%2520Use%253A%2520Report%2520of%2520the%2520Nomenclature%2520Review%2520Committee%2520of%2520the%2520World%2520Allergy%2520Organization%252C%2520October%25202003%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2004%26volume%3D113%26spage%3D832%26epage%3D836%26doi%3D10.1016%2Fj.jaci.2003.12.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamelmann, E.</span></span> <span> </span><span class="NLM_article-title">The Rationale for Treating Allergic Asthma with Anti-IgE</span>. <i>European Respiratory Review</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1183/09059180.00010401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1183%2F09059180.00010401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=61-66&author=E.+Hamelmann&title=The+Rationale+for+Treating+Allergic+Asthma+with+Anti-IgE&doi=10.1183%2F09059180.00010401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1183%2F09059180.00010401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09059180.00010401%26sid%3Dliteratum%253Aachs%26aulast%3DHamelmann%26aufirst%3DE.%26atitle%3DThe%2520Rationale%2520for%2520Treating%2520Allergic%2520Asthma%2520with%2520Anti-IgE%26jtitle%3DEuropean%2520Respiratory%2520Review%26date%3D2007%26volume%3D16%26spage%3D61%26epage%3D66%26doi%3D10.1183%2F09059180.00010401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hairsine, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matharu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramm, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologically Active Sulfoximides: 5-Hexyl-7-)S-Methylsulfonimidoly) Xanthone-2-Carboxylic Acid, a Potent Antiallergic Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm00190a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00190a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1MXhtlamur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1979&pages=418-424&author=A.+C.+Barnesauthor=P.+W.+Hairsineauthor=S.+S.+Matharuauthor=P.+J.+Rammauthor=J.+B.+Taylor&title=Pharmacologically+Active+Sulfoximides%3A+5-Hexyl-7-%29S-Methylsulfonimidoly%29+Xanthone-2-Carboxylic+Acid%2C+a+Potent+Antiallergic+Agent&doi=10.1021%2Fjm00190a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologically active sulfoximides:  5-hexyl-7-(S-methylsulfonimidoyl)xanthone-2-carboxylic acid, a potent antiallergic agent</span></div><div class="casAuthors">Barnes, Alan C.; Hairsine, Peter W.; Matharu, Saroop S.; Ramm, Peter J.; Taylor, John B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">418-24</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The sulfoximidoxanthones I (X = H, SO(:NH)Me, SO(:NCONH2)Me, etc.; Y = H, C6H13, OC5N11; Z = SO(:NH)Me, CO2H, CO2Me) were prepd. by 2 different routes either from a (methylthio)phenol or a [hexyl(methylthio)phenoxy]isophthalate.  The xanthenecarboxylic acids thus prepd. were evaluated for antiallergic activity and 5-hexyl-7-(S-methylsuylfonimidoyl)xanthone-2-carboxylic acid  [58761-87-8] was the most active.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-lkdudmZKbVg90H21EOLACvtfcHk0lgjFRiqP0I4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhtlamur0%253D&md5=97a75bc329c341f1a0ee9548fd602f61</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fjm00190a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00190a012%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DA.%2BC.%26aulast%3DHairsine%26aufirst%3DP.%2BW.%26aulast%3DMatharu%26aufirst%3DS.%2BS.%26aulast%3DRamm%26aufirst%3DP.%2BJ.%26aulast%3DTaylor%26aufirst%3DJ.%2BB.%26atitle%3DPharmacologically%2520Active%2520Sulfoximides%253A%25205-Hexyl-7-%2529S-Methylsulfonimidoly%2529%2520Xanthone-2-Carboxylic%2520Acid%252C%2520a%2520Potent%2520Antiallergic%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1979%26volume%3D22%26spage%3D418%26epage%3D424%26doi%3D10.1021%2Fjm00190a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, G. W.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Experimental Immediate Hypersensitivity Reactions by a Novel Xanthone, RU 31156</span>. <i>Arch. Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1978&pages=328-339&author=P.+Millerauthor=G.+W.+James&title=Inhibition+of+Experimental+Immediate+Hypersensitivity+Reactions+by+a+Novel+Xanthone%2C+RU+31156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of experimental immediate hypersensitivity reactions by a novel xanthone, RU 31156</span></div><div class="casAuthors">Miller, P.; James, G. W. L.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">328-39</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">RU 31156 (I)  [66934-53-0] was a potent inhibitor of exptl. immediate hypersensitivity reactions in vivo.  In the IgE-mediated rat passive cutaneous anaphylaxis (PCA) test, I had an ED50 of 0.0046 (0.0037-0.0057) mg/kg which compared with a figure of 1.21 (1.04-1.42) mg/kg for disodium cromoglycate (DSCG), both compds. being administered i.v.  I was also active when administered orally, having an ED50 of 0.19 (0.07-0.30) mg/kg when given 10 min before antigen.  I partially inhibited an IgG-mediated PCA reaction in the rat.  Both I and DSCG inhibited anaphylactic bronchoconstriction in the rat, giving bell-shaped dose-response curves.  From the upward part of the curves, approx. ED30 values of 0.02 and 2.0 mg/kg were obtained for I and DSCG, resp.  Anaphylactic bronchoconstriction in the guinea pig was not affected by I and pinnal anaphylaxis was inhibited only at relatively high doses of 1-10 mg/kg, i.v.  The effects of both histamine and 5-hydroxytryptamine in the mouse pinna were not affected by I.  In PCA expts., I showed self-tachyphylaxis following both i.v. and oral administration.  It also showed cross-tachyphylaxis with DSCG, indicating that these compds. are likely to share a similar mode of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob5gOPrCwtY7Vg90H21EOLACvtfcHk0lgjFRiqP0I4qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2qsrY%253D&md5=5967135200f85d0814c03ea1f92541bd</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DG.%2BW.%26atitle%3DInhibition%2520of%2520Experimental%2520Immediate%2520Hypersensitivity%2520Reactions%2520by%2520a%2520Novel%2520Xanthone%252C%2520RU%252031156%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1978%26volume%3D231%26spage%3D328%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-Pyridones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">WO2014029830A1</span>, Feb 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=D.+Fiegen&author=C.+Gnamm&title=Substituted+4-Pyridones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%25204-Pyridones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Fiegen, D.</span>; <span class="NLM_string-name">Gnamm, C.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-Pyridones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">EP2888242B1</span>, Jun 13, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=D.+Fiegen&author=C.+Gnamm&title=Substituted+4-Pyridones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%25204-Pyridones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span>; <span class="NLM_string-name">Anderskewitz, R.</span>; <span class="NLM_string-name">Gnamm, C.</span>; <span class="NLM_string-name">Morschhäuser, G.</span>; <span class="NLM_string-name">Peters, S.</span>; <span class="NLM_string-name">Ries, U. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Bicyclic Dihydropyrimidinones and Their Use as Inhibitors of Neutrophil Elastase Activity</span>. <span class="NLM_patent">WO2016016368A1</span>, Feb 4, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=T.+Oost&author=R.+Anderskewitz&author=C.+Gnamm&author=G.+Morschh%C3%A4user&author=S.+Peters&author=U.+J.+Ries&title=Substituted+Bicyclic+Dihydropyrimidinones+and+Their+Use+as+Inhibitors+of+Neutrophil+Elastase+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOost%26aufirst%3DT.%26atitle%3DSubstituted%2520Bicyclic%2520Dihydropyrimidinones%2520and%2520Their%2520Use%2520as%2520Inhibitors%2520of%2520Neutrophil%2520Elastase%2520Activity%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardoel, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zychlinsky, A.</span></span> <span> </span><span class="NLM_article-title">The Balancing Act of Neutrophils</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2014.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chom.2014.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24832448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=526-536&author=B.+W.+Bardoelauthor=E.+F.+Kennyauthor=G.+Sollbergerauthor=A.+Zychlinsky&title=The+Balancing+Act+of+Neutrophils&doi=10.1016%2Fj.chom.2014.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">The Balancing Act of Neutrophils</span></div><div class="casAuthors">Bardoel, Bart W.; Kenny, Elaine F.; Sollberger, Gabriel; Zychlinsky, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">526-536</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Neutrophils are endowed with a plethora of toxic mols. that are mobilized in immune responses.  These cells evolved to fight infections, but when deployed at the wrong time and in the wrong place, they cause damage to the host.  Here, we review the generalities of these cells as well as the difficulties encountered when trying to unravel them mechanistically.  We then focus on how neutrophils develop and their function in infection.  We center our attention on human neutrophils and what we learn from clin. immunodeficiencies.  Finally, we use autoimmune disease to illustrate the harmful potential of dysregulated neutrophil responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGVUnRhHq9eLVg90H21EOLACvtfcHk0licFsPXxXI_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFyntb8%253D&md5=cf22c05b7a54e5d31478ad502611c163</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2014.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2014.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBardoel%26aufirst%3DB.%2BW.%26aulast%3DKenny%26aufirst%3DE.%2BF.%26aulast%3DSollberger%26aufirst%3DG.%26aulast%3DZychlinsky%26aufirst%3DA.%26atitle%3DThe%2520Balancing%2520Act%2520of%2520Neutrophils%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2014%26volume%3D15%26spage%3D526%26epage%3D536%26doi%3D10.1016%2Fj.chom.2014.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korkmaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, F.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fpr.110.002733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21079042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlCh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=726-759&author=B.+Korkmazauthor=M.+S.+Horwitzauthor=D.+E.+Jenneauthor=F.+Gauthier&title=Neutrophil+Elastase%2C+Proteinase+3%2C+and+Cathepsin+G+as+Therapeutic+Targets+in+Human+Diseases&doi=10.1124%2Fpr.110.002733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases</span></div><div class="casAuthors">Korkmaz, Brice; Horwitz, Marshall S.; Jenne, Dieter E.; Gauthier, Francis</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">726-759</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Polymorphonuclear neutrophils are the first cells recruited to inflammatory sites and form the earliest line of defense against invading microorganisms.  Neutrophil elastase, proteinase 3, and cathepsin G are three hematopoietic serine proteases stored in large quantities in neutrophil cytoplasmic azurophilic granules.  They act in combination with reactive oxygen species to help degrade engulfed microorganisms inside phagolysosomes.  These proteases are also externalized in an active form during neutrophil activation at inflammatory sites, thus contributing to the regulation of inflammatory and immune responses.  As multifunctional proteases, they also play a regulatory role in noninfectious inflammatory diseases.  Mutations in the ELA2/ELANE gene, encoding neutrophil elastase, are the cause of human congenital neutropenia.  Neutrophil membrane-bound proteinase 3 serves as an autoantigen in Wegener granulomatosis, a systemic autoimmune vasculitis.  All three proteases are affected by mutations of the gene (CTSC) encoding dipeptidyl peptidase I, a protease required for activation of their proform before storage in cytoplasmic granules.  Mutations of CTSC cause Papillon-Lefevre syndrome.  Because of their roles in host defense and disease, elastase, proteinase 3, and cathepsin G are of interest as potential therapeutic targets.  In this review, we describe the physicochem. functions of these proteases, toward a goal of better delineating their role in human diseases and identifying new therapeutic strategies based on the modulation of their bioavailability and activity.  We also describe how non-human primate exptl. models could assist with testing the efficacy of proposed therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWs076oWNwhbVg90H21EOLACvtfcHk0licFsPXxXI_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlCh&md5=6b7a8706385effb36f5a5789f3866e3e</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002733%26sid%3Dliteratum%253Aachs%26aulast%3DKorkmaz%26aufirst%3DB.%26aulast%3DHorwitz%26aufirst%3DM.%2BS.%26aulast%3DJenne%26aufirst%3DD.%2BE.%26aulast%3DGauthier%26aufirst%3DF.%26atitle%3DNeutrophil%2520Elastase%252C%2520Proteinase%25203%252C%2520and%2520Cathepsin%2520G%2520as%2520Therapeutic%2520Targets%2520in%2520Human%2520Diseases%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D726%26epage%3D759%26doi%3D10.1124%2Fpr.110.002733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadek, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, R. G.</span></span> <span> </span><span class="NLM_article-title">Human Neutrophil Elastase Functions as a Type III Collagen “Collagenase</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(80)80110-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0006-291X%2880%2980110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=6251855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL3cXlvVWrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1980&pages=1815-1822&author=J.+E.+Gadekauthor=G.+A.+Fellsauthor=D.+G.+Wrightauthor=R.+G.+Crystal&title=Human+Neutrophil+Elastase+Functions+as+a+Type+III+Collagen+%E2%80%9CCollagenase&doi=10.1016%2FS0006-291X%2880%2980110-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Human neutrophil elastase functions as a type III collagen "collagenase"</span></div><div class="casAuthors">Gadek, James E.; Fells, Gerald A.; Wright, Daniel G.; Crystal, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1815-22</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Under physiol. conditions, human neutrophil elastase cleaves triple helical human type III collagen into specific fragments in a fashion similar to that of a typical collagenase.  In contrast, elastase does not attack the triple helical portion of type I collagen.  However, unlike a classic collagenase, which is a metalloenzyme, the action of elastase on type III collagen is prevented by serine protease inhibitors.  These findings suggest that the concepts of collagenases and elastases must be broadened and that human neutrophil elastase is capable of mediating a broad range of connective tissue destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqoipK_VXUubVg90H21EOLACvtfcHk0licFsPXxXI_ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXlvVWrsLs%253D&md5=6a8fd341b7aac0c433309f89d868bb75</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2880%2980110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252880%252980110-0%26sid%3Dliteratum%253Aachs%26aulast%3DGadek%26aufirst%3DJ.%2BE.%26aulast%3DFells%26aufirst%3DG.%2BA.%26aulast%3DWright%26aufirst%3DD.%2BG.%26aulast%3DCrystal%26aufirst%3DR.%2BG.%26atitle%3DHuman%2520Neutrophil%2520Elastase%2520Functions%2520as%2520a%2520Type%2520III%2520Collagen%2520%25E2%2580%259CCollagenase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1980%26volume%3D95%26spage%3D1815%26epage%3D1822%26doi%3D10.1016%2FS0006-291X%2880%2980110-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polverino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Mayor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Neutrophil Elastase Inhibitors in Lung Diseases</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2017.03.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.chest.2017.03.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=28442313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtV2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2017&pages=249-262&author=E.+Polverinoauthor=E.+Rosales-Mayorauthor=G.+E.+Daleauthor=K.+Dembowskyauthor=A.+Torres&title=The+Role+of+Neutrophil+Elastase+Inhibitors+in+Lung+Diseases&doi=10.1016%2Fj.chest.2017.03.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Neutrophil Elastase Inhibitors in Lung Diseases</span></div><div class="casAuthors">Polverino Eva; Rosales-Mayor Edmundo; Dale Glenn E; Dembowsky Klaus; Torres Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">249-262</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In many respiratory diseases characterized by an intense inflammatory response, the balance between proteolytic enzymes (proteases, including elastases) and their inhibitors (proteinases inhibitors) is not neutral.  Excess activity of neutrophil elastase (NE) and similar proteases has been reported to cause tissue damage and to alter the remodeling process in many clinical conditions such as pneumonia, respiratory distress, and acute lung injury (ALI).  Several experimental NE inhibitors have been tested in preclinical and clinical studies of different conditions of inflammatory lung injury such as ALI and pneumonia, with contrasting results.  This study reviews the literature regarding NE inhibitors in the field of respiratory diseases and reflects on possible future developments.  In particular, we highlight potential gaps in the scientific evidence and discuss potential strategies for focusing investigation on antielastases in clinical practice through the selection of targeted populations and proper outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZaNJRtWcfVdts4TFFB11gfW6udTcc2eb9z7KhdMetpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtV2kug%253D%253D&md5=2ed4829fc520096354dcb155faf11996</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2017.03.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2017.03.056%26sid%3Dliteratum%253Aachs%26aulast%3DPolverino%26aufirst%3DE.%26aulast%3DRosales-Mayor%26aufirst%3DE.%26aulast%3DDale%26aufirst%3DG.%2BE.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DTorres%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Neutrophil%2520Elastase%2520Inhibitors%2520in%2520Lung%2520Diseases%26jtitle%3DChest%26date%3D2017%26volume%3D152%26spage%3D249%26epage%3D262%26doi%3D10.1016%2Fj.chest.2017.03.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Targeting COPD: Advances on Low-Molecular-Weight Inhibitors of Human Neutrophil Elastase</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">E73</span>– <span class="NLM_lpage">E101</span>, <span class="refDoi"> DOI: 10.1002/med.20247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fmed.20247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21681767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=E73-E101&author=S.+D.+Lucasauthor=E.+Costaauthor=R.+C.+Guedesauthor=R.+Moreira&title=Targeting+COPD%3A+Advances+on+Low-Molecular-Weight+Inhibitors+of+Human+Neutrophil+Elastase&doi=10.1002%2Fmed.20247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase</span></div><div class="casAuthors">Lucas, Susana D.; Costa, Elsa; Guedes, Rita C.; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">E73-E101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major increasing health problem and the World Health Organization (WHO) reports COPD as the fifth leading cause of death worldwide.  COPD refers to a condition of inflammation and progressive weakening of the structure of the lung as well as irreversible narrowing of the airways.  Current treatment is only palliative and no available drug halts the progression of the disease.  Human neutrophil elastase (HNE) is a serine protease, which plays a major role in the COPD inflammatory process.  The protease/anti-protease imbalance leads to an excess of extracellular HNE hydrolyzing elastin, the structural protein that confers elasticity to the lung tissue.  Although HNE was identified as a therapeutic target for COPD more than 30 years ago, only Sivelestat (ONO-5046), an HNE inhibitor from Ono Pharmaceutical, has been approved for clin. use.  Nevertheless, Sivelestat is only approved in Japan and its development in the USA was terminated in 2003.  Other inhibitors in pre-clin. or phase I trials were discontinued for various reasons.  Hence, there is an urgent need for low-mol.-wt. synthetic elastase inhibitors and the present review discusses the recent advances on this field covering acylating agents, transition-state inhibitors, mechanism-based inhibitors, relevant natural products, and major patent disclosures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJWyG-jxrWzLVg90H21EOLACvtfcHk0lhBU-4_0DMt7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbc%253D&md5=5d8977535c358cd1aaf1e6ea24095e18</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1002%2Fmed.20247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20247%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%2BD.%26aulast%3DCosta%26aufirst%3DE.%26aulast%3DGuedes%26aufirst%3DR.%2BC.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DTargeting%2520COPD%253A%2520Advances%2520on%2520Low-Molecular-Weight%2520Inhibitors%2520of%2520Human%2520Neutrophil%2520Elastase%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3DE73%26epage%3DE101%26doi%3D10.1002%2Fmed.20247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohbayashi, H.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase Inhibitors as Treatment for COPD</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">965</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1517/13543784.11.7.965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1517%2F13543784.11.7.965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12084007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Slu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=965-980&author=H.+Ohbayashi&title=Neutrophil+Elastase+Inhibitors+as+Treatment+for+COPD&doi=10.1517%2F13543784.11.7.965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase inhibitors as treatment for COPD</span></div><div class="casAuthors">Ohbayashi, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">965-980</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review. Chronic obstructive pulmonary disease (COPD), characterized by a slowly progressive, irreversible airways limitation, is a major worldwide cause of chronic morbidity and mortality.  The imbalance between human neutrophil elastase and endogenous antiproteases may cause excess human neutrophil elastase in pulmonary tissues, which may be considered a major pathogenic factor in COPD.  Great effort has been devoted to finding a method to restore the balance, resulting in the discovery of two types of potent low-mol.-wt. human neutrophil elastase inhibitors.  In COPD therapy, the human neutrophil elastase inhibitors that have been mainly focused upon include ONO-5046, MR-889, L-694,458, CE-1037, GW-311616 and TEI-8362 as the acyl-enzyme inhibitors, and ONO-6818, AE-3763, FK-706, ICI-200,880, ZD-0892 and ZD-8321 as the transition-state inhibitors.  Various problems that remain to be solved in the clin. use of human neutrophil elastase inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3Vw3Eq2FebVg90H21EOLACvtfcHk0lh6I9mo18o1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Slu7o%253D&md5=ae3c5080e19b8e00b74ee94f3f38c802</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1517%2F13543784.11.7.965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.11.7.965%26sid%3Dliteratum%253Aachs%26aulast%3DOhbayashi%26aufirst%3DH.%26atitle%3DNeutrophil%2520Elastase%2520Inhibitors%2520as%2520Treatment%2520for%2520COPD%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D965%26epage%3D980%26doi%3D10.1517%2F13543784.11.7.965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miglietta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderazzo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, F.</span></span> <span> </span><span class="NLM_article-title">Neutrophil Elastase in Bronchiectasis</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">211</span>, <span class="refDoi"> DOI: 10.1186/s12931-017-0691-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1186%2Fs12931-017-0691-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29258516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKgsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=211&author=A.+Gramegnaauthor=F.+Amatiauthor=L.+Terranovaauthor=G.+Sotgiuauthor=P.+Tarsiaauthor=D.+Migliettaauthor=M.+A.+Calderazzoauthor=S.+Alibertiauthor=F.+Blasi&title=Neutrophil+Elastase+in+Bronchiectasis&doi=10.1186%2Fs12931-017-0691-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase in bronchiectasis</span></div><div class="casAuthors">Gramegna, Andrea; Amati, Francesco; Terranova, Leonardo; Sotgiu, Giovanni; Tarsia, Paolo; Miglietta, Daniela; Calderazzo, Maria Adelaide; Aliberti, Stefano; Blasi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211/1-211/13</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclin. data and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF.  In this context, NE seems to be a predictor of long-term clin. outcomes and a possible target of treatment.  In order to better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence was performed.  Two investigators independently performed the search on PubMed and included studies published up to May 15, 2017 according to predefined criteria.  A final pool of 31 studies was included in the systematic review, with a total of 2679 patients.  For each paper data of interest were extd. and reported in table.  In this review sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and during exacerbations and local or systemic antibiotic treatment.  NE has also been assocd. with risk of exacerbation, time to next exacerbation and all-cause mortality.  This study reviews also the role of NE as a specific target of treatment in bronchiectasis.  Inhibition of NE is at a very early stage and future interventional studies should evaluate safety and efficacy for new mols. and formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVobMcnV9jN7Vg90H21EOLACvtfcHk0lh6I9mo18o1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKgsLbE&md5=0bc9937bc8fcb93ff4d7d7d0e1d6aff1</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1186%2Fs12931-017-0691-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-017-0691-x%26sid%3Dliteratum%253Aachs%26aulast%3DGramegna%26aufirst%3DA.%26aulast%3DAmati%26aufirst%3DF.%26aulast%3DTerranova%26aufirst%3DL.%26aulast%3DSotgiu%26aufirst%3DG.%26aulast%3DTarsia%26aufirst%3DP.%26aulast%3DMiglietta%26aufirst%3DD.%26aulast%3DCalderazzo%26aufirst%3DM.%2BA.%26aulast%3DAliberti%26aufirst%3DS.%26aulast%3DBlasi%26aufirst%3DF.%26atitle%3DNeutrophil%2520Elastase%2520in%2520Bronchiectasis%26jtitle%3DRespir.%2520Res.%26date%3D2017%26volume%3D18%26spage%3D211%26doi%3D10.1186%2Fs12931-017-0691-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voynow, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span> <span> </span><span class="NLM_article-title">Proteases and Cystic Fibrosis</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.biocel.2008.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18395488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslGlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=1238-1245&author=J.+A.+Voynowauthor=B.+M.+Fischerauthor=S.+Zheng&title=Proteases+and+Cystic+Fibrosis&doi=10.1016%2Fj.biocel.2008.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Proteases and cystic fibrosis</span></div><div class="casAuthors">Voynow, Judith A.; Fischer, Bernard M.; Zheng, Shuo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis is the most common, inherited fatal disease in Caucasians.  The major cause of morbidity and mortality is chronic lung disease due to infection and inflammation in the airways leading to bronchiectasis and respiratory failure.  The signature pathol. features of CF lung disease including abnormal mucus obstructing airways, chronic infection with Staphylococcus aureus, Pseudomonas aeruginosa and other gram neg. bacteria, and a robust neutrophil-dominant airway inflammation, are exacerbated by unopposed proteases present at high concns. in the ASL.  There is strong evidence that proteases, particularly neutrophil elastase, contribute to the pathol. of CF by impairing mucociliary clearance, interfering with innate immune functions, and perpetuating neutrophilic inflammation.  The mechanisms employed by proteases to impact airway function in CF will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgb7aa1mlvtrVg90H21EOLACvtfcHk0lh6I9mo18o1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslGlurg%253D&md5=d7ab94dbe8aaf821f7c1f77e02a47695</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DVoynow%26aufirst%3DJ.%2BA.%26aulast%3DFischer%26aufirst%3DB.%2BM.%26aulast%3DZheng%26aufirst%3DS.%26atitle%3DProteases%2520and%2520Cystic%2520Fibrosis%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D1238%26epage%3D1245%26doi%3D10.1016%2Fj.biocel.2008.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.113.301141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1161%2FCIRCRESAHA.113.301141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24951765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=165-175&author=M.+Rabinovitchauthor=C.+Guignabertauthor=M.+Humbertauthor=M.+R.+Nicolls&title=Inflammation+and+Immunity+in+the+Pathogenesis+of+Pulmonary+Arterial+Hypertension&doi=10.1161%2FCIRCRESAHA.113.301141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Rabinovitch, Marlene; Guignabert, Christophe; Humbert, Marc; Nicolls, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension.  The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed.  Pre-clin. studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed.  In addn., we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development.  We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuJ3RliFVC7Vg90H21EOLACvtfcHk0lh6I9mo18o1hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL&md5=d3a2fe2798a44bdcdf4e5e0f8c71ab99</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.113.301141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.113.301141%26sid%3Dliteratum%253Aachs%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26atitle%3DInflammation%2520and%2520Immunity%2520in%2520the%2520Pathogenesis%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D165%26epage%3D175%26doi%3D10.1161%2FCIRCRESAHA.113.301141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R. A.</span></span> <span> </span><span class="NLM_article-title">Alpha1-Antitrypsin Review</span>. <i>Clinics in Chest Medicine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.ccm.2013.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ccm.2013.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24507836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2crmsVKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=39-50&author=R.+A.+Stockley&title=Alpha1-Antitrypsin+Review&doi=10.1016%2Fj.ccm.2013.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Alpha1-antitrypsin review</span></div><div class="casAuthors">Stockley Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alpha1-antitrypsin (AAT) deficiency was first described in 1963 together with its associations with severe early-onset basal panacinar emphysema.  The genetic defects leading to deficiency have been elucidated and the pathophysiologic processes, clinical variation in phenotype, and the role of genetic modifiers have been recognized.  Strategies to increase plasma (and hence tissue) concentrations of AAT have been developed.  The only recognized specific therapeutic strategy is regular infusions of the purified plasma protein, and evidence confirms its efficacy in protecting the lung (at least partially).  Early detection and modification of lifestyle remains crucial to the management of AAT deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWZ0g10qbTe7jnyZkbE8yXfW6udTcc2eYTG_sNw7y7o7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmsVKhsA%253D%253D&md5=6e2d0071ad76060df29f3cf063a2a736</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.ccm.2013.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccm.2013.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DStockley%26aufirst%3DR.%2BA.%26atitle%3DAlpha1-Antitrypsin%2520Review%26jtitle%3DClinics%2520in%2520Chest%2520Medicine%26date%3D2014%26volume%3D35%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ccm.2013.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Clinical Utility of the Neutrophil Elastase Inhibitor Sivelestat for the Treatment of Acute Respiratory Distress Syndrome</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S65066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2147%2FTCRM.S65066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25120368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVynu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=621-629&author=N.+Aikawaauthor=Y.+Kawasaki&title=Clinical+Utility+of+the+Neutrophil+Elastase+Inhibitor+Sivelestat+for+the+Treatment+of+Acute+Respiratory+Distress+Syndrome&doi=10.2147%2FTCRM.S65066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome</span></div><div class="casAuthors">Aikawa, Naoki; Kawasaki, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">621-929</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acute respiratory distress syndrome is a serious condition that can arise following direct or indirect lung injury.  It is heterogeneous and has a high mortality rate.  Supportive care is the mainstay of treatment and there is no definitive pharmacol. treatment as yet.  Sivelestat is a neutrophil elastase inhibitor approved in Japan and the Republic of Korea for acute lung injury, including acute respiratory distress syndrome in patients with systemic inflammatory response syndrome.  The aim of this review is to examine the clin. utility of sivelestat in different disease states, using data from nonclin. and clin. studies.  In nonclin. studies, sivelestat appears to show benefit in acute lung injury without inhibiting the host immune defense in cases of infection.  Clin. studies do not yet provide a clear consensus.  Phase III and IV Japanese studies have shown improvements in pulmonary function, length of intensive care unit stay, and mech. ventilation, but a non-Japanese multicenter study did not demonstrate sivelestat to have an effect on ventilator-free days or 28-day all-cause mortality.  Evidence of improvement in various parameters, including duration of stay in intensive care, mech. ventilation, the ratio of partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/F1O2 ratio) ratio, and lung injury scores, has been shown in patients with sepsis or gastric aspiration, and following the surgical treatment of esophageal cancer.  To date, there are no particular concerns regarding adverse events, and the available data do not suggest that sivelestat might worsen infections.  One study has analyzed cost-effectiveness, finding that sivelestat may reduce costs compared with std. care.  The currently available evidence suggests that sivelestat may show some benefit in the treatment of acute lung injury/acute respiratory distress syndrome, although large, randomized controlled trials are needed in specific pathophysiol. conditions to explore these potential benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo39p761ROLC7Vg90H21EOLACvtfcHk0lhxGazeP4czQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVynu7vN&md5=bdb0d303d81992eda4ace23c560ee23d</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S65066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S65066%26sid%3Dliteratum%253Aachs%26aulast%3DAikawa%26aufirst%3DN.%26aulast%3DKawasaki%26aufirst%3DY.%26atitle%3DClinical%2520Utility%2520of%2520the%2520Neutrophil%2520Elastase%2520Inhibitor%2520Sivelestat%2520for%2520the%2520Treatment%2520of%2520Acute%2520Respiratory%2520Distress%2520Syndrome%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2014%26volume%3D10%26spage%3D621%26epage%3D629%26doi%3D10.2147%2FTCRM.S65066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Von Nussbaum, F.</span>; <span class="NLM_string-name">Karthaus, D.</span>; <span class="NLM_string-name">Anlauf, S.</span>; <span class="NLM_string-name">Delbeck, M.</span>; <span class="NLM_string-name">Li, V. M. J.</span>; <span class="NLM_string-name">Meibom, D.</span>; <span class="NLM_string-name">Lustig, K.</span>; <span class="NLM_string-name">Schneider, D.</span></span> <span> </span><span class="NLM_article-title">Sulfonic Amide and Sulfoximine-Substituted Diaryl-Dihydropyrimidinones and Usage Thereof</span>. <span class="NLM_patent">US/2012/0094968</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=F.+Von+Nussbaum&author=D.+Karthaus&author=S.+Anlauf&author=M.+Delbeck&author=V.+M.+J.+Li&author=D.+Meibom&author=K.+Lustig&author=D.+Schneider&title=Sulfonic+Amide+and+Sulfoximine-Substituted+Diaryl-Dihydropyrimidinones+and+Usage+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BNussbaum%26aufirst%3DF.%26atitle%3DSulfonic%2520Amide%2520and%2520Sulfoximine-Substituted%2520Diaryl-Dihydropyrimidinones%2520and%2520Usage%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen-Haertwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosentreter, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span> <span> </span><span class="NLM_article-title">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85–8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fcmdc.201500131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=26083237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1163-1173&author=F.+von+Nussbaumauthor=V.+M.+Liauthor=S.+Allerheiligenauthor=S.+Anlaufauthor=L.+B%C3%A4rfackerauthor=M.+Bechemauthor=M.+Delbeckauthor=M.+F.+Fitzgeraldauthor=M.+Gerischauthor=H.+Gielen-Haertwigauthor=H.+Haningauthor=D.+Karthausauthor=D.+Langauthor=K.+Lustigauthor=D.+Meibomauthor=J.+Mittendorfauthor=U.+Rosentreterauthor=M.+Sch%C3%A4ferauthor=S.+Sch%C3%A4ferauthor=J.+Schambergerauthor=L.+A.+Telanauthor=A.+Tersteegen&title=Freezing+the+Bioactive+Conformation+to+Boost+Potency%3A+The+Identification+of+BAY+85%E2%80%938501%2C+a+Selective+and+Potent+Inhibitor+of+Human+Neutrophil+Elastase+for+Pulmonary+Diseases&doi=10.1002%2Fcmdc.201500131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span></div><div class="casAuthors">von Nussbaum, Franz; Li, Volkhart M.-J.; Allerheiligen, Swen; Anlauf, Sonja; Baerfacker, Lars; Bechem, Martin; Delbeck, Martina; Fitzgerald, Mary F.; Gerisch, Michael; Gielen-Haertwig, Heike; Haning, Helmut; Karthaus, Dagmar; Lang, Dieter; Lustig, Klemens; Meibom, Daniel; Mittendorf, Joachim; Rosentreter, Ulrich; Schaefer, Martina; Schaefer, Stefan; Schamberger, Jens; Telan, Leila A.; Tersteegen, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1163-1173</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is a key protease for matrix degrdn.  High HNE activity is obsd. in inflammatory diseases.  Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH).  HNE inhibitors should reestablish the protease-anti-protease balance.  By means of medicinal chem. a novel dihydropyrimidinone lead-structure class was identified.  Further chem. optimization yielded orally active compds. with favorable pharmacokinetics such as the chem. probe BAY-678.  While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned Me sulfone substituent.  An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE.  BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI.  BAY 85-8501 is currently being tested in clin. studies for the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfeHJY2lnE7Vg90H21EOLACvtfcHk0lhxGazeP4czQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N&md5=bb2997077d114dde6769896f50574d3c</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500131%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DAnlauf%26aufirst%3DS.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26aulast%3DBechem%26aufirst%3DM.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DM.%2BF.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DGielen-Haertwig%26aufirst%3DH.%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DKarthaus%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DRosentreter%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DS.%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DTelan%26aufirst%3DL.%2BA.%26aulast%3DTersteegen%26aufirst%3DA.%26atitle%3DFreezing%2520the%2520Bioactive%2520Conformation%2520to%2520Boost%2520Potency%253A%2520The%2520Identification%2520of%2520BAY%252085%25E2%2580%25938501%252C%2520a%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Human%2520Neutrophil%2520Elastase%2520for%2520Pulmonary%2520Diseases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1163%26epage%3D1173%26doi%3D10.1002%2Fcmdc.201500131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagelschmitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span> <span> </span><span class="NLM_article-title">The Novel Elastase Inhibitor BAY 85–8501 Provides a New Approach in the Treatment of Pulmonary Diseases</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=3416&author=J.+Nagelschmitzauthor=D.+Kaufelauthor=S.+Stephanauthor=F.+von+Nussbaumauthor=V.+Liauthor=M.+Delbeckauthor=K.+Lustigauthor=T.+Bandelauthor=H.+Watz&title=The+Novel+Elastase+Inhibitor+BAY+85%E2%80%938501+Provides+a+New+Approach+in+the+Treatment+of+Pulmonary+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagelschmitz%26aufirst%3DJ.%26aulast%3DKaufel%26aufirst%3DD.%26aulast%3DStephan%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DBandel%26aufirst%3DT.%26aulast%3DWatz%26aufirst%3DH.%26atitle%3DThe%2520Novel%2520Elastase%2520Inhibitor%2520BAY%252085%25E2%2580%25938501%2520Provides%2520a%2520New%2520Approach%2520in%2520the%2520Treatment%2520of%2520Pulmonary%2520Diseases%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D44%26spage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span>Identifier:
NCT01818544. <a href="https://clinicaltrials.gov/ct2/show/NCT01818544" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01818544</a> (Accessed Oct
26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Identifier%3A%0ANCT01818544.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01818544+%28Accessed+Oct%0A26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holick, M. F.</span></span> <span> </span><span class="NLM_article-title">The Photobiology of Vitamin D3 in Man</span>. In  <i>Vitamin D: Basic and Clinical Aspects</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuman, R.</span></span>, Ed. <span class="NLM_publisher-name">Martinus Nijhoff</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1984</span>; pp  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">216</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2F978-1-4613-2839-1_7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&pages=197-216&author=M.+F.+Holickauthor=R.+Kuman&title=Vitamin+D%3A+Basic+and+Clinical+Aspects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1007%2F978-1-4613-2839-1_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4613-2839-1_7%26sid%3Dliteratum%253Aachs%26aulast%3DHolick%26aufirst%3DM.%2BF.%26atitle%3DThe%2520Photobiology%2520of%2520Vitamin%2520D3%2520in%2520Man%26btitle%3DVitamin%2520D%253A%2520Basic%2520and%2520Clinical%2520Aspects%26aulast%3DKuman%26aufirst%3DR.%26pub%3DMartinus%2520Nijhoff%26date%3D1984%26spage%3D197%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bikle, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, S.</span></span> <span> </span><span class="NLM_article-title">Vitamin D, Calcium, and Epidermal Differentiation</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1210/er.14.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1210%2Fer.14.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8491153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK3sXksVSqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=3-19&author=D.+D.+Bikleauthor=S.+Pillai&title=Vitamin+D%2C+Calcium%2C+and+Epidermal+Differentiation&doi=10.1210%2Fer.14.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D, calcium, and epidermal differentiation</span></div><div class="casAuthors">Bikle, Daniel D.; Pillai, Sreekumar</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    </div><div class="casAbstract">A review, with 207 refs., on the cutaneous prodn. of 1,25-dihydroxyvitamin D3 and on the regulation of keratinocyte differentiation by Ca and 1,25-dihydroxyvitamin D3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XZhA_FxZsrVg90H21EOLACvtfcHk0ligNJ4I51IVUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVSqtbo%253D&md5=206ed1b402513bc01578b450b3b04c25</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1210%2Fer.14.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.14.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DBikle%26aufirst%3DD.%2BD.%26aulast%3DPillai%26aufirst%3DS.%26atitle%3DVitamin%2520D%252C%2520Calcium%252C%2520and%2520Epidermal%2520Differentiation%26jtitle%3DEndocr.%2520Rev.%26date%3D1993%26volume%3D14%26spage%3D3%26epage%3D19%26doi%3D10.1210%2Fer.14.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolagas, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousteni, S.</span></span> <span> </span><span class="NLM_article-title">Perspective: Nonreproductive Sites of Action of Reproductive Hormones</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">2200</span>– <span class="NLM_lpage">2204</span>, <span class="refDoi"> DOI: 10.1210/endo.142.6.8221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1210%2Fendo.142.6.8221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11356663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFGgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=2200-2204&author=S.+C.+Manolagasauthor=S.+Kousteni&title=Perspective%3A+Nonreproductive+Sites+of+Action+of+Reproductive+Hormones&doi=10.1210%2Fendo.142.6.8221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: nonreproductive sites of action of reproductive hormones</span></div><div class="casAuthors">Manolagas, S. C.; Kousteni, S.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2200-2204</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 59 refs.  Estrogens and androgens, the female and male sex hormones responsible for gender dimorphism and reprodn., play also a very important role in tissues and organs that are not directly involved in procreation.  In fact, withdrawal of the effects of estrogens at menopause from nonreproductive tissues like the skeleton, the cardiovascular system, and the brain, is a major risk factor for the development of osteoporosis, coronary artery disease, stroke, and perhaps neurodegenerative diseases like Alzheimer's.  Continuous exposure of reproductive tissues to estrogen during the postreproductive part of life, is a risk factor for the development of breast, ovarian, and uterine cancer.  During the last decade, there have been significant advances in the understanding of the mechanism of action of sex steroids on the skeleton, the cardiovascular system, and the central nervous system.  The purpose of this perspective is to provide a brief outline of these advances with an emphasis on the emergence of several thematic similarities in the action of sex steroids on nonreproductive tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZuVpHbmjpZ7Vg90H21EOLACvtfcHk0ljFmYOYUc7z3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFGgtbc%253D&md5=1fac1b6a1ebc0fa9f107beb62088f2cf</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1210%2Fendo.142.6.8221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.142.6.8221%26sid%3Dliteratum%253Aachs%26aulast%3DManolagas%26aufirst%3DS.%2BC.%26aulast%3DKousteni%26aufirst%3DS.%26atitle%3DPerspective%253A%2520Nonreproductive%2520Sites%2520of%2520Action%2520of%2520Reproductive%2520Hormones%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26spage%3D2200%26epage%3D2204%26doi%3D10.1210%2Fendo.142.6.8221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glerup, H.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Deficiency and Aging: Implications for General Health and Osteoporosis</span>. <i>Biogerontology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1023/A:1015263514765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1023%2FA%3A1015263514765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=12014847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsF2lsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=73-77&author=E.+F.+Eriksenauthor=H.+Glerup&title=Vitamin+D+Deficiency+and+Aging%3A+Implications+for+General+Health+and+Osteoporosis&doi=10.1023%2FA%3A1015263514765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D deficiency and aging: implications for general health and osteoporosis</span></div><div class="casAuthors">Eriksen, Erik Fink; Glerup, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Biogerontology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-77</span>CODEN:
                <span class="NLM_cas:coden">BIOGCN</span>;
        ISSN:<span class="NLM_cas:issn">1389-5729</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Vitamin D deficiency is extremely prevalent in the elderly.  Most often the first symptoms are caused by myopathy with muscle pain, fatigue, muscular weakness and gait disturbances.  More severe deficiency causes osteomalacia with deep bone pain, reduced mineralization of bone matrix and low energy fractures.  Recent data also suggest that hypovitaminosis D increases the risk of cancer of the prostate, colon and breast.  Thus, hypovitaminosis D is assocd. with many diseases assocd. with aging.  In order to diagnose hypovitaminosis D, the assessment of serum levels of 25-hydroxy vitamin D is mandatory.  Screening based on other markers like alk. phosphatase and parathyroid hormone (PTH) will be incomplete.  The treatment of hypovitaminosis D is simple with administration of combined calcium (1 g) and vitamin D supplements (calciferol, at least 800 IU).  Severe cases may demand initial parenteral administration of vitamin D (repeated injections of 300,000 IU 2-3 times with monthly intervals).  More potent analogs are rarely needed.  One should aim at achieving S-25(OH)D values in the range 50-100 nmol/l.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou1cQHHv2EL7Vg90H21EOLACvtfcHk0ljFmYOYUc7z3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsF2lsr0%253D&md5=f9332a098eb399c40958a443d3083740</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015263514765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015263514765%26sid%3Dliteratum%253Aachs%26aulast%3DEriksen%26aufirst%3DE.%2BF.%26aulast%3DGlerup%26aufirst%3DH.%26atitle%3DVitamin%2520D%2520Deficiency%2520and%2520Aging%253A%2520Implications%2520for%2520General%2520Health%2520and%2520Osteoporosis%26jtitle%3DBiogerontology%26date%3D2002%26volume%3D3%26spage%3D73%26epage%3D77%26doi%3D10.1023%2FA%3A1015263514765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span>; <span class="NLM_string-name">Seino, Y.</span></span> <i>Vitamin D and Bone</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>, <span class="NLM_year">1977</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1977&author=H.+Tanaka&author=Y.+Seino&title=Vitamin+D+and+Bone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DH.%26btitle%3DVitamin%2520D%2520and%2520Bone%26pub%3DAcademic%2520Press%26date%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">The Steroid and Thyroid Hormone Receptor Superfamily</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1126/science.3283939</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1126%2Fscience.3283939" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=3283939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1cXktVSqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1988&pages=889-895&author=R.+M.+Evans&title=The+Steroid+and+Thyroid+Hormone+Receptor+Superfamily&doi=10.1126%2Fscience.3283939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">The steroid and thyroid hormone receptor superfamily</span></div><div class="casAuthors">Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">4854</span>),
    <span class="NLM_cas:pages">889-95</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 83 refs., on the activation of the expression of gene networks by steroid and thyroid hormone receptors to coordinate development, differentiation, and physiol. responses to the hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEZIDsZLWoNrVg90H21EOLACvtfcHk0ljFmYOYUc7z3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktVSqsr4%253D&md5=b1c99cfcc0b115ad743a8ea4e24c88cd</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1126%2Fscience.3283939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3283939%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DThe%2520Steroid%2520and%2520Thyroid%2520Hormone%2520Receptor%2520Superfamily%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D1988%26volume%3D240%26spage%3D889%26epage%3D895%26doi%3D10.1126%2Fscience.3283939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christakos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raval-Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernyj, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span> <span> </span><span class="NLM_article-title">Genomic Mechanisms Involved in the Pleiotropic Actions of 1,25-Dihydroxyvitamin D3</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1042/bj3160361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1042%2Fbj3160361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=8687373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK28XjvVahsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=1996&pages=361-371&author=S.+Christakosauthor=M.+Raval-Pandyaauthor=R.+P.+Wernyjauthor=W.+Yang&title=Genomic+Mechanisms+Involved+in+the+Pleiotropic+Actions+of+1%2C25-Dihydroxyvitamin+D3&doi=10.1042%2Fbj3160361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3</span></div><div class="casAuthors">Christakos, Sylvia; Raval-Pandya, Mihali; Wernyj, Roman P.; Yang, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press</span>)
        </div><div class="casAbstract">A review, with 169 refs., on the mechanisms involved in the multiple actions of 1,25-dihydroxyvitamin D3, including the genomic actions of the vitamin D receptor (VDR).  The VDR binds to vitamin D-responsive elements (VDREs) in the 5' flanking region of target genes.  It has been suggested that VDR homodimerization can occur upon binding to certain VDREs but that the VDR/retinoid X receptor (RXR) heterodimer is the functional transactivating species.  Other factors reported to be involved in VDR-mediated transcription include chicken ovalbumin upstream promoter (COUP) transcription factor, which is involved in active silencing of transcription, and transcription factor IIB, which has been suggested to play a major role following VDR/RXR heterodimerization.  Newly identified vitamin D-dependent target genes include those for Ca2+/Mg2+-ATPase in the intestine and p21 in the myelomonocytic U937 cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptLYvt3Ct4qbVg90H21EOLACvtfcHk0lhpShfaNW5szQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVahsb4%253D&md5=fbd55c77e3cf828b1cdadfa46f508ad5</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1042%2Fbj3160361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3160361%26sid%3Dliteratum%253Aachs%26aulast%3DChristakos%26aufirst%3DS.%26aulast%3DRaval-Pandya%26aufirst%3DM.%26aulast%3DWernyj%26aufirst%3DR.%2BP.%26aulast%3DYang%26aufirst%3DW.%26atitle%3DGenomic%2520Mechanisms%2520Involved%2520in%2520the%2520Pleiotropic%2520Actions%2520of%25201%252C25-Dihydroxyvitamin%2520D3%26jtitle%3DBiochem.%2520J.%26date%3D1996%26volume%3D316%26spage%3D361%26epage%3D371%26doi%3D10.1042%2Fbj3160361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramelet, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurat, J. H.</span></span> <span> </span><span class="NLM_article-title">Remission of Cutaneous T-Cell Lymphoma with Combined Calcitriol and Acitretin</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(94)92122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0140-6736%2894%2992122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=7915374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADyaK2czlt1WgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=1994&pages=686-687&author=L.+E.+Frenchauthor=A.+A.+Rameletauthor=J.+H.+Saurat&title=Remission+of+Cutaneous+T-Cell+Lymphoma+with+Combined+Calcitriol+and+Acitretin&doi=10.1016%2FS0140-6736%2894%2992122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin</span></div><div class="casAuthors">French L E; Ramelet A A; Saurat J H</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">8923</span>),
    <span class="NLM_cas:pages">686-7</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFnOsCWFjUMDUE-swuRqsHfW6udTcc2eajsIh0Mklzxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czlt1WgsA%253D%253D&md5=75dfb9b98167c97b213159e8d2a96d2f</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992122-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DL.%2BE.%26aulast%3DRamelet%26aufirst%3DA.%2BA.%26aulast%3DSaurat%26aufirst%3DJ.%2BH.%26atitle%3DRemission%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%2520with%2520Combined%2520Calcitriol%2520and%2520Acitretin%26jtitle%3DLancet%26date%3D1994%26volume%3D344%26spage%3D686%26epage%3D687%26doi%3D10.1016%2FS0140-6736%2894%2992122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">Vitamin D and Analogues</span>. In  <i>Principles of Bone Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilezikian, J. P.</span>; <span class="NLM_string-name">Raisz, L. G.</span>; <span class="NLM_string-name">Martin, T. J.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">1777</span>– <span class="NLM_lpage">1799</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FB978-0-12-373884-4.00087-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=1777-1799&author=G.+Jonesauthor=J.+P.+Bilezikian&author=L.+G.+Raisz&author=T.+J.+Martin&title=Principles+of+Bone+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-373884-4.00087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-373884-4.00087-2%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26atitle%3DVitamin%2520D%2520and%2520Analogues%26btitle%3DPrinciples%2520of%2520Bone%2520Biology%26aulast%3DBilezikian%26aufirst%3DJ.%2BP.%26pub%3DElsevier%2520Academic%2520Press%26date%3D2008%26spage%3D1777%26epage%3D1799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. S.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Signalling Pathways in Cancer: Potential for Anticancer Therapeutics</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1038/nrc2196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrc2196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17721433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=684-700&author=K.+K.+Deebauthor=D.+L.+Trumpauthor=C.+S.+Johnson&title=Vitamin+D+Signalling+Pathways+in+Cancer%3A+Potential+for+Anticancer+Therapeutics&doi=10.1038%2Fnrc2196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D signalling pathways in cancer: potential for anticancer therapeutics</span></div><div class="casAuthors">Deeb, Kristin K.; Trump, Donald L.; Johnson, Candace S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">684-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidemiol. studies indicate that vitamin D insufficiency could have an etiol. role in various human cancers.  Preclin. research indicates that the active metabolite of vitamin D, 1α,25(OH)2D3, also known as calcitriol, or vitamin D analogs might have potential as anticancer agents because their administration has antiproliferative effects, can activate apoptotic pathways and inhibit angiogenesis.  In addn., 1α,25(OH)2D3 potentiates the anticancer effects of many cytotoxic and antiproliferative anticancer agents.  Here, we outline the epidemiol., preclin. and clin. studies that support the development of 1α,25(OH)2D3 and vitamin D analogs as preventative and therapeutic anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55tlJEPhjCrVg90H21EOLACvtfcHk0lhpShfaNW5szQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFSjsb0%253D&md5=a11063de83943ab02e4089c34ccff277</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1038%2Fnrc2196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2196%26sid%3Dliteratum%253Aachs%26aulast%3DDeeb%26aufirst%3DK.%2BK.%26aulast%3DTrump%26aufirst%3DD.%2BL.%26aulast%3DJohnson%26aufirst%3DC.%2BS.%26atitle%3DVitamin%2520D%2520Signalling%2520Pathways%2520in%2520Cancer%253A%2520Potential%2520for%2520Anticancer%2520Therapeutics%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D684%26epage%3D700%26doi%3D10.1038%2Fnrc2196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, R. L.</span></span> <span> </span><span class="NLM_article-title">Ketoconazole Inhibits Self-Induced Metabolism of 1,25-Dihydroxyvitamin D3 and Amplifies 1,25-Dihydroxyvitamin D3 Receptor Up-Regulation in Rat Osteosarcoma Cells</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1016/0003-9861(89)90240-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2F0003-9861%2889%2990240-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=2546501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaL1MXkslWkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1989&pages=459-465&author=T.+A.+Reinhardtauthor=R.+L.+Horst&title=Ketoconazole+Inhibits+Self-Induced+Metabolism+of+1%2C25-Dihydroxyvitamin+D3+and+Amplifies+1%2C25-Dihydroxyvitamin+D3+Receptor+Up-Regulation+in+Rat+Osteosarcoma+Cells&doi=10.1016%2F0003-9861%2889%2990240-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells</span></div><div class="casAuthors">Reinhardt, T. A.; Horst, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    </div><div class="casAbstract">Ketoconazole (I), an inhibitor of vitamin D 24-hydroxylase was used to study the role of self-induced 1,25-dihydroxyvitamin D3 (1,25-D3) metab. on rat osteosarcoma cellular responsiveness to 1,25-D3.  The 18-h treatment with 1,25-dihydroxy-[26,27-methyl-3H]vitamin D3 (1,25-[3H]D3) increased total 1,25-D3 receptors (VDR) from 60 to 170 fmol/mg protein.  In cells treated with both 1,25-[3H]D3 and I, upregulation of VDR was increased by 40% over that obsd. with cells receiving 1,25-[3H]D3 alone.  I alone had no agonistic activity.  Treatment of cells with 1 nM 1,25-[3H]D3 plus increasing doses of I (0-30 μM) dose dependently increased occupied VDR and total VDR.  This upregulation was assocd. with reduced 1,25-[3H]D3 catabolism.  1,25-[3H]D3-induced upregulation of VDR typically peaked at 14 h and declined thereafter.  I lengthened the time to reach peak VDR upregulation to 20 h.  The ability of I to increase cell responsiveness (VDR upregulation) was the result of both increased and prolonged occupancy of VDR by 1,25-[3H]D3.  The t1/2 of occupied VDR was 2 h in the absence of I and >7 h when I was present.  Self-induced catabolism of 1,25-D3 is apparently an important regulator of VDR occupancy and therefore cellular responsiveness to hormone.  The data also demonstrate the usefulness of I as an inhibitor of vitamin D hydroxylases in intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosX0q3-UI3GrVg90H21EOLACvtfcHk0liHLYwrrrCxyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslWkurk%253D&md5=24130f4b5f35064bf2133d9a2061ca91</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1016%2F0003-9861%2889%2990240-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-9861%252889%252990240-3%26sid%3Dliteratum%253Aachs%26aulast%3DReinhardt%26aufirst%3DT.%2BA.%26aulast%3DHorst%26aufirst%3DR.%2BL.%26atitle%3DKetoconazole%2520Inhibits%2520Self-Induced%2520Metabolism%2520of%25201%252C25-Dihydroxyvitamin%2520D3%2520and%2520Amplifies%25201%252C25-Dihydroxyvitamin%2520D3%2520Receptor%2520Up-Regulation%2520in%2520Rat%2520Osteosarcoma%2520Cells%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1989%26volume%3D272%26spage%3D459%26epage%3D465%26doi%3D10.1016%2F0003-9861%2889%2990240-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilicarslan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyndale, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, E. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.3.314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1124%2Fdmd.30.3.314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=11854151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhtl2qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=314-318&author=W.+Zhangauthor=Y.+Ramamoorthyauthor=T.+Kilicarslanauthor=H.+Nolteauthor=R.+F.+Tyndaleauthor=E.+M.+Sellers&title=Inhibition+of+Cytochromes+P450+by+Antifungal+Imidazole+Derivatives&doi=10.1124%2Fdmd.30.3.314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytochromes P450 by antifungal imidazole derivatives</span></div><div class="casAuthors">Zhang, Wenjiang; Ramamoorthy, Yamini; Kilicarslan, Tansel; Nolte, Helma; Tyndale, Rachel F.; Sellers, Edward M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-318</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The interactions of a panel of antifungal agents with cytochromes P 450 (P450s), as a means of predicting potential drug-drug interactions, have not yet been investigated.  The objective of this study was to evaluate the specificity and selectivity of five antifungal agents using selective probe reactions for each of the eight major P450s.  The index reactions used were phenacetin O-deethylation (for CYP1A2), coumarin 7-hydroxylation (CYP2A6), diclofenac 4'-hydroxylation (CYP2C9), omeprazole 5-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), 7-ethoxy-4-trifluoromethylcoumarin deethylation (CYP2B6), chlorzoxazone 6-hydroxylation (CYP2E1), and omeprazole sulfonation (CYP3A4).  Five antifungal agents that include an imidazole moiety (clotrimazole, miconazole, sulconazole, tioconazole, and ketoconazole) were examd. in cDNA-expressing microsomes from human lymphoblast cells or human liver microsomes.  All inhibitors studied demonstrated nonselective inhibition of P450s.  Ketoconazole seemed to be the most selective for CYP3A4, although it also inhibited CYP2C9.  High-affinity inhibition was seen for CYP1A2 (sulconazole and tioconazole Ki, 0.4 μM), CYP2B6 (miconazole Ki, 0.05 μM; sulconazole Ki, 0.04 μM), CYP2C19 (miconazole Ki, 0.05 μM; sulconazole Ki, 0.008 μM; tioconazole Ki, 0.04 μM), CYP2C9 (sulconazole Ki, 0.01 μM), CYP2D6 (miconazole Ki, 0.70 μM; sulconazole Ki, 0.40 μM), CYP2E1 (tioconazole Ki, 0.4 μM) and CYP3A4 (clotrimazole Ki, 0.02 μM; miconazole Ki, 0.03 μM; tioconazole Ki, 0.02 μM).  Therefore, this class of compds. is likely to result in significant drug-drug interactions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYP5Jc4ykk47Vg90H21EOLACvtfcHk0liHLYwrrrCxyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhtl2qt7k%253D&md5=a7b9f9e1080415a5ddf524197d913ca9</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.3.314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.3.314%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRamamoorthy%26aufirst%3DY.%26aulast%3DKilicarslan%26aufirst%3DT.%26aulast%3DNolte%26aufirst%3DH.%26aulast%3DTyndale%26aufirst%3DR.%2BF.%26aulast%3DSellers%26aufirst%3DE.%2BM.%26atitle%3DInhibition%2520of%2520Cytochromes%2520P450%2520by%2520Antifungal%2520Imidazole%2520Derivatives%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D314%26epage%3D318%26doi%3D10.1124%2Fdmd.30.3.314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. S.</span></span> <span> </span><span class="NLM_article-title">Potent, Low-Calcemic, Selective Inhibitors of CYP24 Hydroxylase: 24-Sulfone Analogs of the Hormone 1alpha,25-Dihydroxyvitamin D3</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>89–90</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2004.03.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jsbmb.2004.03.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=15225738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1aitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89%E2%80%9390&publication_year=2004&pages=5-12&author=G.+H.+Posnerauthor=K.+R.+Crawfordauthor=H.+W.+Yangauthor=M.+Kahramanauthor=H.+B.+Jeonauthor=H.+Liauthor=J.+K.+Leeauthor=B.+C.+Suhauthor=M.+A.+Hatcherauthor=T.+Labonteauthor=A.+Useraauthor=P.+M.+Dolanauthor=T.+W.+Kenslerauthor=S.+Pelegauthor=G.+Jonesauthor=A.+Zhangauthor=B.+Korczakauthor=U.+Sahaauthor=S.+S.+Chuang&title=Potent%2C+Low-Calcemic%2C+Selective+Inhibitors+of+CYP24+Hydroxylase%3A+24-Sulfone+Analogs+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D3&doi=10.1016%2Fj.jsbmb.2004.03.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1α,25-dihydroxyvitamin D3</span></div><div class="casAuthors">Posner, Gary H.; Crawford, Kenneth R.; Yang, Hong Woon; Kahraman, Mehmet; Jeon, Heung Bae; Li, Hongbin; Lee, Jae Kyoo; Suh, Byung Chul; Hatcher, Mark A.; Labonte, Tanzina; Usera, Aimee; Dolan, Patrick M.; Kensler, Thomas W.; Peleg, Sara; Jones, Glenville; Zhang, Anqi; Korczak, Bozena; Saha, Uttam; Chuang, Samuel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">89-90</span>
        (<span class="NLM_cas:issue">1-5</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">: Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The new 24-phenylsulfone I, a low-calcemic analog of the natural hormone 1α,25-dihydroxyvitamin D3, is a potent (IC50 = 28 nM) and highly selective inhibitor of the human 24-hydroxylase enzyme CYP24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt9NmFVhdDa7Vg90H21EOLACvtfcHk0lifij6bmkeTbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1aitL4%253D&md5=2c6e2ce35ff0ff066a2bab0368defb09</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.03.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.03.044%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DCrawford%26aufirst%3DK.%2BR.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DJeon%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DSuh%26aufirst%3DB.%2BC.%26aulast%3DHatcher%26aufirst%3DM.%2BA.%26aulast%3DLabonte%26aufirst%3DT.%26aulast%3DUsera%26aufirst%3DA.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DKorczak%26aufirst%3DB.%26aulast%3DSaha%26aufirst%3DU.%26aulast%3DChuang%26aufirst%3DS.%2BS.%26atitle%3DPotent%252C%2520Low-Calcemic%252C%2520Selective%2520Inhibitors%2520of%2520CYP24%2520Hydroxylase%253A%252024-Sulfone%2520Analogs%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D3%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D89%25E2%2580%259390%26spage%3D5%26epage%3D12%26doi%3D10.1016%2Fj.jsbmb.2004.03.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">Conceptually New Sulfone Analogues of the Hormone 1alpha, 25-Dihydroxyvitamin D(3): Synthesis and Preliminary Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3425</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1021/jm990267c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990267c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXltV2lsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3425-3435&author=G.+H.+Posnerauthor=Q.+Wangauthor=G.+Hanauthor=J.+K.+Leeauthor=K.+Crawfordauthor=S.+Zandauthor=H.+Bremauthor=S.+Pelegauthor=P.+Dolanauthor=T.+W.+Kensler&title=Conceptually+New+Sulfone+Analogues+of+the+Hormone+1alpha%2C+25-Dihydroxyvitamin+D%283%29%3A+Synthesis+and+Preliminary+Biological+Evaluation&doi=10.1021%2Fjm990267c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Conceptually New Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Preliminary Biological Evaluation</span></div><div class="casAuthors">Posner, Gary H.; Wang, Qiang; Han, Gyoonhee; Lee, Jae Kyoo; Crawford, Kenneth; Zand, Sarvenaz; Brem, Henry; Peleg, Sara; Dolan, Patrick; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3425-3435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A conceptually new series of vitamin D3-like nonfluorinated and fluorinated 16-ene side chain tert-Bu sulfones I [X = CH2CH2, 1α-OH, 3β-OH; (CH2)3, 1α-OH, 3β-OH; (CH2)3, 1β-OH, 3α-OH; (CH2CH2CF2), 1α-OH, 3β-OH; (CH2CH2CF2), 1β-OH, 3α-OH; (E)-CH2CH:CH, 1α-OH, 3β-OH; (E)-CH2CH:CH, 1β-OH, 3α-OH; (E)-CH2CH:CF, 1α-OH, 3β-OH; (E)-CH2CH:CF, 1β-OH, 3α-OH] were synthesized.  Even though these novel C,D-ring side chain analogs of the hormone 1α,25-dihydroxyvitamin D3 lack a terminal OH group thought previously to be essential for high biol. activity, they are highly antiproliferative and, in several cases, transcriptionally active in vitro but desirably noncalcemic in vivo.  The side chain sulfone group may be binding to the nVDR as a hydrogen-bond acceptor, in contrast to the hydrogen-bond donor function of the 25-OH group of natural 1,25D3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5HbGa4Pytb7Vg90H21EOLACvtfcHk0lifij6bmkeTbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltV2lsL0%253D&md5=37df7a66f770ad8d5660a20ede562fba</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1021%2Fjm990267c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990267c%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DZand%26aufirst%3DS.%26aulast%3DBrem%26aufirst%3DH.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DConceptually%2520New%2520Sulfone%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C%252025-Dihydroxyvitamin%2520D%25283%2529%253A%2520Synthesis%2520and%2520Preliminary%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3425%26epage%3D3435%26doi%3D10.1021%2Fjm990267c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu-Caldera, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabia, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Etten, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennaro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vouros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1alpha,25-Dihydroxyvitamin D(3): Synthesis and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3581</span>– <span class="NLM_lpage">3586</span>, <span class="refDoi"> DOI: 10.1021/jm000215j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000215j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFaqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3581-3586&author=G.+H.+Posnerauthor=K.+Crawfordauthor=M.+L.+Siu-Calderaauthor=G.+S.+Reddyauthor=S.+F.+Sarabiaauthor=D.+Feldmanauthor=E.+van+Ettenauthor=C.+Mathieuauthor=L.+Gennaroauthor=P.+Vourosauthor=S.+Pelegauthor=P.+M.+Dolanauthor=T.+W.+Kensler&title=Conceptually+New+20-epi-22-Oxa+Sulfone+Analogues+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D%283%29%3A+Synthesis+and+Biological+Evaluation&doi=10.1021%2Fjm000215j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Biological Evaluation</span></div><div class="casAuthors">Posner, Gary H.; Crawford, Kenneth; Siu-Caldera, Mei-Ling; Reddy, G. Satyanarayana; Sarabia, Stephen F.; Feldman, David; vanEtten, Evelyne; Mathieu, Chantal; Gennaro, Lynn; Vouros, Paul; Peleg, Sara; Dolan, Patrick M.; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3581-3586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New C,D-ring side-chain-modified sulfone I, with natural 1α,3β-hydroxyl groups but lacking the 25-hydroxyl group characteristic of the natural hormone 1α,25-dihydroxyvitamin D3, was prepd. and characterized.  Novel synthetic features include: (1) chemoselective oxidn. of only a primary silyl ether in a primary-secondary bis-silyl ether intermediate and (2) smooth reductive etherification without interference by a neighboring sulfonyl group.  I, but not its 1β,3α-diastereomer, was powerfully antiproliferative and transcriptionally active in vitro but desirably noncalcemic in vivo.  Although I, designed to resemble Leo Pharmaceutical Co.'s KH-1060 (3), was recognized by catabolic enzymes, the selective biol. profile of I is likely not due to its metabolites that are formed in only minor amts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOUvngld7sQLVg90H21EOLACvtfcHk0ljOMQ_8WHdfcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFaqt7k%253D&md5=24d1f1753bdaf69bfd4e3967d4efc53a</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1021%2Fjm000215j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000215j%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DSiu-Caldera%26aufirst%3DM.%2BL.%26aulast%3DReddy%26aufirst%3DG.%2BS.%26aulast%3DSarabia%26aufirst%3DS.%2BF.%26aulast%3DFeldman%26aufirst%3DD.%26aulast%3Dvan%2BEtten%26aufirst%3DE.%26aulast%3DMathieu%26aufirst%3DC.%26aulast%3DGennaro%26aufirst%3DL.%26aulast%3DVouros%26aufirst%3DP.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DConceptually%2520New%252020-epi-22-Oxa%2520Sulfone%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D%25283%2529%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3581%26epage%3D3586%26doi%3D10.1021%2Fjm000215j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinishtaj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peleg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1alpha,25-Dihydroxyvitamin D(3)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">6854</span>– <span class="NLM_lpage">6863</span>, <span class="refDoi"> DOI: 10.1021/jm040129+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040129%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVansrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6854-6863&author=M.+Kahramanauthor=S.+Sinishtajauthor=P.+M.+Dolanauthor=T.+W.+Kenslerauthor=S.+Pelegauthor=U.+Sahaauthor=S.+S.+Chuangauthor=G.+Bernsteinauthor=B.+Korczakauthor=G.+H.+Posner&title=Potent%2C+Selective+and+Low-Calcemic+Inhibitors+of+CYP24+Hydroxylase%3A+24-Sulfoximine+Analogues+of+the+Hormone+1alpha%2C25-Dihydroxyvitamin+D%283%29&doi=10.1021%2Fjm040129%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D3</span></div><div class="casAuthors">Kahraman, Mehmet; Sinishtaj, Sandra; Dolan, Patrick M.; Kensler, Thomas W.; Peleg, Sara; Saha, Uttam; Chuang, Samuel S.; Bernstein, Galina; Korczak, Bozena; Posner, Gary H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6854-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A dozen 24-sulfoximine analogs of the hormone 1α,25-dihydroxyvitamin D3 were prepd., differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring.  Although these sulfoximines were not active transcriptionally and were only very weakly antiproliferative, some of them are powerful hydroxylase enzyme inhibitors.  Specifically, 24(S)-NH Ph sulfoximine I is an extremely potent CYP24 inhibitor (IC50 = 7.4 nM) having low calcemic activity.  In addn., this compd. shows high selectivity toward the CYP24 enzyme in comparison to CYP27A1 (IC50 > 1000 nM) and CYP27B (IC50 = 554 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89y_8mOPfOrVg90H21EOLACvtfcHk0ljOMQ_8WHdfcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVansrbP&md5=c1c9be3a2448f5bcfec4ae11d183677a</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1021%2Fjm040129%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040129%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DSinishtaj%26aufirst%3DS.%26aulast%3DDolan%26aufirst%3DP.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DPeleg%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DU.%26aulast%3DChuang%26aufirst%3DS.%2BS.%26aulast%3DBernstein%26aufirst%3DG.%26aulast%3DKorczak%26aufirst%3DB.%26aulast%3DPosner%26aufirst%3DG.%2BH.%26atitle%3DPotent%252C%2520Selective%2520and%2520Low-Calcemic%2520Inhibitors%2520of%2520CYP24%2520Hydroxylase%253A%252024-Sulfoximine%2520Analogues%2520of%2520the%2520Hormone%25201alpha%252C25-Dihydroxyvitamin%2520D%25283%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6854%26epage%3D6863%26doi%3D10.1021%2Fjm040129%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petkovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">CYP24A1 and Kidney Disease</span>. <i>Curr. Opin. Nephrol. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1097/MNH.0b013e3283477a7b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1097%2FMNH.0b013e3283477a7b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21610497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntF2ns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=337-344&author=M.+Petkovichauthor=G.+Jones&title=CYP24A1+and+Kidney+Disease&doi=10.1097%2FMNH.0b013e3283477a7b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">CYP24A1 and kidney disease</span></div><div class="casAuthors">Petkovich, Martin; Jones, Glenville</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Nephrology and Hypertension</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">CNHYEM</span>;
        ISSN:<span class="NLM_cas:issn">1062-4821</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Patients with chronic renal disease have elevated serum phosphate levels, elevated fibroblast-like growth factor 23 (FGF-23), and declining vitamin D status.  These changes are related and may be responsible for elevated 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) and dysfunctional vitamin D metab.  This review focuses on the biochem. and pathophysiol. of CYP24A1 and the utility of blocking this enzyme with CYP24A1 inhibitors in chronic kidney disease (CKD) patients.  Recent findings: CYP24A1 is the cytochrome P 450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (25-OHD3) and its hormonal form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], into 24-hydroxylated products targeted for excretion.  The CYP24A1-null phenotype is consistent with the catabolic role of CYP24A1.  A no. of polymorphisms of CYP24A1 have recently been identified.  New data from the uremic rat and humans suggest that dysfunctional vitamin D metab. is due to changes in CYP24A1 expression caused by phosphate and FGF-23 elevations.  Summary: Changes in serum phosphate and FGF-23 levels in the CKD patient increase CYP24A1 expression resulting in decreased vitamin D status.  Vitamin D deficiency may exacerbate defective calcium and phosphate homeostasis causing renal osteodystrophy and contribute to the other complications of renal disease.  These findings argue for increased focus on correcting vitamin D deficiency in CKD patients by blocking CYP24A1 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKFPKp_bEE7Vg90H21EOLACvtfcHk0lgmjXxT2rxSFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntF2ns7s%253D&md5=54d04f8632227833444db3e1451bffc0</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1097%2FMNH.0b013e3283477a7b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMNH.0b013e3283477a7b%26sid%3Dliteratum%253Aachs%26aulast%3DPetkovich%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%26atitle%3DCYP24A1%2520and%2520Kidney%2520Disease%26jtitle%3DCurr.%2520Opin.%2520Nephrol.%2520Hypertens.%26date%3D2011%26volume%3D20%26spage%3D337%26epage%3D344%26doi%3D10.1097%2FMNH.0b013e3283477a7b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, W. G.</span></span> <span> </span><span class="NLM_article-title">Medical Management of Secondary Hyperparathyroidism in Chronic Renal Failure</span>. <i>Nephrol. Dial. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1093%2Fndt%2Fgfg1002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFWhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2-8&author=W.+G.+Goodman&title=Medical+Management+of+Secondary+Hyperparathyroidism+in+Chronic+Renal+Failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Medical management of secondary hyperparathyroidism in chronic renal failure</span></div><div class="casAuthors">Goodman, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">iii2-iii8</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Abnormalities in calcium and phosphorus metab. are common, and metabolic bone disease develops often in patients with chronic renal failure (CRF).  Effective clin. management includes measures to control phosphorus retention and prevent hyperphosphatemia, to maintain serum calcium concns. within the normal range and to prevent excess parathyroid hormone (PTH) secretion by the judicious use of vitamin D sterols.  Certain of these interventions appear to increase the risk of soft tissue and vascular calcification in patients with end-stage renal disease (ESRD), changes that may contribute to the development of cardiovascular disease.  Current therapeutic approaches are thus being re-evaluated in an effort to limit these risks.  Despite the importance of controlling phosphorus retention and preventing hyperphosphatemia in patients with CRF, current management strategies often are inadequate, particularly in those ingesting diets contg. adequate amts. of protein.  Results from clin. trials using daily haemodialysis strongly suggest that thrice-weekly haemodialysis regimens are only marginally adequate for achieving weekly phosphorus balance in many patients with ESRD.  The safety of large oral doses of calcium as a phosphate-binding agent in patients with ESRD has also been questioned because excess amts. of calcium that are absorbed from the gastrointestinal tract may lead to ongoing calcium retention in those with little or no residual renal function.  Arterial calcification and cardiac valve calcification are two serious complications that adversely affect cardiovascular hemodynamics.  The use of large, often supraphysiol., doses of calcitriol or other vitamin D sterols to treat secondary hyperparathyroidism may aggravate hypercalcemia and hyperphosphatemia, further increasing the risk of soft tissue and vascular calcification.  Phosphate-binding agents that do not contain calcium, new vitamin D analogs and calcimimetic compds. offer new therapeutic alternatives for managing renal osteodystrophy.  The integration of these novel agents into existing treatment regimens may provide safer and more effective methods for controlling secondary hyperparathyroidism and renal bone disease, while limiting the risks of soft tissue and vascular calcification in patients with CRF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBdqAxyywh7Vg90H21EOLACvtfcHk0lgmjXxT2rxSFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFWhu7k%253D&md5=54b9720aae84faece1769e7288dc0923</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfg1002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfg1002%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DW.%2BG.%26atitle%3DMedical%2520Management%2520of%2520Secondary%2520Hyperparathyroidism%2520in%2520Chronic%2520Renal%2520Failure%26jtitle%3DNephrol.%2520Dial.%2520Transplant.%26date%3D2003%26volume%3D18%26spage%3D2%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posner, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helvig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuerrier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collop, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharebov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epps, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petkovich, M.</span></span> <span> </span><span class="NLM_article-title">Vitamin D Analogues Targeting CYP24 in Chronic Kidney Disease</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2010.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jsbmb.2010.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20347976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=13-19&author=G.+H.+Posnerauthor=C.+Helvigauthor=D.+Cuerrierauthor=D.+Collopauthor=A.+Kharebovauthor=K.+Ryderauthor=T.+Eppsauthor=M.+Petkovich&title=Vitamin+D+Analogues+Targeting+CYP24+in+Chronic+Kidney+Disease&doi=10.1016%2Fj.jsbmb.2010.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin D analogues targeting CYP24 in chronic kidney disease</span></div><div class="casAuthors">Posner, Gary H.; Helvig, Christian; Cuerrier, Dominic; Collop, Drew; Kharebov, Aza; Ryder, Kara; Epps, Tina; Petkovich, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">13-19</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cytochrome P 450 enzyme 24-hydroxylase (CYP24) plays a crit. role in regulating levels of vitamin D hormone.  Aberrant expression of CYP24 has been implicated in vitamin D insufficiency and resistance to vitamin D therapy.  We have demonstrated amplified CYP24 expression in uremic rats, suggesting that CYP24 has an etiol. role in vitamin D insufficiency commonly assocd. with chronic kidney disease (CKD).  We have designed two new analogs of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), namely CTA 091 and CTA 018/MT 2832, which are potent inhibitors of CYP24.  In vitro studies with CTA 091 show that it enhances the potency of 1α,25(OH)2D3.  In vivo studies demonstrate that CTA 091 decreases serum intact parathyroid hormone (iPTH) levels and increases circulating 1α,25(OH)2D3.  CTA 091 increases both C max and AUC of co-administered 1α,25(OH)2D3.  These studies indicate that CYP24 inhibition can increase cellular responsiveness to vitamin D hormone and potentiate vitamin D therapy.  CTA 018/MT 2832 differs from CTA 091 in that it also has the ability to activate vitamin D receptor-mediated transcription.  CTA 018/MT 2832 effectively suppresses elevated iPTH secretion at doses which do not affect serum calcium or phosphorus levels in a rodent model of CKD.  Studies with both new analogs underscore the potential utility of CYP24 inhibition in the treatment of secondary hyperparathyroidism in CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounHlAlWbmgbVg90H21EOLACvtfcHk0lgmjXxT2rxSFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVCqtL8%253D&md5=7a102feb2c380d8782137c0bdb043406</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2010.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2010.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DPosner%26aufirst%3DG.%2BH.%26aulast%3DHelvig%26aufirst%3DC.%26aulast%3DCuerrier%26aufirst%3DD.%26aulast%3DCollop%26aufirst%3DD.%26aulast%3DKharebov%26aufirst%3DA.%26aulast%3DRyder%26aufirst%3DK.%26aulast%3DEpps%26aufirst%3DT.%26aulast%3DPetkovich%26aufirst%3DM.%26atitle%3DVitamin%2520D%2520Analogues%2520Targeting%2520CYP24%2520in%2520Chronic%2520Kidney%2520Disease%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D121%26spage%3D13%26epage%3D19%26doi%3D10.1016%2Fj.jsbmb.2010.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagamani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, K.</span></span> <span> </span><span class="NLM_article-title">A Theoretical Insight to Understand the Molecular Mechanism of Dual Target Ligand CTA-018 in the Chronic Kidney Disease Pathogenesis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e0203194</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0203194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1371%2Fjournal.pone.0203194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30286109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFKhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0203194&author=S.+Nagamaniauthor=K.+Muthusamy&title=A+Theoretical+Insight+to+Understand+the+Molecular+Mechanism+of+Dual+Target+Ligand+CTA-018+in+the+Chronic+Kidney+Disease+Pathogenesis&doi=10.1371%2Fjournal.pone.0203194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis</span></div><div class="casAuthors">Nagamani, Selvaraman; Muthusamy, Karthikeyan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0203194/1-e0203194/26</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The level of the vitamin D in the bloodstream is regulated by cytochrome P 450 enzyme 24-hydroxylase A1 (CYP24A1).  Over expression of CYP24A1 enzyme is correlated with vitamin D deficiency and resistance to vitamin D therapy.  Chronic kidney disease (CKD) patients are commonly reported with the above said expression variations.  This deregulation could be solved by ligands that act as a vitamin D receptor (VDR) agonists and CYP24A1 antagonists.  Posner et al., (2010) first time reported two new vitamin D analogs namely CTA-091 and CTA-018 to inhibit CYP24A1.  The CTA-018 inhibited CYP24A1 with an IC50 27 ± 6 nM (10 times more potent than the ketoconazole (253 ± 20 nM)).  CTA-018 induced VDR expression (15-fold lower than 1α,25(OH)2D3) and is under phase II clin. trial, whereas CTA-091 was not able to efficiently induce the VDR expression (>2000 nM).  To explore the mol. mechanism, binding specificity of these two vitamin D analogs along with native ligand was extensively studied through in silico approaches.  Through mol. dynamics simulations studies, we shown that the sulfonic group (O = S = O) in the side chain of CTA-018 plays an important role in the regulation of VDR agonistic activity.  The electron lone pairs of the sulfonic group that interacted with His393 lead to be a factor for agonistic mechanism of VDR activity.  Compared to azol-based compds., CTA-018 binds the different sites in the CYP24A1 binding cavity and thus it could be a potent antagonistic for CYP24A1 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5fKsPbaqcxLVg90H21EOLACvtfcHk0lhyaYtfTShYAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFKhtrc%253D&md5=75588e9163efa5c6a2e3333adccd8b22</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0203194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0203194%26sid%3Dliteratum%253Aachs%26aulast%3DNagamani%26aufirst%3DS.%26aulast%3DMuthusamy%26aufirst%3DK.%26atitle%3DA%2520Theoretical%2520Insight%2520to%2520Understand%2520the%2520Molecular%2520Mechanism%2520of%2520Dual%2520Target%2520Ligand%2520CTA-018%2520in%2520the%2520Chronic%2520Kidney%2520Disease%2520Pathogenesis%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26spage%3De0203194%26doi%3D10.1371%2Fjournal.pone.0203194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group">Press
Release, Mitsubishi Tanabe Pharma Corporation</span>. <a href="https://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC_120601.pdf" class="extLink">https://www.mt-pharma.co.jp/e/release/nr/2012/pdf/eMTPC_120601.pdf</a> (Accessed Dec 30, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Press%0ARelease%2C+Mitsubishi+Tanabe+Pharma+Corporation.+https%3A%2F%2Fwww.mt-pharma.co.jp%2Fe%2Frelease%2Fnr%2F2012%2Fpdf%2FeMTPC_120601.pdf+%28Accessed+Dec+30%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delzell, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson-Hughes, B.</span></span> <span> </span><span class="NLM_article-title">The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1002/jbmr.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1002%2Fjbmr.2269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24771492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2cnntFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=2520-2526&author=N.+C.+Wrightauthor=A.+C.+Lookerauthor=K.+G.+Saagauthor=J.+R.+Curtisauthor=E.+S.+Delzellauthor=S.+Randallauthor=B.+Dawson-Hughes&title=The+Recent+Prevalence+of+Osteoporosis+and+Low+Bone+Mass+in+the+United+States+Based+on+Bone+Mineral+Density+at+the+Femoral+Neck+or+Lumbar+Spine&doi=10.1002%2Fjbmr.2269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine</span></div><div class="casAuthors">Wright Nicole C; Looker Anne C; Saag Kenneth G; Curtis Jeffrey R; Delzell Elizabeth S; Randall Susan; Dawson-Hughes Bess</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2520-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The goal of our study was to estimate the prevalence of osteoporosis and low bone mass based on bone mineral density (BMD) at the femoral neck and the lumbar spine in adults 50 years and older in the United States (US).  We applied prevalence estimates of osteoporosis or low bone mass at the femoral neck or lumbar spine (adjusted by age, sex, and race/ethnicity to the 2010 Census) for the noninstitutionalized population aged 50 years and older from the National Health and Nutrition Examination Survey 2005-2010 to 2010 US Census population counts to determine the total number of older US residents with osteoporosis and low bone mass.  There were more than 99 million adults aged 50 years and older in the US in 2010.  Based on an overall 10.3% prevalence of osteoporosis, we estimated that in 2010, 10.2 million older adults had osteoporosis.  The overall low bone mass prevalence was 43.9%, from which we estimated that 43.4 million older adults had low bone mass.  We estimated that 7.7 million non-Hispanic white, 0.5 million non-Hispanic black, and 0.6 million Mexican American adults had osteoporosis, and another 33.8, 2.9, and 2.0 million had low bone mass, respectively.  When combined, osteoporosis and low bone mass at the femoral neck or lumbar spine affected an estimated 53.6 million older US adults in 2010.  Although most of the individuals with osteoporosis or low bone mass were non-Hispanic white women, a substantial number of men and women from other racial/ethnic groups also had osteoporotic BMD or low bone mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB9ouK8Clo_xBrI9DTGjC0fW6udTcc2eaTR5yVqLLca7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnntFGmsA%253D%253D&md5=c2c9f6ac188f871116412e570a636221</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1002%2Fjbmr.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbmr.2269%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DN.%2BC.%26aulast%3DLooker%26aufirst%3DA.%2BC.%26aulast%3DSaag%26aufirst%3DK.%2BG.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DDelzell%26aufirst%3DE.%2BS.%26aulast%3DRandall%26aufirst%3DS.%26aulast%3DDawson-Hughes%26aufirst%3DB.%26atitle%3DThe%2520Recent%2520Prevalence%2520of%2520Osteoporosis%2520and%2520Low%2520Bone%2520Mass%2520in%2520the%2520United%2520States%2520Based%2520on%2520Bone%2520Mineral%2520Density%2520at%2520the%2520Femoral%2520Neck%2520or%2520Lumbar%2520Spine%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2014%26volume%3D29%26spage%3D2520%26epage%3D2526%26doi%3D10.1002%2Fjbmr.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petak, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleerekoper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewiecki, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessah-Pollack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangpricha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimalawansa, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, N. B.</span></span> <span> </span><span class="NLM_article-title">American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016</span>. <i>Endocrine Practice</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.4158/EP161435.GL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.4158%2FEP161435.GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=27662240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FitVehtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1-42&author=P.+M.+Camachoauthor=S.+M.+Petakauthor=N.+Binkleyauthor=B.+L.+Clarkeauthor=S.+T.+Harrisauthor=D.+L.+Hurleyauthor=M.+Kleerekoperauthor=E.+M.+Lewieckiauthor=P.+D.+Millerauthor=H.+S.+Narulaauthor=R.+Pessah-Pollackauthor=V.+Tangprichaauthor=S.+J.+Wimalawansaauthor=N.+B.+Watts&title=American+Association+of+Clinical+Endocrinologists+and+American+College+of+Endocrinology+Clinical+Practice+Guidelines+for+the+Diagnosis+and+Treatment+of+Postmenopausal+Osteoporosis+-+2016&doi=10.4158%2FEP161435.GL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016</span></div><div class="casAuthors">Camacho Pauline M; Petak Steven M; Binkley Neil; Clarke Bart L; Harris Steven T; Hurley Daniel L; Kleerekoper Michael; Lewiecki E Michael; Miller Paul D; Narula Harmeet S; Pessah-Pollack Rachel; Tangpricha Vin; Wimalawansa Sunil J; Watts Nelson B</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">Suppl 4</span>),
    <span class="NLM_cas:pages">1-42</span>
        ISSN:<span class="NLM_cas:issn">1530-891X</span>.
    </div><div class="casAbstract">ABBREVIATIONS:  AACE = American Association of Clinical Endocrinologists AFF = atypical femur fracture ASBMR = American Society for Bone and Mineral Research BEL = best evidence level BMD = bone mineral density BTM = bone turnover marker CBC = complete blood count CI = confidence interval DXA = dual-energy X-ray absorptiometry EL = evidence level FDA = U.S.  Food and Drug Administration FLEX = Fracture Intervention Trial (FIT) Long-term Extension FRAX® = Fracture Risk Assessment Tool GFR = glomerular filtration rate GI = gastrointestinal HORIZON = Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly IOF = International Osteoporosis Foundation ISCD = International Society for Clinical Densitometry IU = international units IV = intravenous LSC = least significant change NBHA = National Bone Health Alliance NOF = National Osteoporosis Foundation 25(OH)D = 25-hydroxy vitamin D ONJ = osteonecrosis of the jaw PINP = serum carboxy-terminal propeptide of type I collagen PTH = parathyroid hormone R = recommendation RANK = receptor activator of nuclear factor kappa-B RANKL = receptor activator of nuclear factor kappa-B ligand RCT = randomized controlled trial RR = relative risk S-CTX = serum C-terminal telopeptide SQ = subcutaneous VFA = vertebral fracture assessment WHO = World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhPe6ovOhjlexsqfvU0ziafW6udTcc2eYUHNyItFmj3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FitVehtQ%253D%253D&md5=82fca4af11d47a928d64d6b49505152f</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.4158%2FEP161435.GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4158%252FEP161435.GL%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DP.%2BM.%26aulast%3DPetak%26aufirst%3DS.%2BM.%26aulast%3DBinkley%26aufirst%3DN.%26aulast%3DClarke%26aufirst%3DB.%2BL.%26aulast%3DHarris%26aufirst%3DS.%2BT.%26aulast%3DHurley%26aufirst%3DD.%2BL.%26aulast%3DKleerekoper%26aufirst%3DM.%26aulast%3DLewiecki%26aufirst%3DE.%2BM.%26aulast%3DMiller%26aufirst%3DP.%2BD.%26aulast%3DNarula%26aufirst%3DH.%2BS.%26aulast%3DPessah-Pollack%26aufirst%3DR.%26aulast%3DTangpricha%26aufirst%3DV.%26aulast%3DWimalawansa%26aufirst%3DS.%2BJ.%26aulast%3DWatts%26aufirst%3DN.%2BB.%26atitle%3DAmerican%2520Association%2520of%2520Clinical%2520Endocrinologists%2520and%2520American%2520College%2520of%2520Endocrinology%2520Clinical%2520Practice%2520Guidelines%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Postmenopausal%2520Osteoporosis%2520-%25202016%26jtitle%3DEndocrine%2520Practice%26date%3D2016%26volume%3D22%26spage%3D1%26epage%3D42%26doi%3D10.4158%2FEP161435.GL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beur, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewiecki, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, R.</span></span> <span> </span><span class="NLM_article-title">National Osteoporosis, F. Clinician’s Guide to Prevention and Treatment of Osteoporosis</span>. <i>Osteoporosis Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2359</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1007/s00198-014-2794-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00198-014-2794-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25182228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2359-2381&author=F.+Cosmanauthor=S.+J.+de+Beurauthor=M.+S.+LeBoffauthor=E.+M.+Lewieckiauthor=B.+Tannerauthor=S.+Randallauthor=R.+Lindsay&title=National+Osteoporosis%2C+F.+Clinician%E2%80%99s+Guide+to+Prevention+and+Treatment+of+Osteoporosis&doi=10.1007%2Fs00198-014-2794-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Clinician's Guide to Prevention and Treatment of Osteoporosis</span></div><div class="casAuthors">Cosman F; de Beur S J; LeBoff M S; Lewiecki E M; Tanner B; Randall S; Lindsay R</div><div class="citationInfo"><span class="NLM_cas:title">Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2359-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF.  Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQwUgxAQsScgpJitSxOdIlfW6udTcc2eZccSvlUgXl8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVKitQ%253D%253D&md5=3c4417881ee5308a6ca77adff62a1061</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1007%2Fs00198-014-2794-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00198-014-2794-2%26sid%3Dliteratum%253Aachs%26aulast%3DCosman%26aufirst%3DF.%26aulast%3Dde%2BBeur%26aufirst%3DS.%2BJ.%26aulast%3DLeBoff%26aufirst%3DM.%2BS.%26aulast%3DLewiecki%26aufirst%3DE.%2BM.%26aulast%3DTanner%26aufirst%3DB.%26aulast%3DRandall%26aufirst%3DS.%26aulast%3DLindsay%26aufirst%3DR.%26atitle%3DNational%2520Osteoporosis%252C%2520F.%2520Clinician%25E2%2580%2599s%2520Guide%2520to%2520Prevention%2520and%2520Treatment%2520of%2520Osteoporosis%26jtitle%3DOsteoporosis%2520Int.%26date%3D2014%26volume%3D25%26spage%3D2359%26epage%3D2381%26doi%3D10.1007%2Fs00198-014-2794-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson-Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosteson, A.</span></span> <span> </span><span class="NLM_article-title">Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1359/jbmr.061113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1359%2Fjbmr.061113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17144789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BD2s7htV2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=465-475&author=R.+Burgeauthor=B.+Dawson-Hughesauthor=D.+H.+Solomonauthor=J.+B.+Wongauthor=A.+Kingauthor=A.+Tosteson&title=Incidence+and+Economic+Burden+of+Osteoporosis-Related+Fractures+in+the+United+States%2C+2005%E2%80%932025&doi=10.1359%2Fjbmr.061113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025</span></div><div class="casAuthors">Burge Russel; Dawson-Hughes Bess; Solomon Daniel H; Wong John B; King Alison; Tosteson Anna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">465-75</span>
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    </div><div class="casAbstract">UNLABELLED:  This study predicts the burden of incident osteoporosis-related fractures and costs in the United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025.  Total fractures were >2 million, costing nearly $17 billion in 2005.  Men account for >25% of the burden.  Rapid growth in the disease burden is projected among nonwhite populations.  INTRODUCTION:  The aging of the U.S. population will likely lead to greater prevalence of osteoporosis.  Policy makers require precise projections of the disease burden by demographic subgroups and skeletal sites to effectively target osteoporosis intervention and treatment programs.  MATERIALS AND METHODS:  A state transition Markov decision model was used to estimate total incident fractures and costs by age, sex, race/ethnicity, and skeletal site for the U.S. population 50 years of age for 2005-2025.  RESULTS:  More than 2 million incident fractures at a cost of $17 billion are predicted for 2005.  Total costs including prevalent fractures are more than $19 billion.  Men account for 29% of fractures and 25% of costs.  Total incident fractures by skeletal site were vertebral (27%), wrist (19%), hip (14%), pelvic (7%), and other (33%).  Total costs by fracture type were vertebral (6%), hip (72%), wrist (3%), pelvic (5%), and other (14%).  By 2025, annual fractures and costs are projected to rise by almost 50%.  The most rapid growth is estimated for people 65-74 years of age, with an increase>87%.  An increase of nearly 175% is projected for Hispanic and other subpopulations.  CONCLUSIONS:  Osteoporosis prevention, treatment, and education efforts should address all skeletal sites, not just hip and vertebral, and appropriate attention is warranted for men and diverse race/ethnicity subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRQS3mhiTMFENoizSOkG_FfW6udTcc2eZEE3WP1fF_ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7htV2htg%253D%253D&md5=d58ecca501867d9a2498c2a68aa36ce5</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.061113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.061113%26sid%3Dliteratum%253Aachs%26aulast%3DBurge%26aufirst%3DR.%26aulast%3DDawson-Hughes%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DJ.%2BB.%26aulast%3DKing%26aufirst%3DA.%26aulast%3DTosteson%26aufirst%3DA.%26atitle%3DIncidence%2520and%2520Economic%2520Burden%2520of%2520Osteoporosis-Related%2520Fractures%2520in%2520the%2520United%2520States%252C%25202005%25E2%2580%25932025%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2007%26volume%3D22%26spage%3D465%26epage%3D475%26doi%3D10.1359%2Fjbmr.061113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref289"><div class="reference"><strong class="refLabel"><a href="#ref289" class="rightTabRefNumLink">289</a></strong><div class="NLM_citation" id="rightTab-cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raisz, L. G.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of Osteoporosis: Concepts, Conflicts, and Prospects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3318</span>– <span class="NLM_lpage">3325</span>, <span class="refDoi"> DOI: 10.1172/JCI27071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1172%2FJCI27071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=16322775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3318-3325&author=L.+G.+Raisz&title=Pathogenesis+of+Osteoporosis%3A+Concepts%2C+Conflicts%2C+and+Prospects&doi=10.1172%2FJCI27071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of osteoporosis: Concepts, conflicts, and prospects</span></div><div class="casAuthors">Raisz, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3318-3325</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures.  This review examines the fundamental pathogenetic mechanisms underlying this disorder, which include: (a) failure to achieve a skeleton of optimal strength during growth and development; (b) excessive bone resorption resulting in loss of bone mass and disruption of architecture; and (c) failure to replace lost bone due to defects in bone formation.  Estrogen deficiency is known to play a crit. role in the development of osteoporosis, while calcium and vitamin D deficiencies and secondary hyperparathyroidism also contribute.  There are multiple mechanisms underlying the regulation of bone remodeling, and these involve not only the osteoblastic and osteoclastic cell lineages but also other marrow cells, in addn. to the interaction of systemic hormones, local cytokines, growth factors, and transcription factors.  Polymorphisms of a large no. of genes have been assocd. with differences in bone mass and fragility.  It is now possible to diagnose osteoporosis, assess fracture risk, and reduce that risk with antiresorptive or other available therapies.  However, new and more effective approaches are likely to emerge from a better understanding of the regulators of bone cell function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr4gmjg9pMWrVg90H21EOLACvtfcHk0lhcF8UODg8EIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtLzJ&md5=77de4d8a09119f8178d1277e441e1bff</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1172%2FJCI27071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI27071%26sid%3Dliteratum%253Aachs%26aulast%3DRaisz%26aufirst%3DL.%2BG.%26atitle%3DPathogenesis%2520of%2520Osteoporosis%253A%2520Concepts%252C%2520Conflicts%252C%2520and%2520Prospects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3318%26epage%3D3325%26doi%3D10.1172%2FJCI27071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref290"><div class="reference"><strong class="refLabel"><a href="#ref290" class="rightTabRefNumLink">290</a></strong><div class="NLM_citation" id="rightTab-cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouresmaeili, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamalidehghan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamarehei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. M.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Overview on Osteoporosis and Its Risk Factors</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2029</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.2147/TCRM.S138000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.2147%2FTCRM.S138000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30464484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOht73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=2029-2049&author=F.+Pouresmaeiliauthor=B.+Kamalidehghanauthor=M.+Kamareheiauthor=Y.+M.+Goh&title=A+Comprehensive+Overview+on+Osteoporosis+and+Its+Risk+Factors&doi=10.2147%2FTCRM.S138000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive overview on osteoporosis and its risk factors</span></div><div class="casAuthors">Pouresmaeili, Farkhondeh; Kamalidehghan, Behnam; Kamarehei, Maryam; Goh, Yong Meng</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2029-2049</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Osteoporosis is a bone disorder with remarkable changes in bone biol. material and consequent bone structural distraction, affecting millions of people around the world from different ethnic groups.  Bone fragility is the worse outcome of the disease, which needs long term therapy and medical management, esp. in the elderly.  Many involved genes including environmental factors have been introduced as the disease risk factors so far, of which genes should be considered as effective early diagnosis biomarkers, esp. for the individuals from high-risk families.  In this review, a no. of important criteria involved in osteoporosis are addressed and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi7cEIQdi2ELVg90H21EOLACvtfcHk0lhcF8UODg8EIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOht73P&md5=11a1e911dfdd0dca7c5bd19b7ef06600</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S138000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S138000%26sid%3Dliteratum%253Aachs%26aulast%3DPouresmaeili%26aufirst%3DF.%26aulast%3DKamalidehghan%26aufirst%3DB.%26aulast%3DKamarehei%26aufirst%3DM.%26aulast%3DGoh%26aufirst%3DY.%2BM.%26atitle%3DA%2520Comprehensive%2520Overview%2520on%2520Osteoporosis%2520and%2520Its%2520Risk%2520Factors%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2018%26volume%3D14%26spage%3D2029%26epage%3D2049%26doi%3D10.2147%2FTCRM.S138000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref291"><div class="reference"><strong class="refLabel"><a href="#ref291" class="rightTabRefNumLink">291</a></strong><div class="NLM_citation" id="rightTab-cit291"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizzoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reginster, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bréart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1007/s00223-011-9499-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00223-011-9499-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21637997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVWis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=91-104&author=R.+Rizzoliauthor=J.+Y.+Reginsterauthor=S.+Boonenauthor=G.+Br%C3%A9artauthor=A.+Diez-Perezauthor=D.+Felsenbergauthor=J.+M.+Kaufmanauthor=J.+A.+Kanisauthor=C.+Cooper&title=Adverse+Reactions+and+Drug-Drug+Interactions+in+the+Management+of+Women+with+Postmenopausal+Osteoporosis&doi=10.1007%2Fs00223-011-9499-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis</span></div><div class="casAuthors">Rizzoli, Rene; Reginster, Jean-Yves; Boonen, Steven; Breart, Gerard; Diez-Perez, Adolfo; Felsenberg, Dieter; Kaufman, Jean-Marc; Kanis, John A.; Cooper, Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-104</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The pharmacol. management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects.  The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis.  We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series.  Bisphosphonates are assocd. with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment.  Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet.  The selective estrogen receptor modulators are assocd. with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke.  Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain.  The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions.  Drug-drug interactions are rare.  Osteoporosis treatments are generally safe and well tolerated, though they are assocd. with a few very rare serious adverse reactions.  While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0zzrjVtMTsLVg90H21EOLACvtfcHk0lhcF8UODg8EIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVWis7g%253D&md5=65258befff9d36b864136a9f58593d4b</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1007%2Fs00223-011-9499-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-011-9499-8%26sid%3Dliteratum%253Aachs%26aulast%3DRizzoli%26aufirst%3DR.%26aulast%3DReginster%26aufirst%3DJ.%2BY.%26aulast%3DBoonen%26aufirst%3DS.%26aulast%3DBr%25C3%25A9art%26aufirst%3DG.%26aulast%3DDiez-Perez%26aufirst%3DA.%26aulast%3DFelsenberg%26aufirst%3DD.%26aulast%3DKaufman%26aufirst%3DJ.%2BM.%26aulast%3DKanis%26aufirst%3DJ.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26atitle%3DAdverse%2520Reactions%2520and%2520Drug-Drug%2520Interactions%2520in%2520the%2520Management%2520of%2520Women%2520with%2520Postmenopausal%2520Osteoporosis%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2011%26volume%3D89%26spage%3D91%26epage%3D104%26doi%3D10.1007%2Fs00223-011-9499-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref292"><div class="reference"><strong class="refLabel"><a href="#ref292" class="rightTabRefNumLink">292</a></strong><div class="NLM_citation" id="rightTab-cit292"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mödder, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, C. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapeutic Opportunities for Skeletal Restoration</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1038/nrd3299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrd3299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21283108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtleku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=141-156&author=M.+Kawaiauthor=U.+I.+M%C3%B6dderauthor=S.+Khoslaauthor=C.+J.+Rosen&title=Emerging+Therapeutic+Opportunities+for+Skeletal+Restoration&doi=10.1038%2Fnrd3299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic opportunities for skeletal restoration</span></div><div class="casAuthors">Kawai, Masanobu; Modder, Ulrike I.; Khosla, Sundeep; Rosen, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men.  Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective estrogen receptor modulators.  Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without addnl. adverse effects.  The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral d., albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis.  After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiol.  Such novel strategies offer promise not only for reducing age-related bone loss and the assocd. risk of fractures but also for restoring bone mineral d. to healthy levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwYNmm8i-PO7Vg90H21EOLACvtfcHk0liDRSveQmb9SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtleku7s%253D&md5=40d0087e886fa8ecac176eb08909304e</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1038%2Fnrd3299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3299%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26aulast%3DM%25C3%25B6dder%26aufirst%3DU.%2BI.%26aulast%3DKhosla%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DC.%2BJ.%26atitle%3DEmerging%2520Therapeutic%2520Opportunities%2520for%2520Skeletal%2520Restoration%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D141%26epage%3D156%26doi%3D10.1038%2Fnrd3299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref293"><div class="reference"><strong class="refLabel"><a href="#ref293" class="rightTabRefNumLink">293</a></strong><div class="NLM_citation" id="rightTab-cit293"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlaepfer, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieg, D. J.</span></span> <span> </span><span class="NLM_article-title">Signaling through Focal Adhesion Kinase</span>. <i>Prog. Biophys. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.1016/S0079-6107(98)00052-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2FS0079-6107%2898%2900052-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10354709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXislaqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1999&pages=435-478&author=D.+D.+Schlaepferauthor=C.+R.+Hauckauthor=D.+J.+Sieg&title=Signaling+through+Focal+Adhesion+Kinase&doi=10.1016%2FS0079-6107%2898%2900052-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling through focal adhesion kinase</span></div><div class="casAuthors">Schlaepfer, David D.; Hauck, Christof R.; Sieg, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Biophysics & Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">435-478</span>CODEN:
                <span class="NLM_cas:coden">PBIMAC</span>;
        ISSN:<span class="NLM_cas:issn">0079-6107</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 249 refs.  Integrin receptor binding to extracellular matrix proteins generates intracellular signals via enhanced tyrosine phosphorylation events that are important for cell growth, survival, and migration.  This review will focus on the functions of the focal adhesion kinase (FAK) protein-tyrosine kinase (PTK) and its role in linking integrin receptors to intracellular signaling pathways.  FAK assocs. with several different signaling proteins such as Src-family PTKs, p130Cas, Shc, Grb2, PI 3-kinase, and paxillin.  This enables FAK to function within a network of integrin-stimulated signaling pathways leading to the activation of targets such as the ERK and JNK/mitogen-activated protein kinase pathways.  Focus will be placed on the structural domains and sites of FAK tyrosine phosphorylation important for FAK-mediated signaling events and how these sites are conserved in the FAK-related PTK, Pyk2.  We will review what is known about FAK activation by integrin receptor-mediated events and also non-integrin stimuli.  In addn., we discuss the emergence of a consensus FAK substrate phosphorylation sequence.  Emphasis will also be placed on the role of FAK in generating cell survival signals and the cleavage of FAK during caspase-mediated apoptosis.  An in-depth discussion will be presented of integrin-stimulated signaling events occurring in the FAK knockout fibroblasts (FAK-) and how these cells exhibit deficits in cell migration.  FAK re-expression in the FAK- cells confirms the role of this PTK in the regulation of cell morphol. and in promoting cell migration events.  In addn., these results reinforce the potential role for FAK in promoting an invasive phenotype in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHm5Ujo-_W7Vg90H21EOLACvtfcHk0liDRSveQmb9SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislaqtbw%253D&md5=5bff0b02efeb62bdbd95f7592ca8ebfa</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1016%2FS0079-6107%2898%2900052-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6107%252898%252900052-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchlaepfer%26aufirst%3DD.%2BD.%26aulast%3DHauck%26aufirst%3DC.%2BR.%26aulast%3DSieg%26aufirst%3DD.%2BJ.%26atitle%3DSignaling%2520through%2520Focal%2520Adhesion%2520Kinase%26jtitle%3DProg.%2520Biophys.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D71%26spage%3D435%26epage%3D478%26doi%3D10.1016%2FS0079-6107%2898%2900052-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref294"><div class="reference"><strong class="refLabel"><a href="#ref294" class="rightTabRefNumLink">294</a></strong><div class="NLM_citation" id="rightTab-cit294"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hambor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasser, W. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smock, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Proline-Rich Tyrosine Kinase 2 Regulates Osteoprogenitor Cells and Bone Formation, and Offers an Anabolic Treatment Approach for Osteoporosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">10619</span>– <span class="NLM_lpage">10624</span>, <span class="refDoi"> DOI: 10.1073/pnas.0701421104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1073%2Fpnas.0701421104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=17537919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnt1Ohtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=10619-10624&author=L.+Buckbinderauthor=D.+T.+Crawfordauthor=H.+Qiauthor=H.+Z.+Keauthor=L.+M.+Olsonauthor=K.+R.+Longauthor=P.+C.+Bonnetteauthor=A.+P.+Baumannauthor=J.+E.+Hamborauthor=W.+A.+Grasserauthor=L.+C.+Panauthor=T.+A.+Owenauthor=M.+J.+Luzzioauthor=C.+A.+Hulfordauthor=D.+F.+Gebhardauthor=V.+M.+Paralkarauthor=H.+A.+Simmonsauthor=J.+C.+Kathauthor=W.+G.+Robertsauthor=S.+L.+Smockauthor=A.+Guzman-Perezauthor=T.+A.+Brownauthor=M.+Li&title=Proline-Rich+Tyrosine+Kinase+2+Regulates+Osteoprogenitor+Cells+and+Bone+Formation%2C+and+Offers+an+Anabolic+Treatment+Approach+for+Osteoporosis&doi=10.1073%2Fpnas.0701421104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis</span></div><div class="casAuthors">Buckbinder, Leonard; Crawford, David T.; Qi, Hong; Ke, Hua Zhu; Olson, Lisa M.; Long, Kelly R.; Bonnette, Peter C.; Baumann, Amy P.; Hambor, John E.; Grasser, William A., III; Pan, Lydia C.; Owen, Thomas A.; Luzzio, Michael J.; Hulford, Catherine A.; Gebhard, David F.; Paralkar, Vishwas M.; Simmons, Hollis A.; Kath, John C.; Roberts, W. Gregory; Smock, Steven L.; Guzman-Perez, Angel; Brown, Thomas A.; Li, Mei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10619-10624</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bone is accrued and maintained primarily through the coupled actions of bone-forming osteoblasts and bone-resorbing osteoclasts.  Cumulative in vitro studies indicated that proline-rich tyrosine kinase 2 (PYK2) is a pos. mediator of osteoclast function and activity.  However, our investigation of PYK2-/- mice did not reveal evidence supporting an essential function for PYK2 in osteoclasts either in vivo or in culture.  We find that PYK2-/- mice have high bone mass resulting from an unexpected increase in bone formation.  Consistent with the in vivo findings, mouse bone marrow cultures show that PYK2 deficiency enhances differentiation and activity of osteoprogenitor cells, as does expressing a PYK2-specific short hairpin RNA or dominantly interfering proteins in human mesenchymal stem cells.  Furthermore, the daily administration of a small-mol. PYK2 inhibitor increases bone formation and protects against bone loss in ovariectomized rats, an established preclin. model of postmenopausal osteoporosis.  In summary, we find that PYK2 regulates the differentiation of early osteoprogenitor cells across species and that inhibitors of the PYK2 have potential as a bone anabolic approach for the treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpENpFzA2DSTrVg90H21EOLACvtfcHk0liDRSveQmb9SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnt1Ohtro%253D&md5=6327da043a470ce6c932d1f09c23fee8</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0701421104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0701421104%26sid%3Dliteratum%253Aachs%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DOlson%26aufirst%3DL.%2BM.%26aulast%3DLong%26aufirst%3DK.%2BR.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBaumann%26aufirst%3DA.%2BP.%26aulast%3DHambor%26aufirst%3DJ.%2BE.%26aulast%3DGrasser%26aufirst%3DW.%2BA.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DSimmons%26aufirst%3DH.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DSmock%26aufirst%3DS.%2BL.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DProline-Rich%2520Tyrosine%2520Kinase%25202%2520Regulates%2520Osteoprogenitor%2520Cells%2520and%2520Bone%2520Formation%252C%2520and%2520Offers%2520an%2520Anabolic%2520Treatment%2520Approach%2520for%2520Osteoporosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D10619%26epage%3D10624%26doi%3D10.1073%2Fpnas.0701421104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref295"><div class="reference"><strong class="refLabel"><a href="#ref295" class="rightTabRefNumLink">295</a></strong><div class="NLM_citation" id="rightTab-cit295"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lakkakorpi, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodan, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, L. T.</span></span> <span> </span><span class="NLM_article-title">Stable Association of PYK2 and p130Cas in Osteoclasts and Their Co-Localization in the Sealing Zone</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">4900</span>– <span class="NLM_lpage">4907</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.8.4900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1074%2Fjbc.274.8.4900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=9988732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref295/cit295&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=4900-4907&author=P.+T.+Lakkakorpiauthor=I.+Nakamuraauthor=R.+M.+Nagyauthor=J.+T.+Parsonsauthor=G.+A.+Rodanauthor=L.+T.+Duong&title=Stable+Association+of+PYK2+and+p130Cas+in+Osteoclasts+and+Their+Co-Localization+in+the+Sealing+Zone&doi=10.1074%2Fjbc.274.8.4900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit295R"><div class="casContent"><span class="casTitleNuber">295</span><div class="casTitle"><span class="NLM_cas:atitle">Stable association of PYK2 and p130Cas in osteoclasts and their co-localization in the sealing zone</span></div><div class="casAuthors">Lakkakorpi, Paivi T.; Nakamura, Ichiro; Nagy, Rose M.; Parsons, J. Thomas; Rodan, Gideon A.; Duong, Le T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4900-4907</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Bone resorption is initiated by osteoclast attachment to the mineralized matrix, cytoskeletal reorganization, cellular polarization, and the formation of the sealing zone.  The present study examines the interaction between PYK2 and p130Cas (Crk-assocd. substrate), suggested to be part of the signaling pathway initiated by osteoclast adhesion.  Using murine osteoclast-like cells (OCLs) and their mononuclear precursors (pOCs), generated in a co-culture of bone marrow and osteoblastic MB1.8 cells, we show that: (1) p130Cas is tyrosine-phosphorylated upon adhesion of pOCs to vitronectin or ligation of β3 integrins; (2) p130Cas colocalizes with PYK2 and the cytoskeletal proteins F-actin, vinculin, and paxillin in the podosomal-rich ring-like structures of OCLs plated on glass and in the sealing zone in actively resorbing OCLs on bone; (3) p130Cas and PYK2 form a stable complex in pOCs, independent of tyrosine phosphorylation of either mol., and this complex is present in Src (-/-) OCLs, in which neither protein is phosphorylated or assocd. with the osteoclast adhesion structure; (4) the assocn. of p130Cas and PYK2 is mediated by the SH3 domain of p130Cas and the C-terminal domain of PYK2.  These findings suggest that p130Cas and its assocn. with PYK2 may play an important role in the adhesion-dependent signaling that leads to cytoskeletal reorganization and formation of the sealing zone during osteoclast activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOWxlVAIkq9rVg90H21EOLACvtfcHk0li9BwMPnjMtRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSls7o%253D&md5=582b7fb186a1ec2fb9e59c28e1e6333e</span></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.8.4900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.8.4900%26sid%3Dliteratum%253Aachs%26aulast%3DLakkakorpi%26aufirst%3DP.%2BT.%26aulast%3DNakamura%26aufirst%3DI.%26aulast%3DNagy%26aufirst%3DR.%2BM.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26aulast%3DRodan%26aufirst%3DG.%2BA.%26aulast%3DDuong%26aufirst%3DL.%2BT.%26atitle%3DStable%2520Association%2520of%2520PYK2%2520and%2520p130Cas%2520in%2520Osteoclasts%2520and%2520Their%2520Co-Localization%2520in%2520the%2520Sealing%2520Zone%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D4900%26epage%3D4907%26doi%3D10.1074%2Fjbc.274.8.4900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref296"><div class="reference"><strong class="refLabel"><a href="#ref296" class="rightTabRefNumLink">296</a></strong><div class="NLM_citation" id="rightTab-cit296"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlynn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span> <span> </span><span class="NLM_article-title">Sulfoximine-Substituted Trifluoromethylpyrimidine Analogs as Inhibitors of Proline-Rich Tyrosine Kinase 2 (PYK2) Show Reduced hERG Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3253</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.bmcl.2009.04.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19428251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref296/cit296&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3253-3258&author=D.+P.+Walkerauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=J.-C.+Liauthor=D.+W.+Kungauthor=P.+C.+Bonnetteauthor=A.+Baumannauthor=L.+Buckbinderauthor=J.+A.+Houserauthor=J.+Boerauthor=A.+Mistryauthor=S.+Hanauthor=L.+Xing&title=Sulfoximine-Substituted+Trifluoromethylpyrimidine+Analogs+as+Inhibitors+of+Proline-Rich+Tyrosine+Kinase+2+%28PYK2%29+Show+Reduced+hERG+Activity&doi=10.1016%2Fj.bmcl.2009.04.093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit296R"><div class="casContent"><span class="casTitleNuber">296</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity</span></div><div class="casAuthors">Walker, Daniel P.; Zawistoski, Michael P.; McGlynn, Molly A.; Li, Jian-Cheng; Kung, Daniel W.; Bonnette, Peter C.; Baumann, Amy; Buckbinder, Leonard; Houser, Janet A.; Boer, Jason; Mistry, Anil; Han, Seungil; Guzman-Perez, Li Xing and Angel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3253-3258</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described.  These compds. were prepd. as surrogates of the corresponding sulfone compd. I.  Sulfone I was an attractive PYK2 lead compd.; however, subsequent studies detd. this compd. possessed high dofetilide binding, which is an early indicator of cardiovascular safety.  Surprisingly, the corresponding sulfoximine analogs displayed significantly lower dofetilide binding, which, for one example, translated to lower activity in a patch clamp hERG K+ ion channel screen.  In addn., the compd. shows good oral exposure in a rat pharmacokinetic model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5iWLOkqSmarVg90H21EOLACvtfcHk0li9BwMPnjMtRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eksb4%253D&md5=5981d4a1e1dfac8e37acb22585742f6e</span></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.093%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBaumann%26aufirst%3DA.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DHouser%26aufirst%3DJ.%2BA.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DXing%26aufirst%3DL.%26atitle%3DSulfoximine-Substituted%2520Trifluoromethylpyrimidine%2520Analogs%2520as%2520Inhibitors%2520of%2520Proline-Rich%2520Tyrosine%2520Kinase%25202%2520%2528PYK2%2529%2520Show%2520Reduced%2520hERG%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3253%26epage%3D3258%26doi%3D10.1016%2Fj.bmcl.2009.04.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref297"><div class="reference"><strong class="refLabel"><a href="#ref297" class="rightTabRefNumLink">297</a></strong><div class="NLM_citation" id="rightTab-cit297"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, N.</span></span> <span> </span><span class="NLM_article-title">Triggers, Targets and Treatments for Thrombosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>451</i></span>,  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">918</span>, <span class="refDoi"> DOI: 10.1038/nature06797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature06797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=18288180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1ynsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=451&publication_year=2008&pages=914-918&author=N.+Mackman&title=Triggers%2C+Targets+and+Treatments+for+Thrombosis&doi=10.1038%2Fnature06797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit297R"><div class="casContent"><span class="casTitleNuber">297</span><div class="casTitle"><span class="NLM_cas:atitle">Triggers, targets and treatments for thrombosis</span></div><div class="casAuthors">Mackman, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">451</span>
        (<span class="NLM_cas:issue">7181</span>),
    <span class="NLM_cas:pages">914-918</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thrombosis - localized clotting of the blood - can occur in the arterial or the venous circulation and has a major medical impact.  Acute arterial thrombosis is the proximal cause of most cases of myocardial infarction (heart attack) and of about 80% of strokes, collectively the most common cause of death in the developed world.  Venous thromboembolism is the third leading cause of cardiovascular-assocd. death.  The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood.  Understanding these processes is crucial for developing safer and more effective antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxKva6uiDjA7Vg90H21EOLACvtfcHk0li9BwMPnjMtRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1ynsb8%253D&md5=dad98f180f1d7416433bb6d993178ec5</span></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=10.1038%2Fnature06797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06797%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DN.%26atitle%3DTriggers%252C%2520Targets%2520and%2520Treatments%2520for%2520Thrombosis%26jtitle%3DNature%26date%3D2008%26volume%3D451%26spage%3D914%26epage%3D918%26doi%3D10.1038%2Fnature06797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref298"><div class="reference"><strong class="refLabel"><a href="#ref298" class="rightTabRefNumLink">298</a></strong><div class="NLM_citation" id="rightTab-cit298"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makaryus, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halperin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. F.</span></span> <span> </span><span class="NLM_article-title">Oral Anticoagulants in the Management of Venous Thromboembolism</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2013.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrcardio.2013.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23689703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref298/cit298&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSiu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=397-409&author=J.+N.+Makaryusauthor=J.+L.+Halperinauthor=J.+F.+Lau&title=Oral+Anticoagulants+in+the+Management+of+Venous+Thromboembolism&doi=10.1038%2Fnrcardio.2013.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit298R"><div class="casContent"><span class="casTitleNuber">298</span><div class="casTitle"><span class="NLM_cas:atitle">Oral anticoagulants in the management of venous thromboembolism</span></div><div class="casAuthors">Makaryus, John N.; Halperin, Jonathan L.; Lau, Joe F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite advances in diagnosis, prevention, and management, venous thromboembolism (VTE) remains a common cause of morbidity and mortality.  For decades, antithrombotic therapy for prevention and treatment of VTE was limited to parenteral agents related to heparin and oral vitamin K antagonists (VKAs).  Both classes of anticoagulants are effective, but have limitations, including considerable variability in dose-response, narrow therapeutic margins between the risks of thrombosis and bleeding, and the need to monitor anticoagulation intensity.  Over the past decade, the introduction of new oral anticoagulants that specifically inhibit coagulation factors IIa (thrombin) or Xa has changed practice in a variety of clin. situations, including VTE prophylaxis and treatment.  In this Review, we outline the use of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the prevention and treatment of VTE, and discuss practical considerations for choosing the appropriate drug for each patient.  Although the introduction of novel anticoagulant drugs is promising, selecting the optimum strategy for an individual patient requires an understanding of the specific circumstances assocd. with thrombus formation and the pharmacol. properties of each agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ3bQp-WZ4zrVg90H21EOLACvtfcHk0lhA0NPU_40AzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSiu7fO&md5=86593dfa9e696e7716cabab22632ebf5</span></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2013.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2013.73%26sid%3Dliteratum%253Aachs%26aulast%3DMakaryus%26aufirst%3DJ.%2BN.%26aulast%3DHalperin%26aufirst%3DJ.%2BL.%26aulast%3DLau%26aufirst%3DJ.%2BF.%26atitle%3DOral%2520Anticoagulants%2520in%2520the%2520Management%2520of%2520Venous%2520Thromboembolism%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2013%26volume%3D10%26spage%3D397%26epage%3D409%26doi%3D10.1038%2Fnrcardio.2013.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref299"><div class="reference"><strong class="refLabel"><a href="#ref299" class="rightTabRefNumLink">299</a></strong><div class="NLM_citation" id="rightTab-cit299"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span> <span> </span><span class="NLM_article-title">Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2012.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrcardio.2012.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=22371104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=385-391&author=K.+P.+Cabralauthor=J.+Ansell&title=Oral+Direct+Factor+Xa+Inhibitors+for+Stroke+Prevention+in+Atrial+Fibrillation&doi=10.1038%2Fnrcardio.2012.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit299R"><div class="casContent"><span class="casTitleNuber">299</span><div class="casTitle"><span class="NLM_cas:atitle">Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation</span></div><div class="casAuthors">Cabral, Katherine P.; Ansell, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-391</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Oral direct factor Xa inhibitors, particularly apixaban and rivaroxaban, are novel and promising alternatives to warfarin for stroke prevention in patients with atrial fibrillation.  Drs Cabral and Ansell review the data from clin. trials of these drugs, and also discuss the challenges of reversing their anticoagulant effects, interactions with other medications, patient compliance, and therapeutic monitoring.  Safe and effective stroke prevention in atrial fibrillation (AF) is crucial as the no. of patients with this condition continues to increase.  Several novel oral anticoagulants are being developed as replacements for warfarin for this indication.  Direct factor Xa inhibitors comprise the largest class of oral anticoagulants in development; the inhibition of factor Xa is recognized to be a promising target for therapeutic anticoagulation, partly because of its location in the coagulation cascade.  Apixaban, betrixaban, edoxaban, and rivaroxaban are small-mol., selective inhibitors that directly and reversibly bind to the active site of factor Xa.  Their pharmacokinetic and pharmacodynamic profiles vary, which might allow patient-specific therapy.  Several of these agents have been tested in clin. trials for various indications, including AF, with favorable results.  In particular, apixaban and rivaroxaban have shown superiority and noninferiority, resp., to warfarin in phase III clin. trials for stroke prevention in AF.  These agents have also been shown to be safe in terms of bleeding risk.  Despite these advantages, factor Xa inhibitors have several characteristics, such as potential interactions with other drugs (inhibitors of cytochrome P 450 and P-glycoprotein) and the inability to reverse their anticoagulant effects, as well as concerns about poor patient compliance, which must be considered when initiating patients on a novel factor Xa inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmYeFmP0LN47Vg90H21EOLACvtfcHk0lhA0NPU_40AzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGmsbs%253D&md5=9b438e79ebc3d2f4a3a7f79117b61a1f</span></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2012.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2012.19%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DK.%2BP.%26aulast%3DAnsell%26aufirst%3DJ.%26atitle%3DOral%2520Direct%2520Factor%2520Xa%2520Inhibitors%2520for%2520Stroke%2520Prevention%2520in%2520Atrial%2520Fibrillation%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2012%26volume%3D9%26spage%3D385%26epage%3D391%26doi%3D10.1038%2Fnrcardio.2012.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref300"><div class="reference"><strong class="refLabel"><a href="#ref300" class="rightTabRefNumLink">300</a></strong><div class="NLM_citation" id="rightTab-cit300"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J. W.</span></span> <span> </span><span class="NLM_article-title">Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-062209-095159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1146%2Fannurev-med-062209-095159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21226611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVWht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=41-57&author=B.+I.+Erikssonauthor=D.+J.+Quinlanauthor=J.+W.+Eikelboom&title=Novel+Oral+Factor+Xa+and+Thrombin+Inhibitors+in+the+Management+of+Thromboembolism&doi=10.1146%2Fannurev-med-062209-095159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit300R"><div class="casContent"><span class="casTitleNuber">300</span><div class="casTitle"><span class="NLM_cas:atitle">Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism</span></div><div class="casAuthors">Eriksson, Bengt I.; Quinlan, Daniel J.; Eikelboom, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41-57</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The last decade has seen the evaluation of several new oral anticoagulants that directly target thrombin or activated factor X (FXa).  All demonstrate a rapid onset of action, a low potential for food and drug interactions, and a predictable anticoagulant effect that obviates the need for routine coagulation monitoring.  Those agents at the most advanced stages of clin. development are a direct thrombin inhibitor, dabigatran, and direct FXa inhibitors, rivaroxaban and apixaban.  Dabigatran and rivaroxaban are approved in more than 70 countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty, and apixaban is being considered for approval by regulatory agencies for this indication.  Dabigatran was shown in a large phase III trial to be more effective and safer than warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and has recently been approved for this indication.  Edoxaban, an oral FXa inhibitor, is also being evaluated in phase III clin. trials.  This review summarizes the pharmacol., clin. trial results, and future role of the new oral anticoagulants in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdVM7dFkKODrVg90H21EOLACvtfcHk0lhA0NPU_40AzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVWht78%253D&md5=95143da0d76c5c7607cba9931e3011ef</span></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-062209-095159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-062209-095159%26sid%3Dliteratum%253Aachs%26aulast%3DEriksson%26aufirst%3DB.%2BI.%26aulast%3DQuinlan%26aufirst%3DD.%2BJ.%26aulast%3DEikelboom%26aufirst%3DJ.%2BW.%26atitle%3DNovel%2520Oral%2520Factor%2520Xa%2520and%2520Thrombin%2520Inhibitors%2520in%2520the%2520Management%2520of%2520Thromboembolism%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2011%26volume%3D62%26spage%3D41%26epage%3D57%26doi%3D10.1146%2Fannurev-med-062209-095159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref301"><div class="reference"><strong class="refLabel"><a href="#ref301" class="rightTabRefNumLink">301</a></strong><div class="NLM_citation" id="rightTab-cit301"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaugule, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarag, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sairam, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship of Potent, Selective and Orally Active Anthranilamide-Based Factor Xa Inhibitors: Application of Weakly Basic Sulfoximine Group as Novel S4 Binding Element</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.ejmech.2012.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=23124211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref301/cit301&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOrsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=136-152&author=V.+Pandyaauthor=M.+Jainauthor=G.+Chakrabartiauthor=H.+Soniauthor=B.+Parmarauthor=B.+Chauguleauthor=J.+Patelauthor=T.+Jaragauthor=J.+Joshiauthor=N.+Joshiauthor=A.+Rathauthor=V.+Unadkatauthor=B.+Sharmaauthor=H.+Ajaniauthor=J.+Kumarauthor=K.+V.+Sairamauthor=H.+Patelauthor=P.+Patel&title=Synthesis+and+Structure-Activity+Relationship+of+Potent%2C+Selective+and+Orally+Active+Anthranilamide-Based+Factor+Xa+Inhibitors%3A+Application+of+Weakly+Basic+Sulfoximine+Group+as+Novel+S4+Binding+Element&doi=10.1016%2Fj.ejmech.2012.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit301R"><div class="casContent"><span class="casTitleNuber">301</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element</span></div><div class="casAuthors">Pandya, Vrajesh; Jain, Mukul; Chakrabarti, Ganes; Soni, Hitesh; Parmar, Bhavesh; Chaugule, Balaji; Patel, Jigar; Jarag, Tushar; Joshi, Jignesh; Joshi, Nirav; Rath, Akshyaya; Unadkat, Vishal; Sharma, Bhavesh; Ajani, Haresh; Kumar, Jeevan; Sairam, Kalapatapu V. V. M.; Patel, Harilal; Patel, Pankaj</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">136-152</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of potent and efficacious factor Xa inhibitors contg. a sulfoximine moiety as a novel S4 binding element in an anthranilamide chemotype has been identified.  Lead optimization at this novel P4 group led to many potent factor Xa inhibitors with excellent anticoagulant activity in human plasma.  Selected compds. were dosed orally in rats and checked for their ex vivo prothrombin time prolonging activity, which resulted in identification of compd. 5-chloro-N-(5-chloropyridin-2-yl)-2-(4-(N-(2-(diethylamino)acetyl)-S-methylsulfonimidoyl)benzamido)benzamide (I).  The detailed pharmacokinetic evaluation and subsequent metab. study of I suggested the presence of an active metabolite.  The compd. I and its active metabolite II demonstrated excellent in vivo efficacy in both arterial and venous thrombosis model in rats and were found to be highly selective against related serine proteases.  Based on this promising profile, compd. I was selected for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquQcyT3ufGirVg90H21EOLACvtfcHk0lhA0NPU_40AzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOrsrrI&md5=cdc06710c5029dc63ba9ce427d367ea4</span></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DPandya%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DChakrabarti%26aufirst%3DG.%26aulast%3DSoni%26aufirst%3DH.%26aulast%3DParmar%26aufirst%3DB.%26aulast%3DChaugule%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DJarag%26aufirst%3DT.%26aulast%3DJoshi%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DN.%26aulast%3DRath%26aufirst%3DA.%26aulast%3DUnadkat%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DAjani%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DJ.%26aulast%3DSairam%26aufirst%3DK.%2BV.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPatel%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Anthranilamide-Based%2520Factor%2520Xa%2520Inhibitors%253A%2520Application%2520of%2520Weakly%2520Basic%2520Sulfoximine%2520Group%2520as%2520Novel%2520S4%2520Binding%2520Element%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D136%26epage%3D152%26doi%3D10.1016%2Fj.ejmech.2012.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref302"><div class="reference"><strong class="refLabel"><a href="#ref302" class="rightTabRefNumLink">302</a></strong><div class="NLM_citation" id="rightTab-cit302"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.cell.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31564456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref302/cit302&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=312-339&author=J.+M.+Longauthor=D.+M.+Holtzman&title=Alzheimer+Disease%3A+An+Update+on+Pathobiology+and+Treatment+Strategies&doi=10.1016%2Fj.cell.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit302R"><div class="casContent"><span class="casTitleNuber">302</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</span></div><div class="casAuthors">Long, Justin M.; Holtzman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">312-339</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiol.  The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathol. criteria for AD diagnosis.  However, a no. of recent fundamental discoveries highlight important pathol. roles for other crit. cellular and mol. processes.  Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clin. trials have failed to demonstrate benefits.  Here, we review recent advances in our understanding of AD pathobiol. and discuss current treatment strategies, highlighting recent clin. trials and opportunities for developing future disease-modifying therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIdXAv0NNRFbVg90H21EOLACvtfcHk0li4_Wt9fE8-5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsbrN&md5=b68edceb2c7ebe4515efded93c9281c3</span></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26atitle%3DAlzheimer%2520Disease%253A%2520An%2520Update%2520on%2520Pathobiology%2520and%2520Treatment%2520Strategies%26jtitle%3DCell%26date%3D2019%26volume%3D179%26spage%3D312%26epage%3D339%26doi%3D10.1016%2Fj.cell.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref303"><div class="reference"><strong class="refLabel"><a href="#ref303" class="rightTabRefNumLink">303</a></strong><div class="NLM_citation" id="rightTab-cit303"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blennow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlawish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masliah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, N.</span></span> <span> </span><span class="NLM_article-title">NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2018.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1016%2Fj.jalz.2018.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=29653606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref303/cit303&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A280%3ADC%252BC1MjisFaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=535-562&author=C.+R.+Jackauthor=D.+A.+Bennettauthor=K.+Blennowauthor=M.+C.+Carrilloauthor=B.+Dunnauthor=S.+B.+Haeberleinauthor=D.+M.+Holtzmanauthor=W.+Jagustauthor=F.+Jessenauthor=J.+Karlawishauthor=E.+Liuauthor=J.+L.+Molinuevoauthor=T.+Montineauthor=C.+Phelpsauthor=K.+P.+Rankinauthor=C.+C.+Roweauthor=P.+Scheltensauthor=E.+Siemersauthor=H.+M.+Snyderauthor=R.+Sperlingauthor=C.+Elliottauthor=E.+Masliahauthor=L.+Ryanauthor=N.+Silverberg&title=NIA-AA+Research+Framework%3A+Toward+a+Biological+Definition+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.jalz.2018.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit303R"><div class="casContent"><span class="casTitleNuber">303</span><div class="casTitle"><span class="NLM_cas:atitle">NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</span></div><div class="casAuthors">Jack Clifford R Jr; Bennett David A; Blennow Kaj; Carrillo Maria C; Snyder Heather M; Dunn Billy; Haeberlein Samantha Budd; Holtzman David M; Jagust William; Jessen Frank; Karlawish Jason; Liu Enchi; Molinuevo Jose Luis; Montine Thomas; Phelps Creighton; Rankin Katherine P; Rowe Christopher C; Scheltens Philip; Siemers Eric; Sperling Reisa</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-562</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease.  Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines.  This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care.  In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers.  The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct.  The research framework focuses on the diagnosis of AD with biomarkers in living persons.  Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)].  This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures.  The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available.  We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures.  However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme.  It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms.  We appreciate the concern that this biomarker-based research framework has the potential to be misused.  Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice.  Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers.  There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document).  Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study.  Importantly, this framework should be examined in diverse populations.  Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia.  We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia.  This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1xBNMNLsPJUH3Rlp_k91zfW6udTcc2eYpVkqFCTWfNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjisFaltA%253D%253D&md5=f19a7f80d1357920644fa33bd7493fc0</span></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2018.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2018.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BA.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DDunn%26aufirst%3DB.%26aulast%3DHaeberlein%26aufirst%3DS.%2BB.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DJagust%26aufirst%3DW.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DKarlawish%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DMontine%26aufirst%3DT.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DRankin%26aufirst%3DK.%2BP.%26aulast%3DRowe%26aufirst%3DC.%2BC.%26aulast%3DScheltens%26aufirst%3DP.%26aulast%3DSiemers%26aufirst%3DE.%26aulast%3DSnyder%26aufirst%3DH.%2BM.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DC.%26aulast%3DMasliah%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DL.%26aulast%3DSilverberg%26aufirst%3DN.%26atitle%3DNIA-AA%2520Research%2520Framework%253A%2520Toward%2520a%2520Biological%2520Definition%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2018%26volume%3D14%26spage%3D535%26epage%3D562%26doi%3D10.1016%2Fj.jalz.2018.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref304"><div class="reference"><strong class="refLabel"><a href="#ref304" class="rightTabRefNumLink">304</a></strong><div class="NLM_citation" id="rightTab-cit304"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duyckaerts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delatour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potier, M. C.</span></span> <span> </span><span class="NLM_article-title">Classification and Basic Pathology of Alzheimer Disease</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1007/s00401-009-0532-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1007%2Fs00401-009-0532-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=19381658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1ahu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2009&pages=5-36&author=C.+Duyckaertsauthor=B.+Delatourauthor=M.+C.+Potier&title=Classification+and+Basic+Pathology+of+Alzheimer+Disease&doi=10.1007%2Fs00401-009-0532-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">Classification and basic pathology of Alzheimer disease</span></div><div class="casAuthors">Duyckaerts, Charles; Delatour, Benoit; Potier, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-36</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The lesions of Alzheimer disease include accumulation of proteins, losses of neurons and synapses, and alterations related to reactive processes.  Extracellular Aβ accumulation occurs in the parenchyma as diffuse, focal or stellate deposits.  It may involve the vessel walls of arteries, veins and capillaries.  The cases in which the capillary vessel walls are affected have a higher probability of having one or two apoε 4 alleles.  Parenchymal as well as vascular Aβ deposition follows a stepwise progression.  Tau accumulation, probably the best histopathol. correlate of the clin. symptoms, takes three aspects: in the cell body of the neuron as neurofibrillary tangle, in the dendrites as neuropil threads, and in the axons forming the senile plaque neuritic corona.  The progression of tau pathol. is stepwise and stereotyped from the entorhinal cortex, through the hippocampus, to the isocortex.  The neuronal loss is heterogeneous and area-specific.  Its mechanism is still discussed.  The timing of the synaptic loss, probably linked to Aβ peptide itself, maybe as oligomers, is also controversial.  Various clinico-pathol. types of Alzheimer disease have been described, according to the type of the lesions (plaque only and tangle predominant), the type of onset (focal onset), the cause (genetic or sporadic) and the assocd. lesions (Lewy bodies, vascular lesions, hippocampal sclerosis, TDP-43 inclusions and argyrophilic grain disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV9FKh5BL9WLVg90H21EOLACvtfcHk0lhUtDTLk_NpUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1ahu70%253D&md5=df9d40a78355a4ef31e76fcf91a5bfdc</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.1007%2Fs00401-009-0532-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-009-0532-1%26sid%3Dliteratum%253Aachs%26aulast%3DDuyckaerts%26aufirst%3DC.%26aulast%3DDelatour%26aufirst%3DB.%26aulast%3DPotier%26aufirst%3DM.%2BC.%26atitle%3DClassification%2520and%2520Basic%2520Pathology%2520of%2520Alzheimer%2520Disease%26jtitle%3DActa%2520Neuropathol.%26date%3D2009%26volume%3D118%26spage%3D5%26epage%3D36%26doi%3D10.1007%2Fs00401-009-0532-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref305"><div class="reference"><strong class="refLabel"><a href="#ref305" class="rightTabRefNumLink">305</a></strong><div class="NLM_citation" id="rightTab-cit305"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span> <span> </span><span class="NLM_article-title">BACE1 (β-secretase) Inhibitors for the Treatment of Alzheimer’s disease</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">6765</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1039/C3CS60460H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1039%2FC3CS60460H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=24691405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=6765-6813&author=A.+K.+Ghoshauthor=H.+L.+Osswald&title=BACE1+%28%CE%B2-secretase%29+Inhibitors+for+the+Treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC3CS60460H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit305R"><div class="casContent"><span class="casTitleNuber">305</span><div class="casTitle"><span class="NLM_cas:atitle">BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6765-6813</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease.  BACE1 is an aspartic protease which functions in the first step of the pathway leading to the prodn. and deposition of amyloid-β peptide (Aβ).  Its gene deletion showed only mild phenotypes.  BACE1 inhibition has direct implications in the Alzheimer's disease pathol. without largely affecting viability.  However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists.  Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed.  These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.  Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics.  In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compds. that have been shown to reduce brain Aβ, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri59_pgGAbxLVg90H21EOLACvtfcHk0lhUtDTLk_NpUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2mt7nJ&md5=dab445bf7efb6fdc0c80e032d3bb0071</span></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=10.1039%2FC3CS60460H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC3CS60460H%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26atitle%3DBACE1%2520%2528%25CE%25B2-secretase%2529%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2014%26volume%3D43%26spage%3D6765%26epage%3D6813%26doi%3D10.1039%2FC3CS60460H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref306"><div class="reference"><strong class="refLabel"><a href="#ref306" class="rightTabRefNumLink">306</a></strong><div class="NLM_citation" id="rightTab-cit306"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Peters, J. U.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Schnider, C.</span>; <span class="NLM_string-name">Wermuth, R.</span>; <span class="NLM_string-name">Woltering, T.</span></span> <span> </span><span class="NLM_article-title">5-Aryl-1-Imino-1-Oxo-[1,2,4]Thiadiazines</span>. <span class="NLM_patent">WO/2015/091595</span>, Jun 25, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+Guba&author=W.+Haap&author=A.+Kuglstatter&author=J.+U.+Peters&author=U.+Obst+Sander&author=C.+Schnider&author=R.+Wermuth&author=T.+Woltering&title=5-Aryl-1-Imino-1-Oxo-%5B1%2C2%2C4%5DThiadiazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit306&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuba%26aufirst%3DW.%26atitle%3D5-Aryl-1-Imino-1-Oxo-%255B1%252C2%252C4%255DThiadiazines%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref307"><div class="reference"><strong class="refLabel"><a href="#ref307" class="rightTabRefNumLink">307</a></strong><div class="NLM_citation" id="rightTab-cit307"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartels, B.</span>; <span class="NLM_string-name">Dolente, C.</span>; <span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Kuglstatter, A.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Peters, J. U.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span>; <span class="NLM_string-name">Woltering, T.</span>; <span class="NLM_string-name">Schnider, C.</span>; <span class="NLM_string-name">Wermuth, R.</span></span> <span> </span><span class="NLM_article-title">Pyridyl-Triazabicycles</span>. <span class="NLM_patent">WO/2016/012422</span>, Jan 28, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=B.+Bartels&author=C.+Dolente&author=W.+Guba&author=W.+Haap&author=A.+Kuglstatter&author=U.+Obst+Sander&author=J.+U.+Peters&author=M.+Rogers-Evans&author=T.+Woltering&author=C.+Schnider&author=R.+Wermuth&title=Pyridyl-Triazabicycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit307&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DB.%26atitle%3DPyridyl-Triazabicycles%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref308"><div class="reference"><strong class="refLabel"><a href="#ref308" class="rightTabRefNumLink">308</a></strong><div class="NLM_citation" id="rightTab-cit308"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anselm, L.</span>; <span class="NLM_string-name">Bartels, B.</span>; <span class="NLM_string-name">Dolente, C.</span>; <span class="NLM_string-name">Guba, W.</span>; <span class="NLM_string-name">Haap, W.</span>; <span class="NLM_string-name">Peters, J.-U.</span>; <span class="NLM_string-name">Woltering, T.</span>; <span class="NLM_string-name">Obst Sander, U.</span>; <span class="NLM_string-name">Rogers-Evans, M.</span></span> <span> </span><span class="NLM_article-title">2,2,2-Trifluoroethyl-Thiadiazines</span>. <span class="NLM_patent">WO/2016/023927</span>, Feb 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Anselm&author=B.+Bartels&author=C.+Dolente&author=W.+Guba&author=W.+Haap&author=J.-U.+Peters&author=T.+Woltering&author=U.+Obst+Sander&author=M.+Rogers-Evans&title=2%2C2%2C2-Trifluoroethyl-Thiadiazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit308&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnselm%26aufirst%3DL.%26atitle%3D2%252C2%252C2-Trifluoroethyl-Thiadiazines%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref309"><div class="reference"><strong class="refLabel"><a href="#ref309" class="rightTabRefNumLink">309</a></strong><div class="NLM_citation" id="rightTab-cit309"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solfrizzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sardone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccininni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stallone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seripa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logroscino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">BACE Inhibitors in Clinical Development for the Treatment of Alzheimer’s Disease</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">857</span>, <span class="refDoi"> DOI: 10.1080/14737175.2018.1531706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1080%2F14737175.2018.1531706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30277096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref309/cit309&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSjtbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=847-857&author=F.+Panzaauthor=M.+Lozuponeauthor=V.+Solfrizziauthor=R.+Sardoneauthor=C.+Piccininniauthor=V.+Dibelloauthor=R.+Stalloneauthor=G.+Giannelliauthor=A.+Bellomoauthor=A.+Grecoauthor=A.+Danieleauthor=D.+Seripaauthor=G.+Logroscinoauthor=B.+P.+Imbimbo&title=BACE+Inhibitors+in+Clinical+Development+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1080%2F14737175.2018.1531706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit309R"><div class="casContent"><span class="casTitleNuber">309</span><div class="casTitle"><span class="NLM_cas:atitle">BACE inhibitors in clinical development for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Panza, Francesco; Lozupone, Madia; Solfrizzi, Vincenzo; Sardone, Rodolfo; Piccininni, Carla; Dibello, Vittorio; Stallone, Roberta; Giannelli, Gianluigi; Bellomo, Antonello; Greco, Antonio; Daniele, Antonio; Seripa, Davide; Logroscino, Giancarlo; Imbimbo, Bruno P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">847-857</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Introduction: The amyloid hypothesis of Alzheimer's disease (AD) affirms that brain accumulation of amyloid-β (Aβ) oligomers and sol. aggregates represent the major pathol. event of the disease.  Several anti-Aβ small org. mols., monoclonal antibodies and antigens were developed to interfere with Aβ prodn. and clearance, including β-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, blocking the first enzymic step of Aβ formation.  All these approaches, including BACE inhibitors, have failed in large randomized clin. trials (RCTs) in mild-to-moderate AD, but further studies are now being carried out in patients at early AD stages and in asymptomatic subjects at risk of developing AD.  Areas covered: The paper provides a comprehensive review of BACE inhibitors for AD treatment, focusing on the most advanced compds. in Phase III RCTs.  Expert commentary: BACE inhibitors inhibited robustly, and dose-dependently, Aβ formation in cerebrospinal fluid of AD patients, but without cognitive, clin., or functional benefit in large RCTs.  BACE inhibition may be not sufficient to decrease brain Aβ plaques and aggregates.  Indeed, several BACE inhibitors were found to be poorly tolerated and some of them failed also in patients with prodromal AD.  This may indicate that blocking the formation of nascent Aβ is not useful in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquBOgMVQQBdbVg90H21EOLACvtfcHk0lhUtDTLk_NpUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSjtbbF&md5=fcbe8aa1c2a43ce6e0bace2759ddfe49</span></div><a href="/servlet/linkout?suffix=cit309&amp;dbid=16384&amp;doi=10.1080%2F14737175.2018.1531706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2018.1531706%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DSolfrizzi%26aufirst%3DV.%26aulast%3DSardone%26aufirst%3DR.%26aulast%3DPiccininni%26aufirst%3DC.%26aulast%3DDibello%26aufirst%3DV.%26aulast%3DStallone%26aufirst%3DR.%26aulast%3DGiannelli%26aufirst%3DG.%26aulast%3DBellomo%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DDaniele%26aufirst%3DA.%26aulast%3DSeripa%26aufirst%3DD.%26aulast%3DLogroscino%26aufirst%3DG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DBACE%2520Inhibitors%2520in%2520Clinical%2520Development%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2018%26volume%3D18%26spage%3D847%26epage%3D857%26doi%3D10.1080%2F14737175.2018.1531706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref310"><div class="reference"><strong class="refLabel"><a href="#ref310" class="rightTabRefNumLink">310</a></strong><div class="NLM_citation" id="rightTab-cit310"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span> <span> </span><span class="NLM_article-title">The Growing Landscape of Lysine Acetylation Links Metabolism and Cell Signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrm3841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnrm3841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=25053359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref310/cit310&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ktbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=536-550&author=C.+Choudharyauthor=B.+T.+Weinertauthor=Y.+Nishidaauthor=E.+Verdinauthor=M.+Mann&title=The+Growing+Landscape+of+Lysine+Acetylation+Links+Metabolism+and+Cell+Signalling&doi=10.1038%2Fnrm3841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit310R"><div class="casContent"><span class="casTitleNuber">310</span><div class="casTitle"><span class="NLM_cas:atitle">The growing landscape of lysine acetylation links metabolism and cell signaling</span></div><div class="casAuthors">Choudhary, Chunaram; Weinert, Brian T.; Nishida, Yuya; Verdin, Eric; Mann, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">536-550</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lys residue acetylation is a conserved protein post-translational modification that links acetyl-CoA metab. and cellular signaling.  Recent advances in the identification and quantification of Lys residue acetylation by mass spectrometry have increased the understanding of Lys acetylation, implicating it in many biol. processes through the regulation of protein interactions, activity, and localization.  In addn., proteins are frequently modified by other types of acylations, such as formylation, butyrylation, propionylation, succinylation, malonylation, myristoylation, glutarylation, and crotonylation.  The intricate link between Lys acylation and cellular metab. has been clarified by the occurrence of several such metabolite-sensitive acylations and their selective removal by sirtuin deacylases.  These emerging findings point to new functions for different Lys acylations and deacylating enzymes and also highlight the mechanisms by which acetylation regulates various cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFJb5kUjj7arVg90H21EOLACvtfcHk0lg3VgpfzJm5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ktbrN&md5=89703cd65c2cebe4a1474cf40f6d0be7</span></div><a href="/servlet/linkout?suffix=cit310&amp;dbid=16384&amp;doi=10.1038%2Fnrm3841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3841%26sid%3Dliteratum%253Aachs%26aulast%3DChoudhary%26aufirst%3DC.%26aulast%3DWeinert%26aufirst%3DB.%2BT.%26aulast%3DNishida%26aufirst%3DY.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DMann%26aufirst%3DM.%26atitle%3DThe%2520Growing%2520Landscape%2520of%2520Lysine%2520Acetylation%2520Links%2520Metabolism%2520and%2520Cell%2520Signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D536%26epage%3D550%26doi%3D10.1038%2Fnrm3841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref311"><div class="reference"><strong class="refLabel"><a href="#ref311" class="rightTabRefNumLink">311</a></strong><div class="NLM_citation" id="rightTab-cit311"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Bromodomains: A New Target Class for drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0030-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fs41573-019-0030-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=31273347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref311/cit311&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=609-628&author=A.+G.+Cochranauthor=A.+R.+Coneryauthor=R.+J.+Sims&title=Bromodomains%3A+A+New+Target+Class+for+drug+Development&doi=10.1038%2Fs41573-019-0030-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit311R"><div class="casContent"><span class="casTitleNuber">311</span><div class="casTitle"><span class="NLM_cas:atitle">Bromodomains: a new target class for drug development</span></div><div class="casAuthors">Cochran, Andrea G.; Conery, Andrew R.; Sims, III, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-mol. targets.  This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chem. probe discovery to understand the biol. potential of new agents that targeted bromodomains.  The original examples, inhibitors of the bromodomain and extra-terminal (BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compds. have since advanced to human clin. trials.  Here, we review the current state of BET inhibitor biol. in relation to clin. development, and we discuss the next wave of bromodomain inhibitors with clin. potential in oncol. and non-oncol. indications.  The lessons learned from BET inhibitor programs should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6QwxqowW9NbVg90H21EOLACvtfcHk0lg3VgpfzJm5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL&md5=88e56eec8edeb7c325d28156ec131ed8</span></div><a href="/servlet/linkout?suffix=cit311&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomains%253A%2520A%2520New%2520Target%2520Class%2520for%2520drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D609%26epage%3D628%26doi%3D10.1038%2Fs41573-019-0030-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref312"><div class="reference"><strong class="refLabel"><a href="#ref312" class="rightTabRefNumLink">312</a></strong><div class="NLM_citation" id="rightTab-cit312"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felletar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of BET Bromodomains</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1038/nature09504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature09504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=20871596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref312/cit312&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1067-1073&author=P.+Filippakopoulosauthor=J.+Qiauthor=S.+Picaudauthor=Y.+Shenauthor=W.+B.+Smithauthor=O.+Fedorovauthor=E.+M.+Morseauthor=T.+Keatesauthor=T.+T.+Hickmanauthor=I.+Felletarauthor=M.+Philpottauthor=S.+Munroauthor=M.+R.+McKeownauthor=Y.+Wangauthor=A.+L.+Christieauthor=N.+Westauthor=M.+J.+Cameronauthor=B.+Schwartzauthor=T.+D.+Heightmanauthor=N.+La+Thangueauthor=C.+A.+Frenchauthor=O.+Wiestauthor=A.+L.+Kungauthor=S.+Knappauthor=J.+E.+Bradner&title=Selective+Inhibition+of+BET+Bromodomains&doi=10.1038%2Fnature09504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit312R"><div class="casContent"><span class="casTitleNuber">312</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of BET bromodomains</span></div><div class="casAuthors">Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; Philpott, Martin; Munro, Shongah; McKeown, Michael R.; Wang, Yuchuan; Christie, Amanda L.; West, Nathan; Cameron, Michael J.; Schwartz, Brian; Heightman, Tom D.; La Thangue, Nicholas; French, Christopher; Wiest, Olaf; Kung, Andrew L.; Knapp, Stefan; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1067-1073</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epigenetic proteins are intently pursued targets in ligand discovery.  So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'.  Potent inhibitors of histone binding modules have not yet been described.  Here the authors report a cell-permeable small mol. (I,JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains.  High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity.  Recurrent translocation of BRD4 is obsd. in a genetically-defined, incurable subtype of human squamous carcinoma.  Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models.  These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chem. scaffold for the development of chem. probes more broadly throughout the bromodomain family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZbtmZM8m_LVg90H21EOLACvtfcHk0lg3VgpfzJm5ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlGmtA%253D%253D&md5=bd9cadac86124d2c6c3cd5b2a92d68c2</span></div><a href="/servlet/linkout?suffix=cit312&amp;dbid=16384&amp;doi=10.1038%2Fnature09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09504%26sid%3Dliteratum%253Aachs%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DPicaud%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DMorse%26aufirst%3DE.%2BM.%26aulast%3DKeates%26aufirst%3DT.%26aulast%3DHickman%26aufirst%3DT.%2BT.%26aulast%3DFelletar%26aufirst%3DI.%26aulast%3DPhilpott%26aufirst%3DM.%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DMcKeown%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChristie%26aufirst%3DA.%2BL.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFrench%26aufirst%3DC.%2BA.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Inhibition%2520of%2520BET%2520Bromodomains%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1067%26epage%3D1073%26doi%3D10.1038%2Fnature09504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref313"><div class="reference"><strong class="refLabel"><a href="#ref313" class="rightTabRefNumLink">313</a></strong><div class="NLM_citation" id="rightTab-cit313"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicodeme, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marazzi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coste, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lora, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinjha, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarakhovsky, A.</span></span> <span> </span><span class="NLM_article-title">Suppression of Inflammation by a Synthetic Histone Mimic</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>468</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1038/nature09589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1038%2Fnature09589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=21068722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref313/cit313&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=1119-1123&author=E.+Nicodemeauthor=K.+L.+Jeffreyauthor=U.+Schaeferauthor=S.+Beinkeauthor=S.+Dewellauthor=C.-W.+Chungauthor=R.+Chandwaniauthor=I.+Marazziauthor=P.+Wilsonauthor=H.+Costeauthor=J.+Whiteauthor=J.+Kirilovskyauthor=C.+M.+Riceauthor=J.+M.+Loraauthor=R.+K.+Prinjhaauthor=K.+Leeauthor=A.+Tarakhovsky&title=Suppression+of+Inflammation+by+a+Synthetic+Histone+Mimic&doi=10.1038%2Fnature09589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit313R"><div class="casContent"><span class="casTitleNuber">313</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of inflammation by a synthetic histone mimic</span></div><div class="casAuthors">Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe; Beinke, Soren; Dewell, Scott; Chung, Chun-wa; Chandwani, Rohit; Marazzi, Ivan; Wilson, Paul; Coste, Herve; White, Julia; Kirilovsky, Jorge; Rice, Charles M.; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin; Tarakhovsky, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7327</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression.  This response, although vital for immune defense, is frequently deleterious to the host due to the exaggerated prodn. of inflammatory proteins.  The scope of inflammatory responses reflects the activation state of signaling proteins upstream of inflammatory genes as well as signal-induced assembly of nuclear chromatin complexes that support mRNA expression.  Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a crit. step in the regulation of gene expression.  Here we present a novel pharmacol. approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins.  We describe a synthetic compd. (I-BET) that by mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis.  Our findings suggest that synthetic compds. specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxc3_PNaiuKLVg90H21EOLACvtfcHk0lgQmv1kha8bWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2rtb%252FP&md5=0dfccd9d01b87859512bf591e1c5a93c</span></div><a href="/servlet/linkout?suffix=cit313&amp;dbid=16384&amp;doi=10.1038%2Fnature09589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09589%26sid%3Dliteratum%253Aachs%26aulast%3DNicodeme%26aufirst%3DE.%26aulast%3DJeffrey%26aufirst%3DK.%2BL.%26aulast%3DSchaefer%26aufirst%3DU.%26aulast%3DBeinke%26aufirst%3DS.%26aulast%3DDewell%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.-W.%26aulast%3DChandwani%26aufirst%3DR.%26aulast%3DMarazzi%26aufirst%3DI.%26aulast%3DWilson%26aufirst%3DP.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DLora%26aufirst%3DJ.%2BM.%26aulast%3DPrinjha%26aufirst%3DR.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTarakhovsky%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Inflammation%2520by%2520a%2520Synthetic%2520Histone%2520Mimic%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D1119%26epage%3D1123%26doi%3D10.1038%2Fnature09589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref314"><div class="reference"><strong class="refLabel"><a href="#ref314" class="rightTabRefNumLink">314</a></strong><div class="NLM_citation" id="rightTab-cit314"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K.</span></span> <span> </span><span class="NLM_article-title">Bromodomain Protein Inhibition: A Novel Therapeutic Strategy in Rheumatic Diseases</span>. <i>RMD Open</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e000744</span>, <span class="refDoi"> DOI: 10.1136/rmdopen-2018-000744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref314/cit314&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=10.1136%2Frmdopen-2018-000744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref314/cit314&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;key=30564450" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=e000744&author=K.+Klein&title=Bromodomain+Protein+Inhibition%3A+A+Novel+Therapeutic+Strategy+in+Rheumatic+Diseases&doi=10.1136%2Frmdopen-2018-000744"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit314&amp;dbid=16384&amp;doi=10.1136%2Frmdopen-2018-000744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Frmdopen-2018-000744%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DK.%26atitle%3DBromodomain%2520Protein%2520Inhibition%253A%2520A%2520Novel%2520Therapeutic%2520Strategy%2520in%2520Rheumatic%2520Diseases%26jtitle%3DRMD%2520Open%26date%3D2018%26volume%3D4%26spage%3De000744%26doi%3D10.1136%2Frmdopen-2018-000744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref315"><div class="reference"><strong class="refLabel"><a href="#ref315" class="rightTabRefNumLink">315</a></strong><div class="NLM_citation" id="rightTab-cit315"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altenburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöbel, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goßen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderliek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschmieder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolm, C.</span></span> <span> </span><span class="NLM_article-title">Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Altenburgauthor=M.+Fringsauthor=J.-H.+Sch%C3%B6belauthor=J.+Go%C3%9Fenauthor=K.+Pannenauthor=K.+Vanderliekauthor=G.+Rossettiauthor=S.+Koschmiederauthor=N.+Chatainauthor=C.+Bolm&title=Chiral+Analogues+of+PFI-1+as+BET+Inhibitors+and+Their+Functional+Role+in+Myeloid+Malignancies&doi=10.1021%2Facsmedchemlett.9b00625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit315&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00625%26sid%3Dliteratum%253Aachs%26aulast%3DAltenburg%26aufirst%3DB.%26aulast%3DFrings%26aufirst%3DM.%26aulast%3DSch%25C3%25B6bel%26aufirst%3DJ.-H.%26aulast%3DGo%25C3%259Fen%26aufirst%3DJ.%26aulast%3DPannen%26aufirst%3DK.%26aulast%3DVanderliek%26aufirst%3DK.%26aulast%3DRossetti%26aufirst%3DG.%26aulast%3DKoschmieder%26aufirst%3DS.%26aulast%3DChatain%26aufirst%3DN.%26aulast%3DBolm%26aufirst%3DC.%26atitle%3DChiral%2520Analogues%2520of%2520PFI-1%2520as%2520BET%2520Inhibitors%2520and%2520Their%2520Functional%2520Role%2520in%2520Myeloid%2520Malignancies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.9b00625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i28"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00960">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67413"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00960?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00960</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Categories applied for the rating of experimental data; measured in vitro properties; biological activities; ADME-related properties; results of the biochemical and cellular assays of selected ATR inhibitors; physicochemical and ADME characterization; available classes of antimalarial drugs and their modes of action; results of the biochemical and cellular assays; pharmacokinetic properties; biological data on arylsulfoximine-substituted PYK2 inhibitors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00960/suppl_file/jm0c00960_si_001.pdf">jm0c00960_si_001.pdf (415.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00960%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00960" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d1d2f8d224bb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
